<SEC-DOCUMENT>0000950123-16-015273.txt : 20170407
<SEC-HEADER>0000950123-16-015273.hdr.sgml : 20170407
<ACCEPTANCE-DATETIME>20160304162005
<PRIVATE-TO-PUBLIC>
ACCESSION NUMBER:		0000950123-16-015273
CONFORMED SUBMISSION TYPE:	DRS
PUBLIC DOCUMENT COUNT:		17
FILED AS OF DATE:		20160304
<PUBLIC-REL-DATE>20170407
DATE AS OF CHANGE:		20160401

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			UroGen Pharma Ltd.
		CENTRAL INDEX KEY:			0001668243
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DRS
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	377-01276
		FILM NUMBER:		161485484

	BUSINESS ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
		BUSINESS PHONE:		972 9 770 7601

	MAIL ADDRESS:	
		STREET 1:		9 HA'TA'ASIYA ST
		CITY:			RA'ANANA
		STATE:			L3
		ZIP:			4365007
</SEC-HEADER>
<DOCUMENT>
<TYPE>DRS
<SEQUENCE>1
<FILENAME>filename1.htm
<TEXT>
<HTML><HEAD>
<TITLE>DRS</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>As confidentially submitted to the Securities and Exchange Commission on March 4, 2016. This draft
registration statement has not been filed with the Securities and Exchange Commission and all information contained herein remains strictly confidential. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="right"><B>Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>SECURITIES AND EXCHANGE
COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>FORM F-1 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>REGISTRATION STATEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>UNDER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>THE SECURITIES ACT OF&nbsp;1933 </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:12pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Exact name of Registrant as specified in its charter) </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Not Applicable </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Translation of Registrant&#146;s
name into English) </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="31%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="29%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>State of Israel <BR></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>Not Applicable<BR></B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" ALIGN="center">(State or other jurisdiction of<BR>incorporation or organization)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(Primary Standard Industrial<BR>Classification Code Number)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">(I.R.S. Employer<BR>Identification Number)</TD></TR>
</TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>9 Ha&#146;Ta&#146;asiya Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ra&#146;anana 4365007, Israel </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel: +972 (9)
770-7601 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Address, including zip code, and telephone number, including area code, of Registrant&#146;s principal executive offices) </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Urogen Pharma, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>689 Fifth Avenue, 14th
Floor </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>New York, New York 10022 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Telephone: &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">(Name, address, including zip code, and telephone number, including area code, of agent for service) </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="24%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><B>Copies to:</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Divakar Gupta</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Daniel I. Goldberg</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Joshua A.
Kaufman<BR>Cooley&nbsp;LLP<BR>The Grace Building<BR>1114 Avenue of the Americas<BR>New York, NY 10036<BR>Telephone: (212)&nbsp;479-6000<BR>Facsimile: (212)&nbsp;479-6275</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Yaron Sobol</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Steven Berelowitz</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Hamburger Evron &amp;
Co.</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>The Museum Tower</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>4 Berkowitz
Street</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel-Aviv 6423806, Israel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Telephone:&nbsp;+972&nbsp;(3)&nbsp;607-4040</FONT></B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Facsimile: +972 (3) 607-4004</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Eric W. Blanchard</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Brian K. Rosenzweig</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Covington &amp; Burling
LLP<BR>The New York Times Building<BR>620 Eighth Avenue<BR>New York, NY 10018-1405<BR>Telephone: (212) 841-1000<BR>Facsimile: (212) 841-1010</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Chaim Friedland</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ari Fried</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Gornitzky &amp; Co.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Zion House</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>45 Rothschild Blvd.</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Tel Aviv 6578403, Israel</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">Telephone:&nbsp;+972&nbsp;(3)&nbsp;710-9191</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Facsimile:&nbsp;+972&nbsp;(3)&nbsp;560-6555</FONT></B></P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Approximate date of commencement of proposed sale to the public: </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center">As soon as practicable after the effective date of this Registration Statement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415 under the Securities Act of 1933,
check the following box.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is filed to
register additional securities for an offering pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same
offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">If this Form is a <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement
for the same offering.&nbsp;&nbsp;<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT> </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>CALCULATION OF REGISTRATION
FEE </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="66%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="15%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>TITLE OF EACH CLASS OF SECURITIES<BR>TO BE REGISTERED</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>PROPOSED<BR>MAXIMUM</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>AGGREGATE<BR>OFFERING&nbsp;PRICE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>AMOUNT OF<BR>REGISTRATION<BR>FEE&nbsp;<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-left:1.75em; text-indent:-1.75em; font-size:8pt; font-family:ARIAL">Ordinary Shares, par value NIS 0.01 per share</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(1)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Estimated solely for the purpose of calculating the amount of the registration fee in accordance with Rule&nbsp;457(o) under the Securities Act of 1933, as amended. Includes the ordinary shares that the underwriters
have the option to purchase. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">(2)</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Calculated pursuant to Rule&nbsp;457(o) based on an estimate of the proposed maximum aggregate offering price. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>The
Registrant hereby amends this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further amendment which specifically states that this Registration Statement shall
thereafter become effective in accordance with Section&nbsp;8(a) of the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine.
</B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><FONT COLOR="#cc062a"><B>The information contained in this preliminary prospectus is not complete and may be changed. We
may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and is not soliciting an offer to buy these
securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><FONT COLOR="#cc062a">SUBJECT TO COMPLETION, DATED MARCH 4, 2016 </FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>PRELIMINARY PROSPECTUS </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary Shares </B></P>
<P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are
offering &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares. This is our initial public offering and no public market currently exists for our ordinary shares. We expect the initial public offering price to be
between $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share. We intend to apply to have our
ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our
Business Startups Act of 2012 and, as such, we have elected to comply with certain reduced public company reporting requirements for this prospectus and future filings. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Investing in our ordinary shares involves a high degree of risk. Please read &#147;<A HREF="#toc142578_2">Risk Factors</A>&#148; beginning on page 13 of this
prospectus. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined
if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="84%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER&nbsp;SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public Offering Price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting Discounts and Commissions<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to UroGen Pharma Ltd. Before Expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">We have agreed to reimburse the underwriters for certain expenses. See &#147;Underwriting.&#148; </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Delivery of the
ordinary shares is expected to be made on or about&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. We have granted the underwriters an option for a period of 30 days to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:16pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="86%"> <P STYLE="margin-bottom:1pt; font-size:16pt; font-family:ARIAL"><B>Jefferies </B></P></TD>
<TD> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:ARIAL" ALIGN="right"><B>Cowen&nbsp;and&nbsp;Company </B></P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Prospectus dated &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , 2016 </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_1">Prospectus Summary </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_3">Special Note Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_4">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_5">Dividend Policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_6">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_7">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_8">Selected Financial Data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_9">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_10">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_11">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_12">Principal Shareholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_13">Certain Relationships and Related Party Transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_14">Description of Share Capital</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_15">Shares Eligible for Future Sale</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">138</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_16">Taxation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">141</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_17">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">147</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_18">Expenses of this Offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_19">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_20">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">156</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_21">Enforcement of Civil Liabilities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">157</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_22">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#toc142578_23">Index to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we nor the underwriters have authorized anyone to provide you with information that is different from that contained in this prospectus, any amendment or
supplement to this prospectus, or in any free writing prospectus we may authorize to be delivered or made available to you. We take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may
give you. We and the underwriters are offering to sell ordinary shares and seeking offers to purchase ordinary shares only in jurisdictions where offers and sales are permitted. The information contained in this prospectus is accurate only as of the
date on the front of this prospectus, regardless of the time of delivery of this prospectus or any sale of ordinary shares. Our business, financial condition, results of operations and prospects may have changed since the date on the front cover of
this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For investors outside of the United States: Neither we nor any of the underwriters have taken any action to permit this offering or possession or
distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the
distribution of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel, VesiGel, Vesimune, BotuGel, UroGen and RTGel are trademarks of ours that we use in this prospectus. This prospectus also
includes trademarks, tradenames and service marks that are the property of other organizations. Solely for convenience, our trademarks and tradenames referred to in this prospectus appear without the
<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or &#153; symbols, but those references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights, or the right of the
applicable licensor to our trademark and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">i </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>MARKET, INDUSTRY AND OTHER DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains estimates, projections and other information concerning our industry, our business, and the markets for our product candidates. Information
that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties, and actual events or circumstances may differ materially from events and circumstances that are assumed in this
information. Unless otherwise expressly stated, we obtained this industry, business, market and other data from our own internal estimates and research as well as from reports, research surveys, studies and similar data prepared by market research
firms and other third parties, industry, medical and general publications, government data and similar sources. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, assumptions and estimates of our and
our industry&#146;s future performance are necessarily subject to a high degree of uncertainty and risk due to a variety of factors, including those described in &#147;Risk Factors.&#148; These and other factors could cause our future performance to
differ materially from our assumptions and estimates. See &#147;Special Note Regarding Forward-Looking Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">ii </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_1"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>This summary highlights selected information contained elsewhere in this prospectus and does not contain all of the information that you should consider in making
your investment decision. Before deciding to invest in our ordinary shares, you should read this entire prospectus carefully, including the sections of this prospectus entitled &#147;Risk Factors&#148; and &#147;Management&#146;s Discussion and
Analysis of Financial Condition and Results of Operations&#148; and our financial statements and the related notes included elsewhere in this prospectus. Unless the context otherwise requires, references in this prospectus to the
&#147;company,&#148; &#147;UroGen Pharma,&#148; &#147;we,&#148; &#147;us&#148; and &#147;our&#148; refer to UroGen Pharma Ltd. and its subsidiary, Urogen Pharma, Inc. The terms &#147;shekel,&#148; &#147;Israeli shekel&#148; and &#147;NIS&#148; refer
to New Israeli Shekels, the lawful currency of the State of Israel, and the terms &#147;dollar,&#148; &#147;U.S. dollar&#148; or &#147;$&#148; refer to United States dollars, the lawful currency of the United States. All references to
&#147;shares&#148; in this prospectus refer to ordinary shares of UroGen Pharma Ltd., par value NIS 0.01 per share. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an
innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are
proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, which is currently used for urothelial cancer treatment only in a water-based formulation as an adjuvant therapy. We are developing our product candidates as chemoablation
agents, which means they are designed to remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer. We believe
that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by replacing costly, sub-optimal and burdensome tumor resection surgeries as the first-line standard of care.
MitoGel and VesiGel may also reduce the need for bladder, kidney and upper urothelial tract removals, which are typically performed on patients whose cancer progresses despite undergoing tumor resection surgical procedures. Additionally, we believe
that our product candidates, which are based on novel formulations of approved drugs, may qualify for streamlined regulatory pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
believe that urothelial cancer, which is comprised of bladder cancer and UTUC, affects a large and underserved patient population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were approximately
$4 billion in 2010 and are projected to be approximately $5&nbsp;billion in 2020. The majority of the historical expenditures was spent on tumor resection surgeries such as transurethral resection of bladder tumor, or TURBT, and bladder, kidney and
upper urothelial tract removals. In 2012, the estimated prevalence of urothelial cancer in the United States was 580,000 with an annual incidence of approximately 74,000. The 2012 prevalence of each of low-grade non-muscle invasive bladder cancer,
or NMIBC, and low-grade UTUC in the United States was approximately 325,000 and 14,000, respectively. No drugs have been approved by the U.S. Food and Drug Administration, or the FDA, for the treatment of UTUC, and no drugs have been approved by the
FDA for the treatment of bladder cancer in more than 15 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and VesiGel are formulated using our proprietary reverse thermally triggered hydrogel, or
RTGel, technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient
or interfering with the natural flow of fluids in the urinary tract. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage throughout the organ of the active drug. Consequently, we believe that
RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and VesiGel are administered locally using the standard practice of intravesical instillation directly into
the bladder or upper urothelial tract via a catheter. Instillation is expected to take place in the physician&#146;s office as a same-day treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under
general anesthesia in a hospital setting and often require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective
chemoablation agent can potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery
and <FONT STYLE="white-space:nowrap">hospital-acquired</FONT> infections. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently evaluating the safety and efficacy of MitoGel, our novel
sustained-release formulation of MMC, in UTUC patients pursuant to an ongoing &#147;Compassionate Use&#148; program. Of the seven low-grade UTUC patients evaluated in the program to date, four achieved a complete response and three achieved a
partial </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">response. Thus far, MitoGel has been observed to be well-tolerated. We have obtained Orphan Drug Designation for MitoGel for the treatment of UTUC. We
expect to file an investigational new drug, or IND, application for MitoGel with the FDA in the second half of 2016, and, if accepted, to commence a single pivotal, open-label, single-arm Phase 3 clinical trial for the treatment of low-grade UTUC
also in the second half of 2016. We intend to pursue the FDA&#146;s 505(b)(2) regulatory pathway for MitoGel, which is a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development. We believe
that MitoGel has the potential to become the first FDA-approved drug for the treatment of low-grade UTUC and to serve as a first-line chemoablation agent, sparing patients from repeated tumor resection surgeries and potentially reducing the need for
kidney and upper urothelial tract removals. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are currently evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose
formulation of MMC, for the treatment of low-grade NMIBC. To date, 18 of 21, or approximately 86%, of the patients evaluated in our ongoing Phase 2a clinical trial who were treated in the VesiGel high dose group (80mg MMC) achieved a complete
response. Moreover, in the clinical program to date, comprised of the Phase&nbsp;2a and earlier Phase 1 clinical trials, over 80% of the patients who achieved a complete response and who have been followed for 12 months thereafter remained
recurrence free. This compares to approximately 40% of patients who historically achieve a 12-month durable complete response with TURBT as first-line treatment. We plan to file an IND for VesiGel in the first half of 2017 and, if accepted, to
commence a Phase 2b clinical trial for VesiGel also in the first half of 2017. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection surgery and become the new
first-line standard of care for the treatment of low-grade NMIBC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product
candidate for the treatment of high-grade NMIBC, as well as BotuGel, which we are developing for the treatment of overactive bladder and interstitial cystitis, also known as painful bladder syndrome. Vesimune is a novel, liquid formulation of
Imiquimod, a toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists play a key role in initiating the innate immune response system. We believe that Vesimune could represent a valid alternative to the current standard of care for the
adjuvant, or supplemental, post TURBT treatment of high-grade NMIBC. BotuGel is our proprietary novel RTGel-based formulation of botulinum toxin that we believe can potentially serve as an effective treatment option for patients suffering from
overactive bladder and interstitial cystitis. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current status of our clinical stage product candidate pipeline. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g20t64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of Upper Tract Urothelial Carcinoma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC refers to malignant changes of the transitional urothelial cells lining in the upper urothelial tract, comprised of the renal pelvis and ureter. UTUC is nearly
three times more common in men than women and affects mostly the elderly. UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence in the United States of up to 7,500 cases.
The prevalence in the United States of UTUC is approximately 35,000, of which approximately 14,000 have low-grade disease. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The key prognostic factor at the time of
diagnosis of UTUC is whether the tumor is in the muscle-invasive or non-muscle invasive stage. The number, size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients diagnosed
annually with UTUC in the United States present with non-muscle invasive UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Treatment Options for Upper Tract Urothelial Carcinoma
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover, the anatomical
complexity of the upper urothelial tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently, patients with
high-grade disease or patients with low-grade disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urothelial tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with low-grade disease that present with a limited number of
tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urothelial tract&#146;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments,
leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57 patients with low-grade UTUC who underwent tumor resections, recurrence occurred in
89.5% of patients with a mean of 5.5 recurrences per patient over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel: Our Solution for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that MitoGel, our novel sustained-release RTGel-based formulation of MMC, has the potential to become the first FDA-approved drug for the treatment of
low-grade UTUC and to serve as a first-line chemoablation agent, sparing patients from repeated tumor resection surgical procedures and potentially reducing the need for kidney and upper urothelial tract removal. We believe that MitoGel can overcome
the significant anatomical and physiological constraints presented by the upper urothelial tract. MitoGel is administered directly into the upper urothelial tract using standard catheters and conforms to the complex anatomy of the upper urothelial
tract. Once instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several
minutes for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of fluids from the upper urothelial tract to the bladder. We believe that this substantial increase in dwell
time of MMC positions MitoGel as a potential first-line chemoablation treatment alternative to tumor resection surgery for the treatment of low-grade UTUC, sparing patients from repeated and frequent tumor resection surgical procedures, and may also
reduce the need for kidney and upper urothelial tract removal. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview of Non-Muscle Invasive Bladder Cancer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for approximately 90% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder cancer is
nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancer is described as non-muscle invasive or muscle-invasive based on how far into the wall of the bladder
the cancer has invaded. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival of 15% to 63%, depending on severity. MIBC has a worse prognosis than NMIBC, which has a five-year survival rate of approximately 90%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each year, which corresponds to an estimated annual incidence and
prevalence of approximately 60,000 and 465,000 cases, respectively. NMIBC is divided into two grades, low and high, with high-grade tumors more likely to recur and progress into muscle-invasive tumors. Overall, approximately 70% of patients with
NMIBC present with low-grade disease at diagnosis. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Treatment Options for Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy treatment. TURBT is a surgical operation for tumor removal
conducted under general anesthesia in a hospital setting and often requires at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome challenges in properly identifying, reaching and resecting all
tumors. Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to MIBC is between 20% and 30%. As a consequence, NMIBC patients have to
undergo periodic and expensive follow-ups that can include multiple repeated TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No drugs have
been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy of drug treatments has historically been limited due to challenges
presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the excretion of the drug from the bladder at first urine voiding. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>VesiGel: Our Solution for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that VesiGel, our novel sustained-release RTGel-based formulation of high dose MMC, has the potential to replace TURBT and become the new first-line standard
of care for the treatment of low-grade NMIBC. VesiGel, a chemoablation agent, is administered locally using standard catheters in a physician&#146;s office as a same-day treatment, in comparison with TURBT surgical procedures, which are operations
conducted under general anesthesia in a hospital setting and often require at least an overnight stay. Once </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
instilled, VesiGel converts into gel form in approximately 15 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually dissolves and releases the active drug, MMC,
over a period of several hours versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of urine out of the
bladder. We designed VesiGel to conform to the bladder&#146;s anatomy and persist in the bladder despite urine flow and bladder movement. VesiGel has demonstrated significantly increased dwell time of MMC in the bladder and prolonged exposure of MMC
to the tissue, enabling the chemoablation of both visible and undetected tumors. We are not aware of any drugs currently in development for the treatment of NMIBC, other than VesiGel, that take into consideration the specific challenges of bladder
physiology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have developed RTGel, a novel proprietary polymeric biocompatible reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of
matter, is liquid at lower temperatures and converts into gel form when heated. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urothelial tract, by
conforming to the anatomy of the target organ while preventing rapid excretion of the drug. RTGel&#146;s components are polymer-based and are all FDA approved as inactive ingredients. We formulate RTGel with an active drug: MMC in the case of
MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow for the improved efficacy of
treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids in the urinary tract. RTGel achieves this by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urothelial tract by significantly extending the dwell time of such drugs while conforming to the anatomy of the bladder and the upper urothelial tract,
which allows for enhanced drug tissue coverage; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urothelial tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Ability to develop non-surgical, first-line drug therapies for uro-oncology.</I></B><B>&nbsp;</B><B></B>Leveraging our innovative formulation
technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line therapy for low-grade UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation agents designed to overcome the
challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be able to replace the current
first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to better eradicate tumors irrespective of their detectability and location within the urinary tract. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in proprietary formulations of existing drugs for clinical benefit.</I></B>&nbsp;We focus on developing proprietary RTGel formulations
of approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. Our expertise has enabled us to develop proprietary RTGel-based formulations for several approved drugs to date, including
clinical stage proprietary formulations of MMC and botulinum toxin. With 10 Ph.D. or medical doctors on our staff, we have a strong research and development team to advance our product candidates. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our pipeline product candidates. </I></B><B></B>We expect
the approval process for each of our current uro-oncology product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to
traditional drug development. Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and Carcinoma in Situ, or CIS, respectively, which we expect will provide
seven years of marketing exclusivity following FDA approval, if received. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation
technology</I></B><B>.</B><B>&nbsp;</B><B></B>We believe that RTGel has multiple potential applications beyond urology. Our formulation know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained
release of active drugs to a variety of targeted body cavities. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual
property portfolio that includes four issued patents in the United States and several patent applications worldwide related to methods, systems and compositions for treating bladder cancer related to our lead product candidates, MitoGel and VesiGel,
as well as RTGel, both on its own and formulated with other drugs. The four issued patents are expected to expire between 2024 and 2030. We also have 11 granted patents worldwide related to our other product candidates, which are expected to expire
between 2030 and 2031. We also have approximately 60 pending patent applications worldwide covering our product candidates. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and
accomplished leadership team with proven track record</I></B><B>.</B>&nbsp;We have an experienced management team, with each member possessing more than 15 years of biopharmaceutical and related industry experience. We believe that our leadership
team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth Strategy
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish each of our lead product candidates, MitoGel and VesiGel, as the first-line therapy in its target indication.</I></B>&nbsp;We
believe that our lead product candidates have the potential to replace costly, sub-optimal and burdensome tumor resection procedures as first-line therapy and may also reduce the need for bladder, kidney and upper urothelial tract removals. We
believe that data from an ongoing Compassionate Use program provide preliminary evidence of the potential safety and efficacy of MitoGel for the treatment of low-grade UTUC. We expect to file an IND in the second half of 2016 and, if accepted, to
commence a single pivotal Phase 3 clinical trial for MitoGel also in the second half of 2016 pursuant to the FDA&#146;s 505(b)(2) regulatory pathway. For VesiGel, which is currently in a Phase 2a clinical trial for the treatment of low-grade NMIBC,
we expect to file an IND in the first half of 2017 and, if accepted, to commence a Phase 2b clinical trial also in the first half of 2017. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our uro-oncology product pipeline.</I></B> A Phase 1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an
aggressive type of high-grade NMIBC. In the study, 10 patients were evaluated for response and a 40% complete response rate with Vesimune as a single-agent treatment was observed. We believe that Vesimune has the potential to serve as a treatment
option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Develop our non-oncology product candidates.</I></B>&nbsp;We are developing additional product candidates designed to take advantage of our
proprietary RTGel formulation technology to better adapt to the specific anatomy and physiology of the urological system. The most notable of these product candidates is BotuGel, our proprietary novel RTGel-based formulation of botulinum toxin for
the treatment of overactive bladder and interstitial cystitis. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary technology to expand our pipeline to other body
cavities and indications.</I></B>&nbsp;We believe that RTGel may be suitable for multiple additional applications. Our know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of
active drugs to a variety of targeted body cavities and for multiple indications. Beyond the urinary tract, we may target the gastrointestinal tract and female reproductive system. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Evaluate and selectively pursue potential collaborations to develop improved formulations and
product life-cycle management strategies.</I></B>&nbsp;We intend to evaluate and selectively pursue collaborations with pharmaceutical companies through a combination of in-licensing, out-licensing, joint venture and partnership transactions in
order to formulate additional drugs using such companies&#146; products or product candidates in combination with RTGel. In addition, we may in-license or acquire additional product candidates for urological indications. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Associated with Our Business </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business is subject to a number of
risks of which you should be aware before making an investment decision. These risks are discussed more fully in the &#147;Risk Factors&#148; section of this prospectus immediately following this prospectus summary. These risks include the
following: </P> <P STYLE="font-size:7pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have a limited operating history and have incurred since inception, and expect to continue to incur for the foreseeable future, significant losses and negative cash flows. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have limited clinical trial experience with our product candidates and to date have generated only limited clinical data for our product candidates.&nbsp;Results of earlier studies and trials may not be predictive of
future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We have not conducted Phase 3 or similar pivotal, or equivalent, registration clinical trials for any of our product candidates, nor have we applied for regulatory approvals to market any of our other product
candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize our product candidates. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">If the FDA does not conclude that MitoGel, VesiGel or our other product candidates satisfy the requirements under Section&nbsp;505(b)(2) of the Federal Food Drug and Cosmetic Act or a similar regulatory pathway for
biologics as it relates to BotuGel, or if the requirements for such product candidates are not as we expect, the regulatory approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail
significantly greater complications and risks than anticipated, and in either case may not be successful. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Even if our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success.&nbsp;Further, if MitoGel or
VesiGel or any of our other product candidates produces undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials, our ability to obtain and maintain marketing approval or physician and market
acceptance for these product candidates would be significantly harmed.</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We are and expect to continue to be dependent on third-party subcontractors and single-source suppliers for the supply of sufficient quantities at acceptable costs of certain raw materials, compounds and components
necessary to produce MitoGel, VesiGel, Vesimune and BotuGel for preclinical studies, clinical trials and, if approved, commercial supply.</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may receive only limited protection, or no protection, from our issued patents and patent applications.&nbsp;If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to
our product candidates and technologies are not adequate, we may not be able to compete effectively. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Our product candidates, if approved, will face significant competition from competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or third-party payor policies. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to be classified as a passive foreign investment company, or PFIC, for U.S. income tax purposes for the taxable year ending December&nbsp;31, 2016, and our U.S. shareholders may suffer adverse tax consequences
as a result, and we have not committed to providing to investors information that would enable them to make the Qualified Electing Fund election. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Information </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
were incorporated under the laws of the State of Israel in April 2004 under the name TheraCoat Ltd. In September 2015, we changed our name to UroGen Pharma Ltd. Our principal executive offices are located at 9 Ha&#146;Ta&#146;asiya Street,
Ra&#146;anana 4365007, Israel, and our telephone number is +972 (9) 770-7601. Our website address is <I>http://www.urogen.com</I>. The information contained on, or that can be accessed through, our website is not incorporated by reference into this
prospectus. We have included our website address as an inactive textual reference only. Our agent for service of process in the United States is Urogen Pharma, Inc., located at 689 Fifth Avenue, 14th Floor, New York, New York 10022, and its
telephone number is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Implications of Being an &#147;Emerging Growth Company&#148; and a
Foreign Private Issuer </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company with less than $1&nbsp;billion in revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148;
as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act. An emerging growth company may take advantage of specified reduced reporting and other burdens that are otherwise applicable generally to public companies. These
provisions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a requirement to have only two years of audited financial statements and only two years of related Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations disclosure in our initial
registration statement; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exemption from the auditor attestation requirement in the assessment of our internal control over financial reporting pursuant to the Sarbanes-Oxley Act of 2002. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may take advantage of these provisions for up to five years or such earlier time that we are no longer an emerging growth company. We would cease to be an emerging
growth company upon the earlier to occur of: (1) the last day of the fiscal year in which we have total annual gross revenues of $1.0 billion or more; (2) the date on which we have issued more than $1.0 billion in nonconvertible debt during the
previous three years; or (3) the date on which we are deemed to be a large accelerated filer under the rules of the Securities and Exchange Commission, or the SEC. We may choose to take advantage of some but not all of these reduced burdens, and
therefore the information that we provide holders of our ordinary shares may be different than the information you might receive from other public companies in which you hold equity. In addition, Section&nbsp;107 of the JOBS Act also provides that
an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards applicable to public companies. We have irrevocably elected to opt out of such extended transition period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon consummation of this offering, we will report under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as a non-U.S. company with foreign
private issuer status. Even after we no longer qualify as an emerging growth company, as long as we continue to qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are
applicable to U.S. domestic public companies, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations with respect to a security registered under the Exchange Act; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on <FONT STYLE="white-space:nowrap">Form&nbsp;10-Q</FONT> containing unaudited financial statements and other specified
information, and current reports on Form&nbsp;8-K upon the occurrence of specified significant events. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Both foreign private issuers and emerging
growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more
stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer. </P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>THE OFFERING </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Ordinary shares to be outstanding immediately after this offering </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Option to purchase additional ordinary shares </P></TD>
<TD>We have granted the underwriters an option for a period of 30 days after the date of this prospectus to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
additional ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We estimate that the net proceeds to us from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, or approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million if the underwriters exercise their option to purchase additional ordinary shares in full, after deducting the underwriting discounts and commissions and estimated
offering expenses payable by us, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover
of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We expect to use the net proceeds from this offering, together with our existing cash resources, to advance our clinical pipeline, including specifically to file an IND for, and to initiate and complete our planned
single pivotal Phase 3 clinical trial of, MitoGel; to file an IND for, and to initiate our planned Phase 2b clinical trial of, VesiGel; to fund continued research and clinical development of our other product candidates; and to fund working capital
and other general corporate purposes. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See &#147;Use of Proceeds&#148; for more information about the intended use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Tax considerations </P></TD>
<TD>Because we have no current revenue-producing operations, we expect to be treated as a PFIC for our current taxable year and possibly thereafter. If we are characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences. See
&#147;Taxation&#151;Material U.S. Federal Income Tax Consequences to U.S. Holders&#151;Passive Foreign Investment Company Considerations.&#148; </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Risk factors </P></TD>
<TD>See &#147;Risk Factors&#148; and other information included in this prospectus for a discussion of factors that you should consider carefully before deciding to invest in our ordinary shares. </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE="margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:9.5pt; font-family:ARIAL">Proposed NASDAQ Global Market symbol </P></TD>
<TD>We intend to apply to have our ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise stated, the number of ordinary shares to be outstanding after this offering is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding as of December 31, 2015 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance by us of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series A-1 preferred shares upon the exercise for cash of all outstanding warrants to purchase Series A-1
preferred shares; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares upon the conversion of all Series A preferred shares and
<FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT> preferred shares into ordinary shares, which will occur automatically upon the closing of this offering; </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan, including
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for issuance upon the exercise of outstanding options at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for issuance upon the vesting of outstanding restricted share
units; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise indicated, all information in this prospectus: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assumes an initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, the midpoint of the range set forth on the cover of this
prospectus; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assumes no exercise of the underwriters&#146; option to purchase up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reflects a&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;-for-1 share split to be effected
on&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, by means of distribution of a share dividend
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares for each ordinary share then outstanding; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">gives effect to the adoption of our amended and restated articles of association prior to the closing of this offering, which will replace our amended and restated articles of association as currently in effect.
</TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SUMMARY FINANCIAL DATA </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present summary financial data for our business. We derived the summary statements of operations data for the years ended December&nbsp;31,
2014 and 2013 from our audited financial statements included elsewhere in this prospectus. We derived the summary statements of operations data for the nine months ended September&nbsp;30, 2015 and 2014 and the summary balance sheet data as of
September&nbsp;30, 2015 from our unaudited condensed interim financial statements included elsewhere in this prospectus. In the opinion of management, these unaudited condensed interim financial statements include all adjustments, consisting of
normal recurring adjustments, necessary for a fair statement of our financial position and operating results for these periods. We maintain our books and records in U.S. dollars, and prepare our financial statements in accordance with accounting
principles generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and related notes appearing elsewhere in this
prospectus and the information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results are not necessarily indicative of our
future results, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER 31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share and per share data) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Per share information:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma loss per ordinary share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average number of ordinary shares outstanding (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER 30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO<BR>FORMA<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(2)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(3)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"><B>(in thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px;MARGIN-RIGHT:0px;WIDTH:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 9 to our annual financial statements and Note 7 to our interim financial statements, respectively, included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted loss per
ordinary share and the weighted-average number of ordinary shares used in the computation of the per share amounts. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented on a pro forma basis to reflect the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series A preferred shares for aggregate gross proceeds of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; since September 30, 2015, the exercise for cash of all outstanding warrants to purchase Series A-1 preferred shares, and the conversion thereafter of all outstanding preferred
shares (including such newly issued shares) into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data presented on a pro forma as adjusted basis to give further effect to the sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering at an assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary
share, which is the midpoint of the price range set forth on the cover of this prospectus, would increase or decrease, respectively, the amount of cash and cash equivalents, total assets and total shareholders&#146; equity by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same and after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease of 100,000 in the number of ordinary shares we are offering would increase or
decrease, respectively, the amount of securities, cash and cash equivalents, total assets and total shareholders&#146; equity by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming the assumed initial public offering
price per ordinary share, as set forth on the cover of this prospectus, remains the same. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other
terms of this offering determined at pricing. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <P STYLE="margin-top:0pt;margin-bottom:0pt; font-size:8pt">&nbsp;</P></div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks and uncertainties described below, in addition to the other
information set forth in this prospectus, including the financial statements and the related notes included elsewhere in this prospectus, before purchasing our ordinary shares. If any of the following risks actually occurs, our business, financial
condition, cash flows and results of operations could be negatively impacted. In that case, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not
currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and results of operations. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Limited Operating History, Financial Condition and Capital Requirements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have a limited operating history and have incurred significant losses and negative cash flows since our inception, and we anticipate that we will continue to
incur significant losses and negative cash flows for the foreseeable future, which makes it difficult to assess our future viability. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical
stage biopharmaceutical company with a limited operating history upon which you can evaluate our business and prospects. We are not profitable and have incurred net losses in each year since we commenced operations in 2004, including net losses of
$5.7 million, $4.5 million and $3.3 million for the nine months ended September 30, 2015 and for the years ended December 31, 2014 and 2013, respectively. We expect to continue to incur significant expenses and increasing operating losses for the
foreseeable future. Our ability to ultimately achieve revenues and profitability is dependent upon our ability to successfully complete the development of our product candidates, obtain necessary regulatory approvals for and successfully
manufacture, market and commercialize our products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that we will continue to expend substantial resources in the foreseeable future for the clinical
development of our current product candidates or any additional product candidates and indications that we may choose to pursue in the future. These expenditures will include costs associated with research and development, conducting preclinical
studies and clinical trials, and payments for third-party manufacturing and supply, as well as sales and marketing of any of our product candidates that are approved for sale by regulatory agencies. Because the outcome of any clinical trial is
highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of our clinical stage and preclinical drug candidates and any other drug candidates that we may develop in
the future. Other unanticipated costs may also arise. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our future capital requirements depend on many factors, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing of, and the costs involved in, clinical development and obtaining regulatory approvals for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in regulatory requirements during the development phase that can delay or force us to stop our activities related to any of our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of commercialization activities if our products are approved for sale, including marketing, sales and distribution costs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of third-party manufacturing of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number and characteristics of any other product candidates we develop or acquire; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish and maintain strategic collaborations, licensing or other commercialization arrangements, and the terms and timing of such arrangements; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent and rate of market acceptance of any approved products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the expenses needed to attract and retain skilled personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs associated with being a public company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in preparing, filing, prosecuting, maintaining, defending and enforcing patent claims, including potential litigation costs and the outcome of such litigation; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing, receipt and amount of sales of, or royalties on, future approved products, if any; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any product liability or other lawsuits related to our products; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">scientific breakthroughs in the field of urothelial cancer treatment and diagnosis that could significantly diminish the need for our product candidates or make them obsolete; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in reimbursement policies that could have a negative impact on our future revenue stream. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have
limited experience and have not yet demonstrated an ability to successfully overcome many of the risks and uncertainties frequently encountered by companies in new and rapidly evolving fields, particularly in the biopharmaceutical industry. Drug
development is a highly speculative undertaking and involves a substantial degree of risk. To date, we have not obtained any regulatory approvals for any of our product candidates, commercialized any of our product candidates or generated any
material revenue. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will require substantial additional financing to achieve our goals, and a failure to obtain this capital when needed and on acceptable
terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our
inception, almost all of our resources have been dedicated to the preclinical and clinical development of our lead product candidates, MitoGel and VesiGel. As of September 30, 2015, we had cash and cash equivalents of $1.6 million. Subsequent to
September&nbsp;30, 2015, we raised $18.1&nbsp;million in a private placement of preferred shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the net proceeds from this offering, together
with our existing cash and cash equivalents, will allow us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. We expect that we will require additional capital to complete clinical trials, obtain
regulatory approval for and commercialize our product candidates. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned, through public or private
equity, convertible debt or debt financings, third-party funding, marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or a combination of these approaches. In any event, we will
require additional capital to pursue preclinical and clinical activities, and pursue regulatory approval for, and to commercialize, our pipeline product candidates. Even if we believe that we have sufficient funds for our current or future operating
plans, we may seek additional capital if market conditions are favorable or if we have specific strategic considerations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any additional fundraising efforts may
divert the attention of our management from day-to-day activities, which may adversely affect our ability to develop and commercialize our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient
amounts or on terms acceptable to us, if at all. Moreover, the terms of any financing may negatively impact the holdings or the rights of our shareholders, and the issuance of additional securities, whether equity or debt, by us or the possibility
of such issuance may cause the market price of our shares to decline. The incurrence of indebtedness could result in increased fixed payment obligations and we may be required to agree to certain restrictive covenants, such as limitations on our
ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions that could adversely impact our ability to conduct our business. We could also be required to seek
funds through arrangements with collaborative partners or otherwise at an earlier stage than would be desirable and we may be required to relinquish rights to some of our technologies, intellectual property or product candidates or otherwise agree
to terms unfavorable to us, any of which may harm our business, financial condition, cash flows, operating results and prospects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If adequate funds are not
available to us on a timely basis, we may be required or choose to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate preclinical studies, clinical trials or other development activities for our product candidates or any of our future product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our other research and development activities; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delay, limit, reduce or terminate our establishment or expansion of manufacturing, sales and marketing or distribution capabilities or other activities that may be necessary to commercialize MitoGel, VesiGel or any of
our other product candidates. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also be unable to expand our operations or otherwise capitalize on our business opportunities, as desired, which
could harm our business, financial condition, cash flows and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Raising additional capital may cause dilution to our shareholders, including purchasers of ordinary shares in this
offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Until such time, if ever, as we can
generate substantial product revenues, we expect to finance our cash needs through equity, convertible debt or debt financings, as well as selectively continuing to enter into collaborations, strategic alliances and licensing arrangements. We do not
currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include
liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as
incurring additional debt, making capital expenditures or declaring and distributing dividends, and may be secured by all or a portion of our assets. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we raise
funds by selectively continuing to enter into collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish additional valuable rights to our technologies, future revenue streams, research programs or
product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity, convertible debt or debt financings when needed, we may be required to delay, limit, reduce or terminate our
product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. If we are unable to raise additional funds through collaborations,
strategic alliances or licensing arrangements, we may be required to terminate product development or future commercialization efforts or to cease operations altogether. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As described in Note 1 of our accompanying financial statements, our auditors issued a going concern explanatory paragraph in their opinion concerning our financial
statements for the two years ended December 31, 2014, expressing substantial doubt that we can continue as an ongoing business for the next 12 months after issuance of their report based on our having suffered cumulative losses and negative cash
flows from operating activities since inception and having an accumulated deficit as of September 30, 2015 of $18.2 million, which they have indicated raises substantial doubt about our ability to continue as a going concern. Our financial
statements do not include any adjustments that might result from the outcome of this uncertainty. If we cannot continue as a viable entity, our shareholders may lose some or all of their investment in us. Subsequent to September 30, 2015, we raised
$18.1 million of capital through the private placement of preferred shares. Following completion of this offering, we expect to have sufficient funds to fund our operating expenses and capital expenditure requirements for at least the next 12
months. However, no assurance can be provided that such amount of capital will be sufficient to run our operations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Business and Strategy
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are dependent on the success of our lead product candidates, including obtaining regulatory approval to market our product candidates in the United
States. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have invested almost all of our efforts and financial resources in the research and development of our lead product candidates, MitoGel and
VesiGel. Our future success depends on our ability to market and sell these product candidates. However, these drugs are in various stages of clinical development and each of these drugs has yet to receive marketing approval from the U.S. Food and
Drug Administration, or the FDA, or any other regulatory agency. Our product candidates&#146; marketability is subject to significant risks associated with successfully completing current and future clinical trials, including: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our timely completion of our investigational new drug, or IND, enabling work for MitoGel, including the ongoing work required to obtain the necessary toxicology and chemistry, manufacturing controls, or CMC, data and
the FDA&#146;s timely acceptance of such data; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s timely acceptance of our IND filing for MitoGel, which we intend to submit in the second half of 2016, and for VesiGel, which we intend to submit in the first half of 2017, and our other product
candidates for which we plan to file an IND. Without such IND acceptances, we will be unable to commence clinical trials in the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of our parameters for regulatory approval relating to MitoGel, VesiGel and our other product candidates, including our proposed indications, primary and secondary endpoint assessments and
measurements, safety evaluations and regulatory pathways; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the number, design, size, conduct and implementation of our clinical trials, our trial protocols and the interpretation of data from preclinical studies or clinical trials;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully complete the clinical trials of our product candidates, including timely patient enrollment and acceptable safety and efficacy data and our ability to demonstrate the safety and efficacy of
the product candidates undergoing such clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the sufficiency of the data we collected from our preclinical studies and are collecting from the ongoing &#147;Compassionate Use&#148; program of MitoGel in upper tract urothelial
carcinoma, or UTUC, to support the submission of an IND without requiring additional preclinical studies or clinical trials, and our ability to commence a single pivotal Phase 3 clinical trial for MitoGel for the treatment of low-grade UTUC
following an IND submission, if accepted, and that the single pivotal Phase 3 clinical trial, even if successfully completed, will be sufficient to support a New Drug Application, or NDA, submission; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s acceptance of the sufficiency of the data we collected from our preclinical studies and are collecting from our ongoing Phase 2a clinical trial with VesiGel in low-grade non-muscle invasive bladder
cancer, or NMIBC, and expect to collect from toxicological studies that we may conduct to support the submission of an IND without requiring additional preclinical studies or clinical trials, and our ability to commence a Phase 2b clinical trial in
the United States for VesiGel in low-grade NMIBC following an IND submission, if accepted; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s willingness to schedule an advisory committee meeting in a timely manner to evaluate and decide on the approval of our NDAs for MitoGel and VesiGel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the recommendation of the FDA&#146;s advisory committee to approve our applications to market MitoGel and VesiGel and our other product candidates in the United States, without limiting the approved labeling,
specifications, distribution or use of the products, or imposing other restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s satisfaction with the safety and efficacy of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse events associated with our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timely and satisfactory performance by third-party contractors of their obligations in relation to our clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success in educating physicians and patients about the benefits, administration and use of our product candidates, if approved, particularly in light of the fact that there are currently no drugs approved by the FDA
for the treatment of UTUC and the FDA has not approved a drug for the treatment of bladder cancer in more than 15 years; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the availability, perceived advantages, relative cost, safety and efficacy of alternative and competing treatments for the indications addressed by our product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our marketing, sales and distribution strategy, and operations, as well as that of any current and future licensees; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to develop, validate and maintain a commercially viable manufacturing process that is compliant with current good manufacturing practices, or cGMP; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain, protect and enforce our intellectual property rights with respect to our product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many of these clinical, regulatory and commercial risks are beyond our control. Accordingly, we cannot assure you that we will be able to advance any of our product
candidates through clinical development, or to obtain regulatory approval of or commercialize any of our product candidates. If we fail to achieve these objectives or overcome the challenges presented above, we could experience significant delays or
an inability to successfully commercialize our product candidates. Accordingly, we may not be able to generate sufficient revenues through the sale of our product candidates to enable us to continue our business. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain regulatory approval for our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The research, development, testing, manufacturing, labeling, packaging, approval, promotion, advertising, storage, recordkeeping, marketing, distribution, post-approval
monitoring and reporting, and export and import of drug products are subject to extensive regulation by the FDA, and by foreign regulatory authorities in other countries. These regulations differ from country to country. To gain approval to market
our product candidates, we must provide clinical data that adequately demonstrate the safety and efficacy of the product for the intended indication. We have not yet obtained regulatory approval to market any of our product candidates in the United
States or any other </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
country. Our business depends upon obtaining these regulatory approvals. There are currently no drugs approved by the FDA for the treatment of UTUC and only three drugs have been approved by the
FDA for NMIBC, with the last approval having occurred over 15 years ago.&nbsp;The FDA can delay, limit or deny approval of our product candidates for many reasons, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to satisfactorily demonstrate that the product candidates are safe and effective for the target indication; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s disagreement with our trial protocol, the interpretation of data from preclinical studies or clinical trials, or adequate conduct and control of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the population studied in the clinical trial may not be sufficiently broad or representative to assess safety in the full population for which we seek approval; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to demonstrate that clinical or other benefits of our product candidates outweigh any safety or other perceived risks; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that the 505(b)(2) or 351(k) regulatory pathway is not available for our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s determination that additional preclinical studies or clinical trials are required; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s non-approval of the formulation, labeling or the specifications of our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA&#146;s failure to accept the manufacturing processes or facilities of third-party manufacturers with which we contract; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential for approval policies or regulations of the FDA to significantly change in a manner rendering our clinical data insufficient for approval; or </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">resistance to approval from the FDA&#146;s advisory committee for any reason including safety or efficacy concerns. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we eventually complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA may grant approval contingent on the
performance of costly and potentially time-consuming additional post-approval clinical trials or subject to restrictive Risk Evaluation and Mitigation Strategies. The FDA may also approve our product candidates for a more limited indication or a
narrower patient population than we originally requested, and the FDA may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. To the extent we seek regulatory approval in
foreign countries, we may face challenges similar to those described above with regulatory authorities in applicable jurisdictions. Any delay in obtaining, or inability to obtain, applicable regulatory approval for any of our product candidates
would delay or prevent commercialization of our product candidates and would thus negatively impact our business, results of operations and prospects. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>To
date, we have only generated limited clinical data for our product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Positive results in preclinical testing and early clinical trials do not
ensure that later clinical trials will be successful. A number of pharmaceutical companies have suffered significant setbacks in clinical trials, including in Phase 3 clinical trials, after promising results in preclinical testing and early clinical
trials. These setbacks have included negative safety and efficacy observations in later clinical trials, including previously unreported adverse effects. For example, to date, we have enrolled only 17 patients into the ongoing UTUC Compassionate Use
program of MitoGel. Thus far only seven patients who were confirmed with low-grade UTUC disease have been evaluated for response, and four achieved a complete response and the remaining three achieved a partial response. Further, we have only
evaluated patients who have been diagnosed with tumors up to three centimeters in diameter. To date in our clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, urgency
in urination and pain during urination. These adverse events are known MMC-related adverse events and are indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that adverse events related to MitoGel and
VesiGel that are not directly attributable to MMC specifically will not occur. While the preliminary data indicates that the product candidate appears to be safe and efficacious for the treatment of low-grade UTUC, our Compassionate Use program is
ongoing and these results may not be replicated in additional Compassionate Use patients or in patients with tumors larger than three centimeters in diameter, or in the planned single pivotal Phase&nbsp;3 clinical trial, which is currently expected
to evaluate between 50 and 70 patients. We expect to enroll and evaluate additional patients in our Compassionate Use program and any negative results or new adverse events could delay our IND filing for MitoGel. After the IND filing, if accepted,
we plan to commence a single pivotal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Phase&nbsp;3 clinical, or equivalent, registration trial for MitoGel in patients with low-grade UTUC. This trial may not be successful. If our clinical trials do not ultimately indicate that our
product candidates are safe or efficacious for their intended application, the FDA may not approve any NDA that we may file to market such product candidates, and our business would not be able to generate revenue from the sale of any such product
candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have limited experience in conducting clinical trials and have never obtained approval for any product candidates, and may be unable to do
so&nbsp;successfully. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a company, we have limited experience in conducting clinical trials and have never progressed a product candidate through to
regulatory approval. In part because of this lack of experience, our clinical trials may require more time and incur greater costs than we anticipate. We cannot be certain that the planned clinical trials will begin or conclude on time, if at all.
Large-scale trials will require significant additional financial and management resources. In addition, due to the significant lack of drug development for urothelial cancers over the past 15 years, neither we nor any third-party clinical
investigators, clinical research organizations, or CROs, and/or consultants are likely to have extensive experience conducting clinical trials for the indications we are targeting. Third-party clinical investigators do not operate under our control.
Any performance failure on the part of such third parties could delay the clinical development of our product candidates or delay or prevent us from obtaining regulatory approval or commercializing our current or future product candidates, depriving
us of potential product revenue and resulting in additional losses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have not conducted Phase 3 or similar pivotal, or equivalent, registration clinical
trials for any of our product candidates, nor have we applied for regulatory approvals to market any of our other product candidates, and we may be delayed in obtaining or fail to obtain such regulatory approvals and to commercialize our product
candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process of developing, obtaining regulatory approval for and commercializing our product candidates is long, complex, costly and uncertain,
and delays or failure can occur at any stage. The research, testing, manufacturing, labeling, marketing, sale and distribution of drugs are subject to extensive and rigorous regulation by the FDA and foreign regulatory agencies, as applicable. These
regulations are agency-specific and differ by jurisdiction. We are not permitted to market any product candidate in the United States until we receive approval of an NDA from the FDA, or in any foreign countries until we receive the requisite
approval from the respective regulatory agencies in such countries. To gain approval of an NDA or other equivalent regulatory approval, we must provide the FDA or relevant foreign regulatory authority with preclinical and clinical data that
demonstrates the safety and efficacy of the product for the intended indication. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Before we can submit an NDA to the FDA or comparable similar applications to
foreign regulatory authorities, we must conduct Phase 3 clinical trials, or a pivotal/registration trial equivalent, for each product candidate. We expect to commence a single pivotal Phase 3 clinical trial of MitoGel for the treatment of low-grade
UTUC in the second half of 2016, pursuant to the FDA&#146;s 505(b)(2) regulatory pathway. These clinical trials will be substantially broader than our previous and ongoing Phase 1 and Phase 2 clinical trials and the Compassionate Use program for
MitoGel for the treatment of patients with UTUC and will require us to enroll a considerably larger number of patients in multiple clinics and medical centers across a number of different countries. For example, based on our discussion with the FDA,
our current expectation is that our pivotal clinical trial for MitoGel will be an open-label, single-arm study, evaluating between 50 and 70 patients with low-grade UTUC in the United States, Europe and Israel. We are also planning to commence a
Phase 2b clinical trial of VesiGel in the first half of 2017. Before commencing these clinical trials in the United States, we must first file an IND, which must be accepted by the FDA. We have not yet discussed the clinical development of VesiGel
with the FDA. Also, while we believe that we have received adequate clarity from the FDA regarding the key safety and efficacy parameters for the planned pivotal trial of MitoGel in low-grade UTUC, we cannot assure you that the FDA will not decide
to materially alter these parameters, including potentially requiring a pivotal study with a control arm, before or during the trial or require us to conduct more than one pivotal trial before submitting an NDA. We have not received regulatory
clearance to commence the clinical trials that we believe are necessary to submit an NDA to the FDA or comparable applications to foreign regulatory authorities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Phase 3 clinical trials often produce unsatisfactory results even though prior clinical trials were successful. Moreover, the results of clinical trials may be
unsatisfactory to the FDA or foreign regulatory authorities even if we believe those clinical trials to be successful. The FDA or applicable foreign regulatory agencies may suspend one or all of our clinical trials or require that we conduct
additional clinical, preclinical, manufacturing, validation or drug </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
product quality studies and submit that data before considering or reconsidering any NDA or comparable foreign regulatory application that we may submit. Depending on the extent of these
additional studies, approval of any applications that we submit may be significantly delayed or may cause the termination of such programs, or may require us to expend more resources than we have available. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of these outcomes occur, we may not receive regulatory approval for the corresponding product candidates, and our business would not be able to generate revenue
from the sale of any such product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to advance our preclinical product candidates into clinical development and through
regulatory approval and commercialization. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain of our product candidates are currently in preclinical development and are therefore currently subject
to the risks associated with preclinical development, including the risks associated with: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating adequate and sufficient preclinical safety and efficacy data in a timely fashion to support the initiation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence clinical trials in any jurisdiction, including the filing and acceptance of INDs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contracting with the necessary parties to conduct a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enrolling sufficient numbers of patients in clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timely manufacture of sufficient quantities of the product candidate for use in clinical trials. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are unsuccessful
in advancing our preclinical product candidates into clinical trials in a timely fashion, our business may be harmed. Even if we are successful in advancing our preclinical product candidates into clinical development, their success will be subject
to all of the clinical, regulatory and commercial risks described elsewhere in &#147;Risk Factors.&#148; Accordingly, we cannot assure you that we will be able to develop, obtain regulatory approval for, commercialize or generate significant revenue
from our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our BotuGel product candidate is subject to a preclinical material transfer collaboration agreement with a large pharmaceutical
company. If that collaboration is terminated or the pharmaceutical company decides not to progress BotuGel into clinical trials even upon successful completion of the preclinical collaboration, our business may be harmed. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have a preclinical material transfer collaboration with a large pharmaceutical company for the conduct of IND-enabling work, including formal preclinical toxicology
and CMC experiments for our BotuGel product candidate for the treatment of overactive bladder. Our current agreement with the large pharmaceutical company grants the large pharmaceutical company an option to obtain, at any time during the course of
the collaboration, a license for the clinical development and potential commercialization of BotuGel for the treatment of overactive bladder. If the large pharmaceutical company exercises its option, the parties will negotiate a license agreement in
good faith. We cannot assure you that the preclinical collaboration will be successfully completed, and even if it is successfully completed, that it will lead to an acceptable licensing transaction with the large pharmaceutical company.
BotuGel&#146;s development in overactive bladder therefore is subject to many risks, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating adequate and sufficient preclinical data to support the decision of the large pharmaceutical company to negotiate a license from us, including satisfactory toxicology and CMC data; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reaching a license agreement on acceptable terms with the pharmaceutical company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generating sufficient data to support the initiation or continuation of clinical trials whether on our own or with a licensing partner; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtaining regulatory approval to commence clinical trials, including the risk that the IND, if filed for BotuGel by the pharmaceutical company, will not be accepted by the FDA; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">contracting with the necessary third parties to conduct a clinical trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">enrolling sufficient numbers of patients in clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">timely manufacture of sufficient quantities of the product candidate for use in clinical trials; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adverse events in the clinical trials. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pharmaceutical company may not cooperate with us or perform its obligations under the agreement. Furthermore, the
pharmaceutical company does not face penalties or other repercussions for failing to develop BotuGel within the designated timetable. We cannot control the scope or timing of the resources that will be devoted by the pharmaceutical company to
performing its responsibilities under the agreement. The pharmaceutical company may choose to pursue alternative technologies in preference to those being developed with us. The agreement may also be terminated for convenience by the pharmaceutical
company. The development and commercialization of the licensed product candidates as well as the anticipated contingent payments and royalties we hope to generate from them will be delayed or never obtained if the pharmaceutical company fails to
conduct its responsibilities in a timely manner or in accordance with applicable regulatory requirements, or if it breaches its agreements with us. Disputes with the pharmaceutical company could also impair our reputation or result in development
delays, decreased revenues and litigation expenses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Clinical drug development involves a lengthy and expensive process with an uncertain outcome, results of
earlier studies and trials may not be predictive of future trial results, and our clinical trials may fail to adequately demonstrate the safety and efficacy of our product candidates. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. A failure of one or more of our clinical trials can occur at
any time during the clinical trial process. We do not know whether future clinical trials, if any, will begin on time, need to be redesigned, enroll an adequate number of patients on time or be completed on schedule, if at all. Clinical trials can
be delayed, suspended or terminated for a variety of reasons, including failure to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">generate sufficient preclinical, toxicology, or other <I>in vivo</I> or <I>in vitro </I>data to support the initiation or continuation of clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain regulatory approval, or feedback on trial design, in order to commence a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and train suitable clinical investigators; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reach agreement on acceptable terms with prospective CROs and clinical trial sites, and have such CROs and sites effect the proper and timely conduct of our clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obtain and maintain institutional review board, or IRB, approval at each clinical trial site; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit and enroll suitable patients to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">have a sufficient number of patients complete a trial or return for post-treatment follow-up; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ensure clinical investigators and clinical trial sites observe trial protocol or continue to participate in a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any patient safety concerns that arise during the course of a trial; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">address any conflicts with new or existing laws or regulations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add a sufficient number of clinical trial sites; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manufacture sufficient quantities at the required quality of product candidate for use in clinical trials; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">raise sufficient capital to fund a trial. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patient enrollment is a significant factor in the timing and success of
clinical trials and is affected by many factors, including the size and nature of the patient population, the proximity of patients to clinical sites, the eligibility criteria for the trial, the design of the clinical trial, competing clinical
trials and clinicians&#146; and patients&#146; or caregivers&#146; perceptions as to the potential advantages of the drug candidate being studied in relation to other available therapies, including any new drugs or treatments that may be developed
or approved for the indications we are investigating. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the
institutions in which such trials are being conducted, by the trial&#146;s data safety monitoring board, by the FDA or by the applicable foreign regulatory authorities. Such authorities may suspend or terminate one or more of our clinical trials due
to a number of factors, including our failure to conduct the clinical trial in accordance with relevant regulatory requirements or clinical protocols, inspection of the clinical trial operations or trial site by the FDA or foreign regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we experience delays in carrying out or completing any clinical trial of our product candidates, the commercial
prospects of our product candidates may be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our
product candidate development and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may significantly harm our business and financial condition. In addition, many of the factors
that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market opportunities for our product candidates may be limited to those patients who are ineligible for established therapies or for whom prior therapies have
failed, and may be small. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Cancer therapies are sometimes characterized as first-line, second-line or third-line. When cancer is detected early enough,
first-line therapy, often chemotherapy, hormone therapy, surgery, radiotherapy or a combination of these, is sometimes adequate to cure the cancer or prolong life. Second- and third-line therapies are administered to patients when prior therapy is
not or is no longer effective. For urothelial cancers, the current first-line standard of care is surgery designed to remove one or more tumors.&nbsp;Chemotherapy is currently used in treating urothelial cancer only as an adjuvant, or supplemental
therapy, after tumor resection.&nbsp;We are designing our lead product candidates with the goal of replacing surgery as the first-line standard of care for certain urothelial cancers. We intend to seek approval of MitoGel for the first-line
treatment of low-grade UTUC and of VesiGel for the first-line treatment of low-grade NMIBC in both cases as a chemoablation agent to replace tumor resection surgeries. However, there is no guarantee that our product candidates, if approved, would be
approved for first-line or even later lines of therapy, and, that prior to any such approvals, we will not have to conduct additional clinical trials. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers who have previously failed prior treatments, and who have the potential to benefit from treatment with our product
candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations or market research, and may prove to be incorrect. Further, new
studies may change the estimated incidence or prevalence of these cancers and the number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or
may not be amenable to treatment with our product candidates. Even if we receive regulatory approval for our product candidates and obtain significant market share, because the potential target populations are small, we may never achieve
profitability without obtaining regulatory approval for additional indications, including the use of the products as first- or second-line therapy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>MitoGel
or VesiGel or any of our other product candidates may produce undesirable side effects that we may not have detected in our previous preclinical studies and clinical trials. This could prevent us from gaining marketing approval or market acceptance
for these product candidates, or from maintaining such approval and acceptance, and could substantially increase commercialization costs and even force us to cease operations. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As with most pharmaceutical products, use of MitoGel or VesiGel or our other product candidates could be associated with side effects or adverse events that can vary in
severity and frequency. Our proprietary reverse thermal gelation hydrogel, or RTGel, which is used in the formulation of MitoGel and VesiGel, has not undergone extensive testing in humans. Side effects or adverse events associated with the use of
MitoGel and VesiGel may be observed at any time, including in clinical trials or once a product is commercialized, and any such side effects or adverse events may negatively affect our ability to obtain regulatory approval or market our product
candidates. To date in our clinical trials, we have observed several adverse events and serious adverse events, consisting primarily of burning sensation, rash, urgency in urination and pain during urination. These adverse events are known
MMC-related adverse events and are indicated as potential side effects of MMC usage on the MMC label. However, we cannot assure you that we will not observe additional drug-related serious adverse events in the future or that the FDA will not
determine them as such. Side effects such as toxicity or other safety issues associated with the use of our product candidates could require us to perform additional studies or halt development or sale of these product candidates or expose us to
product liability lawsuits, which will harm our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, the planned single pivotal Phase 3 clinical trial for MitoGel and the planned Phase 2b
clinical trial for VesiGel will involve a larger patient base than that previously studied, and the commercial marketing of MitoGel and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
VesiGel, if approved, will further expand the clinical exposure of the drugs to a wider and more diverse group of patients than those participating in the clinical trials, which may identify
undesirable side effects caused by these products that were not previously observed or reported. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and foreign regulatory agency regulations require that we
report certain information about adverse medical events if our products may have caused or contributed to those adverse events. The timing of our obligation to report would be triggered by the date upon which we become aware of the adverse event as
well as the nature and severity of the event. We may fail to report adverse events of which we become aware within the prescribed timeframe. We may also fail to appreciate that we have become aware of a reportable adverse event, especially if it is
not reported to us as an adverse event or if it is an adverse event that is unexpected or removed in time from the use of our products. If we fail to comply with our reporting obligations, the FDA or a foreign regulatory agency could take action
including enforcing a hold on or cessation of clinical trials, withdrawal of approved drugs from the market, criminal prosecution, the imposition of civil monetary penalties or seizure of our products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, in the event we discover the existence of adverse medical events or side effects caused by one of our product candidates, a number of other potentially
significant negative consequences could result, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our inability to file an NDA or similar application for our product candidates because of insufficient risk-reward, or the denial of such application by the FDA or foreign regulatory authorities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities suspending or withdrawing their approval of the product; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring the addition of labeling statements, such as warnings or contraindications or distribution and use restrictions; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities requiring us to issue specific communications to healthcare professionals, such as letters alerting them to new safety information about our product, changes in dosage or other
important information; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the FDA or foreign regulatory authorities issuing negative publicity regarding the affected product, including safety communications; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being limited respect to the safety-related claims that we can make in our marketing or promotional materials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being required to change the way the product is administered, conduct additional preclinical studies or clinical trials or restrict or cease the distribution or use of the product; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our being sued and held liable for harm caused to patients. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any of these events could prevent us from achieving
approval or market acceptance of the affected product candidate and could substantially increase commercialization costs or even force us to cease operations. We cannot assure you that we will resolve any issues related to any product-related
adverse events to the satisfaction of the FDA or any regulatory agency in a timely manner or ever, which could harm our business, prospects and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if our product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we are subject
to government regulations and we may experience delays in obtaining required regulatory approvals to market our proposed product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we
complete clinical testing and receive approval of any regulatory filing for our product candidates, the FDA or applicable foreign regulatory agency may grant approval contingent on the performance of additional costly post-approval clinical trials,
risk mitigation requirements and surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be
commercially viable. Absence of long-term safety data may further limit the approved uses of our products, if any. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA or applicable foreign regulatory agency
also may approve our product candidates for a more limited indication or a narrower patient population than we originally requested, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of
our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion,
distribution and recordkeeping. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to comply with the regulatory requirements of the FDA or other applicable foreign regulatory authorities, or
previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory agency refusal to approve pending applications or supplements to applications; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension of any ongoing clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or withdrawal of marketing approval; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an injunction or imposition of civil or criminal penalties or monetary fines; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">seizure or detention of products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bans or restrictions on imports and exports; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issuance of warning letters or untitled letters; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">suspension or imposition of restrictions on operations, including costly new manufacturing requirements; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal of regulatory authorities to approve pending applications or supplements to applications. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, various
aspects of our operations are subject to federal, state or local laws, rules and regulations, any of which may change from time to time. Costs arising out of any regulatory developments could be time-consuming and expensive and could divert
management resources and attention and, consequently, could adversely affect our business, financial condition, cash flows and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if
our product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and use and market acceptance necessary for commercial success. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if we obtain FDA or foreign regulatory approvals for our product candidates, the commercial success of such products will depend significantly on their broad
adoption and use by physicians, for approved indications, including, in the case of MitoGel, for the first-line treatment of low-grade UTUC, and in the case of VesiGel, for the first-line treatment of low-grade NMIBC, and for other therapeutic
indications that we may seek to pursue with any of our product candidates. Physicians treating low-grade UTUC and low-grade NMIBC have never had to consider first-line treatments other than surgery. The degree and rate of physician and patient
adoption of our product candidates, if approved, will depend on a number of factors, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical indications for which the product is approved; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevalence and severity of adverse side effects; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which physicians recommend our products to patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physicians&#146; and patients&#146; willingness to adopt new therapies in lieu of other products or treatments, including willingness to adopt our lead product candidates as locally-administered drug replacements to
current surgical standards of care; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the cost of treatment, safety and efficacy in relation to alternative treatments; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the extent to which the costs of our product candidates are reimbursed by third-party payors, and patients&#146; willingness to pay for our products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether treatment with our product candidates, including the treatment of low-grade UTUC with MitoGel and the treatment of low-grade NMIBC with VesiGel, will be deemed to be an elective procedure by third-party payors;
if so, the cost of treatment would be borne by the patient and would be less likely to be broadly adopted; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">proper training and administration of our products by physicians or nurses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the revenues and profitability that our products will offer physicians as compared to alternative therapies; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effectiveness of our sales and marketing efforts, especially the success of any targeted marketing efforts directed toward physicians, clinics and any direct-to-consumer marketing efforts we may initiate.
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If MitoGel, VesiGel or any of our other product candidates is approved for use, but fails to achieve the broad degree of
physician adoption and market acceptance necessary for commercial success, our operating results and financial condition would be adversely affected. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we
are not successful in developing, receiving regulatory approval for and commercializing our preclinical and clinical product candidates other than MitoGel or VesiGel, our ability to expand our business and achieve our strategic objectives could be
impaired. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we will devote a substantial portion of our resources on the continued clinical testing and potential approval of MitoGel for the
treatment of low-grade UTUC and VesiGel for the treatment of low-grade NMIBC, another key element of our strategy is to discover, develop and commercialize a portfolio of products based on our proprietary RTGel platforms to serve additional
therapeutic markets. We are seeking to do so through our internal research programs, but our resources are limited, and those that we have are geared towards clinical testing and seeking regulatory approval of MitoGel, VesiGel and our other existing
product candidates. We may also explore strategic collaborations for the development or acquisition of new products, but we may not be successful in entering into such relationships. While we expect our lead product candidates, MitoGel and VesiGel,
to commence a single pivotal Phase 3 clinical trial and a Phase 2b clinical trial, respectively, all of our other potential product candidates remain in the preclinical and/or early clinical stages of development. Research programs to identify
product candidates require substantial technical, financial and human resources, regardless of whether any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates,
yet fail to yield product candidates for clinical development for many reasons, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the research methodology used may not be successful in identifying potential product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">competitors may develop alternatives that render our product candidates obsolete or less attractive; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may in a subsequent trial be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a product candidate may not be accepted as safe and effective by patients, the medical community or third-party payors, if applicable; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">intellectual property or other proprietary rights of third parties for product candidates we develop may potentially block our entry into certain markets, or make such entry economically impracticable.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we fail to develop and successfully commercialize other product candidates, our business and future prospects may be harmed and our business will
be more vulnerable to any problems that we encounter in developing and commercializing our product candidates. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our product candidates, if approved, will face
significant competition with competing technologies and our failure to compete effectively may prevent us from achieving significant market penetration. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is intensely competitive and subject to rapid and significant technological change. Our potential competitors include large and
experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in
obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have existing drugs approved for use for the treatment of the indications that
we target. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that other companies, such as Merck Sharp &amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat Biologics, Inc., Viralytics
Limited, AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas Pharma Inc., Cold Genesys, Inc., Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd,&nbsp;Spectrum Pharmaceuticals, Inc., and&nbsp;Handok Inc., are
conducting or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including Carcinoma in Situ, or CIS. In addition, we are aware of several pharmaceutical companies that are developing
drug candidates for muscle-invasive bladder cancer. We do not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or treatments for other indications that we are pursuing,
and we may be unable to ascertain whether such activities are underway in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Competition may increase further as a result of advances in the commercial applicability of technologies and greater
availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from existing standards of treatment, including transurethral resection of bladder tumor, or TURBT, surgery for bladder cancer. If we
are not able to demonstrate that our product candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care, which is first-line
tumor surgical procedures. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have no experience in marketing or distributing products and no internal capability to do so, and are therefore subject to
certain risks in relation to the commercialization of our product candidates once approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have not yet established a commercial organization for the
marketing, sale and distribution of our product candidates. Therefore, even if we receive approval to market our product candidates in the United States or other markets, in order to successfully commercialize our product candidates, we will need to
either build marketing, sales, distribution, managerial and other non-technical capabilities or contract with third parties to obtain these capabilities. This involves many challenges, such as recruiting and retaining talented personnel, training
employees, setting the appropriate system of incentives, managing additional headcount and integrating new business units into an existing corporate infrastructure. The development of our own sales infrastructure or contracting with third parties
will involve substantial expense, much of which we will incur well in advance of any marketing or sales. Moreover, we do not have experience as a company in establishing a significant sales infrastructure, and we cannot be certain that we will
successfully develop this capability or contract successfully with third parties for the necessary services. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain personnel for medical
affairs, marketing and sales. If we fail to establish an effective sales and marketing infrastructure or contract with third parties to do so, we will be unable to successfully commercialize our product candidates, which in turn would have an
adverse effect on our business, financial condition and results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If in the future we acquire or in-license technologies or product candidates,
we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the
future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive
preclinical or clinical testing, or both, and approval by the FDA and applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility
that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies
we in-license is not adequate, we may not be able to commercialize the affected products even after expending resources on their development. In addition, we may not be able to manufacture economically or successfully commercialize any product
candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such products may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed
product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may be materially harmed. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We currently contract with third-party subcontractors and single-source suppliers for certain raw materials, compounds and components necessary to produce
MitoGel, VesiGel, Vesimune and BotuGel for preclinical studies and clinical trials and expect to continue to do so to support commercial scale production of MitoGel, VesiGel, Vesimune or BotuGel, if approved. This increases the risk that we will not
have sufficient quantities of MitoGel, VesiGel, Vesimune or BotuGel or be able to obtain such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently rely on third party subcontractors and suppliers for certain compounds and components necessary to produce MitoGel, VesiGel, Vesimune and BotuGel for our
preclinical studies and clinical trials. We currently depend on single sources for MMC and gel for MitoGel and VesiGel, and Imiquimod for Vesimune. Because there are a limited number of suppliers for the raw materials that we use to manufacture our
product candidates, we may need to engage alternate suppliers to prevent a possible disruption of the manufacture of the materials necessary to produce our product candidates for our clinical trials, and if approved, ultimately for commercial sale.
We do not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
have any control over the availability of raw materials. If we or our manufacturers are unable to purchase these raw materials on acceptable terms, at sufficient quality levels, or in adequate
quantities, if at all, the development and commercialization of our product candidates or any future product candidates, would be delayed or there would be a shortage in supply, which would impair our ability to meet our development objectives for
our product candidates or generate revenues from the sale of any approved products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to continue to rely on these or other subcontractors and suppliers to
support our commercial requirements if MitoGel, VesiGel or any of our other product candidates is approved for marketing by the FDA or foreign regulatory authorities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reliance on third party subcontractors and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance,
the possible breach of the manufacturing or supply agreement by the third party, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. In addition, third party subcontractors
and suppliers may not be able to comply with cGMP or quality system regulation, also called QSR, or similar regulatory requirements outside the United States. If any of these risks transpire, we may be unable to timely retain alternate
subcontractors or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our failure or the failure of our third-party subcontractors and suppliers to comply with applicable regulations could result in sanctions being imposed on us,
including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely
affect supplies of MitoGel, VesiGel or any of our other product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for MitoGel, VesiGel or any other product candidates or products that we
may develop could delay, prevent or impair our clinical development or commercialization efforts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Failure to obtain marketing approval in international
jurisdictions would prevent our product candidates from being marketed abroad. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order to market and sell our products in the European Union and other
jurisdictions, we or our third-party collaborators must obtain separate marketing approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time
required to obtain approval may differ substantially from that required to obtain FDA approval. Regulatory approval processes outside the United States generally includes all of the risks associated with obtaining FDA approval. In addition, in many
countries outside the United States, it is required that the product be approved for reimbursement before the product can be approved for sale in that country. We may not obtain approvals from regulatory authorities outside the United States on a
timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory
authorities in other countries or jurisdictions or by the FDA. We may not be able to file for marketing approvals and may not receive the necessary approvals to commercialize our product candidates in any particular market. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We intend to rely on third parties and consultants to assist us in conducting our single pivotal Phase 3 clinical trial for MitoGel, our Phase 2b clinical trial
for VesiGel and certain clinical trials for our other product candidates. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or
commercialize MitoGel, VesiGel or any of our other product candidates. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have the ability to independently conduct many of our preclinical studies
or our clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, and other third parties, such as CROs to conduct clinical trials on our product candidates. Third parties play a significant role in the conduct
of our clinical trials and the subsequent collection and analysis of data. These third parties are not our employees, and except for remedies available to us under our agreements, we have limited ability to control the amount or timing of resources
that any such third party will devote to our clinical trials. Due to the limited drug development for urothelial cancers over the past 15 years, neither we nor any third-party clinical investigators, CROs and/or consultants are likely to have
extensive experience conducting clinical trials for the indications we are targeting. If our CROs or any other third parties upon which we rely for administration and conduct of our clinical trials do not successfully carry out their
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to
adhere to our clinical protocols, regulatory requirements, or for other reasons, or if they otherwise perform in a substandard manner, our clinical trials may be extended, delayed, suspended or terminated, and we may not be able to complete
development of, obtain regulatory approval for, or successfully commercialize our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We and the third parties upon whom we rely are required to
comply with Good Clinical Practice, or GCP, regulations, which are regulations and guidelines enforced by regulatory authorities around the world for products in clinical development. Regulatory authorities enforce these GCP regulations through
periodic inspections of clinical trial sponsors, principal investigators and clinical trial sites. If we or our third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be deemed unreliable
and our submission of marketing applications may be delayed or the regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, a regulatory
authority will determine that any of our clinical trials comply or complied with applicable GCP regulations. In addition, our clinical trials must be conducted with material produced under current cGMP regulations, which are enforced by regulatory
authorities. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be impacted if our CROs, clinical investigators or other third parties
violate federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In order for our clinical trials to be
carried out effectively and efficiently, it is imperative that our CROs and other third parties communicate and coordinate with one another. Moreover, our CROs and other third parties may also have relationships with other commercial entities, some
of which may compete with us. Our CROs and other third parties may terminate their agreements with us upon as few as 30 days&#146; notice under certain circumstances. If our CROs or other third parties conducting our clinical trials do not perform
their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the
failure to adhere to our clinical trial protocols or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative CROs, clinical investigators or other third parties. We may be
unable to enter into arrangements with alternative CROs on commercially reasonable terms, or at all. Switching or adding CROs, clinical investigators or other third parties can involve substantial cost and require extensive management time and
focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays may occur, which can impact our ability to meet our desired clinical development timelines. Although we carefully manage our relationship
with our CROs, clinical investigators and other third parties, there can be no assurance that we will not encounter such challenges or delays in the future or that these delays or challenges will not have a negative impact on our business,
prospects, financial condition or results of operations </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our ability to market our product candidates, if approved, will be limited to certain indications. If
we want to expand the indications for which we may market our products, we will need to obtain additional regulatory approvals, which may not be granted. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently developing MitoGel for the treatment of low-grade UTUC, VesiGel and Vesimune for the treatment of bladder cancer and BotuGel for the treatment of
overactive bladder and interstitial cystitis. The FDA and other applicable regulatory agencies will restrict our ability to market or advertise our products to the scope of the approved label for the applicable product and for no other indications,
which could limit physician and patient adoption. We may attempt to develop and, if approved, promote and commercialize new treatment indications for our products in the future, but we cannot predict when or if we will receive the regulatory
approvals required to do so. Failure to receive such approvals will prevent us from promoting or commercializing new treatment indications. In addition, we would be required to conduct additional clinical trials or studies to support approvals for
additional indications, which would be time consuming and expensive, and may produce results that do not support regulatory approvals. If we do not obtain additional regulatory approvals, our ability to expand our business will be limited. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our product candidates are approved for marketing, and we are found to have improperly promoted off-label uses,
or if physicians misuse our products, we may become subject to prohibitions on the sale or marketing of our products, significant sanctions, product liability claims, and our image and reputation within the industry and marketplace could be harmed.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and other regulatory agencies strictly regulate the marketing and promotional claims that are made about drug products. In particular, a product
may not be promoted for uses or indications that are not approved by the FDA or such other regulatory agencies as reflected in the product&#146;s approved labeling. For example, if we receive marketing approval for MitoGel for treatment of low-grade
UTUC, the first indication we are pursuing, we cannot promote the use of our product in a manner that is inconsistent with the approved label. However, physicians are able, in their independent medical judgment, to use MitoGel on their patients in
an off-label manner, such as for the treatment of other urology indications. If we are found to have promoted such off-label uses, we may receive warning letters and become subject to significant liability, which would harm our business. The federal
government has levied large administrative, civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. If we become the target of such an investigation or
prosecution based on our marketing and promotional practices, we could face similar sanctions, which would harm our business. In addition, management&#146;s attention could be diverted from our business operations, significant legal expenses could
be incurred, and our reputation could be damaged. The FDA has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we are deemed by the FDA to have
engaged in the promotion of our products for off-label use, we could be subject to prohibitions on the sale or marketing of our products or significant fines and penalties, and the imposition of these sanctions could also affect our reputation with
physicians, patients and caregivers, and our position within the industry. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Physicians may also misuse our products or use improper techniques, potentially leading
to adverse results, side effects or injury, which may lead to product liability claims. If our products are misused or used with improper technique, we may become subject to costly litigation. Product liability claims could divert management&#146;s
attention from our core business, be expensive to defend, and result in sizable damage awards against us that may not be covered by insurance. We currently carry product liability insurance covering our clinical trials with policy limits that we
believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an
amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Furthermore, the use of our products for conditions other than those approved by the FDA may not effectively treat such
conditions, which could harm our reputation in the marketplace among physicians and patients. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to manage our growth effectively, our business could
be disrupted. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2015, we had 24 full-time employees and four part-time employees, of which all except one are based in Israel. We
will need to continue to expand our development, quality, sales, managerial, operational, finance, marketing and other resources to manage our operations and clinical trials, continue our development activities and commercialize our product
candidates, if approved. Our management, personnel, systems and facilities currently in place may not be adequate to support this future growth. Our need to effectively execute our expansion strategy requires that we: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our clinical trials effectively; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">identify, recruit, retain, incentivize and integrate additional employees; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">manage our internal development efforts effectively while carrying out our contractual obligations to third parties; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue to improve our operational, financial and management controls, reporting systems and procedures. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to our
limited financial resources and our limited experience in managing a larger company, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The physical expansion of our
operations may lead to significant costs and may divert our management and business development resources. Any inability to manage expansion could delay the execution of our development and strategic objectives,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
or disrupt our operations; and if we are not successful in commercializing our product candidates, either on our own or through collaborations with one or more third parties, our revenues will
suffer and we would incur significant additional losses. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If product liability lawsuits are brought against us, we may incur substantial liabilities and may
be required to limit commercialization of any of our other products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We face an inherent risk of product liability as a result of the clinical
testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if any product we develop allegedly causes injury or is found to be otherwise unsuitable during product testing,
manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability and a breach of
warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our
products. Even a successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">decreased demand for our product candidates or products we develop; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injury to our reputation and significant negative media attention; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">withdrawal of clinical trial participants or cancellation of clinical trials; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">costs to defend the related litigation, which may be only partially recoverable even in the event of successful defenses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a diversion of management&#146;s time and our resources; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">substantial monetary awards to trial participants or patients; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory investigations, product recalls, withdrawals or labeling, marketing or promotional restrictions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">loss of revenues; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exhaustion of any available insurance and our capital resources; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the inability to commercialize any product we develop. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our inability to obtain and maintain sufficient product
liability insurance at an acceptable cost and scope of coverage to protect against potential product liability claims could prevent or inhibit the commercialization of products we may develop. We currently carry general clinical trial product
liability insurance in an amount that we believe is adequate to cover the scope of our ongoing clinical programs. Although we maintain such insurance, any claim that may be brought against us could result in a court judgment or settlement in an
amount that is not covered, in whole or in part, by our insurance or that is in excess of the limits of our insurance coverage. Our insurance policies also have various exclusions and deductibles, and we may be subject to a product liability claim
for which we have no coverage. We will have to pay any amounts awarded by a court or negotiated in a settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient
capital to pay such amounts. Moreover, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses. If and when we obtain approval for marketing MitoGel, VesiGel or any
other product candidate, we intend to expand our insurance coverage to include the commercialization of MitoGel, VesiGel or any other approved product that we may have; however, we may be unable to obtain this liability insurance on commercially
reasonable terms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to attract and keep senior management and key scientific personnel, we may be unable to successfully develop our product
candidates, conduct our clinical trials and commercialize any of the products we develop. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our success depends in part on our continued ability to attract,
retain and motivate highly qualified management, clinical and scientific personnel. We believe that our future success is highly dependent upon the contributions of members of our senior management, as well as our senior scientists and other members
of our management team. The loss of services of any of these individuals could delay or prevent the successful development of our product pipeline, completion of our planned clinical trials or the commercialization of our product candidates. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we have not historically experienced unique difficulties in attracting and retaining qualified employees, we could experience such problems in the future. For
example, competition for qualified personnel in the pharmaceutical field is intense due to the limited number of individuals who possess the skills and experience required by our industry. We will need to hire additional personnel as we expand our
clinical development and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
commercial activities. We may not be able to attract and retain quality personnel on acceptable terms, or at all. In addition, to the extent we hire personnel from competitors, we may be subject
to allegations that they have been improperly solicited or that they have divulged proprietary or other confidential information, or that their former employers own their research output. Moreover, although we have established a U.S. subsidiary, we
are domiciled in Israel and are predominantly based in Israel, which may make it difficult to hire necessary U.S.-based personnel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our internal computer
systems, or those of our CROs or other contractors or consultants, may fail or suffer security breaches, which could result in a disruption of our drug development programs. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Despite the implementation of security measures, our internal computer systems and those of our CROs and other contractors and consultants are vulnerable to damage from
cyber-security threats, including computer viruses, harmful code and unauthorized access, natural disasters, fire, terrorism, war and telecommunication and electrical failures. If a disruption event were to occur and cause interruptions in our
operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed, ongoing or planned clinical trials could result in delays in our regulatory approval efforts and
significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach results in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary
information, we could incur liability and the further development of our product candidates could be delayed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Under applicable employment laws, we may not be
able to enforce covenants not to compete. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We generally enter into non-competition agreements as part of our employment agreements with our employees. These
agreements generally prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors or clients for a limited period. We may be unable to enforce these agreements under the laws of the
jurisdictions in which our employees work and it may be difficult for us to restrict our competitors from benefitting from the expertise our former employees or consultants developed while working for us. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, Israeli labor courts have required employers seeking to enforce non-compete undertakings of a former employee to demonstrate that the competitive
activities of the former employee will harm one of a limited number of material interests of the employer which have been recognized by the courts as justification for the enforcement of non-compete undertakings, such as the protection of a
company&#146;s trade secrets or other intellectual property. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our employees, independent contractors, clinical investigators, CROs, consultants and vendors
may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are
exposed to the risk that our employees, independent contractors, clinical investigators, CROs, consultants and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or
negligent conduct, breach of contract or disclosure of unauthorized activities to us that violates: FDA regulations, including those laws requiring the reporting of true, complete and accurate information to the FDA; manufacturing standards;
federal, state and foreign healthcare fraud and abuse laws; or laws that require the reporting of financial information or data accurately. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Specifically, research,
sales, marketing, education and other business arrangements in the healthcare industry are subject to extensive laws intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a
wide range of pricing, discounting, education, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities subject to these laws also involve the improper use of information obtained in the
course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. We intend to adopt a code of business conduct and ethics, but it is not always possible to identify and deter misconduct by employees and other
third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a
failure to be in compliance with such laws. If any such actions are instituted against us, even if we are successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business. Violations of such
laws subject us to numerous penalties, including, but not limited to, the imposition of civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare,
Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our
results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">30 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our business involves the use of hazardous materials and we and our third party manufacturers and suppliers must
comply with environmental laws and regulations, which can be expensive and restrict how we do business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our research and development activities and our
third party subcontractors&#146; and suppliers&#146; activities involve the controlled storage, use and disposal of hazardous materials owned by us, including Mitomycin C, or MMC, key components of our product candidates, and other hazardous
compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling and disposal of these hazardous materials. Despite our efforts, we cannot eliminate the risk of contamination.
This could cause an interruption of our commercialization efforts and business operations, environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling and disposal of
these materials and specified waste products. Although we believe that the safety procedures utilized by us and our subcontractors and suppliers for handling and disposing of these materials generally comply with the standards prescribed by these
laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our
resources and state or federal or other applicable authorities may curtail our use of certain materials and interrupt our business operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore,
environmental laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance.</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exchange rate fluctuations between the U.S. Dollar and the New Israeli Shekel may negatively affect our earnings. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and reporting currency. However, a significant portion of our operating expenses are incurred in New Israeli Shekels, or NIS, which is
the lawful currency of the State of Israel. As a result, we are exposed to the risks that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar, that the inflation rate in Israel may exceed such rate
of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our dollar-denominated results of operations would be adversely
affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation (if any) of the NIS against the dollar. For example, although the dollar appreciated against the NIS in 2011, the rate of devaluation
(inflation) of the dollar against the NIS was (7)% and 12% in 2013 and 2014, respectively, which was compounded by inflation in Israel at a rate of (0.1)% and (0.2)%, respectively. If the dollar cost of our operations in Israel increases, our
dollar-measured results of operations will be adversely affected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Our Intellectual Property </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If our efforts to obtain, protect or enforce our patents and other intellectual property rights related to our product candidates and technologies are not
adequate, we may not be able to compete effectively and we otherwise may be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part upon our ability to obtain and
maintain patent protection and utilize trade secret protection for our intellectual property and proprietary technologies, our products and their uses, as well as our ability to operate without infringing upon the proprietary rights of others. We
rely upon a combination of patents, trade secret protection and confidentiality agreements, assignment of invention agreements and other contractual arrangements to protect the intellectual property related to hydrogel-based pharmaceutical
compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating overactive bladder and interstitial cystitis topically without
the need for injections, an in-dwelling ureter catheter system for optimal delivery of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of
bladder diseases. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We seek patent protection for all of our product candidates, and we have established several patent families comprised of issued patents and
pending patent applications covering our proprietary RTGel formulation technology and the formulations, methods of use and manufacturing aspects of our product candidates. In the United States, we currently have three granted patents related to
methods, systems and compositions for treating bladder cancer that relate to the product candidates RTGel, MitoGel and VesiGel and one patent claim related to our RTGel formulation, which are expected to remain in effect until between 2024 and 2030.
We also have five pending patent applications relating to the product candidates MitoGel and VesiGel in Europe, the United States and Israel, and five </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">31 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
pending patent applications relating to the product candidate BotuGel in the United States and the European Union, as well as in each of Russia, China and Israel. In addition, we have
two&nbsp;granted patents related to Vesimune in the United States as well as granted patents in the European Union, Japan, Australia, Mexico and China, each of which is expected to remain in effect until 2031. In addition to the issued patents
mentioned above, our portfolio includes pending patent applications relating to Vesimune in the United States, the European Union, Canada, Korea, Brazil, Israel, Hong Kong and Japan. Moreover, we hold four granted patents in the United States as
well as patent applications filed worldwide that relate to novel formulations of phospholipid drug analogs (saturated lipid conjugate compositions) for the treatment of urinary tract cancer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Limitations on the scope of our intellectual property rights may limit our ability to prevent third parties from designing around such rights and competing against us.
For example, our patents do not claim a new compound. Rather, the active pharmaceutical ingredients of our products are existing compounds and our granted patents and pending patent applications are directed to, among other things, novel
formulations of these existing compounds with our RTGel. Accordingly, other parties may compete with us, for example, by independently developing or obtaining competing topical formulations that design around our patent claims, but which may contain
the same active ingredients, or by seeking to invalidate our patents. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological
achievements, eroding our competitive position in the market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">However, the patent applications that we own or license may fail to result in granted patents in the
United States or foreign jurisdictions, or if granted may fail to prevent a potential infringer from marketing its product or be deemed invalid and unenforceable by a court. Competitors in the field of reverse thermal gel therapies have created a
substantial amount of scientific publications, patents and patent applications and other materials relating to their technologies. Our ability to obtain and maintain valid and enforceable patents depends on various factors, including interpretation
of our technology and the prior art and whether the differences between them allow our technology to be patentable. Patent applications and patents granted from them are complex, lengthy and highly technical documents that are often prepared under
very limited time constraints and may not be free from errors that make their interpretation uncertain. The existence of errors in a patent may have an adverse effect on the patent, its scope and its enforceability. Our pending patent applications
may not issue, and the scope of the claims of patent applications that do issue may be too narrow to adequately protect our competitive advantage. Also, our granted patents may be subject to challenges or narrowly construed and may not provide
adequate protection. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that we infringe, misappropriate or otherwise violate the intellectual property rights&nbsp;of third
parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if our patents do successfully issue, third parties may challenge the validity, enforceability or scope of such granted patents or any other
granted patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be opposed by any person within nine months from the publication of
their grant. Also, patents granted by the United States Patent and Trademark Office, or USPTO, may be subject to reexamination and other challenges. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore,
even if they are not challenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing around our claims. To meet such challenges, which are part of the risks and uncertainties of
developing and marketing product candidates, we may need to evaluate third party intellectual property rights and, if appropriate, to seek licenses for such third party intellectual property or to challenge such third party intellectual property,
which may be costly and may or may not be successful, which could also have an adverse effect on the commercial potential for MitoGel, VesiGel and any of our product candidates. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may receive only limited protection, or no protection, from our issued patents and patent applications. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we encounter delays in our clinical trials or regulatory approval of our product candidates, the period of time during which we could market any of our product
candidates under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any
patent application related to hydrogel-based pharmaceutical compositions for optimal delivery of a drug in internal cavities such as the bladder, the method for treating urothelial cancer using hydrogel-based compositions, the method for treating
overactive bladder and interstitial cystitis topically without the need for injections, an in-dwelling ureter catheter system for optimal delivery </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">32 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
of a drug into the renal cavity, and pharmaceutical compositions comprising an imidazoquinolin (amine) and lactic acid for use in a method for the treatment of bladder diseases or any of our
product candidates or (ii) conceive and invent any of the inventions claimed in our patents or patent applications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The patent application process, also known as
patent prosecution, is expensive and time consuming, and we and or any future licensors and licensees may not be able to prepare, file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is
also possible that we or any future licensors or licensees will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them.
Therefore, these and any of our patents and applications may not be prosecuted and<B> </B>enforced in a manner consistent with the best interests of our business. It is possible that defects of form in the preparation or filing of our patents or
patent applications may exist, or may arise in the future, for example with respect to proper priority claims, inventorship, etc., although we are unaware of any such defects that we believe are of material import. If we or any future licensors or
licensees fail to establish, maintain or protect such patents and other intellectual property rights, such rights may be reduced or eliminated. If any future licensors or licensees, are not fully cooperative or disagree with us as to the
prosecution, maintenance or enforcement of any patent rights, such patent rights could be compromised. If there are material defects in the form or preparation of our patents or patent applications, such patents or applications may be invalid and
unenforceable. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
strength of patents in the pharmaceutical field involves complex legal and scientific questions and can be uncertain. This uncertainty includes changes to the patent laws through either legislative action to change statutory patent law or court
action that may reinterpret existing law in ways affecting the scope or validity of issued patents. The patent applications that we own or in-license may fail to result in issued patents in the United States or foreign countries with claims that
cover our product candidates. Even if patents do successfully issue from the patent applications that we own or in-license, third parties may challenge the validity, enforceability or scope of such patents, which may result in such patents being
narrowed, invalidated or held unenforceable. For example, patents granted by the European Patent Office may be challenged, also known as opposed, by any person within nine months from the publication of their grant. Any successful challenge to our
patents could deprive us of exclusive rights necessary for the successful commercialization of our product candidates. Furthermore, even if they are unchallenged, our patents may not adequately protect our product candidates, provide exclusivity for
our product candidates, or prevent others from designing around our claims. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from
collaborating with us to develop, or threaten our ability to commercialize our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patents have a limited lifespan. In the United States, the
natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available; however the life of a patent, and the protection it affords, is limited. Without patent protection for our product candidates, we may be
open to competition from generic versions of our product candidates. Further, if we encounter delays in our development efforts, including our clinical trials, the period of time during which we could market our product candidates under patent
protection would be reduced. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A considerable number of our patents and patent applications are entitled to effective filing dates prior to March&nbsp;16, 2013. For
U.S. patent applications in which patent claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party, for example a competitor, or instituted by the USPTO to determine who was the first
to invent any of the subject matter covered by those patent claims. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights from the prevailing party. Our business could be harmed if the
prevailing party does not offer us a license on commercially reasonable terms. Our participation in an interference proceeding may fail and, even if successful, may result in substantial costs and distract our management. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our trade secrets may not have sufficient intellectual property protection. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to the protection afforded by patents, we also rely on trade secret protection to protect proprietary know-how that may not be patentable or that we elect
not to patent, processes for which patents may be difficult to obtain or enforce, and any other elements of our product candidates, and our product development processes (such as a manufacturing and formulation technologies) that involve proprietary
know-how, information or technology that is not </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">33 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
covered by patents. However, trade secrets can be difficult to protect. If the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third
parties for misappropriating any trade secrets. Misappropriation or unauthorized disclosure of our trade secrets could significantly affect our competitive position and may have an adverse effect on our business. Furthermore, trade secret protection
does not prevent competitors from independently developing substantially equivalent information and techniques and we cannot guarantee that our competitors will not independently develop substantially equivalent information and techniques. The FDA,
as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is
not clear at the present time how the FDA&#146;s disclosure policies may change in the future, if at all. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In an effort to protect our trade secrets and other
confidential information, we require our employees, consultants, advisors, and any other third parties that have access to our proprietary know-how, information or technology, for example, third parties involved in the formulation and manufacture of
our product candidates, and third parties involved in our clinical trials to execute confidentiality agreements upon the commencement of their relationships with us. These agreements require that all confidential information developed by the
individual or made known to the individual by us during the course of the individual&#146;s relationship with us is kept confidential and not disclosed to third parties. However, we cannot be certain that our trade secrets and other confidential
proprietary information will not be disclosed despite having such confidentiality agreements. Adequate remedies may not exist in the event of unauthorized use or disclosure of our trade secrets. In addition, in some situations, these confidentiality
agreements may conflict with, or be subject to, the rights of third parties with whom our employees, consultants, or advisors have previous employment or consulting relationships. To the extent that our employees, consultants or contractors use any
intellectual property owned by third parties in their work for us, disputes may arise as to the rights in any related or resulting know-how and inventions. If we are unable to prevent unauthorized material disclosure of our trade secrets to third
parties, we may not be able to establish or maintain a competitive advantage in our market, which could harm our business, operating results and financial condition. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As is the case with other pharmaceutical companies, our success is heavily dependent on intellectual property, particularly on obtaining and enforcing patents.
Obtaining and enforcing patents in the pharmaceutical industry involves both technological and legal complexity, and therefore, is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently
implementing wide-ranging patent reform legislation. Further, recent U.S. Supreme Court rulings have either narrowed the scope of patent protection available in certain circumstances or weakened the rights of patent owners in certain situations. In
addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. In
September 2011, the Leahy-Smith America Invents Act, or the American Invents Act, or AIA, was signed into law. The AIA includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be
prosecuted and may also affect patent litigation. The USPTO is currently developing regulations and procedures to govern administration of the AIA, and many of the substantive changes to patent law associated with the AIA. It is not clear what
other, if any, impact the AIA will have on the operation of our business. Moreover, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of
our issued patents, all of which could harm our business and financial condition. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An important change introduced by the AIA is that, as of March 16, 2013, the
United States transitioned to a &#147;first-to-file&#148; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent
application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we had made the invention before it was made by the third party. This will require us to be cognizant going forward of
the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">34 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the
first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third
parties to challenge any issued patent in the USPTO. This applies to all of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in United States
federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim
if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a
district court action. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in
unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by
governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The USPTO and various
foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent prosecution process. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Periodic maintenance fees and various other governmental fees on any issued patent and/or pending patent applications are due to be paid to the USPTO and foreign patent
agencies in several stages over the lifetime of a patent or patent application. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees. While an inadvertent lapse may
sometimes be cured by payment of a late fee or by other means in accordance with the applicable rules, there are many situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or
complete loss of patent rights in the relevant jurisdiction. If we fail to maintain the patents and patent applications directed to our product candidates, our competitors might be able to enter the market earlier than should otherwise have been the
case, which could harm our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Filing, prosecuting and defending patents on our product candidates in all countries throughout the world would be prohibitively expensive. The requirements for
patentability may differ in certain countries, particularly developing countries. For example, unlike other countries, China has a heightened requirement for patentability, and specifically requires a detailed description of medical uses of a
claimed drug. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in
all countries outside the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we
have patent protection, but enforcement on infringing activities is inadequate. These products may compete with our products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of
certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the
infringement of our patents or marketing of competing products in violation of our proprietary rights generally. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Proceedings to enforce our patent rights in
foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not
issuing, and could provoke third parties to assert </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">35 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. In addition, certain countries in
Europe and certain developing countries, including India and China, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In those countries, we may have limited remedies if our patents are
infringed or if we are compelled to grant a license to our patents to a third party, which could materially diminish the value of those patents. This could limit our potential revenue opportunities. Accordingly, our efforts to enforce our
intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own or license. Finally, our ability to protect and enforce our intellectual property rights may be
adversely affected by unforeseen changes in foreign intellectual property laws. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we are unable to protect our trademarks from infringement, our business
prospects may be harmed. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We own trademarks that identify MitoGel, VesiGel, Vesimune and BotuGel and have registered these trademarks in the United States
and Israel. Although we take steps to monitor the possible infringement or misuse of our trademarks, it is possible that third parties may infringe, dilute or otherwise violate our trademark rights. Any unauthorized use of our trademarks could harm
our reputation or commercial interests. In addition, our enforcement against third-party infringers or violators may be unduly expensive and time-consuming, and the outcome may be an inadequate remedy. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become involved in lawsuits to protect or enforce our patents or other intellectual property or the patents of our licensors, which could be expensive and
time consuming. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties may infringe or misappropriate our intellectual property, including our existing patents, patents that may issue to us in the
future, or the patents of our licensors to which we have a license. As a result, we may be required to file infringement claims to stop third-party infringement or unauthorized use. Further, we may not be able to prevent, alone or with our
licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generic drug manufacturers may develop, seek approval for, and launch generic versions of our products. If we file an infringement action against such a generic drug
manufacturer, that company may challenge the scope, validity or enforceability of our or our licensors&#146; patents, requiring us and/or our licensors to engage in complex, lengthy and costly litigation or other proceedings. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, if we or one of our licensors initiated legal proceedings against a third party to enforce a patent covering our product candidates, the defendant could
counterclaim that the patent covering our product candidates is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous
grounds upon which a third party can assert invalidity or unenforceability of a patent. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, within and outside of the United States, there has been a
substantial amount of litigation and administrative proceedings, including interference and reexamination proceedings before the USPTO or oppositions and other comparable proceedings in various foreign jurisdictions, regarding patent and other
intellectual property rights in the pharmaceutical industry. Recently, the AIA introduced new procedures including <I>inter partes</I> review and post grant review. The implementation of these procedures brings uncertainty to the possibility of
challenges to our patents in the future, including those that patents perceived by our competitors as blocking entry into the market for their products, and the outcome of such challenges. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such litigation and administrative proceedings could result in revocation of our patents or amendment of our patents such that they do not cover our product candidates.
They may also put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope to cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is
unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we and the patent examiner were unaware during prosecution. Additionally, it is also possible that prior art of
which we are aware, but which we do not believe affects the validity or enforceability of a claim, may, nonetheless, ultimately be found by a court of law or an administration panel to affect the validity or enforceability of a claim. If a defendant
were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a negative impact on our
business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">36 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcing our or our licensor&#146;s intellectual property rights through litigation is very expensive, particularly for a
company of our size, and time-consuming. Some of our competitors may be able to sustain the costs of litigation more effectively than we can because of greater financial resources. Patent litigation and other proceedings may also absorb significant
management time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the
marketplace. The occurrence of any of the foregoing could harm our business, financial condition or results of operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, because of the substantial
amount of discovery required in connection with intellectual property litigation or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, during the course of
litigation or administrative proceedings, there could be public announcements of the results of hearings, motions or other interim proceedings or developments or public access to related documents. If investors perceive these results to be negative,
the market price for our ordinary shares could be significantly harmed. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may become subject to claims for remuneration or royalties for assigned service
invention rights by our employees, which could result in litigation and adversely affect our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A significant portion of our intellectual property
has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company are regarded as
&#147;service inventions.&#148; The Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, has previously held, in certain cases, that employees may be entitled to remuneration for service inventions
that they develop during their service for a company despite their explicit waiver of such right. Therefore, although we enter into agreements with all of our employees pursuant to which they waive their right to special remuneration for service
inventions created in the scope of their employment or engagement and agree that any such inventions are owned exclusively by us, we may face claims by employees demanding remuneration beyond their regular salary and benefits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Third party claims alleging intellectual property infringement may adversely affect our business. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties, for example, the intellectual property
rights of competitors. Our research, development and commercialization activities may be subject to claims that we infringe or otherwise violate patents owned or controlled by third parties. Numerous U.S. and foreign issued patents and pending
patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our
activities related to our product candidates may give rise to claims of infringement of the patent rights of others. We cannot assure you that our product candidates will not infringe existing or future patents. We may not be aware of patents that
have already issued that a third party might assert are infringed by our product candidates. It is also possible that patents of which we are aware, but which we do not believe are relevant to our product candidates, could nevertheless be found to
be infringed by our product candidates. Nevertheless, we are not aware of any issued patents that we believe would prevent us from marketing our product candidates, if approved. There may also be patent applications that have been filed but not
published that, when issued as patents, could be asserted against us. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Third parties making claims against us for infringement or misappropriation of their
intellectual property rights may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Further, if a patent infringement suit were brought against
us, we could be forced to stop or delay research, development, manufacturing or sales of the product or product candidate that is the subject of the suit. Defense of these claims, regardless of their merit, would cause us to incur substantial
expenses and, and would be a substantial diversion of management time and employee resources from our business. In the event of a successful claim of infringement against us by a third party, we may have to (i) pay substantial damages, including
treble damages and attorneys&#146; fees if we are found to have willfully infringed the third party&#146;s patents; (ii) obtain one or more licenses from the third party; (iii) pay royalties to the third party; and/or (iv) redesign any infringing
products. Redesigning any infringing products may be impossible or require substantial time and monetary expenditure. Further, we cannot predict whether any required license would be available at all or whether it would be available on commercially
reasonable terms. In the event that we could not obtain a license, we may be unable to further develop and commercialize our product candidates, which could harm our business significantly. Even if we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">37 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
are able to obtain a license, the license would likely obligate us to pay license fees or royalties or both, and the rights granted to us might be nonexclusive, which could result in our
competitors gaining access to the same intellectual property. Ultimately, we could be prevented from commercializing a product, or be forced to cease some aspect of our business operations, if, as a result of actual or threatened patent infringement
claims, we are unable to enter into licenses on acceptable terms. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Defending ourselves or our licensors in litigation is very expensive, particularly for a company
of our size, and <FONT STYLE="white-space:nowrap">time-consuming.</FONT> Some of our competitors may be able to sustain the costs of litigation or administrative proceedings more effectively than we can because of greater financial resources. Patent
litigation and other proceedings may also absorb significant management time. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could impair our ability to compete in the marketplace. The
occurrence of any of the foregoing could harm our business, financial condition or results of operations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be subject to claims that our employees,
consultants or independent contractors have wrongfully used or disclosed confidential information of third parties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We employ individuals who were
previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise improperly used or disclosed confidential
information of these third parties or our employees&#146; former employers. Further, we may be subject to ownership disputes in the future arising, for example, from conflicting obligations of consultants or others who are involved in developing our
product candidates. We may also be subject to claims that former employees, consultants, independent contractors, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be
necessary to defend against these and other claims challenging our right to and use of confidential and proprietary information. If we fail in defending any such claims, in addition to paying monetary damages, we may lose our rights therein. Such an
outcome could have a negative impact on our business. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If the FDA does not conclude
that MitoGel, VesiGel, BotuGel or our other product candidates satisfy the requirements under Section 505(b)(2) of the Federal Food Drug and Cosmetic Act, or Section 505(b)(2), or a similar regulatory pathway for biologics as it relates to BotuGel,
or if the requirements for such product candidates are not as we expect, the approval pathway for these product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than
anticipated, and in either case may not be successful. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to commence a single pivotal Phase 3 clinical trial for MitoGel and a Phase 2b clinical
trial of VesiGel under the FDA&#146;s 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the Federal Food, Drug and Cosmetic Act. We expect
that BotuGel will be a candidate under the FDA&#146;s regulatory pathway for biosimilars that rely on previously approved products, as permitted by the Biologics Price Competition and Innovation Act of 2009 and referred to as the Section 351(k)
regulatory pathway. Section 505(b)(2) and Section 351(k) permit the filing of an NDA or Biologic License Application where at least some of the information required for approval comes from studies that were not conducted by or for the applicant, and
for which the applicant has not received a right of reference, which could expedite the development program for MitoGel, VesiGel, BotuGel and our other product candidates by potentially decreasing the amount of preclinical and clinical data that we
would need to generate in order to obtain FDA approval. However, while we believe that our product candidates are reformulations of existing drugs or biologics and, therefore, will not be treated as new chemical entity, or NCEs, the submission of an
NDA under the Section 505(b)(2) or similar regulatory pathway does not preclude the FDA from determining that the product candidate that is the subject of such submission is an NCE and therefore not eligible for review under such regulatory pathway.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the FDA does not allow us to pursue the Section 505(b)(2) or similar regulatory pathway as anticipated, we may need to conduct additional preclinical
experiments and clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates,
and complications and risks associated with these product candidates, would likely increase significantly. Moreover, inability to pursue the Section 505(b)(2) or similar </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">38 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
regulatory pathway could result in new competitive products reaching the market more quickly than our product candidates, which would likely harm our competitive position and prospects. Even if
we are allowed to pursue the Section 505(b)(2) or similar regulatory pathway, our product candidates may not receive the requisite approvals for commercialization. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain competitors and others have
objected to the FDA&#146;s interpretation of Section 505(b)(2). If the FDA&#146;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may be required to change its 505(b)(2) policies and practices, which could delay or even
prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of
sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months depending on the outcome of any litigation.
It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If successful, such petitions can
significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are
able to utilize the Section 505(b)(2) regulatory pathway for our product candidates, there is no guarantee this would ultimately lead to faster product development or earlier approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Moreover, even if these product candidates are approved under Section 505(b)(2) or the 351(k) pathway, as the case may be, the approval may be subject to limitations on
the indicated uses for which the products may be marketed or to other conditions of approval, or may contain requirements for costly post-marketing testing and surveillance to monitor the safety or efficacy of the products. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect current and future legislation affecting the healthcare industry, including healthcare reform, to impact our business generally and to increase
limitations on reimbursement, rebates and other payments, which could adversely affect third-party coverage of our products, our operations, and/or how much or under what circumstances healthcare providers will prescribe or administer our products,
if approved. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals to change
the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2010, President Obama signed into law the Patient Protection and Affordable Care Act and the Health Care and Education Affordability
Reconciliation Act of 2010, or the Affordable Care Act, and collectively, ACA, a law intended, among other things, to broaden access to health insurance, improve quality of care, and reduce or constrain the growth of healthcare spending. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Provisions of the ACA relevant to the pharmaceutical industry include the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an annual, nondeductible fee on any entity that manufactures or imports certain branded prescription drugs and biologic agents, apportioned among these entities according to their market share in certain government
healthcare programs, not including orphan drug sales; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase in the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts on negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage
gap period, as a condition for the manufacturer&#146;s outpatient drugs to be covered under Medicare Part D; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">extension of manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">39 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and by adding new mandatory eligibility categories for certain
individuals with income at or below 133% of the Federal Poverty Level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">new requirements to report annually certain financial arrangements with physicians and teaching hospitals; as defined in ACA and its implementing regulations, including reporting any payment or &#147;transfer of
value&#148; provided to physicians and teaching hospitals and any ownership and investment interests held by physicians and their immediate family members during the preceding calendar year; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expansion of healthcare fraud and abuse laws, including the federal civil False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for noncompliance; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in and conduct comparative clinical effectiveness research, along with funding for such research. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Substantial new provisions affecting compliance have also been enacted, which may affect our business practices with healthcare practitioners, and a significant number
of provisions are not yet, or have only recently become, effective. Although it is too early to determine the full effect of the ACA, it appears likely to continue to put pressure on pharmaceutical pricing, especially under the Medicare program, and
may also increase our regulatory burdens and operating costs.&nbsp;Challenges and amendments have been made to the ACA, and we expect such challenges to continue in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, other legislative changes have been proposed and adopted since the ACA was enacted. For example, in August 2011, President Obama signed into law the Budget
Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of an amount
greater than $1.2 trillion for the years 2013 through 2021, triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to healthcare providers of up to 2.0% per
fiscal year, which started in 2013 and, following passage of the Bipartisan Budget Act of 2015, will stay in effect through 2025 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer
Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five
years.&nbsp;Additionally, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient
programs, and reform government program reimbursement methodologies for drugs.&nbsp;Further, the U.S. House of Representatives recently formed an Affordable Drug Pricing Task Force to advance legislation intended to control pharmaceutical drug costs
and investigate pharmaceutical drug pricing, and the U.S. Senate has requested information from certain pharmaceutical companies in connection with an investigation into pharmaceutical drug pricing practices. If healthcare policies or reforms
intended to curb healthcare costs are adopted, or if we experience negative publicity with respect to the pricing of our products or the pricing of pharmaceutical drugs generally, the prices that we charge for any approved products may be limited,
our commercial opportunity may be limited and/or our revenues from sales of our products may be negatively impacted. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we obtain regulatory approval and
commercialization of MitoGel, VesiGel or any of our other product candidates, these laws may result in additional reductions in healthcare funding, which could have an adverse effect on our customers and accordingly, our financial operations.
Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether
the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of MitoGel, VesiGel or our other product candidates may be. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although we cannot predict the full effect on our business of the implementation of existing legislation or the enactment of additional legislation pursuant to
healthcare and other legislative reform, we believe that legislation or regulations that would reduce reimbursement for, or restrict coverage of, our products could adversely affect how much or under what
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">40 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
circumstances healthcare providers will prescribe or administer our products. This could adversely affect our business by reducing our ability to generate revenues, raise capital, obtain
additional licensees and market our products. In addition, we believe the increasing emphasis on managed care in the United States has and will continue to put pressure on the price and usage of pharmaceutical products, which may adversely impact
product sales. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We may be unable to obtain Orphan Drug Designation or exclusivity for future product candidates we may develop. If our competitors are able to
obtain orphan drug exclusivity for their products that are for the same indication as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan Drug Act of 1983, the FDA may designate a product as an orphan drug if it is intended to treat an orphan disease or condition, defined as
a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the
United States. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the United States, Orphan Drug Designation entitles a party to financial incentives, such as opportunities for grant funding towards clinical
trial costs, tax advantages and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has Orphan Drug Designation, the product is entitled to orphan drug exclusivity, which means the FDA may not
approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity or where the manufacturer
is unable to assure sufficient product quantity. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Although the FDA has granted MitoGel orphan designation for the treatment of UTUC and to Vesimune for treatment of
CIS, we may not receive orphan designation for any of our other product candidates. If our competitors are able to obtain orphan drug exclusivity for their products that are the same or similar to our product candidates, we may not be able to have
competing product candidates approved by the FDA for a significant period of time. Any delay in our ability to bring our product candidates to market would negatively impact our business, revenue, cash flows and operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orphan Drug Designation may not ensure that we will enjoy market exclusivity in a particular market, and if we fail to obtain or maintain orphan drug exclusivity
for our product candidates, we may be subject to earlier competition and our potential revenue will be reduced. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Orphan Drug Designation entitles a party to
financial incentives, such as opportunities for grant funding towards clinical trial costs, tax advantages, user-fee waivers and market exclusivity for certain periods of time. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel and Vesimune have been granted Orphan Drug Designation for the treatment of UTUC and CIS, respectively, in the United States. Even if we obtain Orphan Drug
Designation for our other product candidates, we may not be the first to obtain regulatory approval for any particular orphan indication due to the uncertainties associated with developing biopharmaceutical products. Further, even if we obtain
Orphan Drug Designation for a product candidate, that exclusivity may not effectively protect the product from competition because different drugs with different active moieties can be approved for the same condition. In addition, if a competitor
obtains approval and marketing exclusivity for a drug product with an active moiety that is the same as that in a product candidate we are pursuing for the same indication, approval of our product candidate would be blocked during the period of
marketing exclusivity unless we could demonstrate that our product candidate is clinically superior to the approved product. In addition, if a competitor obtains approval and marketing exclusivity for a drug product with an active moiety that is the
same as that in a product candidate we are pursuing for a different orphan indication, this may negatively impact the market opportunity for our product candidate. There have been legal challenges to aspects of the FDA&#146;s regulations and
policies concerning the exclusivity provisions of the Orphan Drug Act, and future challenges could lead to changes that affect the protections afforded our product candidates in ways that are difficult to predict. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Even if we receive regulatory approval for our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may
result in significant additional expenses, limit or withdraw regulatory approval and subject us to penalties if we fail to comply with applicable regulatory requirements. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If and when regulatory approval has been granted, our product candidates or any approved product will be subject to continual regulatory review by the FDA and/or
non-U.S. regulatory authorities. Additionally, any product candidates, if approved, will be subject to extensive and ongoing regulatory requirements, including labeling and other restrictions and market withdrawal and we may be subject to penalties
if we fail to comply with regulatory requirements or experience unanticipated problems with our products. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">41 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any regulatory approvals that we receive for our product candidates may also be subject to limitations on the approved
indications for which the product may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the
product. In addition, if the applicable regulatory agency approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion and recordkeeping for the product
will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and GCP for any clinical
trials that we conduct post-approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated
severity or frequency, or problems with our third-party manufacturers&#146; processes, or failure to comply with regulatory requirements, may result in, among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory product recalls; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fines, warnings letters or holds on clinical trials </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refusal by the FDA to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product license approvals; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">product seizure or detention, or refusal to permit the import or export of products; and injunctions or the imposition of civil or criminal penalties. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ongoing regulatory requirements may also change from time to time, potentially harming or making costlier our commercialization efforts. We cannot predict the
likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or other countries. If we are slow or unable to adapt to changes in existing requirements or the
adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would adversely affect our
business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our relationships with healthcare professionals, independent contractors, clinical investigators, CROs, consultants and vendors in connection with
our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws. If we are unable to
comply, or have not fully complied, with such laws, we could face penalties. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may currently be or may become subject to various U.S. federal and state
health care laws, including those intended to prevent health care fraud and abuse. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute prohibits, among other things, persons or
entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of
an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid Remuneration has been
broadly defined to include anything of value, including, but not limited to, cash, improper discounts, and free or reduced price items and services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Federal false
claims laws, including the federal False Claims Act, or FCA, and civil monetary penalties law impose penalties against individuals or entities for, among other things, knowingly presenting, or causing to be presented, to the federal government,
claims for payment or approval that are false or fraudulent or making a false record or statement to avoid, decrease or conceal an obligation to pay money to the federal government. The FCA has been used to, among other things, prosecute persons and
entities submitting claims for payment that are inaccurate or fraudulent, that are for services not provided as claimed, or for services that are not medically necessary. The FCA includes a whistleblower provision that allows individuals to bring
actions on behalf of the federal government and share a portion of the recovery of successful claims. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have similar fraud and abuse statutes and
regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. State </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">42 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and federal authorities have aggressively targeted medical technology companies for, among other things, alleged violations of these anti-fraud statutes, based on improper research or consulting
contracts with doctors, certain marketing arrangements that rely on volume-based pricing, off-label marketing schemes, and other improper promotional practices. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, among other things, imposes criminal liability for knowingly and willfully executing,
or attempting to execute, a scheme to defraud any healthcare benefit program or knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
healthcare benefits, items or services. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH Act,
and their implementing regulations, also impose certain obligations, including mandatory contractual terms, on certain types of individuals and entities with respect to safeguarding the privacy, security and transmission of individually identifiable
health information without proper written authorization. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our operations will also be subject to the federal transparency requirements under the Affordable Care
Act, which require certain manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to
the Centers for Medicare &amp; Medicaid Services, or CMS, an agency within the U.S. Department of Health and Human Services, or HHS, information related to payments and other transfers of value provided to physicians and teaching hospitals and
certain ownership and investment interests held by physicians and their immediate family members. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of our business activities, including but not limited to
our relationships with healthcare providers, violate any of the aforementioned laws, we may be subject to administrative, civil and/or criminal penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from
participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings and curtailment or restructuring of our operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Also, the U.S. Foreign Corrupt Practices Act and similar worldwide anti-bribery laws generally prohibit companies and their intermediaries from making improper payments
to non-U.S. officials for the purpose of obtaining or retaining business. We cannot assure you that our internal control policies and procedures will protect us from reckless or negligent acts committed by our employees, future distributors,
partners, collaborators or agents. Violations of these laws, or allegations of such violations, could result in fines, penalties or prosecution and have a negative impact on our business, results of operations and reputation. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms in the United States or abroad may make it more difficult and costly for us to obtain regulatory clearance or
approval of our product candidates or any future product candidates and to produce, market, and distribute our products after clearance or approval is obtained. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress in the United States or by governments in foreign jurisdictions that could significantly change the
statutory provisions governing the regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA or foreign regulatory agency regulations and guidance are often revised or
reinterpreted by the FDA or the applicable foreign regulatory agency in ways that may significantly affect our business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or
lengthen review times of our product candidates or any future product candidates. We cannot determine what effect changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our
business in the future. Such changes could, among other things, require: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any future products would harm our business, financial condition, and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">43 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or
penalties or incur costs that could negatively impact our business. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to numerous environmental, health and safety laws and regulations,
including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological
materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of
contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and
penalties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain workers compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials or other work-related injuries with policy limits that we believe are customary for similarly situated companies and adequate to provide us with coverage for foreseeable risks. Although we maintain such insurance, this insurance
may not provide adequate coverage against potential liabilities. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. These current or future laws and
regulations may impair our research, development or production efforts. Failure to comply with these laws and regulations also may result in substantial fines, penalties or other sanctions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult for us to profitably sell our product candidates if coverage and reimbursement for these products is limited by government authorities and/or
third-party payor policies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to any healthcare reform measures which may affect reimbursement, market acceptance and sales of MitoGel, VesiGel
and our other product candidates, if approved, will depend on the coverage and reimbursement policies of government authorities and third-party payors. Government authorities and third-party payors, such as private health insurers and health
maintenance organizations, decide which medications they will cover and establish reimbursement levels. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A primary trend in the U.S. healthcare industry and
elsewhere is cost containment. Third party payors decide which drugs they will pay for and establish reimbursement and co-payment levels. Government and other third-party payors are increasingly challenging the prices charged for health care
products, examining the cost effectiveness of drugs in addition to their safety and efficacy, and limiting or attempting to limit both coverage and the level of reimbursement for prescription drugs. We cannot be sure that coverage will be available
for MitoGel, VesiGel or our other product candidates, if approved, or, if coverage is available, the level of reimbursement. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is significant uncertainty
related to the insurance coverage and reimbursement of newly approved products. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, an agency within the U.S. Department of HHS, as CMS
decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often follow CMS. It is difficult to predict what CMS as well as other payors will decide with respect to reimbursement for fundamentally
novel products such as ours, as there is no body of established practices and precedents for these new products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement may impact the demand for, and/or
the price of, any product for which we obtain marketing approval. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find
unacceptably high.&nbsp;Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the costs associated with their prescription
drugs.&nbsp;Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate reimbursement is critical to new
product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or subsequently become available.&nbsp;There
may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover,
eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">44 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Reimbursement by a third-party payor may depend upon a number of factors including the third-party payor&#146;s
determination that use of a product is: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covered benefit under its health plan; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">safe, effective and medically necessary; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appropriate for the specific patient; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">cost-effective; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither experimental nor investigational. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Obtaining coverage and reimbursement approval for a product from a government
or other third-party payor is a time-consuming and costly process that could require us to provide supporting scientific, clinical and cost effectiveness data for the use of our products to the payor. Further, no uniform policy requirement for
coverage and reimbursement for drug products exists among third-party payors in the United States.&nbsp;Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination
process may require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. We may
not be able to provide data sufficient to gain acceptance with respect to coverage and/or sufficient reimbursement levels. We cannot be sure that coverage or adequate reimbursement will be available for MitoGel, VesiGel or any of our other product
candidates, if approved. Also, we cannot be sure that reimbursement amounts will not reduce the demand for, or the price of, our future products. If reimbursement is not available, or is available only to limited levels, we may not be able to
commercialize MitoGel, VesiGel or our other product candidates, or achieve profitably at all, even if approved. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Legislative or regulatory healthcare reforms
in the United States may make it more difficult and costly for us to obtain regulatory clearance or approval of MitoGel, VesiGel or any of our other product candidates and to produce, market, and distribute our products after clearance or approval
is obtained. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, legislation is drafted and introduced in Congress that could significantly change the statutory provisions governing the
regulatory clearance or approval, manufacture, and marketing of regulated products or the reimbursement thereof. In addition, FDA regulations and guidance are often revised or reinterpreted by the FDA in ways that may significantly affect our
business and our products. Any new regulations or revisions or reinterpretations of existing regulations may impose additional costs or lengthen review times of MitoGel, VesiGel or any of our other product candidates. We cannot determine what effect
changes in regulations, statutes, legal interpretation or policies, when and if promulgated, enacted or adopted may have on our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes to manufacturing methods; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change in protocol design; requesting additional treatment arm (control); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recall, replacement, or discontinuance of one or more of our products; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">additional recordkeeping. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each of these would likely entail substantial time and cost and could harm our business and
our financial results. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to an Investment in Our Ordinary Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>An active, liquid and orderly trading market for our ordinary shares may not develop, which may inhibit the ability of our shareholders to sell ordinary shares
following this offering. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering there has been no public market for our ordinary shares. An active, liquid or orderly trading market in our
ordinary shares may not develop upon completion of this offering, or if it does develop, it may not be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them or at a price that you
consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may also impair our ability to raise capital in the future by selling shares and may impair our ability to acquire other
companies by using our shares as consideration. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">45 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The market price of our ordinary shares may be subject to fluctuation and you could lose all or part of your
investment. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price for the shares will be determined by negotiations between us and representatives of the underwriters and may
not be indicative of prices that will prevail in the trading market. The price of our ordinary shares may decline following this offering. The stock market in general has been, and the market price of our ordinary shares in particular will likely
be, subject to fluctuation, whether due to, or irrespective of, our operating results and financial condition. The market price of our ordinary shares on the NASDAQ Global Market may fluctuate as a result of a number of factors, some of which are
beyond our control, including, but not limited to: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">actual or anticipated variations in our and our competitors&#146; results of operations and financial condition; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">physician and market acceptance of our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the mix of products that we sell; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our success or failure to obtain approval for and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in earnings estimates or recommendations by securities analysts, if our ordinary shares are covered by analysts; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">development of technological innovations or new competitive products by others; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">announcements of technological innovations or new products by us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">publication of the results of preclinical or clinical trials for MitoGel, VesiGel or our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">failure by us to achieve a publicly announced milestone; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delays between our expenditures to develop and market new or enhanced product candidates and the generation of sales from those products; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">developments concerning intellectual property rights, including our involvement in litigation brought by or against us; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">regulatory developments and the decisions of regulatory authorities as to the approval or rejection of new or modified products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in the amounts that we spend to develop, acquire or license new products, technologies or businesses; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in our expenditures to promote our products; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our sale or proposed sale, or the sale by our significant shareholders, of our ordinary shares or other securities in the future; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">changes in key personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">success or failure of our research and development projects or those of our competitors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trading volume of our ordinary shares; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general economic and market conditions and other factors, including factors unrelated to our operating performance. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These factors and any corresponding price fluctuations may negatively impact the market price of our ordinary shares and result in substantial losses being incurred by
our investors. In the past, following periods of market volatility, public company shareholders have often instituted securities class action litigation. If we were involved in securities litigation, it could impose a substantial cost upon us and
divert the resources and attention of our management from our business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>If equity research analysts do not publish research or reports about our business or
if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The trading market for our ordinary
shares will rely in part on the research and reports that equity research analysts publish about us and our business, if at all. We do not have control over these analysts and we do not have commitments from them to write research reports about us.
The price of our ordinary shares could decline if no research reports are published about us or our business, or if one or more equity research analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease
publishing reports about us or our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">46 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Future sales of our ordinary shares could reduce the market price of our ordinary shares. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If our existing shareholders, particularly our directors, their affiliates, or our executive officers, sell a substantial number of our ordinary shares in the public
market, the market price of our ordinary shares could decrease significantly. The perception in the public market that our shareholders might sell our ordinary shares could also depress the market price of our ordinary shares and could impair our
future ability to obtain capital, especially through an offering of equity securities. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Substantially all of our shares outstanding prior to this offering and our
shares issuable upon the exercise of warrants and vested options are subject to lock-up agreements with the underwriters that restrict the ability of their holders to transfer such shares for 180 days after the date of this prospectus. Consequently,
upon expiration of the lock-up agreements, an additional approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares,
including&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares issuable upon the exercise of our outstanding options or warrants, will be eligible for sale in the public market, of which
approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares will be subject to restrictions on volume and manner of sale pursuant to Rule 144 under the Securities Act of 1933, as
amended. However, we intend to file one or more registration statements on Form S-8 with the SEC covering all of the ordinary shares issuable under our 2010 Israeli Share Option Plan and such shares will be available for resale following the
expiration of the restrictions on transfer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After this offering, the holders of
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be entitled to registration rights, subject to the terms of the lock-up agreements described above. The market price of
our ordinary shares may drop significantly when the restrictions on resale by our existing shareholders lapse and these shareholders are able to sell our ordinary shares into the market. In addition, our sale of additional ordinary shares or similar
securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary
shares or other equity securities, and may cause you to lose part or all of your investment in our ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Investors in this offering will
experience immediate substantial dilution in net tangible book value. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial public offering price of our ordinary shares in this offering is
considerably greater than the net tangible book value per share of our outstanding ordinary shares immediately after this offering. Accordingly, investors in this offering will incur immediate dilution of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, as of September 30, 2015, based on an assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share,
the midpoint of the estimated initial public offering price range shown on the cover of this prospectus. In addition, if outstanding options to purchase our ordinary shares are exercised in the future, you will experience additional dilution. Please
see the section entitled &#147;Dilution.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The significant share ownership position of affiliates of directors may limit your ability to influence
corporate matters. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to this offering, corporate entities affiliated with our directors will beneficially own or control, directly or
indirectly, approximately &nbsp;&nbsp;&nbsp;&nbsp;% of our outstanding ordinary shares (or&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;% if the underwriters exercise their option in full to purchase additional ordinary shares). Accordingly, these entities will be
able to significantly influence, though not independently determine, the outcome of matters required to be submitted to our shareholders for approval, including decisions relating to the election of our board of directors, and the outcome of any
proposed merger or consolidation of our company. These interests may not be consistent with those of our other shareholders. In addition, these entities&#146; significant interest in us may discourage third parties from seeking to acquire control of
us, which may adversely affect the market price of our ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have broad discretion as to the use of the net proceeds from this offering and may
not use them effectively. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to use the net proceeds we receive from this offering, together with our existing cash resources, to advance
our clinical pipeline and specifically, to file an IND for, and initiate and complete our planned single pivotal Phase 3 clinical trial of, MitoGel for the treatment of low-grade UTUC, to file an IND for, and to initiate our Phase 2b clinical trial
of, VesiGel for the treatment of low-grade NMIBC, and to fund continued research and clinical development of our other product candidates and for other general corporate purposes. However, our management will have broad discretion in the application
of the net proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from this offering. The failure by our management to apply these funds effectively could harm our business, financial
condition and results of operation. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">47 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We have never paid cash dividends on our share capital, and we do not anticipate paying any cash dividends in the
foreseeable future. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends on our share capital, nor do we anticipate paying any cash dividends on our share capital
in the foreseeable future. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be investors&#146; sole
source of gain for the foreseeable future. In addition, Israeli law limits our ability to declare and pay dividends, and may subject our dividends to Israeli withholding taxes. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We will incur significant increased costs as a result of operating as a public company in the United States, and our management will be required to devote
substantial time to new compliance initiatives. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a public company whose ordinary shares are listed in the United States, we will be subject to an
extensive regulatory regime, requiring us, among other things, to maintain various internal controls and facilities and to prepare and file periodic and current reports and statements, including reports on the effectiveness of our internal control
over financial reporting pursuant to Section 404 of the Sarbanes-Oxley Act of 2002. Complying with these requirements will be costly and time consuming. We will need to retain additional employees to supplement our current finance staff, and we may
not be able to do so in a timely manner, or at all. In the event that we are unable to demonstrate compliance with our obligations as a public company in a timely manner, or are unable to produce timely or accurate financial statements, we may be
subject to sanctions or investigations by regulatory authorities, such as the SEC or the NASDAQ Global Market, and investors may lose confidence in our operating results and the price of our ordinary shares could decline. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our independent registered public accounting firm was not engaged to perform an audit of our internal control over financial reporting, and as long as we remain an
emerging growth company, as such term is defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act, we will be exempt from the requirement to have an independent registered public accounting firm perform such audit. Accordingly, no
such opinion was expressed or will be expressed any during any such period. Once we cease to qualify as an emerging growth company our independent registered public accounting firm will be required to attest to our management&#146;s annual
assessment of the effectiveness of our internal controls over financial reporting, which will entail additional costs and expenses. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, we are only in the
early stages of determining formally whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material weaknesses or significant deficiencies in our existing internal controls.
These controls and other procedures are designed to ensure that information required to be disclosed by us in the reports that we file with the SEC is disclosed accurately and is recorded, processed, summarized and reported within the time periods
specified in SEC rules and forms. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We expect to be classified as a passive foreign investment company, and our U.S. shareholders may suffer adverse tax
consequences as a result. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, for any taxable year, if at least 75% of our gross income is passive income, or at least 50% of the value of our
assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company, or PFIC, for U.S. federal income tax purposes. For
purposes of these tests, passive income includes dividends, interest gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income (including amounts derived by reason
of the temporary investment of funds raised in offerings of our shares) and rents and royalties other than rents and royalties which are received from unrelated parties in connection with the active conduct of a trade or business. If we are
characterized as a PFIC, our U.S. shareholders may suffer adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable
to dividends received on our ordinary shares by individuals who are U.S. holders, and having interest charges apply to distributions by us and gains from the sales of our shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our status as a PFIC may also depend, in part, on how quickly we utilize the funds we raise in this offering in our business. Since PFIC status depends in part on the
composition and value of our assets (which, assuming we are not a controlled foreign corporation for the year being tested, may be determined in large part by reference to the market value of our ordinary shares, which may be volatile) from time to
time, there can be no assurance that we will not be considered a PFIC for any taxable year. However, because we currently have no revenue-producing operations, we </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">48 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
expect to be treated as a PFIC for our current taxable year. Unless and until we generate sufficient revenue from active licensing and other non-passive sources and otherwise satisfy the asset
test above, we expect to be treated as a PFIC for future taxable years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A U.S. shareholder may be able to mitigate some of the adverse U.S. federal income tax
consequences described above with respect to owning our ordinary shares if we are classified as a PFIC for our taxable year ending December 31, 2016, provided that such U.S. investor is eligible to make, and successfully makes, a
&#147;mark-to-market&#148; election. U.S. investors could also mitigate some of the adverse U.S. federal income tax consequences of us being classified as a PFIC by making a Qualified Electing Fund, or QEF, election, provided that we provide the
information necessary for a U.S. investor to make such an election. However, we do not currently intend to provide the information necessary for U.S. investors to make QEF elections. Prospective U.S. investors should consult their own tax advisors
regarding the potential application of the PFIC rules to them as well as whether any elections would be available and, if so, what the consequences of the alternative treatments would be in their particular circumstances. For more information
related to classification as a PFIC, see &#147;Taxation&#151;Material U.S. Federal Income Tax Consequences to U.S. Holders&#151;Passive Foreign Investment Company Considerations.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a foreign private issuer, we are permitted, and intend, to follow home country corporate governance practices instead of otherwise applicable NASDAQ
requirements. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we will be permitted, and intend, to follow home country corporate governance practices instead of those
otherwise required by The NASDAQ Stock Market for domestic U.S. issuers. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the NASDAQ Global Market may provide less
protection to you than what is accorded to investors under the NASDAQ Rules applicable to domestic U.S. issuers. See the section titled &#147;Management&#151;Corporate Governance Practices.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>As a foreign private issuer, we will not be subject to certain U.S. securities laws including, but not limited to, U.S. proxy rules and the filing of certain
Exchange Act reports. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a foreign private issuer, we will be exempt from the rules and regulations under the Securities Exchange Act of 1934, or the
Exchange Act, related to the furnishing and content of proxy statements, including the requirement to disclose the compensation of our Chief Executive Officer, Chief Financial Officer, President of Israel Operations and the other two most highly
compensated executive officers on an individual basis. Nevertheless, pursuant to regulations promulgated under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law, we are required to disclose the annual compensation of our five most
highly compensated office holders on an individual basis. Such disclosure will not be as extensive as that required of a U.S. domestic issuer. Our officers, directors and principal shareholders will also be exempt from the reporting and short-swing
profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. domestic companies whose
securities are registered under the Exchange Act and we will be exempt from filing quarterly reports with the SEC under the Exchange Act. Moreover, we will not be required to comply with Regulation FD, which restricts the selective disclosure of
material information. These exemptions and leniencies will reduce the frequency and scope of information and protections to which you may otherwise have been eligible in relation to a U.S. domestic issuer. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We would lose our foreign private issuer status if a majority of our shares are owned by U.S. residents and a majority of our directors or executive officers are U.S.
citizens or residents or we fail to meet additional requirements necessary to avoid loss of foreign private issuer status. The regulatory and compliance costs to us under U.S. securities laws as a U.S. domestic issuer may be significantly higher. If
we are not a foreign private issuer, we will be required to file periodic reports and registration statements on U.S. domestic issuer forms with the SEC, which are more detailed and extensive than the forms available to a foreign private issuer. We
may also be required to modify certain of our policies to comply with accepted governance practices associated with U.S. domestic issuers. Such conversion and modifications will involve additional costs. In addition, we would lose our ability to
rely upon exemptions from certain corporate governance requirements on U.S. stock exchanges that are available to foreign private issuers. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We are an emerging
growth company and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are an emerging growth company, as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other
public companies that are not emerging growth companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">49 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For as long as we remain an emerging growth company we are permitted and intend to rely on exemptions from certain
disclosure requirements that are applicable to other public companies that are not &#147;emerging growth companies.&#148; These exemptions include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">being permitted to provide only two years of audited financial statements, in addition to any required unaudited condensed interim financial statements, with correspondingly reduced &#147;Management&#146;s discussion
and analysis of financial condition and results of operations&#148; disclosure; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with the auditor attestation requirements in the assessment of our internal control over financial reporting; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing
additional information about the audit and the financial statements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduced disclosure obligations regarding executive compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will remain an emerging growth company until the earliest of: (i) the last day of our fiscal year during which we have total annual gross revenues of at least $1.0
billion; (ii) the last day of our fiscal year following the fifth anniversary of the closing of this offering; (iii) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (iv) the
date on which we are deemed to be a &#147;large accelerated filer&#148; under the Exchange Act. We have opted out of the extended transition period made available to emerging growth companies to comply with newly adopted public company accounting
requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We
cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market
for our ordinary shares and our share price may be more volatile. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Risks Related to our Operations in Israel </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our headquarters, research and development and other significant operations are located in Israel and, therefore, our results may be adversely affected by
political, economic and military instability in Israel. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our headquarters and research and development facilities are located in Ra&#146;anana, Israel. In
addition, the majority of our key employees, officers and directors are residents of Israel. If these or any future facilities in Israel were to be damaged, destroyed or otherwise unable to operate, whether due to war, acts of hostility,
earthquakes, fire, floods, hurricanes, storms, tornadoes, other natural disasters, employee malfeasance, terrorist acts, power outages or otherwise, or if performance of our research and development is disrupted for any other reason, such an event
could delay our clinical trials or, if our product candidates are approved and we choose to manufacture all or any part of them internally, jeopardize our ability to manufacture our products as promptly as our prospective customers will likely
expect, or possibly at all. If we experience delays in achieving our development objectives, or if we are unable to manufacture an approved product within a timeframe that meets our prospective customers&#146; expectations, our business, prospects,
financial results and reputation could be harmed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Political, economic and military conditions in Israel may directly affect our business. Since the establishment
of the State of Israel in 1948, a number of armed conflicts have taken place between Israel and its neighboring countries, Hamas (an Islamist militia and political group that controls the Gaza Strip) and Hezbollah (an Islamist militia and political
group based in Lebanon). In addition, several countries, principally in the Middle East, restrict doing business with Israel, and additional countries may impose restrictions on doing business with Israel and Israeli companies whether as a result of
hostilities in the region or otherwise. Any hostilities involving Israel, terrorist activities, political instability or violence in the region or the interruption or curtailment of trade or transport between Israel and its trading partners could
adversely affect our operations and results of operations and adversely affect the market price of our ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our commercial insurance does not cover
losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">50 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to
compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, our operations could be disrupted by the obligations of our employees to perform military service. As of September 30, 2015, we had 24 employees based in
Israel. Of these employees, some may be military reservists, and may be called upon to perform military reserve duty of up to 36 days per year (and in some cases more) until they reach the age of 40 (and in some cases, up to the age of 45 or older).
Additionally, they may be called to active duty at any time under emergency circumstances. In response to increased tension and hostilities in the region, there have been, at times, call-ups of military reservists, and it is possible that there will
be additional call-ups in the future. Our operations could be disrupted by the absence of these employees due to military service. Such disruption could harm our business and operating results. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Israeli government grants we have received for research and development activities restrict our ability to manufacture products and transfer technologies
outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we fail to satisfy these conditions, we may be required to refund grants previously received and incur financial penalties. </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have received grants under the Israeli Law for the Encouragement of Industrial Research and Development, 5754-1984, or the R&amp;D Law, from the Office of the Chief
Scientist in the Ministry of Economy and Industry in Israel, or OCS, for some of our development programs. As of September 30, 2015, we had received grants in the aggregate amount of $1.9 million. We have applied, and may in the future apply, to
receive additional grants from the OCS. However, we cannot predict whether we will be entitled to any future grants, or the amounts of any such grants. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A recipient
of a grant from the OCS is obligated to pay royalties generally at a rate of 3% to 5% on revenues from sales of products developed with OCS-funded technology, up to the amount of the grant related to any such products plus accrued interest. Under
the R&amp;D Law, a company that received grants from the OCS may not transfer OCS-funded technology or manufacture products developed with OCS-funded technology outside of the State of Israel without first obtaining the approval of the OCS. We may
not receive any such approval should we request it, which could prevent us, for example, from out-licensing our product candidates. Even if we do receive such approvals, we may be required to pay increased royalties and significant penalties and
other amounts. The OCS may also impose certain conditions on any arrangement under which it permits us to transfer OCS-funded technology outside of the State of Israel. Furthermore, the consideration available to our shareholders in a transaction
involving the transfer outside of the State of Israel of OCS-funded technology (such as a merger or similar transaction) may be reduced by any amounts that we are required to pay to OCS. The restrictions under the R&amp;D Law will continue to apply
even after we have repaid the full amount of royalties due to the OCS. If we fail to satisfy the conditions of the R&amp;D Law, we may be required to refund the amounts of the grants previously received, together with interest and penalties, and may
become subject to criminal charges. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Provisions of Israeli law and our amended and restated articles of association may delay, prevent or otherwise impede a
merger with, or an acquisition of, us, even when the terms of such a transaction are favorable to us and our shareholders. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli corporate law regulates
mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to such
types of transactions. For example, a tender offer for all of a company&#146;s issued and outstanding shares can only be completed if shareholders not accepting the tender offer hold less than 5% of the issued share capital. Completion of the tender
offer also requires approval of a majority of the offerees that do not have a personal interest in the tender offer, unless shareholders not accepting the tender offer hold less than 2% of the company&#146;s outstanding shares. Furthermore, the
shareholders, including those who indicated their acceptance of the tender offer, may, at any time within six months following the completion of the tender offer, petition an Israeli court to alter the consideration for the acquisition, unless the
acquirer stipulated in its tender offer that a shareholder that accepts the offer may not seek such appraisal rights. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">51 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders whose
country of residence does not have a tax treaty with Israel exempting such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli
tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and
dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no
disposition of the shares has occurred. These provisions could delay, prevent or impede an acquisition of us or our merger with another company, even if such an acquisition or merger would be beneficial to us or to our shareholders. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>It may be difficult to enforce a judgment of a U.S. court against us, our officers and directors or the Israeli experts named in this prospectus in Israel or the
United States, to assert U.S. securities laws claims in Israel or to serve process on our officers and directors and these experts. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated in
Israel. The majority of our directors and most of our executive officers listed in this prospectus reside outside of the United States, and most of our assets and most of the assets of these persons are located outside of the United States.
Therefore, a judgment obtained against us, or any of these persons, including a judgment based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli
court. It may also be difficult for you to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. Israeli courts may refuse to hear a claim based on an
alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum in which to bring such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is
applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proven as a fact by expert witnesses, which can be a time consuming and costly process. Certain matters of procedure will also be governed by
Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is little binding case law in Israel that addresses the matters described above. As a result of the difficulty associated with enforcing a
judgment against us in Israel, you may not be able to collect any damages awarded by either a U.S. or foreign court. Please see the section entitled &#147;Enforcement of Civil Liabilities&#148; for additional information on your ability to enforce a
civil claim against us and our executive officers or directors named in this prospectus. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Your rights and responsibilities as a shareholder will be governed
by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rights and
responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of
shareholders in U.S. companies. In particular, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to
refrain from abusing its power in the company, including, among other things, in voting at a general meeting of shareholders on matters such as amendments to a company&#146;s articles of association, increases in a company&#146;s authorized share
capital, mergers and acquisitions and related party transactions requiring shareholder approval, as well as a general duty to refrain from discriminating against other shareholders. In addition, a shareholder who is aware that it possesses the power
to determine the outcome of a vote at a meeting of the shareholders or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be
interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">52 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_3"></A>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and
expectations for our business operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. In some cases, you can identify
forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148; &#147;continue,&#148; &#147;could,&#148; &#147;due,&#148; &#147;estimate,&#148;
&#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;predict,&#148; &#147;potential,&#148; &#147;positioned,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;target,&#148;
&#147;will,&#148; &#147;would,&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. These forward-looking statements include, but are
not limited to, statements about: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the timing and conduct of our clinical trials of MitoGel, VesiGel and our other product candidates, including statements regarding the timing, progress and results of current and future preclinical studies and clinical
trials, and our research and development programs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the clinical utility, potential advantages and timing or likelihood of regulatory filings and approvals of MitoGel, VesiGel and our other product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans regarding utilization of regulatory pathways that would allow for accelerated marketing approval in the United States;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding timing for application for and receipt of regulatory approval for any of our product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ongoing and planned discovery and development of product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding future growth, including our ability to develop, and obtain regulatory approval for, new product candidates; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain and maintain adequate intellectual property rights and adequately protect and enforce such rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our plans to develop and commercialize our product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding the market opportunity for our product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding expenses, future revenues, capital requirements and the need for additional financing; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our planned level of capital expenditures and our belief that our existing cash and the net proceeds from this offering will be sufficient to fund our operations for at least the next 12 months; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of our research and development expenses as we continue developing product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the maintenance of our foreign private issuer status; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of government laws and regulations; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our expectations regarding the use of proceeds from this offering. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Forward-looking statements are based on our
management&#146;s current expectations, estimates, forecasts and projections about our business and the industry in which we operate and our management&#146;s beliefs and assumptions, and are not guarantees of future performance or development and
involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. As a result, any or all of our forward-looking statements in this prospectus may turn out to be inaccurate. Factors that may cause actual
results to differ materially from current expectations include, among other things, those listed under &#147;Risk Factors&#148; and </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">elsewhere in this prospectus.
Potential investors are urged to consider these factors carefully in evaluating the forward-looking statements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The forward-looking statements included in this
prospectus speak only as of the date of this prospectus. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that future results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be achieved or will occur. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes
available in the future. You should, however, review the factors and risks we describe in the reports we will file from time to time with the SEC after the date of this prospectus. See &#147;Where You Can Find More Information.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">53 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_4"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate that the net proceeds from the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in
this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, based on an assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus. If the underwriters exercise their option to
purchase&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional ordinary shares in full, we estimate that the net proceeds to us from this offering will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. Each $1.00 increase (decrease) in the assumed initial public
offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share would increase (decrease) the net proceeds to us from this offering, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming that the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same. We
may also increase or decrease the number of ordinary shares we are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) the net proceeds to us from this offering, after deducting the
underwriting discounts and commissions and estimated offering expenses payable by us, by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , assuming the assumed initial public offering price stays the same. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expect to use the net proceeds from this offering, together with our existing cash resources, to advance our clinical pipeline, including specifically: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to file an IND for, and initiate and complete our planned single pivotal Phase 3 clinical trial of, MitoGel for the treatment of
low-grade UTUC; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;to file an IND for, and to initiate our Phase 2b clinical trial of, VesiGel for the treatment of low-grade NMIBC; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the remainder to fund continued research and clinical development of our other product candidates, and for working capital and other general corporate purposes. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the uncertainties inherent in the clinical development and regulatory approval process, it is difficult to estimate with certainty the exact amounts of the net
proceeds from this offering that may be used for any of the above purposes on a stand-alone basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pending our application of the net proceeds from this offering,
we plan to invest such proceeds in depositary institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">54 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_5"></A>DIVIDEND POLICY </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have never declared or paid cash dividends to our shareholders and we do not intend to pay cash dividends in the foreseeable future. We intend to reinvest any
earnings in developing and expanding our business. Any future determination relating to our dividend policy will be at the discretion of our board of directors in compliance with applicable legal requirements and will depend on a number of factors,
including future earnings, our financial condition, operating results, contractual restrictions, capital requirements, business prospects, our strategic goals and plans to expand our business, applicable law and other factors that our board of
directors may deem relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">See &#147;Risk Factors&#151;Risks Related to an Investment in Our Ordinary Shares&#151;We have never paid cash dividends on our share
capital, and we do not anticipate paying any cash dividends in the foreseeable future&#148; and, for an explanation concerning the payment of dividends under Israeli law, see &#147;Description of Share Capital&#151;Dividend and Liquidation
Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">55 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_6"></A>CAPITALIZATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth our cash and cash equivalents and capitalization as of September&nbsp;30, 2015 on: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an actual basis; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma basis to reflect the issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A preferred shares for aggregate gross proceeds of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million since September 30, 2015, the exercise for cash of all outstanding warrants to purchase Series A-1 preferred shares, and the automatic conversion thereafter of all
outstanding preferred shares into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a pro forma as adjusted basis to give further effect to the sale of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this offering at an assumed initial
public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pro forma and pro forma as adjusted data included in the table below are also
unaudited. You should read this information together with our unaudited condensed interim financial statements appearing elsewhere in this prospectus and the information set forth under the headings &#147;Selected Financial Data,&#148; &#147;Use of
Proceeds&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="67%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS OF SEPTEMBER&nbsp;30, 2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACTUAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO FORMA</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PRO&nbsp;FORMA&nbsp;AS<BR>ADJUSTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 8,000,000 shares authorized,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized pro forma and pro forma as adjusted; 719,059 issued and outstanding,
actual;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issued and outstanding, pro forma;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares issued and outstanding, pro forma as
adjusted.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and A-1 preferred shares, NIS 0.01 par value: 2,000,000 shares authorized, actual;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized pro forma and pro forma as adjusted; 455,183 shares issued and outstanding, actual; zero shares issued and outstanding, pro forma and pro forma as
adjusted.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,236</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total capitalization<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,854</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Each $1.00 increase or decrease in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share, which is the midpoint of the price range set forth on the cover of this prospectus, would increase or decrease, respectively, the amount of cash and cash equivalents, total equity and total capitalization by
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same, and after deducting the underwriting discounts and
commissions and estimated offering expenses payable by us. We may also increase or decrease the number of ordinary shares we are offering. An increase or decrease of 100,000 in the number of ordinary shares we are offering would increase or
decrease, respectively, the amount of cash and cash equivalents, total equity and total capitalization by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, assuming the assumed initial public offering price per ordinary
share, as set forth on the cover of this prospectus, remains the same. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering
determined at pricing. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">56 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of ordinary shares in the table above shown as issued and outstanding on a pro forma basis is based on
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of December&nbsp;31, 2015 and assumes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Series A-1 preferred shares upon the exercise for cash of all outstanding warrants to purchase Series A-1 preferred shares; and
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares upon the conversion of all Series A preferred shares and Series A-1 preferred shares into ordinary shares, which
will occur automatically upon the closing of this offering; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan, including&nbsp;ordinary shares reserved for issuance upon the exercise of outstanding options at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for issuance upon the vesting of outstanding restricted share
units; and </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">57 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_7"></A>DILUTION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you invest in our ordinary shares in this offering, your interest will be immediately diluted to the extent of the difference between the initial public offering
price per ordinary share in this offering and the net tangible book value per ordinary share after this offering. Dilution results from the fact that the initial public offering price per ordinary share is substantially in excess of the net tangible
book value per ordinary share. As of September&nbsp;30, 2015, we had a historical net tangible book value per ordinary share of $1.46. Our net tangible book value per share represents total tangible assets less total liabilities, all divided by the
number of shares outstanding on September&nbsp;30, 2015. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After giving effect to the sale of ordinary shares in this offering at an assumed initial public offering
price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, and after deducting the underwriting discounts and commissions
and estimated offering expenses, our pro forma net tangible book value at September&nbsp;30, 2015 would have been $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share. This represents an immediate increase in pro forma
net tangible book value of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share to existing shareholders and immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share to new investors. The following table illustrates this dilution per ordinary share: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Assumed initial public offering price per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Historical net tangible book value per ordinary share as of September&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in pro forma net tangible book value per ordinary share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma net tangible book value per ordinary share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dilution per ordinary share to new investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share,
which is the midpoint of the price range set forth on the cover of this prospectus, would increase (decrease) our pro forma net tangible book value as of September&nbsp;30, 2015 after this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, and would increase (decrease) dilution to investors in this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ordinary share, assuming that the number of ordinary shares offered by us, as set forth on the cover of this prospectus, remains the same, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. We
may also increase or decrease the number of ordinary shares we are offering. An increase (decrease) of 100,000 in the number of ordinary shares we are offering would increase (decrease) our pro forma net tangible book value as of September&nbsp;30,
2015 after this offering by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, and would decrease (increase) dilution to investors in this offering by approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, assuming the assumed initial public offering price per ordinary share remains the same, after deducting the underwriting discounts and commissions and
estimated offering expenses payable by us. The pro forma information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. If the
underwriters fully exercise their option to purchase additional ordinary shares, the pro forma net tangible book value after this offering would increase to approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per
ordinary share, and there would be an immediate dilution of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share to new investors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the underwriters exercise in full their option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;additional ordinary shares, the
pro forma as adjusted net tangible book value will increase to $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, representing an immediate increase in pro forma as adjusted net tangible book value to
existing shareholders of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share and an immediate dilution of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
to new investors participating in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may choose to raise additional capital due to market conditions or strategic considerations even if we believe
we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our
equity holders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">58 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows, as of September&nbsp;30, 2015, on a pro forma basis, the number of ordinary shares purchased
from us, the total consideration paid to us and the average price paid per share during the last five years by existing shareholders and by new investors purchasing ordinary shares in this offering at an assumed initial public offering price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, which is the midpoint of the price range set forth on the cover of this prospectus, before deducting the underwriting discounts and commissions and
estimated offering expenses payable by us: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom"><B>(In thousands, except share and per share amounts and percentages)</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="4" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SHARES</B><br><B>SUBSCRIBED FOR/</B><br><B>PURCHASED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL<BR>CONSIDERATION</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AVERAGE</B><br><B>PRICE<BR>PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Existing shareholders</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investors participating in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A $1.00 increase (decrease) in the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary
share (the midpoint of the price range set forth on the cover page of this prospectus) would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all shareholders and the average
price per share paid by all shareholders by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, assuming that the number of ordinary shares offered by us, as set forth on the cover page of this prospectus, remains the same and before deducting the
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Similarly, a 100,000 share increase (decrease) in the number of ordinary
shares offered by us, as set forth on the cover of this prospectus, would increase (decrease) the total consideration paid by investors participating in this offering, total consideration paid by all shareholders and the average price per share paid
by all shareholders by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million, $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million and
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, respectively, assuming the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share
(the midpoint of the price range set forth on the cover of this prospectus) remains the same, and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The number of ordinary shares in the table and discussion above is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares
outstanding as of December&nbsp;31, 2015 and assumes: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Series A-1 preferred shares upon the exercise for cash of all outstanding warrants to purchase Series A-1 preferred shares;
and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the issuance of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares upon the conversion of all Series&nbsp;A preferred shares and Series A-1 preferred shares into ordinary
shares, which will occur automatically upon the closing of this offering; </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">but excludes: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary shares reserved for issuance under our 2010 Israeli Share Option Plan, including&nbsp;ordinary shares reserved for issuance upon the exercise of outstanding options at a weighted average exercise price of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per share, and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares reserved for issuance upon the vesting of outstanding
restricted share units; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary shares reserved for issuance upon the achievement of certain milestones under the Vesimune asset purchase agreement with Telormedix SA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">59 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_8"></A>SELECTED FINANCIAL DATA </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following tables present selected financial data for our business. We derived the selected statements of operations data for the years ended December&nbsp;31,
2014 and 2013 and the balance sheet data as of December 31, 2014 and 2013 from our audited financial statements included elsewhere in this prospectus. We derived the selected statements of operations data for the nine months ended September&nbsp;30,
2015 and 2014 and the summary balance sheet data as of September&nbsp;30, 2015 from our unaudited condensed interim financial statements included elsewhere in this prospectus. In the opinion of management, these unaudited condensed interim financial
statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair statement of our financial position and operating results for these periods. We maintain our books and records in U.S. dollars, and prepare our
financial statements in accordance with accounting principles generally accepted in the United States, or U.S. GAAP, as issued by the Financial Accounting Standards Board, or FASB. You should read this data together with our financial statements and
related notes appearing elsewhere in this prospectus and the information under the captions &#147;Capitalization&#148; and &#147;Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations.&#148; Our historical results
are not necessarily indicative of our future results, and our interim period results are not necessarily indicative of results to be expected for a full year or any other interim period. </I></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR ENDED</B><br><B>DECEMBER 31, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED<BR>SEPTEMBER&nbsp;30, </B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(Unaudited) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands, except share and per share data) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Statements of Operations Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Per share information:<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma loss per ordinary share, basic and diluted (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pro forma weighted average number of ordinary shares outstanding (unaudited)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="64%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AS&nbsp;OF&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>AS&nbsp;OF&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>(in thousands) </B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents </P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Working capital<SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,397</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,664</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total shareholders&#146; equity</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 9 to our annual financial statements and Note 7 to our interim financial statements, respectively, included elsewhere in this prospectus for an explanation of the calculations of our basic and diluted loss per
ordinary share and the weighted-average number of shares used in the computation of the per share amounts. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Working capital is defined as total current assets minus total current liabilities. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">60 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_9"></A>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF
OPERATIONS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical
company focused on developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment
options for a variety of urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug MMC, which is currently used for urothelial cancer treatment only in
a water-based formulation as an adjuvant therapy. We are developing our product candidates as chemoablation agents, which means they are designed remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer,
including low-grade UTUC and low-grade bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by replacing costly, sub-optimal and
burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder, kidney and upper urothelial tract removals, which are typically performed on patients whose cancer
progresses despite undergoing tumor resection surgical procedures. Additionally, we believe that our product candidates, which are based on formulations of approved drugs, may qualify for streamlined regulatory pathways to market approval. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary RTGel technology. We believe that RTGel-based drug formulations, which provide
for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the
bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage throughout the organ of the active drug. Consequently, we believe that RTGel-based drug formulations may enable us to overcome the
anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. No drugs have been approved by the FDA for UTUC, and no drugs have been approved by the FDA for
bladder cancer for more than 15 years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of
high-grade NMIBC, as well as BotuGel, which we are developing for the treatment of overactive bladder and interstitial cystitis, also known as painful bladder syndrome. We acquired Vesimune from Telormedix SA, a private Swiss-based biotechnology
company, in the fourth quarter of 2015. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have incurred net losses in each year since our formation in 2004. We incurred net losses of $4.5&nbsp;million and
$3.3&nbsp;million for the years ended December&nbsp;31, 2014 and 2013, respectively, and $5.7&nbsp;million and $3.3&nbsp;million for the nine months ended September&nbsp;30, 2015 and 2014, respectively. As of September&nbsp;30, 2015 and
December&nbsp;31, 2014, our accumulated deficit was $18.2 million and $12.6&nbsp;million, respectively. We expect to continue to incur losses for the foreseeable future, and our losses may fluctuate significantly from quarter-to-quarter and
year-to-year. We expect that our expenses will increase substantially in connection with our ongoing activities as we: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">file an IND for MitoGel with the FDA and, if accepted, initiate a single pivotal Phase 3 clinical trial, and file an IND for VesiGel and, if accepted, initiate a Phase&nbsp;2b clinical trial, each pursuant to the
FDA&#146;s 505(b)(2) regulatory pathway; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">initiate an additional clinical trial for Vesimune, either as a single agent or in combination with another agent, and initiate a dose-ranging study for BotuGel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">continue the preclinical development of our other product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">file an NDA seeking regulatory approval for any product candidates;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish a sales, marketing and distribution infrastructure and scale up external manufacturing capabilities to commercialize any products for which we obtain regulatory approval;</TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintain, expand and protect our intellectual property portfolio;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add equipment and physical infrastructure to support our research and development; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">hire additional clinical development, quality control and manufacturing personnel; and</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">61 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">add operational, financial and management information systems and personnel, including personnel to support our product development and planned future commercialization. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Components of Results of Operations </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Revenue </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently have any products approved for sale, and we have not recognized any revenue to date. In the future, we may generate revenue from a combination of
product sales, reimbursements, up-front payments, milestone payments, and royalties in connection with future collaborations. If we fail to achieve clinical success and/or to obtain regulatory approval of any of our product candidates in a timely
manner, our ability to generate future revenue will be impaired. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Research and development expenses, net </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The largest component of our total operating expenses has historically been and we expect will continue to be research and development. Research and development
expenses consist primarily of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">salaries and related costs, including share-based compensation expense, for our personnel in research and development functions;</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred under agreements with third parties, including CROs, subcontractors, suppliers and consultants, preclinical studies and clinical trials; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">expenses incurred to acquire, develop and manufacture preclinical and clinical trial materials; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facility and equipment costs, including depreciation expense, maintenance and allocated direct and indirect overhead costs. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We expense all research and development costs as incurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30,
2015, we have received aggregate grants of $1.9 million from the OCS for research and development funding. Pursuant to the terms of the grants, we are required to pay royalties to the Government of Israel on revenues from sales of products for which
the research and development was funded, in whole or in part, by the OCS. Pursuant to the terms of the grants, we are obligated to pay the OCS royalties of 3.0% to 4.5% on revenues from sales of products developed from a project financed in whole or
in part by OCS grants, up to a limit of 100% of the amount of the grant received, plus annual interest calculated at a rate based on 12-month LIBOR. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to
paying any royalties due, we must abide by other restrictions associated with receiving such grants under the R&amp;D Law, which will continue to apply to us following full repayment to the OCS. See &#147;Risk Factors&#151;The Israeli government
grants we have received for research and development activities restrict our ability to manufacture products and transfer technologies outside of Israel and require us, in addition to the payment of royalties, to satisfy specified conditions. If we
fail to satisfy these conditions, we may be required to refund grants previously received and incur financial penalties.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently focused on
advancing our product candidates, and our future research and development expenses will depend on their clinical success. Research and development expenses will continue to be significant and will increase over at least the next several years as we
continue to develop our product candidates and conduct preclinical studies and clinical trials of our product candidates. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not believe that it is possible at
this time to accurately project total expenses required for us to reach commercialization of our product candidates. Due to the inherently unpredictable nature of preclinical and clinical development, we are unable to estimate with certainty the
costs we will incur and the timelines that will be required in the continued development and approval of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially
from expectations. See &#147;Risk Factors&#151;Risks Related to Our Business and Strategy.&#148; In addition, we cannot forecast which product candidates may be subject to future collaborations, if and when such arrangements will be entered into, if
at all, and to what degree such arrangements would affect our development plans and capital requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under applicable accounting rules, we deduct the OCS
grants from research and development expenses as the applicable costs are incurred. As a result, our research and development expenses are shown on our financial statements net of the OCS grants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">62 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General and administrative expenses </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses consist primarily of personnel costs, including share-based compensation, related to directors, executive, finance, and human
resource functions, facility costs and external professional service costs, including legal, accounting and audit services and other consulting fees. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We anticipate
that our general and administrative expenses will increase in the future as we increase our administrative headcount to support our continued research and development programs and the potential approval and commercialization of our product
candidates. We also anticipate that we will incur increased expenses related to audit, legal, regulatory and tax-related services associated with maintaining compliance with NASDAQ and SEC requirements, director and officer insurance premiums,
director compensation, and other costs associated with being a public company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if any of our product candidates receives regulatory approval and if we
determine to invest in building a commercial infrastructure to support the marketing of our products, we expect to incur greater general and administrative expenses. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Finance expenses, net </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance expenses, net, consists primarily of
bank fees, gain or loss from foreign currency exchange differentials and finance expenses on warrants and convertible notes. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have yet to generate taxable income in Israel, as we have historically incurred operating losses resulting in carry forward tax losses totaling approximately $7.8
million as of December 31, 2014. We anticipate that we will continue to generate tax losses for the foreseeable future and be able to carry forward these tax losses indefinitely to future taxable years. Accordingly, we do not expect to pay taxes in
Israel until we have taxable income after the full utilization of our carry forward tax losses. We have provided for a full valuation allowance with respect to the deferred tax assets related to these carry forward losses in our financial
statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Results of Operations </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the nine months
ended September 30, 2015 and 2014 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the nine months ended September 30, 2015 and 2014: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Includes share-based compensation expenses as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">63 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and development expenses </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses increased by $1.8 million, or 73%, to $4.4 million in the nine months ended September 30, 2015 from $2.6 million in the nine months
ended September 30, 2014. The increase in research and development expenses resulted primarily from an increase in our activity in preclinical studies and other payments to subcontractors related to the development activity in preparation for our
single pivotal Phase&nbsp;3 clinical trial of MitoGel for the treatment of low-grade UTUC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses increased by $400,000, or 66%, to $1.0 million in the nine months ended September&nbsp;30, 2015 from $609,000 in the nine months
ended September 30, 2014. The increase in general and administrative expenses resulted primarily from an increase in payroll expenses of $117,000 and an increase in professional audit and accounting service expenses of $227,000. The increase was
primarily related to our strengthening of our senior management team and payments to consultants hired by us in preparation for this offering. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Finance expenses,
net </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance expenses, net, increased by $104,000, or 103%, to $205,000 in the nine months ended September&nbsp;30, 2015 from $101,000 in the nine months ended
September 30, 2014. The increase was primarily due to an increase of $175,000 in the fair value of the warrants converted to Series A-1 preferred shares and fair value of our convertible notes that were converted into Series A preferred shares
during the fourth quarter of 2014. This was partly offset by a decrease of $78,000 in the loss from foreign currency exchange. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Comparison of the years ended
December 31, 2014 and 2013 </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our results of operations for the years ended December 31, 2014 and 2013: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses, net<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Finance expenses (income), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>Includes share-based compensation expense as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="78%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Research and development expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development expenses
increased by $1.2&nbsp;million, or 49%, to $3.5 million in the year ended December&nbsp;31, 2014 from $2.3 million in the year ended December 31, 2013. The increase was primarily due to preclinical and clinical work related to the development of
MitoGel and increased clinical activity relating to the development of VesiGel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>General and administrative expenses </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">General and administrative expenses decreased by $165,000, or 16%, to $890,000 in the year ended December&nbsp;31, 2014 from $1.1 million in the year ended December 31,
2013. The decrease in general and administrative expenses resulted primarily from a decrease in share-based compensation expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">64 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Finance expenses </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Finance
expenses, net, increased by $190,000, to $107,000 in the year ended December 31, 2014 from income of $83,000 in the year ended December 31, 2013. The increase was primarily due to foreign currency exchange loss and income in 2014 and 2013,
respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Liquidity and Capital Resources </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Since our inception, we have incurred losses and negative cash flows from our operations. For the nine months ended September 30, 2015, we incurred a net
loss of $5.7 million and used $5.7 million in our operating activities. For the year ended December 31, 2014, we incurred a net loss of $4.5 million and used $4.1 million in our operating activities. As of September 30, 2015, we had working capital
of $1.6 million, and an accumulated deficit of $18.2 million. Our principal source of liquidity as of September 30, 2015 consisted of cash and cash equivalents of $1.6 million. In the fourth quarter of 2015, we completed an $18.1 million private
placement of Series A preferred shares with several of our existing shareholders, new investors and certain members of management and our board of directors. As of December 31, 2015, our cash and cash equivalents totaled $18.0 million. We believe
that the net proceeds of this offering, together with our existing cash and cash equivalents, will enable us to fund our operations for at least the next 12 months. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our independent registered public accounting firm has issued a going concern opinion on our December 31, 2014 financial statements, expressing substantial doubt that we
can continue as an ongoing business after issuance of their report based on our having incurred cumulative losses and negative cash flows from operating activities since inception and having an accumulated deficit at December 31, 2014 of $12.6
million, as discussed in Note 1 of our accompanying financial statements that appear elsewhere in this prospectus. Our financial statements do not include any adjustments that might be necessary if we are unable to continue as a going concern. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Capital resources </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overview </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, we have financed our operations primarily through private placements of equity securities and convertible notes. Total invested capital as of
September&nbsp;30, 2015 was $18.2&nbsp;million, which included, ordinary shares and Series A preferred shares and warrants to purchase Series A-1 preferred shares, as well as from convertible notes. The convertible notes were issued during the first
half of 2014 and were converted in their entirety into Series A preferred shares and warrants to purchase Series A-1 preferred shares on October 20, 2014. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Such
preferred shares will be converted into ordinary shares of the same number upon the closing of this offering, in accordance with our articles of association. The warrants to purchase preferred shares expire upon the closing of this offering. We
expect that all of the warrants will be exercised prior to the closing of this offering and the preferred shares issuable upon exercise of the warrants will automatically convert into ordinary shares. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table summarizes our statement of cash
flows for the years ended December 31, 2014 and 2013 and the nine months ended September 30, 2015 and 2014: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="58%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center"><B>(Unaudited)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by (used in):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,117</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,557</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,656</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,841</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">65 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash used in operating activities </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was $5.7 million in the nine months ended September 30, 2015, compared to $2.8 million in the nine months ended September 30,
2014. The increase was attributable primarily to the increase of $2.4 million in our loss for the period. This increased loss primarily related to our activity in preclinical studies and other payments to subcontractors, including payments for
purchase of materials related to the development activity in preparation for our planned single pivotal Phase 3 trial of MitoGel for the treatment of low-grade UTUC and also payroll and professional audit and accounting service expenses related to
strengthening our senior management team and payments to consultants hired by us in preparation for this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities was $4.1
million in the year ended December 31, 2014, compared to $2.6 million in the year ended December 31, 2013. The increase was attributable primarily to the increase of $1.2 million in our loss for the period. This increased loss mainly related to
preclinical, clinical and regulatory work related to the development of MitoGel and increased clinical activity relating to the development of VesiGel. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net cash
used in investing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The use of cash in investing activities relates primarily to the purchase of property and equipment and changes in restricted
deposits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities was $233,000 in the nine months ended September 30, 2015, compared to $13,000 in the nine months ended September
30, 2014. Net cash used in investing activities was $1,000 in the year ended December 31, 2014, compared to $89,000 in the year ended December 31, 2013. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Net
cash provided by financing activities </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $3.6 million in the nine months ended September 30, 2015, an increase of
$2.8 million from $792,000 in the nine months ended September 30, 2014. In September 2014, we entered into a share purchase agreement, which we refer to as the 2014 Share Purchase Agreement, pursuant to which we raised an aggregate of $8.0 million
in a private placement. Of the $8.0 million, $792,000 was received during the nine months ended September 2014, $3.6 million was received in the fourth quarter of 2014, and $3.6 million was received during the second quarter of 2015. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities was $5.0 million in the year ended December 31, 2014, compared to $3.5 million in the year ended December 31, 2013. The $1.5
million increase was attributable primarily to the 2014 Share Purchase Agreement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Funding Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital
expenditure requirements for at least the next 12 months. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our present and future funding requirements will depend on many factors, including, among other things: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the progress, timing and completion of clinical trials for MitoGel and VesiGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">and preclinical studies and clinical trials for Vesimune or any of our other product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the potential costs of further developing BotuGel in connection with our pharmaceutical partner or alone; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs related to obtaining regulatory approval for MitoGel, VesiGel and Vesimune and any of our other product candidates, and any delays we may encounter as a result of regulatory requirements or adverse clinical
trial results with respect to any of these product candidates; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">selling, marketing and patent-related activities undertaken in connection with the commercialization of MitoGel and VesiGel and any of our other product candidates, and costs involved in the development of an effective
sales and marketing organization; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the costs involved in filing and prosecuting patent applications and obtaining, maintaining and enforcing patents or defending against claims or infringements raised by third parties, and license royalties or other
amounts we may be required to pay to obtain rights to third party intellectual property rights; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">66 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential new product candidates we identify and attempt to develop; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">revenues we may derive either directly or in the form of royalty payments from future sales of MitoGel, VesiGel, Vesimune, BotuGel and any other product candidates. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For more information as to the risks associated with our future funding needs, see &#147;Risk Factors&#151;We will require substantial additional financing to achieve
our goals, and a failure to obtain this capital when needed and on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Contractual obligations and commitments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our known contractual
obligations as of December 31, 2014 are summarized in the following table. The obligations detailed below do not include grants received from the OCS pursuant to which we will owe royalties upon commercialization of our product candidates. As of
December 31, 2014, the maximum royalty amount payable by us under these funding arrangements is $1.5 million, excluding interest. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="54%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAYMENTS DUE BY PERIOD</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>LESS&nbsp;THAN&nbsp;1&nbsp;YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>1&nbsp;TO&nbsp;3&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>3&nbsp;TO&nbsp;5&nbsp;YEARS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center"><B>(In thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Operating lease obligations<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Operating lease obligations consist of payments pursuant to a lease agreement for our Israeli offices and laboratory facility. In November 2014, we entered into a new lease agreement effective from February 1, 2015 for
a period of three years, with an option to extend the lease agreement by an additional three years. We also have an option to terminate the lease with six months&#146; notice after the first 24 months of the lease. If the option is exercised and the
lease is extended, we will not have an early termination option during that extension period. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Off-balance Sheet Arrangements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of the date of this prospectus and during the periods presented, we do not and did not, respectively, have any off-balance sheet arrangements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Quantitative and Qualitative Disclosure about Market Risk </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Market risk is
the risk of loss related to changes in market prices, including interest rates and foreign exchange rates, of financial instruments that may adversely impact our financial position, results of operations or cash flows. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign currency exchange risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar is our functional and
reporting currency. However, a significant portion of our operating expenses are incurred in NIS. As a result, we are exposed to the risk that the NIS may appreciate relative to the dollar, or, if the NIS instead devalues relative to the dollar,
that the inflation rate in Israel may exceed such rate of devaluation of the NIS, or that the timing of such devaluation may lag behind inflation in Israel. In any such event, the dollar cost of our operations in Israel would increase and our
dollar-denominated results of operations would be adversely affected. We cannot predict any future trends in the rate of inflation in Israel or the rate of devaluation, if any, of the NIS against the dollar. For example, although the dollar
appreciated against the NIS in 2011, the rate of devaluation of the dollar against the NIS was (7)% and 12% in 2013 and 2014, respectively, which was compounded by inflation in Israel at a rate of (0.1)% and (0.2)%, respectively. If the dollar cost
of our operations in Israel increases, our dollar-measured results of operations will be adversely affected. Our operations also could be adversely affected if we are unable to effectively hedge against currency fluctuations in the future. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not currently engage in currency hedging activities in order to reduce this currency exposure, but we may begin to do so in the future. Instruments that may be
used to hedge future risks may include foreign currency forward and swap contracts. These instruments may be used to selectively manage risks, but there can be no assurance that we will be fully protected against material foreign currency
fluctuations. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Liquidity risk </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We monitor forecasts of our
liquidity reserve (comprising cash and cash equivalents and deposits). We generally carry this out based on our expected cash flows in accordance with practice and limits set by our management. We are in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">67 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the research and development stage and have not yet generated any revenue from sales of our product candidates; we are therefore exposed to liquidity risk. However, we believe that the net
proceeds of this offering, together with our existing cash and cash equivalents and deposits, will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Critical Accounting Policies and Estimates </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our management&#146;s discussion
and analysis of our financial condition and results of operations is based on our financial statements, which we have prepared in accordance with U.S. GAAP, as issued by the FASB. The preparation of our financial statements requires us to make
estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting
periods. Actual results may differ from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">While our significant accounting policies are more fully
described in the notes to our financial statements appearing elsewhere in this prospectus, we believe that the accounting policies discussed below are critical to our financial results and to the understanding of our past and future performance, as
these policies relate to the more significant areas involving management&#146;s estimates and assumptions. We consider an accounting estimate to be critical if: (i) it requires us to make assumptions because information was not available at the time
or it included matters that were highly uncertain at the time we were making our estimate and (ii) changes in the estimate could have a material impact on our financial condition or results of operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Share-Based Compensation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We account for our share-based compensation
for employees and directors in accordance with the provisions of ASC 718, Compensation&#151;Stock Compensation, U.S. GAAP &#147;Stock-based Payment,&#148; which requires us to measure the cost of share-based compensation based on the fair value of
the award on the grant date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We re-measure equity awards granted to non-employees at each reporting period at fair value until they have vested. The fair value of
equity awards is charged to the statement of operations over the service period using the straight-line method. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Option Valuations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value of our share-based awards. The resulting cost
of a share incentive award is recognized as an expense over the requisite service period of the award, which is usually the vesting period. We recognize compensation expense over the vesting period using the straight-line method, and classify these
amounts in the financial statements based on the department to which the related employee reports. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The determination of the grant date fair value of options using
an option pricing model is affected by estimates and assumptions regarding a number of complex and subjective variables. These variables include the expected volatility of our share price over the expected term of the options, share option exercise
and cancellation behaviors, risk-free interest rates and expected dividends, which are estimated as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Fair value of our ordinary shares</I>. Because our shares are not publicly traded, we must estimate the fair value of ordinary shares, as discussed below in &#147;&#151;Valuation of our ordinary shares.&#148;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Volatility</I>. The expected share price volatility was based on the historical volatility of the ordinary shares of comparable companies that are publicly traded. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected term</I>. The expected term of options granted represents the period of time that options granted are expected to be outstanding. Since adequate historical experience is not available to provide a reasonable
estimate, the expected term for grants to employees for at the money options (except senior management) is determined based on the midpoint between the available exercise dates (the end of the vesting periods) and the last available exercise date
(the contracted expiry date). The expected term for grants to non-employees, senior management, directors, and out of the money options granted to employees, is determined based on the contractual life of the options. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">68 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Risk-free rate</I>. The risk-free interest rate is based on the yield from U.S. Treasury zero-coupon bonds with a term equivalent to the expected term of the options. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Expected dividend yield</I>. We have never declared or paid any cash dividends and do not presently plan to pay cash dividends in the foreseeable future. Consequently, we used an expected dividend yield of zero.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If any of the assumptions used in the Black-Scholes option pricing model change significantly, share-based compensation for future awards may differ
materially compared with the awards granted previously. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the weighted-average assumptions used to estimate the fair value of options
granted on the dates indicated below. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="63%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>YEAR&nbsp;ENDED</B><br><B>DECEMBER&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30,&nbsp;2015<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">68.45&nbsp;-&nbsp;74.78</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">70.55&nbsp;-&nbsp;73</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">3.9&nbsp;-&nbsp;7.3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4 - 7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free rate (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.38 - 2.27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1.4 - 1.9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected dividend yield (%)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table presents the grant dates, number of underlying shares and related exercise prices of options granted to employees and non-employees since January 1,
2014, as well as the estimated fair value of the underlying ordinary shares on the grant date. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="49%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:60.15pt; font-size:8pt; font-family:ARIAL"><B>DATE OF GRANT</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B><br><B>SUBJECT TO</B><br><B>AWARDS</B><br><B>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CLASS&nbsp;OF</B><br><B>SHARES</B><br><B>SUBJECT&nbsp;TO</B><br><B>THE<BR>AWARDS</B><br><B>GRANTED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TYPE OF</B><br><B>EQUITY</B><br><B>INSTRUMENT</B><br><B>AWARDED</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EXERCISE</B><br><B>PRICE&nbsp;PER</B><br><B>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ESTIMATED</B><br><B>FAIR&nbsp;VALUE</B><br><B>PER<BR>ORDINARY</B><br><B>SHARE AT</B><br><B>GRANT&nbsp;DATE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">July - September 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">Options</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">$16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">August - September 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top"></SUP>&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">82,065<SUP STYLE="font-size:85%; vertical-align:top"></SUP></TD>
<TD NOWRAP VALIGN="top"><SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(1)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">ordinary</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Options&nbsp;and<BR>Restricted<BR>Share Units</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">0-16.00</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">9.64</TD>
<TD NOWRAP VALIGN="top">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Excludes 9,000 ordinary shares issuable upon the vesting of restricted share units which were granted contingent upon the consummation of the completed purchase of intellectual property from Telormedix SA, and excludes
9,000 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based
on the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, the midpoint of the range set forth on the cover page of this prospectus, the intrinsic
value of the awards outstanding as of September 30, 2015 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, of which
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related to vested options and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related
to unvested options. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Valuation of our ordinary shares </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Due to the
absence of an active market for our ordinary shares, the fair value of our ordinary shares for purposes of determining the exercise price for award grants was determined in good faith by our management during the fourth quarter of 2015. In
connection with preparing our financial statements, our management considered the fair value of our ordinary shares based on a number of objective and subjective factors, consistent with the methodologies outlined in the American Institute of
Certified Public Accountants Practice Aid, Valuation of Privately-Held- Company Equity Securities Issued as Compensation, referred to as the AICPA Practice Aid. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2010-2013 Awards </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was estimated based on the price
at which the most recent financing (from external investors) took place, based on our assumption that no significant changes have occurred between the financing closing date and the grant date. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">69 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2014 Awards</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary
share price was derived from the price used in the financing round on October 20, 2014, based on our assumption that no significant changes have occurred between grant date and the financing round closing date. The derivation of ordinary share price
was performed under the option pricing method, or OPM, valuation framework, as described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>2015 Awards</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The ordinary share price was estimated based on a valuation performed as of September 30, 2015, as described below, and based on our assumption that no significant
changes have occurred between grant date and the valuation date. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for 2014 Awards&#151;Methodology</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The valuation of the ordinary shares as of October&nbsp;20, 2014 was performed under the OPM framework and using the Backsolve method, which infers the equity value
consistent with the financing round on October 20, 2014. The OPM method is regarded as a common framework for allocating the equity value between the different share classes and other securities. Under this approach, the financial instruments issued
by the company (preferred shares, warrants, employee options and ordinary shares) are deemed as contingent claims whose future payoffs depends on our (future) equity value. The OPM was implemented by using the Monte Carlo simulation technique, which
generates different scenarios of the equity value and the resulting payoff to the holders of our financial instruments. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underlying asset, or the equity value,
was estimated by implementing the Backsolve method, </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the above allocation process, we applied a discount of lack of marketability, or DLOM, to the price
of an ordinary share. Specifically, we applied the average strike put option in order to estimate the DLOM. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Fair value of our ordinary shares for 2015
Awards&#151;Methodology</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a 15% possibility for IPO event in the near future was estimated, the valuation was conducted through the use of the Hybrid model.
The Hybrid approach combines two probability-weighted scenarios: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario I&#151;IPO Event. The probability of this scenario was estimated at 15%. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The valuation of our
financial instruments was based on the estimated range of equity value upon an IPO and the resulting payoff per each financial instrument. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Scenario II&#151;Liquidation Event. The probability of this scenario was estimated at 85%. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The
valuation of the ordinary share price under this scenario was performed under the OPM framework using the Monte Carlo simulation technique, in similar fashion to the approach used for the 2014 valuation, as described above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The equity value used in the OPM method was derived from the financing round in October 2015 (the Backsolve method). As of September 30, 2015, this
financing round was highly expected to be closed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We applied a DLOM to the ordinary share price, using the average strike put option. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of an ordinary share was calculated as the weighted average of the ordinary share prices, derived from the calculations made under the two scenarios
described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Future option awards</I> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of our
initial public offering and the listing of our shares on the NASDAQ Global Market, the determination of the fair market value of our ordinary shares for purposes of setting the exercise price of future option awards or other share-based compensation
to employees and other grantees will no longer require good faith estimates by our board of directors based on various comparisons or benchmarks. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting
treatment of the convertible notes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">During 2014, we issued a series of convertible notes, or the Convertible Notes, in the aggregate amount of approximately
$647,000. The Convertible Notes are to be automatically converted into ordinary shares at a conversion price of $16.00 in December 2017, or to the most senior preferred shares or ordinary shares upon the occurrence of certain events, such as an IPO,
merger, acquisition or a financing round in an amount of at least $5.0&nbsp;million in a single transaction or a series of related transactions, or collectively, the Qualifying Events. The Convertible Notes will convert upon a Qualifying Event into
a number of shares based on the then applicable conversion price that reflects a fixed discount on the price per share reflected in the respective Qualifying Event. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">70 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September 2014, we signed the 2014 Share Purchase Agreement with shareholders and new investors for an aggregate amount
of $8.0 million. In October 2014, June 2015 and July 2015, we issued 421,122 Series A preferred shares at a price per share of $19.00 and warrants to purchase an additional 210,561 shares of <FONT STYLE="white-space:nowrap">Series&nbsp;A-1</FONT>
preferred shares at an exercise price of $25.00 per share. The initial closing under the 2014 Share Purchase Agreement occurred in October 2014. Pursuant to the 2014 Share Purchase Agreement, each investor who invested more than $500,000 transferred
50% of the investment at the initial closing and an additional 50% was invested upon the occurrence of certain milestones as agreed on in the 2014 Share Purchase Agreement, or the Milestone Closing. Investors that invested less than $500,000
transferred their entire investment amount in the initial closing, or at a deferred closing six months after the initial closing. The Milestone Closing occurred in June 2015. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offered the Convertible Note holders an option to convert the notes according the terms of the 2014 Share Purchase Agreement, in lieu of the conversion for discount.
At the initial closing, all of the holders of the Convertible Notes elected to convert the notes according to the terms of the 2014 Share Purchase Agreement, and we issued 34,061 shares of Series A preferred shares to them and granted warrants to
purchase an additional 17,031 shares of Series A-1 preferred shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Convertible Notes are accounted for at fair value through profit and loss at each
reporting period and until final conversion pursuant to the above mentioned 2014 Share Purchase Agreement, in accordance with ASC 480. Under ASC 480, a financial instrument that embodies a conditional obligation, which the issuer may settle by
issuing a variable number of its equity shares, shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on a fixed monetary amount known at inception. We analyzed the terms of the
Convertible Notes at inception and determined that they should be classified as a liability under ASC 480 since the Convertible Notes will be converted into variable numbers of shares based predominantly on a fix monetary amount. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Accounting treatment of the warrants to purchase preferred shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our warrants to purchase preferred shares are exercisable into Series A-1 preferred shares of the company, nominal value NIS 0.01 per share, for an exercise price of
$25.00 per share commencing on the date of the issuance and expiring at the earlier of a qualified IPO, certain M&amp;A events, or four years from the date of issuance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that the warrants are exercised in connection with a qualified IPO or certain M&amp;A events, the holder may elect to convert the warrants on a net share
basis. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The warrants are classified as liabilities in accordance with ASC 480, as they are freestanding instruments, exercisable into Series A-1 preferred shares,
which are redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events. Accordingly, the warrants are measured at fair value at the end of every reporting period, and changes in their fair value are recognized in earnings.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Deferred taxes </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Income taxes are computed using the asset and
liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently
enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. We have provided a full valuation allowance with respect to its
deferred tax assets. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are no
U.S. GAAP standards as issued by the FASB that are effective for the first time for the financial year beginning on or after January 1, 2015 that would be expected to have a material impact on our financial position. See Note 2q to our annual
financial statements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Internal Control Over Financial Reporting </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to achieve and maintain effective internal controls in accordance with Section 404 of the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, could have a
material adverse effect on our business, results of operation or financial condition. In addition, current and potential shareholders could lose confidence in our financial reporting, which could have a material adverse effect on the price of our
ordinary shares. Pursuant to Section 404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">71 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
starting with the second annual report that we file with the SEC after the consummation of this offering, our management will be required to report on the effectiveness of our internal control
over financial reporting. In addition, once we no longer qualify as an &#147;emerging growth company&#148; under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above, our independent registered public
accounting firm will also need to attest to the effectiveness of our internal control over financial reporting under Section 404. We have not yet commenced the process of determining whether our existing internal controls over financial reporting
systems are compliant with Section 404 and whether there are any material weaknesses or significant deficiencies in our existing internal controls. This process will require the investment of substantial time and resources, including by our Chief
Financial Officer and other members of our senior management. In addition, we cannot predict the outcome of this determination and whether we will need to implement remedial actions in order to implement effective control over financial reporting.
The determination and any remedial actions required could result in us incurring additional costs that we did not anticipate. Irrespective of compliance with Section 404, any failure of our internal controls could have a material adverse effect on
our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to
implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of
operations and could result in an adverse opinion on internal controls from our independent auditors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>JOBS Act </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As an &#147;emerging growth company,&#148; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements,
including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to
incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The JOBS Act additionally permits emerging growth companies such as us to take advantage of an extended transition period to comply with new or revised accounting
standards applicable to public companies. We have irrevocably elected not to avail ourselves of this provision and, as a result, we will comply with new or revised accounting standards as other public companies that are not emerging growth
companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">72 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_10"></A>BUSINESS </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Overview </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are a clinical stage biopharmaceutical company focused on
developing novel therapies designed to change the standard of care for urological pathologies. We have an innovative and broad pipeline of product candidates that we believe can overcome the deficiencies of current treatment options for a variety of
urological conditions with a focus on uro-oncology. Our lead product candidates, MitoGel and VesiGel, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, which is currently used for urothelial cancer treatment only in a
water-based formulation as an adjuvant therapy. We are developing our product candidates as chemoablation agents, which means they are designed remove tumors by non-surgical means, to treat several forms of non-muscle invasive urothelial cancer,
including low-grade upper tract urothelial carcinoma, or UTUC, and low-grade bladder cancer. We believe that MitoGel and VesiGel, which are both local drug therapies, have the potential to significantly improve patients&#146; quality of life by
replacing costly, sub-optimal and burdensome tumor resection and kidney removal surgeries as the first-line standard of care. MitoGel and VesiGel may also reduce the need for bladder, kidney and upper urothelial tract removals, which are typically
performed on patients whose cancer progresses despite undergoing tumor resection surgical procedures. Additionally, we believe that our product candidates, which are based on formulations of approved drugs, may qualify for streamlined regulatory
pathways to market approval. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our lead product candidates, MitoGel and VesiGel, are formulated using our proprietary reverse thermally triggered hydrogel, or RTGel,
technology. We believe that RTGel-based drug formulations, which provide for the sustained release of an active drug, may improve the efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or
interfering with the natural flow of fluids from the urinary tract to the bladder. Our formulations are designed to achieve this by increasing the dwell time as well as the tissue coverage throughout the organ of the active drug. Consequently, we
believe that RTGel-based drug formulations may enable us to overcome the anatomical and physiological challenges that have historically contributed to the lack of drug development for the treatment of urothelial cancer. No drugs have been approved
by the U.S. Food and Drug Administration, or the FDA, for the treatment of UTUC, and no drugs have been approved by the FDA for the treatment of bladder cancer for more than 15&nbsp;years. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently evaluating the safety and efficacy of MitoGel, our novel sustained-release formulation of MMC, in UTUC patients pursuant to an ongoing
&#147;Compassionate Use&#148; program. Of the seven low-grade UTUC patients evaluated in the program to date, four achieved a complete response and three achieved a partial response. Thus far, MitoGel has been observed to be well-tolerated. We have
obtained Orphan Drug Designation for MitoGel for the treatment of UTUC. We expect to file an investigational new drug, or IND, application for MitoGel with the FDA in the second half of 2016 and, if accepted, to commence a single pivotal,
open-label, single-arm Phase 3 clinical trial for the treatment of low-grade UTUC also in the second half of 2016. We intend to pursue the FDA&#146;s 505(b)(2) regulatory pathway for MitoGel, which is a streamlined, lower-cost and more well-defined
pathway to drug approval when compared to traditional drug development. We believe that MitoGel has the potential to become the first FDA-approved drug for the treatment of low-grade UTUC and to serve as a first-line chemoablation agent, sparing
patients from repeated tumor resection surgeries and potentially reducing the need for kidney and upper urothelial tract removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we are currently
evaluating the safety and efficacy of VesiGel, our novel sustained-release high dose formulation of MMC, for the treatment of low-grade non-muscle invasive bladder cancer, or NMIBC. To date, 18&nbsp;of&nbsp;21, or approximately 86%, of the patients
evaluated in our ongoing Phase 2a clinical trial who were treated in the VesiGel high dose group (80mg MMC) achieved a complete response. Moreover, in the clinical program to date, comprised of the Phase 2a and Phase 1 clinical trials, over 80% of
the patients who achieved a complete response and who have been followed for 12 months thereafter remained recurrence free and were able to sustain a durable complete response during those 12 months. This compares to approximately 40% of patients
who historically have been able to sustain a 12-month durable complete response following transurethral resection of bladder tumor, or TURBT, as first-line treatment. We plan to file an IND for VesiGel in the first half of 2017 and, if accepted, to
commence a Phase 2b clinical trial for VesiGel, also in the first half of 2017. We also intend to pursue a 505(b)(2) regulatory pathway for VesiGel. We believe that VesiGel has the potential to replace tumor resection surgery and become the new
first-line standard of care for the treatment of low-grade NMIBC to replace tumor resection surgery as first-line treatment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">73 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that urothelial cancer, which is comprised of bladder cancer and UTUC, affects a large and underserved patient
population. Annual expenditures for Medicare alone in the United States for the treatment of urothelial cancer were approximately $4 billion in 2010 and are projected to be approximately $5 billion in 2020. The majority of the historical
expenditures was spent on tumor resection surgeries such as TURBT and bladder, kidney and upper urothelial tract removal. In 2012, the estimated prevalence of urothelial cancer in the United States was 580,000 with an annual incidence of
approximately 74,000. The 2012 prevalence of each of low-grade NMIBC and low-grade UTUC in the United States was approximately 325,000 and 14,000, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our clinical stage pipeline also includes Vesimune, our proprietary immunotherapy product candidate for the treatment of high-grade NMIBC, as well as BotuGel, which we
are developing for the treatment of overactive bladder and interstitial cystitis, also known as painful bladder syndrome. Vesimune is a novel, liquid formulation of Imiquimod, a toll-like receptor 7, or TLR7, agonist. Toll-like receptor agonists
play a key role in initiating the innate immune response system. We believe that Vesimune could represent a valid alternative to the current standard of care for the adjuvant, or supplemental, treatment following TURBT of high-grade NMIBC. BotuGel
is our proprietary novel RTGel-based formulation of botulinum toxin that we believe can potentially serve as an effective treatment option for patients suffering from overactive bladder and interstitial cystitis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Product Candidate Pipeline </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart summarizes the current
status of our clinical stage product candidate pipeline. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g20t64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Uro-Oncological Indications Targeted by Our Product Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates are administered locally using the standard practice of intravesical instillation directly into the bladder or upper urothelial tract via a
catheter. The instillation into the bladder is expected to take place in a physician&#146;s office as a same-day treatment, in comparison with TURBT or similar tumor surgical procedures, which are operations conducted under general anesthesia in a
hospital setting and often require at least an overnight stay. Tumor surgical procedures often have limited success due to the inability to properly identify, reach and resect all tumors. We believe that an effective chemoablation agent can
potentially provide better eradication of tumors irrespective of the detectability and location of the tumors. In addition, by removing the need for surgery, patients may avoid potential complications associated with surgery and hospital-acquired
infections. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">74 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Bladder Cancer </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The bladder is
a hollow organ in the pelvis with flexible muscular walls. Its main function is to store urine before it leaves the body. Urine is produced by the kidneys and is then carried to the bladder through the upper urothelial tract tubes, called ureters.
The bladder wall has four main layers. The innermost lining is comprised of cells called urothelial or transitional cells, and this inner layer is called the urothelium or transitional epithelium. Beneath the urothelium, there is a layer called the
lamina propria. Next is a thick layer of muscle called the muscularis propria followed by a layer of perivesical fat. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g06l57.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">NMIBC tumor types are circled </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Bladder cancer accounts for approximately 90% of all new cases of urothelial cancer in the United States, with a prevalence of approximately 580,000. Bladder cancer is
nearly three to four times more common in men than women, and, with an average age at diagnosis of 73, mostly affects the elderly. Bladder cancers are described as non-muscle invasive or muscle-invasive based on how far into the wall of the bladder
they have invaded. The magnitude and rate of the spreading of the cancer is called &#147;staging,&#148; which ranges from Ta to T1 for NMIBC, and T2 to T4 for muscle-invasive bladder cancers, as defined by the American Joint Committee on Cancer TNM
System. In addition, Carcinoma in Situ, or CIS, a form of NMIBC, has a staging designation of Tis. Muscle-invasive bladder cancer, or MIBC, has an average five-year survival rate of 15% to 63%, depending on severity. MIBC represents a worse
prognosis than NMIBC, which has a five-year survival rate of approximately 90%. NMIBC accounts for approximately 80% of all new cases of bladder cancer diagnosed in the United States each year, which corresponds to an estimated annual incidence and
prevalence of approximately 60,000 and 465,000 cases, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Non-muscle invasive bladder cancers are divided into two grades, low and high, with high-grade
tumors more likely to recur and progress into muscle-invasive tumors. CIS tumors are all high-grade. Overall, approximately 70% of patients with NMIBC present with low-grade disease at diagnosis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">75 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of bladder cancer in the United States. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g58g66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Upper Tract Urothelial Carcinoma </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC
refers to malignant changes of the transitional urothelial cells lining the upper urothelial tract of the renal pelvis and ureter. UTUC typically exhibits high local recurrence and development of metastases. Similar to NMIBC, the prognosis of
patients with UTUC correlates with the stage and grade of disease at the time of initial diagnosis. The key prognostic factor at the time of diagnosis of UTUC is whether the tumor is in the muscle-invasive or non-muscle invasive stage. The number,
size and location of tumors presented also represent important prognostic factors for UTUC. Approximately 40% of the patients diagnosed annually with UTUC in the United States present with non-muscle invasive UTUC. Non-muscle invasive UTUC is also
divided into two grades, low and high. In two studies conducted in 1997 and 2003 of 30 and 20 patients with non-muscle invasive UTUC, 87% and 75% of patients were diagnosed with low-grade non-muscle UTUC, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">76 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below indicates the prevalence of stage and grade of UTUC in the United States. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g21p99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UTUC accounts for approximately 5% to 10% of all new cases of urothelial cancer, which corresponds to an estimated annual incidence
in the United States of up to 7,500 cases. The prevalence in the United States of UTUC is approximately 35,000, of which approximately 14,000 have low-grade disease. UTUC is nearly three times more common in men than women and affects mostly the
elderly. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. Moreover, the anatomical
complexity of the upper urothelial tract, particularly the renal pelvis, presents significant challenges to the proper identification and ability to reach and resect all tumors in tumor resection surgical procedures. Consequently, patients with
high-grade disease or patients with low-grade disease that present with a large number of tumors typically undergo nephroureterectomy, which is kidney and upper urothelial tract removal. In addition, the stage and grade of UTUC are often
misdiagnosed, which we believe is due to the structural complexity of the upper urothelial tract. Due to these factors, the current standard of care for the treatment of UTUC is nephroureterectomy. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor resection, which aims to be a kidney sparing surgical procedure, is conducted only in patients with low-grade disease that present with a limited number of
tumors. Such procedures are followed by adjuvant chemotherapy treatment, typically with MMC. However, the upper urothelial tract&#146;s anatomical constraints limit the effectiveness of surgical procedures and adjuvant chemotherapy treatments,
leading to high rates of recurrence and risk for progression in this patient population. In a study published in 2009 in the Journal of Endourology evaluating 57&nbsp;patients with low-grade UTUC who underwent tumor resections, 89.5% of patients
with a mean of 5.5&nbsp;recurrences per patient over a four-year period. Moreover, approximately 20% of the patients in this study progressed and ultimately underwent kidney and upper tract removal. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that because tumor resection procedures followed by adjuvant chemotherapy therapy are sub-optimal, nephroureterectomy is often used even in patients that may
be otherwise candidates for organ sparing treatments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Non-Muscle Invasive Bladder Cancer </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Patients treated with the current standard of care have up to an approximately 60% rate of recurrence of NMIBC within one year, and the rate of progression of NMIBC to
MIBC is between 20% and 30%. As a consequence, NMIBC patients often undergo multiple repeat TURBT procedures and adjuvant chemotherapy and immunotherapy treatments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">77 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The standard of care for treating NMIBC patients is TURBT followed by adjuvant chemotherapy or immunotherapy treatment.
TURBT is a surgical operation for tumor removal conducted under general anesthesia in a hospital setting and often requires at least an overnight stay. Moreover, TURBT&#146;s success is tied to the physician&#146;s ability to overcome challenges in
properly identifying, reaching and resecting all tumors. No drugs have been approved by the FDA as first-line treatment for NMIBC and only three drugs have been approved by the FDA for NMIBC, all used as adjuvant treatment, following TURBT. Efficacy
of drug treatments has historically been limited due to challenges presented by bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the drug almost immediately and causing the
excretion of the drug from the bladder at first urine voiding. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Urological Indications Targeted by Our Product Candidates </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Overactive Bladder </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Overactive bladder is characterized by urinary urgency,
with or without urgency-associated urinary incontinence. Overactive bladder is often associated with urinary frequency and nocturia, or excessive urination during the night, in the absence of pathologic or metabolic conditions that may cause or
mimic overactive bladder, such as urinary tract infections, polyuria, which is excessive or abnormally large production or passage of urine,&nbsp;transitional cell carcinoma of the bladder, and underlying neurologic abnormalities. Urgency, the
hallmark of overactive bladder, is defined as the sudden compelling desire to urinate, a sensation that is difficult to defer. Urinary frequency is defined as voiding eight or more times in a 24-hour period. Nocturia is defined as the need to wake
one or more times per night in order to void the bladder. Approximately 33 million Americans have overactive bladder. The overall prevalence of overactive bladder in 2012 in the United States ranges from 26% to 33% for men and from 27% to 46% for
women. Behavioral therapy is considered to be the first recommended therapy. The most common drug treatment option for overactive bladder is anticholinergics, which are neurotransmitters that act in the central and peripheral nervous system. In a
2008 study of 1,117 overactive bladder patients, 73.5% reported that they stopped taking their anticholinergic therapy within one year. According to two separate surveys, the top reasons for discontinuing anticholinergics were the side effects and
lack of efficacy. Reconstructive surgery exists as a last resort. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Botulinum toxin is often used as a second-line drug treatment for patients with overactive
bladder who do not respond to or tolerate anticholinergics. When administered into the bladder wall, botulinum toxin has been shown to lead to significant improvement in urge and incontinence. However, the current mode of administration of botulinum
toxin into the bladder wall has several disadvantages, including the fact that the procedure is conducted under general anesthesia, the requirement of cystoscopy, which is a video guide inserted through the urethra into the bladder, a need to inject
the botulinum toxin into the bladder muscle and the non-uniformity of the distribution of such injections, and the occurrence of urinary retention. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Interstitial
Cystitis </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Interstitial cystitis, also referred to as painful bladder syndrome, is a condition of recurring pressure, pain or discomfort in the bladder and
pelvic region, combined with urinary frequency and urgency. It is estimated that at least three million women and one million men in the United States have interstitial cystitis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There is no cure for interstitial cystitis. However, certain treatment options are available to help relieve symptoms. There are several lines of recommended therapy
for interstitial cystitis, including behavioral modification techniques, antidepressants such as Prozac, antihistamines such as Claritin, pentosan polysulfate sodium such as Elmiron, bladder instillations, such as heparin and immunosuppresants such
as Cyclosporine. When these treatments have failed, a fourth-line treatment is botulinum toxin injections into the bladder muscle. Bladder removal, enlargement or urinary diversion surgery exist as last resorts. Elmiron is the only FDA-approved drug
indicated for the relief of pain for patients with chronic interstitial cystitis. However, since 1996, no treatments have been approved for interstitial cystitis. We therefore believe there remains a significant unmet medical need for the treatment
of interstitial cystitis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">78 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Competitive Strengths </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We
believe our lead product candidates for uro-oncology, which are being developed by leveraging our expertise in drug development and our proprietary formulation technology, have the ability to replace the costly, sub-optimal and burdensome tumor
resection procedures that represent the current first-line standard of care. Furthermore, we believe our proprietary formulation technology has broad applications and may allow us to develop additional product candidates for indications within and
beyond the urinary tract. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Ability to develop non-surgical, first-line drug therapies for uro-oncology.</I></B><B>&nbsp;</B><B></B>Leveraging
our innovative formulation technology, we are developing two lead product candidates, MitoGel and VesiGel, as potential replacements to first-line treatment for low-grade UTUC and NMIBC, respectively. Both MitoGel and VesiGel are chemoablation
agents designed to overcome the challenges posed by the anatomy of the urinary tract by increasing the dwell time and enhancing the tissue coverage of MMC. Clinical data generated to date supports our belief that our lead product candidates may be
able to replace the current first-line tumor surgical procedures, providing a chemoablation treatment that has the potential to better eradicate tumors irrespective of their detectability and location within the urinary tract. To date, of the seven
low-grade UTUC patients treated with MitoGel in an ongoing Compassionate Use program and evaluated for efficacy, four have achieved a complete response and the remaining three have achieved a partial response. In the case of VesiGel, to date, 18 of
21, or approximately 86%, of the patients treated with the high dose of VesiGel in the ongoing Phase 2a trial, which is evaluating the efficacy and safety of VesiGel&#146;s chemoablation properties, achieved a complete response. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expertise in proprietary formulations of existing drugs for clinical benefit.</I></B>&nbsp;We focus on developing proprietary RTGel formulations
of approved drugs whose efficacy for a particular indication is limited by current formulations or routes of administration. Our expertise has enabled us to develop proprietary RTGel-based formulations for several approved drugs to date, including
clinical stage proprietary formulations of MMC and botulinum toxin. Our formulations are designed to significantly increase the dwell time and exposure of the drugs to the target sites and limit the need for urine retention, potentially providing
enhanced clinical activity, reduced patient burden and increased patient compliance over existing formulations and modes of administration. With 10 Ph.D. or medical doctors on our staff, we have a strong research and development team to advance our
product candidates. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Lower development risks and costs for our pipeline product candidates. </I></B><B></B>We expect the approval process for
each of our current uro-oncology product candidates to be conducted according to the FDA&#146;s 505(b)(2) regulatory pathway, a streamlined, lower-cost and more well-defined pathway to drug approval when compared to traditional drug development.
Furthermore, two of our product candidates, MitoGel and Vesimune, have received Orphan Drug Designation from the FDA for the treatment of UTUC and CIS, respectively, which we expect will provide seven years of marketing exclusivity following FDA
approval, if received. We expect to submit our IND for MitoGel in the second half of 2016 and, if accepted by the FDA, we expect to commence a single pivotal Phase 3 clinical trial for the treatment of low-grade UTUC also in the second half of 2016.
Based on multiple discussions with the FDA, our current expectation is that our single pivotal Phase 3 clinical trial for MitoGel will be an open-label, single-arm study, evaluating between 50 and 70 patients with low-grade UTUC in the United
States, Europe and Israel. Additionally, we expect that our product candidates will be safe and well-tolerated because they are novel formulations of approved drugs. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Leverageable proprietary formulation technology</I></B><B>.</B><B>&nbsp;</B><B></B>We believe that RTGel has multiple potential applications
beyond urology. Our formulation know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of active drugs to a variety of targeted body cavities. We believe that our proprietary
formulation technology can improve the efficacy of locally administered drugs in body cavities such as the stomach, uterus and rectum that present anatomical and physiological challenges related to frequent wash out, rapid excretion and bodily
secretions. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Strong intellectual property position. </I></B>We have a robust intellectual property portfolio that includes four issued patents
in the United States and several patent applications worldwide related to methods, systems and compositions for treating bladder cancer related to our lead product candidates, MitoGel and VesiGel, as well as RTGel, both on its own and formulated
with other drugs. The four issued patents are expected to expire between 2024 and 2030. We also have 11 granted patents worldwide related to our other product candidates, which are expected to expire between 2030 and 2031. We also have approximately
60 pending patent applications worldwide covering all of our product candidates. Additionally, the FDA has granted Orphan Drug Designation to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">79 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
MitoGel for the treatment of UTUC, which potentially entitles us to marketing exclusivity for MitoGel for seven years following approval, if granted, by the FDA. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Experienced and accomplished leadership team with proven track record</I></B><B>.</B>&nbsp;We have an experienced management team, with each
member possessing more than 15 years of biopharmaceutical and related industry experience. Our Chief Executive Officer, Ron Bentsur, successfully navigated Auryxia (ferric citrate) through the 505(b)(2) streamlined regulatory pathway to FDA
approval. In addition, our Chairman, Arie Belldegrun, M.D., is a seasoned biotech executive and is currently the Chairman, Chief Executive Officer and President of Kite Pharma, as well as a director of Teva Pharmaceutical Industries. We believe that
our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Our Growth
Strategy </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to become the leading biopharmaceutical company focused on the development of novel therapies for local treatment of urological pathologies.
The key elements of our strategy are as follows: </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Establish each of our lead product candidates, MitoGel and VesiGel, as the first-line
treatment in its target indication.</I></B>&nbsp;We believe that data from treatments in an ongoing Compassionate Use program currently being conducted in the United States, Europe and Israel provide evidence of the potential safety and efficacy of
MitoGel for the treatment of low-grade UTUC. We expect to file an IND for MitoGel with the FDA in the second half of 2016 and, if accepted, to commence a single pivotal Phase 3 clinical trial also in the second half of 2016 pursuant to the
FDA&#146;s 505(b)(2) regulatory pathway. We are currently performing a Phase 2a randomized, open-label, single-arm, active-controlled clinical trial of VesiGel for the treatment of low-grade NMIBC outside the United States. We expect to file an IND
for VesiGel in the first half of 2017 and, if accepted, to commence a Phase&nbsp;2b clinical trial also in the first half of 2017. We also expect to pursue a 505(b)(2) regulatory pathway for VesiGel.&nbsp;We believe that these local drug treatments
have the potential to replace the costly, sub-optimal and burdensome tumor resection and kidney removal surgeries to become the first-line standard of care. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Expand our uro-oncology product pipeline.</I></B> A Phase 1 clinical trial of Vesimune was completed under an IND in 12 patients with CIS, an
aggressive type of high-grade urinary bladder cancer. In the study, 10 patients were evaluated for response and a 40% complete response rate with Vesimune as a single-agent treatment was observed. We believe that Vesimune has the potential to serve
as a treatment option for high-grade urothelial tumors. We are also pursuing preclinical oncology programs that take advantage of our RTGel technology. Our preclinical programs are being developed for high-grade bladder cancer and high-grade UTUC.
We may also evaluate in-licensing or acquiring additional product candidates for the treatment of urological cancers. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Develop our
non-oncology product candidates.</I></B>&nbsp;We are developing additional product candidates designed to take advantage of our proprietary RTGel formulation technology to better adapt to the specific anatomical and physiological constraints of the
urological system. The most notable of these product candidates is BotuGel, our proprietary novel RTGel-based formulation of botulinum toxin for the treatment of overactive bladder and interstitial cystitis. BotuGel was evaluated in a 39 patient
Phase 1b proof-of-concept, investigator-initiated study in Europe in patients with overactive bladder. It is also the subject of a preclinical, IND-enabling collaboration with a large pharmaceutical company and in a preliminary 15 patient Phase 1
proof-of-concept study in Israel in patients with interstitial cystitis. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Utilize our proprietary technology to expand our pipeline to other
body cavities and indications.</I></B>&nbsp;We believe that RTGel may be suitable for multiple additional applications. Our know-how may enable us to develop different drug formulations to facilitate the delivery, retention and sustained release of
active drugs to a variety of targeted body cavities. Beyond the urinary tract, we may target the gastrointestinal tract and the female reproductive system. In the future, we may also choose to develop our RTGel technology in combination with other
drugs to treat cancer and other indications endemic to such body cavities. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL"><B><I>Evaluate and selectively pursue potential collaborations to
develop improved formulations and product life-cycle management strategies.</I></B>&nbsp;We intend to evaluate and selectively pursue collaborations with pharmaceutical companies through a combination of in-licensing, out-licensing, joint venture
and partnership transactions in order to formulate additional drugs using such companies&#146; products or product candidates in combination with RTGel. In addition, we may in-license or acquire additional product candidates for urological
indications. Such </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">collaborations would allow us to obtain financial support and to capitalize on the expertise and resources of our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">80 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">
potential partners, which could allow for new and improved versions of approved or clinical stage drugs, and could accelerate the development and commercialization of additional product
candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>RTGel: Our Reverse Thermally Triggered Hydrogel Platform Technology </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have developed RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel, which, unlike the general characteristics of most forms of
matter, is liquid at lower temperatures and converts into gel form when heated. We believe that these characteristics promote ease of delivery into and retention of drugs in body cavities, including the bladder and the upper urothelial tract, by
conforming to the anatomy of the target organ while preventing rapid excretion of the drug. The following images show the progression of four stages of RTGel at different temperatures. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g54a00.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">LT: Liquid at low temperature </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">BT: Converts into gel form at body temperature </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">RTGel&#146;s
components are polymer-based and are inactive ingredients that have been approved by the FDA for use in other products such as Oraqix, a periodontal gel, Namenda, an oral solution for Alzheimer&#146;s disease, and Xeloda, an oral chemotherapy. We
formulate RTGel with an active drug: MMC in the case of MitoGel and VesiGel, and botulinum toxin in the case of BotuGel. The resulting formulations are instilled intravesically in liquid form directly into the bladder or upper urothelial tract using
standard instillation methodologies via catheters and thereafter convert into gel form at body temperature. Subsequently, upon contact with urine, RTGel gradually dissolves and releases the active drug over a period of several hours, and is less
affected by urine creation and voiding cycles as compared to water formulations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that RTGel, when formulated with an active drug, may allow for the
improved efficacy of treatment of various types of urothelial cancer without compromising the safety of the patient or interfering with the natural flow of fluids from the urinary tract to the bladder. RTGel achieves this by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increasing the exposure of active drugs in the bladder and upper urothelial tract by significantly extending the dwell time of the active drug while conforming to the anatomy of the bladder and the upper urothelial
tract, which allows for enhanced drug tissue coverage. For example, the average dwell time of the standard MMC water formulation, currently used as adjuvant treatment, in the upper urothelial tract is approximately five minutes, compared to
approximately six hours when MMC is formulated with RTGel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">administering higher doses of an active drug than would otherwise be possible using standard water-based formulations. For instance, it is only possible to dissolve 0.5 mg of MMC in 1 ml of water while it is possible to
formulate up to 8 mg of MMC with 1 ml of RTGel; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maintaining the active drug&#146;s molecular structure and mode of action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These characteristics of RTGel enable
sustained release of MMC in the urinary tract for both MitoGel and VesiGel, and of botulinum toxin in the case of BotuGel. Further, RTGel may be particularly effective in the bladder and upper urothelial tract where tumor visibility and access are
challenging, and where there exists a significant amount of urine flow and voiding. We believe that these characteristics of RTGel may prove useful for the local delivery of active drugs to other bodily cavities in addition to the bladder and upper
urothelial tract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MMC&#151;Our Target Active Drug for the Treatment of UTUC and NMIBC </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is a generic drug currently utilized off-label as the standard adjuvant chemotherapy for the treatment of low-grade UTUC and NMIBC after tumor resection, such as
TURBT. MMC is typically administered using a water-based </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">81 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
formulation, which has a relatively short dwell time in the bladder limited to first voiding. MMC often causes temporary irritation of the bladder, including the need to urinate frequently and
urgently. This often results in first voiding occurring shortly after instillation. In the upper urothelial tract, the dwell time is limited to approximately five minutes as urine flows continuously and no active retention by the patient is
feasible. Numerous <I>in vitro</I> models, <I>in vivo</I> studies and computer simulations have shown that increased dwell time of MMC in the bladder results in more efficacious treatment of bladder cancer. In one such study, it was shown that MMC
activity increased with exposure time. Specifically, the MIC90, or mean inhibitory concentration that causes 90% inhibition in cell growth, was 11-fold lower when exposure time was increased from 30 minutes to eight hours. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC&#146;s main effect is on the cancer cell&#146;s DNA, and has been demonstrated to be most effective when the cancer cell is in its S-phase, or synthesis phase,
during which the DNA is replicated. Each cancer cell goes through various phases during the cell cycle. However, the cell cycle is not synchronized in all cancer cells, which means that at any given point in time only a portion of the cancer cells
are at their S-phase, or susceptible to the instilled MMC in the bladder. Thus, because our RTGel-based MMC sustained-release formulations, MitoGel and VesiGel, provide for a significantly longer dwell time of MMC in the upper urothelial tract and
in the bladder as compared to standard MMC water formulations, there is a greater chance that tumor cells will go through their S-phase while the instilled MMC is still present using MitoGel or VesiGel, potentially resulting in a higher percentage
of tumor cells being affected by the instilled MMC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>MitoGel: Our Product Candidate for the Treatment of Low-Grade Upper Tract Urothelial Carcinoma </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing MitoGel, our novel sustained-release formulation of MMC, for the treatment of low-grade UTUC. We have observed preliminary evidence of the efficacy of
MitoGel in an ongoing investigator-initiated Compassionate Use program for the treatment of severe, non-resectable UTUC. Based on multiple discussions with the FDA, we do not believe that we will need to perform additional clinical trials prior to
initiating a single pivotal Phase 3 clinical trial with MitoGel. Additionally, the FDA granted MitoGel Orphan Drug Designation for the treatment of UTUC. We plan to develop MitoGel through the FDA&#146;s 505(b)(2) regulatory pathway. We intend to
submit an IND for MitoGel in the second half of 2016 and, if accepted, to commence the single pivotal Phase 3 clinical trial also in the second half of 2016. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Upper Tract Urothelial Carcinoma </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no drugs approved by the FDA for the treatment of UTUC, representing a significant unmet medical need. The current standard-of-care for the
treatment of UTUC is nephroureterectomy, which is complete kidney and upper urothelial tract removal. Recent advances in resection instrument technology have allowed physicians in some cases to treat patients with low-grade UTUC using tumor
resection, a kidney-sparing treatment, rather than nephroureterectomy followed by adjuvant chemotherapy, typically MMC, treatment. However, the specific anatomy and physiology of the upper urothelial tract make the performance of organ sparing
endoscopic tumor resection and instillation of adjuvant chemotherapy challenging, leading to high recurrence and progression rates. Patients often undergo multiple resection procedures, which increases the probability of potential complications of
resection by means of a ureteroscope, a device for examining the inside of the urinary tract, including perforation and ureteral stricture, or a narrowing of the ureter. A recent study published in 2009 in the Journal of Endourology, evaluating 57
patients with low-grade UTUC who underwent tumor resections showed that recurrence occurred in 89.5% of patients, with a mean of 5.5 recurrences per patient, over a four-year period. Moreover, approximately 20% of the patients in this study
progressed and ultimately underwent kidney and upper tract removal. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MMC is currently administered using a water-based formulation, which limits the dwell time in
the bladder until first voiding. In the upper urothelial tract, the dwell time of MMC is approximately five minutes as urine flows continuously and no active retention by the patient is feasible. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: MitoGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is our novel sustained-release
RTGel-based formulation of MMC that we are developing for the treatment of low-grade UTUC. RTGel is liquid at lower temperatures and converts into gel form at body temperature. This temperature-dependent viscosity characteristic allows the simple
and convenient instillation of the cooled MitoGel in its liquid form to the upper urothelial tract via standard catheters. Once instilled, MitoGel converts into gel form in less than 10 minutes at body temperature. Subsequently, upon contact with
urine, MitoGel gradually dissolves and releases the active drug, MMC, over a period of several hours versus several minutes for MMC in its current water-based formulation. We believe that this substantial increase in dwell time of MMC positions
MitoGel as a potential </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">82 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
first-line chemoablation treatment for low-grade UTUC, sparing patients from repeated tumor resection surgeries and potentially reducing the need for kidney and upper urothelial tract removal.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Orphan Drug Designation granted to MitoGel for the treatment of UTUC potentially entitles us to marketing exclusivity for MitoGel for seven years following
approval by the FDA, if granted, as well as priority review of our New Drug Application, or NDA. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Initial Clinical Results for MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">MitoGel is being evaluated in an ongoing investigator-initiated Compassionate Use program for the treatment of severe, non-resectable UTUC. The Compassionate Use
program, which is being conducted in the United States, Europe and Israel, includes patients diagnosed with unilateral and bilateral UTUC, low- and high-grade UTUC, as well as patients with a solitary kidney. Patients in the Compassionate Use
program receive six weekly instillations of MitoGel administered directly to the upper urothelial tract via catheter. Approximately four weeks following the completion of the treatment course, the patients are evaluated for response. To date, we
have treated 17&nbsp;patients, with more than 60 instillations of MitoGel performed. Of the 17 treated patients, 12 were assessed as having low-grade disease. Of these 12 patients, seven have reached the primary evaluation time point to date and
have been evaluated for response, with four achieving a complete response and the remaining three achieving a partial response. Thus far in the study, MitoGel has been observed to be well-tolerated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This Compassionate Use program was allowed by the FDA to accumulate safety and efficacy data. Based on our recent discussions with the FDA, we do not expect that we
will need to perform any additional clinical trials prior to initiating a single pivotal Phase 3 open-label, single-arm clinical trial with MitoGel. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following
images show pre-treatment and post-MitoGel treatment results from one low-grade UTUC patient in the Compassionate Use program. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g76r88.jpg" ALT="LOGO">



<IMG SRC="g142578g21v14.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">(Courtesy of Dr. Gregory Wirth, Geneva Hospital, Switzerland) </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The top left image is a pre-treatment ureteroscopic view of a tumor located in the ureter. The bottom left image is a pre-treatment x-ray revealing an obstruction
within the ureter in which no contrast (black) can be visualized in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">83 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
distal ureter (denoted by arrow). The top right image is a post-treatment ureteroscopic view of the same location following MitoGel chemoablation treatment. The bottom right image is a
post-treatment x-ray of the ureter which reveals no obstruction within the ureter. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>IND-Enabling Studies for MitoGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As part of our IND-enabling work for MitoGel, we have completed a large-scale Good Laboratory Practices, or GLP, toxicity study in an upper urothelial tract swine model
in which more than 250 instillations of MitoGel were performed. This study evaluated the safety of the procedure and MitoGel administration, also utilizing higher dosage levels than those used in the clinical settings. In this GLP toxicology study,
the instillation of MitoGel was found to be safe. We are also currently conducting chemistry, manufacturing and controls, or CMC, studies as part of our IND-enabling efforts. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of MitoGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on
discussions with the FDA, we intend to develop MitoGel through the FDA&#146;s 505(b)(2) regulatory pathway. We plan to submit an IND for MitoGel in the second half of 2016 and, if accepted, to commence a single pivotal Phase 3 clinical trial also in
the second half of 2016. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g66e76.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">*</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Only if clinical trial is successfully completed </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have had several face-to-face, pre-IND meetings with the FDA to
discuss the MitoGel development program for low-grade UTUC. Currently, the proposed design for the planned single pivotal Phase 3 clinical trial is an open-label, single-arm study evaluating 50 to 70 patients with low-grade UTUC. We expect this
clinical trial, if successfully completed, to support an NDA for low-grade UTUC for MitoGel. The patients will initially receive six weekly instillations of MitoGel. The primary efficacy endpoint is expected to be the complete response rate, defined
as the percentage of patients with a complete response at the primary disease evaluation visit, which occurs approximately four weeks following the sixth weekly instillation. In addition, patients who achieve a complete response at the primary
disease evaluation visit will be followed for durability of response. Such patients will also receive monthly MitoGel maintenance instillations for up to 12 months. If this clinical trial is successfully completed, we currently anticipate submitting
an NDA for MitoGel in 2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>VesiGel: Our Product Candidate for the Treatment of Low-Grade Non-Muscle Invasive Bladder Cancer </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel is our novel sustained-release formulation of high dose MMC that we are developing for the treatment of low-grade NMIBC as a first-line non-surgical
chemoablation alternative to TURBT. We are currently conducting a Phase 2a randomized, open-label, single-arm active-controlled clinical trial in Europe and Israel to evaluate the safety and efficacy of VesiGel (40mg and 80mg MMC) in low-grade
NMIBC. To date, 18 of 21, or approximately 86%, of the patients treated in this trial have been observed to achieve complete responses in the 80mg MMC dose group of VesiGel, and therefore did not need surgical intervention. In the clinical program
to date, comprised of the Phase&nbsp;2a and earlier Phase&nbsp;1 clinical trials, over 80% of the patients who achieved a complete response with VesiGel treatment and who have been followed for 12&nbsp;months thereafter remained recurrence free and
were able to sustain a durable complete response during those 12 months after treatment. This compares to approximately 40% of patients who historically have been able to sustain a 12-month durable complete response following TURBT as first-line
treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to complete the ongoing Phase 2a clinical trial in the first half of 2016. We plan to meet with the FDA in mid-2016 to discuss the next steps in
the clinical development plan for VesiGel and timing for IND submission. We expect to file an IND for VesiGel in the first half of 2017 and, if accepted, to commence a Phase 2b clinical trial for VesiGel also in the first half of 2017. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">84 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Non-Muscle Invasive Bladder Cancer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Tumor grade and stage are the most important variables for determining the likelihood of progression from NMIBC to MIBC. The three stages of NMIBC are: Ta (70%), T1
(20%) and CIS or Tis (10%). Approximately 70% of </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">NMIBC patients have a tumor that is classified as low-grade upon diagnosis. Ta and CIS are limited to the
urothelial layer, and T1 is limited to the layer below, which is the lamina propria. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Recurrence, which occurs in approximately 80% of patients, is the primary
threat for NMIBC patients. Multiplicity, or number of tumors, tumor size and prior recurrence rate are the most important variables in determining the likelihood and potential severity of recurrence. In T1 and CIS NMIBC patients, progression, which
occurs in approximately 45% of patients, is the main threat. Treatment ranges from one or more TURBT procedures followed by adjuvant chemotherapy or immunotherapy instillation(s) in NMIBC patients with a low risk of recurrence to cystectomy for the
treatment of NMIBC patients with a high risk of recurrence. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">TURBT is conducted in a hospital setting under general anesthesia and can often have side effects and
complications. The most common complications, risks and limitations of TURBT include: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">bleeding at the time of surgery that requires clot irrigation and mild burning; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">infection of the bladder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">injured urethra and bladder perforation with potential intra-abdominal leakage; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">re-seeding and cell migration; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">repeat TURBT procedures, which are necessary for approximately 10% of patients within three months; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">complete removal of tumor tissue often not being feasible; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">potential recurrence of up to 25% of the tumors at the original treatment site; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">some tumors not being detectable. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Post-operative adjuvant treatments for NMIBC, which are given to prevent re-seeding
of the cancerous cells, consist primarily of chemotherapy in the case of low-grade tumors and immunotherapy in the case of high-grade tumors, and are administered intravesically via catheter. Adjuvant intravesical chemotherapy is used primarily in
low-grade tumors following TURBT in order to try to delay tumor recurrence, but is not used as a chemoablation agent. The rationale is to expose tumors to high local drug concentrations while minimizing the systemic exposure, thereby enhancing the
treatment effect and reducing the drug toxicity. However, these traditional adjuvant treatments to treating bladder cancer have been limited because, after instillation, the drug concentration is reduced and the drug is washed out due to urine
voiding. As a result, the cancerous tissue is not exposed to the chemotherapy drug for the optimal length of time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No drugs have been approved by the FDA as
first-line treatment for NMIBC and only three drugs have been </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">approved for NMIBC, all used as adjuvant treatment: Thiotepa, which was approved in 1959; bacille
Calmette-Guerin, or BCG, which was approved in 1989; and Valstar, which was approved in 1998. MMC is the drug used most often for intravesical chemotherapy. It is used off-label as an adjuvant treatment in the post-operative setting for low-grade
tumors with high risk of recurrence. Other drugs that can be used include docetaxe and gemcitabine. BCG, an immunotherapy-based drug, is used as an adjuvant treatment for patients with high-grade NMIBC. Upon recurrence, which occurs in approximately
35% of patients, the patients undergo another round of BCG therapy with a response rate of 30% to 50%. Radical cystectomy, or surgical removal of the bladder, is also a common treatment option for patients who fail multiple intravesical BCG
therapies. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are not aware of any drugs
currently in development for the treatment of NMIBC that take into consideration bladder physiology, specifically the fact that urine is produced and voided frequently, thus diluting the concentration of the active drug almost immediately. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: VesiGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">VesiGel, an RTGel-based formulation of high
dose MMC, is our product candidate for the treatment of low-grade NMIBC. VesiGel is administered locally using standard catheters and is designed to conform to the bladder&#146;s anatomy and persist in the bladder despite urine flow and bladder
movement. Once instilled, VesiGel converts into </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">85 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
gel form within approximately 15 minutes at body temperature. Subsequently, upon contact with urine, VesiGel gradually dissolves and releases the active drug, MMC, over a period of several hours
versus the time until first voiding, often less than an hour, for MMC in its current water-based formulation, without compromising the safety of the patient or interfering with the natural flow of urine out of the bladder. We believe that the
resulting significantly increased dwell time of MMC in the bladder prolongs exposure of MMC to the tissue and therefore has the potential to chemoablate visible and unseen tumors. As a result of these properties, our goal is to develop VesiGel as a
first-line chemoablation non-surgical alternative to TURBT for the treatment of low-grade NMIBC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Ongoing Phase 2a Clinical Trial </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are currently conducting a Phase 2a randomized, open-label, single-arm, active-controlled clinical trial in Europe and Israel to evaluate the safety and efficacy of
VesiGel 0.06% (40 mg MMC in 64 ml gel) and VesiGel 0.12% (80 mg MMC in 64 ml gel) in low-grade NMIBC compared to the intravesical instillation of 40 mg of MMC in water (MMC 0.1%). We commenced the trial in July 2014. In this trial, patients undergo
six weekly instillations according to their assigned treatment arm. The primary endpoint of the trial is the complete response rate at the primary disease endpoint, which is evaluated approximately four weeks after the sixth weekly installation. To
date, we have enrolled 78 patients, 63 of whom have been evaluated for response. Of the 62 patients evaluable to date, 19, 21 and 23 patients are in the VesiGel 0.06%, VesiGel 0.12% and MMC 0.10% groups, respectively. The results to date indicate
complete response rates of 36.8%, 85.7% and 69.6% for VesiGel 0.06%, VesiGel 0.12% and MMC 0.10%, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In treating low-grade NMIBC, resection of small
tumors is primarily conducted in the outpatient setting, typically without anesthesia using fulguration, a procedure that destroys the diseased area in the lining of the bladder by burning using electric current. The effectiveness of tumor resection
in these cases is high and the one year recurrence rate is estimated to be only 10%. However, larger, multiple tumors are surgically removed using TURBT, a procedure conducted in the operating room in a hospital setting under general anesthesia,
which often requires at least an overnight stay. TURBT is associated with increased risks and costs and higher recurrence rates that can reach up to 60%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When
evaluating the effect of chemoablation on large tumors that would typically be treated with TURBT, we observed a more profound difference in the complete response rate between the VesiGel 0.12% arm compared to the MMC 0.10% control arm. In tumors
less than 1 cm in diameter, the complete response rate was 78% and 86% in the MMC 0.10% control group and the VesiGel 0.12% group, respectively. However, in tumors greater than or equal to 1 cm in diameter, the complete response rate was 40% and 86%
in the control group and VesiGel 0.12% group, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below illustrates the complete response rates by tumor size for the VesiGel 0.12% and MMC
0.10% control treatment arms. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g10q14.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">86 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To date, the incidence of adverse events, or AEs, reported for both VesiGel groups in the study has been low and appear
similar to that of the active control group. The AEs that have occurred were associated with MMC intravesical instillation or the cystoscopy procedure itself. The MMC-related adverse events were primarily burning sensation, rash, urgency and
dysuria, which is painful or difficult urination. These adverse events appear on the MMC label as potential side effects. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following images show cytoscopic
views of complete responses in a low-grade NMIBC patient treated with VesiGel. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g06i09.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The image to the left is a pre-treatment cystoscopic view of a tumor located in the bladder. The image to the right is a
post-treatment cystoscopic view of the same location following VesiGel chemoablation treatment. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I><B><I>Dose Escalation Study for VesiGel</I></B><I> </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In parallel to the ongoing Phase 2a clinical trial, in the first half of 2015, we initiated a dose escalation study for patients with NMIBC in Europe and Israel to
evaluate the safety and efficacy of VesiGel at dose levels higher than 80&nbsp;mg MMC. To date, we have enrolled fourteen patients, nine of whom who have been diagnosed with low-grade NMIBC. All patients to date have been treated with the 120 mg MMC
in 60 ml gel dose, or 0.2% concentration. Of the nine low-grade NMIBC patients evaluated to date, eight have achieved a complete response. However, at the 120&nbsp;mg MMC dose level, we also observed a higher rate of MMC-related AEs than in patients
treated with the 80&nbsp;mg MMC dose. As a result, we have determined to focus our development efforts going forward on the 80&nbsp;mg MMC dose level. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Phase
1 Clinical Trial for VesiGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In early 2014, we completed a Phase 1 clinical trial in India evaluating two earlier formulations of VesiGel. Patients
underwent six weekly instillations according to their assigned treatment of RTGel (40 ml) formulated with either 40 mg MMC or 80 mg MMC. Following completion of the six instillations, patients were evaluated for safety and efficacy. We enrolled 18
patients, 14 of whom were evaluated for response to treatment. Of the 14 evaluable patients, seven achieved a complete response, with two out of five from the 40 mg MMC arm and five out of nine from the 80 mg MMC arm. Patients were followed for one
year after treatment. The results of this study led to the initiation of the ongoing Phase 2a clinical trial, in which we are using a higher volume of RTGel, 64 ml compared to 40 ml, in an attempt to further enhance the efficacy of the 40 mg and 80
mg MMC VesiGel dose groups, by increasing the dwell time of the drug. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I></I><B><I>Durability of Response</I></B><I> </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of the patients in our Phase 2a and Phase 1 clinical trials were followed for 12 months after the primary disease evaluation time point. Those who achieved a
complete response (<I>i.e.</I>, the chemoablation group) did not undergo any additional treatments. Those who had a partial response or no response underwent TURBT followed by adjuvant therapy according to the standard of care (<I>i.e.</I>, the
TURBT group). 54, 49, 46 and 43 patients completed 3, 6, 9 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">87 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
and 12 month follow-up meetings, respectively. In the chemoablation group, 94% 86% 78% and 83% had durable complete responses at 3, 6, 9 and 12 months, respectively. In the TURBT group, 87%, 70%,
53% and 47% had durable complete responses at 3, 6, 9 and 12 months, respectively. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The graph below demonstrates the durability data for the two groups. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g19t80.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that these results support our belief that VesiGel, acting as a chemoablation agent, can replace TURBT, with the
possibility of improving durability of response. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of VesiGel </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We plan to complete the ongoing Phase 2a clinical trial in the first half of 2016. We plan to meet with the FDA in mid-2016 to discuss next steps in the clinical
development program for VesiGel and timing for IND submission. We expect to file an IND for VesiGel in the first half of 2017 and to commence a Phase 2b clinical trial for VesiGel following the IND submission, if accepted, also in the first half of
2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Vesimune: Our Product Candidate for the Treatment of High-Grade NMIBC </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing Vesimune, our immune-modulation product candidate, for the treatment of high-grade NMIBC. A Phase 1 dose escalation study was conducted in 23 NMIBC
patients and Vesimune appeared to be well-tolerated in the study. This was followed by a Phase 1 pilot study under an IND in 12 patients with CIS bladder cancer in the United States. 40% of the 10 evaluable patients achieved a complete response, and
Vesimune was observed to be well-tolerated in the trial. We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combining it with VesiGel or MitoGel. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for High-Grade NMIBC </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">High-grade
NMIBC is a highly aggressive form of bladder cancer. TURBT is the initial treatment of choice for high-grade NMIBC; however, the high rates of recurrence and significant risk of progression to muscle-invasive tumors are particularly dangerous.
Bladder removal can be the first treatment of choice for young, otherwise healthy patients with high-grade disease or for patients who cannot tolerate BCG. BCG, an immunotherapy-based drug, is the current standard of care as an adjuvant therapy
post-resection in high-grade tumors. However, treatment with BCG is associated with severe side effects, as evidenced by a Black Box warning on the label.</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our
Solution: Vesimune </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe that Vesimune, our immune-modulation product candidate, could represent a valid alternative to the current standard of care
for the BCG adjuvant, post TURBT treatment of high-grade NMIBC. Vesimune&#146;s active ingredient is Imiquimod, an imidazoquinoline, synthetic immune modulator, which specifically targets TLR7, which is expressed in bladder cancer cells. Toll-like
receptors are pattern recognition receptors whose importance in stimulating innate and adaptive immunity has been established by recent studies and approval by the FDA of various cancer immunotherapies. Toll-like receptors are able to sense
microbial components as well as host-derived endogenous molecules released by injured tissues and play a critical role in defending against invading pathogens. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">88 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Imiquimod, in its topical formulation, is FDA approved for several indications, including superficial basal cell
carcinoma. Vesimune is a liquid formulation of Imiquimod for intravesical administration that has been optimized for delivery in the urinary tract. Vesimune does not use our RTGel technology. We believe that Vesimune may elicit an adaptive immune
response in the presence of released bladder cancer antigens, which may translate into a long lasting acquired immune response. Vesimune could as a result represent a viable alternative to BCG for the adjuvant treatment of high-grade NMIBC. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained Orphan Drug Designation for Vesimune for the treatment of CIS in the bladder. We have an active IND for Vesimune, which has been effective since 2013.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We acquired Vesimune from Telormedix SA, a private Swiss-based biotechnology company, in the fourth quarter of 2015. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vesimune Clinical Results and Post-Study Follow-Up </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Vesimune was
evaluated in a Phase 1 dose escalation study that enrolled 23 patients diagnosed with NMIBC. Vesimune was well-tolerated at the doses used. Subsequently, a Phase 1b study of Vesimune was conducted under an IND in patients with CIS bladder cancer in
the United States. Patients were dosed with Vesimune 0.4% weekly for six weeks. The study was designed to evaluate the safety and preliminary efficacy of Vesimune in CIS patients. The primary efficacy endpoint was the rate of complete response at
five to seven weeks after the sixth weekly instillation. Twelve patients were enrolled into the pilot study, of which 10 patients were evaluable for response. Four of the 10 patients, or 40%, achieved a complete response. Vesimune was observed to be
well tolerated in this trial. For observational purposes, patients were followed for an additional six month period beyond the completion of the study, referred to as the Post-Study Follow Up. Of the four patients who had achieved a complete
response with Vesimune in the study, two patients remained disease free at the end of the Post-Study Follow Up while receiving no additional therapy. The two other patients who had achieved a complete response with Vesimune in the study also
remained disease free at the end of the Post-Study Follow Up while receiving BCG therapy during this period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The chart below represents the complete response rates
for patients receiving only Vesimune: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g87e13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of Vesimune </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to further investigate the use of Vesimune for the treatment of high-grade NMIBC, as a single agent or possibly combined with MitoGel, VesiGel or other
immunotherapy agents. Such a combination study would evaluate whether this multimodality approach, harnessing the power of the immune system together with the chemoablation properties of VesiGel or MitoGel, can provide a safe and effective approach
for the treatment of high-grade urothelial tumors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">89 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>BotuGel: Our Product Candidate for the Treatment of Overactive Bladder and Interstitial Cystitis </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Overactive Bladder </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are developing BotuGel, a novel formulation of
botulinum toxin and RTGel, for the treatment of overactive bladder. Overactive bladder is a common condition that occurs mostly in adults, affecting an estimated 33 million people in the United States. Overactive bladder is defined by the
International Continence Society as severe urgency and frequency of urination or urinary incontinence. Urgency is defined as a sudden compelling desire to pass urine, which is difficult to defer. Frequency is associated with small volumes of urine
voided, and patients suffering from frequency are usually awoken at night to urinate. These urological symptoms can have a considerable negative impact on an individual&#146;s physical quality of life and the psychological effects of suffering from
overactive bladder can negatively affect relationships, intimacy and self-image. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The safety and efficacy of BotuGel in overactive bladder patients was evaluated in
an investigator-initiated, Phase 2, double-blind, randomized study conducted in the Czech Republic. In this study, which enrolled 39 patients, it was observed that longer contact time of botulinum toxin with bladder tissue may have a positive effect
on the symptoms of overactive bladder. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Overactive Bladder </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The pathophysiology of overactive bladder is not fully understood. Behavioral therapy, including fluid intake regulation, weight loss, caffeine reduction and bladder
re-training, is often the first recommended therapy. The most common drug treatment option for overactive bladder is treatment with anticholinergics, which are neurotransmitters that act in the central and peripheral nervous system. However, 50% of
patients receiving anticholinergics do not respond to the treatment. Where treatment with anticholinergics fails, physicians may rely on invasive interventions such as botulinum toxin injections into the bladder muscle, and neuromodulation, which is
the alteration of nerve activity through application of electrical or drug agents directly to a brain area. Reconstructive surgery exists as a last resort. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Treatment with botulinum toxin is FDA-approved as a therapeutic option for overactive bladder. A Phase 3 clinical trial conducted to support the approval has shown that
botulinum toxin administered by intramural injection into the bladder wall in patients with overactive bladder leads to improvement in urge and incontinence. However, we believe the current mode of administration has several disadvantages, including
the fact that the procedure is conducted under general anesthesia, the requirement of cystoscopy, which is a video guide inserted through the urethra into the bladder, a need to inject the botulinum toxin into the muscle and the non-uniformity of
the distribution of such injections, and the occurrence of urinary retention. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the bladder wall is believed to play an important role in bladder
sensation and the pathophysiology of overactive bladder. As a result, we believe intravesical instillation of botulinum toxin is a potential alternative to injection into the bladder wall. To date, however, we believe the potential efficacy of
intravesical instillation of botulinum toxin has been limited by insufficient duration of exposure of the active drug to the bladder, resulting, we believe, from formulation of the botulinum toxin with saline solution. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Solution: BotuGel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Using our proprietary RTGel technology, we
have developed BotuGel, a novel formulation of botulinum toxin and RTGel for the treatment of overactive bladder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We believe instillation of BotuGel to treat
overactive bladder may be superior to instillation of a botulinum toxin-saline mixture because our RTGel-based formulation has the ability to significantly increase the dwell time of botulinum toxin in the bladder to several hours, without
preventing the patient from urinating. Prolongation of treatment duration may increase botulinum toxin bioavailability and thus increase treatment efficacy. In addition, we believe that providing a potentially more effective instillation treatment
option may increase patient compliance compared to patients treated with the current injection administration procedure for botulinum toxin. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">90 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Initial Clinical Results of BotuGel for the Treatment of Overactive Bladder </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The safety and efficacy of BotuGel in overactive bladder patients was evaluated in an investigator-initiated, double-blind, randomized study conducted at the University
Hospital Ostrava Czech Republic. The study, which enrolled 39 female patients ages 18 to 65 who had experienced overactive bladder symptoms for longer than three months, was designed to evaluate urge to urinate, incontinence and certain quality of
life measures at one month. Patients were assigned to each of two primary treatment arms. Nine patients were administered BotuGel containing 200 units of botulinum toxin and 11 patients were administered saline as placebo. Each received a single
instillation per their respective treatment assignment. The chart below summarizes the results observed at one month. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g58m29.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of BotuGel for Overactive Bladder </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the data from the investigator-initiated study of BotuGel, we intend to conduct a dose-ranging study of BotuGel outside of the United States in 2017. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we have a preclinical collaboration for BotuGel with a large pharmaceutical partner. We anticipate the submission of an IND filing for BotuGel in the first
half of 2017, which, if accepted, may be followed by clinical trials conducted by our partner. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Interstitial Cystitis </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are also developing BotuGel for the treatment of interstitial cystitis. Interstitial cystitis affects at least an estimated four million people in the United States.
Interstitial cystitis is characterized by chronic (<I>i.e.</I>, extending over more than six months) pelvic pain of unknown etiology during urination, coupled with frequent urination. This pelvic pain often changes as the bladder fills and empties.
We conducted an open-label, single-arm pilot trial in Israel evaluating the safety and efficacy of intravesical instillation of BotuGel 200 units in 15 patients with interstitial cystitis. In this trial, we did not observe any discomfort or pain
associated with the procedure and no lasting adverse effects associated with the treatment were reported. Short-term AEs, consisting primarily of constipation, were reported, but were resolved after 24 hours of being reported. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Limitations of Current Therapies for Interstitial Cystitis </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According
to the American Urology Association guidelines, there are several lines of recommended therapy for interstitial cystitis including behavioral modification techniques and symptom control treatments. Symptom control treatments include local and
systemic pain management drugs, ablation of lesions by fulguration, which is a procedure that uses heat from an electric current to destroy abnormal tissue, neurostimulation, botulinum toxin injections to the muscle and surgery. There is currently
only one drug approved by the FDA for the treatment of interstitial cystitis, Elmiron (Janssen Pharmaceuticals). </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There have been several open-label studies that
have tested the efficacy of instillations of botulinum toxin for the treatment of interstitial cystitis. One such study reported short-lived (<I>i.e.</I>, one week) improvement of symptoms after a single intravesical instillation of 200 units of
botulinum toxin diluted in 50 ml of saline. Inadequate dose, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">91 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
insufficient instillation time and/or absence of pre-instillation administration of substances to increase urothelial permeability were believed to account for the lack of efficacy in this study.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Initial Clinical Results of BotuGel for Interstitial Cystitis </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We conducted an open-label, single-arm pilot trial evaluating the safety and efficacy of intravesical instillation of BotuGel 200 units in patients with interstitial
cystitis. This pilot trial was conducted in Israel and enrolled 15 patients. The patients underwent a single intravesical instillation of BotuGel and were followed at two, six and 12 weeks post instillation. We did not observe any severe discomfort
or pain associated with the procedure. The primary end-point was the pain score, per the visual analog scale, or VAS. No lasting adverse effects associated with the treatment were reported. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following chart illustrates the average VAS scores during the pilot trial. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g30w28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Next Steps in the Clinical Development of BotuGel for Interstitial Cystitis </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Based on the reduction in pain score we observed in the interstitial cystitis pilot trial, we intend to conduct a dose-ranging trial of BotuGel outside of the United
States in 2017. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Preclinical Programs </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Using our proprietary RTGel
formulation technology, we are pursuing additional preclinical programs to expand and enhance our uro-oncology product portfolio. In particular, we are pursuing preclinical programs for high-grade bladder cancer and high-grade UTUC. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Intellectual Property </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We seek patent protection for all of our product
candidates, and we have established several patents families comprised of issued patents and pending patent applications covering our proprietary RTGel formulation technology and the formulations, methods of use and manufacturing aspects of our
product candidates. In the United States, we currently have four issued patents in the United States and several patent applications worldwide related to methods, systems and compositions for treating bladder cancer related to our lead product
candidates, MitoGel and VesiGel, as well as RTGel, both on its own and formulated with other drugs. The four issued patents are expected to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">92 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
remain in effect until between 2024 and 2030. We also have five pending patent applications relating to MitoGel and VesiGel in Europe, the United States and Israel, and five pending patent
applications relating to BotuGel in the United States and the European Union, as well as in each of Russia, China, and Israel. In addition, we have two&nbsp;granted patents related to Vesimune in the United States as well as granted patents in the
European Union, Japan, Australia, Mexico and China, each of which are expected to remain in effect until 2031. In addition to the issued patents mentioned above, our portfolio includes pending patent applications relating to Vesimune in the United
States, the European Union, Canada, Korea, Brazil, Israel, Hong Kong and Japan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our patents and patent applications mainly relate to hydrogel-based pharmaceutical
compositions for optimal delivery of any drug to the internal cavity such as a bladder and/or urinary tract; the method for treating urothelial cancer using hydrogel based composition; the method for treating overactive bladder and interstitial
cystitis topically without a need for injections; special catheters and in-dwelling ureter-catheter systems for optimal delivery of a drug into the renal cavity; pharmaceutical compositions comprising an imidazoquinolin-amine (specifically
imiquimod) and lactic acid for treating bladder cancer diseases, and novel phospholipid drug analogs for treating cancer or infections. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preparing and filing patent
applications is a joint endeavor of our research and development team and our in-house and external patent attorneys. Our patent attorneys conduct patent prior-art searches and then analyze the data in order to provide our research and development
team with recommendations on a routine basis. This results in: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">protecting our product candidates that are under development; </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">encouraging pharmaceutical companies to negotiate development agreements with us; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preventing competitors from attempting to design-around our inventions. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We submit applications directly to the United
States Patent and Trademark Office, or USPTO, as provisional patent applications. Then usually we continue filing under the Patent Cooperation Treaty, or PCT, which is an international patent law treaty that provides a unified procedure for filing a
single initial patent application to seek patent protection for an invention simultaneously in any one of the designated member states. Although a PCT application does not issue as a patent, it allows the applicant to seek protection in any of the
member states through national-phase applications. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Competition </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
standard for treating NMIBC patients is the TURBT procedure for tumor resection, followed by post-operative adjuvant chemotherapy or immunotherapy instillations, administered to prevent re-seeding of the cancerous cells. The adjuvant agents used are
predominately generic treatments and regimens. Only three drugs have been approved for bladder cancer: Thiotepa, which was approved by the FDA in 1959, BCG, which was approved by the FDA in 1989 and Valstar, which was approved by the FDA in 1998.
Even though there remain high unmet needs in the bladder cancer market, nothing has replaced these drugs in recent years. BCG has been used to treat patients with CIS and high-grade T1 since 1990. Thiotepa and Valstar are rarely used, and MMC is
used off-label as the standard adjuvant treatment in the post-TURBT setting for low-grade NMIBC patients. In the UTUC space, there are no approved drugs used to treat the disease. Tumor resection surgeries are conducted in some cases of low-grade
UTUC; however, partial or complete kidney and upper urothelial tract removal is the standard of care for frequently recurring UTUC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are several products in
the development pipeline, most of which are second- or third line-treatments mainly targeted for high-grade NMIBC patients who have failed BCG treatment. All are targeted to reduce recurrence, but none are developed to reduce the need for TURBT and
other tumor resection therapies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are aware that other companies, such as Merck Sharp&nbsp;&amp; Dohme Corp., Viventia Bio Inc., Telesta Therapeutics Inc., Heat
Biologics, Inc., Viralytics Limited, AADi, LLC, Biocancell Ltd., Halozyme Therapeutics, Inc., Astellas Pharma Inc., Cold Genesys, Inc., Altor BioScience Corporation, FKD Therapies Oy, Nippon Kayaku Co., Ltd,&nbsp;Spectrum Pharmaceuticals, Inc.,
and&nbsp;Handok Inc., are conducting or have recently conducted clinical trials for product candidates for the treatment of low-grade and high-grade NMIBC, including CIS. In addition, we are aware of several pharmaceutical companies that are
developing drug candidates for muscle-invasive bladder cancer. We do </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">93 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
not know whether these potential competitors are already developing, or plan to develop, low-grade UTUC or high-grade UTUC treatments or other indications that we are pursuing, and we may be
unable to ascertain whether such activities are underway in the future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The biopharmaceutical industry is intensely competitive and subject to rapid and
significant technological change. Our potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing
resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. These companies may develop new drugs to treat the indications that we target, or seek to have
existing drugs approved for use for the treatment of the indications that we target. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These potential competitors may therefore introduce competing products
without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater
availability of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis products that are more effective, easier to administer or less costly than our product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we face competition from existing standards of treatment, including TURBT, surgery for bladder cancer. If we are not able to demonstrate that our product
candidates are at least as safe and effective as such courses of treatment, medical professionals may not adopt our product candidates in replacement of the existing standard of care, which is first-line tumor surgical procedures. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Government Regulation </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA and comparable regulatory agencies in state
and local jurisdictions and in foreign countries impose substantial requirements upon the clinical development, manufacture and marketing of pharmaceutical products. These agencies and other federal, state and local entities regulate research and
development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, packaging, recordkeeping, tracking, approval, import, export, distribution, advertising and promotion of our products. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The process required by the FDA before product candidates may be marketed in the United States generally involves the following: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">nonclinical laboratory and animal tests that must be conducted in accordance with good laboratory practices, or GLPs; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission of an IND, which must become effective before clinical trials may begin; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval by an independent institutional review board, or IRB, for each clinical site or centrally before each trial may be initiated; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate and well-controlled human clinical trials to establish the safety and efficacy of the proposed product candidate for its intended use, performed in accordance with good clinical practices, or GCPs;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">submission to the FDA of an NDA; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">satisfactory completion of an FDA advisory committee review, if applicable; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pre-approval inspection of manufacturing facilities and selected clinical investigators for their compliance with cGMP and GCPs; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">FDA approval of an NDA to permit commercial marketing for particular indications for use. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to the commencement of
marketing of controlled substances, the DEA must also determine the controlled substance schedule, taking into account the recommendation of the FDA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The testing
and approval process requires substantial time, effort and financial resources. Preclinical studies include laboratory evaluation of drug substance chemistry, pharmacology, toxicity and drug product formulation, as well as animal studies to assess
potential safety and efficacy. Prior to commencing the first clinical trial with a product candidate, we must submit the results of the preclinical tests and preclinical literature, together with manufacturing
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">94 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical studies may continue even after the IND is
submitted. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA, within the 30-day time period, raises safety concerns or questions about the conduct of the clinical trial by imposing a clinical hold. In such a
case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Submission of an IND may not result in FDA authorization to commence a clinical trial. A separate submission to the existing IND must be
made for each successive clinical trial conducted during product development, as well as amendments to previously submitted clinical trials. Further, an independent IRB for each study site proposing to conduct the clinical trial must review and
approve the plan for any clinical trial, its informed consent form and other communications to study subjects before the clinical trial commences at that site. The IRB must continue to oversee the clinical trial while it is being conducted,
including any changes to the study plans. Regulatory authorities, an IRB or the sponsor may suspend or discontinue a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health
risk, the clinical trial is not being conducted in accordance with the FDA&#146;s or the IRB&#146;s requirements, if the drug has been associated with unexpected serious harm to subjects, or based on evolving business objectives or competitive
climate. Some studies also include a data safety monitoring board, which receives special access to unblinded data during the clinical trial and may advise us to halt the clinical trial if it determines that there is an unacceptable safety risk for
subjects or other grounds, such as no demonstration of efficacy. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, for purposes of NDA approval, human clinical trials are typically conducted in three
sequential phases that may overlap. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 1&#151;Studies are initially conducted to test the product candidate for safety, dosage tolerance, structure-activity relationships, mechanism of action, absorption, metabolism, distribution and excretion in
healthy volunteers or subjects with the target disease or condition. If possible, phase 1 trials may also be used to gain an initial indication of product effectiveness. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 2&#151;Controlled studies are conducted with groups of subjects with a specified disease or condition to provide enough data to evaluate the preliminary efficacy, optimal dosages and dosing schedule and expanded
evidence of safety. Multiple Phase 2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase 3 clinical trials. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Phase 3&#151;These clinical trials are undertaken in larger subject populations to provide statistically significant evidence of clinical efficacy and to further test for safety in an expanded subject population at
multiple clinical trial sites. These clinical trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling. These trials may be done globally to support global registrations so
long as the global sites are also representative of the U.S. population and the conduct of the study at global sites comports with FDA regulations and guidance, such as compliance with GCPs. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may require, or companies may pursue, additional clinical trials after a product is approved. These so-called Phase 4 studies may be made a condition to be
satisfied after approval. The results of Phase 4 studies can confirm the effectiveness of a product candidate and can provide important safety information. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Clinical trials must be conducted under the supervision of qualified investigators in accordance with GCP requirements, which includes the requirements that all
research subjects provide their informed consent in writing for their participation in any clinical trial, and the review and approval of the study by an IRB. Investigators must also provide information to the clinical trial sponsors to allow the
sponsors to make specified financial disclosures to the FDA. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the trial procedures, the parameters to be used in monitoring safety and the
efficacy criteria to be evaluated and a statistical analysis plan. Information about some clinical trials, including a description of the trial and trial results, must be submitted within specific timeframes to the National Institutes of Health, or
NIH, for public dissemination on their ClinicalTrials.gov website. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The manufacture of investigational drugs for the conduct of human clinical trials is subject to
cGMP requirements. Investigational drugs and active pharmaceutical ingredients imported into the United States are also subject to regulation by the FDA relating to their labeling and distribution. Further, the export of investigational drug
products outside of the United States is subject to regulatory requirements of the receiving country as well as U.S. export requirements under the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">95 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Federal Food, Drug and Cosmetic Act, or the FDCA. Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and the IRB and more frequently if
serious adverse events occur. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information
about the chemistry and physical characteristics of the product candidate as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of
consistently producing quality batches of the product candidate and, among other things, must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and
tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>505(b)(2) Regulatory Approval Process </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section 505(b)(2) of the FDCA,
or 505(b)(2), provides an alternate regulatory pathway to FDA approval for new or improved formulations or new uses of previously approved drug products. Specifically, 505(b)(2) permits the filing of an NDA where at least some of the information
required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. The applicant may rely upon the
FDA&#146;s prior findings of safety and efficacy for an approved product that acts as the reference listed drug for purposes of a 505(b)(2) NDA. The FDA may also require 505(b)(2) applicants to perform additional studies or measurements to support
any changes from the reference listed drug. The FDA may then approve the new product candidate for all or some of the labeled indications for which the referenced product has been approved, as well as for any new indication sought by the 505(b)(2)
applicant. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Orange Book Listing </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Section 505 of the FFDCA
describes three types of marketing applications that may be submitted to the FDA to request marketing authorization for a new drug. A Section 505(b)(1) NDA is an application that contains full reports of investigations of safety and efficacy. A
505(b)(2) NDA is an application that contains full reports of investigations of safety and efficacy, but where at least some of the information required for approval comes from investigations that were not conducted b or for the applicant and for
which the applicant has not obtained a right of reference or use from the person by or for whom the investigations were conducted. This regulatory pathway enables the applicant to rely, in part, on the FDA&#146;s prior findings of safety and
efficacy for an existing product, or published literature, in support of its application. Section 505(j) establishes an abbreviated approval process for a generic version of approved drug products through the submission of an abbreviated new drug
application, or ANDA. An ANDA provides for marketing of a generic drug product that has the same active ingredients, dosage form, strength, route of administration, labeling, performance characteristics and intended use, among other things, to a
previously approved product. ANDAs are termed &#147;abbreviated&#148; because they are generally not required to include preclinical and clinical data to establish safety and efficacy. Instead, generic applicants must scientifically demonstrate that
their product is bioequivalent to, or performs in the same manner as, the innovator drug through in vitro, in vivo or other testing. The generic version must deliver the same amount of active ingredients into a subject&#146;s bloodstream in the same
amount of time as the innovator drug and can often be substituted by pharmacists under prescriptions written for the reference listed drug. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In seeking approval for
a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA patents whose claims cover the applicant&#146;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then
published in Approved Drug Products with Therapeutic Equivalence Evaluations, also known as the Orange Book. These products may be cited by potential competitors in support of approval of an ANDA or 505(b)(2) NDA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any applicant who files an ANDA seeking approval of a generic equivalent version of a drug listed in the Orange Book or a 505(b)(2) NDA referencing a drug listed in the
Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent
is invalid or will not be infringed upon by the manufacture, use or sale of the drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. Generally, the ANDA or 505(b)(2) NDA cannot be
approved until all listed patents have expired, except where the ANDA or 505(b)(2) NDA applicant challenges a listed patent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">96 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
through a Paragraph IV certification. If the applicant does not challenge the listed patents or does not indicate that it is not seeking approval of a patented method of use, the ANDA or
505(b)(2) NDA application will not be approved until all of the listed patents claiming the referenced product have expired. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the competitor has provided a
Paragraph IV certification to the FDA, the competitor must also send notice of the Paragraph IV certification to the holder of the NDA for the reference listed drug and the patent owner once the application has been accepted for filing by the FDA.
The NDA holder or patent owner may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days of the receipt of a Paragraph IV certification
prevents the FDA from approving the application until the earlier of 30 months from the date of the lawsuit, expiration of the patent, settlement of the lawsuit, a decision in the infringement case that is favorable to the applicant or such shorter
or longer period as may be ordered by a court. This prohibition is generally referred to as the 30-month stay. In instances where an ANDA or 505(b)(2) NDA applicant files a Paragraph IV certification, the NDA holder or patent owner regularly take
action to trigger the 30-month stay, recognizing that the related patent litigation may take many months or years to resolve. Thus, approval of an ANDA or 505(b)(2) NDA could be delayed for a significant period of time depending on the patent
certification the applicant makes and the reference drug sponsor&#146;s decision to initiate patent litigation. The applicant may also elect to submit a statement certifying that its proposed label does not contain, or carves out, any language
regarding the patented method-of-use rather than certify to a listed method-of-use patent. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Exclusivity </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA provides periods of regulatory exclusivity, which provides the holder of an approved NDA limited protection from new competition in the marketplace for the
innovation represented by its approved drug for a period of three or five years following the FDA&#146;s approval of the NDA. Five years of exclusivity are available to NCEs. An NCE is a drug that contains no active moiety that has been approved by
the FDA in any other NDA. An active moiety </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">is the molecule or ion, excluding those appended portions of the molecule that cause the drug to be an ester, salt,
including a salt with hydrogen or coordination bonds, or other noncovalent derivatives, such as a complex, chelate, or clathrate, of the molecule, responsible for the therapeutic activity of the drug substance. During the exclusivity period, the FDA
may not accept for review or approve an ANDA or a 505(b)(2) NDA submitted by another company that contains the previously approved active moiety. An ANDA or 505(b)(2) application, however, may be submitted one year before NCE exclusivity expires if
a Paragraph IV certification is filed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a product is not eligible for the NCE exclusivity, it may be eligible for three years of exclusivity. Three-year
exclusivity is available to the holder of an NDA, including a 505(b)(2) NDA, for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials,
other than bioavailability or bioequivalence trials, was essential to the approval of the application and was conducted or sponsored by the applicant. This three-year exclusivity period protects against FDA approval of ANDAs and 505(b)(2) NDAs for
the condition of the new drug&#146;s approval. As a general matter, three-year exclusivity does not prohibit the FDA from approving ANDAs or 505(b)(2) NDAs for generic versions of the original, unmodified drug product. Five-year and three-year
exclusivity will not delay the submission or approval of a full NDA; however, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical
trials necessary to demonstrate safety and efficacy. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Abbreviated Licensure Pathway of Biologics as Biosimilar or Interchangeable under 351(k) </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Biologics Price Competition and Innovation Act, or BPCIA, amended the Public Health Service Act by adding Section&nbsp;351(k), which created an abbreviated approval
pathway for biologics shown to be highly similar to an FDA-licensed reference biologic. Biosimilarity is demonstrated through extensive analytical studies, animal studies (when deemed necessary), and clinical trials. An application submitted under
the 351(k) pathway must include information demonstrating that the proposed biosimilar product and reference product have the same route of administration, dosage form and the strength and the biosimilar product utilizes the same mechanism of action
for the condition(s) of use approved in the proposed labeling to the extent the mechanism(s) of action are known for the reference product. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The BPCIA provides for
a designation of &#147;interchangeability&#148; between the reference and biosimilar products, whereby the biosimilar may be substituted for the reference product without the intervention of the healthcare provider who prescribed the reference
product. After the assessment of biosimilarity, the higher standard of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">97 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
interchangeability must be demonstrated by information sufficient to show that the proposed product is expected to produce the same clinical result as the reference product in any given patient
and for a product that is administered more than once to an individual, the risk to the patient in terms of safety or diminished efficacy of alternating or switching between the biosimilar and the reference product is no greater than the risk of
using the reference product without such alternation or switch. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The timing of final FDA approval of a biosimilar for commercial distribution depends on a variety
of factors, including whether the manufacturer of the reference product is entitled to one or more statutory exclusivity periods, during which time the FDA is prohibited from approving, or accepting applications for, any product candidates that are
purportedly biosimilar to the reference product. The FDA cannot approve a biosimilar application for 12 years from the date of first licensure of the reference product. Additionally, a biosimilar product sponsor may not submit an application under
the 351(k) pathway for four years from the date of first licensure of the reference product. The first biosimilar product determined to be interchangeable with a reference product for any condition of use is also entitled to a period of exclusivity,
during which time the FDA may not determine that another product is interchangeable with the reference product for any condition of use. This exclusivity period extends until the earlier of: (i)&nbsp;one year after the first commercial marketing of
the first interchangeable product; (ii)&nbsp;18 months after resolution of a patent infringement suit against the applicant that submitted the application for the first approved interchangeable product, based on a final court decision regarding all
of the patents in the litigation or dismissal of the litigation with or without prejudice; (iii)&nbsp;42 months after approval of the first interchangeable product, if a patent infringement suit instituted against the applicant that submitted the
application for the first interchangeable product is still ongoing; or (iv)&nbsp;18 months after approval of the first interchangeable product if the applicant that submitted the application for the first interchangeable product has not been sued
for patent infringement. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The Orphan Drug Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Orphan
Drug Act, the FDA may grant Orphan Drug Designation to drugs intended to treat a rare disease or condition &#150; generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan Drug Designation must be
requested before submitting an NDA. After the FDA grants Orphan Drug Designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan Drug Designation does not convey any advantage in, or shorten
the duration of, the regulatory review and approval process.&nbsp;The first NDA applicant to receive FDA approval for a particular active ingredient to treat a particular disease with FDA Orphan Drug Designation is entitled to a seven-year exclusive
marketing period in the United States for that product, for that indication.&nbsp;During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug for the same disease, except in limited circumstances,
such as a showing of clinical superiority to the product with orphan drug exclusivity.&nbsp;Orphan drug exclusivity does not prevent FDA from approving a different drug for the same disease or condition, or the same drug for a different disease or
condition.&nbsp;Among the other benefits of Orphan Drug Designation are tax credits for certain research and a waiver of the NDA application user fee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>NDA
Submission and Review by the FDA </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Assuming successful completion of the required clinical and preclinical testing, among other items, the results of product
development, including chemistry, manufacture and controls, nonclinical studies and clinical trials are submitted to the FDA, along with proposed labeling, as part of an NDA. The submission of an NDA requires payment of a substantial user fee to the
FDA. These user fees must be filed at the time of the first submission of the application, even if the application is being submitted on a rolling basis. Fee waivers or reductions are available in some circumstances. One basis for a waiver of the
application user fee is if the applicant employs fewer than 500 employees, including employees of affiliates, the applicant does not have an approved marketing application for a product that has been introduced or delivered for introduction into
interstate commerce, and the applicant, including its affiliates, is submitting its first marketing application. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, under the Pediatric Research Equity
Act, or PREA, an NDA or supplement to an NDA for a new active ingredient, indication, dosage form, dosage regimen or route of administration must contain data that are adequate to assess the safety and efficacy of the drug for the claimed
indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may, on its own initiative or at the request of the applicant, grant
deferrals for submission of some or all pediatric data until after approval of the product for use in adults or full or partial waivers from the pediatric data requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">98 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA must refer applications for drugs that contain active ingredients, including any ester or salt of the active
ingredients, that have not previously been approved by the FDA to an advisory committee or provide in an action letter a summary of the reasons for not referring it to an advisory committee. The FDA may also refer drugs which present difficult
questions of safety, purity or potency to an advisory committee. An advisory committee is typically a panel that includes clinicians and other experts who review, evaluate and make a recommendation as to </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such
recommendations carefully when making decisions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA reviews applications to determine, among other things, whether a product is safe and effective for its
intended use and whether the manufacturing controls are adequate to assure and preserve the product&#146;s identity, strength, quality and purity. Before approving an NDA, the FDA will inspect the facility or facilities where the product is
manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities, including contract manufacturers and subcontracts, are in compliance with cGMP requirements and adequate to assure consistent
production of the product within required specifications. Additionally, before approving an NDA, the FDA will typically inspect one or more clinical trial sites to assure compliance with GCPs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA receives an application, it has 60 days to review the NDA to determine if it is substantially complete to permit a substantive review, before it accepts
the application for filing. Once the submission is accepted for filing, the FDA begins an in-depth review of the NDA. The FDA&#146;s NDA review times may differ based on whether the application is a standard review or priority review application.
The FDA may give a priority review designation to drugs that are intended to treat serious conditions and provide significant improvements in the safety or effectiveness of the treatment, diagnosis, or prevention of serious conditions. Under the
goals and policies agreed to by the FDA under the Prescription Drug User Fee Act, or PDUFA, the FDA has set the review goal of 10 months from the 60-day filing date to complete its initial review of a standard NDA for an NME and make a decision on
the application. For non-NME standard applications, the FDA has set the review goal of 10 months from the submission date to complete its initial review and to make a decision on the application. For priority review applications, the FDA has set the
review goal of reviewing NME NDAs within six months of the 60-day filing date and non-NME applications within six months of the submission date. Such deadlines are referred to as the PDUFA date. The PDUFA date is only a goal and the FDA does not
always meet its PDUFA dates. The review process and the PDUFA date may also be extended if the FDA requests or the NDA sponsor otherwise provides additional information or clarification regarding the submission. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Once the FDA&#146;s review of the application is complete, the FDA will issue either a Complete Response Letter, or CRL, or approval letter. A CRL indicates that the
review cycle of the application is complete and the application is not ready for approval. A CRL generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical
or preclinical testing, or other information or analyses in order for the FDA to reconsider the application. The FDA has the goal of reviewing 90% of application resubmissions in either two or six months of the resubmission date, depending on the
kind of resubmission. Even with the submission of additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. If and when those conditions have been met to the FDA&#146;s
satisfaction, the FDA may issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA may delay or refuse approval of an NDA if applicable regulatory criteria are not satisfied, require additional testing or information and/or require
post-marketing testing and surveillance to monitor safety or efficacy of a product, or impose other conditions, including distribution restrictions or other risk management mechanisms. For example, the FDA may require a risk evaluation and
mitigation strategy, or REMS, as a condition of approval or following approval to mitigate any identified or suspected serious risks and ensure safe use of the drug. The FDA may prevent or limit further marketing of a product, or impose additional
post-marketing requirements, based on the results of post-marketing studies or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling
claims, are subject to further testing requirements, FDA notification and FDA review and approval. Further, should new safety information arise, additional testing, product labeling or FDA notification may be required. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">99 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If regulatory approval of a product is granted, such approval may entail limitations on the indicated uses for which such
product may be marketed or may include contraindications, warnings or precautions in the product labeling, which has resulted in a Black Box warning. The FDA also may not approve the inclusion of labeling claims necessary for successful marketing.
Once approved, the FDA may withdraw the product approval if compliance with pre- and post-marketing regulatory standards is not maintained or if problems occur after the product reaches the marketplace. In addition, the FDA may require Phase 4
post-marketing studies to monitor the effect of approved products, and may limit further marketing of the product based on the results of these post-marketing studies. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Post-approval Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Any products manufactured or distributed
by us pursuant to FDA approvals are subject to continuing regulation by the FDA, including manufacturing, periodic reporting, product sampling and distribution, advertising, promotion, drug shortage reporting, compliance with any post-approval
requirements imposed as a conditional of approval such as Phase 4 clinical trials, REMS and surveillance, recordkeeping and reporting requirements, including adverse experiences. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After approval, most changes to the approved product, such as adding new indications or other labeling claims are subject to prior FDA review and approval. There also
are continuing, annual user fee requirements for any approved products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. Drug manufacturers and their
subcontractors are required to register their establishments with the FDA and certain state agencies and to list their drug products, and are subject to periodic announced and unannounced inspections by the FDA and these state agencies for
compliance with cGMPs and other requirements, which impose procedural and documentation requirements upon us and our third-party manufacturers. We cannot be certain that we or our present or future suppliers will be able to comply with the cGMP
regulations and other FDA regulatory requirements. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being
implemented, or FDA notification. FDA regulations also require investigation and correction of any deviations from cGMPs and specifications, and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that
the sponsor may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Later discovery of previously unknown problems with a product, including AEs of unanticipated severity or frequency, or with manufacturing processes, or failure to
comply with regulatory requirements, may result in withdrawal of marketing approval, mandatory revisions to the approved labeling to add new safety information or other limitations, imposition of post-market studies or clinical trials to assess new
safety risks, or imposition of distribution or other restrictions under a REMS program, among other consequences. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The FDA closely regulates the marketing and
promotion of drugs. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA. Physicians, in their independent professional medical judgement, may prescribe legally available products for
uses that are not described in the product&#146;s labeling and that differ from those tested by us and approved by the FDA. We, however, are prohibited from marketing or promoting drugs for uses outside of the approved labeling. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the distribution of prescription pharmaceutical products, including samples, is subject to the Prescription Drug Marketing Act, or PDMA, which regulates
the distribution of drugs and drug samples at the federal level, and sets minimum standards for the registration and regulation of drug distributors by the states. Both the PDMA and state laws limit the distribution of prescription pharmaceutical
product samples and impose requirements to ensure accountability in distribution. The Drug Supply Chain Security Act also imposes obligations on manufacturers of pharmaceutical products related to product and tracking and tracing. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Failure to comply with any of the FDA&#146;s requirements could result in significant adverse enforcement actions. These include a variety of administrative or judicial
sanctions, such as refusal to approve pending applications, license suspension or revocation, withdrawal of an approval, imposition of a clinical hold or termination of clinical trials, warning letters, untitled letters, cyber letters, modification
of promotional materials or labeling, product recalls, product seizures or detentions, refusal to allow imports or exports, total or partial suspension of production or distribution, debarment, injunctions, fines, consent decrees, corporate
integrity agreements, refusals of government </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">100 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
contracts and new orders under existing contracts, exclusion from participation in federal and state healthcare programs, restitution, disgorgement or civil or criminal penalties, including fines
and imprisonment. Any of these sanctions could result in adverse publicity, among other adverse consequences. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Healthcare Regulations </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our business activities, including but not limited to, research, sales, promotion, distribution, medical education and other activities following product approval will
be subject to regulation by numerous regulatory and law enforcement authorities in the United States in addition to the FDA, including potentially the Department of Justice, the Department of Health and Human Services and its various divisions,
including the CMS and the Health Resources and Services Administration, the Department of Veterans Affairs, the Department of Defense and state </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">and local
governments. Our business activities must comply with numerous healthcare laws and regulations, including those described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Anti-Kickback Statute
prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, the
referral of an individual for, or purchasing, leasing, ordering, or arranging for the purchase, lease or order of, any good, facility, item or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration
has been interpreted broadly to include anything of value. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and practices
that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular
applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the federal Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative
review of all of its facts and circumstances. Additionally, the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively the ACA, amended the intent requirement of
the federal Anti-Kickback Statute, and other healthcare criminal fraud statutes, so that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute, or the specific intent to violate it, to have violated the
statute. The ACA also provided that a violation of the federal Anti-Kickback Statute is grounds for the government or a whistleblower to assert that a claim for payment of items or services resulting from such violation constitutes a false or
fraudulent claim for purposes of the federal civil False Claims Act. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal civil and criminal false claims laws, including the federal False Claims Act,
prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government, including the Medicare and Medicaid programs, or knowingly making, using,
or causing to be made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, and our business activities, are subject to the civil monetary penalties statute which imposes penalties against any person or entity who, among other things, is
determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As a condition of receiving Medicaid coverage for prescription drugs, the Medicaid Drug Rebate Program requires manufacturers to calculate and report to CMS their
Average Manufacturer Price, or AMP, which is used to determine rebate payments shared between the states and the federal government and, for some multiple source drugs, Medicaid payment rates for the drug, and for drugs paid under Medicare Part B,
to also calculate and report their average sales price, which is used to determine the Medicare Part B payment rate for the drug. In January 2016, CMS issued a final rule regarding the Medicaid Drug Rebate Program, effective April 1, 2016, that,
among other things, revises the manner in which the AMP is to be calculated by manufacturers participating in the program and implements certain amendments to the Medicaid rebate statute created under the ACA. Drugs that are approved under a
biologics license application, or BLA, or an NDA, including a 505(b)(2) NDA, are subject to an additional requirement to calculate and report the manufacturer&#146;s best price for the drug and inflation penalties which can substantially increase
rebate payments. For BLA and NDA drugs, the Veterans Health Care Act requires manufacturers to calculate and report to the Department of Veterans Affairs a different price called the Non-Federal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">101 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
AMP, offer the drugs for sale on the Federal Supply Schedule, and charge the government no more than a statutory price referred to as the Federal Ceiling Price, which includes an inflation
penalty. A separate law requires manufacturers to pay rebates on these drugs when paid by the Department of Defense under its TRICARE Retail Pharmacy Program. Knowingly submitting false pricing information to the government creates potential federal
False Claims Act liability. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, created additional federal criminal statutes that
prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations or promises, any of the money or property owned by, or
under the custody or control of, any healthcare benefit program, regardless of whether the payor is public or private, knowingly and willfully embezzling or stealing from a health care benefit program, willfully obstructing a criminal investigation
of a health care offense and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits,
items or services relating to healthcare matters. Additionally, the ACA amended the intent requirement of some of these criminal statutes under HIPAA so that a person or entity no longer needs to have actual knowledge of the statute, or the specific
intent to violate it, to have committed a violation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, the federal Open Payments program pursuant to the Physician Payments Sunshine Act, created under
Section 6002 of the ACA and its implementing regulations, require some manufacturers of drugs, devices, biologicals and medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program (with
specified exceptions) to report annually information related to specified payments or other transfers of value provided to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians
and teaching hospitals and to report annually specified ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments,
transfers of value and ownership or investment interests may result in civil monetary penalties of up to an aggregate of $150,000 per year and up to an aggregate of $1.0 million per year for &#147;knowing failures.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended
by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, impose requirements relating to the privacy, security and transmission of individually identifiable health information. Among
other things, HITECH makes HIPAA&#146;s security standards directly applicable to business associates, independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service
on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file
civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health
information in some circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Many states have also adopted laws similar to each of the above federal laws, which may be broader in scope and apply to items or services reimbursed by any third-party
payor, including commercial insurers. We may also be subject to state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by
the federal government, and/or state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Enforcement actions can be brought by federal or state governments or as &#147;qui tam&#148; actions brought by individual whistleblowers in the name of the government.
Depending on the circumstances, failure to comply with these laws can result in penalties, including criminal, civil and/or administrative criminal penalties, damages, fines, disgorgement, debarment from government contracts, exclusion of products
from reimbursement under government programs, refusal to allow us to enter into supply contracts, including government contracts, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations, any
of which could adversely affect our business. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">102 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Coverage and Reimbursement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ability to commercialize any products successfully also will depend in part on the extent to which coverage and adequate reimbursement for our products, once
approved, and related treatments will be available from government health administration authorities, private health insurers and other organizations. Government authorities and other&nbsp;third-party&nbsp;payors, such as private health insurers and
health maintenance organizations, determine which medications they will cover and establish reimbursement levels. Assuming we obtain coverage for a given product by a third-party payor, the resulting reimbursement payment rates may not be adequate
or may require co-payments that patients find unacceptably high. Patients who are prescribed medications for the treatment of their conditions, and their prescribing physicians, generally rely on third-party payors to reimburse all or part of the
costs associated with their prescription drugs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover all or a significant portion of the cost of our products. Therefore, coverage and adequate
reimbursement is critical to new product acceptance. Coverage decisions may depend upon clinical and economic standards that disfavor new drug products when more established or lower cost therapeutic alternatives are already available or
subsequently become available. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Government authorities and other third-party payors are developing increasingly sophisticated methods of controlling healthcare
costs, such as by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices as a condition of coverage,
are using restrictive formularies and preferred drug lists to leverage greater discounts in competitive classes, and are challenging the prices charged for medical products. Further, no uniform policy requirement for coverage and reimbursement for
drug products exists among third-party payors in the United States.&nbsp;Therefore, coverage and reimbursement for drug products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming
and costly process that will require us to provide scientific and clinical support for the use of our products to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first
instance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We cannot be sure that coverage and reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the
level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only
to limited levels, we may not successfully commercialize any product candidate for which we obtain marketing approval. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Healthcare Reform Measures
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The United States and some foreign jurisdictions are considering or have enacted a number of legislative and regulatory proposals designed to change the
healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated
goals of containing healthcare costs, improving quality and/or expanding access. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For example, in March 2010, the ACA was passed, which is changing health care financing by both governmental and private insurers and significantly affecting the
U.S. pharmaceutical industry. The ACA, among other things, subjected manufacturers to new annual fees and taxes for specified branded prescription drugs, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug
Rebate Program, expanded health care fraud and abuse laws, revised the methodology by which rebates owed by manufacturers to the state and federal government for covered outpatient drugs under the Medicaid Drug Rebate Program are calculated, imposed
an additional rebate similar to an inflation penalty on new formulations of drugs, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, expanded the 340B program
which caps the price at which manufacturers can sell covered outpatient pharmaceuticals to specified hospitals, clinics and community health centers, and provided incentives to programs that increase the federal government&#146;s comparative
effectiveness research. We continue to evaluate the effect that the ACA has on our business. There have been judicial and U.S. Congressional challenges to certain aspects of the ACA, and we expect there will be additional challenges and amendments
to the ACA in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">103 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011,
the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years
2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#146;s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers up to 2% per fiscal year, which
went into effect in April 2013, following passage of the Bipartisan Budget Act of 2015, and will remain in effect through 2025 unless additional U.S. Congressional action is taken. In addition, in January 2013, President Obama signed into law the
American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of healthcare providers and increased the statute of limitations period for the government to recover overpayments to providers from
three to five years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices.
Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and
reform government program reimbursement methodologies for drugs. Additional health reform measures may continue and affect our business in unknown ways. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>The
Foreign Corrupt Practices Act </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Foreign Corrupt Practices Act, or FCPA, prohibits any U.S. individual or business from paying, offering or authorizing
payment or offering of anything of value, directly or indirectly, to any foreign official, political party or candidate for the purpose of influencing any act or decision of the foreign entity in order to assist the individual or business in
obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the United States to comply with accounting provisions requiring the companies to maintain books and records that accurately and fairly reflect all
transactions of the companies, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Foreign Regulation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition to regulations in the United States,
we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to develop or sell any products outside of the United States. The approval process varies
from country to country and the time may be longer or shorter than that required to obtain FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Manufacturing, Supply and Production </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not own or operate
manufacturing facilities for the production of our product candidates, nor do we have plans to develop our own manufacturing operations in the foreseeable future. We currently rely on third-party contract manufacturers for all of our required raw
materials, active ingredients and finished products for our preclinical research and clinical trials, including the proposed single pivotal Phase 3 clinical trial for MitoGel. We do not have long-term agreements with any of these third parties. We
also do not have any current contractual relationships for the manufacture of commercial supplies of our product candidates if they are approved. If product candidates are approved by any regulatory agency, we intend to enter into agreements with a
third-party contract manufacturer and one or more back-up manufacturers for the commercial production of those products. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Development and commercial quantities of
any products that we develop will need to be manufactured in facilities, and by processes, that comply with the requirements of the FDA and the regulatory agencies of other jurisdictions in which we are seeking approval. We currently employ internal
resources to manage our manufacturing contractors. The relevant manufacturers of our drug products for our current preclinical and clinical trials have advised us that they are compliant with both cGLP and cGMP. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our product candidates, if approved, may not be producible in sufficient commercial quantities, in compliance with regulatory requirements or at an acceptable cost. We
and our contract manufacturers are, and will be, subject to extensive governmental regulation in connection with the manufacture of any pharmaceutical products or medical devices. We and our contract manufacturers must ensure that all of the
processes, methods and equipment are compliant with cGMP and cGLP for drugs on an ongoing basis, as mandated by the FDA and foreign regulatory authorities, and conduct extensive audits of vendors, contract laboratories and suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">104 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Marketing, Sales and Distribution </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Given our stage of development, we do not have any internal sales, marketing or distribution infrastructure or capabilities, and our marketing department currently
consists only of a marketing director, whose main responsibility is to produce marketing and communication materials, exhibitions, website content and to identify unmet needs in the urology market, assess their commercial potential and advise on the
prioritization of the development of our future product candidates accordingly. We have recently formed a U.S. subsidiary, Urogen Pharma, Inc., to support our U.S. development and potential commercialization efforts. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event that we receive regulatory approvals for our products in markets outside of the United States, we intend, where appropriate, to pursue commercialization
relationships, including strategic alliances and licensing, with pharmaceutical companies and other strategic partners, which are equipped to market or sell our products through their well-developed sales, marketing and distribution organizations in
such countries. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, we may out-license some or all of our worldwide patent rights to more than one party to achieve </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">the fullest development, marketing and distribution of any products we develop. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Employees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2015, we had 24 full-time employees and four
part-time employees, 27 based in Israel and one based in the United States. Of these employees, 19 are primarily engaged in research and development activities and nine are primarily engaged in general and administrative matters. A total of 10
employees have an M.D. or Ph.D. degree. None of our employees is represented by a labor union. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli labor laws govern the length of the workday and workweek, minimum wages for employees, procedures for hiring and dismissing employees, determination of
severance pay, annual leave, sick days, advance notice of termination, payments to the National Insurance Institute, and other conditions of employment and include equal opportunity and anti-discrimination laws. While none of our employees is party
to any collective bargaining agreements, certain provisions of the collective bargaining agreements between the Histadrut (General Federation of Labor in Israel) and the Coordination Bureau of Economic Organizations (including the
Industrialists&#146; Associations) are applicable to our employees in Israel by order of the Israeli Ministry of Economy and Industry. These provisions primarily concern pension fund benefits for all employees, insurance for work-related accidents,
recuperation pay and travel expenses. We generally provide our employees with benefits and working conditions beyond the required minimums. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Facilities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our principal executive offices are located at 9 HaTa&#146;asiya St., Ra&#146;anana 4365007, Israel, where we lease an approximately 617 square meter facility. This
Israeli facility houses our administrative headquarters and our research and development laboratories. We believe that our existing facility is adequate to meet our current needs, and that suitable additional or alternative spaces will be available
in the future on commercially reasonable terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Environmental, Health and Safety Matters </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions, primarily Israel, governing, among other things: the
use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage; chemicals, air, water and ground contamination; air emissions and the cleanup of contaminated sites, including any contamination that results from
spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations use chemicals and produce waste materials and sewage and require permits from various governmental authorities including, local municipal
authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the Ministry of Health, local authorities and the municipal water and sewage company conduct periodic inspections in order
to review and ensure our compliance with the various regulations. These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such laws,
regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business activities. In addition, we may
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">105 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
be required to pay damages or civil judgments in respect of third-party claims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle,
transport, manufacture or dispose of), property damage or contribution claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a
responsible party under such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations.&nbsp;In addition, laws and regulations relating to environmental, health and safety matters are
often subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties for activities which were previously permitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal and Corporate Structure </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our legal and commercial name is UroGen
Pharma Ltd. We were formed as a company in the State of Israel in April 2004. Urogen Pharma, Inc., our wholly owned subsidiary, was incorporated under the laws of the State of Delaware in October 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Legal Proceedings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From time to time, we may become party to litigation or
other legal proceedings that we consider to be a part of the ordinary course of our business. We are not currently involved in any legal proceedings that could reasonably be expected to have a material adverse effect on our business, financial
condition or results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">106 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_11"></A>MANAGEMENT </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Executive Officers, Key Personnel and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets
forth information relating to our executive officers, key personnel and directors as of December 31, 2015. Unless otherwise stated, the address for our executive officers, key personnel and directors is c/o UroGen Pharma Ltd., 9
Ha&#146;Ta&#146;asiya Street, Ra&#146;anana 4365007, Israel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="62%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:22.25pt; font-size:8pt; font-family:ARIAL"><B>NAME</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>POSITION</B></P></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Executive Officers</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Executive Officer and Director</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">President, Israeli Operation</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chief Financial Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Key Personnel</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Mark Schoenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Medical Director</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><I>Non-Employee Directors</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chairman of the Board of Directors</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chaim Hurvitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Director</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:14pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ron Bentsur </I>has served as our Chief
Executive Officer since August 2015, and as a member of our board of directors since October 2015. Mr. Bentsur has served as a member of the board of directors of Stemline Therapeutics, Inc. since 2009 and as Executive Chairman of Advanced
Inhalation Technologies, Ltd. since August 2015. Mr. Bentsur has more than 15 years of experience in the biotech industry. Until 2015, Mr. Bentsur served for more than five years as the Chief Executive Officer of Keryx Biopharmaceuticals, Inc., and
during his tenure, Keryx received FDA approval pursuant to the FDA&#146;s 505(b)(2) regulatory pathway for Auryxia (ferric citrate) and launched it commercially in the United States. Prior to that Mr. Bentsur served as Chief Executive Officer of XTL
Biopharmaceuticals Ltd., a position he held from January 2006 until April 2009. From October 2000 Mr. Bentsur was with Keryx and served as its Chief Financial Officer from June 2003 until his departure in January 2006. From July 1998 to October
2000, Mr.&nbsp;Bentsur served as Director of Technology Investment Banking at Leumi Underwriters, where he was responsible for all technology/biotechnology private placement and advisory transactions. From June 1994 to July 1998, Mr.&nbsp;Bentsur
worked as an investment banker in New York City, spending most of this period at ING Barings Furman Selz. Mr. Bentsur is a Director of Stemline Therapeutics, Inc. and Executive Chairman of Advanced Inhalation Therapies (AIT) Ltd. Mr. Bentsur holds a
B.A. in Economics and Business Administration with distinction from the Hebrew University of Jerusalem, Israel and an M.B.A. (Magna Cum Laude), from New York University&#146;s Stern School of Business. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gil Hakim</I> has served as our President, Israeli Operation since August 2015 and, prior to that, served as our Chief Executive Officer since August 2010. Mr. Hakim
has more than 20 years of experience in the biotech industry. Prior to joining us, Mr. Hakim served as Director of New Product Development at Medispec Ltd. from 2004 to 2010, and was in charge of product development in fields such as cardiology,
urology and dermatology. Prior to Medispec, from 2002 to 2004, Mr. Hakim was Director of Marketing and Clinical Research at MTRE Advanced Technologies Ltd., a wholly owned subsidiary of Mennen Medical Ltd. that develops thermoregulation devices.
Prior to that, from 2000 to 2002, he was Business Development Manager at Omrix Biopharmaceuticals, Inc. (acquired by Johnson &amp; Johnson in 2008), which develops biological glue and blood derivative products. Before that, from 1998 to 2000, he
served as European Product Manager at Biosense-Webster (Johnson &amp; Johnson) in Belgium, following Johnson &amp; Johnson&#146;s acquisition of Biosense Israel, where he was also part of the Research and Development team. Mr.&nbsp;Hakim holds a
B.Sc. in Life Sciences from Ben-Gurion University, Israel. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">107 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Gary Titus</I> has served as our Chief Financial Officer since July 2015. Mr. Titus has been a member of the board of
directors of ImmunoCellular Therapeutics, Ltd. since January 2013. Mr. Titus has more than 20 years of business experience in the healthcare and biopharmaceutical industries, primarily in senior management roles. Prior to his appointment as our
Chief Financial Officer, from 2014 to 2015, Mr. Titus held the position of Chief Financial Officer of BioCardia, Inc. Prior to that, from 2008 to 2013, Mr. Titus was Senior Vice President and Chief Financial Officer at SciClone Pharmaceuticals, Inc.
From 2006 to 2008, Mr. Titus was Senior Vice President of Finance and Chief Financial Officer at Kosan Biosciences, Inc. From 2003 to 2006, he was Chief Financial Officer and Vice President at Nuvelo, Inc. Earlier in his career, Mr.&nbsp;Titus held
a variety of positions at other companies, including Metabolex, Inc., Intrabiotics Pharmaceuticals, Inc. and Johnson &amp; Johnson. Mr. Titus holds a B.Sc. in Accounting from University of South Florida and a B.Sc. in Finance from University of
Florida. Mr. Titus also completed the Global BioExecutive Program at the University of California Berkeley&#146;s Haas School of Business. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our Key Personnel
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Mark Schoenberg, M.D.</I> has served as our Medical Director since February 2016. Dr. Schoenberg has over 20 years of experience in clinical practice
and research focused on the care of patients with all forms of bladder cancer. Since April 2014, Dr. Schoenberg has been Professor and University Chair at The Montefiore Medical Center and The Albert Einstein College of Medicine of Yeshiva
University. Prior to joining Montefiore, from 2005 to 2014, Dr.&nbsp;Schoenberg served as Director of Urologic Oncology and Bernard L. Schwartz Distinguished Professor of Urology at Johns Hopkins Hospital. Dr. Schoenberg is also the past chair of
the Medical Advisory Board of the Bladder Cancer Advocacy Network, the author of The Guide to Living with Bladder Cancer, co-editor of The Textbook of Bladder Cancer, a contributor to Campbell&#146;s Urology and a seminars editor of the journal
Urologic Oncology. Dr.&nbsp;Schoenberg received his M.D. (Alpha Omega Alpha) from the University of Texas Health Sciences Center and completed his residency in General Surgery and Urology at the Hospital of The University of Pennsylvania, where he
served as chief resident and urology instructor, before completing basic research and clinical urologic oncology fellowships at Johns Hopkins under the auspices of The American Cancer Society. Dr. Schoenberg is a fellow of the American College of
Surgeons, as well as a member of the American Association of Cancer Research, the Society of Urologic Oncology and the American Urological Association. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Our
Directors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Arie Belldegrun, M.D.</I> has served as our Chairman since December 2012. Dr. Belldegrun is Professor of Urology, holds the Roy and Carol
Doumani Chair in Urologic Oncology, and Director of the UCLA Institute of Urologic Oncology at the David Geffen School of Medicine at UCLA. Prior to joining UCLA, he was a research fellow at the National Cancer Institute/National Institute of Health
in surgical oncology and immunotherapy under Dr.&nbsp;Steven A. Rosenberg. Dr. Belldegrun has more than 20 years of experience in the life science and biotech industry. In 1996 he founded Agensys, Inc., a biotechnology company, and served as its
founding Chairman of the board of directors and as a board member until 2007, when it was acquired by Astellas Pharma Inc. Dr.&nbsp;Belldegrun was also a founder and the Vice-Chairman of the board of directors and Chairman of the scientific advisory
board of Cougar Biotechnology, Inc., a biotechnology company, from 2003 to 2009, when it was acquired by Johnson &amp; Johnson. He currently serves as Chairman and Chief Executive Officer of Kite Pharma, Inc. (NASDAQ: KITE), Chairman of Arno
Therapeutics, Inc., and Two River Group and as a board member of Teva Pharmaceutical Industries Ltd. Dr.&nbsp;Belldegrun completed his M.D. at the Hebrew University Hadassah Medical School in Jerusalem, Israel, his post graduate studies in
Immunology at the Weizmann Institute of Science, Israel, and his residency in Urologic Surgery at Harvard Medical School. Dr. Belldegrun has authored several books in oncology and more than 500 scientific and medical papers related to urological
cancers, immunotherapy, gene therapy, and cancer vaccines. Dr.&nbsp;Belldegrun is certified by the American Board of Urology and is a Fellow of the American College of Surgeons and the American Association of Genitourinary Surgeons. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Stuart Holden, M.D.</I> has served as our director since December 2015. Dr. Holden has been the Chairman of ProQuest Investments&#146; Scientific Advisory Board
since it was founded in 1998. Since May 2014, Dr. Holden has served as a member of the UCLA faculty as a Health Sciences Clinical Professor of Urology, Spielberg Family Chair in Urologic Oncology, in the Department of Urology at the UCLA David
Geffen School of Medicine and Associate Director of the UCLA Institute of Urologic Oncology. Dr. Holden has worked in the field of prostate cancer for more than 36 years. Dr. Holden also serves as Medical Director of the Prostate Cancer Foundation
since the foundation&#146;s inception in 1993. Dr. Holden was the director of the Louis Warschaw Prostate Cancer Center at Cedars-Sinai </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">108 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Medical Center and the first holder of the Warschaw, Robertson, Law Families Chair in Prostate Cancer. Dr.&nbsp;Holden has served as a member of the board of directors of Telormedix SA since
2008, and served as a member of the board of directors of Acurian, Inc. from 1999 through 2014. In addition, he was a founding partner at Tower Urology in Los Angeles. Dr. Holden received a B.A. degree from the University of Wisconsin-Madison and
completed his medical degree and received his surgical training at Weill Cornell Medical College and the New York Hospital&#151;Cornell University Medical College. He completed his urology residency at Emory University School of Medicine and
fellowships in urology and developmental genetics at Memorial Sloan-Kettering Cancer Center. He also was awarded a clinical fellowship from the American Cancer Society. Dr.&nbsp;Holden was appointed to serve on our board by ProQuest Investments IV,
L.P., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior to this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Chaim
Hurvitz</I> has served as our director since May 2013. Mr. Hurvitz has 31 years of experience in the life sciences industry. Mr. Hurvitz currently serves as Chief Executive Officer of CH Health, a private venture capital firm, a position he has held
since May 2011. Prior to that, Mr. Hurvitz was a member of the senior management of Teva Pharmaceutical Industries Ltd., serving as the President of Teva International Group from 2002 until 2010, as President and Chief Executive Officer of Teva
Pharmaceuticals Europe from 1992 to 1999 and as Vice President Israeli Pharmaceutical Sales from 1999 until 2002. Mr. Hurvitz served as a director of Teva Pharmaceutical Industries Ltd. from 2010 to 2014. Mr.&nbsp;Hurvitz served as a director of
Aposense Ltd. from 2010 to 2014. Mr. Hurvitz currently serves as Chairman of Galmed Pharmaceuticals Ltd. Mr. Hurvitz has been Chairman of the pharmaceuticals branch of the Manufacturer&#146;s Association of Israel since 2001 and is a member of its
board. Mr.&nbsp;Hurvitz received a B.A. in Political Science and Economics from Tel Aviv University, Israel. Mr. Hurvitz was appointed to serve on our board by Shirat HaChaim Ltd., one of our shareholders, pursuant to rights granted to such
shareholder under our articles of association as in effect prior to this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Ran Nussbaum</I> has served as our director since May 2013. Mr. Nussbaum is a
managing partner and the co-founder of The Pontifax Group, a group of Israeli-based life sciences venture funds focusing on investments in development stage bio-pharmaceutical and med-tech technologies and a shareholder of our company. He also
serves as a board member on many of Pontifax&#146;s portfolio companies, including Kite Pharma, Inc., BioBlast Pharma Ltd., Eloxx Pharmaceuticals Ltd., Nutrina&nbsp;Ltd., OCON Medical Ltd and Quiet Therapeutics Ltd. Mr. Nussbaum was appointed to
serve on our board by Pontifax (Israel) III Limited Partnership and Pontifax (Cayman) III Limited, two of our shareholders, pursuant to rights granted to such shareholders under our articles of association as in effect prior to this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Pini Orbach, Ph.D.</I> has served as our director since October 2014. Dr. Orbach has served as a director of Quiet Therapeutics Ltd. since January 2013. Dr. Orbach
has 10 years of experience in executive positions. Since February 2010, Dr. Orbach has been the head of Pharma and Life Science at Arkin Holdings. Dr. Orbach was the Chief Executive Officer of NanoDoc Technology, Inc. from 2010 to 2015, Chairman of
the board of directors of cCAM Biotherapeutics Ltd. from 2014 to 2015, and served as a Director of Quiet Therapeutics Ltd. since January 2013, FusiMab Ltd. from 2011 to 2014, HealOr Ltd. from 2010 to 2013, Metallo-Therapy Ltd. from 2011 to 2015,
Insuline Medical Ltd. from December 2013 to January 2015, and CollPlant Holdings Ltd. from May 2013 to August 2014. Prior to joining Arkin Holdings, Dr. Orbach served as Chief Executive Officer of several healthcare companies in Israel. Dr. Orbach
received his Ph.D. from the Department of Physiology and Functional Genomics at the University of Florida, and was a postdoctoral fellow at the Cardiovascular Research Center at Harvard Medical School. Dr.&nbsp;Orbach was appointed to serve on our
board by Arkin Communications Ltd., one of our shareholders, pursuant to rights granted to such shareholder under our articles of association as in effect prior to this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Arrangements Concerning Election of Directors; Family Relationships </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
board of directors consists of six directors. Currently serving directors will continue to serve pursuant to their appointment until the first annual general meeting of shareholders held after this offering.<SUP
STYLE="font-size:85%; vertical-align:top"> </SUP>We are not a party to, and are not aware of, any voting agreements among our shareholders. In addition, there are no family relationships among our executive officers and directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Corporate Governance Practices </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">After completion of this offering, we will
have an audit committee comprised of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;members, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of whom
will meet The NASDAQ Stock Market independence requirements, and one of these members will also possess </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">109 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the requisite financial expertise. In addition, under Israeli law we are required to have an audit committee which includes all of the external directors and consists of a majority of
&#147;unaffiliated directors&#148; as defined under the Israeli Companies Law, 5759-1999, or the Israeli Companies Law. See &#147;Board Committees&#151;Audit Committee&#151;Israeli Companies Law Requirements.&#148; Furthermore, under the Israeli
Companies Law, we are required to have a compensation committee consisting of at least three members, including all of the external directors, who must constitute a majority of the members of the compensation committee. See &#147;Board
Committees&#151;Compensation Committee and Compensation Policy&#151;Israeli Companies Law Requirements.&#148; Subject to certain conditions in the Israeli Companies Law, our audit committee may also serve as our compensation committee. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Companies incorporated under the laws of the State of Israel, whose shares are publicly traded, including companies with shares listed on the NASDAQ Global Market, are
considered public companies under Israeli law and are required to comply with various corporate governance requirements under Israeli law relating to such matters as external directors, the audit committee, the compensation committee and an internal
auditor. This is the case even if our shares are not listed on the Tel Aviv Stock Exchange, or TASE, which our shares are not expected to be. These requirements are in addition to the corporate governance requirements imposed by the NASDAQ Rules and
other applicable provisions of U.S. securities laws to which we will become subject (as a foreign private issuer) upon the closing of this offering and the listing of our ordinary shares on the NASDAQ Global Market. Under the NASDAQ Rules, a foreign
private issuer may generally follow its home country rules of corporate governance in lieu of the comparable requirements of the NASDAQ Rules, except for certain matters including the composition and responsibilities of the audit committee and the
independence of its members within the meaning of the rules and regulations of the SEC. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to rely on this &#147;home country practice exemption&#148; with
respect to the following NASDAQ requirements: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Quorum</I>. As permitted under the Israeli Companies Law and pursuant to our amended and restated articles of association to be effective upon the closing of this offering, the quorum required for an ordinary meeting
of shareholders will consist of at least two shareholders present in person, by proxy or by other voting instrument in accordance with the Israeli Companies Law, who hold at least 25% of the voting power of our shares (and in an adjourned meeting,
with some exceptions, at least two shareholders), instead of 33<SUP STYLE="font-size:85%; vertical-align:top">1</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the issued share capital required under the NASDAQ Rules.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Nomination of Directors</I>. With the exception of external directors and directors elected by our board of directors due to a vacancy, our directors are elected at an annual general meeting of our shareholders to
hold office until the next annual general meeting following his or her election. See &#147;Board Practices&#151;Board of Directors.&#148; The nominations for directors, which are presented to our shareholders by our board of directors, are generally
made by the board of directors itself or a duly authorized committee thereof, in accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law. Nominations need not be made by a nominating committee
of our board of directors consisting solely of independent directors or otherwise, as required under the NASDAQ Rules. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Select Board and Compensation Committee Requirements</I>.&nbsp;We will not be required to and, in reliance on home country practice, we do not intend to comply with certain NASDAQ Rules applicable to domestic
companies listed on the NASDAQ Global Market, which require a listed company&#146;s board of directors to be comprised of a majority of directors deemed to be independent under the NASDAQ Rules, and a listed company to maintain a compensation
committee subject to specific requirements of the NASDAQ Rules, including membership consisting solely of directors deemed to be independent under the NASDAQ Rules (subject to IPO transition requirements). In accordance with Israeli corporate
governance requirements, we intend to maintain a compensation committee, whose responsibilities would overlap with those required by the NASDAQ Rules, and our board of directors, or&nbsp;a committee thereof, will oversee the tasks that would
otherwise be required of independent directors or a nominating committee under the NASDAQ Rules. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Proxy Statements.</I> We will not be required to and, in reliance on home country practice, we do not intend to comply with certain NASDAQ Rules regarding the provision of proxy statements for general meetings of
shareholders. Israeli corporate law does not have a regulatory regime for the solicitation of proxies. We intend to provide notice convening an annual general meeting, including an agenda and other relevant documents. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">110 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><I>Shareholder Approval.</I> We will not be required to and, in reliance on home country practice, we do not intend to comply with certain NASDAQ Rules regarding shareholder approval for certain issuances of securities
under NASDAQ Rule 5635. In accordance with the provisions of our amended and restated articles of association and the Israeli Companies Law, our board of directors is authorized to issue securities, including shares, warrants and convertible notes.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We currently intend to take all actions necessary for us to maintain compliance as a foreign private issuer under the applicable corporate governance
requirements of the Sarbanes-Oxley Act, the rules adopted by the SEC and the NASDAQ Global Market&#146;s listing standards. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Practices </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Board of Directors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of
directors is responsible for setting our general policies and supervising the performance of management. Our board of directors may exercise all powers and may take all actions that are not specifically granted to our shareholders or to management.
Our executive officers are responsible for our day-to-day management and have individual responsibilities established by our board of directors. Our Chief Executive Officer is appointed by, and serves at the discretion of, our board of directors,
subject to the terms of the employment agreement that we have entered into with him. All other executive officers are also appointed by our board of directors, and are subject to the terms of any applicable employment agreements that we may enter
into with them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association, to be effective upon the closing of this offering, our board of directors must consist of
at least &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors and not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directors, including at least two external
directors required to be appointed under the Israeli Companies Law. Our board of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directors will consist of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; directors upon the closing of this offering, including two new directors who are our nominees to serve as external directors and whose appointment will be effective upon the
closing of this offering. The appointment of the external director nominees will be effective upon the closing of this offering, but their appointment as external directors is subject to approval at a general meeting of our shareholders to be held
no later than three months following the closing of this offering. Other than external directors, for whom special election requirements apply under the Israeli Companies Law, as detailed below, the Israeli Companies Law and our amended and restated
articles of association provide that directors are elected annually at the general meeting of our shareholders by a vote of the holders of a majority of the voting power represented present and voting in person, by proxy or by other voting
instrument at that meeting. We have only one class of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors is required to employ independent judgment
and discretion when voting, and is prohibited from entering into any voting arrangements with respect to actions taken at meetings of the board. Further, the Israeli Companies Law provides that in the event a director learns about an alleged breach
of law or improper conduct of business relating to a company matter, said director must promptly take action to summon a meeting of the board of directors to address any such breach. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the exemptions available to foreign private issuers under NASDAQ rules, we do not intend to follow the requirements of the NASDAQ rules with regard
to the process of nominating directors. Instead, we intend to follow Israeli law and practice, in accordance with which our board of directors (or a committee thereof) is authorized to recommend to our shareholders director nominees for election.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our amended and restated articles of association, nominees to serve as directors may also be proposed by any shareholder
holding at least 1% of our outstanding voting power. However, any such shareholder may propose a nominee only if a written notice of such shareholder&#146;s intent to propose a nominee has been given to the company. Any such notice must include
certain information, including, among other things, a description of all arrangements between the nominating shareholder and the proposed director nominee and any other person pursuant to which the nomination is to be made by the nominating
shareholder, the consent of the proposed director nominee to serve as our director if elected and a declaration signed by the nominee declaring that there is no limitation under the Israeli Companies Law preventing his or her election, and that all
of the information that is required under the Israeli Companies Law to be provided to us in connection with such election has been provided. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">111 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill
vacancies on our board of directors, including filling empty board seats up to the maximum number of directors permitted under our articles of association, for a term of office equal to the remaining period of the term of office of each director
whose office has been vacated. Vacancies on our board of directors, other than vacancies created by an external director, may be filled by a vote of a simple majority of the directors then in office. A director so appointed will hold office until
the next annual general meeting of our shareholders in which the other directors then in office are proposed to be replaced or reappointed. External directors are elected for an initial term of three years and may be elected for additional
three-year terms under the circumstances described below. External directors may be removed from office only under the limited circumstances set forth in the Israeli Companies Law. See &#147;External Directors.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our board of directors must determine the minimum number of directors who are required to have accounting and financial expertise. See
&#147;External Directors.&#148; In determining the number of directors required to have such expertise, our board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our
board of directors has determined that the minimum number of directors of our company who are required to have accounting and financial expertise is one. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>External Directors </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we are required
to include on our board of directors at least two members who qualify as external directors. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;have agreed to serve as our external directors, subject to ratification at a meeting of our shareholders to be held no later than three months following the closing of this
offering. Upon their approval by the shareholders, we expect that both external directors will also serve on our audit committee and compensation committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
provisions of the Israeli Companies Law set forth special approval requirements for the election of external directors. External directors must be elected by a majority vote of the shares present and voting at a meeting of shareholders, provided
that either: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">such majority includes at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in the election of the external director (other than a personal
interest not deriving from a relationship with a controlling shareholder) that are voted at the meeting, excluding abstentions, to which we refer as a disinterested majority; or </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the total number of shares voted by non-controlling shareholders and by shareholders who do not have a personal interest in the election of the external director against the election of the external director does not
exceed 2% of the aggregate voting rights in the company. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term &#147;controlling shareholder&#148; is defined in the Israeli Companies Law as a
shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. The term &#147;office holder&#148; is defined under the Israeli Companies Law as a general manager, chief business manager, deputy
general manager, vice general manager, any other person assuming the responsibilities of any of these positions regardless of that person&#146;s title, a director and any other manager directly subordinate to the general manager. A shareholder is
presumed to be a controlling shareholder if the shareholder holds 50% or more of the voting rights in a company or has the right to appoint the majority of the directors of the company or its chief executive officer (referred to in the Israeli
Companies Law as the general manager). With respect to certain matters, a controlling shareholder is deemed to include a shareholder that holds 25% or more of the voting rights in a public company if no other shareholder holds more than 50% of the
voting rights in the company, but excludes a shareholder whose power derives solely from his or her position as a director of the company or from any other position with the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The initial term of an external director is three years. Thereafter, an external director may be reelected by shareholders to serve in that capacity for up to two
additional three-year terms, provided that either: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:ARIAL; font-size:9.5pt">his or her service for each such additional term is recommended by one or more shareholders holding at least 1% of the company&#146;s voting rights or by the
external director himself or herself and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">112 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="font-family:ARIAL; font-size:9.5pt">
disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company, provided that the external director and certain of his or her related parties meet
additional independence requirements; or </P></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders by the same majority required for the initial election of an external director (as
described above). </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term of office for external directors for Israeli companies traded on certain foreign stock exchanges, including the NASDAQ
Global Market, may be extended indefinitely in increments of additional three-year terms, in each case provided that the audit committee and the board of directors of the company confirm that, in light of the external director&#146;s expertise and
special contribution to the work of the board of directors and its committees, the reelection for each such additional period is beneficial to the company, and provided that the external director is reelected subject to the same shareholder vote
requirements as if elected for the first time (as described above). Prior to the reelection of the external director at a general meeting of shareholders, the company&#146;s shareholders must be informed of the term previously served by him or her
and of the reasons why the board of directors and audit committee recommended the extension of his or her term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">External directors may be removed from office by a
special general meeting of shareholders called by the board of directors, which approves such dismissal by the same shareholder vote percentage required for their election or by a court, in each case, only under limited circumstances, including
ceasing to meet the statutory qualifications for appointment, or violating their duty of loyalty to the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If an external directorship becomes vacant and
there are fewer than two external directors on the board of directors at the time, then the board of directors is required under the Israeli Companies Law to call a shareholders&#146; meeting as soon as practicable to appoint a replacement external
director. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each committee of the board of directors that exercises any of the powers of the board of directors must include at least one external director, except
that the audit committee and the compensation committee must include all external directors then serving on the board of directors. Under the Israeli Companies Law, external directors of a company are prohibited from receiving, directly or
indirectly, any compensation from the company other than for their services as external directors pursuant to the Israeli Companies Law and the regulations promulgated thereunder. Compensation of an external director is determined prior to his or
her appointment and may not be changed during his or her term subject to certain exceptions. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law provides that a person is not qualified to
serve as an external director if (i) the person is a relative of a controlling shareholder of the company, or (ii) if that person or his or her relative, partner, employer, another person to whom he or she was directly or indirectly subordinate, or
any entity under the person&#146;s control, has or had, during the two years preceding the date of appointment as an external director: (a) any affiliation or other disqualifying relationship with the company, with any person or entity controlling
the company or a relative of such person, or with any entity controlled by or under common control with the company; or (b) in the case of a company with no controlling shareholder, had at the date of appointment as an external director, any
affiliation or other disqualifying relationship with a person then serving as chairman of the board or chief executive officer, or a holder of 5% or more of the issued share capital or voting power in the company or the most senior financial
officer. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The term &#147;relative&#148; is defined under the Israeli Companies Law as a spouse, sibling, parent, grandparent or descendant; spouse&#146;s sibling,
parent or descendant; and the spouse of each of the foregoing persons. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the term &#147;affiliation&#148; and the similar types of
disqualifying relationships include (subject to certain exceptions): </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an employment relationship; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a business or professional relationship even if not maintained on a regular basis (excluding insignificant relationships); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">control; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">113 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">service as an office holder, excluding service as a director in a private company prior to the initial public offering of its shares if such director was appointed as a director of the private company in order to serve
as an external director following the initial public offering. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, no person may serve as an external director if that person&#146;s
position or professional or other activities create, or may create, a conflict of interest with that person&#146;s responsibilities as a director or otherwise interfere with that person&#146;s ability to serve as an external director or if the
person is an employee of the Israel Securities Authority or of an Israeli stock exchange. Furthermore, a person may not continue to serve as an external director if he or she received direct or indirect compensation from the company including
amounts paid pursuant to indemnification or exculpation contracts or commitments and insurance coverage for his or her service as an external director, other than as permitted by the Israeli Companies Law and the regulations promulgated thereunder.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the termination of an external director&#146;s service on a board of directors, such former external director and his or her spouse and children may not
be provided a direct or indirect benefit by the company, its controlling shareholder or any entity under its controlling shareholder&#146;s control. This includes engagement as an office holder or director of the company or a company controlled by
its controlling shareholder or employment by, or provision of services to, any such company for consideration, either directly or indirectly, including through a corporation controlled by the former external director. This restriction extends for a
period of two years with regard to the former external director and his or her spouse or child and for one year with respect to other relatives of the former external director. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at the time at which an external director is appointed all members of the board of directors who are not controlling shareholders or relatives of controlling
shareholders of the company are of the same gender, the external director to be appointed must be of the other gender. A director of one company may not be appointed as an external director of another company if a director of the other company is
acting as an external director of the first company at such time. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">According to the Israeli Companies Law and the regulations promulgated thereunder, a person may
be appointed as an external director only if he or she has professional qualifications or if he or she has accounting and financial expertise (each, as defined below). In addition, at least one of the external directors must be determined by our
board of directors to have accounting and financial expertise. However, if at least one of our other directors (i) meets the independence requirements under the Exchange Act, (ii) meets the standards of the NASDAQ Rules for membership on the audit
committee, and (iii) has accounting and financial expertise as defined under the Israeli Companies Law, then neither of our external directors is required to possess accounting and financial expertise as long as each possesses the requisite
professional qualifications. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A director with accounting and financial expertise is a director who, due to his or her education, experience and skills, is
proficient in, and possesses an understanding of, business &#150; accounting matters and financial statements, such that he or she is able to understand the financial statements of the company, in depth, and initiate a discussion about the manner of
presentation of financial data. A director is deemed to have professional qualifications if he or she has any of (i) an academic degree in economics, business management, accounting, law or public administration, (ii) an academic degree or has
completed another form of higher education in the primary field of business of the company or in a field which is relevant to his or her position in the company, or (iii) at least five years of experience serving in one of the following capacities,
or at least five years of cumulative experience serving in two or more of the following capacities: (a) a senior business management position in a company with a significant volume of business; (b) a senior position in the company&#146;s primary
field of business; or (c) a senior position in public administration or service. The board of directors is charged with determining whether a director possesses financial and accounting expertise or professional qualifications. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has
accounting and financial expertise and possesses professional qualifications as required under the Israeli Companies Law. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Leadership Structure of the Board
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accordance with the Israeli Companies Law and our amended and restated articles of association, our board of directors is required to appoint one of its
members to serve as chairman of the board of directors. Our board of directors has appointed Arie Belldegrun, M.D. to serve as chairman of the board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">114 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Board Committees </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the
Israeli Companies Law and our amended and restated articles of association, our board of directors is permitted to form committees, and to delegate to any such committee powers allotted to the board of directors, subject to certain exceptions. In
general, the board of directors may overturn a resolution adopted by a committee it has formed; provided, however, that the board&#146;s decision shall not affect the ability of third parties, who were not aware of such decision, to rely on the
committee&#146;s resolution prior to the time it is overturned. Only members of the board of directors can be members of a board committee, unless the committee is solely advisory. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Audit Committee </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the listing of our ordinary shares on the
NASDAQ Global Market, our audit committee will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;.
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as chairman of the audit committee. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli
Companies Law Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, we will be required to appoint an audit committee following the closing of this offering. The audit
committee must be comprised of at least three directors, including all of the external directors, one of whom must serve as chairman of the committee. The audit committee may not include the chairman of the board, a controlling shareholder of the
company, a relative of a controlling shareholder, a director employed by or providing services on a regular basis to the company, to a controlling shareholder or to an entity controlled by a controlling shareholder, or a director who derives most of
his or her income from a controlling shareholder. In addition, under the Israeli Companies Law, the audit committee of a publicly traded company must consist of a majority of unaffiliated directors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, an &#147;unaffiliated director&#148; is defined under the Israeli Companies Law either as an external director or as a director who meets the following
criteria: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">he or she meets the qualifications for being appointed as an external director, except for the requirements that the director (i) be an Israeli resident (which does not apply to companies such as ours whose securities
have been offered outside of Israel or are listed for trading outside of Israel) and (ii) possess accounting and financial expertise or professional qualifications; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">he or she has not served as a director of the company for a period exceeding nine consecutive years. For this purpose, an interruption in service of less than two years shall not be deemed to interrupt the continuation
of the service. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>NASDAQ Listing Requirements </I></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the
NASDAQ Rules, we are required to maintain an audit committee consisting of at least three independent directors, each of whom is financially literate and one of whom has accounting or related financial management expertise. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ Stock Market. Our
board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an audit committee financial expert as such term is defined by the SEC rules and has the requisite financial
experience as defined by the NASDAQ Rules. Each of the members of our audit committee is &#147;independent&#148; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act and satisfies the independent director requirements under the NASDAQ
Rules. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Audit Committee Role </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee charter, to be
effective upon the listing of our shares on the NASDAQ Global Market, sets forth the responsibilities of the audit committee consistent with the rules and regulations of the SEC and the NASDAQ Rules, as well as the requirements for such committee
under the Israeli Companies Law, including the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">oversight of our independent registered public accounting firm and recommending the engagement, compensation or termination of engagement of our independent registered public accounting firm to the board of directors in
accordance with Israeli law; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the engagement or termination of the person filling the office of our internal auditor; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending the terms of audit and non-audit services provided by the independent registered public accounting firm for pre-approval by our board of directors. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">115 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee provides assistance to our board of directors in fulfilling its legal and fiduciary obligations in
matters involving our accounting, auditing, financial reporting, internal control and legal compliance functions by pre-approving the services performed by our independent accountants and reviewing their reports regarding our accounting practices
and systems of internal control over financial reporting. Our audit committee also oversees the audit efforts of our independent accountants and takes those actions that it deems necessary to satisfy itself that the auditors are independent of
management. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, our audit committee is responsible for: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top">determining whether there are deficiencies in the business management practices of our company, including in consultation with our internal auditor or the independent auditor, and making recommendations to the board of
directors to improve such practices; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve certain related party transactions (including transactions in which an office holder has a personal interest and whether such transaction is extraordinary or material under the Israeli
Companies Law) (see &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#148;); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top">establishing the approval process for certain transactions with a controlling shareholder or in which a controlling shareholder has a personal interest; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD ALIGN="left" VALIGN="top">where the board of directors approves the working plan of the internal auditor, examining such working plan before its submission to the board of directors and proposing amendments thereto; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD ALIGN="left" VALIGN="top">examining our internal audit controls and internal auditor&#146;s performance, including whether the internal auditor has sufficient resources and tools to fulfill his responsibilities; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD ALIGN="left" VALIGN="top">examining the scope of our auditor&#146;s work and compensation and submitting a recommendation with respect thereto to our board of directors or shareholders, depending on which of them is considering the appointment
of our auditor; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD ALIGN="left" VALIGN="top">establishing procedures for the handling of employees&#146; complaints as to the management of our business and the protection to be provided to such employees. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our audit committee may not approve any actions requiring its approval (see &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of
Directors and Executive Officers&#148;), unless at the time of the approval a majority of the committee&#146;s members are present, and a majority of those members present, consists of unaffiliated directors including at least one external director.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Compensation Committee and Compensation Policy </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the listing
of our ordinary shares on the NASDAQ Global Market, we intend to establish a compensation committee. The members of the compensation committee will
be&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will serve as chairman of the compensation committee. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Israeli Companies Law Requirements </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the
board of directors of a public company must appoint a compensation committee. The compensation committee must be comprised of at least three directors, including all of the external directors, who must constitute a majority of the members of the
compensation committee. However, subject to certain exceptions, Israeli companies whose securities are traded on stock exchanges such as the NASDAQ Global Market, and who do not have a controlling shareholder, do not have to meet this majority
requirement; provided, however, that the compensation committee meets other Israeli Companies Law composition requirements, as well as the requirements of the jurisdiction where the company&#146;s securities are traded. Each compensation committee
member who is not an external director must be a director whose compensation does not exceed an amount that may be paid to an external director. The compensation committee is subject to the same Israeli Companies Law restrictions as the audit
committee as to who may not be a member of the committee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duties of the compensation committee include the recommendation to the company&#146;s board of
directors of a policy regarding the terms of engagement of office holders, to which we refer as a compensation policy. That policy must be adopted by the company&#146;s board of directors, after considering the recommendations of the compensation
committee, and will need to be approved by the company&#146;s shareholders, which approval requires what we refer to as a Special Majority Approval for Compensation. A Special Majority Approval for Compensation requires shareholder
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">116 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
approval by a majority vote of the shares present and voting at a meeting of shareholders called for such purpose, provided that either: (i) such majority includes at least a majority of the
shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such compensation arrangement, excluding abstentions; or (ii) the total number of shares of non-controlling shareholders and shareholders who
do not have a personal interest in the compensation arrangement and who vote against the arrangement does not exceed 2% of the company&#146;s aggregate voting rights. We will be required to adopt a compensation policy within nine months following
our listing on the NASDAQ Global Market. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Even if the company&#146;s shareholders do not approve the compensation policy, the board of directors may resolve to
approve the compensation policy if and to the extent the board determines, in its judgment following internal discussions, that approval of the compensation policy is in the best interests of the company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation,
insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#146;s long-term objectives, business
plan and policies, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#146;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the
following additional factors: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the education, skills, expertise and accomplishments of the relevant office holder; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the office holder&#146;s roles and responsibilities and prior compensation agreements with him or her; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between the terms offered and the average compensation of the company&#146;s personnel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the impact of disparities in salary upon work relationships in the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of reducing variable compensation at the discretion of the board of directors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the possibility of setting a limit on the exercise value of non-cash variable equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as to severance compensation, the period of service of the office holder, the terms of his or her compensation during such service period, the company&#146;s performance during that period of service, the person&#146;s
contribution towards the company&#146;s achievement of its goals and the maximization of its profits, and the circumstances under which the person is leaving the company. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation policy must also include the following principles: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the link between variable compensation and long-term performance and measurable criteria; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relationship between variable and fixed compensation, and the ceiling for the value of variable compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conditions under which an office holder would be required to repay compensation paid to him or her if it was later shown that the data upon which such compensation was based was inaccurate and was restated in the
company&#146;s financial statements; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum holding or vesting period for variable, equity-based compensation; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">maximum limits for severance compensation. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Compensation Committee Roles </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation committee is responsible for (i) recommending the compensation policy to our board of directors for its approval (and subsequent approval by our
shareholders) and (ii) duties related to the compensation policy and to the compensation of our office holders, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending whether a compensation policy should continue in effect, if the then-current policy has a term of greater than three years (approval of either a new compensation policy or the continuation of an existing
compensation policy must in any case occur every three years); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">recommending to the board of directors periodic updates to the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">assessing implementation of the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether to approve the terms of compensation of certain office holders which, according to the Israeli Companies Law, require the committee&#146;s approval; and </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">117 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">determining whether the compensation terms of a candidate for the position of the chief executive officer of the company needs to be brought to approval of the shareholders. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our board of directors intends to adopt a compensation committee charter setting forth the responsibilities of the compensation committee, which include: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the responsibilities set forth in the compensation policy; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing and approving the granting of options and other incentive awards to the extent such authority is delegated by our board of directors; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reviewing, evaluating and making recommendations regarding the compensation and benefits for our non-employee directors. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Disclosure of Compensation of Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For so long as we
qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our Chief Executive
Officer, Chief Financial Officer, President, Israeli Operation and other two most highly compensated executive officers on an individual, rather than on an aggregate, basis. Nevertheless, under regulations promulgated under the Israeli Companies
Law, we are required to disclose the annual compensation of our five most highly compensated office holders (as defined under the Israeli Companies Law) on an individual basis, rather than on an aggregate basis, as was previously permitted for
Israeli public companies listed overseas. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the notice (which is generally part of the proxy
statement) for our 2017 annual general meeting of shareholders, which will be filed under cover of a Report of Foreign Private Issuer on Form 6-K and we may elect to provide such information at an earlier date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Internal Auditor </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, the board of
directors of an Israeli public company must appoint an internal auditor recommended by the audit committee. An internal auditor may not be: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who holds more than 5% of the company&#146;s outstanding shares or voting rights; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a person (or a relative of a person) who has the power to appoint a director or the general manager of the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an office holder (including a director) of the company (or a relative thereof); or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a member of the company&#146;s independent accounting firm, or anyone on its behalf. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The role of the internal auditor
is to examine, among other things, our compliance with applicable law and orderly business procedures, and to report to the chief executive officer, the chairman of the board and the chairman of the audit committee. The internal auditor is entitled
to receive notice of audit committee meetings and to participate in them. In addition, the internal auditor may request that the chairman of the audit committee convene a meeting within a reasonable time to discuss an issue raised by the internal
auditor. The internal auditor is responsible for preparing a proposal for an annual or periodical audit plan and submit such plan to the board of directors or the audit committee for their approval. We intend to appoint an internal auditor following
the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Approval of Related Party Transactions under Israeli Law </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Fiduciary Duties of Directors and Executive Officers </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli
Companies Law codifies the fiduciary duties that office holders owe to a company. Each person listed in the table under &#147;Executive Officers and Directors&#148; is an office holder under the Israeli Companies Law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An office holder&#146;s fiduciary duties consist of a duty of care and a duty of loyalty. The duty of care requires an office holder to act with the level of care with
which a reasonable office holder in the same position would have acted under the same circumstances. The duty of loyalty includes an obligation that an office holder act in good faith and in the best interests of the company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">118 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of care includes a duty to use reasonable means to obtain: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">information on the advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all other important information pertaining to any such action. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The duty of loyalty includes a duty to: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any conflict of interest between the performance of his or her duties to the company and his or her other duties or personal affairs; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from any activity that is competitive with the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">refrain from exploiting any business opportunity of the company to receive a personal gain for himself or herself or others; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">disclose to the company any information or documents relating to the company&#146;s affairs which the office holder received as a result of his or her position as an office holder. </TD></TR></TABLE>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that an office holder promptly disclose to the board of directors any personal interest that he or she may be aware of and all
related material information or documents concerning any existing or proposed transaction with the company. An interested office holder&#146;s disclosure must be made promptly and in any event no later than the first meeting of the board of
directors at which the transaction is considered. A personal interest includes an interest of any person in an action or transaction of a company, including a personal interest of such person&#146;s relative or of a corporate body in which such
person or a relative of such person is a 5% or greater shareholder, director or general manager or in which he or she has the right to appoint at least one director or the general manager, but excluding a personal interest stemming from one&#146;s
ownership of shares in the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A personal interest also includes the personal interest of a person for whom the office holder holds a voting proxy or the
personal interest of the office holder with respect to his or her vote on behalf of a person for whom he or she holds a proxy even if such person has no personal interest in the matter. An office holder is not, however, required to disclose a
personal interest if it derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. Under the Israeli Companies Law, an &#147;extraordinary transaction&#148; is defined as
any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction other than in the ordinary course of business; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that is not on market terms; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a transaction that may have a material impact on a company&#146;s profitability, assets or liabilities. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If it is
determined that an office holder has a personal interest in a transaction, which is not an extraordinary transaction, approval by the board of directors is required for the transaction, unless the company&#146;s articles of association provide for a
different method of approval. Further, so long as an office holder has disclosed his or her personal interest in a transaction, the board of directors may approve an action by the office holder that would otherwise be deemed a breach of his or her
duty of loyalty. However, a company may not approve a transaction or action that is not in the company&#146;s interest or that is not performed by the office holder in good faith. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">An extraordinary transaction in which an office holder has a personal interest requires approval first by the company&#146;s audit committee and subsequently by the
board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The compensation of, or an undertaking to indemnify or insure, an office holder who is not a director requires approval first by the
company&#146;s compensation committee, then by the company&#146;s board of directors. If such compensation arrangement or an undertaking to indemnify or insure is inconsistent with the company&#146;s stated compensation policy, or if the office
holder is the chief executive officer (apart from a number of specific exceptions), then such arrangement is further subject to a Special Majority Approval for Compensation. If the shareholders of a company do not approve the compensation terms of
office holders at a meeting of the shareholders, other than directors, the compensation committee and board of directors may override the shareholders&#146; decision, subject to certain conditions. Arrangements regarding the compensation,
indemnification or insurance of a director require the approval of the compensation committee, board of directors and shareholders by simple majority, in that order, and under certain circumstances, a Special Majority Approval for Compensation. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">119 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Generally, a person who has a personal interest in a matter which is considered at a meeting of the board of directors or
the audit committee may not be present at such a meeting or vote on that matter unless the chairman of the audit committee or board of directors (as applicable) determines that he or she should be present in order to present the transaction that is
subject to approval. If a majority of the members of the audit committee or the board of directors (as applicable) has a personal interest in the approval of a transaction, then all directors may participate in discussions of the audit committee or
the board of directors (as applicable) on such transaction and the voting on approval thereof, but shareholder approval is also required for such transaction. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions </I></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to Israeli law, the disclosure requirements regarding personal interests that apply to directors and executive officers also apply to a controlling shareholder
of a public company. In the context of a transaction involving a shareholder of the company, a controlling shareholder also includes a shareholder who holds 25% or more of the voting rights in the company if no other shareholder holds more than 50%
of the voting rights in the company. For this purpose, the holdings of all shareholders who have a personal interest in the same transaction will be aggregated. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The approval of the audit committee, the board of directors and the shareholders of the company, in that order, is required for (i) extraordinary transactions with a
controlling shareholder or in which a controlling shareholder has a personal interest, (ii) the engagement with a controlling shareholder or his or her relative, directly or indirectly, for the provision of services to the company, (iii) the terms
of engagement and compensation of a controlling shareholder or his or her relative who is not an office holder or (iv) the employment of a controlling shareholder or his or her relative by the company, other than as an office holder. In addition,
the shareholder approval requires one of the following, which we refer to as a Special Majority: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at least a majority of the shares held by all shareholders who do not have a personal interest in the transaction and who are present and voting at the meeting approves the transaction, excluding abstentions; or
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the shares voted against the transaction by shareholders who have no personal interest in the transaction and who are present and voting at the meeting do not exceed 2% of the aggregate voting rights in the company.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that any such transaction with a controlling shareholder is for a period extending beyond three years, approval is required once every
three years, unless, with respect to certain transactions, the audit committee determines that the duration of the transaction is reasonable given the circumstances related thereto. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Arrangements regarding the compensation, indemnification or insurance of a controlling shareholder in his or her capacity as an office holder require the approval of
the compensation committee, board of directors and shareholders by a Special Majority. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to regulations promulgated under the Israeli Companies Law, certain
transactions with a controlling shareholder or his or her relative, or with directors, that would otherwise require approval of a company&#146;s shareholders may be exempt from shareholder approval upon certain determinations of the audit committee
and board of directors. Under these regulations, a shareholder holding at least 1% of the issued share capital of the company may require, within 14 days of the publication of such determinations, that despite such determinations by the audit
committee and the board of directors, such transaction will require shareholder approval under the same majority requirements that would otherwise apply to such transactions. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Shareholder Duties </I></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law, a shareholder has
a duty to act in good faith and in a customary manner toward the company and other shareholders and to refrain from abusing his or her power in the company, including, among other things, in voting at a general meeting and at shareholder class
meetings with respect to the following matters: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an amendment to the company&#146;s articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an increase of the company&#146;s authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the approval of related party transactions and acts of office holders that require shareholder approval. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">120 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A shareholder also has a general duty to refrain from discriminating against other shareholders. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, certain shareholders have a duty of fairness toward the company. These shareholders include a controlling shareholder, a shareholder who knows that he or
she has the power to determine the outcome of a shareholder vote and a shareholder who has the power to appoint or to prevent the appointment of an office holder of the company or other power towards the company. The Israeli Companies Law does not
define the substance of the duty of fairness, except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exculpation, Insurance and Indemnification of Directors and Officers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under
the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages
caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association which will be effective upon the closing
of this offering include such a provision. A company may not exculpate in advance a director from liability arising out of a breach of the duty of care with respect to a distribution. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder in respect of the following liabilities and expenses incurred for acts performed by him or her
as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such
investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding, and (ii) no financial liability was imposed upon him or her as a substitute for the criminal
proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">121 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the
following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the
shareholders. See &#147;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers.&#148; </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and
restated articles of association to be effective upon the closing of this offering will permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by the Israeli Companies Law. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained directors and officers liability insurance for the benefit of our office holders and intend to increase such coverage in an amount standard for a
company of our size prior to the closing of this offering. We intend to maintain such increased coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. In addition, prior to the closing of this
offering, we intend to enter into agreements with each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to
the fullest extent permitted by our amended and restated articles of association to be effective upon the closing of this offering and Israeli law, including with respect to liabilities resulting from this offering to the extent that these
liabilities are not covered by insurance. In the opinion of the SEC, however, indemnification of directors and office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Code of Business Conduct and Ethics </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to adopt a Code of Business
Conduct and Ethics applicable to all of our directors and employees, including our Chief Executive Officer, Chief Financial Officer, controller or principal accounting officer, or other persons performing similar functions, which is a &#147;code of
ethics&#148; as defined in Item 16B of Form 20-F promulgated by the SEC. Upon the effectiveness of the registration statement of which this prospectus forms a part, the full text of the Code of Business Conduct and Ethics will be posted on our
website at www.urogen.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus and is not incorporated by reference herein. If we make any amendment to the Code of Business Conduct and
Ethics or grant any waivers, including any implicit waiver, from a provision of the code of ethics, we will disclose the nature of such amendment or waiver on our website to the extent required by the rules and regulations of the SEC. Under Item 16B
of Form 20-F, if a waiver or amendment of the Code of Business Conduct and Ethics applies to our principal executive officer, principal financial officer, principal accounting officer or controller and relates to standards promoting any of the
values described in Item 16B(b) of Form 20-F, we are required to disclose such waiver or amendment on our website in accordance with the requirements of Instruction 4 to such Item 16B. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Compensation of Executive Officers and Directors </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate compensation
paid and equity-based compensation and other payments expensed by us to our directors and executive officers with respect to the year ended December 31, 2015 was
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;million. This amount does not include business travel, relocation, professional and business association dues and expenses reimbursed to office holders,
and other benefits commonly reimbursed or paid by companies in our industry. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">122 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2015, options to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares granted to our directors and
executive officers were outstanding under our 2010 Israeli Share Option Plan at a weighted average exercise price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share and
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; restricted share units were granted to our directors and executive officers under our 2010 Israeli Share Option Plan. Such number excludes options to purchase up
to&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;restricted share units, which are contingent upon the closing of this offering.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We do not have any written agreements with any director providing for benefits upon the termination of such director&#146;s relationship with our company, other
than our employment agreement with our Chief Executive Officer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Executive Officers; Consulting and Directorship Services Provided by Directors
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, we will have entered into written employment agreements with all of our executive officers. These agreements contain
standard provisions for a company in our industry regarding non-solicitation, confidentiality of information, non-competition and assignment of inventions. Our executive officers will not receive benefits upon the termination of their respective
employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment, which varies for each individual. In addition, we have entered into an
agreement for management services with the chairman of our board of directors. See &#147;Certain Relationships and Related Party Transactions&#151;Agreements and Arrangements with, and Compensation of, Directors and Executive Officers&#148; for
additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>2010 Israeli Share Option Plan </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In September
2010, we adopted our 2010 Israeli Share Option Plan, or the 2010 Plan. The 2010 Plan provides for the grant of share options and restricted share units to our company&#146;s employees, non-employee directors and consultants. The reserved pool of
shares under the 2010 Plan is &nbsp;&nbsp;&nbsp;&nbsp; shares. Generally, shares that are forfeited, cancelled, terminated or expire unexercised under the 2010 Plan shall be available for issuance under new awards. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for the grant by us of awards pursuant to Sections 102 and 3(i) of Israeli Income Tax Ordinance [New Version] 5721 - 1961, or the Ordinance, and
the rules and regulations promulgated thereunder. The 2010 Plan is effective with respect to awards granted as of 30 days from the date we submitted it to the Israeli Tax Authority, or the ITA. Section 102 of the Ordinance allows employees,
directors and officers who are not controlling shareholders and who are Israeli residents, to receive favorable tax treatment for compensation in the form of shares or options. Section 102 of the Ordinance includes two alternatives for tax treatment
involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. Section 102(b)(2) of the Ordinance, which provides
the most favorable tax treatment for grantees, permits the issuance to a trustee under the &#147;capital gains track.&#148; In order to comply with the terms of the capital gains track, all options granted under a specific plan and subject to the
provisions of Section 102 of the Ordinance, as well as the shares issued upon exercise of such options and other shares received following any realization of rights with respect to such options, such as share dividends and share splits, must be
registered in the name of a trustee selected by the board of directors and held in trust for the benefit of the relevant employee, director or officer. The trustee may not release these options or shares to the relevant grantee before the second
anniversary of the registration of the options in the name of the trustee. However, under this track, we are not allowed to deduct an expense with respect to the issuance of the options or shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan provides for awards to be granted to our employees or those of our affiliates, directors and officers who are not controlling shareholders, as defined in
the Ordinance, and who are considered Israeli residents, to the extent that such awards either are (i) intended to qualify for special tax treatment under the &#147;capital gains track&#148; provisions of Section 102(b)(2) of the Ordinance or (ii)
not intended to qualify for such special tax treatment. The 2010 Plan also provides for the grant of awards under Section 3(i) of the Ordinance to our Israeli non-employee service providers and controlling shareholders, who are not eligible for such
special tax treatment. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The 2010 Plan is administered by our board of directors. Awards under the 2010 Plan may be granted until 10 years after the effective date
of the 2010 Plan. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The terms of options granted under the 2010 Plan, including the exercise price, vesting provisions and the duration of an option, will be
determined by our board of directors and set forth in an award agreement. Except as provided in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">123 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
the applicable award agreement, or in the discretion of the compensation committee, an option may be exercised only to the extent that it is then exercisable and, generally, shall expire for
employees 90 days following termination of the service of the grantee. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Restricted share units are awards covering a number of hypothetical units with respect to
shares that are granted subject to such vesting and transfer restrictions and conditions of payment as our board of directors may determine in an award agreement. Restricted share units are payable in cash, ordinary shares of equivalent value or a
combination thereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of any dividend (excluding any ordinary dividend) or other distribution, recapitalization, share split, reverse share split,
reorganization, merger, consolidation, split-up, split-off, combination, repurchase or exchange of shares or similar event (including a change in control) that affects the ordinary shares, the board of directors will make any such adjustments in
such manner as it may deem equitable, including any or all of the following: (i) adjusting the number of shares available for grant under the 2010 Plan, and (ii) providing for a substitution or assumption of awards. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">124 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_12"></A>PRINCIPAL SHAREHOLDERS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of December 31, 2015 by: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">each of our directors and executive officers individually; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all of our executive officers and directors as a group. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The beneficial ownership of our ordinary shares is determined
in accordance with the rules of the SEC and generally includes any shares over which a person exercises sole or shared voting or investment power, or the right to receive the economic benefit of ownership. For purposes of the table below, we deem
ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days of December 31, 2015 to be outstanding and to be beneficially owned by the person holding the options for the purposes of computing the
percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
percentage of shares beneficially owned has been computed on the basis of 2,569,611 ordinary shares outstanding as of December 31, 2015, which reflects the assumed exercise of all of our warrants to purchase preferred shares and the subsequent
conversion of all of our preferred shares into ordinary shares.&nbsp;For purposes of calculating the number of ordinary shares into which each preferred share will convert immediately prior to the consummation of this offering, we have assumed an
initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share, the midpoint of the range set forth on the cover page of this prospectus. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December 31, 2015 and based on their reported registered office, 42 of our shareholders were U.S. persons, holding in aggregate approximately 25.0% of our
outstanding ordinary shares immediately prior to this offering. We have also set forth below information known to us regarding any significant change in the percentage ownership of our ordinary shares by any major shareholders during the past three
years. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such shares. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, all of our shareholders, including the shareholders listed below, will have the same voting rights attached to their ordinary
shares, and neither our principal shareholders nor our directors and executive officers will have different or special voting rights with respect to their ordinary shares. See &#147;Description of Share Capital&#151;Voting Rights.&#148; A
description of any material relationship that our principal shareholders have had with us or any of our predecessors or affiliates within the past three years is included under &#147;Certain Relationships and Related Party Transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">125 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Unless otherwise noted below, the address of each shareholder, director and executive officer is c/o UroGen Pharma Ltd., 9
Ha&#146;Ta&#146;asiya St., Ra&#146;anana 4365007, Israel. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER AND<BR>PERCENTAGE</B><br><B>OF&nbsp;ORDINARY&nbsp;SHARES</B><br><B>BENEFICIALLY&nbsp;OWNED</B><br><B>PRIOR TO OFFERING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="3" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENTAGE&nbsp;OF&nbsp;ORDINARY</B><br><B>SHARES BENEFICIALLY</B><br><B>OWNED AFTER THE</B><br><B>OFFERING</B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING</B><br><B>NO</B><br><B>EXERCISE</B><br><B>OF&nbsp;OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(15)</SUP></B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ASSUMING</B><br><B>FULL</B><br><B>EXERCISE</B><br><B>OF<BR>OPTION<SUP STYLE="font-size:85%; vertical-align:top">&nbsp;(15)</SUP></B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:112.40pt; font-size:8pt; font-family:ARIAL"><B>NAME OF BENEFICIAL OWNER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PERCENT</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>5% or Greater Shareholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arkin Communication Ltd.<SUP STYLE="font-size:85%; vertical-align:top"> (1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">539,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax (Israel) III Limited Partnership<SUP STYLE="font-size:85%; vertical-align:top"> (2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">289,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pontifax Cayman III Limited Partnership<SUP STYLE="font-size:85%; vertical-align:top"> (3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,072</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">ProQuest Investments IV, L.P.<SUP STYLE="font-size:85%; vertical-align:top"> (4)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263,158</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Telormedix SA<SUP STYLE="font-size:85%; vertical-align:top"> (5)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Tatham Investments Ltd.<SUP STYLE="font-size:85%; vertical-align:top"> (6)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="13"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Directors and Executive Officers</B></P></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Arie Belldegrun, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (7)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68,342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ron Bentsur<SUP STYLE="font-size:85%; vertical-align:top"> (8)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,526</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Chaim Hurvitz<SUP STYLE="font-size:85%; vertical-align:top"> (9)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">126,395</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Pini Orbach, Ph.D.<SUP STYLE="font-size:85%; vertical-align:top"> (10)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,013</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Stuart Holden, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> (11)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">216,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.4</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gil Hakim<SUP STYLE="font-size:85%; vertical-align:top"> (12)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,926</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Gary Titus<SUP STYLE="font-size:85%; vertical-align:top"> (13)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ran Nussbaum<SUP STYLE="font-size:85%; vertical-align:top"> (14)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">424,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16.5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">All directors and executive officers as a group</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">899,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Indicates beneficial ownership of less than 1% of the total ordinary shares outstanding. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 421,053 ordinary shares issuable upon conversion of preferred shares and (ii) 118,422 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares and conversion thereof
into ordinary shares. Mr. Moshe Arkin is the sole beneficial owner of Arkin Communication Ltd. The percentage ownership of Arkin Communication Ltd. increased from 15.8% as of December&nbsp;31, 2014, in connection with its initial investment, to
21.0% as of December&nbsp;31, 2015, in connection with its additional investment. The address of Arkin Communication Ltd. is 6&nbsp;HaChoshlim St., Bldg. C, Herzliya 46724, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(2)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 85,216 ordinary shares; (ii) 175,814 ordinary shares issuable upon conversion of preferred shares; (iii) 26,910 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares
and conversion thereof into ordinary shares and (iv) 1,382 ordinary shares issuable upon exercise of outstanding options. Does not include 10,232 ordinary shares issuable upon exercise of outstanding options which have not vested. Pontifax
Management Fund III L.P. is the general partner of Pontifax (Israel) III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are directors of
Pontifax Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax (Israel) III Limited Partnership. The address of Pontifax (Israel) III Limited Partnership is 14&nbsp;Shenkar St., Herzliya 4672514, Israel.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 39,784 ordinary shares; (ii) 82,080 ordinary shares issuable upon conversion of preferred shares; (iii) 12,564 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares
and conversion thereof into ordinary shares and (iv) 644 ordinary shares issuable upon exercise of outstanding options. Does not include 4,768 ordinary shares issuable upon exercise of outstanding options which have not vested. Pontifax Management
Fund III L.P. is the general partner of Pontifax Cayman III Limited Partnership, and Pontifax Management III G.P. (2011) Ltd. is the general partner of Pontifax Management Fund III L.P. Tomer Kariv and Ran Nussbaum are directors of Pontifax
Management GP and, as such, hold voting and/or dispositive power over the shares held by Pontifax Cayman III Limited Partnership. The address of Pontifax Cayman III Limited Partnership is 14 Shenkar St., Herzliya 4672514, Israel. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(4)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 263,158 ordinary shares issuable upon conversion of preferred shares. ProQuest Associates IV LLC is the managing member and sole general partner of ProQuest Investments VI, L.P. Jay Moorin and Alain
Schreiber are the managing members of ProQuest Associates IV LLC and, as such, hold voting and/or dispositive power over the shares held by ProQuest Investments IV, L.P. The percentage ownership of ProQuest Associates IV LLC increased from 0% to
10.2% during 2015 in connection with its initial investments. The address of ProQuest Investments IV, L.P. is 2430 Vanderbilt Beach Road, 108-190, Naples, FL 34109, USA. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">126 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(5)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 216,000 ordinary shares issuable upon conversion of preferred shares. Does not include up to 87,000 ordinary shares that may be issued in the future upon the achievement of certain milestones under the
Vesimune asset purchase agreement with Telormedix SA. 62.6% of the beneficial ownership of these securities is held by ProQuest Investments IV, L.P., and 37.4% of the beneficial ownership of these securities is held by Aravis SA. Alain Schreiber,
Stuart Holden, Johanna Holldack and Jean-Philippe Tripet, through these entities, share voting and dispositive power over the shares held by Telormedix. The percentage ownership of Telormedix SA increased from 0% to 8.4% during 2015 in connection
with its initial investments. The address of Telormedix SA is Via della Posta&nbsp;10, <FONT STYLE="white-space:nowrap">H-6934</FONT> Bioggio, Switzerland. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(6)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 35,500 ordinary shares; (ii) 81,372 ordinary shares issuable upon conversion of preferred shares and (iii)&nbsp;13,153 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred
shares and conversion thereof into ordinary shares. Tatham Investments Ltd. is beneficially owned by Shimon Elkabetz. The address of Tatham Investments Ltd. is <FONT STYLE="white-space:nowrap">2-4&nbsp;Arch,</FONT> Makarios&nbsp;III Ave, Capital
Center, 703&nbsp;Nicosia, Cyprus. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(7)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 26,316 ordinary shares issuable upon conversion of preferred shares held by Bellco Capital, LLC through several entities controlled by it, a company beneficially owned by Arie Belldegrun, M.D. and his
spouse Rebecka Belldegrun, M.D. and (ii)&nbsp;42,026 ordinary shares issuable upon exercise of outstanding options. Does not include 50,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(8)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 10,526 ordinary shares issuable upon conversion of preferred shares. Does not include 86,000 ordinary shares issuable upon outstanding restricted share units which have not vested, and 9,000 ordinary shares
issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(9)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i)&nbsp;31,250 ordinary shares, 78,948 ordinary shares issuable upon conversion of preferred shares and 13,158 ordinary shares issuable upon exercise of outstanding warrants to purchase preferred shares and
conversion thereof into ordinary shares beneficially held by Shirat HaChaim Ltd., a company beneficially owned by Chaim Hurvitz, and (ii)&nbsp;3,039 ordinary shares issuable upon exercise of outstanding options. Does not include 15,000 ordinary
shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(10)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,013 ordinary shares issuable upon exercise of outstanding options. Does not include 15,000 ordinary shares issuable upon exercise of outstanding options which have not vested. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(11)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of beneficial ownership of securities held by Telormedix SA described in note 5 above. Does not include 15,000 ordinary shares issuable upon exercise of outstanding options which have not vested.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(12)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 5,882 ordinary shares; (ii) 1,316 ordinary shares issuable upon conversion of preferred shares and (iii)&nbsp;40,728 ordinary shares issuable upon exercise of outstanding options. Does not include 39,554
ordinary shares issuable upon exercise of outstanding options which have not vested, of which 15,000 were granted in January 2016. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(13)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 5,263 ordinary shares issuable upon conversion of preferred shares. Does not include 32,000 ordinary shares issuable upon exercise of outstanding options which have not vested, of which 15,000 were granted
in January 2016. Does not include 3,000 ordinary shares issuable upon exercise of options, the grant of which is contingent upon the closing of this offering. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of beneficial ownership of securities held by Pontifax (Israel) III Limited Partnership and Pontifax Cayman III Limited Partnership described in notes&nbsp;2 and 3 above. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right"><SUP STYLE="font-size:85%; vertical-align:top">(15)</SUP>&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Underwriters&#146; option to purchase additional ordinary shares, as set out on the cover page of this prospectus. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">127 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_13"></A>CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements with Shareholders </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Registration rights agreement
</I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an investors&#146; rights agreement dated September 18, 2014, as amended on October 1, 2015, or the Registration Rights Agreement,
with certain of our shareholders. The Registration Rights Agreement provides that certain holders of our ordinary shares have the right to demand that we file a registration statement or request that their ordinary shares be covered by a
registration statement that we are otherwise filing. Any registration rights with respect to this offering have been waived. The registration rights are described in more detail under &#147;Description of Share Capital&#151;Registration
Rights.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Agreements and Arrangements with, and Compensation of, Directors and Executive Officers </B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Employment agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into written employment
agreements with each of our executive officers. These agreements contain customary provisions and representations, including confidentiality, non-competition, non-solicitation and inventions assignment undertakings by the executive officers.
However, the enforceability of the non-competition provisions may be limited under applicable law. The agreements are terminable by us at will, subject to prior notice, which varies for each individual. Our executive officers will not receive
benefits upon termination of their respective employment with us, other than payment of salary and benefits (and limited accrual of vacation days) during the required notice period for termination of their employment. However, Ron Bentsur, our Chief
Executive Officer, and Gary Titus, our Chief Financial Officer, will be entitled to accelerated vesting of their stock options in the event of termination without cause. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Consulting and option agreements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into an agreement
with our chairman of the board of directors, Arie Belldegrun, M.D., for management services pertaining to the development of our business. These services include serving as chairman of the board of directors, assisting us in our financing activities
and overseeing our clinical development activities. In consideration of these services, as of December 31, 2015, we have issued Dr. Belldegrun options under our 2010 Israeli Share Option Plan to purchase 40,000 ordinary shares at $12.85 per share
and 52,026 ordinary shares at $16.00 per share. The agreement has no fixed term and is terminable at will (i) by Dr. Belldegrun upon 30 days&#146; prior written notice and (ii) by us at any time pursuant to the directions of our board of directors
or shareholders. The agreement contains customary provisions and representations, including confidentiality and inventions assignment undertakings by Dr. Belldegrun. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have also entered into an option agreement with our other non-executive directors, Pini Orbach, Chaim Hurvitz and Stuart Holden and option agreements with Pontifax
(Israel) III Limited Partnership and Pontifax (Cayman) III Limited Partnership, which are represented by our non-executive director Ran Nussbaum, according to which each was granted options under our 2010 Israeli Share Option Plan in the number and
on the terms set out in the section above titled &#147;Principal Shareholders.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Financing agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Between 2012 and 2015, Arkin Communications Ltd. or Arkin, which appointed Pini Orbach, Ph.D., to our board of directors, Pontifax (Israel) III Limited Partnership, or
Pontifax IL, and Pontifax (Cayman) III Limited Partnership, or Pontifax CM, which appointed Ran Nussbaum to our board of directors, Shirat HaChaim Ltd., or Shirat HaChaim, a company controlled by our director Chaim Hurvitz, Bellco Capital LLC, or
Bellco, through several entities controlled by it (the beneficial owners of Bellco Capital are Rebecka Belldegrun, M.D. and our chairman Arie Belldegrun, M.D.) and ProQuest Investments IV, L.P., or ProQuest, which appointed Stuart Holden, M.D. to
our board of directors, invested in the company an aggregate amount of approximately $22.4 million in consideration of the securities described below: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">From January
2012 through April 2013, we entered into share purchase agreements with Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 429,764 ordinary shares at $16.00 per share, of which 85,216,
39,784 and 31,250 ordinary shares were issued to Pontifax IL, Pontifax CM and Shirat HaChaim, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">128 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On September 18, 2014, we entered into a share purchase agreement, or the 2014 Share Purchase Agreement, with Arkin,
Pontifax IL, Pontifax CM, Shirat HaChaim and other investors, pursuant to which the company issued to the investors 455,183 shares of Series A preferred shares at $19.00 per share and 227,592 warrants exercisable to shares of Series A-1 preferred
shares at $25.00 per share, of which 236,842, 53,820, 25,126 and 26,316 shares and 118,422, 26,910, 12,564 and 13,158 warrants were issued to Arkin, Pontifax IL, Pontifax CM and Shirat HaChaim, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">On October 1, 2015, we entered into a share purchase agreement, or the 2015 SPA, with ProQuest, Arkin, Pontifax&nbsp;IL, Pontifax CM, Shirat HaChaim, Bellco and other
investors, pursuant to which the company issued to the investors 951,774 shares of Series A preferred shares at $19.00 per share, of which 263,158, 184,211, 121,994, 56,954, 52,632 and 26,316 shares were issued to ProQuest, Arkin, Pontifax IL,
Pontifax CM, Shirat HaChaim and Bellco, respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Indemnification agreements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and office holders to the fullest extent permitted
by the Israeli Companies Law. Immediately prior to the closing of this offering, we intend to enter into indemnification agreements with each of our directors and executive officers, undertaking to indemnify them to the fullest extent permitted by
Israeli law, including with respect to liabilities resulting from a public offering of our shares, to the extent that these liabilities are not covered by insurance. We have also obtained Directors and Officers insurance for each of our executive
officers and directors. For further information, see &#147;Management&#151;Exculpation, Insurance and Indemnification of Directors and Officers.&#148; </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other
Relationships </B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">ProQuest beneficially owns 62.6% of Telormedix SA. Stuart Holden, M.D., one of our directors, is a member of the board of directors of Telormedix
SA. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Family members of Chaim Hurvitz beneficially own more than 10% of Pontifax IL and Pontifax CM. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">129 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_14"></A>DESCRIPTION OF SHARE CAPITAL </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following descriptions of our share capital and provisions of our amended and restated articles of association which will be effective upon the closing of this
offering are summaries and do not purport to be complete. A form of our amended and restated articles of incorporation will be filed with the SEC as an exhibit to our registration statement, of which this prospectus forms a part. The description of
the ordinary shares reflects changes to our capital structure that will occur immediately prior to the closing of this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>General </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, our authorized share capital will consist
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares, par value NIS 0.01 per share, of
which&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares will be issued and outstanding (assuming that the underwriters do not exercise their option to purchase additional ordinary shares). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our outstanding ordinary shares are validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All ordinary shares will have identical voting and other rights in all respects. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Number and Purpose of the Company </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our registration number with
the Israeli Registrar of Companies is 513537621. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity. Following the completion of this offering and the resulting registration of our shares
for trading, our registration number will change to reflect our becoming a public company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Conversion of Preferred Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the closing of this offering, all of our preferred shares outstanding will automatically convert into ordinary shares, and will have no further preferences,
privileges or priority rights of any kind. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer of Shares </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our
fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a
stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel,
except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Election of Directors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a
meeting of shareholders have the power to elect all of our directors, subject to the special approval requirements for external directors described under &#147;Management&#151;Board Practices&#151;External Directors.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under our amended and restated articles of association to be effective upon the closing of this offering, our board of directors must consist of at least
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;and not more than &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directors, including at least two external directors required to be appointed under the
Israeli Companies Law. Our board of directors will consist of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;directors upon the closing of this offering, including two new directors who are our nominees to serve as external
directors and whose appointment will be effective upon the closing of this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of association, each of our
directors, other than the external directors, for whom special election requirements apply under the Israeli Companies Law, will be appointed by a simple majority vote of holders of our ordinary shares, participating and voting at an annual general
meeting of our shareholders. Each director will serve until the next annual general meeting following his or her election and his or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">130 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
her successor is duly elected and qualified or until his or her earlier death, resignation or removal by a vote of the majority voting power of our shareholders at a general meeting of our
shareholders or until his or her office expires by operation of law. In addition, our amended and restated articles of association allow our board of directors to appoint directors to fill vacancies on the board of directors, including filling empty
board seats up to the maximum number of directors permitted under our articles of association, to serve until the next annual general meeting of shareholders. External directors are elected for an initial term of three years, may be elected for
additional terms of three years each under certain circumstances, and may be removed from office pursuant to the terms of the Israeli Companies Law. See &#147;Management&#151;Board Practices&#151;External Directors.&#148; Our amended and restated
articles of association do not have a retirement age requirement for our directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Dividend and Liquidation Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Israeli Companies Law, dividend
distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#146;s articles of association provide otherwise. Our amended and restated articles of association do not
require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the
Israeli Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the end of the period
to which the financial statements relate is not more than six months prior to the date of the distribution. If we do not meet such criteria, then we may distribute dividends only with court approval. In each case, we are only permitted to distribute
a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to
their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the
future. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Exchange Controls </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">There are currently no Israeli currency
control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of countries that are, or have been, in
a state of war with Israel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Shareholder Meetings </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli law, we
are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All meetings other than the annual general meeting of
shareholders are referred to in our amended and restated articles of association as extraordinary general meetings. Our board of directors may call extraordinary general meetings whenever it sees fit, at such time and place, within or outside of
Israel, as it may determine. In addition, the Israeli Companies Law provides that our board of directors is required to convene an extraordinary general meeting upon the written request of (i) any two or more of our directors or one-quarter or more
of the members of our board of directors, or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% of our outstanding voting power, or (b) 5% or more of our outstanding voting power.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the provisions of the Israeli Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general
meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Israeli Companies Law requires that resolutions regarding the
following matters must be passed at a general meeting of our shareholders: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">amendments to our articles of association; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment or termination of our auditors; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">131 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">appointment of external directors; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approval of certain related party transactions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">increases or reductions of our authorized share capital; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a merger; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of our board of director&#146;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law requires that a notice of any annual general meeting or extraordinary general meeting be provided to shareholders at least
21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, notice must be provided at
least 35 days prior to the meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and under our amended and restated articles of association, shareholders are not permitted to
take action by way of written consent in lieu of a meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Israeli Companies Law, whenever we cannot convene or conduct a general meeting in the manner
prescribed under the law or our articles of association, the court may, upon our, shareholders&#146; or directors&#146; request, order that we convene and conduct a general meeting in the manner the court deems appropriate. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law allows one or more of our shareholders holding at least 1% of the voting power of our company to request the inclusion of an additional agenda
item for an upcoming shareholders meeting, assuming that it is appropriate for debate and action at a shareholders meeting. Under recently adopted regulations, such a shareholder request must be submitted within three or, for certain requested
agenda items, seven days following our publication of notice of the meeting. If the requested agenda item includes the appointment of director(s), the requesting shareholder must comply with particular procedural and documentary requirements. If our
board of directors determines that the requested agenda item is appropriate for consideration by our shareholders, we must publish an updated notice that includes such item within seven days following the deadline for submission of agenda items by
our shareholders. The publication of the updated notice of the shareholders meeting does not impact the record date for the meeting. In lieu of this process, we may opt to provide pre-notice of our shareholders meeting at least 21 days prior to
publishing official notice of the meeting. In that case, our 1% shareholders are given a 14 day period in which to submit proposed agenda items, after which we must publish notice of the meeting that includes any accepted shareholder proposals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Voting Rights </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Quorum Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a
vote before the shareholders at a general meeting. As a foreign private issuer, the quorum required for our general meetings of shareholders consists of at least two shareholders present in person, by proxy or by other voting instrument in
accordance with the Israeli Companies Law who hold or represent between them at least 25% of the total outstanding voting rights. A meeting adjourned for lack of a quorum is generally adjourned to the same day in the following week at the same time
and place or to a later time or date if so specified in the notice of the meeting. At the reconvened meeting, any two or more shareholders present in person or by proxy shall constitute a lawful quorum. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Vote Requirements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association
provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Israeli Companies Law or by our amended and restated articles of association. Under the Israeli Companies Law, each of (i) the approval
of an extraordinary transaction with a controlling shareholder, and (ii) the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#146;s relative (even if such terms are not
extraordinary) requires the approval described above under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers&#151;Disclosure of Personal Interests of Controlling
Shareholders and Approval of Certain Transactions.&#148; Additionally, (i) the approval and extension of a compensation policy and certain deviations therefrom require the approvals described above under &#147;Management&#151;Compensation
Committee&#151;Israeli </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">132 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Companies Law Requirements,&#148; and (ii) the terms of employment or other engagement of the chief executive officer of the company require the approvals described above under
&#147;Management&nbsp;&#151;Disclosure of Personal Interests of an Office Holder and Approval of Certain Transactions.&#148; Under our amended and restated articles of association, the alteration of the rights, privileges, preferences or obligations
of any class of our shares requires a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all
classes of shares voting together as a single class at a shareholder meeting. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Further exceptions to the simple majority vote requirement are a resolution for the
voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Israeli Companies Law, that governs the settlement of debts and reorganization of a company, which requires the approval
of holders of 75% of the voting rights represented at the meeting and voting on the resolution. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Access to Corporate Records </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, shareholders are provided access to: minutes of our general meetings; our shareholders register and principal shareholders register,
articles of association and annual audited financial statements; and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be
provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Israeli Companies Law. We may deny this request if we believe it has not been made in good faith or
if such denial is necessary to protect our interest or protect a trade secret or patent. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Modification of Class Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law and our amended and restated articles of association, the rights attached to any class of shares, such as voting, liquidation and
dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, as set forth in
our amended and restated articles of association. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have entered into the Registration Rights Agreement with certain of our shareholders as part of the 2014 Share Purchase Agreement. Upon the closing of this offering,
holders of a total of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our ordinary shares will have the right to require us to register these shares under the Securities Act under specified
circumstances and will have incidental registration rights as described below. After registration pursuant to these rights, these shares will become freely tradable without restriction under the Securities Act. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Demand Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any time after 180 days after the
effective date of this registration statement, we receive a request from holders of at least 30% of the registrable securities then outstanding that we file a Form F-1 registration statement with respect to registrable securities then outstanding
having an anticipated aggregate offering price of at least $5.0 million, then we shall (a) within 10 days after the date such request is given, give demand notice to all holders other than the initiating holders; and (b) as soon as practicable, and
in any event within 60 days after the date such request is given by the initiating holders, file a Form F-1 registration statement under the Securities Act covering all registrable securities that the initiating holders requested to be registered
and any additional registrable securities requested to be included in such registration by any other holders, as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will not be obligated to file a registration statement at such time if in the good faith judgment of our board of directors, such registration would be materially
detrimental to the us and our shareholders, because such action would (a) materially interfere with a significant acquisition, corporate reorganization, or other similar transaction involving us; (b) require premature disclosure of material
information that we have a bona fide business purpose for preserving as confidential; or (c) render us unable to comply with requirements under the Securities Act or Exchange Act. In such event we may defer the requested filing for a period of not
more than 60 days. We may not invoke this right more than once in any 12-month period and, during such 60 day period, we shall not register any securities for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">133 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
our own account or that of any other shareholder other than &#147;Excluded Registration&#148;: (i) a registration relating to the sale of securities to our or a subsidiary&#146;s employees
pursuant to a stock option, stock purchase, or similar plan; (ii) a registration relating to an SEC Rule 145 transaction; (iii) a registration on any form that does not include substantially the same information as would be required to be included
in a registration statement covering the sale of the registrable securities; or (iv) a registration in which the only ordinary shares being registered are ordinary shares issuable upon conversion of debt securities that are also being registered.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition we shall not be obligated to effect, or to take any action to effect, any demand registration (a) during the period that is 60 days before our good
faith estimate of the date of filing of, and ending on a date that is 180 days after the effective date of, our initiated registration, provided that we are actively employing in good faith commercially reasonable efforts to cause such registration
statement to become effective; (b) after we have effected two demand registrations; or (c) if the initiating holders propose to dispose of shares of registrable securities that may be immediately registered on Form F-3. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Form F-3 Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If at any time when we are eligible to
use a Form F-3 registration statement, we receive a request from holders of the registrable securities then outstanding that we file a Form F-3 registration statement with respect to outstanding registrable securities of such holders having an
anticipated aggregate offering price of at least $3.0 million, then we shall (a) within 10 days after the date such request is given, give a demand notice to all holders other than the initiating holders; and (b) as soon as practicable, and in any
event within 45 days after the date such request is given by the initiating holders, file a Form F-3 registration statement under the Securities Act covering all registrable securities requested to be included in such registration by any other
holders, as specified by notice given by each such holder to us within 20 days of the date the demand notice is given. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We shall not be obligated to effect, or to
take any action to effect, any Form F-3 registration (a) during the period that is 30 days before our good faith estimate of the date of filing of, and ending on a date that is 90 days after the effective date of, our initiated registration,
provided, that we are actively employing in good faith commercially reasonable efforts to cause such registration statement to become effective; or (b) if we have effected two Form F-3 demand registrations within the 12-month period immediately
preceding the date of such request. A Form F-3 registration shall not be counted as &#147;effected&#148; until such time as the applicable registration statement has been declared effective by the SEC, unless the initiating holders withdraw their
request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement, in which case such withdrawn registration statement shall be counted as &#147;effected.&#148; </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Piggyback Registration Rights </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, if we propose to register
(including, for this purpose, a registration effected by us for shareholders other than the holders) any of our securities under the Securities Act in connection with the public offering of such securities solely for cash (other than in an Excluded
Registration), we shall, at such time, promptly give each holder notice of such registration. Upon the request of each holder given within 20 days after such notice is given by us, we shall, subject to underwriter requirements, cause to be
registered all of the registrable securities that each such holder has requested to be included in such registration. We shall have the right to terminate or withdraw any registration initiated by us before the effectiveness of such registration,
whether or not any holder has elected to include registrable securities in such registration. The expenses of such withdrawn registration shall be borne by us. Any piggyback registration rights with respect to this offering have been waived. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Other Provisions </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We will pay all registration expenses (other than
underwriting discounts and selling commissions) and the reasonable fees and expenses of a single counsel for the selling shareholders, related to any demand or piggyback registration. The demand, Form F-3 and piggyback registration rights described
above will expire with respect to each holder of registrable securities upon such time as Rule 144 or another similar exemption under the Securities Act is available for the sale of all of such holder&#146;s shares without limitation during a
three-month period without registration. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Termination of Registration Rights </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No holder shall be entitled to exercise any registration rights after, and all such rights shall terminate upon the earlier to occur of (a) (i) any dissolution or
liquidation of us; (ii) any bankruptcy or insolvency proceeding under any bankruptcy or insolvency or similar law, whether voluntary or involuntary, is properly commenced by or against us; and (iii) a receiver or liquidator has been appointed to all
or substantially all of our assets, and (b) the fifth anniversary of the completion of this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">134 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, the registration rights shall terminate as to any shares of registrable securities when such shares have been
(i) registered under the Securities Act pursuant to an effective registration statement filed thereunder and disposed of in accordance with the registration statement covering them, or (ii) publicly sold pursuant to Rule 144. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Acquisitions under Israeli Law </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Full Tender Offer </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#146;s issued and outstanding share
capital is required by the Israeli Companies Law to make a tender offer to all of the company&#146;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli
company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders who hold shares of the relevant class for the purchase of all of
the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do
not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not
accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon a successful completion of
such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to
determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who
accepted the offer will not be entitled to petition the Israeli court as described above. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If (i) the shareholders who did not respond or accept the tender offer
hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of
the tender offer, or (ii) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares from shareholders who
accepted the tender offer that will increase its holdings to more than 90% of the company&#146;s issued and outstanding share capital or of the applicable class. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Special Tender Offer </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law provides that,
subject to certain exceptions, an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the
company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Israeli Companies Law provides that, subject to certain exceptions, an acquisition of shares in a public
company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than
45% of the voting rights in the company. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A special tender offer must be extended to all shareholders of a company. A special tender offer may be consummated only
if (i) the offeror acquired shares representing at least 5% of the voting power in the company and (ii) the number of shares tendered by shareholders who accept the offer exceeds the number of shares held by shareholders who object to the offer
(excluding the offeror, controlling shareholders, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any of their relatives or any entity controlled by them).
If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the
target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender
offer. Shares purchased in contradiction to the tender offer rules under the Israeli Companies Law, will have no rights and will become dormant shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">135 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Merger </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli
Companies Law permits merger transactions if approved by each party&#146;s board of directors and, unless certain requirements described under the Israeli Companies Law are met, by a majority vote of each party&#146;s shareholders. In the case of
the target company, approval of the merger further requires a majority vote of each class of its shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of the shareholder vote, unless a court rules
otherwise, the merger will not be deemed approved if a majority of the votes of shares represented at the meeting of shareholders that are held by parties other than the other party to the merger, or by any person (or group of persons acting in
concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#146;s own
controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same Special Majority approval that governs all extraordinary transactions with controlling shareholders (as
described under &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Disclosure of Personal Interests of Controlling Shareholders and Approval of Certain Transactions&#148;). </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of
certain shareholders as provided above, a court may still approve the merger upon the petition of holders of at least 25% of the voting rights of a company. For such petition to be granted, the court must find that the merger is fair and reasonable,
taking into account the respective values assigned to each of the parties to the merger and the consideration offered to the shareholders of the target company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern
that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger is filed with the Israeli
Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Anti-Takeover
Measures under Israeli Law </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Israeli Companies Law allows us to create and issue shares having rights different from those attached to our ordinary
shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and
restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or
prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and
restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to
participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Israeli Companies Law as described above in &#147;-Voting Rights.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Borrowing Powers </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the Israeli Companies Law and our amended and
restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including
the power to borrow money for company purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">136 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Changes in Capital </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended
and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Israeli Companies Law and must be approved by a resolution duly passed by our shareholders at a general
meeting by voting on such change in the capital. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of
both our board of directors and an Israeli court. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The transfer agent and registrar for our ordinary shares is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. Its address
is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and its telephone number is&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to have our ordinary shares listed on the NASDAQ
Global Market under the symbol &#147;URGN.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">137 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_15"></A>SHARES ELIGIBLE FOR FUTURE SALE </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, no public market existed for our ordinary shares. Sales of substantial amounts of our ordinary shares following this offering, or the
perception that these sales could occur, could adversely affect prevailing market prices of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the
underwriters do not exercise in full their option to purchase additional ordinary shares with respect to this offering and assuming no exercise of options outstanding following this offering, we will have an aggregate of
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding upon the closing of this offering. Of these shares, the
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by
&#147;affiliates&#148; (as that term is defined under Rule 144 of the Securities Act, or Rule 144), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be held by
our existing shareholders and will be deemed to be &#147;restricted securities&#148; under Rule 144. Subject to certain contractual restrictions, including the lock-up agreements described below, restricted securities may only be sold in the public
market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration under Rule 144, Rule 701 or Rule 904 under the Securities Act. These rules are summarized below. Sales of these shares in
the public market after the restrictions under the lock-up agreements lapse, or the perception that those sales may occur, could cause the prevailing market price of our ordinary shares to decrease or to be lower than it might be in the absence of
those sales or perceptions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Eligibility of Restricted Shares for Sale in the Public Market </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following indicates approximately when the ordinary shares that are not being sold in this offering, but which will be outstanding at the time at which this
offering is complete, will be eligible for sale into the public market under the provisions of Rule 144 and Rule 701 (but subject to the further contractual restrictions arising under the lock-up agreements described below): </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">upon the closing of this offering,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares held by non-affiliates of our company that have been held for at least
one year will be available for resale under Rule 144(b)(1)(ii); </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">beginning 90 days after the closing of this offering, up to approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares,
constituting&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares issuable upon exercise of outstanding options under our 2010 Israeli Share Option Plan that have vested as of, or within 60 days
of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, may be eligible for resale under Rule 701 and Rule 144, of which
approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;are held by our affiliates and would therefore be subject to the volume, current public information, manner of sale and other limitations
under Rule 144; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">approximately&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be eligible for resale pursuant to Rule 144 upon the expiration of various six month
holding periods, so long as at least 90 days have elapsed after the closing of this offering, and subject to the current public information requirement under Rule 144 and, in the case of affiliates of our company, such eligibility will also be
subject to the volume, manner of sale and other limitations under Rule 144. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Lock-Up Agreements </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, all of our directors and executive officers and holders of substantially all of our outstanding shares and our shares issuable upon the exercise of vested options
have signed lock-up agreements. Pursuant to such lock-up agreements, such persons have agreed, subject to certain exceptions, not to sell or otherwise dispose of ordinary shares or any securities convertible into or exchangeable for ordinary shares
for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and Cowen and Company, LLC. Jefferies LLC and Cowen and Company, LLC may, in their sole discretion, at any time without prior notice,
release all or any portion of the ordinary shares from the restrictions in any such agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">138 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 144 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held for
Six Months </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 144 as currently in effect, and subject to the terms of any lock-up agreement, commencing 90 days after the closing of
this offering, a person (or persons whose shares are aggregated), including an affiliate, who has beneficially owned our ordinary shares for six months or more, including the holding period of any prior owner other than one of our affiliates (i.e.,
commencing when the shares were acquired from our company or from an affiliate of our company as restricted securities), is entitled to sell our shares, subject to the availability of current public information about us. In the case of an affiliate
shareholder, the right to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions and notice requirements, and to a volume limitation that limits the number of shares to be sold thereby, within
any three-month period, to the greater of: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1% of the number of ordinary shares then outstanding; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the average weekly trading volume of our ordinary shares on the NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The six month holding period of Rule 144 does not apply to sales of unrestricted securities. Accordingly, persons who hold unrestricted securities may sell them under
the requirements of Rule 144 described above without regard to the six-month holding period, even if they were considered our affiliates at the time of the sale or at any time during the ninety days preceding such date. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Shares Held by Non-Affiliates for One Year </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under Rule 144 as
currently in effect, a person (or persons whose shares are aggregated) who is not considered to have been one of our affiliates at any time during the 90 days preceding a sale and who has beneficially owned the shares proposed to be sold for at
least one year, including the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144 without complying with the provisions relating to the availability of current public
information or with any other conditions under Rule 144. Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the closing of this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Rule 701 </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In general, under Rule 701, any of our employees, directors,
officers, consultants or advisors who received or purchased ordinary shares from us under our 2010 Israeli Share Option Plan or other written agreement before the closing of this offering is entitled to resell these shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The SEC has indicated that Rule 701 will apply to typical share options granted by an issuer before it becomes subject to the reporting requirements of the Exchange
Act, along with the shares acquired upon exercise of these options, including exercises after the closing of this offering. Securities issued in reliance on Rule 701 are restricted securities and, subject to the contractual restrictions described
above (see &#147;Lock-Up Agreements&#148;), may be sold beginning 90 days after the closing of this offering in reliance on Rule 144 by: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons other than affiliates, without restriction; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">affiliates, subject to the manner-of-sale, current public information and filing requirements of Rule 144, in each case, without compliance with the six-month holding period requirement of Rule 144. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Options </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September 30, 2015, options to purchase a total of 369,676
ordinary shares were issued and outstanding, whether under our 2010 Israeli Share Option Plan or otherwise. Such number excludes 9,000 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the
consummation of the completed purchase of intellectual property from Telormedix SA and an additional 9,000 ordinary shares issuable upon the vesting of restricted share units, the grant of which is contingent upon the closing of this offering. Of
the total number of issued and outstanding options, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;will be vested upon the closing of this offering. See &#147;Management&#151;2010 Israeli Share Option
Plan.&#148; All of our ordinary shares issuable under these options or restricted share units are subject to contractual lock-up agreements with us or the underwriters. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">139 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Form S-8 Registration Statement </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the completion of this offering, we intend to file a registration statement on Form S-8 under the Securities Act to register up to
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, in the aggregate, issued or reserved for issuance under the 2010 Israeli Share Option Plan. The registration statement on Form S-8 will
become effective automatically upon filing. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Ordinary shares issued upon exercise of a share option and registered pursuant to the Form S-8 registration statement
will, subject to vesting provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless they are subject to the 180 day lock-up period or, if subject to the lock-up, immediately
after the 180 day lock-up period expires. See &#147;Management&#151;2010 Israeli Share Option Plan.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Registration Rights </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Following the closing of this offering, holders of a total of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary
shares will have the right to require us to register these shares under the Securities Act under specified circumstances and will have incidental registration rights. After registration pursuant to these rights, these shares will become freely
tradable without restriction under the Securities Act. For more information on these registration rights, see &#147;Description of Share Capital&#151;Registration Rights.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">140 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_16"></A>TAXATION </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>The following description is not intended to constitute a complete analysis of all tax consequences relating to&nbsp;the acquisition, ownership and disposition of
our ordinary shares. You should consult your own tax advisor&nbsp;concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under&nbsp;the laws of any state, local, foreign or other taxing
jurisdiction. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Israeli Tax Considerations and Government Programs </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following is a brief summary of the material Israeli tax laws applicable to us. This section also contains a discussion of material Israeli tax consequences
concerning the ownership and disposition of our ordinary shares purchased by investors in this offering. This summary does not discuss certain tax benefits, including under the Law for Encouragement of Capital Investments, 5719-1959, to which we may
become eligible in the future if we establish a manufacturing facility for our products in Israel. This summary also does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal
investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of such investors include residents of Israel or traders in securities who are subject to special tax regimes not covered in this
discussion. Because parts of this discussion are based on new tax legislation that has not yet been subject to judicial or administrative interpretation, the appropriate tax authorities or the courts may not accept the views expressed in this
discussion. The discussion below is subject to change, including due to amendments under Israeli law or changes to the applicable judicial or administrative interpretations of Israeli law, which change could affect the tax consequences described
below. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>General Corporate Tax Structure in Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Israeli
companies are generally subject to corporate tax, currently at the rate of 25% of a company&#146;s taxable income. In addition, capital gains realized by Israeli companies are subject to tax at the regular corporate tax rate. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of our Shareholders </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Capital gains taxes applicable to
non-Israeli resident shareholders.</I> Capital gain is generally subject to tax at the corporate tax rate of 25% in 2016 and thereafter, if generated by a company, or at the rate of 25% if generated by an individual, or 30% in the case of sale of
shares by a substantial shareholder at the time of sale or at any time during the preceding 12-month period. A person is considered to be a substantial shareholder if it holds, directly or indirectly, alone or together with another affiliated party,
10% or more of a company&#146;s means of control, which include, among other things, voting rights, the right to receive profits of the company, the right to receive proceeds upon liquidation and the right to appoint a director. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Notwithstanding the foregoing, a non-Israeli resident who derives capital gains from the sale of our shares that were purchased after the shares were listed for trading
on the NASDAQ is exempt from Israeli tax on such capital gains so long as they were not attributable to a permanent establishment that the non-resident maintains in Israel. In the case of a shareholder that is a corporation, in order for it to
qualify as a non-Israeli resident for these purposes, it must be incorporated in, as well as managed and controlled from, a jurisdiction other than the State of Israel, and persons who are Israeli residents may not either: (i) have a controlling
interest (directly or indirectly, alone or together with another, or together with another Israeli resident) exceeding 25% in one or more of the means of control in such corporation or (ii) be the beneficiaries of, or entitled to, 25% or more of the
revenues or profits of such corporation, whether directly or indirectly. Such exemption is not applicable to a person whose gains from selling or otherwise disposing of the shares are deemed to be business income. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, a sale of shares by a non-Israeli resident may be exempt from Israeli capital gains tax under the provisions of an applicable tax treaty. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. In
transactions involving a sale of all of the shares of an Israeli resident company, such as a merger or other transaction, the Israel Tax Authority may, among other things, require from shareholders who are not liable for Israeli tax the execution of
a declaration in the form specified by that authority or a specific exemption from the Israeli Tax Authority to confirm their status as non-Israeli residents may be required to be presented, and, in the absence of such declaration or exemption, may
require the purchaser of the shares to withhold taxes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">141 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In addition, with respect to mergers involving an exchange of shares, Israeli tax law allows for tax deferral in certain
circumstances, but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the
participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions in which the sellers receive shares in the acquiring entity that are publicly traded on a stock exchange, the tax deferral is
limited in time, and when such time expires, the tax becomes payable even if no disposition of such shares has occurred. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Taxation of non-Israeli shareholders on
receipt of dividends.</I> Non-Israeli residents are generally subject to Israeli withholding tax on the receipt of dividends paid on our ordinary shares at the rate of 25%, unless relief is provided in a treaty between Israel and the
shareholder&#146;s country of residence (subject to the receipt of a valid certificate from the Israel Tax Authority, allowing for such reduced withholding tax rate). With respect to a person who is considered a substantial shareholder at the time
of receiving the dividend or at any time during the preceding 12 months, subject to the terms of an applicable tax treaty, the applicable withholding tax rate is 30%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Convention between the Government of the United States of America and the Government of the State of Israel with respect to Taxes on Income, or the
U.S.-Israel Tax Treaty, the maximum rate of tax withheld at source in Israel on dividends paid to a holder of our ordinary shares who is a U.S. resident (for the purposes of the U.S.-Israel Tax Treaty) is 25%. However, with regard to dividends paid
to a U.S. resident corporation which held 10% or more of our outstanding voting rights throughout the taxable year in which the dividend was distributed and which maintained its shareholdings at or above such threshold during the entire previous
taxable year, the maximum rate of withholding tax is generally 12.5%, provided that no more than 25% of our gross income for such preceding year consists of certain types of dividends and interest. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. residents who are subject to Israeli withholding tax on a dividend may be entitled to a credit or deduction for U.S. federal income tax purposes in the amount of
the taxes withheld, subject to detailed limitations under U.S. laws applicable to foreign tax credits. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><I>Excess Tax</I>.<I> </I>Beginning on January 1, 2013, an
additional tax liability at the rate of 2% was added to the applicable tax rate on the annual taxable income of the individuals (whether any such individual is an Israeli resident or non-Israeli resident) exceeding NIS 810,720 (in 2016) which amount
is linked to the annual change in the Israeli consumer price index, including, but not limited to, dividends, interest and capital gain. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Material U.S. Federal
Income Tax Consequences to U.S. Holders </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following discussion describes the material U.S. federal income tax consequences to U.S. Holders (as defined below)
under present law of an investment in our ordinary shares. The effects of any applicable state or local laws, or other U.S. federal tax laws such as estate and gift tax laws are not discussed. This summary applies only to investors who hold the
ordinary shares as capital assets (generally, property held for investment) and who have the U.S. dollar as their functional currency. This discussion is based on the U.S. Internal Revenue Code of 1986, as amended, or the Code, U.S. Treasury
regulations promulgated thereunder, judicial decisions, published rulings and administrative pronouncements of the U.S. Internal Revenue Service, or the IRS, and the U.S.-Israel Tax Treaty, all as in effect as of the date of this offering. All of
the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following
discussion does not address all U.S. federal income tax consequences relevant to a holder&#146;s particular circumstances or to holders subject to particular rules, including: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">U.S. expatriates and certain former citizens or long-term residents of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons subject to the alternative minimum tax; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons holding our ordinary shares as part of a hedge, straddle or other risk reduction strategy or as part of a conversion transaction or other integrated investment for U.S. federal income tax purposes;
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">banks, insurance companies, and other financial institutions; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">real estate investment trusts or regulated investment companies; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">brokers, dealers or traders in securities, commodities or currencies; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">142 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">partnerships, S corporations, or other entities or arrangements treated as partnerships for U.S. federal income tax purposes; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">tax-exempt organizations or governmental organizations; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that own or are deemed to own 10% or more of our voting stock; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons that hold their shares through a permanent establishment or fixed base outside the United States; and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons deemed to sell our ordinary shares under the constructive sale provisions of the Code. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>U.S. HOLDERS ARE
URGED TO CONSULT THEIR TAX ADVISORS REGARDING THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE U.S. STATE AND LOCAL AND NON-U.S. TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF THE
ORDINARY SHARES. </B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For purposes of this discussion, a &#147;U.S. Holder&#148; is a beneficial owner of our ordinary shares that, for U.S. federal income tax
purposes, is or is treated as any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an individual who is a citizen or resident of the United States; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a corporation, or entity treated as a corporation for U.S. federal income tax purposes, created or organized under the laws of the United States, any state thereof, or the District of Columbia; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a trust that (1) is subject to the supervision of a U.S. court and the control of one or more &#147;United States persons&#148; (within the meaning of Section 7701(a)(30) of the Code), or (2) has a valid election in
effect to be treated as a United States person for U.S. federal income tax purposes. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you are a partner in a partnership (or other entity taxable
as a partnership for U.S. federal income tax purposes) that holds our ordinary shares, your tax treatment generally will depend on your status and the activities of the partnership. Partnerships holding our ordinary shares and the partners in such
partnerships should consult their tax advisors regarding the U.S. federal income tax consequences applicable to them. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As indicated below, this entire discussion is
subject to the discussion of the U.S. federal income tax rules applicable to a &#147;passive foreign investment company,&#148; or a PFIC. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Passive Foreign
Investment Company Considerations </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are classified as a PFIC in any taxable year, a U.S. Holder would be subject to special rules generally intended to
reduce or eliminate any benefits from the deferral of U.S. federal income tax that a U.S. Holder could derive from investing in a non-U.S. company that does not distribute all of its earnings on a current basis. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A non-U.S. corporation is classified as a PFIC for U.S. federal income tax purposes in any taxable year in which, after applying certain look-through rules with respect
to the income and assets of subsidiaries, either (i) at least 75% of its gross income is &#147;passive income&#148; or (ii) at least 50% of the average quarterly value of its total gross assets (which, assuming we are not a controlled foreign
corporation for the year being tested, would be measured by fair market value of the assets, and for which purpose the total value of our assets may be determined in part by the market value of our ordinary shares, which is subject to change) is
attributable to assets that produce &#147;passive income&#148; or are held for the production of passive income. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Passive income for this purpose generally includes
dividends, interest, royalties, rents, gains from commodities and securities transactions, the excess of gains over losses from the disposition of assets which produce passive income, and generally includes amounts derived by reason of the temporary
investment of funds raised in offerings of our ordinary shares. If a non-U.S. corporation owns directly or indirectly at least 25% by value of the stock of another corporation, the non-U.S. corporation is treated for purposes of the PFIC tests as
owning its proportionate share of the assets of the other corporation and as receiving directly its proportionate share of the other corporation&#146;s income. If we are classified as a PFIC in any year with respect to which a U.S. Holder owns our
ordinary shares, we will continue to be treated as a PFIC with respect to such U.S. Holder in all succeeding years during which the U.S. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">143 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
Holder owns our ordinary shares, regardless of whether we continue to meet the tests described above unless the holder makes a so-called &#147;purging election&#148; with respect to our ordinary
shares. <B>U.S. Holders should consult with their tax advisors regarding the availability and consequences of any PFIC purging elections.</B> </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We must determine our
PFIC status annually based on tests which are factual in nature, and our status will depend on our income, assets and activities each year. In addition, our status as a PFIC may depend on how quickly we use the cash proceeds from this offering in
our business. However, because we currently have no revenue-producing operations, we expect to be treated as a PFIC for our current taxable year.&nbsp;Unless and until we generate sufficient revenue from active licensing and other non-passive
sources and otherwise satisfy the asset test above, we expect to be treated as a PFIC for future taxable years. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are a PFIC, and you are a U.S. Holder, then
unless you make one of the elections described below, a special tax regime will apply to both (a) any &#147;excess distribution&#148; by us to you (generally, your ratable portion of distributions in any year which are greater than 125% of the
average annual distribution received by you in the shorter of the three preceding years or your holding period for our ordinary shares) and (b) any gain realized on the sale or other disposition of the ordinary shares. Under this regime, any excess
distribution and realized gain will be treated as ordinary income and will be subject to tax as if (a) the excess distribution or gain had been realized ratably over your holding period, (b) the amount deemed realized in each year had been subject
to tax in each year of that holding period at the highest marginal rate for such year (other than income allocated to the current period or any taxable period before we became a PFIC, which would be subject to tax at the U.S. Holder&#146;s regular
ordinary income rate for the current year and would not be subject to the interest charge discussed below), and (c) the interest charge generally applicable to underpayments of tax had been imposed on the taxes deemed to have been payable in those
years. In addition, dividend distributions made to you will not qualify for the lower rates of taxation applicable to long-term capital gains discussed above under &#147;Taxation of Dividends and Other Distributions on our Ordinary Shares.&#148;
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain elections exist that may alleviate some of the adverse consequences of PFIC status and would result in an alternative treatment (such as mark-to-market
treatment) of our ordinary shares. If a U.S. Holder makes the mark-to-market election, then in lieu of being subject to the tax and interest change rules disclosed above, the U.S. Holder generally will recognize as ordinary income any excess of the
fair market value of the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any excess of the adjusted tax basis of the ordinary shares over their fair market value at the
end of the taxable year (but only to the extent of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the U.S. Holder&#146;s tax basis in the ordinary shares will be
adjusted to reflect these income or loss amounts. Any gain recognized on the sale or other disposition of ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated as an ordinary loss (but only to
the extent of the net amount of income previously included as a result of the mark-to-market election). The mark-to-market election is available only if we are a PFIC and our ordinary shares are &#147;regularly traded&#148; on a &#147;qualified
exchange.&#148; Our ordinary shares will be treated as &#147;regularly traded&#148; in any calendar year in which more than a <I>de minimis</I> quantity of the ordinary shares are traded on a qualified exchange on at least 15 days during each
calendar quarter (subject to the rule that trades that have as one of their principle purposes the meeting of the trading requirement are disregarded). The NASDAQ Global Market is a qualified exchange for this purpose and, consequently, if the
ordinary shares are regularly traded, the mark-to-market election will be available to a U.S. Holder. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>We do not currently intend to provide the information
necessary for U.S. Holders to make QEF elections. U.S. Holders should consult their tax advisors to determine whether any of these elections would be available and if so, what the consequences of the alternative treatments would be in their
particular circumstances. </I></B></P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are determined to be a PFIC, the general tax treatment for U.S. Holders described in this section would apply to indirect
distributions and gains deemed to be realized by U.S. Holders in respect of any of our subsidiaries that also may be determined to be PFICs. A mark-to-market election cannot be made with respect to the stock of any of our subsidiaries. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each U.S. Holder that is an investor of a PFIC is generally required to file an annual information return on IRS Form 8621 (Information Return by a Shareholder of a
Passive Foreign Investment Company or Qualified Electing Fund) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">144 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
containing such information as the U.S. Treasury Department may require. The failure to file IRS Form 8621 could result in the imposition of penalties and the extension of the statute of
limitations with respect to U.S. federal income tax. U.S. Holders should consult their tax advisors regarding whether we are a PFIC and the potential application of the PFIC rules. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Dividends and Other Distributions on our Ordinary Shares </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion under &#147;&#150; Passive Foreign Investment Company Considerations,&#148; above, the gross amount of any distribution to you with respect to
our ordinary shares will be included in your gross income as dividend income when actually or constructively received to the extent that the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S.
federal income tax principles). To the extent the amount of the distribution exceeds our current and accumulated earnings and profits, it will be treated first as a return of your tax basis in our ordinary shares, and to the extent the amount of the
distribution exceeds your tax basis, the excess will be taxed as capital gain. We do not intend to calculate our earnings and profits under U.S. federal income tax principles. Therefore, a U.S. Holder should expect that the entire amount of any
distribution will generally be reported as dividend income. Any dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If we are not a PFIC for a given year in which a dividend is paid and the taxable year preceding the dividend, non-corporate U.S. Holders may qualify for the
preferential rates of taxation with respect to dividends on ordinary shares applicable to long-term capital gains (i.e., gains from the sale of capital assets held for more than one year) applicable to qualified dividend income (as discussed below).
We believe that we qualify as a resident of Israel for purposes of, and are eligible for the benefits of, the U.S.-Israel Tax Treaty, although there can be no assurance in this regard. Further, the IRS has determined that the U.S.-Israel Tax Treaty
is satisfactory for purposes of the qualified dividend rules and that it includes an exchange-of-information program. Therefore, subject to the discussion under &#147;&#151;Passive Foreign Investment Company Considerations&#148; above, if the
U.S.-Israel Tax Treaty is applicable, such dividends will generally be &#147;qualified dividend income&#148; in the hands of individual U.S. Holders, provided that certain conditions are met, including holding period and the absence of certain risk
reduction transaction requirements are met. The dividends will not be eligible for the dividends received deduction generally allowed to corporate U.S. Holders. As discussed in &#147;Taxation&#151;Israeli Tax Considerations,&#148; payments of
dividends by us may be subject to Israeli withholding tax. For U.S. federal income tax purposes, U.S. Holders will be treated as having received the amount of Israeli taxes withheld by us, and as then having paid over the withheld taxes to the
Israeli taxing authorities. As a result of this rule, the amount of dividend income included in gross income for U.S. federal income tax purposes by a U.S. Holder with respect to a payment of dividends may be greater than the amount of cash actually
received (or receivable) by the U.S. Holder from us with respect to the payment. Dividends will generally constitute foreign source income for foreign tax credit limitation purposes. Any tax withheld with respect to distributions on our ordinary
shares at the rate applicable to a U.S. Holder may, subject to a number of complex limitations, be claimed as a foreign tax credit against such U.S. Holder&#146;s U.S. federal income tax liability or may be claimed as a deduction for U.S. federal
income tax purposes. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares generally will constitute
&#147;passive category income&#148; or &#147;general category income.&#148; The rules with respect to the foreign tax credit are complex and involve the application of rules that depend upon a U.S. Holder&#146;s particular circumstances. You are
urged to consult your tax advisor regarding the availability of the foreign tax credit under your particular circumstances. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Taxation of Disposition of the
Ordinary Shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the discussion above under &#147;&#150; Passive Foreign Investment Company Considerations,&#148; you will recognize gain or loss
on any sale, exchange or other taxable disposition of an ordinary share equal to the difference between the amount realized on the disposition of the ordinary share and your adjusted tax basis in the ordinary share. The tax basis in an ordinary
share generally will be the cost of such ordinary share.&nbsp;Any such gain or loss will be capital gain or loss, and will be long-term capital gain or loss if you have held the ordinary share for more than one year at the time of sale, exchange or
other taxable disposition. Otherwise, such gain or loss will be short-term capital gain or loss. Long-term capital gains recognized by certain non-corporate U.S. Holders, including individuals, generally will be taxable at a reduced rate. The
deductibility of capital losses is subject to limitations. Any such gain or loss you recognize generally will be treated as U.S. source income or loss for foreign tax credit limitation purposes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">145 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Medicare Tax </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain U.S. Holders that are individuals, estates or trusts are subject to a 3.8% tax on all or a portion of their &#147;net investment income,&#148; which may include
all or a portion of their dividend income and net gains from the disposition of ordinary shares. Each U.S. Holder that is an individual, estate or trust is urged to consult its tax advisors regarding the applicability of the Medicare tax to its
income and gains in respect of its investment in our ordinary shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Certain Reporting Requirements With Respect to Payments of Offer Price </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. Holders paying more than $100,000 for our shares will generally be required to file IRS Form 926 reporting such payment for our ordinary shares to us. Substantial
penalties may be imposed upon a U.S. Holder that fails to comply. Each U.S. Holder should consult its own tax advisor as to the possible obligation to file IRS Form 926. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Information Reporting and Backup Withholding </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">U.S. backup withholding
tax and information reporting requirements may apply to certain payments to certain holders of our ordinary shares. Information reporting will generally apply to payments of dividends on, and to proceeds from the sale or redemption of, our ordinary
shares made within the United States, or by a U.S. payer or U.S. middleman, to a holder of our shares, other than an exempt recipient (including a payee that is not a U.S. person that provides an appropriate certification and certain other persons).
Certain U.S. Holders are exempt from backup withholding, including corporations and certain tax-exempt organizations. A U.S. Holder will be subject to backup withholding if such holder is not otherwise exempt and such holder: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to furnish the holder&#146;s taxpayer identification number, which for an individual is ordinarily his or her social security number; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">furnishes an incorrect taxpayer identification number; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">is notified by the IRS that the holder previously failed to properly report payments of interest or dividends; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fails to certify under penalties of perjury that the holder has furnished a correct taxpayer identification number and that the IRS has not notified the holder that the holder is subject to backup withholding.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Backup withholding is not an additional tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against
the U.S. Holder&#146;s U.S. federal income tax liability, provided the required information is timely furnished to the IRS. U.S. Holders should consult their tax advisors regarding their qualification for an exemption from backup withholding and the
procedures for obtaining such an exemption. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Additional Reporting Requirements </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain U.S. Holders who are individuals (and under proposed regulations, certain entities) are required to report information relating to an interest in our ordinary
shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by financial institutions) by filing IRS Form 8938 (Statement of Specified Foreign Financial Assets) with their federal income tax return.
U.S. Holders should consult their tax advisors regarding the possible implications of these tax return disclosure obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">146 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_17"></A>UNDERWRITING</B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Subject to the terms and conditions set forth in the underwriting agreement, dated
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016, Jefferies LLC, 520 Madison Avenue, New York, New York 10022, and Cowen and Company, LLC, 599 Lexington Avenue, 27th&nbsp;Floor, New York, New
York 10022, are serving as the representatives of the underwriters named below and the joint book-running managers for this offering. Pursuant to such agreement, we have agreed to sell to the underwriters, and each of the underwriters has agreed,
severally and not jointly, to purchase from us, the respective number of ordinary shares shown opposite its name below: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF<BR>ORDINARY&nbsp;SHARES</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Underwriter</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters
of officers&#146; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the ordinary shares if any of them are purchased. If an
underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of
their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ordinary shares as permitted by
applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as
to the liquidity of the trading market for the ordinary shares, that you will be able to sell any of the ordinary shares held by you at a particular time or that the prices that you receive when you sell will be favorable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriters reserve the
right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary
authority. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Commission and Expenses </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us
that they propose to offer the ordinary shares to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in
excess of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;per ordinary share to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be
reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">147 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table shows the public offering price, the underwriting discounts and commissions that we are to pay the
underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase additional ordinary shares. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="56%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PER ORDINARY SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITHOUT<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WITH<BR>OPTION TO<BR>PURCHASE<BR>ADDITIONAL<BR>ORDINARY<BR>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Underwriting discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds to us, before expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; . We also have agreed to reimburse the underwriters for up to
$&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for their FINRA counsel fee. In accordance with FINRA Rule 5110, this reimbursed fee is deemed underwriting compensation for this offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Determination of Offering Price </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Prior to this offering, there has not been
a public market for our ordinary shares. Consequently, the initial public offering price for our ordinary shares will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be
prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors
deemed relevant. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We offer no assurances that the initial public offering price will correspond to the price at which the ordinary shares will trade in the public
market subsequent to the offering or that an active trading market for the ordinary shares will develop and continue after the offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Listing </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We intend to apply to have our ordinary shares listed on the NASDAQ Global Market under the symbol &#147;URGN.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stamp Taxes </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If you purchase ordinary shares offered in this prospectus, you
may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. However, no stamp taxes will be payable to the State of
Israel in connection with the sale of shares offered hereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Option to Purchase Additional Ordinary Shares </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an
aggregate of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares from us at the public offering price set forth on the cover page of this prospectus, less underwriting discounts and
commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional ordinary shares proportionate to that underwriter&#146;s initial purchase commitment as
indicated in the table above. This option may be exercised only if the underwriters sell more ordinary shares than the total number set forth on the cover page of this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">148 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>No Sales of Similar Securities </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We, our officers, directors and holders of substantially all of our outstanding share capital have agreed, subject to specified exceptions, not to directly or
indirectly: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#147;put equivalent position&#148; within the meaning of Rule 16a-l(h) under the Exchange Act,
or</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>otherwise dispose of any share capital, options or warrants to acquire shares, or securities exchangeable or exercisable for or convertible into shares currently or hereafter owned either of record or
beneficially, or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and Cowen and Company, LLC.
</TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This restriction terminates after the close of trading of the ordinary shares on and including the
180<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day after the date of this prospectus. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Jefferies LLC and Cowen and Company, LLC may, in their sole
discretion and at any time or from time to time before the termination of the 180-day period, release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our
shareholders who will execute a lock-up agreement, providing consent to the sale of shares prior to the expiration of the lock-up period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Stabilization </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters have advised us that, pursuant to Regulation M under the Exchange Act, certain persons participating in the offering may engage in short sale
transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the ordinary shares at
a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#147;covered&#148; short sales or &#147;naked&#148; short sales. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Covered&#148; short sales are sales made in an amount not greater than the underwriters&#146; option to purchase additional ordinary shares in this offering. The
underwriters may close out any covered short position by either exercising their option to purchase additional ordinary shares or purchasing our ordinary shares in the open market. In determining the source of ordinary shares to close out the
covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may purchase ordinary shares through the option to purchase
additional ordinary shares. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">&#147;Naked&#148; short sales are sales in excess of the option to purchase additional ordinary shares. The underwriters must close out
any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of our ordinary shares in the open
market after pricing that could adversely affect investors who purchase in this offering. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A stabilizing bid is a bid for the purchase of ordinary shares on behalf
of the underwriters for the purpose of fixing or maintaining the price of the ordinary shares. A syndicate covering transaction is the bid for or the purchase of ordinary shares on behalf of the underwriters to reduce a short position incurred by
the underwriters in connection with the offering. Similar to other purchase transactions, the underwriters&#146; purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our ordinary shares or
preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the
underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the ordinary shares originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore
have not been effectively placed by such syndicate member. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither we, nor any of the underwriters make any representation or prediction as to the direction or
magnitude of any effect that the transactions described above may have on the price of our ordinary shares. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">149 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters may also engage in passive market making transactions in our ordinary shares on the NASDAQ Global Market
in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of our ordinary shares in this offering and extending through the completion of distribution. A passive market maker must display its bid at a
price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#146;s bid, that bid must then be lowered when specified purchase limits are exceeded. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Electronic Distribution </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">A prospectus in electronic format may be made
available by e-mail or on the web sites or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The
underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other
than the prospectus in electronic format, the information on the underwriters&#146; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or
endorsed by us or the underwriters and should not be relied upon by investors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Other Activities and Relationships </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial
and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may
in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively
trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities
and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies.
The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our
affiliates, including potentially the ordinary shares offered hereby. Any such short positions could adversely affect future trading prices of the ordinary shares offered hereby. The underwriters and certain of their respective affiliates may also
communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire,
long and/or short positions in such securities and instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Notice to Investors </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Australia </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus is not a disclosure document for the
purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out below.
Accordingly, if you receive this prospectus in Australia: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You confirm and warrant that you are either: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;sophisticated investor&#148; under section 708(8)(a) or (b) of the Corporations Act;&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;sophisticated investor&#148; under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&#146;s certificate to the company which complies with the requirements of
section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b) of the Corporations Act. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">150 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor or professional
investor under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You warrant and agree that you will not offer
any of the shares issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the
Corporations Act. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In relation to each
member state of the European Economic Area which has implemented the Prospectus Directive, each referred to herein as a Relevant Member State, with effect from and including the date on which the Prospectus Directive is implemented in that Relevant
Member State, referred to herein as the Relevant Implementation Date, no offer of any securities which are the subject of the offering contemplated by this prospectus has been or will be made to the public in that Relevant Member State other than
any offer where a prospectus has been or will be published in relation to such securities that has been approved by the competent authority in that Relevant Member State or, where appropriate, approved in another Relevant Member State and notified
to the relevant competent authority in that Relevant Member State in accordance with the Prospectus Directive, except that with effect from and including the Relevant Implementation Date, an offer of such securities may be made to the public in that
Relevant Member State: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>to any legal entity which is a &#147;qualified investor&#148; as defined in the Prospectus Directive;&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>to fewer than 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the
representatives of the underwriters for any such offer; or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>in any other circumstances falling within Article 3(2) of the Prospectus Directive, </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">provided that no such offer
of securities shall require the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to the public&#148; in relation to any securities in any Relevant Member State means the communication
in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Relevant Member State
by any measure implementing the Prospectus Directive in that Relevant Member State and the expression &#147;Prospectus Directive&#148; means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, the &#147;2010 PD Amending
Directive&#148;)), and includes any relevant implementing measure in the Relevant Member State. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business
is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other
circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32)
of Hong Kong. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed
at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons
outside Hong Kong or only to &#147;professional investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong
Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the
restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">151 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Japan </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The offering has
not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or
for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or
resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial
guidelines of Japan. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus has not been and
will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not
be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to the public or any member of the public in Singapore other than
(i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person as defined under Section 275(2), or any person pursuant to Section 275(1A) of the SFA, and in
accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Where the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor; or</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an accredited investor, </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">shares, debentures and units of shares and debentures of that corporation or the beneficiaries&#146; rights and interest in that trust shall not be transferable for six
months after that corporation or that trust has acquired the Offer Shares under Section 275 of the SFA except: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section 275(2) of the SFA, or to any person pursuant to an offer that is made on terms that such shares, debentures and
units of shares and debentures of that corporation or such rights and interest in that trust are acquired at a consideration of not less than $200,000 (or its equivalent in a foreign currency) for each transaction, whether such amount is to be paid
for in cash or by exchange of securities or other assets, and further for corporations, in accordance with the conditions, specified in Section 275 of the SFA;&nbsp; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>where no consideration is given for the transfer; or&nbsp; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>where the transfer is by operation of law. </TD></TR></TABLE> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Switzerland </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading
facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under
art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may
be publicly distributed or otherwise made publicly available in Switzerland. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Neither this prospectus nor any other offering or marketing material relating to the
offering, the company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial
Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in
collective investment schemes under the CISA does not extend to acquirers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">152 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This
prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within
Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to
whom it may lawfully be communicated. Each such person is referred to herein as a Relevant Person. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This prospectus and its contents are confidential and should not
be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its
contents. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Israel </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">This document does not constitute a prospectus
under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any
offer of the ordinary shares is directed only at, (i) a limited number of persons in accordance with section 15A of the Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting
primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50
million and &#147;qualified individuals&#148;, each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the
Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree
to&nbsp;it. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(A) Resale Restrictions </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The distribution of ordinary shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt
from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made.&nbsp;Any resale of the ordinary shares in Canada must be made under applicable
securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory
authority.&nbsp;Purchasers are advised to seek legal advice prior to any resale of the securities. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">(B) Representations of Canadian Purchasers </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">By purchasing ordinary shares in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase
confirmation is received that: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is entitled under applicable provincial securities laws to purchase the ordinary shares without the benefit of a prospectus qualified under those securities laws as it is an &#147;accredited investor&#148;
as defined under National Instrument 45-106&#151;<I>Prospectus Exemptions</I>, </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser is a &#147;permitted client&#148; as defined in National Instrument 31-103&#151;<I>Registration Requirements, Exemptions and Ongoing Registrant Obligations</I>, </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where required by law, the purchaser is purchasing as principal and not as agent, and </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the purchaser has reviewed the text above under Resale Restrictions. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(C)</TD>
<TD ALIGN="left" VALIGN="top">Conflicts of Interest </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers are hereby notified that the underwriters are relying on the exemption set
out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105&#151;<I>Underwriting Conflicts </I>from having to provide certain conflict of interest disclosure in this document. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">153 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(D)</TD>
<TD ALIGN="left" VALIGN="top">Statutory Rights of Action </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Securities legislation in certain provinces or territories of Canada may provide a purchaser
with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit
prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#146;s province or territory
for particulars of these rights or consult with a legal advisor. </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(E)</TD>
<TD ALIGN="left" VALIGN="top">Enforcement of Legal Rights </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">All of our directors and officers as well as the experts named herein may be located
outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons.&nbsp;All or a substantial portion of our assets and the assets of those persons may be located
outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </P>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(F)</TD>
<TD ALIGN="left" VALIGN="top">Taxation and Eligibility for Investment </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Canadian purchasers of ordinary shares should consult their own legal and tax
advisors with respect to the tax consequences of an investment in the ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the purchaser under relevant Canadian legislation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">154 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_18"></A>EXPENSES OF THIS OFFERING</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the costs and expenses, other than the underwriting discounts and commissions, payable by us in connection with the sale of our ordinary
shares being registered. All amounts are estimates except for the SEC registration fee, the FINRA filing fee and the NASDAQ Global Market listing fee. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="89%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:18.65pt; font-size:8pt; font-family:ARIAL"><B>ITEM</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT&nbsp;TO<BR>BE PAID</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">FINRA filing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">The NASDAQ Global Market listing fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Printing and engraving expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Miscellaneous expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be completed by amendment. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">155 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_19"></A>LEGAL MATTERS</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The validity of the issuance of our ordinary shares offered in this prospectus and certain other matters of Israeli law will be passed upon for us by Hamburger Evron
&amp; Co., Tel Aviv, Israel. As of the date of this prospectus, Hamburger Evron &amp; Co. beneficially owns an aggregate of 26,228 of our ordinary shares. Certain matters of U.S. law will be passed upon for us by Cooley&nbsp;LLP, New York, New York.
Legal counsel to the underwriters are Gornitzky &amp; Co., Tel Aviv, Israel, with respect to Israeli law, and Covington &amp; Burling LLP, New York, New York, with respect to U.S. law. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_20"></A>EXPERTS</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The financial
statements as of December 31, 2014 and 2013 and for each of the two years in the period ended December 31, 2014 included in this prospectus<B><SUP STYLE="font-size:85%; vertical-align:top"> </SUP></B>have been so included in reliance on the report
(which contains an explanatory paragraph relating to the company&#146;s ability to continue as a going concern as described in Note 1 to the financial statements) of Kesselman &amp; Kesselman, Certified Public Accountants (Israel), an independent
registered public accounting firm and a member firm of PricewaterhouseCoopers International Limited, given on the authority of said firm as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">156 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_21"></A>ENFORCEMENT OF CIVIL LIABILITIES</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this
registration statement, most of whom reside outside of the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located
outside of the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have been informed by our legal counsel in Israel, Hamburger Evron &amp; Co., that it may be difficult to assert U.S. securities law claims in original actions
instituted in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to bring such a claim. In addition, even if an Israeli court agrees to hear
a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact which can be a time-consuming and costly process. Certain
matters of procedure will also be governed by Israeli law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have irrevocably appointed Urogen Pharma, Inc. as our agent to receive service of process in any
action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. Subject to specified time limitations and legal procedures, Israeli courts may enforce a U.S.
judgment in a civil matter which, subject to certain exceptions, is non-appealable, including a judgment based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a
non-civil matter, provided that among other things: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was obtained after due process before a court of competent jurisdiction, according to the laws of the state in which the judgment was given and the rules of private international law currently prevailing in
Israel; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the prevailing law of the foreign state in which the judgment was rendered allows for the enforcement of judgments of Israeli courts; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adequate service of process has been effected and the defendant has had a reasonable opportunity to be heard and to present his or her evidence; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is not contrary to public policy of Israel, and the enforcement of the civil liabilities set forth in the judgment is not likely to impair the security or sovereignty of Israel; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment was not obtained by fraud and do not conflict with any other valid judgments in the same matter between the same parties; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an action between the same parties in the same matter is not pending in any Israeli court at the time the lawsuit is instituted in the foreign court; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the judgment is enforceable according to the laws of Israel and according to the law of the foreign state in which the relief was granted. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and
transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in
force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price
index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">157 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_22"></A>WHERE YOU CAN FIND MORE INFORMATION</B> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary shares. This prospectus does not
contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus
concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as
an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">You may read and copy the registration
statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#146;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the
documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also
maintains a website that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through the SEC&#146;s website at <I>http://www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Upon completion of this offering, we will be subject to the information reporting requirements of the Exchange Act that are applicable to foreign private issuers, and
under those requirements will file reports with the SEC. These other reports or other information may be inspected without charge at the locations described above. As a foreign private issuer, we will be exempt from the rules under the Exchange Act
related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition,
we will not be required under the Exchange Act to file reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We maintain a corporate website at <I>http://www.urogen.com</I>. Information contained on, or that can be accessed through, our website does not constitute a part of
this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">158 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc142578_23"></A>INDEX TO FINANCIAL STATEMENTS </B></P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAGE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"><FONT STYLE="font-size:10pt"><B>Audited Financial Statements:</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_1">Report of Independent Registered Public Accounting Firm</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_2">Balance Sheets as of December 31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_3">Statements of Operations for the years ended December 31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_4">Statements of Changes in Shareholders&#146; Equity for the years ended December 31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_5">Statements of Cash Flows for the years ended December 31, 2014 and 2013</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_6">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Unaudited Condensed Financial Statements:</B></P>
<P STYLE="font-size:4pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_7">Balance Sheets as of September 30, 2015 and December 31, 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_8">Statements of Operations for the nine months ended September 30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_9">Statements of Changes in Shareholders&#146; Equity for the nine months ended September 30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_10">Statements of Cash Flows for the nine months ended September 30, 2015 and 2014</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><A HREF="#fin142578_11">Notes to Financial Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g142578g89m59.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_1"></A>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">To the shareholders of </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD.
</B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B></B><B></B><B></B><B></B><B></B><B></B>In our opinion, the accompanying balance sheets and the related statements of operations, changes in
shareholders&#146; equity and cash flows present fairly, in all material respects, the financial position of Urogen Pharma Ltd. (the Company) at December 31, 2014 and 2013, and the results of its operations and its cash flows for each of the two
years in the period ended December 31, 2014 in conformity with accounting principles generally accepted in United States of America. These financial statements are the responsibility of the Company&#146;s management and Board of Directors. Our
responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards
require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the
financial statements, assessing the accounting principles used and significant estimates made by management and Board of Directors, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis
for our opinion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As discussed in Note 1 to the financial statements, the Company is in the research and development stage and has not yet generated revenue from
its operations. During its years of operation, the Company has incurred cumulative losses and negative cash flows from operating activities. As of December 31, 2014<B> </B>the accumulated deficit was $12,584 thousand. As the<B> </B>Company expects
to continue to incur negative cash flows from operations, there is substantial doubt about the Company&#146;s ability to continue as a<B> </B>going concern. These financial statements have been prepared assuming that the Company will continue as a
going concern and do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="30%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="68%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom">Tel-Aviv, Israel</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">/s/ Kesselman &amp; Kesselman</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">March 4, 2016</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Certified Public Accountants (lsr.)</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">A member firm of PricewaterhouseCoopers International Limited</TD></TR>
</TABLE> <P STYLE="font-size:50pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="51%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="font-size:1px; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" STYLE="BORDER-LEFT:1px dotted #000000; BORDER-TOP:1px dotted #000000; padding-left:8pt">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:1px dotted #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-TOP:1px dotted #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><I>Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv 6812508, Israel, </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; font-size:9.5pt; font-family:ARIAL"><I>P.O. Box 50005 Tel-Aviv 6150001 Telephone: +972-3-7954555, Fax:+972-3-7954556, www.pwc.com/il </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_2"></A>BALANCE SHEETS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,148</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NON-CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and Shareholders&#146; equity</B></TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT LIABILITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">150</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NON-CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COMMITMENTS AND CONTINGENCIES (Note 5)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SHAREHOLDERS&#146; EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 8,000,000 and 10,000,00 shares authorized at December&nbsp;31, 2014 and 2013, respectively; 719,059 issued
and outstanding as of December&nbsp;31, 2014 and 2013</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and A-1 preferred shares, NIS 0.01 par value: 2,000,000 shares authorized at December&nbsp;31, 2014; 270,973 shares issued and
outstanding at December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,108)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,225</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_3"></A>STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RESEARCH AND DEVELOPMENT EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,479</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">890</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,389</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>FINANCE EXPENSES (INCOME), NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(83)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NET LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>LOSS PER ORDINARY SHARE BASIC AND DILUTED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER ORDINARY SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_4"></A>STATEMENTS OF CHANGES IN SHAREHOLDERS EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt" ALIGN="center">


<TR>
<TD WIDTH="37%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B><FONT STYLE="white-space:nowrap">PAID-IN&nbsp;CAPITAL</FONT></B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="10" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY 1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">498,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,839</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,802)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>CHANGES DURING 2013:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of share capital, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,467</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,306)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,306)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER 31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,108)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>CHANGES DURING 2014:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="9" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of preferred shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">236,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,025</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,026</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Issuance of preferred shares in respect of conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34,061</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(*)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,476)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,476)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.56em; text-indent:-1.56em; font-size:9pt; font-family:ARIAL"><B>BALANCE AS OF DECEMBER 31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">(*) Represents amount less than one thousand </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_5"></A>STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(4,476)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,306)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments required to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating asset and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(330)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">239</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(4,117)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,557)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(32)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of preferred shares and warrants, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,304</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,951</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,468</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>INCREASE IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">833</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,215</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE YEAR</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SUPPLEMENTAL DISCLOSURES OF NON-CASH FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Conversion of convertible notes into preferred A shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">579</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Conversion of convertible notes into warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_6"></A>NOTES TO THE FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 1-NATURE OF OPERATIONS </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UroGen Pharma Ltd. (formerly TheraCoat Ltd.,
the &#147;Company&#148;) is an Israeli company incorporated in April 2004. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is a clinical stage biopharmaceutical company focused on developing novel
therapies designed to change the standard of care for urological pathologies. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is in the research and development stage and has not yet generated
revenue from its operations. During its years of operation, the Company has incurred cumulative losses and negative cash flows from operating activities. As of December&nbsp;31, 2014 the accumulated deficit was $12,584. As the Company expects to
continue to incur negative cash flows from operations, there is substantial doubt about the Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management plans
include raising capital from existing and external investors and applying for research and development grants. There are no assurances, however, that the Company will be successful in obtaining sufficient financing needed for its operations. If the
Company is unsuccessful in raising capital, it may need to reduce or curtail activities or cease operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements have been prepared assuming
that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 2-SIGNIFICANT
ACCOUNTING POLICIES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Basis of presentation </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
Company&#146;s financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#147;U.S. GAAP&#148;). </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Use of estimates in the preparation of financial statements </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The
preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the
financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results may differ from those estimates. As applicable to these financial statements, the most significant estimates and assumptions relate to
the fair value of share-based compensation and the fair value of the warrants for preferred shares. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Functional currency </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The U.S. dollar (&#147;dollar&#148;) is the currency of the primary economic environment in which the operations of the Company are conducted. Therefore, the functional
currency of the Company is the dollar. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar
currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations, the following exchange rates are
used: (i)&nbsp;for transactions&#151;exchange rates at transaction dates or average rates; and (ii)&nbsp;for other items (derived from non-monetary balance sheet items such as depreciation and amortization, etc.) - historical exchange rates.
Currency transaction gains and losses are presented in financial expense (income). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Cash and cash equivalents </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or
less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>e. Property and
equipment </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Property and equipment are stated at cost, net of accumulated depreciation. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The Company&#146;s property and equipment are depreciated using the straight-line method on the basis of their estimated useful lives. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Annual rates of depreciation are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Leasehold improvements are amortized using the straight-line method over the shorter of the expected lease term and the estimated useful life of the improvements. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>f. Impairment of long-lived assets </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company tests long-lived
assets, comprised solely of property and equipment, for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future undiscounted cash flows of the assets is less than the carrying amount of such
assets, an impairment loss would be recognized. The assets would be written down to their estimated fair values, calculated based on the present value of expected future discounted cash flows or some other fair value measure. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2014 and 2013, the Company did not recognize an impairment loss for its long-lived assets. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>g. Contingencies </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Certain conditions may exist as of the date of the
financial statements, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company&#146;s management assesses such contingent liabilities and such assessment inherently
involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims that may result in such proceedings, the Company&#146;s management evaluates the perceived
merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management applies
the guidance in ASC 450-20-25 when assessing losses resulting from contingencies. If the assessment of a contingency indicates that it is probable that a loss has been incurred and the amount of the liability can be estimated, then the estimated
liability is recorded as accrued expenses in the Company&#146;s financial statements. If the assessment indicates that a potential loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature
of the contingent liability, together with an estimate of the range of possible loss if determinable are disclosed. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In accruing a provision for loss, the Company
recognizes an accrual for the amount within a range of loss that represents the best estimate within the range. When no amount within the range is a better estimate than any other amount, the Company accrues for the minimum amount within the range.
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>h. Financial instruments </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues preferred
shares, it considers the provisions of ASC 480 in order to determine whether the preferred share should be classified as a liability. If the instrument is not within the scope of ASC 480, the Company further analyses the instrument&#146;s
characteristics in order to determine whether it should be classified within temporary equity (mezzanine) or within permanent equity in accordance with the provisions of ASC 480-10-S99. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">When the Company issues other freestanding instruments, the Company first analyses the provisions of ASC 480 in order to determine whether the instrument should be
classified as a liability, with subsequent changes in fair value recognized in earnings in each period. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">If the instrument is not within the scope of ASC 480, the
Company further analyses the provisions of ASC 815-40 in order to determine whether the instrument should be classified within equity or rather classified as an asset or liability, with subsequent changes in fair value recognized in earnings in each
period. See also note 6 and note 7. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>i. Share-based compensation </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company accounts for employees&#146; and directors&#146; share-based payment awards classified as equity awards using the grant-date fair value method. The fair
value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. The Company estimates forfeitures based on historical experience and anticipated future conditions. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the straight-line method
and to value the awards based on the single-option award approach. Performance-based awards are expensed over the requisite service period when the achievement of performance criteria is probable. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Equity awards granted to non-employees are re-measured at each reporting period at fair value until the commitment date had been reached which is usually the date the
service is completed. The fair value of equity awards is charged to the statement of operations over the service period using the straight-line method. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>j.
Research and development costs </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Research and development costs are expensed as incurred and consist primarily of the cost of salaries, share-based
compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities and professional services. Grants received from the Office of the Chief Scientist of Israel&#146;s Ministry
of Economy and Industry (the &#147;OCS&#148;) are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant
will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>k. Income taxes: </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">Deferred taxes </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Income taxes are computed using the asset and liability method. Under the asset and
liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation
allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Uncertain income tax positions </TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The Company follows a two-step approach in recognizing and measuring
uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this
threshold is met, the second step is to measure the tax benefit as the largest amount that is more likely than not of being realized upon ultimate settlement. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>l. Loss per share </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Basic loss per share (&#147;LPS&#148;) is computed
by dividing net loss for the year, after reducing cumulative dividends on preferred shares by the weighted average number of ordinary shares of the Company outstanding for each period. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The calculation of diluted net loss per share excludes potential share issuances of ordinary shares upon the exercise of share options, warrants to preferred shares,
convertible note and convertible preferred share as each of their effect is anti-dilutive. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>m. Fair value measurement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market
participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest
priority to Level 1 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the
extent possible and considers counterparty credit risk in its assessment of fair value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2014 and 2013 the fair value of the assets and
liabilities, approximate their carrying amounts. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>n. Concentration of credit risks </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents. The Company deposits cash
and cash equivalents with highly rated financial institutions, and, as a matter of policy, limits the amounts of credit exposure to any single financial institution. The Company has not experienced any credit losses in these accounts and does not
believe it is exposed to significant credit risk on these instruments. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>o. Comprehensive loss </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has no other comprehensive loss components other than net loss. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>p. Segment reporting </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Operating segments are reported in a manner
consistent with the internal reporting provided to the chief operating decision-maker, who is responsible for allocating resources and assessing performance of the operating segments. The Company operates in one operating segment. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>q. Newly issued and recently adopted accounting pronouncements </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In June 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No.&nbsp;2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements,
Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. This ASU removes the definition of a development stage entity from the ASC, thereby removing the financial reporting distinction between development stage
entities and other reporting entities from GAAP. In addition, the ASU eliminates the requirements for development stage entities to (1)&nbsp;present inception-to-date information in the statements of operations, cash flows, and shareholders deficit,
(2)&nbsp;label the financial statements as those of a development stage entity, (3)&nbsp;disclose a description of the development stage activities in which the entity is engaged, and (4)&nbsp;disclose in the first year in which the entity is no
longer a development stage entity that in prior years it had been in the development stage. ASU 2014-10 is effective for annual periods beginning after December&nbsp;15, 2014, with early adoption permitted. The Company has early adopted ASU 2014-10
and reflected this adoption in its financial statement presentation contained herein. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In August 2014, FASB issued ASU 2014-15&#151;Presentation of Financial Statements&#151;Going Concern (ASC Subtopic 205-40): &#147;Disclosure of Uncertainties about an Entity&#146;s Ability to Continue as a Going
Concern&#148;. The update requires management to assess a company&#146;s ability to continue as a going concern and to provide related footnote disclosures in certain circumstances. All entities are required to apply the new requirements in annual
periods ending after December&nbsp;15, 2016, and interim periods thereafter. Early application is permitted. The Company is required to adopt these provisions for the annual period ending December&nbsp;31, 2016. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 3&#150;PROPERTY AND EQUIPMENT </B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cost:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Computers and software</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Furniture</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">131</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less- Accumulated depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(60)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(30)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Depreciation expense was $30 and $18 for the years ended December&nbsp;31, 2014, and 2013, respectively. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 4-EMPLOYEE RIGHTS UPON RETIREMENT </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is required by law to
make severance payments upon dismissal of an employee or upon termination of employment in certain other circumstances. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates a number of
post-employment defined contribution plans. A defined contribution plan is a program that benefits an employee after termination of employment, under which the Company regularly makes fixed payments to a separate and independent entity so that the
Company has no legal or constructive obligation to pay additional contributions if the fund does not hold sufficient assets to pay all employees the benefits relating to employee service in the current and prior periods. The fund assets are not
included in the Company&#146;s financial position. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company operates pension and severance compensation plans subject to Section 14 of the Israeli Severance Pay
Law. The plans are funded through payments to insurance companies or pension funds administered by trustees. In accordance with its terms, the plans meet the definition of a defined contribution plan, as defined above. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 5-COMMITMENT AND CONTINGENCIES </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Lease agreement </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In February 2011 the Company entered into a lease agreement for its Israeli office. In September 2013 and October 2014 the Company signed an additional lease agreement
in order to increase the office space rented. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The rent expenses for the years ending December&nbsp;31, 2014 and 2013 are approximately $74 and $31, respectively.
</P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In November 2014 the Company entered into a new lease agreement effective from February&nbsp;1, 2015 until January&nbsp;31, 2018. In October 2015 the Company
signed an additional lease agreement in order to increase the office space rented. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The future minimum lease payments required in each of the next three years under
the lease agreement are as follows: 2015 - $101, 2016-2017 $104 per year. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Grants from the Office of the Chief Scientist of the State of Israel (the &#150;
&#147;OCS&#148;) </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has received grants from the OCS for research and development funding. Up until 2007, the OCS participation in the funding of
the Company&#146;s operations was as part of the Director General Directive 8.2 of Israel by grants provided to Granot Ventures. Since 2008, the funding was provided directly to Company. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is committed to pay royalties to the Government of Israel on proceeds from sales of products in the research and development of which the OCS participates
by way of grants. At the time the grants were received, successful development of the related projects was not assured. In the case of failure of a project that was partly </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
financed as above, the Company is not obligated to pay any such royalties. Under the terms of the funding from the OCS, royalties of 3%-4.5% are payable on sales of products developed from a
project so funded, up to 100% of the amount of the grant received by the Company (dollar linked); with the addition of annual interest at a rate based on 12-month LIBOR. The Company is subject to several conditions, including restrictions on its
intellectual property. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2014, the maximum royalty amount payable by the Company under these funding arrangements is $1,471 (excluding
interest). </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Financing success fees </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company entered into
agreements with third parties and shareholders in connection with fundraising efforts. In consideration for the services rendered, the Company undertook to pay those third parties and shareholders certain success fees from funds actually received by
the Company and/or options to purchase equity of the Company, at a rate agreed between the parties. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Total success fees during the years ended December&nbsp;31,
2014 and 2013 were $50 and $212, respectively. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company granted to these third parties 859 and 13,584 options to purchase ordinary shares during the years ended
December&nbsp;31, 2014 and 2013 respectively. Total Fair value of options granted to these third parties was $2 for options granted during the year ended December&nbsp;31, 2014&nbsp;and $171 for options granted during the year ended
December&nbsp;31, 2013. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 6-FINANCIAL INSTRUMENTS AT FAIR VALUE </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Convertible Notes </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">During 2014, the Company issued a series of convertible notes (the &#147;convertible notes&#148;) in the aggregate amount of approximately $647. The convertible notes are to be automatically converted into ordinary
shares at a conversion price of $16.00 at December 2017, or to the most senior preferred shares or ordinary shares upon occurrence of certain events (each a &#147;Qualifying Event&#148;), such as an IPO, M&amp;A or a financing round in an amount of
at least $5 million in a single transaction or a series of related transactions. Conversion of the convertible notes upon a Qualifying Event is to a variable number of shares, at a conversion price that generally reflects a fixed discount on the
price per share reflected in these events. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">In July 2014, the Company offered the convertible noteholders an option to convert the
note according the terms of the next financing round in lieu of the conversion for discount. In October 2014, at the initial closing of the Share Purchase Agreement (the &#150; &#147;SPA&#148;) (see note 7) the Company issued 34,061 shares of Series
A preferred shares and granted warrants to purchase additional 17,031 shares of Series A-1 preferred shares upon conversion of the convertible notes. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">Accounting treatment of the convertible notes </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Under ASC 480, a financial instrument that embodies a
conditional obligation, that the issuer may settle by issuing a variable number of its equity shares shall be classified as a liability if, at inception, the monetary value of the obligation is based solely or predominantly on a fixed monetary
amount known at inception. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">At inception the Company concluded and determined that the convertible notes should be classified as a liability under
the provision of ASC 480. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The convertible notes are accounted for at fair value at each reporting period with changes in fair value recorded in the
statement of operations, within financial income (expense). </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">As of October&nbsp;20, 2014, the fair value of the convertible notes was measured in
accordance with an option pricing method (&#147;OPM&#148;). The fair value was determined mainly based on the SPA price per share of $19.00 of Series A preferred shares and assumptions related to achieving the required milestone for additional
investment that was determined in the SPA the change in fair value until conversion was $28.00, and, expected volatility at a rate of 68.9%. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Warrants for preferred shares </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">As part of the SPA, the Company issued warrants (the &#147;A-1 warrants&#148;) for preferred shares, see note 7a3. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">The A1 Warrants are exercisable into preferred A-1 shares of the Company, nominal value NIS 0.01&nbsp;per share, for an exercise price of $25.00 per share commencing on the date of the issuance and terminates upon the
earlier of an IPO, M&amp;A events or four years. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The warrants are exercisable for preferred A-1 shares, in consideration for cash
representing the exercise price. In the event that the warrant is exercised in connection with an IPO or M&amp;A events, the holder may elect to convert the warrant on a net share basis. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The A1 warrants are classified as liabilities in accordance with ASC 480, as they are freestanding instruments, exercisable into preferred A-1 shares,
which are redeemable upon certain events that represent &#147;Deemed Liquidation&#148; events (see also Note 7c3). Accordingly, the A1 Warrants are measured at fair value in every reporting period, and changes in their fair value are recognized in
earnings, within financial income (expense). </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31 2014, the fair value of the warrants for preferred shares was measured using an
option pricing method (&#147;OPM&#148;). The fair value was determined mainly based on the SPA price per share of $19.00 of Series A preferred shares and assumptions related to achieving the required milestone for additional investment that was
determined in the SPA, and, expected volatility at a rate of 68.3%. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. The table below sets forth a summary of the changes in the fair value of the financial
instruments liabilities classified as Level 3 for the year ended December&nbsp;31, 2014 </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="72%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CONVERTIBLE&nbsp;NOTES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Conversion of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(619)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 7-SHARE CAPITAL: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Share capital </I></B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">As of December&nbsp;31, 2014 and 2013 the share capital of the Company was as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="59%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AUTHORIZED</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ISSUED AND<BR>OUTSTANDING</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and A-1 preferred shares of NIS 0.01 par value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">During 2013, the Company signed investment agreements for $3,468 in consideration for 220,501 ordinary shares, net of issuance costs of $70 at a price per share of $16.00. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In September 2014 (closing in October 2014), the Company signed a SPA with shareholders and new investors for an aggregate amount of up to $8,000 in exchange of 421,051 shares of Series A preferred Shares at a price per
share of $19.00 and warrants to purchase an additional 210,526 shares of Series A-1 preferred Shares at a per share exercise price of $25.00. According to the SPA, each investor that invests more than $500 shall transfer 50% of its investment at the
initial closing in October 2014 (the &#147;Initial Closing&#148;) and additional 50% once the Company meets certain milestones the (&#147;Milestone Closing&#148;) or upon an investors&#146; waiver of attainment of the milestone. As part of the SPA,
in October 2014 the convertible notes were converted (see note 6). </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Following the Initial Closing the Company approved the
reclassification of ordinary shares from the authorized share capital of the Company, into 1,000,000 preferred A share, par value NIS 0.01 each and 1,000,000 preferred A-1 Share par value NIS 0.01 each. </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">During 2014, the Company received $4,304 and additional amount of $130 in January 2015, net of issuance costs of $67, in exchange for 236,912 shares of
Series A preferred shares and 118,456 A-1 warrants. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Subsequent to December&nbsp;31, 2014, at the Milestone Closing the Company issued for total
consideration of $3,500, 184,210 shares of Series A preferred shares and 92,105 A-1 warrants at $25.00 price per Series A preferred share. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Terms of the
Company&#146;s ordinary shares </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Each ordinary share is entitled to one vote. The holders of ordinary shares are also entitled to receive dividends whenever
funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Terms of the
Company&#146;s convertible preferred shares: </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Preferred shares of the Company include A and A-1 preferred shares. The exercise price of a preferred A share
is $19.00 and the exercise price of a preferred A-1 share is $25.00. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">The holder of each preferred share shall: (i)&nbsp;be entitled to the number of votes which is equal to the number of ordinary shares into which such preferred share is then convertible (ii)&nbsp;have voting rights and
powers equal to the voting rights and powers of any holder of ordinary shares and shall vote as a single class with the holders of ordinary shares; and (iii)&nbsp;be entitled to notice of any meeting of the shareholders. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">From and after the date of the issuance of any preferred shares, dividends at the rate per annum of 8% of the Original Purchase Price (as defined) per share shall accrue on such preferred shares (subject to appropriate
adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to the preferred shares). </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">In the event of: (i)&nbsp;any dissolution or liquidation of the Company; (ii)&nbsp;any bankruptcy or insolvency proceeding under any bankruptcy or insolvency or similar law, whether voluntary or involuntary, is properly
commenced by or against the Company; (iii)&nbsp;a receiver or liquidator has been appointed to all or substantially all of the Company&#146;s assets, (iv)&nbsp;a Deemed Liquidation (as defined below) event (each of the foregoing, a &#147;Liquidation
Event&#148;), or (v)&nbsp;distribution of Dividends, then any Dividends, assets or proceeds of the Company available for distribution to the shareholders (&#147;Distributable Proceeds&#148;), shall be distributed among the shareholders pursuant to
the following order of preference: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">First, the holders of the preferred shares shall be entitled to receive out of the Distributable Proceeds, prior to and in preference to any distribution to any of the holders of the ordinary shares an amount per
preferred share equal to the higher of: (i)&nbsp;the Original Purchase Price plus any Accruing Dividends (as defined), accrued but unpaid thereon, whether or not declared, together with any other dividends declared but unpaid thereon less any amount
of Distributable Proceeds previously paid with regard to such shares (collectively, the &#147;Preferential A Amount&#148;) and (ii)&nbsp;such amount per share as would have been payable had all preferred shares been converted into ordinary shares
immediately prior to such Liquidation Event. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">If the assets (or securities) available for distribution shall be insufficient to permit the payment to holders of the preferred shares of the full Preferential A Amount, then the entire assets (or securities) available
for distribution shall be distributed pro-rata among the holders of the preferred shares in proportion to the Preferential A Amount each such holder is otherwise entitled to receive. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Second, after payment in full of the Series A Liquidation Amount, the remaining assets of the Company available for distribution to the Company&#146;s shareholders shall be distributed among the holders of ordinary
shares, pro rata based on the number of shares held by each such holder. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Any of the following events shall be deemed a Liquidation Event (each a &#147;Deemed Liquidation&#148;): a transaction or a series of related transactions which entails (i)&nbsp;any sale of all, or substantially all, of
the Company&#146;s assets or technology, including by way of granting an exclusive license that is equivalent to the sale of all, or substantially all of the Company&#146;s intellectual property; (ii)&nbsp;the consolidation, merger, or
reorganization of the Company into any other entity, in which the Company is not the surviving entity; except, in each case, any transaction in which the shareholders of the Company prior to the transaction hold more than fifty percent (50%)&nbsp;of
the outstanding share capital of the Company or the surviving company, as applicable, immediately following such transaction; provided, however, that shares of the surviving entity held by shareholders of the Company acquired by means other than the
exchange or conversion of the shares of this Company shall not be used in determining if the shareholders of the Company own more than fifty percent (50%)&nbsp;of the outstanding share capital of the surviving entity (or its parent), but shall be
used for determining the total outstanding share capital of the surviving entity); and (iii)&nbsp;any sale of all, or substantially all, of the Company&#146;s issued and outstanding share capital. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The holders of preferred shares shall have the following conversion rights: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Optional conversion- each preferred share shall be convertible, at the option of the holder thereof, at any time after the date of issuance of such share into such number of fully paid shares of ordinary shares as is
determined by dividing the Original Purchase Price by the conversion price applicable to such share, in effect on the date that the certificate is surrendered for conversion. The initial conversion price of the preferred shares shall be the Original
Purchase Price; and provided, however, that the conversion price for the preferred shares shall be subject to certain adjustments. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Automatic conversion- Each preferred share shall automatically be converted into ordinary shares at the Conversion Price at the time in effect for such preferred share, on the consummation of any one of the following
events: </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">i)</TD>
<TD ALIGN="left" VALIGN="top">Upon the closing of an IPO, where the Company&#146;s pre-money valuation is $75,000 or more with net proceeds to the Company of $25,000 or more (a &#147;Qualified Public Offering&#148;); or </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="7%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">ii)</TD>
<TD ALIGN="left" VALIGN="top">In the event that holders of a majority of sixty percent (60%)&nbsp;of the then outstanding preferred shares, voting as a single class, consent to such. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The preferred shares also confer on their holders certain anti-dilution rights that adjust the conversion ratio in the event that the Company issues new shares at the price lower than the price original issue to the
respective preferred shareholders. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">The preferred A shares are classified within permanent equity as they are not subject to liability
classification under the scope of ASC 480, and meet all the requirements of equity classification under ASC 480-10-S99. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Share-based compensation
</I></B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In October 2010, the Company&#146;s board of directors approved a share option plan (the &#147;Plan&#148;) for grants to Company employees, consultants,
directors, and other service providers. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The grant of options to Israeli employees under the Plan is subject to the terms stipulated by Section&nbsp;102 of the
Israeli Income Tax Ordinance (&#147;Section 102&#148;). The option grants are subject to the track chosen by the Company, either the &#147;regular income&#148; track or the &#147;capital gains&#148; track, as set out in Section&nbsp;102. The Company
registered the Plan under the capital gains track, which offers more favorable tax rates to the employees. As a result, and pursuant </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">
to the terms of Section&nbsp;102, the Company is not allowed to claim as an expense for tax purposes the amounts credited to the employees in respect of options granted to them under the Plan,
including amounts recorded as salary benefits in the Company&#146;s accounts, with the exception of the work-income benefit component, if any, determined on grant date. For non-employees and for non-Israeli employees, the share option plan is
subject to Section&nbsp;3(i) of the Israeli Income Tax Ordinance. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The expected volatility is based on the historical volatility of comparable companies. The
risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. The expected term is the length of time until the expected dates of exercising the options, and is
estimated for employees (except senior management) using the simplified method due to insufficient specific historical information of employees&#146; exercise behavior, and for non-employees, directors and senior management using the contractual
term. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2014, 87,765 options remained available for grant under the Plan. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2014 and 2013, the Company granted options to certain employees and non-employees as follows: </P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>1)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Options granted to employees and directors:</B> </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:3%; font-size:9.5pt; font-family:ARIAL">Set forth below are grants made by the Company to
employees as of December&nbsp;31, 2014. The majority of the options vest over a period of four years and expire on the seventh anniversary of the date of grant. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">During 2014 and 2013, the Company granted 50,873 and 37,544 options, respectively, to employees and directors with an exercise price of $16.00&nbsp;per share. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">In October 2014, the Company modified the terms of the options granted during 2010-2013 to certain retired directors in, by extending the life of the options until the earlier of: (i)&nbsp;24 months from the retirement
date, and (ii)&nbsp;an initial public offering or an M&amp;A event. At the date of modification, all of the options were fully vested. At the date of the modification, the Company recorded an expense of $15.9 based on the incremental increase in the
value of the awards. </TD></TR></TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to employees and directors during 2014 and 2013 was $128 and $378,
respectively. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; margin-left:7%; font-size:9.5pt; font-family:ARIAL">The total unrecognized compensation cost of employee options at December&nbsp;31, 2014 is $368, which is expected to be recognized
over a weighted average period of three years. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>2)</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Options granted to consultants and other service providers: </B></TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">During 2013, the Company granted 37,325 options to consultants and service providers with exercise prices ranging from $0.01 to $16.00 per share. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">During 2014, the Company granted 9,859 options to consultants and service providers with an exercise price of $16.00 per share. </TD></TR></TABLE>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of options granted to consultants and other service providers during 2014 and 2013 was $12 and $395, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the options on the date of grant was computed using the Black-Scholes model. The underlying data
used for computing the fair value of the options are as follows: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Value of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">68.45-74.78%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">69.56-74.86%</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.38%-2.27%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.73%-2.28%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expected term</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.9-7.3 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.7&#150;7.5 years</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the ordinary shares for 2014 was measured in accordance with an option pricing model. The fair value of the ordinary shares for 2013 was based on the
capital investment by third parties (see note 7a2) </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">3)</TD>
<TD ALIGN="left" VALIGN="top">The following table summarizes the number of options outstanding under the Plan for the years ended December&nbsp;31, 2014 and 2013, and related information: </TD></TR></TABLE>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>EMPLOYEES AND</B><br><B>DIRECTORS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>CONSULTANTS AND</B><br><B>SERVICE PROVIDERS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER<BR>OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE&nbsp;PRICE<BR>PER SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF</B><br><B>OPTIONS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED<BR>AVERAGE<BR>PRICE&nbsp;PER<BR>SHARE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at January&nbsp;1, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">111,283</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,544</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">37,325</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">16.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2013</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">148,827</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">13.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">12.60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,873</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,859</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.06</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Canceled/Forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13,500)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>Outstanding at December&nbsp;31, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,200</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.82</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">103,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">4)</TD>
<TD ALIGN="left" VALIGN="top">The following tables summarizes the outstanding and exercisable options as of December&nbsp;31, 2014: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="26%"></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="14%"></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="13" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>DECEMBER&nbsp;31, 2014</B></P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" COLSPAN="7" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>OPTIONS OUTSTANDING</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="5" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>OPTIONS EXERCISABLE</B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXERCISE</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>PRICE PER</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>SHARE </B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF OPTIONS<BR>OUTSTANDING AT END<BR>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED AVERAGE<BR>REMAINING<BR>CONTRACTUAL LIFE</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER OF OPTIONS<BR>EXERCISABLE AT END<BR>OF YEAR</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WEIGHTED AVERAGE<BR>REMAINING<BR>CONTRACTUAL LIFE</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">$&nbsp;&nbsp;0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">3.8</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">$&nbsp;&nbsp;7.84</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,297</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.7</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">$12.85</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,177</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.2</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">$16.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,605</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">5.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,661</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">4.9</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL" ALIGN="center">$21.53</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,207</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">2.7</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">290,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">207,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2014 and 2013, no options were exercised. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The aggregate intrinsic value of the total vested and exercisable options as of December&nbsp;31, 2014 was $1,783.
</P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">5)</TD>
<TD ALIGN="left" VALIGN="top">The following table illustrates the effect of share-based compensation on the statements of operations: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">541</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 8&#150;TAXES ON INCOME </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is taxed under Israeli tax laws:
</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Tax rates </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The income of the Company is taxed at the regular
rate. The corporate tax rate for 2014 and 2013 was 26.5%, and 25% respectively. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Tax assessments </I></B></P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company received final tax assessments until tax year 2011. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>c. Losses
for tax purposes carried forward to future years </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of December&nbsp;31, 2014, the Company had approximately $7,800 of net carry forward tax losses
available to reduce future taxable income without limitation of use. </P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>d. Deferred income taxes: </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">In respect of:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net operating loss carry forward</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,067</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,527</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and Development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Less&#151;valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,551)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The change in valuation allowance for the years ended December&nbsp;31, 2014 and 2013 were as follows: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the beginning of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(910)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes during the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(721)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(920)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at the end of the year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,551)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,830)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The main reconciling item between the statutory tax rate of the Company and the effective rate is the research and development expenses, share based compensation and
provision for full valuation allowance in respect of tax benefits from carry forward tax losses due to the uncertainty of the realization of such tax benefits. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>e. As of December&nbsp;31, 2014 and 2013, the Company had not accrued a provision for uncertain tax positions. </I></B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 9-LOSS PER ORDINARY SHARE: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the calculation of basic and diluted loss per share for the periods indicated: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2013&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holders of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,476</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend accumulated for preferred shares during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to ordinary equity holders of the Company, after deducting dividend accumulated for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,306</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">661,559</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share (LPS)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">For the years ended December&nbsp;31, 2014 and 2013, all ordinary shares underlying outstanding options, A-1 warrants, convertible notes and convertible preferred
shares have been excluded from the calculation of the diluted loss per share since their effect was anti-dilutive. Diluted LPS does not include 209,417 and 171,116 ordinary shares underlying outstanding options for the years ended December&nbsp;31,
2014 and 2013, respectively, 34,061 shares issuable upon conversion of the convertible notes, 135,487 shares issuable upon exercise of the A-1 warrants for preferred A-1 shares for the year ended December&nbsp;31, 2014 and 270,973 shares issuable
upon conversion of preferred shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 10-RELATED PARTIES-TRANSACTIONS AND BALANCES: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Related parties include the Chairman of the Board of Directors and the Chief Executive Officer of the Company. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Transactions with related parties </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;YEAR&nbsp;ENDED&nbsp;DECEMBER&nbsp;31,&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Management fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">431</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">495</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Balances with related parties: </I></B></P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2013</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 11-SUBSEQUENT EVENTS: </B></P>
 <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">The Company has evaluated subsequent events through March&nbsp;3, 2016: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE="font-family:ARIAL; font-size:9.5pt"><B></B>In August 2015, the Company entered into an employment agreement with a new CEO. In addition to the annual compensation, the Company will pay the CEO an
annual bonus subject to performance targets which will </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE FINANCIAL STATEMENTS </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S.
dollars in thousands, except share and per share data) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
not exceed 35% of the annual compensation. Further, the Company issued to the CEO 77,000 ordinary shares (as restricted shares) and undertook to issue an additional 18,000 ordinary shares (as
restricted shares) at the occurrence of two future events (9,000 at each event), as specified in the agreement. Each issue of shares shall vest over a 4 year period, whereby 25% of the shares underlying the respective issue shall vest upon the first
anniversary of the issue of the respective shares, and thereafter an additional 1/48 of the shares shall vest at the end of each subsequent month, over the course of the following three years. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In August 2015, the Company entered into an agreement with a large pharmaceutical company (&#147;Pharma Co.&#148;) pursuant to which the Company undertook to supply its gel product and supporting services to the
Pharma Co. for consideration of $750, to allow Pharma Co. to conduct certain scientific investigations aimed at testing the utility of the Company&#146;s gel product for the delivery of a certain proprietary product of Pharma Co. Further, the
Company granted Pharma Co. a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#146;s product in combination with Pharma Co.&#146;s product.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In September 2015, the Company granted its directors options to purchase up to 5,065 ordinary shares, at an exercise price of $16.00 per each share. All options were fully vested at the date of grant.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company entered into an asset purchase agreement with Telormedix SA (&#147;TMX&#148;) pursuant to which the Company purchased all of the intellectual property assets of TMX in consideration
for 216,000 Series A preferred shares of the Company. The Company will issue an additional 29,000 Series A preferred shares of the Company upon occurrence of three milestones, representing up to 87,000 Series A preferred shares of the Company in the
aggregate. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company signed a SPA with shareholders and new investors for an aggregate amount of up to $18,064 in exchange of 951,774 shares of Series A preferred shares of the Company at a price per
share of $19.00. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>f.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company granted the Chairman of the Board an option to purchase up to 50,000 ordinary shares, at an exercise price of $16 per each share that shall vest in four equal annual consecutive
amounts of 12,500 ordinary shares. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>g.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company reclassified 2,500,000 Ordinary Shares from the authorized but unissued share capital of the Company into 2,500,000 preferred A shares NIS 0.01 each, so that the authorized share
capital of the Company, after giving effect to the additional preferred A shares above, was as follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:69.50pt; font-size:8pt; font-family:ARIAL"><B>CLASS OF SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred A shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Preferred A-1 shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>h.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 175,000 ordinary shares to a total amount of
567,665 options. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>i.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In December 2015, the Company granted its directors options to purchase up to 75,000 ordinary shares, at an exercise price of $19.00 per share that shall vest in three equal annual consecutive portions.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>j.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In February and March 2016, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 100,000 and 65,000 ordinary shares
respectively, to a total amount of 732,665 options. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_7"></A>CONDENSED BALANCE SHEETS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,</B><br><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,</B><br><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Assets</B></TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;</B></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT ASSETS:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,005</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">398</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,288</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NON-CURRENT ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">226</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">71</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL ASSETS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" COLSPAN="8" ALIGN="center"><B>Liabilities and Shareholders&#146; equity</B></TD>
<TD VALIGN="top"><B>&nbsp;&nbsp;</B></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CURRENT LIABILITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">578</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">573</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">403</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">981</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">891</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NON-CURRENT LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>COMMITMENTS AND CONTINGENCIES</B> (Note 4)<B></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,196</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>SHAREHOLDERS&#146; EQUITY:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares, NIS 0.01 par value: 8,000,000 shares authorized at September&nbsp;30, 2015 and December&nbsp;31, 2014; 719,059 issued and
outstanding at September&nbsp;30, 2015 and December&nbsp;31, 2014</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Series A and A-1 preferred shares, NIS 0.01 par value:</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">2,000,000 shares are authorized at September&nbsp;30, 2015 and 2014; 455,183 shares and 270,973 shares issued and outstanding
at September&nbsp;30, 2015 and 2014, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Additional paid-in capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">19,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,236)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>TOTAL LIABILITIES AND SHAREHOLDERS&#146; EQUITY</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,835</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,359</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-21 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_8"></A>CONDENSED STATEMENTS OF OPERATIONS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE MONTHS ENDED</B><br><B>SEPTEMBER&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>RESEARCH AND DEVELOPMENT EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,438</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>GENERAL AND ADMINISTRATIVE EXPENSES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,009</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">609</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>OPERATING LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,447</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,174</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>FINANCE EXPENSES, NET</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>NET LOSS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>LOSS PER ORDINARY SHARE BASIC AND DILUTED</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>WEIGHTED AVERAGE NUMBER OF ORDINARY SHARES OUTSTANDING USED IN COMPUTATING BASIC AND DILUTED LOSS PER ORDINARY SHARE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-22 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_9"></A>CONDENSED STATEMENTS OF CHANGES IN SHAREHOLDERS&#146; EQUITY </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8.5pt" ALIGN="center">


<TR>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ORDINARY SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PREFERRED SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ADDITIONAL</B><br><B>PAID-IN<BR>CAPITAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>RECEIPTS<BR>ON&nbsp;ACCOUNT<BR>OF SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>ACCUMULATED</B><br><B>DEFICIT</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>TOTAL</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER<BR>OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER<BR>OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="14" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>AMOUNTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY 1, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">270,973</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">15,744</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(12,584)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,163</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>CHANGES DURING THE NINE MONTHS ENDED SEPTEMBER 30, 2015:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Issuance of preferred shares, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,277</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,652)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,652)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>BALANCE AS OF SEPTEMBER&nbsp;30, 2015</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">455,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">19,279</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(18,236)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>BALANCE AS OF JANUARY 1, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10,847</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(8,108)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>CHANGES DURING THE NINE MONTHS ENDED SEPTEMBER 30, 2014:</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Receipts on account of SPA agreement</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.65em; text-indent:-1.65em; font-size:8.5pt; font-family:ARIAL"><B>BALANCE AS OF SEPTEMBER&nbsp;30, 2014</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,049</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,383)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(187)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-23 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_10"></A>CONDENSED STATEMENTS OF CASH FLOWS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED</B><br><B>SEPTEMBER&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM OPERATING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(5,652)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(3,275)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Adjustments required to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Depreciation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">78</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Share-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(28)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Fair value adjustment of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in operating asset and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(607)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(187)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:4.42em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Increase in employee related accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">153</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(5,656)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,841)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM INVESTING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Change in restricted deposit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(233)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(13)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>CASH FLOWS FROM FINANCING ACTIVITIES:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of preferred shares and warrants, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Proceeds from issuance of convertible notes, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">647</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Receipts on account of preferred shares to be issued</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:2.95em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">792</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>DECREASE IN CASH AND CASH EQUIVALENTS</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,286)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,062)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,037</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL"><B>BALANCE OF CASH AND CASH EQUIVALENTS AT END OF THE PERIOD</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">975</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">The accompanying notes are an integral part of these condensed financial statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-24 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="fin142578_11"></A>NOTES TO THE CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 1- NATURE OF OPERATIONS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">UroGen Pharma Ltd. (formerly TheraCoat Ltd., the &#147;Company&#148;) is an Israeli company incorporated in April 2004. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is a clinical stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for urological pathologies. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company is in the research and development stage and has not yet generated revenue from its operations. During its years of operation, the Company has incurred
cumulative losses and negative cash flows from operating activities. As of September&nbsp;30, 2015 the accumulated deficit was $18,236. As the Company expects to continue incur negative cash flows from operations, there is substantial doubt about
the Company&#146;s ability to continue as a going concern. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Management plans include raising capital from existing and external investors and applying for research
and development grants. There are no assurances, however, that the Company will be successful in obtaining sufficient financing needed for its operations. If the Company is unsuccessful in raising capital, it may need to reduce or curtail activities
or cease operations. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments
that might result from the outcome of this uncertainty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 2-BASIS OF PRESENTATION </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The unaudited interim condensed financial statements of UroGen Pharma Ltd. have been prepared in accordance with accounting principles generally accepted in the United
States of America (&#147;U.S. GAAP&#148;) for interim financial statements. Accordingly, they do not contain all information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed
interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#146;s financial position as of September&nbsp;30, 2015, the results of operations and cash flows for the
nine-month periods ended September&nbsp;30, 2015 and 2014. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">These unaudited interim condensed financial statements should be read in conjunction with the audited
financial statements and notes thereto included in the Company&#146;s annual financial statements for the year ended December&nbsp;31, 2014. The condensed balance sheet data as of December&nbsp;31, 2014 was derived from the audited financial
statements for the year ended December&nbsp;31, 2014, but does not include all disclosures required by U.S. GAAP. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The results for the nine-month period ended
September&nbsp;30, 2015 are not necessarily indicative of the results to be expected for the year ending December&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 3-FAIR VALUE PRESENTATION
</B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction
between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure
fair value into three broad levels, which are described as follows: </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement
date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 2: Observable prices that are based on inputs not
quoted on active markets, but corroborated by market data. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Level 3: Unobservable inputs are used when little or no market data is available. The fair value
hierarchy gives the lowest priority to Level 3 inputs. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-25 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and
minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company&#146;s assets
and liabilities that are measured at fair value as of September&nbsp;30, 2015 and December&nbsp;31, 2014 are classified in the tables below in one of the three categories described above: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,&nbsp;2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>DECEMBER&nbsp;31,&nbsp;2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;LEVEL&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;TOTAL&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;LEVEL&nbsp;3&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;TOTAL&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The table below sets forth a summary of the changes in the fair value of the warrants for preferred Shares classified as Level 3: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="90%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>WARRANTS</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">305</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Issuance of warrants for preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Changes in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Balance at September&nbsp;30, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The convertible notes that were issued during 2014 were converted to preferred A Shares and warrants in October 2014. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The fair value of the preferred share warrants as of December&nbsp;31, 2014 was measured in accordance with the Option Pricing Method and for September&nbsp;30, 2015
was measured in accordance with the Hybrid Method. The Hybrid Method combines the probabilities of an IPO scenario which was estimated at 15% and a liquidation event scenario which was estimated at 85%. The valuation methodology was changed in 2015
to the Hybrid Method due to management assessment of the probability of an IPO. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30 2015, the fair value of the warrants for preferred shares
was determined mainly based on a SPA signed during October 2015 (see note 8b) with a price per share of $19.00 of Series A preferred shares, and assumptions related to expected volatility at a rate of 69.3%. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">As of September&nbsp;30, 2015, the carrying amounts of financial instruments included in working capital approximate their fair value either because these amounts are
presented at fair value or due to the relatively short-term maturities of such instruments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 4-COMMITMENTS AND CONTINGENCIES </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In August 2015 the Company entered into an agreement with a large international pharmaceutical company (&#147;Pharma Co.&#148;) pursuant to which the Company undertook
to supply its gel product and supporting services to the Pharma Co. for consideration of $750, to allow Pharma Co. to conduct certain scientific investigations aimed at testing utility of the Company&#146;s gel product for the delivery of a certain
proprietary product of Pharma Co. Further, the Company granted Pharma Co. a time limited option to negotiate an exclusive, worldwide right to research, develop, make and have made, use, sell, offer to sell and import the Company&#146;s product in
combination with Pharma Co.&#145;s product. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-26 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The amount receivable from Pharma Co. is deducted from research and development expenses in the statements of
operations as the applicable costs are incurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 5-SHARE CAPITAL </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Issuance of preferred shares and warrants </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">In June 2015, the
Company reached the Milestone Closing as per the Company&#146;s share purchase agreement signed in 2014, and as such received the second installment of the investment. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The total proceeds received by the Company during the nine months ended September&nbsp;30, 2015 were $3,603, net of issuance costs. </P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Share-based compensation</I></B><B></B><B><I></I></B><B></B><B><I> </I></B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">1)</TD>
<TD ALIGN="left" VALIGN="top">In September 2015, the Company&#146;s Board of Directors approved, subject to certain terms and conditions, the grant of options to purchase 5,065 ordinary shares to certain directors, with an exercise price of $16.00
per share. The options were fully vested at the date of grant. The Company estimated the fair value of the options on the date of grant using the Black-Scholes option-pricing model to be approximately $29,364 based on the following weighted average
assumptions: dividend yield of 0% for all years; expected volatility of 73%; risk-free interest rates of 1.93%; and expected life of seven years. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">2)</TD>
<TD ALIGN="left" VALIGN="top">In August 2015, the Company entered into an employment agreement with a new CEO. In addition to the annual compensation the Company will pay the CEO an annual bonus subject to performance targets which will not exceed
35% of the annual compensation. Further, the Company issued to the CEO 77,000 ordinary shares (as restricted shares) and undertook to issue an additional 18,000 ordinary shares (as restricted shares) at the occurrence of two future events (9,000 at
each event), as specified in the agreement. Each issue of shares shall vest over a 4 year period, whereby 25% of the shares underlying the respective issue shall vest upon the first anniversary of the issue of the respective shares, and thereafter
an additional 1/48 of the shares shall vest at the end of each subsequent month, over the course of the following three years. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table
illustrates the effect of share-based compensation on the statements of operations: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">100</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">General and administrative expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">132</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">260</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">202</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 6-RELATED PARTIES- TRANSACTIONS AND BALANCES: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>a. Transactions
with related parties </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Related parties include the Chairman of the Board of Directors and the Chief Executive Officer of the Company. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="70%"></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="12%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Management fees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">309</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-27 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B><I>b. Balances with related parties: </I></B></P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2015&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2014&nbsp;&nbsp;&nbsp;&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Accounts payable and accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 7-LOSS PER ORDINARY SHARE: </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following table sets forth the
calculation of basic and diluted loss per share for the periods indicated: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="74%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NINE&nbsp;MONTHS&nbsp;ENDED&nbsp;SEPTEMBER&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Basic and diluted:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to equity holder of the Company</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Dividend accumulated on preferred shares during the period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">459</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss attributable to ordinary equity holders of the Company, after deducting dividend accumulated on preferred shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,275</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Weighted average number of ordinary shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">719,059</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Loss per ordinary share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Diluted loss per share does not include 455,183 Ordinary Shares issuable upon conversion of preferred A shares into Ordinary Shares for the nine months ended
September&nbsp;30, 2015, 227,592 shares issuable upon exercise of warrants for the nine months ended September&nbsp;30, 2015 and 238,865 and 195,800 Ordinary Shares underlying outstanding options for the nine months ended September&nbsp;30, 2015 and
2014, respectively because the effect of their inclusion in the computation would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>NOTE 8-SUBSEQUENT EVENTS: </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The Company has evaluated subsequent events through March&nbsp;3, 2016: </P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>a.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company entered into an asset purchase agreement with Telormedix SA (&#147;TMX&#148;) pursuant to which the Company purchased all of the intellectual property assets of TMX for consideration
of 216,000 shares of Series A preferred shares of the Company. The Company is required to issue an additional 29,000 Series A preferred shares of the Company upon occurrence of three milestones, up to 87,000 Series A preferred shares of the Company
in aggregate. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>b.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company signed a share purchase agreement (the &#147;SPA&#148;) with shareholders and new investors for $18,064 in consideration for 951,774 shares of Series A preferred shares of the Company
at a price per share of $19.00. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>c.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company granted the Chairman of the Board an option to purchase up to 50,000 ordinary shares, at an exercise price of $16 per each share that shall vest in four equal annual consecutive
amounts of 12,500 ordinary shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-28 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>UROGEN PHARMA LTD. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>NOTES TO THE CONDENSED FINANCIAL STATEMENTS </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(U.S. dollars in thousands, except share and per share data) </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>d.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company reclassified 2,500,000 Ordinary Shares from the authorized but unissued share capital of the Company, into 2,500,000 preferred A Shares NIS 0.01 each, so that the authorized share
capital of the Company, after giving effect to the additional preferred A shares, shall be follows: </TD></TR></TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" ALIGN="center">


<TR>
<TD WIDTH="73%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00px solid #000000; width:69.50pt; font-size:8pt; font-family:ARIAL"><B>CLASS OF SHARES</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>NUMBER&nbsp;OF&nbsp;SHARES</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>PAR&nbsp;VALUE</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">Ordinary shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">preferred A shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.47em; text-indent:-1.47em; font-size:9.5pt; font-family:ARIAL">preferred A-1 shares NIS 0.01</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>e.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In October 2015, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 175,000 ordinary shares to a total amount of
567,665 options. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>f.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In December 2015, the Company granted its directors options to purchase up to 75,000 ordinary shares, at an exercise price of $19.00 per share that shall vest in three equal annual consecutive portions.
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><B>g.</B></TD>
<TD ALIGN="left" VALIGN="top"><B></B>In February and March 2016, the Company increased the number of ordinary shares reserved for issuance under the Company&#146;s share option/incentive plans and arrangements by 100,000 and 65,000 ordinary shares,
respectively, to a total amount of 732,665 options. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">F-29 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Ordinary
Shares </B></P> <P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g142578g15c64.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:30pt; margin-bottom:0pt; font-size:20pt; font-family:ARIAL" ALIGN="center"><B>UroGen Pharma Ltd. </B></P> <P STYLE="font-size:72pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:11pt; font-family:ARIAL" ALIGN="center"><B>PRELIMINARY PROSPECTUS
</B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:31%">&nbsp;</P></center>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Jefferies </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cowen and Company </B></P>
<P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Through and including &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016 (25 days after the
date of this prospectus), all dealers that buy, sell or trade our ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to a dealer&#146;s obligation to deliver a prospectus when
acting as an underwriter and with respect to an unsold allotment or subscription. </P> <P STYLE="font-size:60pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item 6.
Indemnification of Directors, Officers and Employees. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may not exculpate an office holder from liability for a breach
of the duty of loyalty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care, but only if a provision authorizing
such exculpation is included in its articles of association. Our amended and restated articles of association to be effective upon the closing of this offering include such a provision. A company may not exculpate in advance a director from
liability arising out of a breach of the duty of care with respect to a distribution. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may indemnify an office holder
with respect to the following liabilities and expenses incurred for acts performed by him or her as an office holder, either pursuant to an undertaking made in advance of an event or following an event, provided its articles of association include a
provision authorizing such indemnification: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial liability imposed on him or her in favor of another person pursuant to a judgment, including a settlement or arbitrator&#146;s award approved by a court. However, if an undertaking to indemnify an office
holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#146;s activities when the undertaking to
indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder (1) as a result of an investigation or proceeding instituted against him or her by an authority authorized to conduct such
investigation or proceeding, provided that (i) no indictment was filed against such office holder as a result of such investigation or proceeding; and (ii) no financial liability was imposed upon him or her as a substitute for the criminal
proceeding as a result of such investigation or proceeding or, if such financial liability was imposed, it was imposed with respect to an offense that does not require proof of criminal intent; and (2) in connection with a monetary sanction; and
</TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reasonable litigation expenses, including attorneys&#146; fees, incurred by the office holder or imposed by a court in proceedings instituted against him or her by the company, on its behalf, or by a third party, or in
connection with criminal proceedings in which the office holder was acquitted, or as a result of a conviction for an offense that does not require proof of criminal intent. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder,
if and to the extent provided in the company&#146;s articles of association: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a financial liability imposed on the office holder in favor of a third party. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law, a
company may not indemnify, exculpate or insure an office holder against any of the following: </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe
that the act would not harm the company; </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a breach of the duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an act or omission committed with intent to derive illegal personal benefit; or </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a fine, civil fine, monetary sanction or forfeit levied against the office holder. </TD></TR></TABLE> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Under the Israeli Companies Law,
exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to certain office holders or under certain circumstances, also by the
shareholders. See &#147;Management&#151;Approval of Related Party Transactions under Israeli Law&#151;Fiduciary Duties of Directors and Executive Officers.&#148; </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Our amended and restated articles of association to be effective upon the closing of this offering will permit us to exculpate, indemnify and insure our office holders
to the fullest extent permitted or to be permitted by the Israeli Companies Law. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We have obtained directors and officers liability insurance for the benefit of our
office holders and intend to continue to maintain such coverage and pay all premiums thereunder to the fullest extent permitted by the Israeli Companies Law. In addition, prior to the closing of this offering, we intend to enter into agreements with
each of our directors and executive officers exculpating them from liability to us for damages caused to us as a result of a breach of duty of care and undertaking to indemnify them, in each case, to the fullest extent permitted by our amended and
restated articles of association to be effective upon the closing of this offering and Israeli law, including with respect to liabilities resulting from this offering to the extent that these liabilities are not covered by insurance. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as the indemnification for liabilities arising under the Securities Act of 1933, as amended, or the Securities Act, may be permitted to directors, officers or
persons controlling the registrant, we have been informed that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;7. Recent Sales of Unregistered Securities. </B></P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The following list
sets forth information as to all securities we have sold since January&nbsp;1, 2013, which were not registered under the Securities Act. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Between January 1, 2013 and December 31, 2013, we issued shares to certain new investors and existing shareholders totaling 220,501 ordinary shares for total consideration of $3.5 million. </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In February 2014, we issued a series of unsecured subordinated convertible promissory notes to new investors and several of our existing shareholders These notes were amended in July 2014 and are referred to as the 2014
notes, as amended. Pursuant to the 2014 notes, we initially received an aggregate principal amount of $647,112, bearing interest at 6% per annum. The principal and all accrued interest on the 2014 notes was to be, on the consummation of the
investment of a specified amount, automatically converted into either: (i) Series A preferred shares at a five percent (5%) discount on the price per share; or (ii) into ordinary shares at a fifteen percent (15%) discount on the price per share, on
the date of conversion, as determined by our board of directors, all at the election of the 2014 note holders. On October 20, 2014, in lieu of such automatic conversion, we offered the holders of the 2014 notes the right to convert the 2014 notes
into Series A preferred shares at a price per share of $19.00 and to receive warrants for no additional consideration, all as if they were subscribing to purchase securities pursuant to the 2014 Share Purchase Agreement. All of the 2014 note holders
elected to convert the principal amounts of their notes on these terms immediately prior to the initial closing of the 2014 Share Purchase Agreement and waived their right to interest due or payable on the principal amount. All 2014 notes were
cancelled. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On October 20, 2014, June 28, 2015 and July 7 and 28, 2015, (i) we issued to certain investors and existing shareholders, 421,122 preferred shares for approximately $8.0 million, which will be converted into ordinary
shares prior to this offering. We further granted such investors and existing shareholders 210,561 warrants to purchase preferred shares (to be converted into warrants to purchase ordinary shares prior to this offering) at an exercise price of
$25.00 per share; and (ii) we issued to the 2014 notes holders 34,061 preferred shares and 17,031 warrants to purchase preferred shares (to be converted into ordinary shares and warrants prior to this offering) at an exercise price of $25.00 in
exchange for their conversion of all principal and accrued interest due on the notes in an aggregate amount of $647,112. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On November 12, 2015, we issued to Telormedix SA, or TMX, 216,000 preferred shares in consideration for any and all owned knowledge or data of TMX, whether registered or unregistered, including, but not limited to,
intellectual property, goodwill, clinical studies, and licenses. These shares will be converted into ordinary shares prior to this offering. We also undertook to issue to TMX 87,000 additional preferred shares upon the achievement of certain
milestones, which may be met in the future. </TD></TR></TABLE> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman; font-size:7pt"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#110;</FONT></FONT></TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">On December 10, 2015, we issued to certain investors and existing shareholders 951,774 preferred shares, which will be converted into ordinary shares prior to this offering for $18.1 million. </TD></TR></TABLE>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The sales of the above securities were deemed to be exempt from registration under the Securities Act because they were made outside of the U.S. to certain non-U.S.
individuals or entities pursuant to Regulation S or, in reliance upon the exemption from registration provided under Section 4(a)(2) of the Securities Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Additionally, we granted share options to employees, directors, consultants and service providers under our 2010 Israeli Share Option Plan covering an aggregate of
745,202 ordinary shares, with exercise prices ranging from $0.01 to $19.00 per share. Such number excludes 9,000 restricted share units, the grant of which is contingent upon the closing of this offering. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">We claimed exemption from registration under the Securities Act for these option grants described above under Section 4(a)(2), Regulation S, or under Rule 701 of the
Securities Act as transactions pursuant to written compensatory plans or pursuant to a written contract relating to compensation. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">No underwriters were employed in
connection with the securities issuances set forth in this Item. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;8. Exhibits and Financial Statement Schedules. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(a) Exhibits.</B> See the Exhibit Index attached to this registration statement, which is incorporated by reference herein. </P>
<P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL"><B>(b) Financial Statement Schedules.</B> Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is
shown in the financial statements or notes thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Item&nbsp;9. Undertakings. </B></P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreement certificates in such denominations
and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Insofar as indemnification for liabilities arising under
the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the SEC such indemnification is against
public policy as expressed in the Securities Act, and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer,
or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the
opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question of whether such indemnification by it is against public policy as expressed in the Securities Act and will be
governed by the final adjudication of such issue. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">The undersigned Registrant hereby undertakes that: </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">for purposes of determining any liability under the Securities Act, the information omitted from the form of prospectus filed as part of this Registration Statement in reliance upon Rule&nbsp;430A and contained in a
form of prospectus filed by the Registrant pursuant to Rule&nbsp;424(b)(1) or (4)&nbsp;or 497(h) under the Securities Act shall be deemed to be part of this Registration Statement as of the time it was declared effective; and </TD></TR></TABLE>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="3%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">for the purpose of determining any liability under the Securities Act, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities
offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the
requirements for filing on Form F-1 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Ra&#146;anana, Israel on this
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;day of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2016. </P>
<P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9.5pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="93%"></TD></TR>


<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" COLSPAN="3"><B>UROGEN PHARMA LTD.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="12"></TD>
<TD HEIGHT="12" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center">Ron Bentsur</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9.5pt; font-family:ARIAL" ALIGN="center"><I>Chief Executive Officer</I></P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Ron Bentsur and Gary Titus, and each of them acting
individually, as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Registration Statement, including <FONT
STYLE="white-space:nowrap">post-effective</FONT> amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&nbsp;462(b) increasing the number of securities for which registration is sought, and to file the
same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys&nbsp;-in&nbsp;-fact and agents, with full power of each to act alone, full power and authority to
do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact
and agents, or his or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:9pt; margin-bottom:0pt; font-size:9.5pt; font-family:ARIAL">Pursuant to the requirements of the Securities Act,
this Registration Statement has been signed by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="41%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="38%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:49.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>SIGNATURE</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:23.50pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>TITLE</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:22.00pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><B>DATE</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ron Bentsur</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Executive Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Executive Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Gary Titus</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chief Financial Officer</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center"><I>(Principal Financial Officer and Principal Accounting Officer)</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Arie Belldegrun, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Stuart Holden, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Chaim Hurvitz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Ran Nussbaum</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:9pt; font-family:ARIAL" ALIGN="center">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:ARIAL" ALIGN="center">Pini Orbach, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,2016</TD></TR>
</TABLE>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:9pt">


<TR>
<TD WIDTH="5%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="35%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="4"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top" COLSPAN="3"><B>Urogen Pharma, Inc.</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="3" VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="text-indent:2.00em; font-size:9pt; font-family:ARIAL">Authorized U.S. Representative</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,&nbsp;2016</TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Name:&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ron Bentsur</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">President and CEO</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="center">II-4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>EXHIBIT</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1.00px solid #000000; width:33.85pt; font-size:8pt; font-family:ARIAL"><B>NUMBER</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE="border-bottom:1.00px solid #000000; width:83.90pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>EXHIBIT DESCRIPTION</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;1.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Underwriting Agreement</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amended and Restated Articles of Association of the Registrant, adopted October 28, 2015</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;3.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of Amended and Restated Articles of Association of the Registrant, to be effective upon closing of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;4.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Specimen Share Certificate</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">&nbsp;&nbsp;5.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Opinion of Hamburger Evron &amp; Co., Israeli counsel to the Registrant, as to the validity of the ordinary shares</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Form of director and officer indemnification agreement by and between the Registrant and each of its directors and executive officers, to be effective upon closing of this offering</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">2010 Israeli Share Option Plan</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.3*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Investors&#146; Rights Agreement, dated September&nbsp;18, 2014, among the Registrant and certain of the Registrant&#146;s shareholders</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">10.4*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Asset Purchase Agreement, dated October&nbsp;1, 2015, between the Registrant and Telormedix, SA</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">21.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Subsidiary of the Registrant</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Kesselman &amp; Kesselman, a member firm of PricewaterhouseCoopers International Limited, an independent registered public accounting firm</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">23.2*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Consent of Hamburger Evron &amp; Co. (included in Exhibit 5.1)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="top" NOWRAP><FONT STYLE="font-size:10pt">24.1*</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Power of Attorney (included in signature pages of Registration Statement)</TD></TR>
</TABLE> <P STYLE="font-size:9pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="right">*</TD>
<TD WIDTH="1%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">To be provided by amendment. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g142578g06i09.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g06i09.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1O$4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $D< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @  ' )0  E':6P@
M2&%K:6T< @4 %U!O=V5R4&]I;G0@4')E<V5N=&%T:6]N #A"24T$)0
M$(<PH8'YU#==A J(]@A[''TX0DE-!#H      .4    0     0      "W!R
M:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT
M90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).
M86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '(
M;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !";'1N
M96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P     "
M+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#<'1N
M8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O;
M    0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;       16UL
M1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !21T)#
M     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M    0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M  !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q 6;5@0
M      IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P    !0
M9U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L=
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M0DE-!!D       0    >.$))30/S       )           ! #A"24TG$
M    "@ !          $X0DE- _4      $@ +V9F  $ ;&9F  8       $
M+V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $ +0
M  8       $X0DE- _@      '   /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z   .$))
M300(       0     0   D    )      #A"24T$'@      !      X0DE-
M!!H      S4    &              $=   "AP         !
M              $              H<   $=                      $
M                        $     $       !N=6QL     @    9B;W5N
M9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG          !,
M969T;&]N9P          0G1O;6QO;F<   $=     %)G:'1L;VYG   "AP
M  9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2    !W-L
M:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN96YU
M;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E96YU
M;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M  !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M $)T;VUL;VYG   !'0    !29VAT;&]N9P   H<    #=7)L5$585     $
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M7V0;_K-G!VNW#'XV?^8JQUWH]F/F--;A5<R1BVO)]-];CN=C6-:'>_\ T?\
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MNU=A_C.R#C=.^KEX$["Z1X@U,#_^BO,,N^[)?;?<[=8\$N/;CVM;_):O2O\
M&S_R+T#^U_YZ8F))-VX%-K'/:X.W-<-TC@S]!:%)W. ^DXZ@>:Y/I?4&X[A7
M>?T,^U_[OD?^#_ZA=1C7"L>ONEY$L+3(@\0HR*9X2!%NUCY()%3C^CHESQ^\
M]$#]SVM)+M[@YY' _-61CWR6[CH3+CY^*,_,#-WN.IT[(+@=74S+PY_IL$0=
M7#40/%8G7NH5TMT=[6B73YH>7U2JACG.>!IR3PN2ZCU%^;9I(J' /)/[SDX!
MCG-[C_%%>[(^L/4[7?G8S8'@/4T"]2R,6C*K-5[!8P\@B5Y1_B:_Y;ZC_P"%
M6?\ GQ>KY%[,>BR^P$LJ:7NVB3#1+M$]A<3(^JC&G?A9#ZBWZ%;SO9SNV^[W
M-X_,<L!E%S,@58X]/+O?6UK3!:S<+'7.V_G;?1^A_+_2+KG=?Z2UVQV0 Z8(
MVN,._<EK2WU/Y"SV-^K[>H,S6Y!]:W;96"'$.%@?Z6P;?\)N?L4<L8)!H;ZM
MC'S$X0G'B/J%1ZTBQOJGC-R&5YMK\J&;]KC[9!V_1'M6IUBFJGZO]0KJ:&L;
MB7  ?\6]"_;W176G)&4"UC2PPQYF2':0WW?1V?U_8EU?J&'?TKJF-58'75XE
MY<T ]JS/N^@[Z;/\]2::5IHU[D23(DDG<ZO_T^.KZ?\ 5<UL=;U?*986@O8W
M#8X-<1[FM><IF_:[^2I'IWU2C7K.7_[ L_\ >Q<RDDI] PL'&94PU=6S+&:;
M!=@LW?V-V?7<M5M'LUSLB>Q=AU3_ ."=1WKRI)3X>O\ ._\ 4VOS'Z/\UU_G
M_P#N7T?,PFOGUNJY=?,;<*O?_8W9]CO\Q<^[IWU5W.W]9S=\^_=@MW3_ "]V
M9N7,)**?S'??]/YOJS8_DC\NW^3_ )O_  'I7].^J6TSUG+B#_VA9_[V+N?\
M88P,SI?2*^HV9/3*JMWH6FBJ_P!7]&P?0HS=U/L]WZ1>0I)JYZ4=-^K/_EW?
M_P"P'_OZKO3NG=*$G#ZUDFL?2!P!Z9_S\[9_F+C4D#LNCOU^CZ,W%Q]P_P H
MV$]MN&!_\<'*&1AT./OZI:SX80/_ ,<%YXDF_8O/^$]9E=-Z'ZGZSUO(W=IP
M-/E^NH/[-^K/_EW?_P"P'_OZN923V,OJW^+)G3<+JF8_IE^1U:U]#194W'KQ
M]C=\BS?D9NU_N]NUJ]%=U'*@[NEY4=Y=BQ'_ +&+YD220_2>1G9#\>QE'3[J
MGF0+"<1P#IU+F_:S^<J=EW73(=68B037C Q^=]+.L;Z?NKV_V'_I/YNSYX22
M2_1V'E=0JG[7B/R7& STVXM<1NW'^G6;M[4W6<^YW1^H-_9N0R<:X.>78Q '
MINESMF6YZ^<DDD/_V0 X0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E
M "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!
M$@ #     0 !   !&@ %     0   &X!&P %     0   '8!*  #     0 "
M   !,0 "    '@   'X!,@ "    %    )P!.P "    "@   +"':0 $
M 0   +P   #H  ^P]   )Q  #[#T   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@
M*%=I;F1O=W,I #(P,38Z,#,Z,#,@,30Z,C$Z,C@ 1VEL($AA:VEM      .@
M 0 #     ?__  "@ @ $     0   H>@ P $     0   1T         !@$#
M  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,    !  (
M  (!  0    !   !1@("  0    !              !(     0   $@    !
M.$))30/]       (          #_X0%(34T *@    @ " $2  ,    !
M  $:  4    !    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >
M    ?@$R  (    4    G $[  (    *    L(=I  0    !    O    .@
M  /      0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD
M,C Q-CHP,SHP,R Q-#HR,3HR. !':6P@2&%K:6T      Z !  ,    !__\
M * "  0    !   "AZ #  0    !   !'0         & 0,  P    $ !@
M 1H !0    $   $V 1L !0    $   $^ 2@  P    $  @   @$ !     $
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $* EP# 1$
M A$! Q$!_\0 'P    4% 0$               4&!P@" P0)"@L!_\0 <Q
M 0($! ,$! 8)"!4(!P0+ 0(#! 4&$0 '$B$(,4$)$R)1"A1A<1DR@9&8UA46
M&B-"6%FAL3A25\'1T^'P%R0S-SE68G5V=WB3E;*SM+:WU-?Q&"4V4W*"DI8F
M)S1#1+6X*$ESID5&1U5C9H64HJ3#_\0 '0$  00# 0$               (#
M! 4!!@<("?_$ $X1  $"! 0"!P8$! 4# @0$!P$"$0 #!"$%$C%!46$&$R)Q
M@9'P!S*AL<'1%"-"X0@54O$D,U-BDD-R@A8T):*RTA=$8W.#)C63PL/B_]H
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M*/A[+3LR5<^SJX%_DX2LA$_XM C! %J&_F ?F#%7P6O9DVM\'5P*_1)R#O\
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M(R"_W?X('/$^9@?!:]F5^3JX%?HD9!?[O\$#GB?,P/@M>S*_)U<"OT2,@O\
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M3[T_XPP01YZWI8O]$3R5_N*<N?\ 7GQ'8(=1IX_01TU^C>_T%?@D_K1G=_\
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M%(XJJ_JFAH5,OI^IY=GCFK150MREN)1%M26/G-&\,<CF$VDK+Z%+8E,RB(J
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ML?K#\X_<P?F?Z2O-/W@>7_J#_BO[0/6Q^L/SC]S!^9_I*\T_>!Y?^H/^*_M
M];'ZP_./W,'YG^DKS3]X'E_Z@_XK^T?/6Q_U:O\ Q)QAYG^BOS1_]T9_+_U4
M^2OM%HS%()!:5L;?&'[F,O,_TE>:?O!^5O/ECP5_]L71&#_JU?\ B3C#S/\
M17YH_P#N@_+_ -5/D?M ];'_ %2O_$G \S_17YH_^Z#\O_53Y*^T?/7/_P"$
M?_&/W,9_,_TE>:?O&'E_Z@_XK^T5>MC]8?G'[F#\S_25YI^\#R_]0?\ %?V@
M>MC]8?G'[F#\S_25YI^\#R_]0?\ %?V@>MC]8?G'[F#\S_25YI^\#R_]0?\
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M-0GF[O>):*+JA[K^!.OAJYTV>P8,*J<[37BIF4/8UTA]P6 <<E$B2@'D20(
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M+;P ;?87WAV7ATTLU0^FDTGP(TOKMK$;JLJ*(>2XD%8LA9#C>X5N3M8BXOY
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M$:<SR;;AP:$6[&NI4I21$,D^ )%K)WOXK'D>EC\@()PQ4X1B=/(F345Q.0.
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M/+8$J%@  #PL-7[^\;[:Z1CUS&7P\0LZE:=*E [7T7-OX\\2I/\ E!];V_\
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M*!"!-2@_FDFR>>KQ/Z,=#QB9Q&E*$=9(IIZ5@A/O&23J92GL4WX\;")0</\
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M0D/#J>:2MYUT*0DH2E=] .M1^(%$$89J:J132BI2B-2S![#D=-+GY:()+7]
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M>#61[;#"]8++A<)U#6DVLJUB;*5;F/.US8;XA3L.QNEEK6?SI2!F6G,HJ4.
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M!(OML>9V\OS8@5&$8I2IES DA,TJ"2&V8WML#<@<8>S3U)/XI-D.4 [G]6@
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M82 2K6T@I4D$/%*[K-KBPL;)%I$B0E4U/7]F7V@HDV'9+6!!#EM>4-*)+Z
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MY8G ],L,RS)!7,I+&4A5!3+ 2-C/6B8I0?\ 426B=)Q&@GJ%!586GKI78F5
MJ\I62Y?JD2TY2 1;,19^4)R/1$NH7!PT,TZIXJWUI23O<V 3>YVY==MNFX8-
MT@QVL 1489(F$,',^BIG;=A)0VIX[[1M%)28'2 3%5:J<F^04U34,X  S))!
MX:<.0AW*'E+D/+0[&"*:,,@*$*E!.LCJG87V&PYB_.]B.UX'-P0(E]=B5/)F
ME">LE]05%$QNVC.E0"LJK @,<KZ0QB&$4.4S9">M4OMI)JE(4H*[0.14WL9K
M$I(#:%F:'8TQLP[EE<1I2!X@H$>]-SL+GEN-KVY[6V)4N"U#J1C4M@'RIE3
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M(WYV&W/$972+#IW_ +FFG(_[A/[B>S(2VMM]8FSZ6CJEYD30ER[IS)!W_K2
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M=C&KOC2X<H+.3*N*F$O@VXBN:9$5,Y0\@DOQ"$0VMU@I2DZR4 -I!!%TI.Y
MQE)(6Y(YNY?1SQ;2WG%%C%.5YUE+V2Q;<!B;'EW@=T<S$TEL9*IA%2Z.AWH>
M,@WC#1#+R%H<0^V+.(4E8"@H*2O8@$ &XV.)R2X?BY^/*-+6DI400S6\F%N/
MA!K2:D_;%29N+"?2X$WY%<S5I_\ %8V\[8S&./\ VI__ ,8]FC@(_4>Y _V
MRO\ SN+P0F)0Q@+<.XLD[D;<[7-C;<<[GR_/?&&>JD+_ $I"WL+ I3Y0B:<M
M*Q.JP;ZWF$G7QOP#1SV\0LSALV..^42IM0<10L1#T\E"5:K.NS81)40+V4 !
MJ4=P!SL ,>$/;3B@K/;-@>& E0-;AE(4:I"TU3DY2D#2<_S5P]=]":8X9[.Y
ME0H"6I>'U2\V4)4>LIU)1<$D7 (W<.UHBEVK52+;JJ5TZA05"-0L'!I0D@J#
MJP4@6239.^JX%C<G;<XK>E*QB_2O#,,E'-/H<LM:$O=1)EETD)UN/>.UP\;I
MT6G&BZ*S:WW#,3.F&:+$_J]X DAFL;7L-C9X*<O6ULP#BD*)1!*04$$7*X=:
M]]K_ +=ASWV]Z82CJ< P*F8)73T:4*8!TDH0"-/]IW.I[H\8].,03B72E4U!
MS@+J HZWRJU.0$Z:DW+>/2ED=3;4!(8$I:*2F$:&KE:R=[G8<R 0;;XG10_W
M\XD<RWW:+7!]H-P1;;R]N""+I(&Y( ]NV""/N"$J&8-I O@A/5\_A^\4E(5S
MO\Y'Z",$9#(U.O+^\?.[1[?_ !*_=P1G,GC\#]H^@H&P(]VJY_.;X(5ZT;YP
M-2?UR?G&""*KWW&XP00,$$-/F'*&(^5Q:;$&W+GSV4.O,7!V Z';DU4$]4)3
ML9BBS%OT\=6OQ&AAN?VJ=,P_]-9 )_I-MW:[7VCGTR#A8C*;C2K21)>M#SF?
M-QR$J24'2_":;I!MX5:%$Z;I\)O<@X\">TJGF8/[<Z$J!DIGHD 93D!5/II(
MN$YMU#74DNP=O9*JA&,^RRDE ]:F11A9&8J"2B>M98$!B!=][VUAJNTNI9BF
M,^*:JUM82ZS'0\]6+V%D3EV(('GLD[ F^JW4W@U<Q>&>U.2@]CK:J25$'*H$
M3BD%TDW+W+G0<(M.B:_QGLXFI':2FGGIRJ+H/Y"2V4AAM9AWF-F'!A7:IM*)
M4ZI0"7(:!"@".H1O;5N3[/SX^@TQ0G2,)FH]TRY14H;_ )"==#<L;QXOQ!.3
M$Z]( #3I@ 9@#UAX$]S!F'E'*;Z5F\'^T&R.<'7@FRY_UY\1UOS6Q(AN7IX_
M01QO-\E^X?IP0HZCO^ABVD%1"4BZE$  =238#Y3@C,;!N!7)$5W7S58SV ,5
M3],1#SC>MMP"*BU-A;:U'26UAL.-N641IVVU85+7+2L9U,/$A]+MZY0VLA([
M_MHW=P&H#QO6E[;S"T-LLE#+"N[8'(!E*%)2FW0  &Q ]E]L6@71SI9EB>A)
M4WZ5_IN_N[Y>/$0R%I)RYK]Q9]WM:P/E#@02%.H2M6DBP&VQU?*/9Y_M8950
MJ4W4+ZS=DD@/IJ6Y;PJ'"E<(Z(4J"5$;^1MXO._3ES'.UO-RGI<6HR9DNE7-
M"D%)&:7V0X)5VI@X)-G/#B(E85!"2!JMK<"DDV=V$** #0;(4;7L!YWN?*Y/
ME\O/SBU.)U\E^OILC78]43ST5?C\8;DH1,_S"SZZ\.0_OJT&\6TPN#N(>[J=
MD:1N0K<_.?=:Y^2GF8K*JG3,EI)2XNA&IUV/CS$/SI=+3(2I:TA.C@*L7[C#
M;S!CNT++C3P?-P$IV2E/ZTB_,7/R6]V-9Q3"\+J@5SYR:=)#N$*(XYCE0?/C
MK%G24%=4TJJNBD+FTZ0HF:E2  $IS$LI25&S&P</;1H0D8PMYI:&M)"25. I
ML0GJ+J &K?>WF.=CC6__ $3A]7)554%=U\L**"4F:D=8D J2RDI]TF[,YWM9
MZAQ>9^&FK0GK),F;,3-F-[DQ!"5)O<L2'8:D,3"0=@7HE]H2Z$4M))24)^,I
M:20J]CL%*OI)L-P!N;8<P#H9TEQ3$4X9T=PN=BU:L_E2)<ZG0I0=O>J9LI&V
MZ];@VB/C/3W">C&%KQO':F5AV$H)"ZR:B;,0"%-E*)$J=.+EV:685TNRLJ2*
M=+DQ4F40Q*2@)+<2ZVD\^]:2M0)!WL%&P//?'IWH/_#)T_QA-/7=(L?PW"::
M<G/_ .G9])/F5U$$J4E5.NJIJB?1K6L#.E4OL@+3O:/-OM)_C,Z+]'4SL.P7
MH1B5=-D$RCTIE56')H:O,E*A4RZ6?*E5R4)S=64S&62@[$$.-+,LJ+E[:')G
M'*F<8E7A*$NPFZ.94$H(2HFQ(N +63<7./1M%_#CT*HZ:2F?AM1,J$) GU!G
MRC+F+=RJ7+,DJ2EM'*C>][1Y8F?Q>=)L1K*GJ^D-'U<Q;TM'(I*R3.DI )*9
MJ\XEJ4E5G!#Z#=EPS)J00@-M!S0 -0#SI -OB@=UR]Y  Z^<NGZ"^RN4LTWX
M6B$Z2>I4%TDHJSRSU:LROP3%0(OQ-WBGG^TOVGS5*JZ/&\8J!/49X3+Q.L0E
M(FDS @!=<D) "F  %@ !J(N"$D+SB@TLI*AI;4XXL@J(TIV* >9'7?WXV(>S
M+H(N3FE8?1+2H$=FED)+$-V5&F#*(N#=C$S#O;C[8J52I0GXM)*0K+43\1F3
M9,M0]V9-EC$"I<I) ,Q(NM((W!BXJBVUPZW51;+SO1I*%I5RL#K42W8>V^W6
MPOC1,8]B6#U07_*,1G8,H E*%39Y"VOE'X9,MGL+V#/P$=9Z+?Q>>U;HG*2K
MI!T<POV@2RM*5_RG#\/P^8$$@%05BU5,]P=HG<9@'=H:VHY-.H'O$HATLH*;
M^)"'%:=6W\S6NY-K['8''%^D/LTZ<=%951BLO!IW2##:(&9-JNOHRC(X1FR5
ME3UI#J_TR0=M8]']%_XJ/9/TWG4E-TAQI70/I'5K1*I^C54*^?\ B9RW'5/A
M-!-P_4$CK)R1;4$/#;+=C@E7K$2JVLI3W86+Z2"4Z1<C>R3<#GY G'+*KI11
M)7U6+8%+H5&QS2Z16I8_Y*9FG&^D>D:6?@9D29TO$T+3.3FEJ"*@!08$$/+<
M.X-P+W:"XN.O.NZ6W4J;20LNDE!',G?<W/E[SY81/H^C.+TC2ERZ-16A?7I0
MI-P[I>5)"[N+:;$&QA^G7,ZV944:C/E(!2HATB]]%E-P. /A">7%DN+9[E*T
MINHJN+'<@[7!V!^;W;5DS"J6@;\/5==IE'YG::X':2-6+ D6B2BL5/)2HW2;
M@<;<^_=X)(F(A^_+B'.[0!]\%UD(MR&Z3>^_Q;[854R>D"),N9(PN9,E*S95
MB9( +:V,T'3B!INT+3/HPM:)DY*5I [)2HL[_P"V]Q;T8J5%A04&PEQ)3=*D
M ?%2!O<\N8.X!//?&O*JZ^FF9JVC5*;7,9:FNSG*M7P>W"'PJC5=,T'_ ,5,
M>=TM\!YP3/1S*6UJ5K[TDZ$@FY&P!Y>=]_GVM@F8SALZ=+"ZA$M24!)243+W
M).B.;'^\"LR0\D!:=RDL ;V;71N_O@J@ J(>[YUM26PNRPX-E)(\7GX3?\WN
M&+9(I*E'^&F)F%@P (+\>TD7MW[Q#F+6HLO1N3<]R>^-7G'ADM!21^ S2IZ"
M83 S")9ET\AT)(O$:8GNXI'+0-.C6>9601<DC$J0DR$"3,[*P5=DZW)+DAQ<
M$'EO>-0Q>GF?BIL[(3*(E@*!2 60D*#.]E"Y('*^NL!TE2M5@+A'Q;Z=D)&U
MP-]M_;?$B*D$: \;,V_TCJP]$M_5UUS_ &JW_P#2VE\$-K]X^'R$>E6.0]P_
M1@A,<6_I@OCR0X<M._\ S_4W^6I3SP0)NNVV5_,_>. R32N*G$TE\MA$%Q^-
MBX>&0$Z;@NOMM:MR!9)6#[>E\-KF(0E16ID@$DWL/ 'RUY0])DS)DV5+0G,N
M9,0A*7 S*6H)2') #D@7('.-VF767L-0M&2J10:4F(4ER,C"$V4XY%+2\"38
M#<;@7VL!L3C7JV:)I.1>9SL"+/S'GYF.G81AYIT 3I75D/KE)N23H[$\G86U
M$+4M$)"!X2;)'OO[-O,?-;$242EPIP[ZGN9[]_=NT6*DJ3/2ICU27S*?8I(Y
M6=G#:[PLH=89ER(>UU*01[B1:_YO^.'\PX^AZ\=HFRE!FWX[:=P']XLRIM^
M>N23<E5CU\0('S6V_P". $'0OY_9M_VB2H@I#$F^FFW/1N_Q)A?0KJWW68G=
M+=R%G?;8=-S\W7&8;+W\F\_GZX0ZDM?"X1*!;38V(_"O;;^ CE[L/R2!F<_T
M\^/"(]2_9MJE3&W)K^/AYLYE%PR9C$MPA22-03?RW!L/D/3;IB2GM>[?X?.(
MG6I2 Y8Z.7+-=Q8Z\1H^L2"DE)P<!%=^YX2VC6V=@"OJ+]".7R@WP\ $@ GM
M$GN 8<M_0A/7I*G"GN _:/D-_+B&UA,3Z,@4S?N8EM+K?=DD*%R3>X_-86'3
M:V%*,MR'MN[^3MY/H><7%,LE-MMOGY-N&TX0\TBB752*']7"(2&=4@):3LO2
M-K&V]S;5UV]UL,DC-9CWLUN'DWRVBR0I!8$[7W.G=HVYV[S!/6-61$O@7I0A
MAXHB6^[;B0FZ$M*%G%:@;@)MN#8[C;&/3^OMW'2+20E"@"DO\N/C]]=80DK=
MADRU4,ML/)2CO&G1914 GF+&X^47]F,Y#Z;Y'Y&($Z7.2I14D@%18N&U[R0_
MAN#PC*1"-QK004ZD,D%NU]P#S&WD+6-KX,JN'=I\OF_=$14X)=U=J^KD<AHV
ML.;"TTR&)>L->**0CNT6W2%[:[_@Z;@[F_+?"5W=@S/SXFSZ7X!_HVFIFI/N
MG=G8N?MW</&#"%D[$M+[B4W6;BY%_%>VPYG?\_/$1<M=R$['<>>N_P"Y8PN?
M63%R9B=R&8$AV-]P'L_=X,Z-(2#UO^68C2T&QJTGPE8Z)%_#=5[#YL1E!0U&
MCMXG47?5VY#G$.29I<,Q-[D7=N8N26'APB1LKE[TG[F72ZZ'(]@.,BQ/=J6!
MK.P%CO<=/+?#84"<HN=;;CZ^!;D\6!0R"9CH3QS7?0:%S\FAYZ3IQZ =;]?0
MGOBWWC[Y38NJ*D&Q-KD6N;<C8^["LIX16U"@D=@YB-B7]?MY+R:Z>[*0K1#I
MV2"+7).X'7RMMOR%[8>D@A2N&GQB B8LE76#*!HP%_)]FWU<PUM0S7U5A3*"
M !SMU'0V&_(G<#;GSVQ-EE(]X\V.WWXM^\(FJ*KIT8>=QR#.._<<HXUH^AX.
M+"@2L:NO+4;\_+VXD9TJ8@N'X'@>40)B5%K.P)/=$0LPT%V%B0A=B5W O:XM
M:_,=01Y[<L+!!=CM]1_?^\"4JL,NQ^!?NL+_ %AD_5VTMMNO!2@C4E25_%<0
MMM3:A;R )Y]<)SH2H9B-O*$5B9:Z8R[&: KLM=CI?1KWOIPCG1[1;)1B@LVC
M5DIAT-R"M8<1 2V%);1-4)6'5:K )4I1&H<E%1W//$Y"T$ )+VY^.W/TQCG%
M9)F2EJ*T*%[7!MW/W=_D^OVGK"J:? "0/MDD) 3\6WV1=^+[-Q;V8<B,G0]R
MODF/9KX"OU'V07]@4L_SR+P0B)*SI\LP"N@-SN>=KG\POY>RV&Z(YZ?.HL1G
M-[_K6-K[;?:&*JRI*=E3$#C;,D?%SM\[\YF70:B^T$S5C7BIPMUVYW8/(%"G
M2";;^&PV\QUY8^?G2T2ZW^(C!Y2U@_\ QT&6""2N:F92I">U8,3^IA'N:=2I
MD^S*C$L=J9AU*" 6/:DS2=6'N@GZ/I"GM')AZ_GR(5XJ6T)G+FT"Q(&EA-K\
MTC>VVPW'R3NAE/\ C?;EBTF>!U<G%ZF0E"F(_*GSF %_Z1L_G%O*332?9E.0
M%@5,J@F*6@!04@=6G,2K+E=+@V47ON[;!>""GX5^'AG2WX?5N:0HGPPCJ"0+
M$[+(!MMO<;7./>8_**DV2B6F6!;LAP S#Z<=6CP31KEXQ58DJC4*F;(FI*\K
MI*2J9,2;S<NH!!8Z#G&^R@X-N!D<,VB]A#H! !N"H @6 OT\OX7$J"@X+Z7O
M]8=FR)LA66:@H5HQ8Z=Q(A8B*T^ +3ORNM(.VY 2?$+;D[; 7Y86$DZ GPA@
MJ2-2WIXP(^=R^7M*<CYC!PB$ *4J(BF4)M[;J&&ES9<NRU!)Y\HD2J>?/;J9
M2UOHPMQU+#QAN9KGIE3)2XW'5M3;#K1"7$&=2XN"X*A][];0H"P)-^5MP,-*
MK*9/O3DCFRCKW \8G#!L2[)-), 6<J74@.KA[Q.QU AMX_C&R*@RXD5?"Q:F
M2I*Q /P$3<IY_$F%_E.WMQ$7C&&RG,RK2 -71,MN]I?TB\D= ^E=3+$V1A$Z
M9+9RH3J4,#<$A4Y+6U)^D-[$]H'P_M+4@SB.NESNOYE#6*CT_P#;Q;WFP.(Y
MZ18.?=KI=BQ[$YWX7E=_%VB13>SWI54=:4X1/5U12%#KJ4,5.S_XBY+'3A"G
ME7&UD--185$J"(0IPF-7!L#0A(4M7CCP-(OYW)V%SMAY&,T"[IJ4%]LDQO Y
M \-S>@G22G)ZS#)H%K&;2FU^$X_O\(6TGXHLE9\H"!KJ2J65EI+;DSE222 "
M"1ZXM=CJ%B>>^VV)$O$:-9RB>DJU8)6[<2,L5U3T4QVG29JL/FB2G689D@I!
MU(M,>SC:';DV8%(3MI)E=02:/42040L?"O+!))%T-.K.XZ]=SA]%5(F+ZM$P
M*7_2RG^($5"J"L2'-.L"]^R18L;A1A4?9*' )[QL )"B;V "N6_+?RO?V8D
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M=BWKX<_B-ZR;,WNS;GALWQ\=7M"7JMY9:L7%-*;18-@E)L!L5"]KGJ1>_,X
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M4"< <H!!  AZ*%KV55)"O4Y5#+;D1$(4VW$Q#6SS@0$-A"W#H%E*U%0/+4H
M\A[/Z)^T[HOTN11X+55E#.J9DDRS)JYU(15+ L,BJI174*9I2)<MUJL!'S&]
ML_L'QWV35V*XKT'GX^G-/G+H:ZGDST3,,"@.I2JKI*3/+PXJ(%5-GS%B5*=3
ME@(1M=4-]K"UQ</#J?DSRR"^I&MN$4LE24:TI2CN+ [\[BX\(VXG[6?9%5X$
MJIZ8]%ZN=-H %SL3HBR9](ZU%Z>GI:=0,@C(\R=-3VBUK/W[^%[V_=)>DDA/
MLZ]HN)2*'I#(3,5A-;^-6K#L9HDIHI<NGD5N)3I:ZK'E3YU2LX=32)A-'33*
M@%T3$AHT*AEK4&'FVMB0"4H!2=DE!4=[]/(?F\[KP[I)3Y:R>$5L^K)4JG6N
MHF(D20RY) $D+3,F(5^:E5@H,#:/9TZN*4I"%S)E.A2DRU3@$3S,%II4A)82
MRH#JE/VQ>*8.5F(="S&*<\1(0AUJUM[V Y_G%_?B1)GU$K_W>#4*MF7+G$O;
M5PGCO<<M8A&IDJLJ:M+\,OU(=M!WWA4" CH= +)<" 1X564#[=M1O:W+:V^V
M'9E3A<Y8,S"J&0K*4]B7E)N2_;4"]R"6VXZM%$J80J55S\NA8H9PY:V8"Q^
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M?"XHE:^ ^0CTJ!R'N'Z,$8CB_P#3 &%+R7X<6DC6')]43:1O<J5&4PTH;>2
M%;;WN#MC%DI[GU\_#>,I1GF#7PTN?W^0CF3X:J;AJ0R\D5H5MF+F,*F)><0D
M!;J5..O-J<5:YT]]U\@-[[T-;4%14,H%B!KM;1S_ &\&Z9T?I$2Z<S">T$!0
M"@-;FW'AW;C6'[F,6AXE12%+4G2FX//\UN7._7WXJLYX#S^NFOUB^ZP\OC]X
M(X2&NXI\MIU))TJMR)&G:^P_1R]F,A3EF]?7PA.8D$$ =VNQ^SBX9MH6$G,
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MC>PMU OR]WRY>WRY'CQNW&+.75K 8)3;>_!N/TA1FG9? OMLI@VW2[OX&TW
MN=CM\:VQY[^TX?\ 7GOXPQF)*U$ZJ42QTN3LQ^9W@VAI&RU$1#F@M(N"@)Z6
MW\(\Q8=/EWP:^OG^\ 6U[$[YGV8_;[P8/01=+/=A2E H24_@DDC?:URGV>W#
M2TY?EZL/30H3";]G@#KX:[EH4TGI]Y46R$I_"2I2EG9/OZ_G-O;B)/4\N8G1
MTL3ZM\QP,"5N0 Q)M8.+]UA?SM$Q*41#R63-,0C32XV-0$%6C4A(&[I%NN@*
M N>=COBOE2PX.8GP')N#Z?V>%3$A3 N&/FXOQN_=N8<*,B(H2V#AD!2$VNO0
M2D.?]H<N9Q8H&6X#L&/WYZ1#FR$H!6)BB;#*6UW]6,8T,5PKS9!TIT=XH<B/
M$BY&_D>OOP*FJ1HE)XN+#8<MO@T0U("]R&M9O6^GHI*J7&(V(UN.%MO>ZR0-
M1(Y>6W6P\L1S4J4SI%N9A*9(220I5[7;1[[;\^3O#'U3&(E[+J&6A9)U*4";
MK0+[JL>?E;;<^[&.N5IEX<=?V=H5EX<7\&MVF.EVY1&^>5%!KB0]W3B65/:5
MFQMO87-]A;8W.VPYWPE4PJX /Q)YOL>_OTU$.)E)()*B&X90VVG,\-!"+GS[
M,S=;9@UHT%6RAS4.7B\_;MM[,)SG7;37OU;T=AP86A L[MN3]FUUO"7BJ:89
M9+SS39L5$[#G>Y.]S<[^SF?*SDN2F8<Q4H$_I<-8:N03H'TN8K)Q4)RE!3!D
MMP8#7R>&@J>3PCQ?7ZNUW+C9:+:K%"VS\8*!YA5M[]-S;8XG2I"0&SJ?<EMK
M@V'IHJZI9FEE$^;V#6OHW/7RCEZXJ,MX/+;BEBI9 0;<-+)I/I=.)7#MI"&F
MT1LX4\5)2D!(TDJ2 !9(VM;G92E'(P#Y  Y-V&A/K:-3JY0ES%LHD$J)O?F]
MN'@[QZV_ 7MP>Y!?V RL_P#^W%G$@:"( +_'X%HD?/F"N7.INI7-1W&]B3:]
MNMK;6(OAG/\ _$:8OE S$<"2P' ZBPU.\8,I$RD5*FJ*$ @E0L0 O-=[<G-F
M/<(YON-AQ&5'%I1M3(2(* JZ#B"7D%* N9P4S8= ?4--UK[T-"_C(MIWQX;_
M (H^CU;2=*:3I+ADI4VJ144=:$K0OJBJGG/,E!<I (S) ([14<NEH]>>Q/%:
M;$NC53A"YJ7E4E3(DE*D*6I:I12ATE:M2K9-@+"(Y\86=<@SXB(/+:@H)J.J
M.50D+$U;/FV._;E4.MMLAA3J?&J(4AQI24(6%74NPVQHV'T%1TH508I6R5T<
MRD&9*:<+$N:X(2J9UH*E!+N&+9G<L+=Q]G_1>HH:JIDJ>IDU2@%)GH.1"206
M " 'N7)8:6L22/*Z@:GDN7L%!TO'QDUCI:\A,=%SN+=6T(1;H"X>&@G-#J4H
M4KPZKA.F_08[[+QC$\0P>GH@DG\ E"4E,Q85, *$NM!5F#)3FM9SP+1N:NA'
M0G!,4,V=A.&HJJW.H50HI?7H6TQ2_P T);\P'(IV.47U++VHYUE?E=)IGFQ7
M%5Q]+P$8C[$RJ%ATQ+#J9JP5-NNL)88<<+:@CO XAIT[W-P</4<C.GKJC.+=
MA)*@01J=&=_+2(]=B7\K:@H,+PZ:D*S3IBY*5"8@DE,LA!OJRM"P<7>(&9@<
M<U 4U1LSE64TL<KRLYU&OQS]5SL/QJH!X$'ORB9RZ'N4,(*6@'04*(*;J(&$
MK%+)=I$E4Q2B\R8'7=PP5<C6Y&NO=92)N*8EU=1E71RI:$H134PF2Y(<OH4W
ML0E(+ =P$,5D_P ;.;DBJIJ/K!;<ZD#BVUQL.TVVP(9IX@1"K)0XHI2WJU!L
M"Q WM<8B@R0O.$H!O8 6?8C0C8C<Z<#=SL"J*FC,R9453@.$@ @,'!)ZO].H
M^#1T*989GY65Q2LHJZGHV7)HV8R$=]&LJ[]Z#FB4([R'=0IM*VW$K+@(44MW
M"0 24DSIE12F4E(0B4C*P(]Y*V+@M8#5LHU +1Q?%J'')51,E*FSZB>JH(D9
MBN7+6@J#:_T)+*.Y'.':ES$V51TMG,DD_P!L<MBG7&&EM(#42$DIT.^,%:DZ
M5I5=/+23?<88E)F$)""I3O;7@00UR^]A<#:T:?4U*::O505<WJL0L0#,/X8I
M8J.=:B%)[(4XREU,-W@BBJ)K23QT3.:N;0[1KL"I34.IQMR*ET2;%!82OQW"
M4N!5AS">5K8FRT+E3DR*U;IFI*D!:AV4@78JX C01:4^.TE95T6'84A/XY29
MGXF8A!Z@S4*'5I,P*<IF)+.I.I.4M>$,,G)9F)34=6M%U@ZN"9,5"?85P GU
M@) .G4Z$A6M=@"@DV5O<VQ#J,%D5&:9*J9Q0,P[(2M(?B"!?QL+V#1M$GIOB
MO1K'96"XSA%#U"LJOQDKK53<H7;M@]4S YV!+->&-J[*NH<NLOXV:S^%;1.V
M4Q$7"=ZQITP@;\+RB3M<:[$6LI/46!U*KPR?13,TN;,7V$W<?U'7JP0XW[P&
M<1TW!>F&'])ND<FDH)R3AI$N5,5+5I49B9B&=0.4901S-W(C4E6_%+%2Z(AX
M>AIA%Q%12J8K$2M$8M#8<0?$E'WI8"47T%(4=TWVY8KI5!4S9\F<9]7)"5%8
M4"#F>P8$ LX+$G1F?4]JQO#*6GH524IIZE,X!.7(C,E(2"RBDJS%9)-P&%M2
MX+)%QR9Q0L>P:GIR5U++(:,0^[#QL/"&)<2AV[O\M.)2M:](*038V &UM^@2
M)U+^'DRI\F1-FH2,TV:$F8L_U*).JOMPMQ\]"L7345%528GBLF3.=4NEE$HD
M2D,P1+2F460+V[7G$TJ5XT<DZVJ^EGYM.9A1D%'Q,+ 1=',M3"(EK<QBFDM@
M/,0TI<A7F5/*)+A<<;*A=#I1N7C+I)LP*"A)0X/5R\H0%,'8; D.6ORNT:[B
M6$=(**29*:4UJPDI%14HJ%3E!R4YE"4 2D6#MII8Q,21RVH9,S5T5#2Q4RDT
MTF"33\ZDTU,#ZG+9C#OJ8>:=;4@M*:;"5EM32=#NE!3MC-!,GTLN932)M3/E
MIG+4A4Q1[*9A42&26"0UF(XEHT+&\/Z$],::CIJ"GDR\3II:I>(2YE)2H"JZ
M60)H"Y<R8H]MP0M 7Q N0Q5)9<YJ<+T[J/-O)J<OYRT4B(B%SZ'F.EZ:TX^[
M"PK"M<SF$:Z(AY"5E8++1<2; #PV.GXM@5'+QV;TJ($^ME4513AT!4DF;3F6
M@J64]9UDOLF60H$6%P!#6+JP^?AF'=%,<H%X4TZ2*88=)0JHG!,UTJ,N<L)Z
MI2BZRE%@Y%](3UGG2YQ!YD048^X\_%O3]3TSA78E<1$2Y]F.,0ZPZ/5T!/=*
M6H(UV^(;\L:U[+^C^(HZ<X?TAJ9<VOJ*6KD5DN74A<V3,2DE4M!4$E75D]H
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M^88@B9)&2QFI2H7<A3DO:^T2TXHDIF)Q!*!+"3U94F_6@@!@SOE*KCPU@_\
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M:U(B:SG@4@)U!2%S&F2M-B.6UN6PZ8CU*\DNVI=C>UBW[:>,6.%21/FI!O=
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MA4N:ELA1F2IB65=[=DGPB0A-02%"<M-MBR1RN>%@>/BZJ@/$X%-AU0 (4+!
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M]U0RJ+@[;[<(9>9U"\Z@->M(U7N0J^K?SOMRW'LY@;XC3L3Q'#K3,(FS&W=
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MA%D2U*6;I*0DI+/F(S/=XYC)3&SW,FN)O4511[LUFT9'OMQ<0XD6O"J6AME
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MT+2M!4QN3E7<N1P-GL2 0 P$<&Q*7744JKZ24,V758FM354D$YY"IJD+F)S
MI4<F5O\ .5V205*/:B$=(SV<YWYW3FJRTI<GAXAF44JTNVEF2RUU,.PL;D)#
MK:$JML%*45!*;V'=>B>&%-'^)('Y8!U!U#.'2^AX^.T>(/:ITAEU6*]52K4N
M=6J7_,4E*FDJS%8"76&!6[YNMN>;QIH](2I]R1<7F24$XBRU<(M 1"@;*L7L
MVL\;@%*0+72;<_?C;8Y6@.- ;ZG7Y1J X4Y\Q3M:Y$Q;<0A+\34,_@XM#ILA
MMEV+0AM=[6NLJLG^J&)$C*%)+,2[ECM87XV;RM$6J2I25ZV&@/>UOGWQTJTU
M-T/--@*;!";D#8WML?*_NQ:K*3+64^^$$I5;LJ +=S$:^/"-5G2BI;-=19^9
M9N+:>.^K0YDOGJU!(92I32OO=P=@H;W&VW+GY[>6((G58_ZJCL.TWT?2$&BF
MA[D/PNYO_MN_P\;K:"C&@XTXM9;<5L2%'>X//Y^9]NXW.'I%97)F _B)@ 3,
M:X!]Q0X>>NM]7@32F6<TYERP0%I4;*!9(# "UV[X5(6A2$N(62L%-COU4-1V
M]]NI/NPFFJ:A,M.6<H%<B8M1!%UI/943HX#-P[XLS^$(;JT9*)8ETB6M(0K\
MPIEW# K<WW+CC"-B0A$R>;+:5(<0_$I21L8H*0 [O^&E*-(5SMMTW]P4ZUTG
ML0DXA)49<Z1T1IIZYJ;+!5ADNHF*'%2IZU32Y *U$[Q\TL27A]1_$X,/KI$N
MHEU/3B9B5/*6'2,7EX[,I)=9[P:<FCD2Y"5L2):$@!X:.MF751BUJ&C4H[GS
M(!-B#Y=>5MC[?$=7*H*S$Z2>FFEF;/5.5.64D*FJZM2G478Z$6;B8^J-'55(
MJ9KSEMU-.&=G"4LUF]T!G+VTUAMG0E"EW2WX--MM@%;VM<<P+\NF-/2FK04%
M$U:!,?K&/O,2 X*2[!QWZ$QN]36+HJN?24R<E-*5+ZJ2CW)07+3,4P>P6M2E
MDOJ3!3&1,#W;A(^^>"P0";DJZ^VW[7MQ.7^)$MQ-6"P+A3%]B=O+0\&>)U-7
MS%75+.MRQO?_ +FXOMX0G(MEQPJ40XAH&R;CP@ #I:_/W_GQ'EXG74TLR5S5
MK!4I7:)N#9GMPVW\8LDU%!,(-72RUSV8*6DE60/DOFT<GG?6\)B:-K4!W 4X
MH I*@!= VVZ7L!RVZ[<\5=37TTPGKZ1,T_[DD_'K.?JT3Y(IE?Y$M*!_M'$]
M[<'<\QM!:Q )0E*EJU+M=25'D22;6M8?MVQ'E89@]0T\4LA"YER"FXV#]HFP
M&_W$./6!1")RTH#9 "6 ;8%)\M](QXU;B$E)AV5(((L@**RD6 UZ1\;EJWY^
MRYQ=2<)I /RU)E@$>[IIS3O9BT3$)JRSS5^8%M0]AJY&NUN,83)@'W4CO$%2
M2/ V?$@[7'B (T\M^6(AINE=(I4R2F8N4%*,IEDO+=T?I%LK6VY$1,%?+ "5
M2 HI9))!N0&/ZQJQ[W,51*R 2A2DLW!L@I(/*W($<[[CEY],-GI#TCE'JY^%
MJF(+(6I25J(2076Y6-$G<%P-XPJMDS 4?AT]L%+Y="1E>RV&NK:]\?#&NNI*
M4EQ2;<TI!">EQL=QL1OS^3"DXI0O^=12U@$@YY9+Z_\ ZC\?5H@)P9"=%@,[
M7'+EW[E]M(Q%*1#NAQU]UWO-EIL-6FW(62+ ;>7RX<54X!6H-++PVGDSIPRH
MGB60J6JQS!1F+NP(<@Z^,"\.5*09B)ISI#I((!?3^FQ/AK"2J-B#>0A]6EHC
MD%@!2[D#E????D;6Y[6PQ+P(#_(JP@V RJ 9[N_5EK=V]XGTB:P(M.F/;]5K
M;.Q^Y>Q<PFV&!;^9N(LKPJT@-D&VU_T6\MK[W=5@N+Y'I\8GRVNZ9J06OF >
M27%@X<=[0+ZU"RJI6I<IB&-QFT=[7;GOI"FA Y#)*U+T@)L57 T@>VW0W]QV
M.,4\S%*"8D5-;/J4@BRU!3O=RP1LUVTA*S1K#+DH4DZA0Y<,S_L'A5R*<Q$.
MXIU$R*V$!-TJ<^/N1IL +V]G_'8)F-2UR)<Q%*)=13=I$X)(6"OL$I)6>T4D
M@V!N.$5%92T,U4BDDT\I-/6*6BNE)20BI1*2)LI,YR<PES$YTC5[B'+HFKXF
M)K2G85U"DLQ,S9A20"6E%ZX\DDW W Y]<=+]C=7*I?:1@LNBI_PS2JR2A4L%
M/5RYTE76)!*B E3NI^>^GGO^*7!Z.J]CN-_C**34R^OHYTQ$Q.83%R*E)EDB
MQ)0W9T9P(5'$NMX3:F7(=8;;9;F4$K3X=09=:6E/,$@>L$HVL"3YDXZW_$+A
M$NHJ,.K' G?R.6#,MF<U=<7?*7TY.>6OG7^ S&IE9B'M P2JS?RO#%8U-HJ"
M8_4R)U/(Z-HD3T2W)2N7+GKE@NV4LVYBZ_ /&R;)*256MS2.]<MN"![+?)CQ
M_1X>2J89E020593F!N_-'IO&/HNBIR2*4REE.:JF(.7=(E^XSBP(<=^SM&8U
M)81#94^A*W%I *A;7L!I'7D!S\@,3$RZE(R)G+*4D@%V>_).VG"->GXM.$U:
M%E4PA1#D.3L+Y@-+ ;<[1<AH1,'H#?>):N#I(\7,[J%M7.]C[.8&#JJFX,Q7
M_*QMMV?MYQ#5B"5W5)S7W3KW=KN=_ ;1L"[ B>&<]K'FI#H#>B5900T$O1\:
MS$XH[O"?:IUM)5_5(%[!.)B 4I2%:A*4EK[-<\M2;"\:3B,Y:ZB>ZCEZZ8$I
M_I25J(3OH&&ITCOOV(]A&%Q5+)#-ZTCEX])<BD0V6&1+:[??I_4 3>^P2J3#
M2.8 N?S\L5V(I2968AS>^^W*+_ U*2OLEG4DEF'#E]HY!Y5=+BEI'QR$CR)4
M2$CV_P >F-=8!_&W@'NSQT"42I(*KLY[CQ]<(<6"B6>Y0@E+:P!J N"=C[+^
MT'WX;XL]SY\/'C^T.1F)T:PZ7"$IOR_JA;D![;[>=S;E@!;2QX^!?S?3PO"D
MAR.'[&%1+YFP6C#I5=9.WNV]GYOVSC.93:\FWMO^_P!H<RCAR]>GARI1-(25
MR=S6M!=<.^HG8* 5?E;90M;;VXR5*:Y=PS<KC77N_8P-;L@/QMIOL7_8Q5"J
MF4YC(<0BG'6U7&EHW"$J%A?E;5OUWWPG5O)^[[")4@%TO?XC3D^NC<8=:24>
M^VPM;K2VRA*E66+7*A=5CN2=@3\@. $C0Q9I5+(VV'#ZV@0\M9=B T5!);7J
MY;D _%-P!SOY^7MQG,H[D[Z^)M&70;!N',:[^!\8=J0PT1#,/K6WHAPA&ES2
M G22J]MB;$"YZ[>X8:4M8591'PU^D"65.3H4M<'1W=R.;OQ\8/:=GL,F9OM%
MAR+:">YUI05-J<=4+#D1=-]-["UM^6,9YC:GO?9]N-^#_&+A29*);Y$@L7MV
MM7\>=_G$\,MLO78:4,S!J6KLXM,0D: "TIP!1.W(D&^_.X^4"E%5R_?:_P _
MO\8IYE2LK4E*F0[ 68#ER'![E]#J\TUE+$++WG8EQI#KD*E#;:P K4$CF/,'
M8G;J-AB5* /FW'OYA]^%H9F9UW)U!)<\+ V^XVT,12G3\1#3A4/XM@=(]M]R
M/._/??KMA+EVV&[:"_+7@UGM>)"D@(20G] \VOZVY:PZ-#1OK"V6@Y90!)42
M=MB;[[  "_YO/&"M=P3I;7A;Q_N1$5=B+ZA0^!,2,I:H(A+JI5#NN)6^R4".
MWTI;<&@K:4!8E(5J3:^XN/;C,H;_ "/[^O)F7+<LQMPL.-N+>N,*>.C%P;SD
M(A]3H,.K6M2B?$1=2K[\S:Y!\_<,I))&:XWT8=^GQBP0@A+E+=QT;GSWXO"&
M<JD0\N=0Y$I%W%C91MX3<#8]3;:^][8="D EF![MW-[G[@0U- %RPY]Q<[?>
M&*J&:&<Q"FEG6K59IM)*C:_,>0WZ6Z'F<+SO9[.[ZZ::<W8V^<0#V'4BQ8C2
M_GS;EHVH,.-2E-P+D@>;F#6AQ2%;.-B_=D6\K7N03^?VX)L-3=@=F;3Q\]HB
M"8LS&*R0^YL_,?N'>**51$4M"1C4#+WHA*8E3J5-MGD3X;VWM<$@GYN>&)ZF
M"6)&I-_GQ%^7$Q8*E(ZM+RP2H[#4, W$WOI\0T.+#U.]&,MQ,>'X0W'>=_J3
MRY"QV( N.77RYYE+7_6;6[]=' ].(KUR)(4XE)!XW<$,.Y^+7WM#:5U4D%'+
M[B'*G5-W'WL7"P3<J.W4_/L,6$I8*23?>[Z?7O&]^4(8#1/ ![,X]<+Z&XB+
M=8S.'=9>]4"P\WJ!V4D!0O<%5K B]^FV%D(OF .Y?Q:PU?Y]UXTQ2PX2HA^?
MGL_W^$15J6I9BRZMIQH+0BY%[E)-MS[[WOO>X-SB%-EI,PD(#=DZ:V'<U]FT
M\X;<E+DW9G[K? 6?YQ&FO*SB7VXAH -A"5!=E$!6WS;BUK7]O/"3( OE'*VK
MV+=WA%=.4ZFV'+<:WWWMZ&N?."JVD][WSC:6!&R^&022 J)?C;:!MN;[GR_/
MBWI)$M*4$(2%$!S;S<VT[Q]*3$)C)5>S;^&GG^VICTY. 7?@ZR!M87H. -AR
MOZY&&_S[XN!8#P^+#E&K&ZCXZ<@;P]&:$A3-I3$$LZTB%*"2D6"%&ZPJ^UN2
ME7_-O=4DCJER@+*!MQ)U=^(/IH,ZTC-F+)WU;9SNW,VXZ1SQ9F4=*,O\S:YR
MYS!3%R7+/-68S*?P%41K:$2NGZA#KK*(%:BI;3"(MA^$<ARI(2H)1[\<.Z88
M4F5.GSTRRB2D+GS2@ _Y8)!T#C4%SH^[MZU]B7M!F8+)E5$FH>LH_P#)E+5E
M3-2HIZV5F"G2Z$G*6>VHAILQLELJ<[I9(>'RO7'DTS(I;&1TOKYMAMM^5Q</
M%3%]#0BHV#2P(=Y2^^46BZ+*) (L<:O25U'-1+ED)[,HDS,A3<%2RDN;-F?4
M@NSG2/0_2'#:O$Z"?TVIY:DXC/JY4X4R% S2\N1^:E+J5F201VE(;<"T:7LX
MLM:NX+LY5T)%S%<PH:90KT91E4/Q!7!SZ!O%H0N%=A85J%4ZT(9P.!3B+)2L
M)NHI!IL8P_K)$ZHE)<I*" $V4%+2+MS469QI>QCKWL;]I1Q&1^!Z0S9B9E/+
M6B7+J?>.0D:9SLQV9R6(-Y/Y8YI)GLNAWTQ*']"4$]VO6F_7GM[SN#[N>N4L
MY:%B4H%!2---/E]R[QWBNPVDKY*JJDRY)CN0UB7L[V+OOK8C1Y5RRN9?'RM4
M!'J0EI[2DMN"Z5@*2J]KD[%-]KGD>E\7OX__  QD*F$.4EB;.#Y'@'YZV;G%
M9@%12U@J*9RM#LH$9P2"[&W%CR=]8<S+FL(W+R=0LYI.-"4%U)B8)#O=B(9U
M#4 DDWTA-@"+*O;ESM\,J52%H6%YA;,DC7=B!K:W'0QI72[ )?2:AF4N*4O6
MS$H(ES)@?(IBQ"]$ER>.]M8GVU6M-9A*;G[41#-S1<(&Y@SLEQ#H2F[:QL04
MJ*38C8Z1SQNAQ%-6B4!,[(4"96R"S%N.S[1YQF='L7Z.S!1$SQ12YQ,E(5^4
ML7()#>\SC4. =!"5E<Q:AYA$0KJT*LM2D$;D E1&P]VW7Y<)-4$**9?94'TW
M'>7Y[?.+VMIEKII<R6",P2%>#7W-^#<H/%3ON&WKN*\2P4[]+;^0'G;GAU=6
MM:4?F*L"[F^NG&W+:*\T'6JDE* <H(-M]@U^!&G[(*9S]&M]2WR.[^+<GPGE
MM<\O?<<\0IU2AE*47(T)U[WM^W .T;)289V98$M-V>VH%[LW!SRU/ NB9U+)
M3*EQ$S?91ZX''4N1*@.]2H !"3L;[&R>I/RXB3*B7+I\V8)4I^UQ#/SYO\[1
M(EX?45=<E%)+6.J*99$MPQ&COM?QM$9JCS&G\UCGI;((UZ#D8^\NK0X6VM"2
MHOO)2239*$J3X0=@3:^YHE5LQ"NLE]E-NV"QL=F(OKR;QCJ^&]%L)P^G37XI
M(ES<02#-!4G.L'($H0K06%^_?AINS9SPX@\]LXYKD%P*9>SG-.LY&^45'/I3
M#.K]0C6DK7%,*B6HE" PT2TE:G6=5R 0 03N_1KH@*U2<8K929DJL29J7&94
MPYLCK=(9T@@LK@QLY\S^U_\ B<K>C557]&NCLA4JJP^<*>94RTS$*"NI"FEF
M74Y5,5#*3+3Q4(-8OLTNW)DTN>KIREIC,(E,(J9O4XFH0[$N:T^L/0K<(PG4
M70;MJ:LI>H6%S:^\U'0S!JA*4RJ"GE.PS( 2JX;2X/P>P?8>9Z/^(3VAR:E>
M(RL2Q 3UE2@H9@OMD$W$P[^>I#0EN'//C.:*K^?\.F<>74RIG/RFFG'YA))^
MVJ$?9A65MI=B(@//-KT]Y&000XE] 6'D^!)V/,^EG0Z;@DSK)4D)DJ9G&5LP
M+9@$6)9W!(4-'#Q[0]CG\2E)TPH$4.+U$R;BTI!"W=?6JED(6K.J>ZB_O(RN
M";G^G;EEW0DZH6F*H<A9Y+XJ8UN$O5%5T#%!9E*72$_8&51B;_? ;=ZRXMQ0
MN1J2;6UE=>:2D4B3^6J8DRS,2XR+59LUF420XU\+QMW4TN/8TBJQ2E%6$3NN
MIJ>:D*S90%(7D!S"7+9)238;YM"E>)#-*#C:#HK)&1+?F=3=V(6HIPL6?E\D
M>#<*85QUO4%+B6X:*2ILK(4%*N;&^-BZ)X8NL5(_&2S4F6" N;<D=XVL"#;1
MWVCA/MAZ83>BE=B$R@KIM NO6HS)5*IDLI7;!=G4O,0H90&2G9HDAP7Y+Q0=
MEJO55EMMAE2%:!=0U)VY=#^<=>G>::6FEIQ)D@2T90"@63;C?:UOL(\,8M4"
MOQ&97(/;GJ*JA?ZISG-VV=[DD<-3&BGTG.1B2\<^1T$6RTH<&67JE)(L=L[.
M(5E)YC\!I*0;<DC#L,(#@WWY\!P(CF;HN>_8!.4DT"TH,#5$>ZLJ.C2VN8P*
M5+U;;)2%*N=O">F,@L01M&)B<R5:N01IR[F\3X&T=,]'3],=)99,F'DOL1DO
M@8A*KW2IM000I)',:K;^?SXGRIH[*<P[5M>?Q?E\#%#,DJ2O,):NR<QMJQ>]
MPUK_ $-A#N2F;J4E-P=.H#4;J'+SL//E^X,2!+27TL>;;Z>OE!FF$.B4L^!M
MR-N#PY,#.T69;U6N0+I\QOROY@^6PYCJH25=I0!+I6[/;LE[@W'&VL,3LZT]
M6M.0%2 27#=L%O'UPA82^<+U%*W"ZM1N =P$&X)5\X',']&(=,,Z$! <IIYJ
M" -%$NE.]R[CQTNT@4P$Z;3@CKIZDSY,K]4R2A*4K6A+N4)*@%&P2>>MIPIB
ME//DC2B';8"QR]82HCN//6"H C>][WMMCW)EFS/85+HI:<T^?T(DHZI+%;?R
M>0DG+Q2M"TD.""D@A]/F9.HZ>H_BC36%2>IH/: K#U3E.$HQ.5TDJWH5$J Z
M\">E60@DA8(!!!A*U(PMUI*DI;.C42'!>UT[6Y_+<<O8;X\329<A%92*$U*D
M2E3A.6#:6>J4GMW8=JVS6'*/J/+6DKGSI:DJDRY<@+FI8H2?=8G:Y">9/'1H
M(SN^^>$1H392+=V-MD'XU_?UWYXUQ2B)2>K&9\S6<ZG3QM&ZS:R92XC6JZB9
M,3/5(4A022%9)*$JRE*6+$LX-B.^$E&NLN1"U)64(0--^A(O<D^5K;#R'.V(
M<M-:I;?AYI2_]#@,?^WPY\+VMZ;%E) )I9H!U)3,3SMV=>>\%C[[+;1*'M=C
M;;H;C:P/RVY >P8F3)LV0L2IE/,!*<Q)22&4^OIQ:)OY-=_B%$2E-U>51(-G
M(4Q(/ZOZ;AX2\2''=9*@3>Z2;"]MP+>WE;F-_+<2:)?^:R'8$**@SN]LPL.;
M>=HDR6E>Z0IN![SI?D6C"3&*;:4%-+2L7"UVV', [<[WWMM?<XKZC"Z)2US9
M==3H"B%)1UB218!B\Q[<^,6")TZQ"%$'1@6;AH/CP;>$V_%H=BU%PPZA:WB2
M 5>\7MJ\]S<F_.^(OX">"TF8)C%GEY%-Y*+[C3E$^7.G%WEJUX,?BD/?T\4P
MKT(2L-(4%:E7NH(%K[Z3M<7L1;;IA2Z'I?3C.)[R[%*?\(X0;H!_+)L+7+]Q
MB3^+"4]JGF#CV5E]+V2W?Y=]N.AFW5ZV>_<"3?9U1N  0.9&_*_S\MHAQKI+
M)/53Y*EI)"5L)7N$@*]V0=0^_==H:7B4@]C(49NRYS;EG-@US?;NC >>?" I
M;+K37X*0JXO?F;>W<@]//H]UT@VFH,L:$JS #4Z6YW?F(;%,@!S4R[C4+EWY
M6421;469^$5(?AT+NMQ.E3?BN20!S!M<7WMM;;VX1/3AD^1,E"LD29JTLDJF
M  *L3=2P- USY6A7X4I!4F>F80;)!22HV#,%;</B-D-4,8A]]EM#K2DI<\2+
M"^D'8\_=??ESVMBNE80L_P"1B$F:1?L*E*VY*-M?I%M2F:$,9:@W $7^)\3]
MH,I:\P%%M/=I&C4;J&Q 'BZG:^][^WKBSDX+BR3F29BAEU"4$'3A;Z? Q%K'
M4"%I5+25"ZK#>UP/I!XJ#4Y#^!];KBC8(21;1Y@7 -C;VX?DR:^FG SJ>9,8
MN>QP?^D>M8J"JG0V>?+'>H!A9]WX6MJ_,9\HD#XNM9>6#:[9TIT@G;KU_.>@
MY&^FUP72B2*.:)BAV4M,S+4""0FSG*SGAW1#G5=/*GTLQ,Z6I$M4TS5A0(EA
M2,J2M5PG,IAWPMZ)DBH"L*2B'$J"6I] +42=20A+Q6I5TW "4BYW\_;CI7LD
MK94SVF85*""%'KD*LIT*F4[)>VY*6=QIOKP?^*'%Z:E]C&/54R:@2:15,J>M
M2F$H&H= 40EW4 <NI)AW.(CNHF/I]ULBR5S%044J5W@*8 @I/,!5E!.UO 2.
M1QW/V]TB5?@)2Y\M$V7@TM!EJ*0H?XJN<CM79R+Z;N=/'7\$.,(F]).GN(B6
MJ105LG&I=-53$J3*JYLU/1R9+ZM2T@*5,2E92$OF"%%-H83U9">\N6EE25;E
M!"K*<6JQ!-P+$'V7O?KCQ0FD4A4P&>@%U6=#NY8:FY>^ICZ2TT]?44@4#V:N
M8LN+I090 4; C,6OW.&O!>ZPTGO1=M+ETVWT[6%K _(-O,WQ:4,J=+ID).91
M!F%TI!!=9.J;$>/B(C&IZHE"I2R05'11=R2#8-N/."J,4B&;+S\0VEAAF(>>
MNJR4H9:UW))\()&)F6:?T*;5\EG?=M?7,0E5?*1[\M2>+A?VX>MXDYZ-+/VJ
ME[4C/:<,+#D/%4).F&G$JU!;35:4TVSH.X(T-I&WX6KIA!<'2[WMS#OP8?;A
M&DUTQ,VHGK&BY\Q0[B5%N.X'SCT3\$5RP2S!]?I')?Z4;/1*J)X8X;9*(RIJ
M@9NHV!M'TU8;[<O/RYWQ!KP\IA<LIAX>N^+[!2TP/J5I^( XZ7]/'*S2$()C
M&H*[A*TH3?\ J5J N/?O\^-8=LSD G8_V/(:W?BQC?Y:DA+9@"6 ON?/<_M"
MSC8-B$C.[#BEV '+:XZ'V;_-MC&AU+6[^/=LXOP-X?=["_[_ '@[9*GT(9A6
MRZ[;XJ038"ZB2!RLD$_)C&M_6PUXW?QA2>R758<2&:S:P:2>7AF)7$/VUI-^
MY5L 1:ZK'J"/X[G&(<"D'10Y^,'<;$IC'TAA6IT@,A %[;@DD#;8IV\@3;"N
M/"VX\/A^\/R0DJ.8@#+N3Q'KU9]LOFTRMMH/-++ZP@N>$@A()MTVO?G[/;?&
M-?M]7-H>7E2!E(/%KZ\]?"U_.'3FD>^N"#+#O<EY1)!VN!_Q(]NV,&VI'G\H
M3+61FXN+:<6(W?O?D;P00<-]^;0I].MUU!<6HA.Q(N+D^P]=S88PXXCS_>'@
M5;)5Z'K;1X=*I)NQ%RR5R.2J!>*"T^I'BUJLD*(MMO\ PC"5,3[WZ7W(LX%^
M6EK.VND2Z;LWF=DNX!<:?/3;^[OY4T= .14M7%I(?A@DN@@"R@H6OMT!Z[_-
ML@ZDGDV^M[:-Q A=;/=(""Y.W<]A9M+OYQL\IEV!8I=$NEBD/Q;B]?<LD=Z@
M@6TJT]>1%][$>S D$J+![[#;CSY:CO8Q4)4LJ<@@<6#.?(>;7.T-+5S<S@%O
MQ$Y?4A6@EMI9W:222$GI<#F;#<;BV)J.R 5?$\>\;<!N(MI>0I!4L NP!)L7
M/,7TU^4,&R(>>3Q;JM](T@@G?F.?R#=-_9MALFY&Q5;< /;OWL;;P[,[(OH!
M8Z9@.!UO<]VL.BJ7F4P;2H=H,Q3A  2;:[D"PM^N)._G\M\%KLWQ?P\->_N:
M&H%2GU3_ +1RU9N6K<-[0OI?'S"4(@IM%0+VF%:^_:5>+NVO&O8WWTIV)Z^5
M\)=/ALYX[_/OMPB5+2+.-KDG:U]?/Y;1]F59,14 ]'M18AD@J8#3ERXL.FYT
MJV%P?+Y\!.K$.!9MVMZTY1))2998]H@6L[]U^_?CM"1@U*C"2=+T)XG''3N!
MU!L/;:]_>=N2,RM6XV+N/@W=OPO%;-< N.]@;:.7TY'=]'@ZI^FY=,IOI2IH
MK!#J4@:;Z2-(N1N-^5_=YX<E/G#BQW+6'+GKSL;:Q7JF(2"5+2!I=F+WU+._
M?R,.\Z[#2=IZ$BH<I4E(2' DD:;@6) ML-S;Y1B02!8D-=G/'3NT>USI$5':
MF H<@&^5CRW'J\)" G#$F3,$@%*'GU/(4H$7U#<CS Y#WXCSF(3<:F_KXQ<+
MM*0"&O87=C?GQ9^.FT)BIJK8BI6ZRR]H<6=-P-K*Y[C:X-O=?RVQF6[N2!LU
MON3S[H@3>XN#OSXF_+SXPSIFT%#.-PL5%=TFQ4MZ_B)U>(;;D$#W=.=L205;
M7 ;;EPU\BSOQB,& (.MR'WM;7GZ:& S2J*$[IQF4J20"KO%@_&43NHVW!4 G
MG?;;I@*E<&X^M1H^NE^9CK!.@?AI9V#<]"]M^$0XJ2:K;:6IQT@^,Z/X3T_2
M3TP_+"2D9M2_(ZG9QK:&5JRI+AN3Z.VNW(&UR(BK6D[4A#SJ7B"0XA*3>]K;
M[7V]IMTZX>R9MG\?W_M%9,4@:E+]]M[B[;?M&N?/ZH4M&F):AQ/K,RJ:6K<0
M5#79J8)2DJ3<$!14;'8;7L;XL) 8)U#);33A?]S;;>-8Q":E2E@*2IE%V+Z
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MRBU&0\>V(&-AXEI6AQMU+_=K\)! -K*.P*@0<0)M-4"C6N9(F!22GM&6SDJ
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M["YV2LE0O;K8BV& M2Y8SC(FRB56#/X6:[ZL>\C=J'#9==3KF50RI*5RTDZ
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M2U)"B/>D:"SVG*)LW*[,\/\ 732R5@AK%[W&KEKWY_(1GEP(0 V2MP?&'Q;
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MP;Y$.X+5,LN,!:]E75==E7 "N1LF^PY7'L]N'UTU6DY91(0 &]S1GT*GUO\
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M( WV( ()!)Y8D2I1;2X'VYGO>*Z9,W)?A\+'=_0VAJ*DAHQYU9UK0EM))7J
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MEYE5.S,^IELIV@BJOAEKVF8N&B*1S6E%15DB#1$/R!4' 0:XADI"R0[&3-2
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M2.#9>B8V,<6%JU)8AD./!M"67%+4I ;2$'4H$6-WU25A)4.TV8Z[:'7G:]]
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M$*Z<5H -DY9J0QNZ2=#;:?X0L'5@70;$)LNF4F55X\JJEL):>L0K"L+E]8"
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M.JC+22UQ9H(.YER-145JU$\RD@7]H )_/MY8U@4TPZ#D]V[O=UC<E8M4R_\
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M5-3K.9#KDMS&H*90$HF$0DOI:J"2Q+GV/[^(0ZJ(7$.NPZHCUEU3Z&UH7<I
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MLV:)5)+")@+*4@DEWV<J%C;2WPA'1Z7YC&PD$VM:7(N)[IPI-UM,%0#BU<@
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M804)!2+W2"#=1M:_,$GD+WMRPW#O/UQWXMY/$V953*'6H.&AT=VS!J;<<=_
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MU-MN&PX1#GNG0@Z6OPWMST+[[VAGZVJPQC;T0MW2T#;NRY96_ET\^M_?AXN
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M4J)"0G:Q5J(.KJ#ROL=N>'@[$[::\?W\-MXP@.IQH>&O==O/0,=8:.83A8G
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M:901<@65I -E$VQU$X7[-N@-#-JDU=.542.L&>NPVLG%V20B6A$N8J82K9F
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MH<E>)NK\JW3 KBC'T^X]#=_!.%;CH2G4A265J?"4$IZ:#<C%?/HI<^Y"@_\
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MI_,//JG:PJNELLJ-D%7YBU',)%1LU=@)[.(204Q(IG4$3(Y<RJ2/32;/P$)
M2Y^/A6XB,+SK33I ;>'*^O 0ZD9QK<.D/#T(E%>N32-S2B*J@*(DU+4K5E35
M+/8^AHQ$)6TIA*<DT@F<\9G-,1!=9GLIF$NA)M"*:B28*'7"O!HC ??^WKOB
M7$,AMYF'B%LA+CB&WSWC)9<2XXP$**VE*6IISNR6U(4M2D"Z"H[DD9C)#;8M
M9"=K$;#8CE;RMS'MWP01\[INY.A-S<DV%R202?ETI^8>6""/@99%K-H%@ /"
M-@ 0!\RB/EP00'$ITWTBX4D@VZW _1@@CSV/2Q?Z(GDK_<4Y<_Z\^([!#J-/
M'Z",+L9NP6R.X^.!RCN(JN:CB);4,ZK6OJ?>A8>&2^4L4U-TP4,I12X%??$*
MY+%Q;]:=R$*)<W=C\]OIP^,;7ON47A>_IPF?^#F_W_!&'/+R'V@?<HO"]_3A
M,_\ !S?[_@@<\O(?:!]RB\+W].$S_P '-_O^"!SR\A]H'W*+PO?TX3/_  <W
M^_X('/+R'V@?<HO"]_3A,_\ !S?[_@@<\O(?:!]RB\+W].$S_P '-_O^"!SR
M\A]H'W*+PO?TX3/_  <W^_X('/+R'V@?<HO"]_3A,_\ !S?[_@@<\O(?:!]R
MB\+W].$S_P '-_O^"!SR\A]HK3Z*1PRH^)6LS;3SV@M)]]DQ  ]EK'K[<$#G
M^S#EM!A!^BSY RQ05+LS*@A2GXI;ADBP]EW21O?F3[\*"R/W?[P D;PL)3Z-
M'EA)%N.P6<-2(4^G2H^K))-^N[G/W6]F,YSP$&8\?OYZP=CT<++ZPOG%41-M
MS]CV-S\JK_/AL@DDOJ7_ %?_ '0:W<7OO]H*)CZ-=EI.$)3'YN5*.Y(T:81F
MQY D$+%AM?>VYVQF!V]<?7VA(QOHMV0LT),RS.J&)*@0HKADFX.Q! <2;$7O
M8@^1ZX('/=W6^4%*O12>&58\5;31Q)YZH*Y^0*B#??S/+! YT^8!^<4?<HO"
M]_3A,_\ !S?[_@@<\O(?:!]RB\+W].$S_P '-_O^"!SR\A]H'W*+PO?TX3/_
M  <W^_X('/+R'V@?<HO"]_3A,_\ !S?[_@@<\O(?:!]RB\+W].$S_P '-_O^
M"!SR\A]H'W*+PO?TX3/_  <W^_X('/+R'V@?<HO"]_3A,_\ !S?[_@@<\O(?
M:!]RB\+W].$S_P '-_O^"!SR\A]H'W*+PO?TX3/_  <W^_X('/+R'VB?W9U]
MA_DSV>F<,XS=H&>1<TFLUIUR0/0ST(AH)95'P49WJ"%*&M7JB=0YW-K[8(P2
M\;VP=A\;EU!O\NW/!!&CKMHNRQGW:<4'EK2D@JV%I5VA9C-8UQ46PZI#QC%R
MPI*"C??['(%B#X3?!&1OW1SG_<AV9/[,<@_O,9_L>,L.(^/VC&8_T_!$#[D.
MS)_9CD']YC/]CP,.(^/V@S'^GX(@?<AV9/[,<@_O,9_L>!AQ'Q^T&8_T_!$#
M[D.S)_9CD']YC/\ 8\##B/C]H,Q_I^"('W(=F3^S'(/[S&?['@8<1\?M!F/]
M/P1 ^Y#LR?V8Y!_>8S_8\##B/C]H,Q_I^"('W(=F3^S'(/[S&?['@8<1\?M!
MF/\ 3\$0/N0[,G]F.0?WF,_V/ PXCX_:#,?Z?@B/K?HB&9B' M&<DA04\EAN
M,!'N_E3YQUQCQ^?V@))&GA8?M!]!^B:YR2Q*A!9Z2QI0(*>Z1%I N03IM#)'
M,7.U[^[!&0H@</G]@_+@-X64/Z+MQ'03*&H7B$@.[20.Z4S$J%K"]U*AR3_#
M;$5=,E:U*(#JU)WV8^&G=$V569)81<%.MW9W-KOOO;E!_#>C*\1T&Z@MY\RE
MZPL0MJ* O:Q_^%( %CR-O+IA'X-+;#Z7?]OE#O\ ,&V/>0/OZX1F1_HS_$C'
MI2E6>DF38 ?S.*'+V>J[^73]W'X).C_OZT:#^8.S$> U^?C\&A-17HO/$!&-
MV7GI*=P4G[W%WW'EZM;KUV.%"D2"]CIMSC"L0MN#<C3[[Z<NZ$Q$^BG9X19/
M?YYRQ>H$$%B(L0=C?[P3\HQ(ZL<?AM#'XGD?,#^WP^<$<1Z)-FS%7+F=LGN1
MR4U%@$^T^K*(]N,I1<%_AZ^7="%3@I*@ 7+C4%_%_",!?HA^9"P5KSDD*G3S
M46HLGGY^JGI_PPXW,?'[0QG.5LNG<7N^G+O^.EK[D.S)_9CD']YC/]CP,.(^
M/VC&8_T_!$#[D.S)_9CD']YC/]CP,.(^/V@S'^GX(@?<AV9/[,<@_O,9_L>!
MAQ'Q^T&8_P!/P1 ^Y#LR?V8Y!_>8S_8\##B/C]H,Q_I^"('W(=F3^S'(/[S&
M?['@8<1\?M!F/]/P1 ^Y#LR?V8Y!_>8S_8\##B/C]H,Q_I^"('W(=F3^S'(/
M[S&?['@8<1\?M!F/]/P1 ^Y#LR?V8Y!_>8S_ &/ PXCX_:#,?Z?@B#:4>B09
MCRZ:RN..;TA5]CXZ C5D-1)UI8<?*D"\,-P&&21M<N(ZXQ&7?]V^&PX>'".V
M_A[RPB,G,ELN\LHJ-^R,51E/0\E=C$I7HB.Z<?6I:;BX"E/E0!&W*W(8(Q#X
MW'M^8_N8((%Q[?F/[F""!<>WYC^Y@@@7'M^8_N8((%Q[?F/[F""!<>WYC^Y@
M@@7'M^8_N8((AOQ]9+U]Q"<*^9F4V6"*?<KBIFI$J1-U5%Q$OI]R)E-02R;J
M;FL7#P,P>:@W&X);;X:@WG'$++: E2@H$$:]N([@QXJ.*ZG^(NIJMI3+?+2L
MIYP5UOPGY.T))JXCJADDXGE;S/[-36L:FJ-JEY3]KLD3'2^10DF@8>536,E<
ML:F+SIB8AQIA1 ./=I;3S]&W&%9Q6\('%%F_F/G F7M0&8.75?95T_1^6$),
ML[JVRMIG*F=P]-S:553%5105&2MI[,Q$WG41#3:">C)]"MM,K5+GX9<*A0>(
M-/-W'A]N$49><+O&!PX-M1^5%,Y75].<S^&;)?)K,-BJJQF,AALN:^R<I^I:
M;E-32F(9IV9BLZ,FD)4JHB=27N9)'-.R=E$"Z1-GS#D$8N1_"1Q:\+,CR5GV
M7=.96YA5E!<*]'\/&9=/SVM9M3LJIV=4A.(^<RFKJ8FK=.S/[-R81$WB_LO)
M5P4HB(AN'ATP+[*@D((/7K]X9"2=FGQ T=(.$NM9A3U-YF5GE3D7F!DCFEEO
M(,ZLP,G8?NZFS$3F-**LHBO*3A8:,BGH2,,7+)K3\VA&H*/A8F"<3$EZ5PZR
M0>6WKU](ECP^\#U?94YB<,E61T@H.42O+B0\1<PKR4T[453SGU"L<Y9S2L?+
MD22:53]D9Y48;@Y/&,SV=S./@GWHU2HMF&)B%@$'KYMZYF-MC5PTV%:BH(2"
M5!15< 7N;;F_,]>>""+EQ[?F/[F""!<>WYC^Y@@@7'M^8_N8((MNJ 0HDV L
M22"  % DDG8 #<D[ ;G!!'GK^EB$*[1+)4I((/!3EU8@W!_]>G$=R/7!#J-/
M'Z".>#AVXS.,#)K*^6T)E!Q6\2>5-#P4SF4=!T;EMGGF?0U*0D=&Q??QD9#4
M]3%4RN4,146^2]$Q#4&AY]TEQU:U[X(4P.H!\(?GX2?M%OQ^N-7Z4^>?U[P0
M,. \A ^$G[1;\?KC5^E/GG]>\$##@/(0/A)^T6_'ZXU?I3YY_7O! PX#R$#X
M2?M%OQ^N-7Z4^>?U[P0,. \A ^$G[1;\?KC5^E/GG]>\$##@/(0/A)^T6_'Z
MXU?I3YY_7O! PX#R$#X2?M%OQ^N-7Z4^>?U[P0,. \A ^$G[1;\?KC5^E/GG
M]>\$##@/(0/A)^T6_'ZXU?I3YY_7O! PX#R$#X2?M%OQ^N-7Z4^>?U[P0,.
M\A ^$G[1;\?KC5^E/GG]>\$##@/(0/A)^T6_'ZXU?I3YY_7O! PX#R$#X2?M
M%OQ^N-7Z4^>?U[P0,. \A ^$G[1;\?KC5^E/GG]>\$##@/(0/A)^T6_'ZXU?
MI3YY_7O! PX#R$#X2?M%OQ^N-7Z4^>?U[P0,. \A ^$G[1;\?KC5^E/GG]>\
M$##@/(0/A)^T6_'ZXU?I3YY_7O! PX#R$#X2?M%OQ^N-7Z4^>?U[P0,. \A
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82UJ)1!L1<QCHAIE+T7$+<(RPX#R$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g142578g06l57.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g06l57.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[4XF4&AO=&]S:&]P(#,N,  X0DE-! 0
M     '$< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'
M' %:  ,;)4<< 5H  QLE1QP!6@ #&R5'' (   *NHAP"4  )1VEL($AA:VEM
M' (% !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;@ X0DE-!"4      !!SHP'5
M=/<-:6"/-0F>)ZZJ.$))300]     ""H @   "!N:5<     7 !< #$ ,  N
M #$ .  W "X ,0 S #$ +@ R #4 7 !) $X 0P!( %  3P!0 %( 3@ P #<
M.0!% %@       $$  ;< )P?0_^ !P$ "0#J"F\(9  !  \ 6 ("  $ 6 (#
M    3 !E '0 = !E '(
M                                                 0         #
M     P   !T!  #_____                     $1)3E4B '@)M OH$Y/F
M168                                     3@                 !
M  H    "  (  @ "  (  @ "  (  @ "  (            -
M
M       !                                    #P
M
M
M
M
M
M
M
M
M         0              > D  %--5$H     $ !H"4@ 4  @ %4 ;@!I
M '8 90!R ', 80!L "  4 !R &D ;@!T &D ;@!G "  4 !# $P (  V "
M* !V #4 +@ X "X ,  I    26YP=71":6X 1D]235-/55)#10!215-$3$P
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M %1R=64 2%!#;VQO<DUO9&4 0T],3U)?34]$10!#;VQO<DUO9&4 ,C1B<'
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M90!44E5% %!A<&5R4VEZ941E9F%U;'1&;W),;V-A;&4 175R;W!E86X
M
M
M
M
M
M
M
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M4OWA<N(E?3W^/'<S7+LSS96LGLZ9(0R=B(B(B(B(B/Z!=][*=$T
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                               !  $
M                   X0DE-!#H      2$    0     0      "W!R:6YT
M3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T     26YT90
M  !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE
M5$585    !\ 7 !< #$ ,  N #$ .  W "X ,0 S #$ +@ R #4 7 !) $X
M0P!( %  3P!0 %( 3@ P #< .0!% %@       ]P<FEN=%!R;V]F4V5T=7!/
M8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+
M #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M  !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V
M8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P
M  $       !21T)#     P    !29" @9&]U8D!OX            $=R;B!D
M;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2
M;'0               !";&0@56YT1B-2;'0               !2<VQT56YT
M1B-0>&Q 8&            IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M    4&=0<P    !09U!#     $QE9G15;G1&(U)L=$!=0            %1O
M<"!5;G1&(U)L=$!P@  &         %-C;"!5;G1&(U!R8T!9
M$&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M  ,Q    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L
M;VYG   ".P    MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /
M     0 ! \     !  $X0DE-!"8       X  #_0  ! :JJK/X   #A"24T#
M\@      "@  ________   X0DE-! T       0   !X.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-! H       $  #A"24TG
M$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F  8
M  $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $ -0    $
M+0    8       $X0DE- _@      '   /__________________________
M__\#Z     #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M.$))300(       0     0   D    )      #A"24T$'@      !      X
M0DE-!!H      S4    &              ($   "70         !
M                  $              ET   ($
M  $                         $     $       !N=6QL     @    9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M  !,969T;&]N9P          0G1O;6QO;F<   ($     %)G:'1L;VYG   "
M70    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4    2
M!W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &;W)I9VEN
M96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9     !4>7!E
M96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   "!     !29VAT;&]N9P   ET    #=7)L5$585
M  $       !N=6QL5$585     $       !-<V=E5$585     $       9A
M;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $    (8V5L
M;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R
M>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%4VQI8V56
M97)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T    115-L
M:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M  IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N9P
M   +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "/_
M   X0DE-!!$       $! #A"24T$%       !     \X0DE-! P     (G$
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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MV@ , P$  A$#$0 _ .ZZ-T7HUG1\&RS QGO?C4N<YU-9))8V2X[%<_8/0_\
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M'H?_ )78O_;-?_D$OV#T/_RNQ?\ MFO_ ,@KQX3IJFA^P>A_^5V+_P!LU_\
MD%2ZWT7HU71L^RO QF6,QKG,>VFL$$5O+7-<&K<5#K__ "%U'_PK?_Y[>DI_
M_]#T?H7_ ")T_P#\*T_^>V*\J/0O^1.G_P#A6G_SVQ7DE*22224AOR\7&V_:
M+JZ=\[?4<&S'.W>0A?M;I7_<S'_[=9_Y)5+QBW_6"BNP,MC$N&UP#H/J8_BK
MWV#!_P"X]7^8W^Y*U53#]K=*_P"YF/\ ]NL_\DE^UNE?]S*/^W6?^257+MZ;
M2"*\:I[AR=C8'X>Y9=]]>C;&55;C :65\DZ1[0URKYN;Q8SPZSETC <4F?'R
MV2>V@\7==UGI#?I9V.#X>JS_ ,DAGK_1P8^UU&?![?\ R2Y\C'+F-%+2VP$.
ML]-HK:6.VN]1[AMKV[?TB<58S\BRC[/6T,!=ZSFM%9(_2>SV#U?Y*B^]<P?E
MY>5?UCPEF')]Y=+>A;UOH[O^UN.">QM8/^_*?[6Z5_W,H_[=9_Y)<WZF!Z'V
ML-K]$OV[FL!,_G->W8U6:;*FANVJHL< 0-C((_>VN;]'_,1'.\)K-CEC\2/2
MMER<@+!\->_9V_VMTK_N;C_]NL_\DE^UNE?]S<?_ +=9_P"25;&LZ9;[;,:E
MCN"=C8G[O9_:5S[!@_\ <>K_ #&_W*U"<9CBB;#6E$Q-2%,/VMTK_N91_P!N
ML_\ ))?M;I7_ ',H_P"W6?\ DD#JN%AMZ7F.;CU C'M@AC?W'>2-BX.$<6DG
M'J)-;==C?W1Y)RUK9GU@QL>R& 75>G5;ZK'@M+;+VX;ML;MWI;_4_P# U4=]
M<^GC48^1M;!M)8T;98;0SZ>U]GJ;,;8QW\[9_H/TJV']/P'NI<_&J<[&DT$L
M:367?3]'3]'O_.V*+NE=,?NW8=#M\;YK89VL=CLW>W\RA[Z6_P#!?HTE-'%^
ML^#DY5&,RJ]GVEQ97;8P,9N;6W)=6[>_U&V;7[/3]/?O_P""_2JSU_\ Y"ZC
M_P"%;_\ SV]';@8++*[6XU3;*9])X8T.9(%;O3='LW5L:SVH'7_^0NH_^%;_
M /SV])3_ /_1]'Z%_P B=/\ _"M/_GMBO*CT+_D3I_\ X5I_\]L5Y)2DR=,2
M )/"2G&V,KZ@+RW])6]S-W?8]P<YOX,>H]=Z_AX-8;;<*FO.W=J2XCZ3:VLW
M/<EGWU.O<ZOW,< 7N.C?W2X._<]JYOI3[\G-=UFS$?E.N!^QR0!70UQJ9Z0=
M[?4L=]-5L0XCEC9X('U&'S7D^3'&4N*,?EE+]/Y&V8&1Q\('&8W4](@0^:<O
ME_Q6Y1U/#SP\8>36<G1K*; :W2=#[7M^@KM=-IMI9=15<*&S9D. $O.NVD?R
M/;NWK#^L;^A8%#:WFQG5!%N.:8?<QQ[W6$MK]#^2_P"G_@5D=1^LO6LZIM#;
M&T4N8 ]] +7O,>XNM=[ZVO\ I>E3Z2?'#AQ1,L5D_P"4X_5E]6TN./#Z&SC&
M64ACD !+B]O+7MQG0UC$7+UQC^AQSX__ $GV5M&%5T[,SWOLS'.;8][ 2[=M
M.]U%5+=N_;]#?_Y[7.GZ\=,<*_\ )]SVTP:)<SVQ]$LU?M0\3ZP]3IK986U^
MG72,9MV5<1NM)-MU_J.]_K66^ELK;_-,I94L5^"^#:ZQN1N<=]];@\&P^]^Y
MS?HO]VY5X3R@RL[FQ>OT;&+$+E'+*S=QJ6O;Y8O9=,^MG1\YXH8]V+:_BG(#
M6AQ/9EK2ZESO[=:NY->8W)NMIK-N^H ,+SI8#$,9[?I5_F+SFS$T((D'L5T?
MU0ZIG.ROV5DW-?C&MQI]638W;_@J7_1?7M_,O=^C_P &I#EB(GW!<:UTXO\
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MTL]3?3D_]K?YKT<=7&HRROK%UEC7V4X%A-+7M=5Z5K@ZX6,;6QKQ6W<WTO\
M"5_HOTW_  /IH/5NK]7=C9%%^+LQLJC):7[+/8T-RVU2XUMKW;::K;GOL_PM
M?I5?X9:72\CKW[4?BYU/ZFUEA&1MV[GBP"G9%MOLMI=;^C=_->FS_C+K?7_^
M0NH_^%;_ /SV])3_ /_3Z'[+@9.!7AWY[<9N;@88O;907-::F.LK)S'[<:KU
M*FV_H;/T_P"C]:JQ6;/J[T:PV;>I5LOO]2NRUIK#WN8YV5DM>[=OL>SV>O\
M\36]ZN=,Z#T_*Z9BY-S2Z^_#QJ_4AI+&UL!BG>QVS?O=ZBC9]3<*RYQ==9Z#
MV.997#)(FMV/6+/3_F\;T=[?^U-S_P"EY.17^C24KI'2.FU=5&;@YC'M95:R
MO%K:QH;5;:ZT;?3VN^S,>W;C^WTO]$K'5\[/;792W L+'/#&VBVENX#W;F-=
M9O\ =M1L/H&'A]3LZE4^PVV-L;Z;BTL:+GMR+=C0QK_YRMGYZ77 315Y//\
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M>E=1R:* V_[+<?4+G.,BFVK=[W.]VRRS=^_ZGJ?SBWE0Z_\ \A=1_P#"M_\
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MJ'7_ /D+J/\ X5O_ //;U?5#K_\ R%U'_P *W_\ GMZ*U__6]'Z%_P B=/\
M_"M/_GMBO*CT+_D3I_\ X5I_\]L5Y)2DDDDE*22224X'6_JR<M[,WIM@Q.H4
M3Z3X]A:?I4V-_P!$]<[=7U\[\>WI[:LES@1>_(FICA]*ZFO6W:]OYGT%Z"AV
MTU7-V6L#VGLX2FFXCT"!(^7W!,QC^EP_JYX_3_4GQXV2&2422)SCQ?-[9 ,O
M\:,_^_>(PZ_V?CTL/KTOJM%EKF0XWV/][[G01M^CZ;6?I/9_+4>AXIKZY]8&
M416]EC*ZG1(:+?4RCI^[]!=9?TC%V/->]AVF&M,]N/=N7&_5G/Q^H?67K=(<
M75WW-NJL9K[:7G#_ )7TO48H3/.3>6,3.R1PR],_\:/H;^/+ XI#%'AC"(L;
M_IQE_A.G[G5UEQLNR,.P[F;0UMKG?FM<[_!5_P K\Q2=T_IY:3946V6NW/#7
MDM:>?0KV!N^O^S_;6^WH^*(W.L?'8N@?^![%9IP\6C6FIK#^\!K_ )WTDRN<
MF2+QXHGJ.+),?]&"R7.Q'R<5^'H_K?H_UOZKB5X[GD>M-36@-;7]%T<-9^[5
M6W<SZ?Z5/9DD^I;=8!74U]+;*M398X3LEP_-6Q9A8CK7Y%E;2]S/3>YW!;WW
M(.( <J^FMK68N-L8Q@ CU2/6M?\ YEE"9]QB#ZIF4IGYOTC+YN*4O[C7EFE.
MS0](_P#06M@XN?AX9=335ZA<UQHEP)8&[=C;'';7=^[N_1?X/V?SE=S$ZECY
M5CZJ]S;JVM=;4]I:]F_< U[#^=[%;52KI>#3EG,JJV9#@0^P%TN#M7;_ '>_
MC\Y6N"4>$0K@&AC+]W^JQB42)<=\7Z,H_O?U_P"JYO5.F=<OZB[-P\AE5;:A
MCLIW/:YU;CZN2\6_I*:+[;&U55O^S7/J97ZOJ_X)9V-TOZT>DVJJ\TLH#ZK2
MZPM=;^CK8YU3_1<[WV,_09UC?59_/>AZ?Z.[4ZATKJV3U+UZLMU>(17+&V6,
M=#'M?;0VJLMI_21ZOVK^D?\ :/\ HEEBS</H_P!9KZZG7Y%F(WWMMJ?D6OL+
M7-962'LLNK_26-LOK]_J8OT*OT?\W(QMBGI/UH]1[K.H%K-[7UL#Y'M:?38Y
MQHW/9NV,R/\ N5Z?VC]%ZOIJSD8U^)]3\C%R'%]U.#:Q[W/-I<6UO;O]:P->
M_?\ RD3I'3.J8>9?;EY1R*'UULJ8ZRQY#F#:YVVSV5^W;_I;;W_IK;58Z_\
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MYB23V-^G?VWT7_N?C?\ ;U?_ )-+]M]%_P"Y^-_V]7_Y-?,222GZ=_;?1?\
MN?C?]O5_^35+K?6.DV=%ZA77FX[WOQKFM:VUA))K?#6@.7S>DDI__]D .$))
M300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@
M;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V
M     0 X0DE-!"(      49-30 J    "  ( 1(  P    $  0   1H !0
M  $   !N 1L !0    $   !V 2@  P    $  @   3$  @   !X   !^ 3(
M @   !0   "< 3L  @    H   "PAVD !     $   "\    Z  3_3   "<0
M !/],   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S
M.C S(#$T.C(Q.C,T $=I;"!(86MI;0     #H $  P    '__P  H ( !
M  $   )=H , !     $   ($          8! P #     0 &   !&@ %
M 0   38!&P %     0   3X!*  #     0 "   " 0 $     0   48" @ $
M     0              2     $   !(     3A"24T#_0      "
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M     0   @0         !@$#  ,    !  8   $:  4    !   !-@$;  4
M   !   !/@$H  ,    !  (   (!  0    !   !1@("  0    !
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M 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %Z ;L# 1$  A$! Q$!_\0 'P
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M=<FZGZ?H(0?</?"]_%2M+^DE^_O3J"6YFX %M_9^6L(#X'OA> 9^U1M/./\
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MG4Q.D5TA!C_9I"#2$&/]FD(,:0CK6MML#F]5!(PG/4_0.GIU.NN9-1*2%++
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M ^./XZ:XI7F!YC<V&OH?]<X0*(2,GYA_L[_QGY]2I64.IFT<']_H(0<P^/\
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M)C<RDUJDR@5,S8DD !Q&4J2M/N+;<0ZTXE*T+2+3J43*:?\ E5!:9RE%P6S
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M0EC#2W'"A+)0^M8;(.J51X1BDZ74K,A(ETB5KFL%NDR_B)47 RL<R2 =&5<
M\RM+C4/HX.YMTOMMK>+EM1XC_"GO/Q+[H<(ED;BMO;][0O5!F[+*J]&JE%=D
M&D.H9JYMR9/;:BW#\E*<:7.33UN+:CN)E!*HX4X.^9A&*2:*3B$V0$TLTI'>
M@'*ZTA: "_\ DDAC<.0"02!$%:;LYR]#9K$W;3=B^L7K;/CWX>-VM]M^N':T
M+L?5N1PU0H]1W<C5BA5&BT6W8$A11[8FX)RFZ9-CL*]^2MA[E:9"G2>0<VNJ
M=AN(T\JFJ)LM"J:K6A$GNTJSJ,Q\C.HA3LQR@MH6+QSV?8%N7G=FABM_?X0[
MX6FW-WS+,J6_KUR3J>XAB95K'LBZ+DMM,CSEQWF6*U$B>S2S&6VKSEQO-;"2
MGD4OKJL)X4QO*I2J3('=()8I1L%L%)"]R,PU#@;\%3$ L_T/H'T'O2);]G]X
MMN=^=O[:W4VGNVBWUM_>$'Y0MRZ*!(]IIU2BY6A?(LX<;>8>;<8DQWD-O1WV
MULO-I<2H"@3Y4VEG&GJ$=W-<V&]BI]]4W=R"-+1R%P^WN_SA4=<(F#2$=3JE
M)\OE .5@')QW![=>I/IGI]&N*BQ2VI4Q\M_T$([=<H0:0@TA!I"#2$&D(-(1
M0]C]!_9IT][_ +0CY@_'A_+;XN_RE=[O[1[CTB3^@^T;V/@G?S47 A^3W9G]
M0]K@?C'E^\1$I&N<(-(0:0@TA!I"."^V>Y]/7X^AZ=LZX*#>(:N'Y&_[MOH(
M1SUSA!I"#2$&D(U$/\+='F[%\&[#:F$/N[Z70AMR2&_9FUFU(Z$.2?-"FRPA
MPI6^' 4>2E85@=\J=E13_4\024DE5++ *;E+3'?1S=K @G3>/-/-B-+*^6]O
M^1=ASUT:(4K=DO\ #9XAW -NIQ17-PV[^1F;AHC-$M7A"DVC0W[86BH0&+7K
MUX1K%M^G4NHU2'7:BS+,"<I=1JJ:=+8<DI:Y%KNNOJD8EPYC-+*34IG2JF=+
M3,K$U!EA2EJ"F[]:\J6LZ&2@J!8L6ZI*2E82%$@J223E#>9&@?5] [\XDRX#
MMU]M-GO\(B\1"Z-U+^M';NW9%O[JTJ/6KSK]-MZER*F_>MAO,0&9E2D1V79;
MK,=]U$=M9=+3#J\<J%$6KCM-45/!F!=S3KG*0FG<RI:E$)[J9KE<MS/,ZQV)
M.54P9F=1;,1J3HYZ/H;$-8ZNT_PD+CLL)O@$MK:S93<JW+SF\3U_1Z.:A8M>
M9K+$RR+"FL5"YFH\VCNR&'VI%:%*I<J.ZX"XLK92A:D+3JB< 8'-J,3GU%7+
M,I%*%3'F) '>362@.<U@E*[@A0<WVCM4H::^O[<RP/,.UP(AJ\'KBUV2V&\5
M[:RE[90KVV]V0WYV<M796[*?N3&32'WMU6;;@-_++4>"PQ"=A3[[I3+%/ES4
MK4TBKRG7W$NE)U?/&E*O$\#75SY\FHK*:9?N,QERT(F*$H!"@5)7W&0+((!4
MHWT$>:6<AT=U'<%PJYT+#Q/;J"PV<OP>Q>$JH^-'XJ$+B_9V>>V]EW!N8S C
M[Q)MWY-7/?N]QJ:FA&X,K16OD]3ODNTTB<V<+;4VL!2?%B<_&*;@W!3A51/E
M>.C[Q5-F3;(X2O*6*=E$@I+W%[P$]XL&8 ?_ !'#@,72S=6"F.[;1'?PZHF-
M^'7XVR-OTU9'#@W>>UC.WBWG7!0S/1NX\FF,1VI#AD?*QLP0/.4M',J*64/K
M+B4:J-6I<S&>%U=ZB7B)D57?*$MR&D.7T)=9 OH7(-H[,MB.0EAN@)>^Y(*6
M?F#H\+/Q5T[@5>\"/A$JU!;VC^W+AR[3CMR+/70T[IAZ77:V;A;O845T55QA
M=$8B%I5?0ZMJ2F&&2V^XD'C0UN.GBJKD8I-J)M"J2Q%2A2Z<E*$Y13A0(ENR
M@Z3D#WN!'2@,#\&8K4[:Y05/F8C8AO/5KC&_$/HF[M>XHO"KH]>KEEVOO'4.
M"_A^8J-<WZ30Y-E4FZ$TV<7Y.XPN!B=0GZ> CEDBIL/QE.%L+1SD)UZN'9E/
M^3XNG2$S9<M%;6*E?EQ,4L(&<'(F4RBI\V7(0<QL1 @J2E*WNE(/,CO%MY-9
MSR]6D=MBQ]Q[(\.+Q5QO%N7P/[BW7/X=:>+35PIP-LX=>IMNQZHLUP70JPZ)
M19:J0_4':88C<]+\?VI"U-\B^8*LT5_YW'L#055O=RZCQ*G*J4'X%6'YA:U9
MB/\ )+6LV\3D*$J"79TER4*.NV4Z#D>=]!&OO4-O^)FT>"+ARK.X-$VWM_@H
MXA;MF6XUO'1-IK(N7<2RI-'O=+=81<ETQZ5'OAFH)+#]0H\/Y8:9JU*C/TR/
M("4NQTY0G8EAE5B%7(E5$[\[04Z1W!FSPE4ONU% ,M<P4R@5,%D(8%BK8GBE
M"@I2KE6=6I !4#=CJ&U9Q:P! CZ)>R.R]/X>?#3H>S7#_=%6OE-D\+ETL[57
MBP(C55NVN5NR:[<=O7#2VRM,-EZJ7!5F9%)CK7B*'(S+[JPVIS6NU5/-;CIJ
MZN6F2LUR$*06R)0E:)90IF! 0"%L^9B2&-O;+#) .P%R#?D?LPU9KDZ:DO@K
M5;PU+/X6.-^]>/\ INV=4W8IEXUJGWA"W3ID>M[@S;0DTJ3S4NPH$]J54W;G
MJ%RFH1I$BW6TU%BHJA.S)33+;;J,G\0''UUF 4F SU9)TDG_ +90E2_S*5YI
MQG)20"A,LI+*\"AF8*5'0&\3L2"#I_CO;3-F#<V8P\K?7C4X%MDO RW'A^'I
M N_;BU]X+HE[/V_1[QAW/3+F?O"\ Y.W!<A56IN*:KCE(M]N7#G52C29%):'
MLT!]?M"TA5)P7!\5K>-%(Q3NUS</RSYTP!)E)*<HEDA5B2IEA[YDN#9XYK7X
M"VAMK<_\K\R'!4"P!\H@TX$^*[9KA<XV?#ZW+VRI-^V)3Z79- V=XF:G>T!N
MDT:Y*U=ER55NXJS3U4Z,RY4J,U%JM+<0JIJ<?Y*/#6^I*8REB_<7H3BN'8]3
M39TFI$N65T1EJ6I4KNTF9+),QTA069B24E@A;-:_G3F"E%K$I)#@C<*TN72W
M_P!0U$24\5'#7N;Q.^-?Q_5+ARN:KT'B#V/VEL#?C8:KVU*:COU:Z;6HNWK?
MV/IE.2(\8M7+0JG,BLNO/!M;Q93RN-NK!L^DQ"71\&4%)4(0F7558E3)DP9N
M[!7.=1!ME44Y%YA9))!L2.]:%$$@DES8*-PR;CFH&X^1N6AIDWB8W!XO^(3Q
M1]\[*MJY[2W-N#PUC1-P;6BH<8K% N&U-P-AZ!NQ!2EYN*_[&VU3JT\^E"0Z
MF MUEHO*;"S5ZC#*?"<.X;DE:*B6K$N]204H*5+E5DQ$E2BZ2J65I#Z*(ZL8
M25#-8.7N=&\(<#Y$@Z7<6AZ?![<_@I[?^#';=4XH[9L&Z[ZNBN2J=N30J'%B
MR.(NIWVW=H$!=K2T'[)*)1J;0X\&:9K4FGVXJGQYK)6_*FI8?\6-#B^?Q'.I
ML+G5":$T<N9+EB84T)D*E@+4L%617]P+2G-_<3X%!D@&.$MB76D9LQ"KG,&T
MROXA8@M8.]S>$=\;6I[%7E;GA+/\'T:/:&R\ZW+FIVTB-RJ)/H5'I41F^*-$
MA3[HI=Z,K=^0$U$+ESWZDV[3YM/+LA'FQ'O>]/9ZJ=+5Q JNS&9+6GO>ZS*5
MWB9*KH[IE>1203< O<3/)()'PY+EF#9BXNVHTO\ +=^W!UMUNS:%J\9-2WJW
M:\/O<:7*X1=Z8UF4KAFI>TT#<6-4E6S.=K$IQVR+?HU5;HBJ0F4BH,%U<89;
MYVTA&1;N)5XJZS"A*5B&48E3%2*G\V)=IP:]0M8)?*S.7!))-XB4A,M"KE1R
MKN2@FX=V226N=;C2-8W;*S^*ZV?#_OO>>S;)VUKW"Q5MSZKMIN;=<S;:P[PW
M$L*L3:;;03437:Q2G[NH-'J2*A#C4B51ZDRPQ5&GD+5%<F-NOY7J<0H$X[24
MJYDU-7*H3.E2\\_*KXTJ4J6E?=3LH!=!0I64I)=/P]2I1*\QS&YNP S N [*
M(S#39O-H^A+X-6Q&V/#AX>.P]!VIW D[I6==] 5NK]FS\-J%\KU:^&F:S6(L
M*C,K=>IS=(EH^1TTR0X].9E1'Q)<+JN5.O'%=:JIQNIF5)1)G"H7*2EOC 60
M"6#!4P*S.+ ,EG%Z@C-D%KI !LXZ;[:;7]1&H[OG8.S=5XJ>-K?;@ZXI.'>[
M'YUSW77][-BN-G;2+;5=IZ14ZG4J];MF5+<"DO1Z\I^NP9]'2NVGJ/<T6+(I
M[+SQ#R'ADOAZMJD8=A^&SJ6LI9%5,2B744BIQ1.7E*25F2M!" @YR)J9DH76
M#S\:T@J)>P=5LM^@26T.Z56T:)U?!COOAMX[?#JW"I=R<)6R-FIV:NR^6)5G
M4NSQ7-O%W75+2-05>UJ0[N=KCM(JE48 34V(LGDCNL-EGD;< U:&.RI^!8Z@
M45;4I*YB'6F;EF('>A60J0$!2&4XL[DI6Y3'>QF).9F (9K'8D#;J";%M(:1
M_@P&RNSU[6=Q=WO>.VE@7)=.WO$1;C]F73<%K46I5FS4PJ?79;+ENU:;$=E4
M017F&I#2H+K"67&6UC!0DIKO:7B%<4X%2RJV<J5-E35U$L324DE$D9E)T*KL
M%$$LH[1$M"0J869@EFL06+MR>WRYQ"_XD_%3LSQ0>(/QV7I?\"_+]M"F;9W-
MLIPV2K$B?*E,I%]VU!IE,M^NU43F7O8K?E5VGU65/73_ "Y#XD+=BJ\M0.KQ
MX=2K!.',-G2ILB6FH6B56(6G.J;*G+>>)90P$U.9*4$Y@"EB6<'HFMFN/A42
M#H'L$O<DC5VO?PF'#;O\4][\1/\ @YFV%E0*U6*E<'#QQ"V[M7O2S"ENNS8^
MVT.+=E0V[F7,F0I,A='2)E)H\7R N*W)I<1AP^8TKEIU-A5+0\;5LV<B4@8A
MA_?4$Q64@5#H3-&C!;^,Z%E.+1S3,( %QXR#M90S!F<ZA0&SNP9HRCBTXC>!
MS:[@XX5[(V/X(.&;B/V5J&S%EW3N-NC(NK["=W+8W=CU&5!N&VZU)H]8INY:
MYCU31-=G-3*?*@2(KZ2AU4!$)>O#A^'8S7XWB\NNKJNF12]ZJ5>4JC,M!!E?
MVUALI0I*P9;*N<URN.M/=N PSD!B0K,2;*+L0""&8[,SVA1-\=Q(6[/B'^ E
MN%3+)IVW%,N?:C9*;3+%I,NI3Z7:].9W.JT2%1J=,K#S]3D1(T>.TEAR8^Z^
M6R.=Q8 UYL)ES)6!\7";-3.\%5FFI8%2U2$**F2 D"X!"1JEFCM*KHRAKR[:
MMXU6?T>_F&VQ*K</>_%_>(UXK'$CPFS:]&XGN#O>RWMT]OJ-0)+:';ZM6HU*
MM4S<.QW6GWX[+WRM0VTR4M+\Y<E$.33FF%N2VPGT5-?)DX#P]AF(2Y:J*MHT
M>,%EA8E.A!47 3,6&<ME4$JS)2"_6RR5ERP5F.NAF+NPW#O;5)TNXPK:;?VY
MN*0>/%O_ ++4FX:'7-S>'*R;B%$IJG6JS2(J[OH#.X-+*WD17EL4^E1J]'EN
MA#;S]/0\MILN*"3WUM!3X;4\+T$^<B?3(F2RF:M(R_\ Y:?D2I*K.)JDB[#-
MYQW)F*5+639R2VH \ ^1=1Y-K%OV8WNX/-G_  FMMH^W'"=PX<5>Z]XW!N11
M^*N/N96Z?:NY5BHBP&Y\"LT&I3ZM1;O;@KI(IJ:-,L]V5%1-3)3%1\I&6VGV
MXE)QFOXFGTR*ZKI,.[F0FB_(E":68A2"2)R5.A?B<*=EY<C  ".H@,G-\9S!
MU.2 #X6MZW>[[VC:,_P?S>>RMZ^ .AUG;S92A;"V?;>XMWVC1;(H%>N.Y(+R
M*:S3)<BN*JMSR950DSJE)GOJGK0X(ZWVUN(;;4I:1BCBJCF4&+&1/J$U*\F9
M"PE*<J05I"0!H0$OS96^I]4DDHOJ"0;,3U/SB<35NQVP:0CSR<!"22H8<3T!
M(SGIA70Y'J0>G3K\-=<PLE]P00'9RXY:ZZ0CT#4A1) 8>P\(-<X0:0@TA!I"
M#2$&D(H>Q^@_LT:[\_TA'S!N._\ EM<7?Y2V]W]H]QZ0/[?:-[+P3OYJ+@0_
M)[LS^H>UP/QCR_>$2D:YP@TA!I"#2$&D(HH9'\=#@X/UZ?6$'I_X?W:#Y=(1
M3F'S]\?@J[_#MKCF%^C V._I]=(0<PR1UR/@E1_8-<G]^4(H%I(R,X_]%7PS
M\/AJ'#/^AA[]_.&0\;'A]<-'B VU95H\2=J5:Z:-8-P3[DMINDU^HVZ_$J=1
M@"G35/2( YI##L5*0&G/=2M(4"%9S5,+QS$,$F39V&K2B=,2E"N\02DAW&W/
MYZ1PRNJY+;,W/1O?[-,V&\![PVN'#=.UMX]OME:A)O6RYR*I;3]U7;6;EIM)
MJ[#B'8=78I<Q?LKE0@NMI<@O/I<3'=5YH1SI2I-2KN,<<KJ-=#,F21*67FID
MR4RE+S?$\S-?,]W%P[EH=V,SW]39^;7TUU-XM^^7@*^')Q![M7SO7N7M9==5
MOK<2O2[DNJ="O^NTV',J\Y2527VH,=7EQTN+2%<C*N09(P.P4?&N/8=2(HY*
MY*J>2D)2)U.F:PL  ""HL $_#8#>(,L$@NH/JRF?J??6S",DM+P/?#VLJI['
M5&G[6U^I,</-2J%9VRH=>O"KU:WZ95*K6G+AG2I]*?\ O%46]5UHF+3+):4Y
M&BA;92URGR5/%.,+D342YDN4*@C.),KNBH*<$.@$IL3<@ /J-(YI2D%1;4;W
M8#DY 'EZ0X+B6\-;A)XL;GVPO+=7;4,7=L[5Q7K!N>RIOV%U>DU!N:Q4&U.N
MT9IA,UMNH1(\QA$EMWRI#7.DIYE9\M'C>)44NHDRU$2IZ1G[PIF@D"Q#ETJ
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M2UKY&T$N//NK4IR1*D+=DON**W75DY%MSJB?63E5%4I<R>229BR"5."+>(D
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M>CC^??SA%/N<7$/W^Z6\4&?3_)Z#]/7[]@]>O88]-0P?-ZV+#T]/2)))#/\
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MEJJX\;Q">*:MS%(<>4%HIT>%Y9("5<SKODC)/N@G\V,XL+$_Q)4:IOY9,O\
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MB@_^E'H/YN[WH,]QGZM>IC;3[_J_SCS9LYO\0Z!/V_6.S[G)Q#GJ/$NXG_\
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M<N6EGG+:EN8PGF3DCMU[5ZFQJOI<DQ%3E1_[PW/7;47'SYR9,NIESIBD.99
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M"#2$<2,D>O?T'U?[.^H(?YO\HA^?5O+G^\,2XAWB_?\ 3XSJ6G$PZ,F5!YT
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MN!U(V-VB[*_@=$A2LB@E:$YB+FXS*+OHX!2.FUKSS0)+<R+'ELKYV)3*'V%
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M+D!>8@.-0 P:PT=]6LN0[AVRJM.H=PXF4JNA]]FJ--GD9D..*=D0Y><#!4Z
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MC3;&;/Q']O\ Q'Q+Q'B/8_V58BO#*##%*H^.>,**8N36_GD*6*CA[ ZN4O\
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M45!R "Y9RH)=SU$4#@/!J_$.*,,X6QR3.E]UDFRZE 6@"0"E25+64D!&6SV
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M&E5%/(H\B4RI#&6D>(( !#@ON%$EW*R23N8J.,2>'I^'R,+JY,M=-+4@24!
MRH4@@I\(#,G* &#@[B%BE6#Q17AML]M=4:E*<LJ3=CESF@RZ@4MIJ[[K[BW@
MCS2HM'SG%E RD*/,!U!U3D89AV'UHG)5*2L)"2D.$E24"7G  LLILYU)?X@Y
MMY^$J2LF59I9!JI-/W/>H 3.3+#%/C S,+'4Z#=WPV5P[WW;$$.3*3[0A*0L
MKBE+OEXR 2![W50_TNV0",ZNBCQ"F;*A:#9O\AIZ6ML^SQ4!Q%(G*DR9,U!4
M4IR(S7R@#+8GE9P==P[1@;ML/-J6E]#C;K92'$.!*5-JP<H*0 H9'X61GMJJ
M(5+G.RLS7MK]G(;1H]XK@595EE!G U')V!!'WY;1XUV]SNI0IHD%))/;FSV/
MS="#TZ8.>G77,(&@?330_P"AY\V-H]":@*26*3KY!N9 '7]Q%CEVR04Y;"LE
M93@XQR@]^O4#N.X/ITZZZ"X.@\K;"_[_ &9XZT31?Q$/I<L>5W>_Z[QC,JA9
M*O=5TZ=L@?#_ %>W8D_FZZ!+D;#<MI>^S?+Y;#O2M1T42Q'IHY#O^@.AYQC,
MJB)3D*R">N,=_0@'KT(^/?\ 6)F92$E)ON/=[\OY$563-4$ $@&SWTMTZ7;]
MW.+R*+S/!">BU/(#*TY"TN<P#92M/5M:5$%*N88(SW/3H*_RTN=5 D=T,WEK
MIY>5[,.?8*R2F55?F)29R!+*DJ(!);,P-A<C<"VD;B'AZ;97G9O#_8U4WBW2
ME7"U/C0I5$HJWDRY[-&?CMKB4EUQ'.M_D0M*02,H!*5'.M5>.NU+%*^OJ*:;
M5S)6#RUFF%-WBU*FD$@J"!8 I#LK1[O&C/:=Q#,3C55A^%X6)$Y2UE=89626
MA94P!60'*;.;\@8E!$ZDR;;J9MVG(:8@QPM$-R*IH>TC*FE*;*07".4JQUR<
M$YSK'=76TU515'Y:C5+RHSS@H.J8"IAE+ZEA8Z/RC D^17*Q24*^K$V8M7@F
MA>9(5K96P<LPT>VT814:-6YLJ@W/;U)@)ETUM-2J;[[:4.2UH;0H0XRED*0>
M=)"L=L@>@S;"\,K#,D<1R*):*FB&="5 $J0GQ DN]@'_ $BMR<1%-+J,(K:I
M2I%0.Z"024HS I*QEMF+YG+@!,9Y;-8KUY6R[6G4-4VJN2Y+;+"DI=1'5'64
M!E8&2K*D^\2?@1G.KZPV?CV/TLW%$3)4BK0Q4"P*D)2X0=6%R!KN[ &+5Q:C
MHL,JY=*TR9(6F6I+N2<[DFW,;#?E#6MWMX:#:MW0:1N#9T:M7,]3U1J(8:?/
M\Y3SJ4-GE'.&0%J1DKQR %61KC@W!F/]I>(BEG865"0KNYJY>7QI'Q+S9@[)
M!Z#<&[9DX,X/Q#$\*778%B9HI$D]_42E*"5D(^- *TCPDIN1KH =(3*I^SVF
M\_37GHSK-?0S5&*<TXDR8<N64N+B+"22EME*O\X1DJ'3&,:]'&W9A6=F6'3J
MP2EIP>8R Z 6G*!*[))-B][ZQD&@DU-;3S*Q%-.FSJ=2J>=,_P %I1X<R2<J
M3FO[:,J9)I<V+++JGJ6_37$J?D.9#2TJ0M"$]SVR"#TYL]?35F4]=(DX?([D
M9C-0")P8MF90!(8@I-N;=8\X25)5)3+[M2%J44I=TW?ZDDZ6CC N@LS'J17&
M"Q J;H<MR6H91'D#_-I7@GE)4>;E5\>HQK)O9]QW^6G_ -"GK_,+F%\Q43W1
MS 9'.@6[6LT>"IH9JE%<I7]Q()FI3JI"0%$DEKA@?]PL]+J#LF,B-(1Y52;2
M&GQCE#N!T?; _""DX42GIG(^?6=IR._$M4N7E*DYE,-0=#\NO+SBV520E1FA
M>=!40X)8$68DMY;F',\.-#<DW)7*^L>9!@06H48J3@(FJ<*I"D$Y!YTE*21_
MJXUG;LIPE"9<ZK(=QX5=26]6#GV8PSVG8D0B32A3*4JZ0^@N7Z:0]%E?,"DG
MJ#^HX/\ ?K,J)F92T_\ $E/J/+U]VC#;-MS^MX[]=L(-(0:0@TA!I"#2$&D(
M-(0:0@TA!I"#3K[W_>(.A\C]H^8-QX?RV^+O\I7>[^T>X](G^/?OTM&]CX)_
M\U%P(?D]V9_4/:0B4C2$&D(-(0:0@TA!I"#2$&D(ZW%<B5*.< $J.>B4I&5'
MZAJ"6!)T%_I]WT](@@D,-[>_>K0AVX6^-K6C'\J%*9K%9?2I$:GPW \M*AE)
M7(2V20A"\<R<<^2!@>EO8OC***7EIGFUBQX)8!WL'U&NS^<73@W#-5B/]^;_
M &:1"@%S"1XAJ6<N+.Y(;7E#:IUNW9>S54W OV:[1[;I\:1-Y90Y>=AMD%#<
M!A?NQD+1[ID$>8H9'09.L8\12Z\8978[C<W\I)HZ>;4E!4V<2TDY&UN!;EU>
M,ET.)87@BZ3#<#":JMGK2A1 S9'-R2 -#XO1MQ#$:?+H=1J5<<=B!IAQ^9,\
MN0I:VUJ<4/9RW(4 0?* ]QLX2H_#&OG/C'%=+Q168O,4ENYFK,APP-QE )UW
MT?I<&-C*835X33E+F=E FI%UI8',6 -G:^GZ,@\1>\W]M>&2KL1JK+^6-S*K
M3[+A1UO9#-$EH?JE:*4IY2M*:= 5"*N;W%U!I1!['=?_ .'5V>)XS[>:3B6K
ME=[A_ 6 UF/+)!*%8I/5+P["994Q23+F54ZK -R:8,S$QJQ^+WC)7#O9)689
M3K$NLXIQ"EP,?\Q3 +JZ]0#A27D4YDY] 9P!=V. >%OL?9U-X8-U]YMR(11#
MO>X%T6F22D(D-VQ:33+3DV&][Q EW'/J$7  6ERD)6,I6-?1_P#$WCW]0XNP
MC I:RJGX?P_OIR4G3$L5/>*!! #RZ&7292"1_?F)4Q3&//P/\/8K@N$5'$V'
M)$K%N*<65242U ,<+PM'=@E0.;+-KEUH*;#^Q+5?,##OMB*OL^S>JZ!1[7JD
M]ZJ,R1#J%;>5/<*6TI'D<KG5E+B2DX4E/4D]^AU["YDN2;$DA@I2@2'Y)T;J
M=+M=G^D''5'Q;)PBGJJ[%DRB@(6J7)=%Q=RO,22"Y#6+;VA\;%OVK8<%^I0:
M1"A5.8?,1&0EMA.>I(6]R_>8[2 I:UY';J=4?\Z9.=$[*7N^O_\ $02&\]2>
M480J\5QG&ERJ>943ZN5+9"3F4KU9V).@L[:1KW>(CXGK](J=<V>X?ZXU4+E=
M;=@7MN3#=+[% *E*:70;94 ELR6D>8)$Q!64+/*%<PSJR\:QO*52:==SJL$>
M;)9QYER27\HS[V<]FJYW<8CB,G+2(92:=223FRNF9,/,'Q!-@  =3&ONM=0J
MT^54JG.F56I3WURI]2J#SDJ9*>=6I;CCLAY1=*G%K4I1Y\ J/IJS9TZ;-)4I
M143S)^?5N7*-D:2@I<.IQ*I$I0-0PY Y0/H6<\@(S*@1767FY#:,@%2%  X6
MTI/*L*QT/3\$^B@%9!&=7%P/Q=BW ?%.$<4X1-R5F%5*)JI:E*$FKIENBJHY
MX!&:352%+E+22Z21,0RT)4,>]JO9_@7:UP#Q'P!Q/([R@Q^A73B>$@U&'UTL
MB;0XE2J(>74T-4B5/ED67D5*6\M:TJSYMEDOH:>&6UJ26G#@<O,?<6>_NJ'N
MN(Z$'O[R,:^E7:UPO@_;WV0T'%7#J4U&*T6'3.(.'RD U!F=P^*8#-L%)FS%
M23(,LAOSU+(-D$KCX>_AWX^XC_"-^(S%N N,U3*3A_%,8E<(\7(F*4FD3)-4
M4X!Q;3ARE4B2BI35HG!U'"JZI!=8"!GU+H!<+7NE*0>RDY"OH.#U[XSTZ:^6
M1E$*4A22%)44*20Q24EBD@W!!<,S@BXC[T+KI:T"9+6%H6D+2M*@I"DJ *5)
M(L4J2000S@ZD6A5+.V]DW+6J?1(S02NI3([96D=6DK=2GGR4].1.2HXQGH>Y
MTJBI,L9;. "1\1YZ_?F8HF(XBJEI5S!,8E*E$O9LI+Z^5M7&\2>TK9B?:EBS
M*'MO+H]NWD_$2S$O"M4Q%6CPIYR5.RX?*"^P1S-X3DI*@KER,:H\A4Q52$JL
M@J !)MY:L1IK]8PYQ!C%752&IIJDJ3,4OF20"QU!UOJ+;B&-6K?/&K<W%=?_
M  L?XW-JH53L.RX5YO7A_B]YH]5:F1HKJ*<U&#A<9<Y'T,APA(R,Y3W-_P!5
M@F#RL*EUZY0,PJ4%.$E(RI=QX7!YO:UN<8%I\?XBJN*,3PPU1*4TZ5N H*.;
M8@K(&CN'<?*.S?3=GC0X=[2@[M;E';)FUI&Y=O61'VK@TMF?6[KI%3642JY&
MJ;;SCL5R8MAQ[V5M*GH9>2@I;]U.O)AN#877(/<H3+4J5,7G8)0%)25@LSY;
M,2X4Y?9H]6*<3X]@,^3/[_/,3-DRTRDE144*4$DE04QF<AERL&))N7.;M;0T
MBX*#%O:@4A5*J+U,@5:73  "&9\-J8N.X2 7)$=+X:=*AS<S9YL'F&K=3*53
M5JI0T.@Y#6YY7/GL!&P'"W$=174<F96*/?K"7)LI1!N#ST\A#.G[:2#^!RJ(
M*4=BH'/4=_\ 1ZCU[>NJEE5G+"Q%PQVL&W]WZY'15I[I*@6&V8M<C_+R?D_5
MWBP2K<ZE*F@%)!P"#T).23G'3'KTP3VQJ,B2UOOUY>L=R:A1_P K>V9Q;D>O
MK&+U&WE$D(1[IP%)/<)'PZ8 ]1C.>FN"T*9DFRM1UT&OUW]-/1+G3'#$B]_Y
M9VY^6G7!*C0"@N%+9"1TY>7\+)[_ !^(_-]1,E) ^V_/70\N9]6BLR%E64*6
MDYBSO;6QY'?ZCI&"U"BE)4KDY2@A25Y4DH6D@I5T&?=4E.0!U[8/;71-DIF)
MF2E61,!220#Z-MK?4;["/5W:9)/>$*E*#'2_^GL6_<SB^$MOO56ZC==J7!$J
M5Y5JAQ&'Z NI2G%PJ93F6W$EM+3ZBVWE0;2@IPH  ]M:>]M>!2.%L5HL:DT<
ME4F8@E5.E(*%5 6%&;,2"QS!0&O2Y,8#[9.$TU- )DJH324"DB9,F(0G\S,F
MDEY:5 9LI9Q;4@<FGZHMZ5Z:J!5+BD1Z0]+2746Y3.5QUUM:L)3)"4D\P9*5
M*.3@D^H.L52<85452*FI DBH">ZD2P E5K!02X9B&S ^9C4BJP>DE25RI<N:
MD)<"JGZYAH4DF[EOA;KN(S*L;A,V&ER?<#>:!*2TZ@LMA;L!MQ..93* 5N).
M05E*<A7?&=5R7C\W"E]U.I55<FI\*9*$_"E?AL X#/EN/47,4>GP&=BS(H#,
MF5$M92I3.%*268E[.7;4@:Z/#=MR]U;HH5+EUW9Z.Y-HDM,F567)C2VD15NM
MA973$N<O*M *EK/*1GH.O363^!.SS'^*9Z9U!*J:2@JII"D*\(ERU%B]P^IO
MRT#W&4.%."J.MJZ:EXJ5*152YLL2TJ6Y7+<$!>KC=M&-[F&_<-TFH[A79=-9
MOJ"W5/9H:IE*KM302^U4"A:4Q83CPY2C" I7EDE*T]<'EQO-P5V:4/ E)+ED
MI54U"1GGALTM1+D @VS9C8CKUC+?:-3T7#>&X52<-S^[3.4B75RJ=267)"DY
MC,2@#PCH6OS>&?7]4JS OZN.+F3/;H]=E.*6I]Q:V@VZ5-CF!Y4,!L(Y4= $
MG\'J<7/Q)P=@?%G#.(X+BM'+F2)DF;W$U274B>4*"5W!\696K/9GO&<>%:'#
ME<,TW]N4),^C!FJ9 <J3XU.;A2-CLP=X>C94N9-I](^R=J4X*A2$2H\1&5,O
MJY2H.MI!Z>8%#J<#)[^FOD[Q-P+B79SQ=BF$UB9L_"5+,RAFJ#H2%C,D)-PU
MRVC 'I&#.(!14U54R\/G(F!$]2>]9+D AP1H68]+6&\7^7SUQ$&G4]M$R532
MX]*:>46'8R4<R6E'F Y21]Z2OKCOC!U:N*39TM=%BV$ R9]-4H-6$^$KE@C,
M21=N;N-2&TBD29DN6E4Z:0!,:6!8J\8\0L'+D.;BVF[KS3:.Q=EDP[DBNRFG
M8#RZ757HKI34Z#-:('D.([K8=2,H=4%#E5DD=1K>'A%<KBGA/#\8PZ:F;4TD
MM":V2DNIP+N!=CLX^K/B_$,9E2,7G85,1W,J8ZI2R,J%OHH./B=G9@6A]FR%
M^6N[28]JMI9I=<CI2I33O*#4_=&)3<C 1(=6D<RP%$@GL#WV<X+QW"Y^'4U'
M3I133Q+"9B6;Q:$E]W/,:\HP1QS@N)2ZV97K4NIIE*>60YR)\OKYAW:\.18Q
MW/X9&2<YZ9[?1GMGOJ_94H2DL^8FY5S>[>0C'N8J+D,P9KACY?;3ZV].B;J!
M=SO\F]?E"#7;"#2$&D(-(0:0@TA!I"#2$&D(-(0'L=(@Z'RWCY@W'A_+:XN_
MRE=[O[1[C_@Z1,;V/@G?S47 A^3W9G]0]I")2-(0:0@TA!I"#2$&D(-(0:0C
MBM(6DI/8C!^C4$ AC#<'E>$;INQ^W=&KE0K[-';D5.I3S4''9A2^(S[F"KV0
M.)^\MJ6 HH2>7/PU34X52IG)GJ3WDP*)"E@'+N &#:W\^K17/^HL13(%/*6F
M5+"<BDRW 5<@J4"6S$%K"$0XPZ[(IM@Q+1I$EMBIW//9CM,NN!J.JGQ079S0
M/NC[XR@IP/4Y]>NO_P")7&)F'<%3Y,J:43JL&F0C-E"D3$E)+#4\N@(8W:^N
MRC#_ ,SQ :Q:.\ER$JF>,9@%E0V.:YZ<W( B,V2BIW.S'H-,C1:3'AR"AR<P
MI*G%AD>\E*1@\I.!DY^ Z9&OF@C#IQ'=T^5$]"1,J0" Z=2>9;5SITTC;N2F
M5AP54$Y^\2QE* R)&@87N>O,::Q"QXLUX.N7CM?MLW452V:%;\ZXI;)62&Y=
M2F+I45?)GE2I35+E)[ D 8Z:^Y__ ,+?@HX5V<<=\95"%=_CW$E/@\B:ILJJ
M7!Z&54S$H-["?B("KLZ=+ Q\P_QU<0IJN)>#.&I!24T>%56,3Y8+S$S\1JE4
MLAV:RI5(LIL7)+*-XD&X5]P11=K]K>'ZIVY#7:S-LQZ35VL8D&I3&5U*H2WD
MA);6\]5)#[F<$A8"U%1)QV=IF-2*KBS'>(*B<5R,2Q.J7**U>!-*B:95*J7F
M\27D(E$)-DAPS!H^BG9WV,S.SGLDX(G2YRZ?&J'AW"9]0 4I%/6U=)+JZR4H
MI9U)G3YLM9&IT4=8?G8.U>W.WU3?J-$BO.R8A+4>344H=G/.R4H]UA]Q*"L9
M]U(1Z)/H =8UD\5894F;)D5$I:PZ4^,$EK$AC;UN'M:X\^-<6<08]1(H:VHS
MY24%*)A"<J XSAR;N]K7B(?Q:/$"?VZ@N</>U%4;>W"N6$I5\5Z)+<#EFT=Q
MWE33H;S#@Y*I-0AUM?*KG8:RI6.<:MK',2,I!E(4DS)CF80YRAP0D7ML^G(;
MQD7LGX!J:RHIL4K90%,#FE2U,!,&5N\*2YN3X 78.IA8C66884MTK/FNN/N*
M=DOO+4MYYYUSF=D.K62MUQUQ2E+4X2I:E%1Z]=6-,*R@S5?"Y<N_I_Z3^SW>
M-MI**:D1+DR$A,M" E8 RBVAL .@#'G;?-J?30M: W\W.0G*>_4$]<]R>WP/
MIKH3-EV<KWU\K;6?KIHSM'3/GH <%FT;0"S<OT&L*?0Z&,!*$Y]3VP>X&0,#
MO@_3D]LZ[DI*R"+N['ZW-P'OH=+<HILR: "LZ&X+G7SU]8R.MVV_'IPFMHYO
M93EXH1RD-+(RI6!D^6OKS$]$J/P&MX_P@=HR\/Q.O[.L5J#^3Q7/B/#XFK)$
MC$I2'KJ*6ZBG+6TZ14(2D#^]33&#S2WRH_\ B,]C4K&L%PKMEP"B Q/ .[P?
MBXR$)"JK!9RQ_3,2FY4A1F895*52S)A)>GJY0LFG#JGMJ4W!2P@ *F4UQ#$G
M(&5(6%&.X?4\Z$*3G&.9M6#W QO^)?LY' _'T_$:"F$C >+.]Q2@3+0$2*>M
M"D?U2BEY0$(3+J)HJ)<L-DDU2$A(2D1E_P#!5VU'M/[)J3!L7K557%G (I\!
MQ9<Z:J955F&Y9G]#Q*85DK6J=1R54DZ:HJ[RIHIJU$K61#P]B:5'@;C6XY-2
MWY:WTM$*"< OJ"6U*'8G)['_ 'ZXS4DH)9]PXUYCF'$;.<2JFS*57<+)=*PH
M75E(&:W+<:6( \I4&J V'%(Y#E2U90D% 6V%$I) Z=,@G)ZXZ:HRY*IDV7;(
MD+!)1X7'S TO9HPU4SE2E=TN8K-F5;S'S.G/KN1$8NU%NS/NO_$:Z]3I;5.<
MV)H19FJBO"&I<6GTIUY#4A:0RZ\E"  AMPJ*S@CL#D2J[O\ Z<E2,Z5G/,S!
M1!4 H)#MRUN1KZQB"BGU4GC3$ZHI*4*ID("O$$J *K9C8G2PYO#:9VZ.SG$W
MQAHW*WDOZJ[8;.[ UJ)0]N=LZQ!K,J1?=^4F8A/V2S:6F!(A,TQZ4I]+CKK9
M,D #F  5KNII2,+P=2I:9*ITV4%N3F*992_=@)<C,0ZF((^$[Q39M358SQ)+
MG3S,$BEGJ0)8=*%3$J"<Y!^( $A#.G_(':)J[V@PG;:JE4>1'2Q,@.OQ_+:#
M:'5S&BJ*MML)2$MJ2XE3:0 4HY4D)Y!BR)*#4U"JJ999-TBR6.A'+5G?S>-@
M,$K2J?(IY(RA&7/K9N5W'4&^UM(C>DVF![RD!#F?5H<Q()YL8! Z_'U]1Z5E
M:,K+2ESE !<,_+VX&[-&7T3FEH0X8)N;E]_TMSM&+U"UE%MQQ2'.B59PE)6K
MY\@X!SCN!\#CIKJ5*( +.#[:_P!(]-/5+4@K(2$IU;EN>6NOM_7:VQ5[[@O<
MML4)^9'2 AZH%M28*%#*CS/\O*M2&RGF0,G)(^!UYIV=*7RNO8 '3K^@+=.O
M@K.,,.P_,B?.0A187(<FXN+OJSOOJ\+"G@(K\AO_ ,LW2W3)"D$EEF$9('3*
M>10_"RI7+UP4K'KG5,74K(;(4KT8<CI=MCL_UBD#C^@=)$\95, 0;@G1KMU'
MEUA&+]X'+LIT.2NA5UBLOM*!0U(93$==0<]$A> M0.<A))^GKKHJ:Y<E*$S1
MDO<D$;-8_5R--0T5C#N/I-4E<I"D3!*+)*G)L=3?6S;!W.L('M+=%U\-F[U(
MJ=916*'3%5"$Q=<>.7F15:7&D R6VEH(2\GE!40"?,[ 8[X\[2>&:;B[!%@R
MS,F(E*3*6D@3$+M=*B;Z!*27"2057>+DQZ33<2X.@2PB:ON2!+^)(F%);PF[
M.UP3U.T;-=C\:/#%3K7I][SKOIPDUJ*ER#!GNH=J$-IAD!Q3K?O+C.<O4-J*
M>8@=,C6I>%\'XWAM95(FT9K.[444W? J,O*HIS/<&Q\+,-6VC4O'NS7C7$JP
MTTBG:B2HDK0,J2%%P&%V:RCL[#>(S=W_ !>+*/$Q:U,I]'^6=A&@U0[FJ"_,
M5.2N1+;0:PQ&6.5Z/$*E*<3@\S"24D$:V,[->S6B542<3XAD3"I2Y9%+-2E2
M EWS%WRM9@S\Q&2N'^Q_$,)X9JYZBN7C'=*7**4 2RMB4L/B*7#6N!<N#$X5
MMU>T;CMBCU>UI%.KFWUU0V)E/F,>6XP(LUI*BE)1[OEJ\SRPVI/,TI)2KH#K
M<O Z##L+I4IPJ3*EI8Y E"4@$#_TBS#;9O,QAB;+Q&15U'YZ;.E8M1K)RFQ.
M4LEB6<!@0>7.T-IXBZ3<UDQZ*FP8BJ;0FWEN TI/E%#RN510^&\%QLJ4HYQW
M5\"<U21539RFJUJ6 HE*2_A+AP'.C ,]V#",K]F=7A.+S:G^OS$3IZ4%,T5)
M"DIEI!"52P?A\AR<Z/'/;3A[M?<:)"W O2'5(M7ER$/38GF%N+/=C<J0Z^PX
M#EIP)PM*B0X#U^?V+KE(!*05)4Z>Z/PFWQ#GN'YNUH\O%''U=@BZG <#GRYF
M'D%*%'-GE)7;(DI4 +7!##0EWBZ[S;E;96U5:5:D13D6N4$(]E>@M<L2&A#>
M&HDA;:,!I:< -J("2.V.HPOVL=G*.,^&:RIHJ<+Q62E51(4A"5$)EZH43XKM
MLS6CS\'\'<38W1SL7(2::>5*1WJ_&M>ZDI*K[Z!]-PQMU.N-ZIU&+5+>@-27
M'H245@M(!96TOE"'PX.JP'<+*5$GU[#7S=FRYTFLJJ";([F=2J53U\H@A(2Y
M25(LQ4-K[W'/VU>&&@EJE5\T(F!2LB 6.9(+#GJX#.6Y%X6OAZO=NR=RY%!N
M-#$VV[R>,*IJ=2%Q4SI"?\F<>2L%"5E?WA! YATQC&LB?ANXIQ'A/M$J,"K%
MFIX9QA2DROS2EJ6)DQ@ D'^V&4X  %KWC&/:A@?YWAV1BM&D4]?2J"T+E#*I
M03KF(()"@=--[O#KK]V+JU!?57+(>DSH33WM+<2.[Y=3I.3SH^37$@<Z>8#F
M;6<<N,IQKZ"8WP558=4*Q' ES/&K.9>8)0'N0 EBQ\^KQA[!.-:6MEIPW&)4
MLJ2GNU3%^-RS$G," KH6_2%;V4O>^JRX[0;KMZ>PFG,837I37E!]2 G_ "-X
MJ42Y):!YG'$#RU= #TU?7#53B<ZE2C$4)"D) S#-F< !B_WTVBS>*J#":><9
M^&S5$3%WE>'( HDY@ /0-8#<:0XW5S90[_ZT:+/CBM12A2@,D D ?[C^PZY0
M-O?RB.&G^(YM_(\0NO>'A4+/N>E7W V[BWY0]PI"X+EFW"^_3C69-K,!MP3(
M]>BTA#LYIAQ!5+CLO.M(Y&ED(XES]_+T!O\ ;7RCJVY\2C;#<;C@W[X*:?;5
M;IU3X>]NXU^7ENI5IE.B6(^L2?9JQ1J>Z72]YEO$D5F6\M#4%YMQJ2AE21E]
MHD/NSZ]-]_3E_#[D[@VBMFUI2+GMU46^5-)LR0FKP5M72J33U52,FW7$/E%9
M4] 0J:VF"IWS8H\]HJ:!4$0Y<\OVZ_?]W;'(F^FS\Z^GML(FZ.WLK<6,\\Q(
ML6-=U$>NYE]AH//,.V\W-54T/LMGS'63'\QMLA:TI&<( D@']/I?[O':_O/M
MBQ?@VN=W%L5C<EUIE]BPG;IHJ+N<9?8$EE8MY<P50AZ/_E#/+%(<:(6"4G)F
MW/T^W\NQY0\5[<V<V-_;;<[Q=F]S+&-%N&X7+QM5-#M2H3:5<M8-=IHI=OU*
MFK9:J$"MSO:3&ITR&X^P)4>2XV['4^TAU*5+2#!;;WY0<[Z[-]OW.@#7>\(?
M:W%;;-T<4.\7#0W1I%/E[/;4;;;LU&^I=1I_V-UBC;CO5AJ)'B<KH>C?)B:2
MI^3+D$1W6G4J:7A))1-VYGWI8F%8L[>K:[<*)7IUB;CV%>$6U2X+HDVS=5&K
ML:@%EMUUX55RG37Q3PEIEQPJF%D!+;BNR%86YN^FWOZ^FT.6Y _,>C7Y<WYB
M$RK?%':#E7V]I6V<JTMVTW;N/0[$N:3:FX]CI^P*'7J)5*U"K]0C2JNB16/,
M:IH3'HM(0_5YC3QE18KL=AYQ*%_+S_=F8<K.="1"AT#?7:&Z+OG6!;VZFWEP
M7S35RFZA9]%NZA3[EA*@J2W.$JB19[M0:7"4K$I*V IE1PL#&-2WO]F@Y(T9
M_=W'RYQ\V?CP_EM\7?Y2N]W]H]QZB.1_;[1O8^"=_-1<"'Y/=F?U#VD(E(TA
M!I"#2$&D(-(0:0@TA!I"#2$>9WRUDMK]4@Y'<'FZ?-T/[<'762"HI<.$A5G?
MH;>K:_I!K="_\Q%=Q779$K^[M#MU3[+T&V:8^Z6RX1Y52DI2E3:EY'*X6#D
M_P"NH#OT^>WXDN,)F*\54_#J5*5(HQWJP"2@+E@EB +$N27]>4;0]CN$FEP>
M?7]V1-J"H(4$^++8"SFS;L.9T8M<29CGRTY%2Y28D1Q[RYZTI2"VH96AC'*2
M0>G?)4/0]-:P+34$U=73J3GJ4III:$EUDD@ I0/$7;0#77KFWOI(E($]E*8
MI9RX-U&W2S6VZQKO<6<>?N=QN1+/CH=JDA=3V^LV/%*O,<=4ZW"DSF/>Z\SL
MVI3W%)5V6ZL'IK]%7X0<&7V>?A$P*HGI[BMFX3Q+Q)4K*2A:JNKG57Y9:P7(
M4),BDE V\,M-A'R;[>#(XU_%90X',.;#D8QP;P\M*F4F50H-)/KQH 4I-563
M"GJI,;"_"[PUUNAWM"N*]XS3/D0Y$B'1W&TK<+R$X4\^KG/(6PK" E)&.N>O
M30GMEXAJ$88B1*69:YJ<J&)!'C^(@-[]#'UF[7^U2AJ<!G8?P_-=)*)7>H#
M:-W89LH2R6?DS1([6;4H]?I,J%(I\:+(++Z8,N,RE+\!Y;*T-/HY>ZFU*"@,
MC.",@==:LTG$.)8?/5/14370ZB,ZKZGZ,?MI:-3,.Q[$:6KDU!J)DT&:A4R6
MM16%)S.?_:2-&^3"-=YCPO\ :JBW%N?<>X=0NW?;<NY*K<$]#Z:)*<"%/J><
MAPX25/N-&1%*DI+JG>4<GNI Z'TS^TG$:Y=.D&<ACE5D*DE938S%*^(J4H.1
M\(&@  ;<+!^UJ914V&RZ?N:64E$GOES9J4 . 5)(8!*<MA=R2Y81KW;H[/WE
MM)N%6;-O.UZE:-2:ENRX](K"4MS&:6^^Y["72DJ0%I80A2D))P.AP<:S3@^(
M)Q"BE'-F!ER^]<%+3,@*BQN'4=^I#,8VEP+&Z/'<*I\0I5HFRYB HJE+$Q*B
M=TJ38W_XV!<;F,ELNP+BK[@9M^A5*JN* "A$B.J;4#TR'% (*E?,22#D>FJB
MH4R264EQ?4 G]N8_W'BQ#%:>G4I*BE.4L02';:VH?F6#\H</0^'W=B.TEZ18
M%?99R%!U3(* G!/*E(45=0<9/J1^>94]*5$ AB  2S'GH[N_3]K2K.**;,9:
M52W!R_&#KR//GIOLQC+(]DRXZG*;6Z;)B"2VN)(C2XZFU%MU/E.)/-[I*D%0
MSUZGIUZZNCA[&JO ,:PG'<.F]U6X1B%)B-+,2IB)M+.1.""1\25Y2A:2X4@J
M2002(MKBK#\)XTX2Q[A;&)4N=AW$.%U^$UB%IS#N:ZFFTY4-LTLK$R4H%)2M
M"5)(4 0A.WTQ5@[G.4"JN*C4V;.-%FN2DJ90EMQTFFSW4J!Y4)<4TI2\CRV7
MG5%7*%)5].>U'!J#MK[%I/$&#RDSJ^3AR>)<%"0%3I=532U#$L.2HL4KF2T5
M-,4BRY\J58C*8^(_85Q)B?X:_P 2E1PIQ!/7(PFIQB9P9Q'F442)M%5S@<&Q
M9:0%@HDSIM)5I78RY$^>,Z76#))0+<<:7&E, QULJ;D1I#8!=66RE:%(*<%0
MR I(!QUS]'S"FR/#?5@XN5;O;IH?UO'VYF3I:Y:BZ52UCPD$$%*OA;H1<%]+
MB'];:[BPY]/8I=S8B5!IM#;=0404.\O^FO*<I6K&2,]3G'KCQ*H%34E24L4N
MKSV 8:ZWU^M\6X[A;*G5*&+.0$A[DCJY/D"WRAPD"CT!]Y=3B_(CDMYA*7ZR
MPS$:J3S82 &7YB4"4XR E \I;A0 E(Y>P"7*JIDGNB5,+-?5_GKH#;=]3%C5
M6'95R9J4>*:646O8 >=Q>VC",9J]N;90PY+J=N6.[( 4X%O6W1),AQPG)475
MP2[SJ6 KG*R2KWB<]==TF77 =Q-4I4LVLY #>1&G2_E'?18332IA699SE7Q9
M"U_7S8WL"T-[W%K2[KYJ?3F5,4AM2>5;AY"^M'NA(;0 $MI("48Z!( QTZU&
M52)0X2D!09R1J07MT!U&]FB^L*H95,M,].4&99M&:SEVV\O*$)FV@Z$K*$CG
M+BSR'"@O ))&?0'/7XCMU&N2I8< W9FM;;IO??>T7I)K09F4K&5*6!?I:Y_=
MASYVJC[<.W)<M&H;#;C3E2E-,J3CF:*"2X]S=4C\ *^'?(([ZBI 0"P#LYTL
M=&^1\AI'.HQ--)A\[*K_ !(S"X^FG5R6WY0DOB9[)5CA\V O#?O:?>/=VR+G
MCW#8U$;MFB7(J'9\9NI2T4^>]'IS)"FW7VAS*4KF'F$$GF&=>GA]-+43U2ZA
M 62HLDNQ&0Z,QUY';S!U7[0,1KEB942JB9+"#ES)41?. YNSD$[6$9%4N%2X
MJ9L[8-_5/C'W>LC;BHVQ95^;U3*W,E5ZM/M2Z=$E(CVO48:U2J1&5+F 2$%A
MU;JN7"0D8%/GJPQ&)F09:&5X0"X"%%5E=2D.$@V<W):/-3T]>K#)%0:A;9TJ
M*@7S@-;.39V<MJ' :[H]P8;Y5MK;#B.N7<&[[@OW:';C<]=!V:O&IM.U2Z+M
MI4^7(BQJ:T$H7.>G2E",W&;E--AAU96K" LCR<28;2!-.)22"4)*PVBRIF26
M((4EEG5G]!6>$,9J$3,3,U:E(ES5F4K,2Z '#BS%*LR0^K1;[JW>VCXEJA<6
MUBK9NBP=W*!;[]QT:AWG$B0Y]7BQDNK=1&<I[C@"V&F7%R6WUI6CE/,@9QJF
M3L G2Z-,Y)!DOD4"'&8 $NX218[M8:V,99X%[1OS&*HPPS&8I4E)4[@JRYAJ
M" ;*NX<<Q$>]6@R&U*97(?2E#JT! <<2D\A*3@)4D%)QT./JSJG_ -*PV7W9
M5(EJ6ILR@FVO.^FYN";QM)23!-$I242_[@22X&X=W(]=M(2NM4[+CN2,\I00
M>@4T<]">N.;_ $L=2>7J>X[PB7(.64DH Y#334[ACY 6?:*M(K)DZ8>\0D2I
M0,LRV'CVN-[6TU\HF^\'SC-?MNN.\+FY]24[;E>>+FW%1J$M2_D^H.E?M-"4
MIT*"6EGE5$Y'$)2<(2GJHZN_AW%%2E_EUK#&XN&=CL]N3./I;7CMEX'L<?PV
M5EFRP9L]*$',J7J4D LX?4C8BP+1LC.PFZA'E46:&WG(;:I-.7(0A?FI_"'X
M>0<=$>I *0>XU><D&=-S"R2758N>36ZZ"-;T3ORDR3525*0)ZN[J4H401L;)
M9VN26.G2&9RN)ZX[?W"=M2K4F/#HL>4(1B)^\OM(REH.H*6N17F#+F!@]<9Z
M:JIE3#**\MA8I TL=&N"[-]8S-*[*Y&(</)QNCJ3/GS)1G!1.8DI=1S',S A
MB&<#RNFO$)M'5)E?^SJV&UU2E7 VQ/7&;4E<V*5M#F^]J6%+96!@83S @X!!
MU[<.GKHY13W>=%0A2%@@$)0MP<SOJYUL=S:+J[-^,Z6BH5X'B@[F?0KF2^\(
M:5,4%:@Y6LX)25:QD^R*ZM;%F(J-2@S$4N94G*9YK[*VG6'4EQ2.4+3S>05(
M. <)'X7PUH5^)3@G#>%9TWB3"Y6654U"/SIEI'=CO,Q42I+A_.XVWBD\<SL-
MQ3&),B@G([\RTS60L',@\Q9E/:YA2USFG55:?##*XTE<<TN4A)2(]78]Y"U'
M&4NM2 %#J!U[]#G6SAG'*7^HT&-2/#*I)H4A:0SS4J;DW0OLY(BRJRAFUM/.
MPV>0.[0IPJYRJUN5 '9CMINT3%[+W>[>%AT>?.*%U-F&U&JH"@M8EQFT-O%S
M Z\ZAS=1D@Y&1KZN]G/%0XIX?I*M:PN9W*,[',?A:]@7:X!]=6C2KBW!Q@^+
MU,M (29A*5 9$DNY"=<S<P^VAA6XZ$(4<)">89"0D)"<]^OJ3@=<=>NKYDI"
M<Q8 %18:,.HMYNV\6TI2E#Q*S#J7UZ1Z\CYO]VN]_P!HXP$X!)[ 9^K2'Z1J
MG<74R;MAX@W%+Q=T&AMU^J\(VXG!1?57C(997-;VVORT;NVTW$3"E276X5*2
M:9<E/G3JG-;>;B0*:\IM"'2A8>V^7OTB SFVN_IM[]=1")[)VO=,S</?^_:[
M1'&=P>)7PQN+/?NK4BGTUR+/F2MT=T;RG6XVY CN/IF5)RWT45A$B VB-/2I
MB5$92A]*=(D69MF:_OYO#B[-XA=D[VM#P$MJ;0W-M^Y;^H$JTGKIMZU)WRO5
M[3%O\/M5H%;9K_R>B0W;]<IU7:D0TTFJ+C51Z9$DEB*Y[.LB2+GIRZ<_WCB#
M9+[_ *Z>^5X9+9E(V;V?WCV.N"W*CPX<6-EW5QA3F[9W-MVX[AVE\0JS=R*M
MN5,85'W HCQG7)?46V92ZA N:DU.-2*5-MJG-%2F&Y#4A#GMT\OU_7E$OOKU
M\S_KV+O,X5+=\/:?8-"W%XO[D^3..^?QN7":Y<%3J-Q,\2Z=X*9NC4Z785M0
M(%/;<N]JPG+99HL=FGPX7V&.T-P/K<+)\T0?GY7]_O$;"YY,VX58VZ <M](2
M[<G?C9[;CP__ !=MHK[W"M^WMUZ_QD[V0*-MK.?6;YJ"KRJMD2K:F,6NVVY5
M%4>J1([LQJMICJH[,-EV3+FQVFUJ" _50\K^6_IMK"F;Y71MY9^[W'M6MU:#
M=UTV3!\/C@517+<LJXJC:<VK!^I5AB+$K5T4H.3*!9STQ;2+OJR6GFH=NBHO
MO-.MME"FHMKMHWK[M>)W]#:_,;=/G\H1'A@K-'IO&?OQ"M%OA1L2EW)X9>\-
M;K^U7"-<<ZY+7H4RGSH*K;.XURI=;H-[7FFDO+F1:["IL6>Q%E2(\Y!4%.*G
M46]V/1[-O](@ZC0;V&[I'\;6.D*[8.S6T>UO"%X,57L*T*+8=1W)XA=N+@W
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MZQ4!.[TLL.& RDDV(^HZ#T+N8RFT=T*G:<?Y-JZ9,R P5>S265K1*C(6GE6
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M>PU<J6CQE*D+2?#N@ZD;MJ3L-(V.[',3PB9AT[A\RI4NIE%4Q1F96F)47;Q
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MTF*SR+ 5'OW_ +B+V<.UWL-N7S;TOJ8QNXO%AWIC[0V4S0^&:*UQ:.\6MO\
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MH,@W/1VJ-5IKTVU9Q8$B9';Q)2A85I_OKY>_K$;N]@^Q%O7Z^0TO#))W#GQ
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M'WIZ02CE.>;WN0E7*!CWB?UZ]@IAX="4VW\QY:W'D.L6/B&%4<F8/ @"ZK)
MY6;S>W^RX*UX<R6ZE^8MV0ZX4E3CRBLX('^L2$]>PZ')/3U-4IY26'1N>NO1
MK':UVBWZD2I"F0R4M< 7;KY^=P_E#@+>I6/*PV">4A601@]#DC]GSX^C55"0
ME.GFP\RW5_XBWJR>P+*(S.  ;-8$\K\AY!XA]\6W:Q=#K^UV[$)CRVZW!FVE
M4WFT@<M0HZDU*F+=<&"7'HDF2AK/7EB*ZC&-;N_A/X@[[#^)>%9R@HTLV1B]
M,A1=Y52/RM6E*?\ BF9+D*5;6<(^;_XUN',E=PCQI3I*3,348%6+ 8B;(/YZ
M@6I6N92%524C82HF=X-KT1NIPT[07KYX?ES;2A4VI%!&456WO,H520YD9Y_:
MZ<XYCOAQ/<'6M/:9@/\ TWQ_Q3A.0RY<C%9\^F#:TE;EK:8C<@R9\L6Y$;1M
M;V7<5#BGL[X0QPK3,FU6"4B*DNY_.4@_)5:2W^0J*>:]MODZE$,).<<OQP.Y
MZ>OQ/\#5D-[Z^^M^47N:@$6OR+[7<W&UH](B@]<J/;H$GOZ_P/U:EQSCH[XO
M8 :WS?MH_MXZG8F""!D>F04X^8?W#I^W4!M.0;F?46CMEU#N%"_F_OZZ=8M;
M]/2KF'+RE0Z#YQGZ?XSKBH#0L-^1_F[O[?TIG@M=Q:_0^OWC#*E2T'G;Y1T'
M.?7F/H G'7KZ=,#Z3KJ(8GG%3D3B"E0VVN!S+_5N9%N4)=6Z6$H4L )Z'(QC
MMUZC'T_5VZ ZZI@?*[^6H\F\S]C%:IIX)RE1(5=@='U(?GJW[0B5PTU.7L-@
MYR#W&?FSC'S$=.W?L#T*0+EAI>WV\Q[8Q69:P"GHL='OOR;J[<MX;I=5);2Y
M)0M)/-S'MD(4.O*GYQT)U3)P+=.0L W[Z^D7/0S;CD#?;9N5WOYO#9[IIB5%
M:@5*<0X1DG'NJ"L)^<?ZWITSZ$ZIDQ)=^0W.W-_]?I%XT,P+8'8#S^6GEUO:
M&]7' 0USA??E5CXGH".^>^1Z_F^'BF)+%M-?J[?SY"*[1*3WBK;6^6W\?K#>
M+EBY;7A*1DJR0H '*NWT_JQTUXU)=)'O]]'\SRBNTJB% N]VU=N6K_79@UH0
M>X(G(XL >Z<_/GYLY&?[\?-KR$* 8@C-N7%[ZO\ /Y'I%P2EL4J!N.6XL= W
M00C-:CJ:4IYM.5MK#Z>N"5LD.)P1T"LH[GIU&<]-1+6F3/ES"2P4'2F[@VTZ
MON'N>L5>9+%323)0^*8@I!8;Z]6.C;]-8W).#O<1>Y_")M->3SPD52A4^DOR
MTI(/L_R:XNGB.OESS/(:2%+!(]U6>AUEO":RGFT\@=VI)#;;.PTZCZ@7$:0<
M=88<*XQK: (RHG)S/_BLJ&8DM:[LSNX.D*_=_#K1=PMQV;JFU9^ V]'A39=.
M0TVIFK,)900ZEP'F;(6?+44D=4E)&#UKD^L,A4TVFH0W]IAF# /F.HWUT=[$
M1SP?M'KL X?GX73R>\"3,DA94W=.3E &X:SLY;F8:]Q";67?]G[B*=3I,^C.
M-16HLB.D2$TZ+'0&^:0A&76VDI&5+2/PL#&<9M+&^U/A7A614UN)S4(4F6J6
MBD24F:%J'@_RT!3<ZDL3:,O=F_&6#4_#Y775$NGJ<ZYBT* 1WBULK+M=1=GV
M/*'8;6;)W)==F6W%=K;ELVU3FRWY;#?-4ZTXK*7BAQ8"HL3/X'9;G<CX:.]I
MW&V)]K"FPM::6AHEJ:8"$S"G,IV4D%3,7-P-W9VP/QMVCR,,XHQ"=*ID5,VI
M)*"<I2G,/#F=P.;)\75K1BC=,I]LWW5[5\JZ]QZ910U+A3:2HF32YS2LN4Z2
MZDAI>4CG2024#*%)SVU>I\0.&<32S34<[%YE#5H)5+"LX(<K6DM= 8 EPY4&
M! +=RL9K,3X?14&;0X>NMEE$V3.$L@H46!#,0HD@W%AKUEDV1WQM#<BG"FT]
MQVF5RCH;C3J'4CY=2B>4A+?*\TH@K4GE3E:04Y_5]4NQ_M:P7C#":7#I@-%B
ME+*3+F4TY33"E"4 DDER7M<7 LS1JMQ;PI7X)5+G3%RZF34*7.$V1= S$G0:
M7T')M(<2EP$X&>5.02?B.O3J>F-9]+AE"^8!@]KZ'IZ6/U%D)4[C=-E>?+]^
M6D=VICE!I"#2$&D(Q618]HR[LIU]RK<HLB\J12YU#I=SO4Z,Y7*=1JDZR_/I
M4.I*;,J/!F/QV79,9MQ+3KC:5*3S#.D0W7W_ *WU^T95I$P:0@TA!I"#2$&D
M0=#Y'[1\P;CP_EM\7?Y2N]W]H]QZ1)Z]/M;Z1O(^#Q2DU_P@."NWUNN,(KW#
M);]&<?:P76&ZI2IL%;[:%8"U,B1Y@02D**0"1I$$LQ.GTT)\[Z:_6,+X=/#K
MXNN'B%MUM]2?$2N6M["V%*$%O:*3L5M_#15K',F2X]:3MULO+K<?SHTI4558
M:=,Y& \E0<&=(/OMZ>EW;IY]&A/:?X,U>I3--M"F\8>ZD;9C;[>"D[P[-;/J
MLVT/D:W*S2KQ%Y1Z=?\ 764,U_<^!39@>:M]ZM3F)5*+B'$N.)2IHR;O<::W
MN>=]X#8,1MSL.L.9O7PVJ1?6R_&GM%(W0K,!CC,WA@;NU>M(H$%R38TJ#4;'
MJ7R-3HGM7DU-EYRRVT>?)=94A%06I*5%E(7!^W[OTYQ N>7/Z"Q?I]+M&5;K
M>'W1]T=P=X[\D[B5>DN;O<(CG"=)@1J+"?31*:X*D#>3#SDA!ESA\H=*:\A+
M"2V,.D%0TB7N[-U>S/UO]/5KQ[N'_@)H^PMS7Q<</<"JW$N\^&/87AK=CRZ+
M$AI@0-C;,J5GQ;J9<9?<+LROMU SY$%24,PW&4M,N+0HJ*(>[=7V%W<-YL=W
M?EI#6W/",DV]9_"]&V=XH+VVHW2X;K'K^U:]S(5FVU<@O3;BZ+@<N"JTLVK<
M!FTFWKEASW2]0[KI?+5*6^>=!6E/E)0=^@O<^5Q^[VMST?#P/<(C?!AMG=.U
MT+<JYMT*16]QKKW!@U^](D-N[42;RFFJUEFNU.$4M5N6[5W9<I,_V6'RL/-Q
MTL!+0)1(]^MX=O7[AH5JTB?7[EK%,H%#I4=<RIUBL38]/IM/BMXYY$R9*<:8
MCLIS[SKJTH3ZJ'0$;7.@@?>O[&$7/%5PSN %&_VSQ PH'_&':_4@^G_E/\WQ
MZ]-<$D*)"59B0X +V;;;?Y0RE12 ')4 !S<LPYO$5&_?%'L3N-NM5?+W=VW,
M:V0F@4J6+TH(9^_H2[/>;<3-+;B"M*6T+&<'L0#K0;\0(Q7B#'IE)24E3/E4
MDE20I"'EB:%'<=#?</=M]I>S--#@F%S/S,Y$J9/DF8H&TQ>8;.U_/8 :WAJE
MY\4FR]E2:FQ"W%VWN:75),&F)9EWA1'8L: QY9>6K,M84E2?=;*0HE7ND]"=
M9*_#=P=5X3AM3C6)T\N34+DF6@3 <VKDY#JY N79M+QF;!9%#BU(FHIL2%+^
M62HJ45F65S"X2 >0/B+[G:,[5QM; 65<MM6W9MQ[5,,5CV7Y:JJ+LHC#,)4K
MD 0E:)*@[A1)<]Y/)T*B!K954@SJ><A1EDS""E0)L_)B&8>]8HZL#&,TV(5>
M+8W.G2Z/O>YEY\X44YLKAA\0 &MW&X+1%^&Y&IS/B*UB)#E1WX33F\K-+E-O
MI=CR667*C[(ZPZE2DR$/Q6^=A2"OS I+B">BANWVSR36=AN!35,\M'"-2IG_
M ,Z%,HY2!SGVYBT?*?L FHHNW_BJ0,Q1-3QA2H;4Y,7ES$9@3_QD[G7YQD7C
M=;D)DU';ZP&9*5NSI]0J5380I*@B)2SRTQ]2.JAYKBEI"CT'(2">NOFWQ3-%
MDHV\)?\ R8L WOYQ]M^QW"ERZ9,Y2 ):B#H0<Q2"7+"SDWMRV>(,Z T7%-))
MSE0Z>N"/>./KQ\WKU(U8Z+DL?IN^X]\WWC8*J(2E.6P &NX ZOJY'+0-"^6N
MP5/H_P!$I6E/;N#D)(3V('8D$=3KW21X1?1^NI-GZ'2PBDUBW05-MX6#!DC3
MS#%G%H<I:L0@-%0P4G(P.JATR.A'3&3UZ@?3KU#493>^OKY[19U44J[S,[F_
M4;@\F?\ FXAT5F00DQ"KWDJPXI6>B01D)^!^;&>@(/PU[Z<J&O7;5B]^7G%M
M52B' /\ %Q[_ %AV-E0PI*,)RIQ8"#@=AD]L8Q]>=>T9C>S'0;OL_P#N+0Q(
MA2KDF]SZ#3Y;;VAU]J0.9" !CWDC '7IWZC_ '?1C55IDJ <D$  \K[7]CYM
M%FXC,0"5)S;IZ:7L1T?[$[N'MRG)Z9 [(QW[^O0_2>_T_'50S I &ODVI]_/
M;2+3JYQF$A(9K $#0?MM[=J'B6;7HOWA+O&HLL^;.V\J%,OJ(H J4VU3@]3Z
MER84/_Y?4GRK(("$J5C(!&<?P\XVO NTO"9:E!,C&Y,_!9P>RE501.IP;'_]
M3(E ,0ZBD/<QK?\ B8X;1Q%V38^O+FJ<!,G'Z=AXDFASIJ6#C6EG3P=?""6U
M9+/!=OY=?V5W"VY?>+CUC7HU5832U#+5-NN$72EM(]X-B?39JU'! 6\1_I#5
M]?BGP3\GQ;@V-RT )QC"3(FJ"3>HPZ;W9*CIF_+SI*; G*D>F+_PC<0*KN!,
M6P-:U*7@.-+5)!RLBDQ.4*A*4C5A4RZI;E_%,5>)ID1T >\/>SU.3Z=OX'36
ML =KZQM<Y\_?O[WCT<J3@8[?^/\ 'S_3H0#'%\NMQ]?+K\XX+92L?.#TQGJ/
M7X?KT8#W[>(S@Z ^](MCL8943G(SU_/W^'3/\9UQ4VXT&KM9]N9OZ'GI'>F8
M4V&GU_7=_P"-L<GQ4E"U]"4)('3J1Z_2?H^<ZA3'-TZ;O^KL?VUJ4B:^4?3?
M]QI;IM"9UB&VI*^I(*>?KCN,X]WU./0_5@G7GF"X/1O35OX\](K-+,(4.3WV
M.O3[[,]K0A]R0"I+A Q[Y.<=QS=?S8S^W72397)N3;-J;'9OVBX9<P64"[-^
MG/T^CPWF\H:5_?%$(_SQ&>G,D#EYCC/S:\,YLI+AB _S'MM7BXJ":2,UP 02
M2S#Y[Z^]$ J]E5^NNNMT:B3JB5-DE;##G(E0'NGS" D JR 2>I5ZG5$G5$M*
M^6UQ87YG:[BWRBXZ7&:*F5DF3 ;.P(:[V)&]G;3E:$3NO8[=9MM;B[*J :]X
M^9E*CCYL9)('7E[CI[O75/J*V1+!!)936<$/S&HOH=[; Q6*''Z"8M2DS"1<
M[$O?J-V9GU/HSV]K?J5&=<@52!*I[R%$A$EI;9)ZE..=*>8*P2,!73Z]>,U$
MM@1F5FT";DG3G:Y\XO+#JRGJBGNUI2W_ "( ZW!(T+7(?D(;C<3 4><+*5$*
M"E*&!U)P0,=CT((/74K&>6DZ%RP58V OSOLX]+O%VTR='F(RVRJS>%AK?^+#
M2,SVPX-]^.(2*Y4]M;.E5:DH=6A=64A;<8*;)"SYBDE) 4A2>@[XQK&>+\<X
M5@L^?+J5S%S*9E+E2DI46]2+W!8$L+G413,<XYP/AI29>(UDJ2I1&196@)*A
MR!(/)CRZQ/EX=^TV^VP6Q=Q;9;D695E^5<%7DT!5/0'%/(J2O=9>0OD+:$/9
M"%#F2$D* '4:[*#M\PR4@)DR:A00S*[I +Y1F%B7+@L!?5MHUM[0>(^'L:Q6
M5BM/5RC.9*9F92"\M-PS*8'>XTWY246G3;WNRL08*%/V6BUJ*RU7!+CM2WG7
MG%I6Q#94H*3R<F7%N<R2"%#&0=4+BKMPKL9E5"< [ZAFRY9$^=.0E(9*+L!F
MW(&AW&QC$6-XIAF&TW>2LM8O$)AF2D2\K)#93F/0@M8CX><+/:-+H=">EOU!
MERL/UE]UI5<<C##R% )$<=5(;;;*"<(2D GJ3K PQZJQ.:NIQ^558AWZC+$U
M"24 J\+Y#EZE\K_6+%QC$:FI1*5*K$4J9 2LTQFLH+!=P$LYV#=3UC$[<9NZ
MF7O<%ITBJLBWH?E5&$N7'YWF%3.9:H:"$G+39*1S]0D'EZ8U9N&R\1I>(:V@
MPNK[NFGYQW*B  ;$YM<I8M:Q/0AZEB0P^JP2BQC$94Q=:M:9>>6Q$SNU$.LE
M0 T+,"HAKQ@5STR[]L+IIZ;:J5)ANW;,>D5)Z64>RHD-(4IY38=0I;CCR>5(
MZX!Z@=.MM\12,>X;Q!*L,FT]/4SE)5-FJRJ3,2HL2"I!?<&P)T#.XN;"*K!.
M),/F2ZZGGA%!+'=B2/$5!F+)4&UN"=.1B]5.H3;>K-OWVGY,IMP1ZG&B+E4I
M:%"L1Y:DA^/*9;2D%QX\ZDE05R)2#S G&KYX'XBQ#"N(<&KI4T_FJF;*E5*Y
M;)"\Z@5D@!F)!+WL; '3P4N'TV)2,1PTRESI*),Q<E4YRJ4E RA(6;Y18,'N
M][O$IMLU=-:H\&HH('GQFBI(_P!%TMCF"NPRE1[CH0/J^N6"U?YS"<.J%W7,
MII*E=%90[-]!KTC6[%*)6'U]33*'_AS%A)YI!(!]_P 1D@[#/? SC57BGCKK
M%=(0:0@TA!I"#2$&D(-(0:0@TA!I$'0^1^T?,%X[_P"6UQ=_E+;W?VD7'G]>
MI?R^0_:)_C^?K&\;X/U6- \'G@TKR8Z9*Z%PN42M(962EMY=*I$Z<EE;B3SH
M2Z8X0HI!4$DD=1J':^D0P) /^5OU^EX;OMCQR>)WN'L!2.+:'PW<+50V(D6W
M4MQ)5)@[K7O"W)?L6B.3'9S<.-.H3E#8N'V"$](:CR)JH:GD^4IWKD3;G?R#
M?<_:\0SDO?H^SVV%[<_6)#*/XC_"#.=VEI%8WBMFV+UWGL_;R\[+V_K+LAJ[
MYM+W-B&1;)^2FH[KA#[R'8CLA*C&8?0@.NH2\TI4==M(F]M.O/HT9E9O';PE
M;A;W5CAQLK?6P+BWKH<BM0IMAT^LMN514^W4A==IT)U240JC4J0@E=2@0),B
M5$0VZMUH):<*4'UZ?<Z6;ZQC56\1C@LHE]T3;6J\1&VM.O>O7Q6MN8% FULQ
MY2+QH%331*I1*@5L"/2I;=9*:;&54GHT>9)/EQ'GE8!1#EQH>@Z[BW)]P]S9
MC&0;B\<7#+MMNA&V%N?>.QZ'OC66Z.S0MNZK/EHJ\V9<T6:];JULQ(<AQ%-G
MN0G4KG@^4RV@E:D.%""B?7Y>G.U]N?UA&J'XC?#AMOL1M/N?Q*;\;&6=5]R:
M/*JD)5F714ZW;E6BQJC/BJJ=MM3X#-ROT)A$7DFUBHTN-#1-$A'GG&=+F^\0
M&%K>W;UMIS?U?[:%W6[?EMT:\+1K%.N&U[CIT2L6_7:1,8GTRL4B>RF1!J,&
M7&6XR_&E,+2XTXA9!!(.""-(Y??W[_F/!N#8%G[HV?7;#OZWZ==-HW)!73J[
M0*JUYT"J05J2MR-);!25-J4A*L @A2000<:'0\FO$-OR]L?KY/\ -E50\-#@
M,IU-E2E<,&URD1XK\CWJ*YE(8;4XDX,G *2!U[GUQC7BJIZ*6DG3D> HDS"D
MEQHE6MP1H=]_./12RU3JNF0DW,U"18%LR@'TO];Z DQ$]6."'@ZJE3K<6B[&
M;=,A^5.G*<:IJE^Q.%QP(;RI\^6WA)..IQS<I.OF1QUVD<5CC#%:'"JL=V:K
M)FSJ9"G"2D,63<O9HW!P? :&GPJAF55$)\R9*1<IL4EK-INQ?3D\)-</AX<&
MU)@T;<"[-OK(I=):>Y)5+AT]?_E9T.J2AEM"G.=SF#>5%M0Y4],ZW<[(Y&+3
M>"Z2LQB;+G3:@ARD%2LRBZ;^6Y-KW-HO+#DR\1$SA_!L"5,G=TI?>)3X90&J
MEL20')8->YYQC"/#]X2KGNF%>UM;;[<,[=N3X\BH1Y$9Y+L5;!2E^"E"G2&D
M.$#W><85T!ZXUE"93A(!2)802Q4;%)NZ2X=]&(/K%473?TN@G8'586?ZG,EJ
M)"98)F9OA6G*&;1PIFY:0P#A7-.VT\2E=-I<6/2J+3=P-R*)2X45)1&@T9V/
M6FZ;&CI)REEB#[.VWDG"$CJ=;O<>*E8A^'>DJD.M$C .'*I))<_]JJDEGT2R
MF?0"/DOV84R\)_%?C&$U,M*)D_'^+\/5+(("5SQ53Y=FL<Z4'34V$,'XX=U9
MF\'$ON%7I$]$ZFT2>[;-#<:4?9S @2'U!QOJKWBIPI41CF4@Y]2?EMC50N=5
M+ T!T#VU8-;Z:;1^@O@;")>'X#3D(NJ1+)?=2@Y(^1:^[6V06W4^^P!@J(Y@
M?AC'3Z#\?S=,]*$FQ.SGS]\VT\V:+CGWEB[Z#EO\]AI];&'#VH@%]"A_J(5V
M]X=RKE^DY_-@_ ZJ4@NCU_?ZZ/HS;Q0ZY;2BF]DV.PV\GO[>'+VJTM7E*2GG
M!YDGT">8\N?3.03V]/AZ^I+Y@?EKR&E]GWZ[Q9M4JRR"][MH Y:YYGZF'46?
M'0 WE1(#:4#E!QS$=LYST)Z^FO;)T]#]XMFL4&+V T^=@=.3\X=S9,5;9BXP
M?+0E:?\ I!0ZD?0,>A!.<CX5-" 4@[&S;AO?/8Q9=<MU+(8:@]'_ (T].;0Z
MVTD)6ELA02HX201C)5Z]NO8$XZ_#ITU5I8:6&M<7]1O^^T6?6%PHNVK=0+[\
MF\_D8</;K"4-@*PI0#:3C.,K'<'U/P_C'<EB$O;3Z^OO[VM.^)1U'MQ\][L(
MNNX%F1;ZVPOZR);:7H]VV7<U!<;7^"HU>CRX*#D9(*''TK2H9(4D$#H-7+P_
MB$S",:P?%9*BF9AV)T->A7)5+4RY_P CD(;</UBU.)J"7C."8QA,] 7*Q3#:
M_#YB5&RD5=+.IU#0D6F6U;6\:_/@^W7*L#BLOO:^J*\DW59]>H[S!R1\OV75
MV)C8&2CWDQ45A',4$D'&!GIN]^);#Y6,]GN"\0TXS##\2I*E"VN*+%Z52%$L
MYO-%)9V!N\?/3\+&(S< [2>)^$JE02:_#ZN04.;U^!5OPHS ?_IYM8IR 60'
M$;//3 _6?SG\W\=]:&1]!AX<Q%V;Y$]/?2#T_CO_ +OC\^D3JL\P"WOU@_6?
MX'\?#2.#V;J_\1UN("P?H(^GO]&/V]=00_J&]^_T;L2H%AI[YQC\IL 'O@Y
M]!ZC ].G\#.C N>8:/;(4Y\F?T:_WA/:JRD)6""$]<*'7!)[?'ZL:\LVROG:
MV_3WI:*U+4<N]VY:ZV>XYZPBUS,-E.1T*N8'N<GWCD^@ST"AD=OSZ\Y +@[V
MW 8\];N2V]W;>*Y0A<U/DY]1I\^C[^<(_7]N]S;DM2X*IM10[4K][4UV#\@4
M>^9\FF6O5>=]/RDW-FQ0IYL,QR5L)!2E;N$N*ZZ\9E2PL(*]2P!(YWMY-S>]
MCMUXYQ O#:%:4C*O(H \V9FOM?;D/-@&UO&5QL[C[W[Y\-UI[!\/-/NKAO33
MSN"XFYJJW!G,3CEIJV9!)]NG\J5MM-NAM DJ; 5C)'.NP:F_+(J.\2#,S,ES
M;(SGD;FW[1AZBXIQ.NK9\IY@4E22'58A9)2 .F6[MJW08QN/QU<26U$^P+WW
MSX=:9M[LIN-ND-LJ-'>J<AS=..N0_'A0JY*I:I)IWLDF3*CE#@=6I4=14I"#
MD"D2N'9%1(G31,"^[EE9#L 6)4D.^;*!JP'(VO697%.(8;/")ZEI[R8$)NY)
M5\*B!H^AU4"YVBS5+?&W-Z.)+B(X<+_HMIVU;FRU,H\JD7_4I[-,DSI-;0A,
M5F=,E.)CH</G'RVTIYU+3R)Y]4RNX?FT]-(JZ=6=*BOPW+=V0'-F*5 N&VMN
MT9!X/[15*Q0T54M20CN0Y597>E1+7L4A-[7<'468#OG8M0V\NN30920]$4%2
M*9+0KF:ET]]*'8ZV%E(YPIE:"A8'*L*RGIJC)F+5>=X $*#'1DAB=0.5RP(9
M^<;=8!54^+4T@4\X3$I(6O*740]W8L3;*0+<KD1.5X0[5Y/;1U!;6XE,H]%^
M4WD0:$^PDS&5^<\75+6ZE(+;BNJ.51"@,=]:5]ITR3_U54(D57Y0E*1-"IQ"
M9LPI1E6VB0S Z@J!>-<.WV=AJJR1)10SZB8A2P9B4@]W9+@DJ>Y<^%@&]#-W
M0YM2I].J"KA7&D(IZ7'VZK%*/*E-A)()0/P'$_@D8"<]M6UA"I4J1/%0L+"
MHIG)4YSZ@A0L4EQ=B=";QJ[5)3,G2TTXF2^\8*ES 00YO\AKMJ=H3"Z*M<%/
MM6HUBT!$15JX^I)C55X"2\E66XGLW^DXHH5E* >H)SVP*%B%3B$NDJOZ?4I
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M1)+*@XRP\ZH*2%"2Q'J?T^D/OE&O-U:M^D1D6W<NQVY7#[P%\%NQVS]PT7Q
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M(P&W=R7+'J$@25N.T6;AN:TGF*V%Y(2\PH$<A0<*]?H.J56+&5)3\0:V_/\
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M%^QO/A!R3J_)^+(5B\M80G*I.8Y@5%B7RD^5K :^L8=EX4JBPR90/-SE)"U
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M)1*E2V=Q=O)E&N*GSZ(Q?%GNT^MTI3S2*I2&[CHY8J-/4^@.,)GT],QZ.IU
M<:$ADJ2%IP"^GZ1)]^^L89P_;'6;PW[,;<[$V)(JTJS]L+9A6G;K]P36Y]:=
MIL ++*ZE-;8C(DRB75EQU$=E!S@-I QI''4ZWV;EUN1H=FUL89OQ->&+L?Q)
M[IRMX)5W[V;17E<EOP[-W,?V,W!<V^C;P6G EMOPJ%N3'CP97RS&AL)=A,S&
M'(=0%/EOL!\A#10]?.WOWUT ZV+;-^UC\F;G:%[LW@^V>L#=S;O>*T(%3M^M
M;7[(2^'^T+;A5'-JPK%E5:G5IP.0W8ZYDFL)FTQI2JFY+)>2I]QYIQ]U3FD"
M]PVNGZN1_%^>L)Y4O#MX?*WPY[N<,%>CW96ML]Z+_OG<NYG7Z^&+EI5S7S=#
MEW5&3;5<A1([](5 JCBD4IYM"Y,>(5LK?<*E.%[_ -P)ONY<GY7T/5V!MSL
M>O?WP]-A]\]NMGK 6;XVNG; IIC&S>Y6SMQ)LS<G;N-3*>W2E0Z'<;<22LP:
ME!9;15H#T5Z/*<0'U)2][^GOW[_2#EQ9QO\ 3J_GTYZPE]4\*3AXG[&6ALC"
MN+>JA52S-P'=V*3OU0=QJC#X@'=SI+;T6I7M5+_<CNB?/JE-?<I$N(]3E0/D
MQ+$:-%92P-3L;L=O?H.7G![Z.G6Q%]1=[-<@>L7*V?"QX?*/L1N'L74KAW@N
M\;M;E6UNGNANS>MZ-UW=N^KML^M4BKVY(K=SR*<&W(5,9H=.H\:*U3FVVZ6S
MY(/F++NH@'+V\.@'EY_;^8LNXOA+<-FX>ZLV_)MR;TV[9]>O*C[DWUL):&X+
M]O[%;@W[0GH\F-=MWV9%A!<NJ5&9$B2JM[+4HK%1EQDO/L@N.<[;IRW\_H(
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M=^;,P=^O*21\#GC\-U4*;M3PM!=JO#\5IAU)I%30X\Y3^8$:O_BFH%578[Q
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M#,E:7HX(<Y5*00<:>_3GZZP+;#D= [M=RS@6;[1&IXB='XKMTJWQN;,2=O\
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MG-O;%LJC[$V)O34;CK>YM%:K='1>2O\ *(=Q6U,:B.T*WZ>C"8ETRYB8U2D
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MC5ZG5&8AZWZ&%HCPMR:I;%,EM0W+YBQ&)+M-=9@2&6RRK,Z,>NGE]O=N<O\
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M+FK #OE15)J)>9Q=!'*+J_#KQKBU=P?PEQ'(J9RE8:^!8AE,PE-7A294D!9
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M;Q'3&=1WG!OS$M9'?)!/^0 &O_(6\C8Y2X=Q:1CV&4V*T"D"EFI$QTE)2I)
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M2P:E3+?98DMI14)4Z-F.R'5$MMJ<YTC*B.O3X9\V!U<G#<8IJBI2H(DK"U)
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M:?OI:.":V#D/<Z@4@))<("5#H">O;UP#V_,==2U900U_A<=''K^MH[!1O8V
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M[MH0\2B[9WS!OVUXE<B!IMU17&G0PH%46=&5Y<I@G)R&W>;E4?PAC'7M]+N
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MZF0J_4D49JNT7=:\AN79EU.K4'6X-*K<*H3HD5Q"WVFW*?R276W5J;3$2?\
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MDT?9_;3>.LU&5?\ ;5*NBGT"8E%$IM3BLOF*'1S*J#,A.'?95\W*VUSE*1Z
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M0B-5>VZ!:5&D*;;>JU1K+#SD8$^\X8B,K7A/9&/>)Z=M5.3PU6S+]WEYYB
M_,V;T!ML;Q:.*=M7#M 2B34"H.7,0A!4H$%F \3N#T=B+/$D>TG@A;96>W'N
M#?2\JY?TJ')"S;-LI]FH]2'0-QYS2$^?R\^?,4AU">3\+5?H^&9,HI75*<A0
M\*2"?4Z@'H-#Y1BO'NW+$JHS)>%4J )H,O-/&1LP8%* 6*MSH+,^T244:)M'
MP]V]!LVWZ)0=I[>88::^3;?CMNW"\PR$H2J;,;^^+2X@@K6HJ4D$]1@XNZ1A
MZ:>63*EIEAA8'QLUG+>6O*SW!LV@PGBGC&9,K2B;7JNO+,5DI$J\1M;)9B
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M:FXA+34E$5F2N$XRHYFT27&?5EQ3W)][_P .?;+P[^*/L<F2<7[I/$='22\
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MS%E).AZW_2&E;@UFB6=O#,:I\?SYLA5"N1-/A)0X[+K$=2FI$1OI[DB:RL*
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MD7*FIE5""J8F7G,O)G6?"[',0DD6(.L6KQ76"NPN9,$D@4Z]%?VU3 G-?7,
M&9R'+1-;3ZG3*?&I5&54HYGB&PEF,N0VV^^AII(4XVA:@5H&"04 A0'3OK>*
M964TJHE42ZF6*A3$(L%+2-&V'/7;2,-_EZFHES*R72S%2'+F6E2I:+Y64K2Q
MU=N@(-\B;D<WEA625\W7E*1[H]>;J/JS\V,:]BE@*"2",Q.3?,VNUO;F/)E4
MDL2E3:Y69-NECMY1VH>!Z'J>N<=>QQC/09^;OJ2K*64+\MVYW;]/U)P="X%G
MZ\K6Y_*.?..^#]6HSCK]/WB8Y$A()/0#OKGY0B SQ9;QXB-UMV+ X9.&*_FK
M$N';3:/<+BPO^IL7!(MR;-J%H-+@[.66[(]MI;$^EW3<\.JFKP4S),=R-$;1
M5([<=UI;CWI'$/Y^=CK;0;ZZ=(5BO^)I=E1V/X+E\.FUD7??B>XQK0@5JSMN
MY-:E6C8EOL6Q3('^-RZ;QO*3!_\ )5MVK5GGX4;R8C\RJR2T(;2XR@ZJ=NO,
M[_9S^GE!KGEJ!^G-G:T,!M[BWWJG6UXJUY\1.WM_6=<.W.^/!W9SNS,/=FH0
M(5J3:G4&*35ZAM_>UN^:XS9]Q5!3=:B"/&9<K5,9;B55A!=>"8YMZ/Z^V?H(
M$_S\QNW[>FH?=Q;^(_Q'<.E9W!NJU^%>W97#_LE(I+>X&X6[&\%$VVN;<2G&
MG4^L7'(V%M*>IU=Z.6]2WYH2[47H*:Y4HHC4]))64A?U+=/8@S7U8&Y-_3;]
M]^MZWB\1??"X-QF-K>!OAL;XB+MM79NU-]]Y3?-V';.CV;:-]4)JXK"L^@S?
M9)7V1[EW537'GXU*8(IT5*&Q)DMN*Y=3]&^;_HWS\X-ZCZ;7W<_3R>$^WQ\5
MW<N@U>SMOMA]A;0G;PQ]IK;W@WNLGB1W@M_8]&UM/NJGSI5LV)">JSRG[KOR
MNS*;/:99I++M+@0V(K]5E179S#1CW8;^_P"!!O7;R&C6W^3Q6H>+[<6XU*X0
M/M6M@9.\%S\7%M[Q-4JUZU<(M==B[B;2SJ91:U2KIK"6WZ<BT*+7)%3CURYX
MJWT/1HD!=+:?=J" A^GOU\HAF#D#4AWM:]F9CM8.]X:CQ9>(9QG;C<,MC2=N
M-FK<VOWEV^XY+#X>^(>UE[MOQ*9$O&!7$3K?MNT+II]*DJN"PMP&_8_EZI/I
MA3J7%"F5PGTN.A$L#\C^NM^7IH.<3OKYZ6=M+;Z7 YWC9&VUFWY4K(MFH[G4
M&BVO?\VD1)%W6[;E7=KU#HU=6@>V0*76'HT1VHPV%8#4M<9A3HZEM.HB6N??
MRTM]WVC.M('0^1^T?,&X\/Y;?%W^4KO=_:/<>D<C^@^T;V/@G?S47 A^3W9G
M]0]K@KXD^?[1$2D:YP@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"."
MQE*L#)Q\,]?]OZ]+[,_72#@7.F[:Q:Y]/8J$54>2RB0RXA2'&'V@XVXA8P0I
M*@>G7/KT'KKR5=+2UDE<BKIDU"%C+E4 H7VO^H'K'9)GSY$U$ZFG&2M!<%)9
MFY<CMJ/VC"XQ/#CV\XB;2J=,8I+;$MYUV7';:+4>;2YZ@2*A;DU2%(@R\_YU
MEU#L&8V/)F1W4<O+87".&<7]CG&,[COLSQ,29M:I"<<X5JU+7@..T865*D5-
M,A<ONZE*5*_+5<M2)].IE)4M(5+5<V.3^&^TOAQ?"G']"9B922<*QZG2E&)X
M74A.5,^1.6E;H)">]E*094Y(*5I#N-3[>G@BXJN#^^W*U:D6[)4:D2WW:3>%
MF(FPJY%:CK&!5*/$=7/:RVH%U<85&D2$%8]J5]\91] >$?Q!=CO:U0GA/B_^
MEX'CM9+_ "^(<%\:RZ=$BL64D+_IE56H&'XK()!,LR9B:J6,IF2)9RDZ;<1=
MCO:5V<U_]>X3FU^+X93J,ZDXAX8F3354\M*O",0HZ=1JZ5>RPI$VF6Q:8H.F
M+-!\13BBHSR6JG-MVJ5^GM^RBK5NUE1[ACN-%(YY#E-E4H.26U) 49<5S)Z.
M(5VU;V)?@?\ P]8KBLG'Z+!<:P28)AJ1)X=XFKZ+#)XFJ"V-,55$H22?@33J
ME!*3E00DM%SX;^+[MTPC"YG#]1BF'XC)2 @C%\&3,K92I:2@%2I<RF)6'=7?
M2U%2F*GN]AKTSC-XX[B@/5]%Z7O%BN#V)R7%<HEBV\T\ EV2SSMQ*.R0TR2X
MMKVJIR$MAML2'5(;5D7$^*.PG\.N J7BF-\/<*R),GNQ+GUJ*SB#$52DE29$
MN3GGXG63EDLE 2)>96990@*4FSI.&=MO;[C4BG11XSC8F3TJ25R58=P]AHG%
ME5*U+$FAD2T)!4I8[R<4@IEA:B$JD#X<K5F\)--GLV[&1]G=9;8:NFYY43RZ
MB\RTL/(I-.2XKS(%%9?"5AD'S9S[29<O"TQV(NGW%G;;A7;=B"9]#BHIL!HE
M*5@^%*6$9$K 3^<K03EF5D\7)^&1*5W$MVF+F_9?\.7X0^">R[A"3_4JB3CO
M&>-4J)G$&,25 TZ%%15+P[#04=Y+H:5TA2E>.JGI543+&5+E2)6'N);&\]JW
M/(WEA1U/6>U%=CU-AKRG9*9B'"EC(YBM]/(">0COG'75FS%5\E2I?]F=1RFR
MS)!2I2-?^)#OL+L=3O%\8SPWC'!F.4M!PC/F*EXI,4A<E:F0 G*HJ(! &71[
M'X=6$4VBW3V<H%PO6U1*!4*2BO*$!NNOJ2\[)<</*PTX!]\0V5JQASE P1TR
M-==1WRY 69*TRYN9"9A<A1+LD!F;H.7./1QCPAQK54",1Q"LD50P](F_E@?"
MG*'47)+J"1JV[::Q&^.!#7;VXFQ>X[J<,UFW*I:CODMY5YE+\Y]AT+ZH4GWD
MJ"#\,^FL8<1(FH*4J!2;C*;/W;@MMN]N@>]KI[ L41A\G$J5>8A55,[U(N4F
M:@S0R2>:2'Y$1(]X0L:3;_ ?;,IN,%S[DNNYZDD)<"W'E5">E"'BH'HM*$<Z
MD=T@'MUU7\"EIEX<B:LY2;H)W.BFW+,YW^<8G[9%FHXZG+)*S)I)2U ,6422
M4Z-RMRLV\.(WEX4?LNJ+=S46LQ*3+<\LUEJ0R#%E<J2MV1D%)3)&4I\Q2L<H
MP00,B[J&K6OPR!F*4D* 8!AJ7+@B[WVCV<'=K%3@U,,/-.9J<S2RV=2; !+"
M]A<#K>.[:[<W9K92GIL1BOL3Z@N9RU*H,M.N1USY*@TIM<A"?**0L<O?"<@$
MZ[)U/^80)G>&RG*TADN-G+'PZ7%R^T=7$_#_ !=QE/5CTVBGHI4RWE9U $(2
M<P)N,IN!EO9KOKDF\=L[8VE#5O JE17:XVAIR V5(\B9*D*PPXMC"2IQ*W![
MXR0#]&J0O$Z'#IAF8C74U-+2? 9TU"0MMR'=G'D]HI_"F(\1XK._Z7F5,U-"
M%9)ZBI23*0DL4@DE+^CW=R &;[MOO!OQ>E[QETGR)-&5(99J<*6TIFFPH7.5
M.K:<4I.7O+QRH.0.49"0<Z\B.,N%YL]:9>*8?4K4%).68&!(TL6&_+4 $EHR
M1Q;P3P5@&"$S5$5IE%2%RU@S%3<H8V#D9K<[N6B0:NWO MNF)D2RPLAL<R65
MH<4H\@Y@ W_HA1/+G/P!!UBOM![5,"X30J<%2UY7*1WF8JN+  N&+=?I&OU#
M@4S%)[(4L(2HJ"E.$ .X))U.5M-SO80F#MXU6O(3,,R-"MYYEX%MOI*7SI/*
M[SK)Y2V,YP,=<X&>NM7%'X@4XY0S.['Y-LTM"P2E11L=1ZF_T$73)P6EI%"4
MF7,G5H4E0FL\L#_BQM<OMZEC"3RJ[!I4E"F*BJK1TO!UE#@+I>6L\OEKS^$I
M &04# ], @ZU?QCCE576(FR9TS$:D+)E2997,SK-LK"VI>_4C6+GFT=2NFSS
M\F&]TAUS5L@%(T/A+\AEU<O>\*_MWLQ<F\-;1.J#Z[7MM?() =<:9DS(S93E
M,6,K#I+@)Y'5)Y!_JD:R!P/V1<3]JF(T=?Q#6IPG!D*0H4A4F4N=+S J&4NH
MDI#'EHXN(L3BGC_#^$:)4FAIOS^)34*RU205!*BFRB= +Z%SZZ.T8F(V_<?V
M^V<HE,0ND,MLU^[*L@2&S)"4A<58;Y')<@I5EPI/*C('+Z:VCK\:PWLJHT<)
M]GV&4DRME2TIK:]:$J*U3 R@I1:X.X<CH+Q@NJF5'$(&,<5U\]0G+4JFHY2L
MK!-PZ7?30J+@$0U7<NT=Q;/76=Q*)>L*D/U&9'$RAT6,8D.HOR5I;4M+<I10
MAU.0H>7U5[Q5D]#B'N\5XDQZDD+3)E3\1J4)K9E+\:$E8*U#*E@+$%GU&@TK
M5#B.&+I5R/RDZ<FGD3%2#,95T D!6][ZV/UBV[!6-4).X=QW=?[+[M?C0(LB
M F>@*><$UQ(-12!S)*TA/*TIL )0L'IG5S<<X!*P+$Z? DH2C#C*E5!"K3IT
MT,<SMXO$22+WRQY*O&CB."4U;3-*(FS*68E (0@)<9%6&K;\B(]O%K<$6;]B
M]C4R4J55FZHW6)28_-[1%;2RM$0<Z?\ -.K=4A:4J()2.@[8\N"\#J[1^(J+
M#)* ,*I@A,R<0 4 ,E0S,V8$',URXNT,"QNIX1P^NQ4T\R>:V6J2E)_R&;,2
MD;L0P.Q)U>_/9WA@OVX;MIM9N'Y2@T-M,2I?*+\I2IDGV=2%ML/!:RH-C*LM
M@#(Y/GQO'P3V=83V?R_R%%+EU%,M#S)Y"3,3-9)2RF<!^6E_.,:8YQ)4XTDS
M)3R#.4TV7\)"5?&-=?HXT&[NN)7A?E;P,6W<=DWA6+'W+L6-BUJ[#EN(@N*3
MU7%J<))"),:0,H(604A70ZI?'O"%;Q A,_!JN9AV(4K+1/S%(6S^$7?IIS8:
MQ>?9MQ_2\']_A>+8;3XK@6(IR5B)DL+J)*5,"J4HV< /"5;,\8-?M>YHVR?%
M52&[!W'94J-2KK4AUFT[Q0"$QI%.J!+D=F6^WT,9QP%3@('7W=6IPQVEU>#5
MDKAKC:4JEKY9[BFQ"<#W,\  )5G&8,IPRB0'L3>+IXM[+*#$J*;Q-V>SSBF$
M3AW\VAE*"JJB!<*2M)RJ\%LR=0"6)TA[]?W&M*RC;K58J;3:;LJS-)HCS2PX
MU)DRF5O-CG!(PIM!5S#IU2-9=GX_14JY(GU4F8JH8R9H6"C*KX4 N'4WD^Y%
MXPG28)6U*JB3)IIH73A2ITO(H*3EL2H;#0%S"BM/\Y2H+!2L)6 ".H*?3UZC
MJ.@';UU694TS):9AE^%3$$M=QJU_9BG+3E64YAF264 SVM?UZ_(QZ71S-+ S
MU2<<N.;Z1GIGX9[:] -@?(Q!B%RG>$KMIO[O_P 2G$CQL6LU?UY[C7^BD;2T
MJF7Q7D4RR=D;2ABFVI24+I#E)4W.KR_.K=>@NA]IB:ZEI+BPC.D<7>^K<K7:
M^IZ^VAOMJ^&GQ1\*]6MFY.%,;;5IWA?WKW-J7#18^Y%S5+Y&NCALWUATJ1?.
MTU:J;3 DV=5+'KM+8=M"L-N3TR8[DA,AA#2VVTS:YV]MR??E$DV9P;%]NATT
M]CR;AQ1[3[U[&[!\>&X'%W?.S4'<WC*WLX2;KVXLZS+@8CK(L:]*'#KMD6_2
M:FMNJ7"]:7RK"A-U*.9DRMM(<J+K,=)2G4"WOF"_W_F(+D=00/J&?70#7EM"
MJ\8GAB\5_$%NWQ+3J/:W#=NO:^_5GL4[;7=S?2K7?,N+A\IR[.CTJ58EM[<T
MZH,4*6OY3C)E4.Z6H[<FG.39$NH>V*RTF0=#[.][M:VFO.!%_P#3[Z6^1>QZ
M."XB-PL\>7#O>KN]W"S1-G[MO[>;AQV:V>W=L+=:[I$*A[:7UL]:K-LV[N#:
M%?I$".;OI?LBGOE.A/-0U27V0XR4I=Y6XB2WI;H+>7GH;&$LX@/#>XFZGN[;
MO$E L/A4XQ=UMQMC[-VQW[MWB HR[9MBC[A6)#F?8]N;MG*@I>EPZ4I=2F4V
MX[4<=4:JPU$F,O1W@2B6YN&O[#CVT19W#>9/GIKUY0Z#;'@/W3V^WLX![^)V
MN1;G#UMWQ!TO=%%B42-8E$BW3N]+MNIT^!8UHPHY9708$JG3H:YLE_VYY++$
MR877Y#JA!]^6WTB7< !G"BXYO8V\[N^_G")[N^'OQ+U/;?B=58R-MJE?-V>(
M'9'&!M;;U?N273J+<=K6<W!2+?K]78B%=NU*HN(>]_RY2&0UREP>:A:)'ET]
M3R_:.-B2;;%^@(U]1RMZQ.+MW-O>IV3;%0W)HE&MJ_9='AOW90;=JKE:H=*K
M3C>9D&F55UEAVH0V',AF2XTA2T]<$8.HCD[^_?OZ9KI Z'R/VCY@O'?_ "VN
M+O\ *6WN_M(N/^#I$QO9>"=_-1<"'Y/=F?U#VN!/B3[UM")2-<X0:0@TA!I"
M#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$=:FTGKC))ZX/\?[OFUP*$J-
MP[M8Z<OM[VB02-(3?<#;.TMP:>JFW%18TY+@*$RU-MB5'/0A;,CD+J%# Z X
M.,$$'5F\4\$X'Q13]Q6T,I<]3Y*O(GOI)TSIF 9P1=B"X,5K".(,4P6;WM#4
M*E_\D.<BAR*78[W9Q]X[[VX+)E!JLJKV]3*/>L%'M,B.Q5H5+<J<-"$E;;"7
M'HZEOJ*L)22KF!2"#GMKCQ?V9=I7#TB<.$^.^,YTA0/=T<CB;&I-/)E@6EB3
M*K9<L !DI3D;*&##7,&!<;\%8A(ERL<X<P-6(+6GO*R;A%"N85:DF<NG4NZ@
M^8D'F=X;6F@5&SITV77J8:%/=<5)%&GL+8;82QT2(_*!'"5(P"4JQCW0.G34
MOB+@SB_##58UQ7,Q*MGRU*F9ZV;45<Y2@Y!,R<N9,468.5/III&=,(Q3 :NG
ME4N%KIJ=*TI2$4R9,F6E/,)EA"6W\('WC#WJ5:MX4:?.K-L,KG2GGDF8RPAQ
MQMG*@'2ZE.4AD>^$Y"E8&.N=4;A/CW%!)J3)Q6;A9DE292,TR4IDDA(8:&W/
M7IK?$O$<7PBHID46(*,I*$#NT+(2Q\6C[^;;[WPB9MW3X%LO6W2I#?R?7)3;
MTF4E*D2?/!/LG,H@<J6L!("NW;L=9#X:_$/Q[@&(RI$V:<3PQ2BA<Q1F++ .
M"7-G 9_I>*S38[-7BDO$:X+F3Y"5"6%J<792RELWQ 6;<:,[8C0]B7K<K--J
M]T59+,1F;'7#BTMOSI+TN.Z'V0ZZDK+85@>8D 9"L$C6T?#?XG<,QJFH\)Q"
MF3(JILY*90EH5F4O,UG) N7?E>*EC7:&BNP^LIJ:0%$H4E:UY@$I4"E0"=VV
M!%B ;PP;_""$M(L7AA4R>0KJ5:<"0>58"Z8Z2LHSG/-@'(&#K)G$DU-1^4GI
MTFRC,%],^51UO=_/;RM3L9F3%56/%U _GI+$'3^V;6Y WY"VD2*^& [2K7X%
M=DI\Z8E,9SY2F.R720TP\[)?/(X0G*4XQG((!/4XUV4>+T%%A$FIJZN53T]&
MI?YE4TC>P#%^7(';:+5[4*>;4<;XC*E',?RU,S:J"DG2]SZOKY0_"XMQ;7J-
M"F,MM.UB(]'<;=7";<+;J<%MQ*'4@95U *@3G.<]M6+C7;;P/A(5.IZM4]*;
M%4C-D*GW(Z@._G%D8?@-=)J$3E*$E25!8<A5P7^&X.]MFMJ88X[L!1WJS$K#
M5/=H=$7)$LM/R&I "BX74J6@!2FPM7)W'?X:PQQ5^)'')LQ=+A-,FGHIB6$Y
MR" ?\G=(;39]6):,YTG'4V1@RL,([U>3+X4%&H2&!?2P/T\EANBU7+A=I<"L
M38]3B-(:$9#Q/L\8QN93*BR5% *<I&<$DGMT&M5..<<XQXJFF;_U-52I!^(H
MJYB1+!4#X0E8Z'KJ;WBU*"?+I3554F1,E3%3,RNZU.:Y+_Y$J%[MIUBXL5"%
M9"/D^,W#D/RFU*Y8+:&B5)3@^T+0$I"<<V%9. /AUU;*NT-'9_AR$IQ.JQC$
M"'+3IBU(4V7,X5H&?GZZ\*A$S&U U*YP"#83%E0R\DI)+:"VC&+91;GA>68L
MND2I\R;(6(X;8=GLN+<62AA*@EQ*5(_! 41T(*3KAA/:!BW&LP*G8)BV)S9K
M"4>[F+E!1&^8L&-G8WL0]H\E72R:!'>KK)5/*3\20I*0PV !LY<E@6(WU"K6
MKP_[G[ESV)8H#]JT=WF079SGLBF&^8\KS41*PVZAQ*N@*<D?A  C&0<%_#=V
MB]H&)4\VME3L$PR9E2E /=Y914+J22SY>AZ7BR\9[4>',#D*D4\Y-55@$B8!
MF.8,DAP'!<:NP+,1#N[?X4[.VZM^KUQUK[(KKATR1*A^WMMK@)J49E:VBU'*
M#R)+G*DD$'IE)UN3PW^&/A3L[X<JZU<N7C.-4M(9U.9\I$Q/YE";92I+W._.
MPMKAK$NU+&>(*^12(G*D4<^<F6L9E9C+)%C=D]-V#<F9W)WHMBEU&UJA%9KL
MJY(599D7'*4)D%N(TQ(Q*IT>,2VP\RIQ*VF4!M8\M *E#.L:]G&#<<X_Q@!_
M3:J@H*>J4DK&9%,$]XP"4A@ D:NY-F#:>S'DIPZB$_$:B3.DSD-32TJ"U(LV
M93CPGD.8)=KE9[LOV5M8V+N^QR=5K:W!EN7+"?:6EIR)-G(8"Z<^TL%73D"@
MO& >@P.NK\XZ[(N*I/$<VNPY2:I564J5*200DLUF(<]"'&HY"W)=7AE312E3
M:L)F)\"99#_V] ;<Q?D[[EX;#6KGW$W_ +RIU(A4YZ' 1,;73J-'Y^1D*4@.
MS)ZDD(6XD#F;).$G(2/75_=F'9#48?5S,9QR7EKZ<B;)IE,0I3L;GT//3G;R
MUW$]/A=!.IJ6FS&=+[M51E)7X_"&.H S,!9[[WB0'<79*Y6]M*!/LV?+C[CV
M[3&XSDJ(XEM=18;:<\R+,*_=>2SE'E=?PD@CKJ_^.NRK#>-YM/4+(IJN2E*0
MI&0$( R^%6MAJQ'6*!@?%*\!HZBCJ*1%=3U*C,0A:"H(FJ=0(+N'L^GH'AKN
MRG#3N#=-^L7'N*W4&VXLQ$V>_.(6].=94E;6'%%1Y&G  A&<<G;I@:JW!' .
M$<#2A3TX$Z;+!S3R 5*6M05XBD DAV-]M.?EQ''\1Q,'OD_EY)#(ITDA,M-@
M&#MMRW=[Q+Y$ALQ&6F&D!#;+8:0D 8Y0E(Z\H ].FL@.5$GGY\SSOHV_\T$!
MK>9]=WZF/0II"AU2.V,X_CX:X*0%/SMKTB8;]O\ ;.;3[LV74*=N?"IJ*?#;
M]I8KLHQHLVBOL^^W,AU%:0]%<:4G(4AQ/4=>F=6-QIPWPYC%"N?BYIZ>92RU
M+15_VQ,ED#FV;J&N]XO#@[B7B+ ,1EC!EU$U-0H)F4(4LR*A+CPJE)4Q'5GC
M6?WMWIN:TKXI.WEK[LS=R;(VQNN/6K<K3TIUV2AR$\0*4J65_P"4HB,#R/:0
M/OH7CFY01K0/B?B_%,/QY-)1XO4UV%896)F4JGF@+ 4Q 46SI2 P &74WM'T
M_P"SOLXP/'^#JS'L0X<I<+Q_%\.F4TR24RGS&6Z9QL<JE%1ZZV</&S5L'NM;
M^].UMJ7Q;TQ#[-4I,-$E""2[#J+#*$2XSJ3U#C;X6DE716,@D$9WZ[/.**3C
M#AJAQ&DFJSRI2$3Y:G"DS$#*I*TFY8N/3>/F'V@\*U_!W%.*8/B$E4F8BIG&
M2NQ"I2UDRUI4EP04_(L"!"\)Z-IYL_@#FSW[#.<?KQJ_OI%F,UG?9^>WUCB'
M4$'DZ\A*<)Q^$.G+W[Y]._Q TCB[ MMKMH/*]HX*6TKN.;RU#/;*#Z]CD*'8
MIZ$G'TZ0?0MK<_S\WMU/.$IO_8S9C=>LV=<>YFUUB7_6]MZF:Y854NRV:57I
MEIU<NQY!J5!>J4:08$M3\2(Z7F"E?FQF5=5-)(/^G[?01&[%/V//ZDZ_,FT*
MDWY(PH)2<JP"D9 4,H/7MD?@GUP,%(QC3W[^\+:Y2?H1T'4=/F\=BT,KSS)Y
MLD>F.J1TZC! ZGJ3C).<:1-C=CZMJ#TO]'8;[\0& /+\I(&>B2$D _'X#/3J
M.^1I ,#U-[ZO\A^]]!':DH7E/+VP<>GS=.W8@_/GUP=(E@;-^U_?IK'(MH5C
M*0>4Y (Z9 Y1GXX'IV['N!I!@&:WM_?[._(  D_''KTZ? :1,5TB#H?(_:/F
M#<>'\MOB[_*5WM_M'N/2.1_0?:-['P3OYJ+@0_)[LS^H>UP+9@YY;=?>T1$I
M&N<(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I" ]?F^C4$/Z/
M]81TN(]WH3^%GKUQGU].W^[KUUUJ!2DM=_?77<Z-K".M,= 2GIDCJ<@$J/4Y
M)/S=!\,_3KE+ ";@%W=P"_4^O4^;1Q(W38N]K>_6,7N.Q+7NN*_#N"ATRIQW
MT%MQ,F&PZZ4J[@/*1YB0>@.% =/SZHF+\,X'CDE<C$\/IZF6OX@N6DN_IZ?S
M>*E0XOB6'SDSJ6JFRE2RZ %J"=3LY3YAMX:[>7!C8E9"7[9J%5M1U@J4S#I[
MZD4Q;A!(\^)T0X >_7L,$XZZP?Q#^&S@C%$3S0T<JBF3E+6!)0$,5;!C:[&^
MM[B,B85VLXS23I:ZP?F0C*"5$@L&V#[7LW00A5=X,]PFX:HT"XZ75FTN>:P#
M!1#?"D$J2EUY+Q*TJ_!)*0.H(P0!K$6.?A@KZ>D[C")A)$UPL9"HI8#*KQ#2
MPU/WC)&&]M>&+G*FUDE<L]WERARASE<ADEMOD2;AX2"\-@=T[?\ DFIUZ@4^
MGTVFU2GNOS(E0$QUQ?M"6_O<=)!"E)&5<W-TSGKVMZC_  _<2T'$7#U9W*?R
MV'5$N=4S"&<)(44J 6S6)9CIS>+IPSM+X?Q#OI-.,TR>E1(*2&VS#P#0D#H_
M,1KS?X03<B'[]V0LE YGZ+0)U97]])]V87&$)$?\%',<CGZDCIG'76TG$*1)
MG4\EPTNF0+&P-AIZ,SQG7L2I!-PO$*Y)\4ZO/A;4(00ER=<QUL/I$F/AFR(6
MX'AXV/2J2ZR[(HJ*C"E-X)\J9#F+==;6DXST/EX_TL]@.FK)QGAJIXDX.XCP
MBGSFKJO_ ,JL$YI:LY5X2"+$$#5N<6AVEE%!Q[^9G^"344<M686#!!8:G>]V
M9NEWTTG9#>RH4")%HE"B,M2VP]&5(#4>.67$A1;<Y%_>UJYLY2G'0'&M-:?L
M [6J6BG8>FF3-ES)Y,N?/S9V*G!<S""6'\:/8-7VA<,49G&=4),Z20"$J))O
M890G79QO>QC-V>%_?6MPTPJXS283)\L%N+."PI" .CK@4E9P1D#H/G.=7&?P
MP=IV-4Z*.IKT4:  "NG*0LBQ;,I;_%R(LT4@=KW"=,HS94I4Q0T"TKL>:72S
M>7+D#&64C@:NIZ2Y*JE\>S1Y"6TBE)C^<(Q0 %*;D>T\QYP,=$CH!GN<7E@G
MX-\4[GN<9QN>M+A+!0!(W5,:9J#IY;VBB5O;Q2RU*314"6;X@V51.A8IV&KM
M>XT>%KMW@EV^@/(E5>I56LNA*4.QWWE"&OEP2"UD@=R!A60"1DYUDOAS\&?9
M]A-2*S$E3,4F%25KE52 N6^I%U&QW:UW'.+&Q'MFQZK*Q2H13)4",R"O,.1<
M,.1)/[0XFU=G=O++0I-OVO2(940M2A#:<6IQ*>7S"MQ*CS8ZY3R]>HUL#PYV
M7<$<+E\(P*@D)!# T\HA-[$9DF^I^9C'^(\5X]BC_FL1J5))/A$U83?46(<<
M@=/6%$3":"0D)2@#LE"0D =,# P!C'I]>LA2I4J6&ERI: "P"4)2 !L +-?I
MZ1;TQ2II=:E$M<E1).\<UQFUI*5)2I*AA25)2H%) !!SWZ?'OU'KKFN7+F)*
M9B$S$D,RP%#Y&(25(*5(44E+$$6+C0@BX/40U2YN%:V[HW*9OJH.1DPXY:<;
MHT:*AF,IQI:5E3C22&E*<*<J44Y)R>^O)1T-/AJ%HHY4J0)DPS%E,M"3F47L
M0--GUO'?/K*VJ2)=353ITM'P(6LJ"1T<N[6Y7A?:M8-K5ZDQ:-6*-"ETZ$VA
MJ-&<CMEMA*4A \I)"@@I  ]W!/0Z]8RF:F=E29B%$@D!3G6[N[CUUY1Y2DL/
M&L9="%,S%_?[6BQVYMS8UD^TSJ);E/IS[3;JU36X[8D<J4*407>3/+@$CT&>
MYUUUM0O)/JIA$HRY2ENADI:6DJT 8/E8C1GL;QZ):IE2N7)),QUH0 1JZ@ >
M>IYZM"%<.&_5<WPK6[4@TF*Q:]HW9.MJWIT90<%1^3EH9DK4H!(YP\%@IP0"
M/S:Q=P/Q97\2XEBE6L)%'33)E-*2EPD]VL)=^99VT^<9 X[X2I^%J7")29LU
M5764<JIG(F,"A2T9V0'^$$L'NQOSAVS+/,4)(\K"05)0$IR<9P>4#MGKZ9SC
MH-93!!8$#<NY.MV]']VC')S*NI2G(#N7N!T_=M(N6NR)%AS@TA&$WM8-M[A4
M65;5VTUJL4&<,3*<^IQ#,E .0VZ6E(64Y[@*P0>HQG5'Q7!J+%Y7<5DA,R43
MXTNPF"UE,1:U_O'KHJZKPZIE5='.5)GR59D+3J"+[VUNQ!!MRAI]?\/+A7JL
M1<=K:^@TA2DN)0_3(Z6'&RX"%+Z*'.K!SS*YE9P<C6-,3[$.!L0FJG)PJ5(6
MI)!3*< FYSDYGS!S=^KB,OX5V_\ :1A*I.3')TZ1)8)D32TL@ !B$@,& ')G
M&\*1P\<,MJ\-],K="LFJUEVWJO*3.;I-1E*DL4Z1R<CI@%Q:O+;>Y0M38..<
M921JY.#^!J+@]*Y&&SIR)"RZI)N@EKOS/4WTZ1:O'O:#B/'U7*Q#%9$A%5*3
ME[R2",P)<YB;[[._+2'-.=&U9/X*>YYCV'?W?>)^CJ>VK_C'I-G'U]^AY:QK
MD[B[?W%QN\0?B(U#<#BNW8V28X+)%-M+8FU]HMP)^WM*L5UFS&;_ %;LWS3X
ME4BLWO*K-9:;@>5<C!H2:9#7"9!4MQ8G1M_9$ 3U&H+. 6Y^I/J][W0_8RYM
MS..[?SA$NK>'=C=^G,Q_#LC;\UZS-I;_ +DV[M;<C<FS]V:A3Z36J_2Z%*;,
MMNJM45AZ1$9_R:>BHR(SJ9$!;,=,#WO$ZO<@<P6V^1W^L)9N?0-RKBX#:CXA
M\CC)WTM'?3=K?VTH%R6 SN;/A6%1[6?W[H]M,\/5!LE-4APZ#4:/3("":G3H
ML>YGU&4F9&7%D+:+]O?+1_8B')"@">@<BX+6Z]?(&,D\1^Z+VDW+Q8[@;6;E
M\8^\6XO#]$CW#0*SM?N,WLOP_P#"74K>M>CUYRU*TTJIMTO=:XGI#<.K5^EU
M:GR7ZFQ-5!B!+WG@R-1;5O6^W^XEV=K .[6&FXWYV_4PXZL61N-QF\;]HV!>
MO$1O;8.W=1\,S;'=>^+3VHO:LV,B[[YJ]QI+-93/H\Z.Y0)$:;(7+DNTEE#M
M3;#<":\8B T8AKOR+C]PVO\ ,-HJD_BWW\X.N"LP[[W5WXI%EWIQ*V]NGLSM
MSO='V4XC]Z[>VIO6XK/L"\8=ZLSH=6NMFQJ=3XT:YJ5 ;5(K<^I4^?+<\QE8
M=>Q[_7T.L#LQ(M<BQ]#SL.08GE:8OP@;S1=7#'7*2;_WGN^586[%\V7/MCB!
M92]NOL_)I\J-,.TUSW*F7-7>J[33/#,&Z9#J9,Z"]':>:;4QRA >_;G3?VTJ
M^D3!I"#2$?,%X[_Y;7%W^4MO=_:1<?[>^D(WLO!._FHN!#\GNS/ZA[7$MFV>
MS?,O[]81*1KE"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@TA!I"#2$&D(-(0:0@T
MA!IK8P@TTL(0:0CKY59)!^CKWZ#/I@? ?0-<,C.RB']\XB_($?OTZ#YQQ<Z
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?$V;+?62MZ3)>=><42I:U'KKBKXCZ?:.2?A'K]X__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g142578g10q14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g10q14.jpg
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M/H?')?2$^_ BKUBASZ'QR7TA/OP(J]8H<^A\<E](3[\"*O6*'/H?')?2$^_
MBKUBCZX)& , BV30,_9=GPM\V5,ZUD(JHSDW8H"%H6L75/EK#.2,#-U*+EMB
MV:4N=K=V#J]6+',M6$7'MXEDK,O G5U!%E'1S/*-4%'M<:M<*E:1"_Q;W>('
MG]8\&:VTZ0TQ%VO9,1:]><'!M+-M/P;"ENH.RG,YJLG0:\[OUA<6R:CIQQ3Z
M%-2U=CP@J[7$Y-T\\>OP37029 ;MJK=M?;5O>\0KB]48=O*P^5PX+LS;F9;
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M#JO6>SL%W1'^KXB[WBQ!7+!#JO6>SL%W1'^KXB[WBQ!7+!'>Y!(P!@# & ,
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MG<:':][[S&F9D# & , N8X"_[#2_SA8/Z4;GDGO/[$;9%G;\D3(S49C & ,
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M[7O?>8TS,@8 P!@%S' 7_8:7^<+!_2C<\D]Y_8C;(L[?DB9&:C,8 P!@# &
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M0XRP0<O1(]&/4<QSB<7KZ\X>&:D73?2LMV5Q:U_GK\6A;H1U?EJQP)H9B2,
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M)W&AVO>^\QIF9 P!@# +F. O^PTO\X6#^E&YY)[S^Q&V19V_)$R,U&8P!@#
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M$C & , 8 P!@%,OAB?U3T9_,5V_MM>SOV@?TW./V7)WWM+.$Z<?0LWO:J?\
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MM _IN<?LN3OO:4<)TX^A9O>U4_[JC%&F62*ZC & , G3X-YJ#SA=:[;BNZ;
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M>8TS,@8 P!@%S' 7_8:7^<+!_2C<\D]Y_8C;(L[?DB9&:C,8 P!@# & , 8
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MP,['LY:&F(QRD\CI.,?H$<LGS)T@8Z+AJZ;J)K(JIF,4Y#@(#[N02=K@# &
M, 8 P!@# & , 8 P!@# .ALTC-14*\?U^NJVN60%OT6!1DX^'4>@JZ117$LC
M*'38M^BMU%78@L<.=*@**7&JH0! Q3J#=S?:%:J-DE:TM0"[#:^,*%%S4]"2
M<I9F*4:I*OED&\.NN#56/9I&6=-ES<X5+C4#C*4<EJ$5<(\;#E2'"-T1$FB
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M & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & ,
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MQ->-WS3:)>I6"61U?KD[>083-S"/FVM[6M;5_&RZMQJ,;*G9LAV)V:E6N,'
MM(UU<V6Q]?478<<S>1T??*=6;DQCY " _8L[/"LIMLS>@D8Z72VR+XB+CFCG
M2%4AQ3.8G),.#JJ,SV6 5 \,RZ7&#W=(,(6V66(8EKM?5*RBYV4CVA5%&R@J
M*%;M'22('4$.,YP)RC#[IA'-LE+R54M>K::I3:E.#>KN1(K4NVY.@\#6P;2E
MUY&TSM?;VY2%:R#MU(R%ALSB6/$TVM)+N5CKJ+SUD>Q$"R3YT/\ .?I$()0X
MLQE+]I)517,RDO\ 9;=<(]R(V:\OUJX*]*WQ3F-<MU?EW&H8/>M6D-H0Z"2<
MCL6/9P&O^$)<CLX^9D"OH-C.K4W:LTR3?,N=<VBQB9&.;FZ0:6DVJU",*GJK
M:6R[7JM)3JL=2UU1=_S;C?'5'..VF-J1F>#8S:<+6US"9^$2K%RUGCV.D&[Z
M,2G>#UM:9C4ILL70@K#A$KF)'JVSE((C59C;3+2*,_,1]6G(G%:ZM6V];?$"
M>WNCXAP/*Q6\;3H./E[Q<YU&=UC!;RX26NMAO$JA2*],S5BCXHMIUO<I8U*K
M%=;.++,251EJ$\7:L$PL4Y?($SUJX>MFBZ4M1W^3):N5<'V:R(PUZVM5[W5\
M.T_,WM/A7I2CZB)S3AILB@:'UM?WQ&H:1@*G9MA7,;<ZG2WK\H!F<U^3"#E8
M%M3$E=:#"SC%)M+2<K/N91U%-4T)-M4&W?%)7;==>P5]L$X56N-7RM[3/7"F
M/%/I;@T0>RRL6VGK+N(S+:3*672&J2$@EKBZR6NZY<55^0Q>5B1V,T@R=#E"
M>*)>>:U^/?)J$=IMEHDZX6PJQ427#79M.DL<M3:M>]<:;T1;J9I6J;"GMHS-
M]M&KHW7*KAE=Z55:$[9TF/8SD-8Z+ VFT0M@:V>3)(5=[*.8"KN7+5J@M)*R
MQ&IMUV0C'7&OA"W6*E4H*VR%M7RV&.Z'M#>>X)S7]*8;?-4&SNB\)Z3?; JM
M)H\D[V"&F=Z5K5^O[M$MK-$3T!%,+9"29)^628QCF+DV[MV2!)%)NHB4C%2C
M5^[5%U147R"C!=NW=9"KQM/AJ"[WG8^U=(;-G=G34$K?.!34=E25$CVU/1J4
MK8)![#GF6+)K)UU[-E9J2<D25,HSF FVIS-F"<JG$*&CU3@D[U*AMAX[.TA5
MN,:FDX>+M>\^U$V/NJ7UQP1E;AO1]%R?"AA8RU6*^-J=K.)&FB34G7=E1*&U
MDZK(UPDQ:G1BN74C<8^VJK!#64:_&Q*#V-802"_:JLU7UV]G*.TG%)WV^*]=
M[[SF:OO-EOFZM!N[/,MK6XK3OAKT2+O+-DP8-[Y TNW:Q@(JT]&B$T84';E!
MF+"56@T&T*ZF(Z0=1;-BR619MS4$_P#\U7.#O&O_ -N]>-MNLL<S$R& , 8
MP!@# & , 8 P!@# & , 8 P!@# & , 8 P!@# & , 8 P#K9:%AY]D>-G8F-
MFHY0Z:BC"68-9%D=1(W+24.U>)+(&.D< ,F8R8F(;WQ1 ?=S=,4B?HTXIVC3
M\]1YU)I3LQ.2YJ<2E*$I*7-RI,I)JIJ-:J9JGIB8I,VYJD3,U2)IM-S<]-R)
MV;;DN*;D2U*DMIUIPJ=AT\11*/7W@2,#3:K"2!4U$2OHBO1$:\*DJ  JD#IF
MS17!-0  %" ?DG   P#Q9OG\I91I4W]%2:?3:1--J4YN?I4_/3?E2;'Y$Y.2
MI,5J<(K4:)C)V3Z-.?2T:@4.CSJ3DJ<F*+,34XD[5Y<W(DRH/6HP>L[9Q!PK
MN5CIYU#Q;F<B&[YI$S+B/:+2L6UE.CA)MHZ141,\9-Y$&K4'R+99)-WT9OT@
MJG,I\GQ'L.C>Z]H,E9V5WD:/3W]SC4TTHZW/:S"NK.P22Y7-)LI]=DI*M4T^
M4;FR(.TRDY1N2 <8X!\(_6>MXD)P(K7U(C LSYM)V0(^J0+(+!),G8/V<A.
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M465D%E3NU#K#$0>F22202300331113(DBBD0J:22290(FFFF0 (1,A  I"%
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/ P!@# & , 8 P!@# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g142578g15c64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g15c64.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1E84&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M             $D   #G          $                          0
M            YP   $D                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P   $D     4F=H=&QO;F<   #G    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   !)
M     %)G:'1L;VYG    YP    -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $    !#A"24T$#      /,0    $   "@    ,P   >
M %^@   /%0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ ,P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
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M8]>KIEIP.GXM53&P&U5M@NTF8K4XQ 4#9G7%PQ/#P#QDQ2RZ7M&^&R.+B/\
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MD;=VWV_SG^C9^B]_^$:O'^M'UPRFVOW65-)VVO\ 9C5_O>E^^[_B_5N_TB]
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M_]D .$))300A      !5     0$    / $$ 9 !O &( 90 @ %  : !O '0
M;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @
M $, 4P V     0 X0DE-!"(      2Y-30 J    "  ' 1(  P    $  0
M 1H !0    $   !B 1L !0    $   !J 2@  P    $  @   3$  @   !X
M  !R 3(  @   !0   "0AVD !     $   "D    T  .I@   "<0  ZF
M)Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$T
M.C S.C$Q   #H $  P    '__P  H ( !     $   #GH , !     $   !)
M          8! P #     0 &   !&@ %     0   1X!&P %     0   28!
M*  #     0 "   " 0 $     0   2X" @ $     0              2
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M  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
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M  (1 0,1 ?_$ !X   (# 0 # 0$            )!P@*!@,$!0L"_\0 01
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MF'=^=P#D5R!VT[K7C+(6.O5=Z8+A:8!1AEL7>[?$21ZYPV5;]R2!8('9)D6
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M]?F\<CI]'.M<6_=W<-OI-[T)R#W[Q\JBK35S*[<J!L3;FMJO8$P-KB,I2HN
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M<0OQZ5)SEX_AX!&P)"00&S^1*D@@,/3T%Y'ZCN5EY'MR"/J#KRX^,EE/5FB
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M<QR9K%1R#GCE'O0*PY'!'*D^X/MIXMURR0;6W)/">V:' 9B6)@.2LD>.LNA
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M?/W_ "S_ %\9Z9/'U?V?;^OV_K)X_P#'2DY:\O#-S^Y?U)Y]OW^_U'YJ.?J
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M.LO#B8\L:=O$#MQUB*=8_23VFKC)M&\DL=^*RYG'4;CK&VM%<-L<X8_DUO\
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2HT:.C1HZ-&CHT:.C1HZ-&O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g142578g19t80.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g19t80.jpg
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MMK<90E,F0V%C<?_$ !L! 0$! 0 # 0             ! @,$!08'_\0 2A$
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M_JSP3N$'&%=0]UT0U39J)!RK-Z^J$Z^;$$O&Y*1@YCCRD<?B"!A;R#!LJ!1
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M#9^E$C*(NDFS+UEDVM;]G0HKK<D;2F)=T0%DPR&R)%EZ5$3Q(3"'F":M+7D
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M_P"7M*\F8?\ (HY3B>)\U!@. \E<9%4PB81,(F$4/1?\+9?+BW>N%\T[]O\
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M=*R[20/%M%T6.^\B#3#?.C'";X$6N3XM>K#JDUR]D6YF\TTU&J[&A7YG) (
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M9RF(<HB4P" B&0W@@AI!%""UI!!Q!%+P5IE8;VOAES'L<',>QSFO8YIJUS7
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M\-7JK8]#.EDI*&U='WR.F]AWN;:FB<VRU-5H&MJQY"'_ .>AQFMJ8S(<&.R
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MQ><L^>H*G8/"  "B]9';NT#E*HBNF<I3!XTS*2TY#,*:@0IB&?V16-> <QK
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M(OZ1T_!2[6->Q,U$RC*8356B'<=),WK6510 175C7#995)\FB "*JC4ZI4P
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M2-ZZ3Z 3G[D8NR/,=DOS'(]TYAJ1O72?0"<_<C%V1YCLE^8Y'NG,-2-ZZ3Z
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M_(<SV6'L3C40:_.@O$TLJ(P\F"QDK#.'5*ES)?E!3(>L)D.H!-HD*8Y"F-L
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M@/)4>15,(F$7'W"?EZT5_3ZO&7J8J^LT^X8J446.I=AJ$)6(:.GX]Q8M0;A
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MUIL&9O7>696EI?3ZTR#6C5)NG1[@](A7XI(CMH6LBU<E(T2*"[<7-F;..15
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M,)+[/KQYE3^+,4&8Z]DJ<CT[J.LUJD%9O3Y0U&N* MK:]6(DL6L<H[,:BW-
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M%_\ AO%#NYCNE1OY'LG6!"^*[Q^'%_\ AO%#NYCNE1OY'LG6!"^*[Q^'%_\
MAO%#NYCNE1OY'LG6!"^*[Q^'%_\ AO%#NYCNE1OY'LL5.W>+>PDPS;1%X4<.
MXJ0;()]75\)QUEVBR21..>N%(7C'.4O&.8I2[=IA  $<4X<QW4)N..!V'LK:
MOI*MX&$073.DLC$1J2R2A1*HFJFS1(HF<H[!*<AP$IBB " @(#W\'$\2J,!P
M"R^15<(6[PKL_E#->LG.=Q@. \EP.)XGS79E/\$JOY/0WJYMG$XGB?-=A@.
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MDU%*P-]A*9<'#+2@9"NQNDMI?ZA7*4@RQ[YM6'S:D0EEI@N;5,O$%'_=:+T
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M;O7:YIC>,(L-NH6PRQ[]=[8>@*"RB=+--^ !>IF"-5JS :6QL9J!,-:ZY2)
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@CGD>5V)\IR?*<3E.33X_%XW$+MXH=!< ,ES-Y)S7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g142578g20t64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g20t64.jpg
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M 0$! 0$! 0'_P  1" $= ET# 1$  A$! Q$!_\0 'P !  $$ P$! 0
M      <%!@@) P0* @$+_\0 91   00" 0$ #0@#"@L""@<)!0(#! 8!!P (
M"1$2$Q06%Q@95Y66UA5355:4E]35(=+3(C$V5%AU=I.TM2,U-SA2=Y*VM]'7
M070D)3(S.5%9<7BQ"B="87*'LT-B<X&#D:+"P__$ !T! 0 !!0$! 0
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M5E)5E/@*DC((YP:B[EZK=.*4XI5^ZQUO9=MW8/K^H(A.6$XT8>@H(R\08>4
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M9=.\WC#OA(&!SC'>86L#[KJ?2H&/L)X/U% 9QFL6F\!ZS254>]3B5E&5ZTE
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MI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*55!O\
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M;.@OSJJU7U]LLS70\ Q;*W7RULL[\7,UFL4T2:)PI]G/.1N]93 $L2%YE31
MS"OE4X$@D-3M+;NS]E2+'=FX'Z$W,TD-I<W$-G:JXC-U>S0Q/':VX;5F29E&
MB.:7&Z@F>/9[/V+?;30O:+ ?TJV\*375M;RW=TRZUM;.*:5)+JX*XQ'"K'6\
M,6=[/ DD3\W%:JG%*<4KUX=@"_S1MG?_ !$63_AQJ_GQK_TA/\M=G?[,V/\
MS/;%?77L"?Y';1_VDO/^6;(K1_V8;_TC/43_ /E)_P "]9<]Z]AC_JUY-_\
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M4]#?U">L?37M*[_!'']T)R4^!^4/J=F_Q*G<%Y4_"NP/7;1_AU>B.MC7@U=
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MOL>XF@UZ=.O<R-'JTY;3JTYTZCC.,GGJI&UHCXQK56QG.-0!QGAG&>? J_\
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MK2.*58[C?(CR"99]RL:ZRY!%2UVIW0MUW[S:] U;M56/@[.S*2NDD#3IU$\
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M\78]JRQO$XBC)BGV3. 2V"VR+>2WA4\>:59"TGA# :<#A5+0A@1D\4F3P?\
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M/X<,;-58A&)3G=SQNY7)??:,$C4/Z,(H SQQX*R2LW8RBB[;:=M:VZA).O\
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M,:X0RM*75N.74B5@.*D8!!J\903Q3@8TC<:CQ"! I7AWK=X#QU#B>&*K(OK
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MA'#T>#%?L_HGU%/Q46U$;JU$IYBG&X8_Y2 SH$^=1 &GZ[7'YT8O6B28T^%
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M@%2[9% :,"U,%30K,\+*AKC4DU6;!7I4I96ODIHHE'(508B9.ILNJO%12I
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M\E7:K([["0PMAGOS,M7</+[EQK';2K(Y.\HK'8D5U'><G[';)N)(W22[W.J
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M[>VD@L(+-[F2::&SBMFO'U;Z62.%8FN6R[-O'8&5LR,VHG+D]]6N#T?6Z?\
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MFUWF\=%BFC,#;N>W;0S2K(<N1JB7O2<%<-A70-N,>3'3W^O_ ''/8@SX<QZ
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M@@M+F6/1%?+*]JVM"TJ0RF%WW:L9$7>JR*9%42%6T:@I-%D1GD13EHBH?@<
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M]36ZD9:7>*(U&]D&H2"(GOLK')EU& SU&!3I!#PLVL!92#@)H8R-WD9TE#(
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MK'8M9W+8E/JFKI5>C%+)JMNH003%"E2-B&6J#4"P#7.OZW8JN0'7=;HD(32
M,5V4<5)@99VE%C4+>9IXHKJ"VFENUD*179G:0W"BV0W$Z275Q+%,KV^'=-XD
M@CPU.Z;WRA2R,X"$99-(&G+D*I"*"I#< <$$Y%R7/I_:M03;PYFR1HTS9VV]
M<[BAN%ZTS8 08]K$-IB $#&Z^LL.\;*V1GZ9&RSL)).OS9, W.@#B(N=$A&D
M6H=HF)[)C$2MK9W-DP24QR21W3WS2.DFAMS*JWS+&VF10T:LRNI9*EHLB09]
MW(DG%<@%!& ",C4"8QGB#@D @\:OC3VM7-6U.6!DEAYDD7M5MN9B2$KZ:C6F
MC%Q/33Q&-6*HDJ=S7@K4F8O+4)XV8FR9:YA8F4GDR,R4[8O+GLN82!&14AA@
M0/)OI2D,:QJ99M$>\D(7BP1% THB*BJHJ1="X)!)+,<#2,L23A<G R?&3X22
M234J<Q*KIQ2G%*<4IQ2G%*R>T5_B(U_.R/[&SRT_/\G[S5U.;Y?W"IRY15=.
M*4XI6(?7AH UU,]*&X-4T^2D=LR0#AW/31O+S$1P!NS69D=L/41=LA(REL:B
M/L"L@&ITW*T)0+?GMO95'=>;7M=B7R;.VI:74HU6P<PWB8)WEG<HUO=II'NL
MP22%1[\*1Q JQ<Q&:!T7@^ T9\4B$,ASX.^ R?%FM/\ M3L>?5W<NA/5@LT%
MC67?=_ZN[+UB]<6EZR9U9(B[-*[$;N"&Z $SM627TI<Q^GV).KA8ND;"+R->
MV,=KMM;)I,P?7G%=;:[?V5#MNZ9',=C!LF/9&Q;R1+D&V2W,1,[]C!;R%KLB
MY=IX$%Q&UQC1I:3& ]I.UM&"-4K3F>YC!3ORVKO1KS&V[[P!'.@A3QYJC@UV
M-_J=!ZNZ%6Z?I"V7[8&F]Y[%V2/INY-D].)O4/3]6;ML[69W-+M5)KJZP.AA
M8(JI%;;1S73,3(']53Y,_78X?<:9878T'(3E#LU[G;9EO8K>"\LK:W:6TMMH
M)=7\L%M<H9HIGWC%R\JQ3IM)%CNE N&:&9 6H-I,$MM,99HY7<!WB*1*S)WI
M4:>&%+*8<E#E0'4FI?UUT@=:/3%? '4Y2-*Q=P6R-8.R ZRLVGA^R]:5W8-?
MUMU&]5A7>6KMW:>LET(OZP<M;0V(-C6JHVTV$EO@R4,8^VJ=#G#F,.XVML?:
M4#[-FO#:1&/8-S'=M;7$EO)<[/V6ME<V=Y'"HN1%K+&*:)) '4L.]*L;B6]Q
M"PF6,2$&Z0QAU#JLLYD22,MWFK&-2L0<$#GR*C[:O15V43>O3)7/+U<;;MZ1
M#ZJHVRB/2\?G])D^^RM#"J =K@ %<#,:BTSI=V;>(VQ"<?8Y>@VYJ?KQT7"%
MQ8MLDV@-$D*R+7;/)JRVC)V#%':!MEFV7:<8VJL OFG21WB0S3;3MH#;J;=)
MXB+@,S$PB-R*I>WO)(5WK-)^FUF$[C5NPA4!B%6!VU'65;*$8&K(X9+=#W0[
MOK1>X.D&X6H%:X5'UYH[K,!6(+=;IJLZ2TX5W5M;25IH.J@L/6V!M;S66QM+
MM!86+H@XG4*,W(S5(A?Y.BAL/:[;6VK&]M-K0Q/$TT]YL=XWAAN8UO%L[6]C
MGNG-QJDWNJ:)&>=DEGQO2FHOB[;VTL<D#,&TK'< AF0E#))&RH G>XPK$!<J
MON<\V=Y_.*K94XI3BE:Q]^_P+W5_1?8_]TF>9EO_ $L'^DB_M+6)/_1S?YDG
M]DU_//YZI7%4XI3BE?25*0I*T*4A:%84E2<Y2I*DY[:5)5CM92I.<8SC.,XS
MC..WCBE9)"R]JW:+LY'9MYB5C7E!;C6ZWEJ]0*NDY8;(<GQZZ'<R"K;5);V)
ML,O(GS'D&[S98CT40S:B4FS-///Q2V*52!D$49>63*(&D?2JJ"S=\V\W42@#
MO8T.6T#1@96\"T@)=M,:=\Y55R68@#O1IWDAXG+L.]#G5DX:UD:A:M4R?*U7
M:H-DIPR"(>*6?8CU7TND"8-RBL0;53J[=<Y-439"?R*0*B!]=NEE20KS,DNM
MZ+D-:(E?KWV@ 3(4<EM*1:Y]2J%)==$8?2-05BT:8; XZD+4[O))C(*@#+.4
MBP3D!6UOIU<"0 S=[D_U6TU0[TP[HK,<V\>KH89(K[EY;F"7KY05V"3G6.96
M;^X%KS%G=-GX]3CP9LXM*"P)\9H;#E$67GH4=U]%*W<#Z=+,0^[P=W)I&^QN
MPS%-*ER0 &(XD \:DP2KG4H!&O(UIG]'G7@!B3IP2< \./-5.>Z>-I,&(%<R
M/J[ECES9PZ;7H^QM=2#E7EB0Q*PFTWD4U:ES:)'K@4,7(6B=;V0T"K(%$XUC
ME"YHZ=%CU=DPZ2V6T@ AC%*%<%@J[LE,2:V90@CU%]2Z 0P)C=/D#"ZB2-.N
M/(T@EM8U=X% )8OI"X.K&#CBL?3]L^IUDO=#0ZO,5(1FN8388M[HQ(:<5;'K
M$P#3471UBE+N#CS]/MD:>U66RCH*96CL$^@9.%S(S1;F%W6-2Q=M?>[N0%=&
M@MK!4:.#H1KQJ#J5R&!(Q.JEB!I&GO@Z$'5JQIPW?>Y;.G."I!X@BH6Y?JW3
MBE.*4XI7JT["#_F<[&_U]7?_ (<:MYP_*3_#X_\ 58_^+-71[(_P9_\ 3M_P
MXJQCYIZVM.*4XI3BE.*4XI3BE3N]ME4,%KD %^2XS(NGLUZV%$UZ#FP9:7L"
MR6.8*CG9$5PB@>] F#5/8&/L>$-.R1KKKD9Z9&<H*YU'CX<#/#W(&<<WSTS5
M[XW0+.V"QD;,?G.R57>WSM?&Y0Y^<BAC[+7K1 @$Q$!+:OD@>)-.U6>@:(83
M+"YA8, ![A<;&9=C3P&!X!D$C!XCGSG/A_93]M56)L\$E@0..[24<E(J-C!W
M*WQ8-V@V(E&(V*(7APJM8_DAHT=+-PHL>)C%_@0:^2B)D5PFY$&P@I1NDH>.
M%QXAP(YO%X./$ <W@-3GY?3^?Q>/XL51+=M2M%=<2*^,?K;8Z14*<#%4Q4#8
MTDL"/AT $FC;;$RP,:V"2I,D:9F^-H%@E8#[9=V,8"1%V$\_ D*VK)\9).0,
M_,,GAX"!\=1_/\_SX:L^I$Z> I*BS]N$D;?.1($3ZP6CW1$D71VI^)4^M5N9
M#K4X$@K=N[G1YT]\S A" \R7%;P]-.SWQE1!)X#A\>./C/AX<,>/Y!E5>V!?
MQIFEW$2[LAVZ+.7.MFZ:$6!+0\5"N#V;4F4+[9*#%&U93390-#\5J;()UA>(
M6%,SUMC!V7"@Y&5QWN"<YR>'S\W.>/'XZGK\7\X^(=5<:-@ L5/$3QL4FKXU
MN[5U:<^32V4+O2Z^X,1<N^> ^*B^U;%(V%FR.%4VQMU/BJV.4,::?S&DYSCC
MJSJ_\.<XY\^CP#P^,4_G'I\?\\?!Z:O:+M2#>=@W%N1/E%L$MH&RNJ&Y$.)W
MJI""E8VO!ASZV+*/P!XQX8;)Z[.QZS"7%G'"@(<P/BS#;$5M;!"CT :O3Q7/
MSC/'P5'Y_P _)55/V&74 M>"W#81%C9LH5?L#[^8#V>,<J+I8UK5\3/F2)HQ
M.R6F"02LVVNPCDL"S8H;!1<4</<JZ()&53C)R%YB. (XX!X$\W GFYO'4_S^
M8_\ BK:3M^K#,$I$<PLG;&@LR&Y<L!7TNV6RKUC=*VFTLXF143(\I)DR%C1#
M!%B(=FOC&;@39@FI$I,>0A\(X> 9YAJSCYO%X\4\/\\^.OP\_AYZ[53/'[\
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M  7&AO%TCKIK7Q]!ZJ>5&A_6!K["3_!<:&\72.NFM?'T'JIY4:']8&OL)/\
M!<:&\72.NFM?'T'JIY4:']8&OL)/\%QH;Q=(ZZ:U\?0>JGE1H?U@:^PD_P %
MQH;Q=(ZZ:U\?0>JGE1H?U@:^PD_P7&AO%TCKIK7Q]!ZJP2VY DVFM;.&!$IE
MR[&#ND 0C*T1T2I)> 2CP$Y<D9:0PEYV0UC*WU-H;PKNG<HPE6<9,)"21,W
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M^Q5?\@YZ'VHV;YI'\[_:KE.SKOR[]'53TE'7+_*+N?V*K_D'':C9OFD?SO\
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ME;(2].)RS=N@2?D*#-I3@/,)6[^<Q$1@RFV<."!(<+'N\'+%0SB+F"H>^(D
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MYCR;>A4@I"0!@J&F83L0/&:+S<$!A)Q0E\?:4W9CC8W$H9[(SMB& %9U"$(
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M,<T,FZ1I'"[Q2%4<2 \:ZAG@"N1DC5I!!K*73_31H4@;[%I(DVG6U\E;IVS
M!;0I<0'M1@C>Q1'=2A!",4D6"F!:UB+3(&,48VVT:AND9G_A=;180W;-\PY[
MNY"[7 66,00%H7+0D1L(,@C2[-F0_I%[TA1P;2W>U?C@B+;/R8WWL@$B@29<
M&8CCE O>CO&&1QXKJ7OJPWLG2:X*J6Q2E:W9J78=[TR);L&W-6T]V[O':H#3
M8!-5,$0]H*4X9K^_M5&PG10VV+H]J-1XJ92C *38JY#GFHF<MYEX@\$T4<[:
M(97W>EVTLZ@H',L>M58IO$7FTMI8A3C-;X5RLL;O&-4D:Z\J-04X8J$?2Q ;
M0S#CE2R@FJH'Z/XC JE-[2ZBM(:1O^RP 2TT?6NP5[&?,YKMJBM3Z:9OI^H4
M&S4W5\&YC94$O7?'$_!E)!$1]AL$4!7YL4H]2U\<N8;6XN(HF9))8]T%U(<2
M+&KR)),8R"'T*1J!52S @2+?@FN:&)G 94?>9"MQ5G*1LJ!A@C4P.DAF"J0:
MJ<GIUL(+0^Q:>:US)1U#5_K2U;HN.,:8Q,LR)IR@[>1,I8U4-]Z(0:.6@,"=
MAN0ER8Y-V./DP)3T5YMQV!<JUQ%(LO\ >SV,]P3S)A9+?$ASQ&E&;.<8!.:G
M<D0R*4.^6ZBB YV[Y)<H,9SEE7&,YX8YZ^YO1(\[.LE$IO4)HW8N^J<-.$;!
MHNH2M@/GI3U6A2B5JK=)O)*B#M6[#N%:@PISTX!5+G/R86/GQJ7,M<MA##P7
M_!)'MKB*VD*A;B01!1K.$:2,2&:*-B1AW0:<@R! <B.QLDHLT+R@,3$I?5WH
MRRJY01.X&255SG#!"Y S8-+Z9H9'7M;V=MC=VL=!UB_NEVM9L7J!L>R62]Q@
M1-\&7LL"MZPHMY)B*.-/PR %ZU'VAK,\R++#Z[#/2!!5$*Y)=D2M%#!+<O'C
M?;LQ*L98:E0M+)&&D*D,$7)"LI8J&!-*P]XKR2)$KYT:P[%PIPS 1HY"A@5R
MVG)!"YP:EV?TMWW1L/<(@]#Z?]DI*]'8O?<*RK(6&V1P6OK-NFET8#:]4&@V
M!4!O8)"1,'3H,DLU*$,TDV5BD&XYU;P=FR+N.X,!4W,6+UK<IA4+2);R2LDR
MMJ)C&""%PV\52.]XFLP/$'SN7S;K+JRS 1M,B!HR,#6>!&>&AB#QX59@_H\C
MQ6:D$V-U$:1U%MB^@J_9*MJ6\JV-DQ%%7 ?%+TKQ_MM=H)W7^M)UQ$3QI8/
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MMQ.FN5X)1*D:@2R-)IG5N_!1G*ZHDEUJ VD-D5<<PS%9'E,;:$61"C,28T"
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MMJN,!I\I8D7*WLJ^,/#&V6E*-.YKN<2<L0,.N)?_ /!<I[]^YY%Q:S2)M4*
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MUYYU>>Y0VVV@)E:UJSGM82G&<YSP;RT'$W5N .))GBX?_P J;B?R,OR1N?\
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M''BZ(E:UM>6"9JR$+$2DQ8Q637FICP8LYA\D_,F3 4%B"0. 4$\W ]\>&3C
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MXQ^VH/,?B/[*P3Y?JQ6CLY_CHQ_.A#^UO<]-C_HX_P#,7^R*\KF_I9?](_\
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MB&1:[?Y/VM_>"RMHK&.;9UO:IM"*':,*-<QS[^YE6*UV@NTK6"Y73"FZO&D
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MT(?M4\Z_67J[)_9*_P#MN.T-[YW']*7[-/;!L_S.3Z$/VJ>=?K+U=D_LE?\
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M*BA5 +M(W >%G=F/@XX "@ 7?RY5JLX'?\QLU_W$E_Q"5SA=L_XSF_\ V/\
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M85@;@-$D*:2MQQ V:B?%PTYG]TUE,E"5+RG]*TX[C/Z,\G'$'Q9Z:57@%Z(
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MX[4J.P]*#J=!D771+%?U+N*S5Y2Y2B,HG *5^Q5"M0CI>]C)->V-,E,%Z*T
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MNK\PNQ7:;G9EG8M(;FYN7B-S+;6[6]NFMMS#;2RS2K+,@3 NX@D 8N_?ZY(
M$,DI-)*!H1 ="NP=SCOF=0JE4.?Z-LOC X85N.FS+WMC>(SJ7/5@VH:-IB0?
M0V]7JQ7+N9BR UVVELW? "Q)-SVZLVR?K9&35'1EFAM(B8.@ZU4U1FATB<7:
MBW8;6R;9L<J!FF,FVQ)))"A#PVUM8O'H&])CD42AHCQT222Y+!5U4.\@F*G
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MF,-IL-MWK:5,K))?-H!PL+:W[X2$+CI,X( &MG*KWSD*,O=8. IQ@1#./=#
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..%*<4IQ2G%*<4IQ2O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g142578g21p99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g21p99.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %$ 7\# 1$  A$! Q$!_\0
M'P !  $$ P$! 0            8%!P@*! D+ @$#_\0 6A    8" 0 $! P3
M! @& @,  @,$!08'  $("1$2$Q05%B$V55976':2E9:7T]8*%Q@9&B(Q-SA!
M4G>TM;:WTM35(SEXE"0R-%-A=).S-4)1<7*Q)M&!IKC_Q  < 0$  04! 0
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M8WYNLS^.7$2RN3Q#*G@%^4,SRU_.D0&VMYO:SHPV$:1%FYP>'9>*/)XZZ=2
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M+]KA5J3YZ17=EFMT<#JW,O/+B6X.JQ.@1 O2!)AJE1@22"SG!Y(;D8##1[T
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M[>;.^9T5>KCY60-GECBZ4NL[97"-["7,VD-&NWOR7-<0TMRK42R8U;SFXO\
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MM/MQQR/BMM<]KGM:8W2-:S>P#0Z-?J=P73]RT_"JY,_X@KF_>-),Z7PW]CN
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MV ZMA:0Z0Z-!!4%9*OLN3%:.C==SJ0$[9#9+HYDB3^ZE;CB=8K;CW_1B!O4
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M]TV!%UZ;P>&GFK>PET4'PHXQ3U=Z8(>[G3T!TA$M4=-SE[Z(=*=H9K)_O]X
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M,KCNK?8[Z/1CV1,'D>E*U;H;KMV<1Z6.9H#W)7H2L1V]*7 XLLY:?U]ZK-
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M7(^YCOZ>GD:\>N5//<0;YD8Z_#Y)QO\ F'S].HS^5<C[F._IZXD9"[M\UE3
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MGZM^]*3M J92%NXR-L*M&>+C7EXE;?:TQ<(DSO[BZE.S^[P^O34:0+5XV/\
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M >) 6!QU:2TM5BVGC@<EJ^S+)LJ5[K<N W1#J)2M:V/*GH3O-70][5SX*DQ
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M47_IO8\F +7@A28$0@NO@I1O91".[!8MO'$58312=!/I'PD_AXCZ7J;+JLT
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M:91'WDCF"8=Z_;$#7C$??56LK7F@N0AV0GZW/#+K9E9I"R.5SS#$T&0-[UQ
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M/>]SW.>]SGO<2YSWDN<XGM+G$DDGPDG4K/:UK&M8QK6,: &M: UK0.P-:-
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MR?N5?C3ZK>+'>[9^)5F'/9TFB,5D:E.4D42".,;V>D(,&<2E.=6Q*O-3DG&
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MTUAO;*7^#Y53W(Q2281,(F$3")A$PB@55?>OK?VA0_\ 9YNR3S7JSEO;._\
MO4JC<-ZCXKVMH_NL2GN1BDDPB81,(F$3")A$PB@=<>A]Q]OEI_O.E^265]-1
M>UN&_@]%1N*]*R^V69_C%Y3S(U2281,(F$3")A$PB@3=]]"8>T*M_P!H;5R3
ME]1J'MGEOW7"J-B]6+WM;BOWK,J>Y&*23")A$PB81,(F$4#A_P#X[:'M\1_N
MXK[)*_Z6P_M:_P#BN34=1],9;VQ9_"\:IYD:I%,(F$3")A%#+'^]Y//:9*/U
M&NS/Q7JIC?Q^G^\1K ROJ7DOQ"Y^[R*5(_\ 8TG_ "Q'_:#F$_T;O[SO]2LR
M/ZW'_<;^J%R<I5:81,(F$3")A$PB@4P]$-5>WUQ_=?9&2=#TKFO:R+^,XE1M
M[TUAO;*7^#Y53W(Q2281,(F$3")A$PB@55?>OK?VA0_]GF[)/->K.6]L[_[U
M*HW#>H^*]K:/[K$I[D8I),(F$3")A$PB81,(H'7'H?<?;Y:?[SI?DEE?347M
M;AOX/14;BO2LOMEF?XQ>4\R-4DF$3")A$PB81,(H$W??0F'M"K?]H;5R3E]1
MJ'MGEOW7"J-B]6+WM;BOWK,J>Y&*23")A$PB81,(F$4#A_\ X[:'M\1_NXK[
M)*_Z6P_M:_\ BN34=1],9;VQ9_"\:IYD:I%,(F$3")A%#+'^]Y//:9*/U&NS
M/Q7JIC?Q^G^\1K ROJ7DOQ"Y^[R*5(_]C2?\L1_V@YA/]&[^\[_4K,C^MQ_W
M&_JA<G*56F$3")A%\C& L C#!A++ '8AC&+00 "'76(0A"WK00ZUY][WO6M:
M\^\ :\AS)Y #PIKIS/(*D>4<>]/6;WT0_+Y<Z&7[5)^8[XE;Z:+[;'^>WXT\
MHX]Z>LWOHA^7QT,OVJ3\QWQ)TT7VV/\ /;\:@<OD+!N059O3XS[T&>.(A;TY
MHMZ#KZ6-C!ZQ?V_FUVA!#U[\W6+6ON[UDG0BEZKFOI<G/&1 =X[G]6,2>7+Q
M G\BC;TL76L/],CY9*4GOV\OJ1E1SY^,@?E4[W)(]K77M^9=:U^/;HAUK_OY
M&=#-]JD_,=\2DNFB^VQ_GM^-?/E/&O5"Q^^R#^8S[T$_VF7]&_XE\Z>#[=%^
MD9\:J"-P;W (AH%R-< &]!&-&I)4A!O?7U:$(D8]!WOJWU:WO6_-O*',>PZ/
M:YI\3FEI_P 0%6U['C5CFN'C:X.'^!*YF4JI49^D<>BS>8[R=]9HXTE"" US
M?G1"T-Y8Q]?8 8M<#TZ8 A]6^R$1NMBZM]6M]6\N10S3O$<$4DTAYB.)CI'G
M3MT:P%QT^\K<LT,##)/+'#&.U\KVQL'WW/( ]U6[^J!H7U[:B^,F&_UK,WN/
MEO)>1]Y6?DEB=U<7Y2H>_*_RB?5 T+Z]M1?&3#?ZUCN/EO)>1]Y6?DD[JXOR
ME0]^5_E%!ZQOJC$U;5ZF4W14Z=0G@\3(/(/L6'E'$'%,+>6:2<48\!&6:6,(
M@&%C"$8!AV$6M;UO62.8Q64?E\H]F-OO8_(WG-<VG8<US7692US7",AS7 @@
M@D$'4*.Q&3QK,3BVNR%%KFXZDUS76X YKA6B!:X&0$$$:$'F#R*G'U0-"^O;
M47QDPW^M9'=Q\MY+R/O*S\DI'NKB_*5#WY7^43ZH&A?7MJ+XR8;_ %K'<?+>
M2\C[RL_))W5Q?E*A[\K_ "BG4:F$2F:0QPA\ICDK0$F:)-6QI[;'U(4;O7:T
M48I:U2HD!FP_;: (>A;UY^KJS$GK6*S@RS!-7>1J&3Q/B<1XPV1K3I[.BR8;
M$%AI?7GAG:#H70R,E:#XB6.< ?RJ1Y95Y,(K53R]J/JQ82WV=<E55RO4%!.3
MH9Y8<1B"P\D?^H:2FD#PW'&E"_\ *8  @"_%O>2%3%92^TOHXW(76 Z%]2G8
MLM!':"Z&-X!'B)6#:RF-HN#+N1HTW$:AMJW7KN(\8$LC"1[("M_]6?P\]E?Q
MJ^/6KOG3F7YVN(_N?S?P5?\ D%B>>/A[R[AOA2C\NGU9_#SV5_&KX]:N^=./
M.UQ']S^;^"K_ ,@GGCX>\NX;X4H_+J%0'F)Q&1L:XE9RFXXI31S2R50"E-WU
MD08)*NL64KD*D(#9.$0DZQ$H3K$IVM;+4)3R5!(AE&@&*0R?#O$$EF-S,%F7
MM&/Q+"68RZX!\>*IQR,)$!&Z.1KF/;VM>US7 .!"C\9Q!@8ZTC7YO$,<<AEG
M@/R5-I+),K<DC> 9@=LD;FO8[L<QS7-):05-?JS^'GLK^-7QZU=\Z<C_ #M<
M1_<_F_@J_P#(*0\\?#WEW#?"E'Y=?NN9O#T6]!#RNXU[WO>M:UJ]*OWO>]^;
M6M:U*>O>][\VM:^[CSM<1^0,W\%7OD$\\?#WEW#?"E+Y=7UC,KB\U9TTAALD
M8):P+>UM&^1EX;GYG5]CJT+P9S:E*I$?V>O7:[H\?5UZZ_NY%3UYZTCH;,,U
M>9OHHIXWQ2-U[-S)&M</RA2D,\%F-LU>:*Q$[T,L,C)8W?W7L+FG\A5?RRKJ
MALQL:O:\3)UE@3N&P9&K&(M(JF,G9(RF4F UK8P)SWI<B*.&#6];$$L0MAUO
M77K77F36IW+CBVI5LVG-T+FUH)9W-U[-1$UQ&O@U6/8N5*C0ZW:KU6NY-=8G
MBA:=.W0R.:#^16Z^JEXR>R,HCXW:_P#G#F9W"S?D;*_!]OY%8?=S"^6,7\(5
M/ED^JEXR>R,HCXW:_P#G#CN%F_(V5^#[?R*=W,+Y8Q?PA4^64(0<G>-8;(E:
ML7(6C@I3X17R<E2*V8%I.<H2OUF&J2"CMO\ W9AR<M8D,/* +8R0*DXS A">
M5L4C+A,R<328,3DR]N1RCW,%"UN:U];#ACBWHM0UYC>&DC1Q8\ DM.D?'F<.
M,K=><KC0QV/QC&O-ZKM<YEG+%[0[I="Y@D87 '5H>PD .&LW^JEXR>R,HCXW
M:_\ G#D=W"S?D;*_!]OY%2'=S"^6,7\(5/ED^JEXR>R,HCXW:_\ G#CN%F_(
MV5^#[?R*=W,+Y8Q?PA4^65TXM,HA.6P+W"I5&Y@S",$2%WBSXV2!L$:#6MB*
M"O:52M+LP.MZV(&C>UK6];WK77K,">M8JOZ*S!-7DTUZ.>)\+]/'LD:UVGLZ
M+.@L5[+.EK3PV(]=.D@E9*S4=HWQN<W4>+523+*O+BJUR)  )BY8E1%B%V0F
M*U!*< A=77V0C.& .Q=7GZM;Z^K*FM<[DUKG'MT:"?\ 14N<UHU<YK1XW$ ?
MXJG^4D=]/V7WT0_+Y5T,OVJ3\QWQ*GIHOML?Y[?C3RDCOI^R^^B'Y?'0R_:I
M/S'?$G31?;8_SV_&H)$)%'POMG;V^LVM"G:00=[<T6M"#]+J ![0>L_SZ[01
M!Z]>;K#O7W=;R2O12]6P_P!+D]37_P!AWE7)^PHZC+%UC+?3(_5%G]MODS&^
MRIWY21WT_9??1#\OD;T,OVJ3\QWQ*1Z:+[;'^>WXU^AD4?&+00OK,(0MZ"$(
M7-%L0M[WU:UK6C][WO>_-K6O/O>.AE^U2?F.^).EB^V1_GM^-5G+:N+4CY"<
MR+AY*39[DI=A32*U>-S7%UW (=*'R),R:*$J3265WD08ZN;5,EDKVA 6[N*A
M[4+DS6>O,;64A&B3ZV=["X-\SG XC$U7WL?7OY.Q#'+:L6HVS%CY&AQB@W B
M.)NNT; W> "_<_5Q\D\8>:#G,KE+4=*]8HXZ":2*M!6D=#N8QVT23%I!DD?I
MN._4-)(9HW0+'KREF/J_LGXR)W\X<W'SL</>1L=[UB_E6G^>//>5\A[ZE_F7
M\S9!+#RC"#YW8IQ)Q8RCB3;%G)A1I1@=@,+,+'(-@&6,&]A& 6MA$'>PBUO6
M]ZSZWAKA]K@YN'Q[7-(<US:T8<UP.H((&H(/,$<P>87P\19UP+79:^YK@0YI
MLR$$$:$$%VA!'(@\B%^ZD$MUYM3NQM:UYM:U8TY\W_\ 8,>=KA_R/C_>T?Q+
M[YX\]Y7R'OF7^9/*&7>KVQ]?\0V/.@[U_P"V]2'6];_XZWK>/.SP_P"1L?[V
MC_E3SQY[ROD/?4O\RZWN>5B<F*EC[-8E9\D+M8FDQP T/3'JQY.K3%;4=?@J
MM,:M<%"C0N^V G8!&B[0!"&,6]E@[6O9CAW%5-DL&.HMC>2TL-.LX-/@T)CW
M:'7PZGEVGP=%X#S<N5M38W)RV+$AC,T$YMVF/[ST;'!DS6D;=7:Z<B-!VK#+
MCGTO'/;CO9#!.6GD18TL;$#BE.?(;,Y"ODD6D3: X&U:%S9G!0)*H[Y-WI11
MHNP<F$9WR0Y,J 4I*U2]P_A,E ^M;QE,L>"!+#6A@L1$CD^&>*-LC'-/?::E
MCB-'L>TEIZJVM+5/2XZW:JV6=\S=:LSUI'#LCLUII9(I8G>A>=HE:TDQ21O
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M4?I(@0($XPE)D9  D)0=9*8!1 0%A]3T:53&58J5"!E:M"T-8Q@T+B  997
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MVHKT@5I4G"Z^X[H7J96[ 9? G>L*>02!C1+%<69*?BL@#.W92J;U2EX)EY+
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MBW[)\][:W?V[ULG#/V/87VMJ?L6K"/I_?[JWDE_RT0_:QJR8\SK[*JGXM?\
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MO6!Z+X(A]')Q2"'6Q"%2C2$(=:Z][%L3AK6M:_'O>]]6M9YIXR^RS,_CW_\
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MY])7BH( ^6C3<@>7%\C1,'3%NTK@A;NL-7FPYWB19H7MR;6A0H/31QZCZ5X
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M#JK)(YG0O!Z2-KY99FM$C=6.(9O#7'8YKM'#TD"BBR2RR2@!+**  HHL&M!
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K12;")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g142578g21v14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g21v14.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1[^4&AO=&]S:&]P(#,N,  X0DE-! 0
M     #D< 5H  QLE1QP"   "   < E  "4=I;"!(86MI;1P"!0 74&]W97)0
M;VEN="!0<F5S96YT871I;VX .$))300E       0.2EYEG^3EMI5F%K4QQHA
M*CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /<')I
M;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M#W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4
M<       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0
M<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P
M<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O
M;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
M3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O
M;VP      $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B
M0&_@            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M         $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M             %)S;'15;G1&(U!X;$!3@           "G9E8W1O<D1A=&%B
M;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C
M4FQT                5&]P(%5N=$8C4FQT                4V-L(%5N
M=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R
M;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M   -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M    .$))30/M       0 \     !  $#P     $  3A"24T$)@      #@
M           _@   .$))300-       $    >#A"24T$&0      !    !XX
M0DE- _,       D           $ .$))32<0       *  $          3A"
M24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M 0 R     0!:    !@       0 U     0 M    !@       3A"24T#^
M    <   _____________________________P/H     /______________
M______________\#Z     #_____________________________ ^@
M_____________________________P/H   X0DE-! @      !     !   "
M0    D      .$))300>       $     #A"24T$&@     #-0    8
M         3@   #$          $                          0
M        Q    3@                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P   3@     4F=H=&QO;F<   #$    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   $X
M %)G:'1L;VYG    Q     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
M     #A"24T$*       #     (_\        #A"24T$$0       0$ .$))
M3004       $     SA"24T$#      4E@    $   !E    H    3   +X
M   4>@ 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_; (0
M# @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01# P,
M# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\  $0@
MH !E P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!          ,  0($
M!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $# @0"
M!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"T4,'
M)9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6TE<34
MY/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$!08'
M!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,58W,T
M\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3TI;7%
MU>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ ]4*Y=F+]
M;:;<NQI-UCWWNQ/4L'I,K#\UV-CV4BSWW/WX-OVC_0?J;Z\;[+^L=0>%RQZ9
M]9WG+./DC&L?;<6/<1N=#\^[$V[Z[V_97>MTBMS/]'1DU?\ ')2U+/KJRDN8
MYSCMMVUY!H+RZQW4+*7W/J+JV6U-;TFNNFEWV7]+;_Z#GZ?F_6G[2^G)J%PQ
ML7UWB&5N?:\OKQ\+U0Y^/ZWI4_:K[:OT/K7^E^AI4+,+ZUNMR;6VM]MMAHE[
M?4-3[,=WHT'TG54_J]5U-%EK?YS^=K_P]A^@X/UAQ,AM?4+Q9B58E5+6M<'
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M?3J_-]OI^S^;5*^K)V/M.-5DEUEE]>'<\"RMMCG6-L-+=S/4VN_2676?J_\
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M!TS'KM]-UKK;JZ&,;/TK3L:YVQMMFUO_  =5KU1Q_K=TRVK'NM#\=F26BLV
M$":*,T^JYA<VO9]J92__ (1EG^#24[J2P/\ GAT\ NLJR*FM>18ZRLM].L,]
M;[5D;O=338QEOH;_ -+=Z?Z-7>G==P>I6BG%]0O%?JV!U;@& 6/QO3M?]!MS
MK:+]M>[_  7J?S:2G!^O'61@WX5-3!;DD.M@F&L#+*;&/='N?OLI]FW_ $:T
MOJCUNKJO2]C:O0NPMN/97.YOM:/2LK?#=S+&?YC_ /MQ0^MW0*.JXK,@-?\
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M[$U.H=3Q^GG%%X>3F9#,6K8)]]@<YN_7VU_HUE-^NO2GU&\57BH5UV%[A6P
MWVVX6)0[U;F?I<C(QK&_Z"K^=R;J*EK=0Z;A]1I;3EL+VL>VVLM<YCV6,.ZN
MVJVES+:WM_D/5.GZK="HQ78M.,65.957I9;N QWV9.*:[?4]6NRB^^VUEU;_
M %?Y:2G/_P"??3@]SS1;]C;C"\Y(=6X"PY%G3?LFUEA:Y_VRKT69%5MF)_A/
M7^S?K"M],^MF!U3*JQ<.B][[*WV6.BLUU"NQ^)9ZUS+GUO=Z]6QGV9V1ZO\
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MS&(B9#4@>EWTDDE8:"DDDDE*22224I))))3_ /_9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    H   "PAVD !     $   "\    Z  +YN   "<0  OFX   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C R.C(W(#$X.C0X.C(Q
M $=I;"!(86MI;0     #H $  P    '__P  H ( !     $   #$H , !
M  $   $X          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "@   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#(Z,C<@,3@Z-#@Z,C$ 1VEL($AA:VEM
M      .@ 0 #     ?__  "@ @ $     0   ,2@ P $     0   3@
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M 0$!             0($!08' P@)"O_$ $T1  $# P(#!04&! ,%!08'  $
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M<+C7;LVQM,M9063JQV7%4K'V>9AWJ;?V_@7<R>(&"),.!=M&*,FX=!'' A2
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M8JJ5-N8S=@=^^6/[;93G#5Z?B<($:HF.A.PWR1^:S]DUER64G^S4$D$%VPF
M# .0,SR/-8:VL9Y##N:&^*F[Q=_CZXR\:G$(LRK?AU-L4D)$EXM11<$$Q4.E
M\*X,DB0>I3EY 1$=>M!L.Z#&=\"1\CT)^,JN[X/:EI T;'_NFP>FT=,&!SPK
M<[K38>^UMU 3@*F,2134C)D ^'E:[9XUQ\2QG8E4WZP6_P 6@4#F;J)J&;K'
MX\"/.=HO  DP!B1U] )(Q^2U2YX+;N)AK,Y'\)LP=_%,SF0,Y$<RK$=@NZ&<
MNK>1V[9I<(JY8QZ5H^B)M4 &-R#27(K-8J?B5EC>\:>@W3!^RG&*B0*H(J1#
MHJJA7P%3[%V4X[3J6EK9.<#6H>&-3Y<TN)]HL U#5L"<0!M ^6OM0[$_<.(W
M-_:V^FQK-#Y8RF&TJ\F8IAX+:=3VB0 &NUET:@76E,R$3 Z1P(43J<\E 1*8
MOGJ<2=0ZG.'!CE_W3>.3<<COQ&H!S1OOMD\\\XVY]<2N*4B:+BQPATD=1 G,
M#&=R.74KDT^ 4 OW @_;[<\_ZZM16!J]QSTE_P #'3]?=S5R6_C.YQ'Q,_F%
MNM>RA-$31$T1-$31$T1-$31$T1-$50_K'M; ?:E4GS!TNC5(C<EMNFLBA[?+
M5>AIYFIZ*K.4.;DB#%&:<0;M=RH8OEH4JAQ*<P"185W&FG'/J&WV0K7XP-0?
M^EG%%B'S)%ZY@"R9LD;A%VJ+9)!0L:XDS1KB,,W2!,RAF9F2A2B50!,3,?'I
MS]WPG^JA)M^P##8@F?0PNF/Z)8:I=+UAF50SQ/0[^85G[&BIM0N\V]8VO\24
MD#RLHXN;&%<,BR@+I,WZ92-VI53DZP-A//Z^O-.HY[QU\^OORL(;9;;1L?;O
M<'U?&\]C3<)9[3N>N+6;IEG@KM3]YN#8Z>OR86"SW2SU3(<- 7#&4")C/HR.
MNV+I!B# JC,KT&A!(,H)@$_$;>Y<K&?C,!M>VOVK/2-N?[3ZWZG.XJ0W-)&5
MG&<<G19&#RU&X\E[NNNZ46_JZ8Y"?TH[\C]ZE% Z/&KK*']HB2D?'?X?#DIW
MVC8<]]MNOU"Z-[24WM\]6:V[/8.Q5;"4QNLH=BAET6-E5;SF(H_!&-&%Z5KS
M=K)HSDQ3Y1XPD?PXL'.,R&(5<T<\:E5*"4J#!CJ.?K\E8!Z32%8G=X>6KMA[
M,E'R9BQKA)I SZNWC'LW4=N;BYNY^JR$(DD]D;E>H=;)+.%CYOW&T9(L7Y8\
MLV$FB].4RZ3Z^OK?*'T\_/ZCR7HU1Z'%-4JH./<(8XK<@;L(*'+P''RE%/K[
M8E*!0 Y#&Z@83<E2,/\ ,MR1B<[>BX"X1;2<KE@A7[=)VPF861B7K1<J*B#I
MO)M%6*C9=)=-5%5%<''MG35(=,P&X5(HGV(;RNQ-I4&\M('J20/FKBQ=HXK;
M/.S*U-YYX8X...> <""=I"\:D%0LE[;XZS9.V[UJ8O6/FV0+W$YNVUI+OWJ;
M)Y!661=)VC%'/Q4A7;&\KSUBFI G"3AIA=NT48P[0"K%7X=Q;NJEYW54]W5:
M\FE6!P73FE5!P&D@:*HC0>\UE[=#6?8[=="PX;<VS2^G4MV.JT0TR&N$BM0,
ME^L G72DM<-!IMIO[QU20RS;"^\[%=>R-4+ :57*HR?5_)%=>M&-AK$THV%X
MI"SJ"*;E$3"J!HV=K2R:)V_==B (2!$'+?5N(4' D.:X.:=MCG8P0>OF,G"V
M7A5X'ACZ;@YI&\[$8)WW'KC&5"3,^2LF[6D!2RC3U;?6W29D$KRQ14@5G?<Y
M_:0=OP16@U?:1ZBFFXCE7*)3@158_&L/3M02,$YB<<\G$;1'3F(6VBYBF270
M "3,@"=Y/+;YCIG!4E?&NXBP4L:7&A'1#F*;UR4C@DTI5RHZ?.F#>-4=O&R3
M=-=$\\$:HJW%$J() ='H!3=0N>Y#*H:-L3/.8@X&#/T><FJ#2U3 ,]2  2=X
MW@=8YX4[-^%;C*'M)K5;,Y"*_1.4HP-D6O5-1233-,.G2+1 @D3X6>*G^B9Q
M)P'4 $3".3+!H,\AR&PZ#&!G<_T6'%7^+R(GGT^@H>VBL[O]R4G&2[>D,(VN
MHL4F[268*J$>S;7V"I*/DFZB+A%JM+-1,Z.NR31709K./AUDP^<N,J4M3Q&_
MBG'(#>8\O@<K,4JSV-#FPV(#3JC> .8@$3SC5@+,U0V^T#;.\KF3L\3XV:PH
M2BB^.\:4M,JIRV-LVC%5I6636-)R$VYB5#LR+&64%,"NTTSD*4" %3*89)<>
M1TM&^TYD$P9SB3R]E>5:YO'$-IEND$&HZH:G^7)G0>\;%0@;GPLC+3(4R*CN
MFQW:[3'4>RMK+C"ZRSP\7"0>1:\Z@W$A((@<RL'7G#\S%-14@(JI>XZ9R3L4
MTC]C]Q[ZJ;4.3M$8$^F\@#>9/3KE8^HZY$3X@>9>0.;B1DZO9/..8V63<D-+
M1 /:]DO&AA1R)C60"9JPH'4!&7?KBC\36GYVIDE'<<\-%(&?("<"!V2$"%]S
MD<EP6^JVO$-;7G2TM('B(W.T'/Z")W6,XSPNWXQPQ]G7IAQ>Q[7>S)!!W>X.
M.VVT'8[3Z -O6;:WN(Q#3<JU=4",[%$,W3^/$Y3NH*:,@@,Q7G_ B9*0@GYE
MHUZBH4BR3ENH14A3%$NOH;A?%*5[1IO&"\-D:7 !T"1DGF=^D+XC[5\"J\$X
MG<6CX_@U'!CM;7:J9=%-Y+6M&IS=)<! !)B%GMJ(&,4P"(B!1*;G\_KJ\-$"
MX-;/LEL<M^0CUYQ'FL%3?JI-',$#GR']<K?Z]E*:(FB)HB:(FB)HB:(FB)HB
M:(L6W^A5?*M%M5!O,6VG*Q=(%>'L$<Y1*<[I%RGT1(*)TU4$7397J[9K <XQ
M\BW:N$A[HE.4GU]?6%U$DA2-NF.:C"3UE=1%/KR=<H]??S3B7G) YC<LJ]%2
M#UBQ>N5%%C$-'%^0[9LU:(&552*IU*19<]XB9BH,3)E116,FH@D"A4B$*FH5
M)$2"F7JF @4%OABN%"* F0R7MF.H0AQO]1]<E\J)-T5'3HS-L85&A2.%&R)C
M*O@)[AC-5"BD4J@(%/RB4ZG!SJJ ($,!@ BX2Z7"LX\KLE8K=()PT P!JM(3
M*Z0N63!20EV$.07!@Y5$57DDB*BAD0(@@"RZQR$2.($GH?(_J%V2/<H/&S>2
M8.BR#5V@@Z:+('Y278.&Z*K91)0HB19$Y#"X2$IN (X#CZ\B2/GS^LPM^5BW
M$$S@90QR)BF5;W!]P43@ F2[!Y]HP@4XI_L]BE-]2AHB^A0 %0X$P_( !V,(
M@  ''!?R#QSQ^8B/WT5#I#I G'3S7%R#1%P4ON@!5$3E426YZG1/Y)RB;CDI
MUB',V-P)>4ECE$1 P@/G<2;=X&X&H>7BB/><>4YD;31>&W#*CHD.S(P)D3!Y
MR?CRY+SW7/'ZN*MSF>L=K-.L7=5(?,5,,HU+\.\:RR+J!F&S0X<D%S'RM7<N
MGJ1 \)R#54P\KCKB/:2TJ4JUS<0Z:;35IF'1)+CD1&F1I )\U]D=BN)T..=F
M:3KG2;BTI]P&LJ!NG2QK6AS/:<2V'' $.&>2Z-#46JP=@L5JA:K"0\[;'B3R
MRS3!NW924[+)(.&P2LVLDD5>1?J)NW7O.W!CJJ&<+&$WSFUI)N*M: ^#Y:>I
M$QT/NRMXLN'TZ=$U*8A^D:LDZB!B?#&!($[;<\=H*;N0&'LIDCG8F<OUSE!1
MHD*( @9DJT^CE5R5/W0Y#]@X%$.->[:;FCP#T#LR< $XZ=,<]]_)EW6[\4W.
M;HD@>&' 3&#YQ'([[PJE]UNW.,Q1-2^X/%*J%?CH9Q%O+_3D!(P;E:6V69Q*
M$M$*-0]L)Y.;F(]R2+421.<P*.2K#\*8PJE-_BK$?Q(S Q ,#'[9C.V5?W-P
MZG4[FG_E>'V@)+MW>(<\DB3'GD+=R$+E[=\I0VUQ50AL;8]:M13>)(JDE)><
M=&(HT6E2(@HDNH@Q1:E%L#A<Z)CG<J>W\:7MC:U[>-<UK2S1@?Y9D[[X_.3,
MKQ&C<8,S[QOTYC($3,>0F_ ;;*;"RU3L<XX#\7JYC.V3>+2,S*+P6:K<H+E3
M+U6;"BJL@BV,(%1*H3CPF ![6G>U:[#7,L)+H C.E\9QSW7M2OJ['M%/3,D
MEH)B#TW]<^L**U7>R.9\L9SS?.F*#6B2J&*\=1JJ@F7B(.O1Z4](KQ1R^X1E
M*R4O9G)7K]$Z:KINTC$%0$K!(=1Q"X>P::>D:7$R6 N((#=$R?" V6B(U.='
MM$++V=0M>75'&2 V 8:"TN<7:#C6[7!=!<6L:W9HB*&Y/+=:B(-Y3#G-,61&
M/8.&S) RTG.0LXV<-#A,'<-DG'%E*L0_Q0$5^( ZKGLL/GMAZ=S=57-:0SQ.
MP2 P#<C)@#$[3\<+/4_N99+RX$-DPX9QR$GKX>?J)(L2V=;AX;*..H6 L=F;
MIY'JT4D6PPLPB^;S3J.5+[?XE%I/&Y ESBT0:(/%06(J55 C<Q3 D0PY_AKJ
M-5\5B=8(&'-$[#&>H/3$$+3>-]_:7S38AO=7!!>7L+_9T@0Z#$C<@[[PK!-D
M]Z<8)W'KXP<N%TJ-G![+*M2.RH(,HG(,1'2,N:017%T8@A<&;"4>NP(0JKF8
M>M_>!1<W;72N"7K;2YI4Z9AKR!+BTQ_*2 3JU8;GF1&QCE_VQ]D.'U^S;>.4
M!6_Q&D*-2M#^\IU0XL;69H@"D&:G5,:L4],"95]# RQG!_<%/J)/H7MS[@<B
M;ZE*' )BD/(<^3"'TXUUUK@^G3=S+0>41\3SG'+\OD1C8I$N'C[UP/33I;IY
M#,SF/*<+FM$31$T1-$31$T1-$31$T1-$31%6[ZD 9QJ6':EGK!5GE8>3VXY,
MC<OY!ID>V2>IY,Q)&1,]!Y'K3QH9!5TLXCZQ/O[C'%:JI#^*UAG\@I\ET15&
M9?SEG>[;*K3O2A;O:&L#N7WDX0DL(T&7B(EZEBW$"+:&I@13N&D8E=XTF9JS
M5VS6R05?KJJ),IZ.,W*@CT$\3\<#:.GKR_JH.W/'GYG:<>[XX6"=X^YK+8[G
MMVK?)&>+Q@_(^'[W!16T?&%<RGCZAFND$:RN4(:R1.)K-29FU9CDKFV;1K&7
M1CIDL>1E,/%8YFS='9.FTCG/N^/ZY^6%)G!'7GMZ*26\;+&]O'=[I>'J1D2X
ML;1ZBF L2P&)9YU%QZ$7@G.L<C,QN9IMQ'FBOB8Z'81,_CF>,TDGJAV4RXG"
MJ.0:"V:M2+).U+-&4]ZF"]W^X/+TA8ZKB2$VQ6+"*&/K S08(AE*E4QZ.:<D
M)HN62+L%XNU0!4ZRX*L"*2$BHN(*JII'*3G]?7K_ &5EWIDV.YV78AMJF;P=
MZK81ICQF9R]Y.[DX6-LDW&59VH<Y"BL+NK,X945P+\PGY 1X$PD4_P!/_9D_
M9'Y0\E_9^GV_=HBTS]O= 0'Y0+_QY'_RUXOG6"#B-O>?)%M'1 .!#=>P&, &
M\\=3$^<#!^?!RAP <?X!Y]V@/;#OY?S^&QY>?DO%[8(($B1[B#.W/:?DJ_\
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M>TP676)'U>'*NNJP8)F5.X<IQCL7BA6QBK>/$*U.FXT@,"'D@072/,D@?AW
MYD8E95P<XFXJ!S3ITAFK4UC0!L0UK721,D%TB 6@D&\:I46$Q[&X>A6R::;=
MW#SZ_P . )!'2=K6)$(@Z?B<AG"BJC)&/:()G="DA\(JHFB K*:PFJFZHT><
MPXD@N,9Y8@1!,=,DK$?>IJU=4ZB6L$2(I :@-));JUN>2\ $C2TR&A?B9#JE
M4.^/_:1%P1<3&*4R#H#&26$A1+\R:1C'*@F'!CGZ% WV&_<&4J+J@$:0W/J0
M,3SR.1Q\L]9CO'M/(<HS)!V^(. 85,>$[E:&E?R1C.K2E9K"MCS_ &9Y:<@Y
M -[4;2(YPWB6)"J(G=,/C0D4&QG3)0';4HG1<-RE4,W.<<::?WD[CVB"78CE
MD ^[;8<E<W-PZ@"YK7ES6X:!),<AC)]WHLZ-ZWM1Q\ ,(B6A)R<54%66N<B]
M83$[,N"\G,];.7?OLD9!RJ'NJG!FHW.*BH)MB<D]NR?:%AY0)&YQ."=R<D^(
M\RKVSJUZQP1D@9TCEL2!)Y_'K"Q;D.]4YM-8]NM,C$T)^J7:*B$YQHR;-G,H
MTFU>[R D%HY)JT!NDFP9O"D<-E%?<D%CD%-)0J86=HVL+UX:X:0]L1D9@'&8
MF,$^LE;!4MJ56WIFH"7T&N+R9C)),$.@\I_"8'639'DN.EI.LQEKK*ZC&XU%
M]7[_ %T_*RGP;^&DV$H5NORI[AT1Z&CW@ =/W8Q9V!@(43#K;;2_?1N*.HNP
MYAQ'X3/3ETZ@$;2M4XS;TNT5C7X.UHDM-$]Z"&.TSGPEA\4;S)ZRK^]IN<8O
M<-ANL9&CP]MTND>)GFAC%.O'V&-31)*-7'7CVU%#J$>I)F(4P,G;03 8!*<_
MT)P:]9>6=)PU:FM (/H.< '>8Y A?#_:_@-7LYQ>OPZJYA(/>-[LDLTN<]H@
M.+G #20)<9(<=C DUK++54T1-$31$T1-$31$T1-$31$T1<2JQ6.)P 6YP61,
MDX55)V.N0Q!2!%1,2F**74PJ&$3B)S)E3$H%.8Y2?7[K];QA&Z::11*!$TP2
M3!,/8(A]>QFR)0,1 P\@/R#Y$H#R&BB/U]WD/KS7%/*G$O747(N(J)<R4(F(
MQ+UVS3<N8Y0S<[54C1PHF*J!7#=55!59/JI[1S%]LP&$ )T\OKZ_JN2;1JR7
MO>XY,H"AP,DF(F,5N4I"B4H&-Y54*L97A<Q2'^']A'J (%Y*5CK+>)V67<<W
M'&,K(N(>!NI&[.7<Q(F3=+1)Y-J_F(Y1 HI)'3FFC96'?"980<,7[H52&_V*
MA%W:KU6,IE:A*I7&S=C#5J%CX*"9II%219,8QFBR;(E(F7J!020()NI0Y$1^
M7QSHB[*0I2%*0H<%* %* ?8 #@ _D&B+15'@W/YD$O\ Q'_QU$YCRE1!G5RB
M//,G]%L7*@I(\B03IF,/<2B &(!"',!@YXY$3% H  \^>?MJMHF?3Z_JO.LY
MK1D$@G$;CGU^CE=7M=IBZI5Y.Q3DD6+AXB.=R+Z2<II>VQ:-TQ4,=4AE0,H(
ME W4"@83"0P#P :MZM=E/5JU1$R(F.0R<DQ&W[J^X90?<5:5.FW4][@UNHD9
M)&20'"!B=XC,[KRI^IEOUK6 <DLK#&T>MS^XZPP*1X%W:(9A-AABDOVY'<1$
ML4%@5.G;'Z0,%)TK51LS2?,UW"$@].BD*O+^T_%+5E0L92>:A9I!+6%C!&(\
M<AXP-42'1 *^G^Q'9V\JVAIU+RG3HL>X^"M6IU+AX?J?WCA2(-M4.K^%+FU&
M.&J(7GZNF8=PN[6Q,I[-&1+-8VT8X5-#PSMX]7B8A YR.&Y&D4=VX10*==1P
M8?9*"A4A2*0AQ#@.>5[A[?XSM532(.=3HDF&R1 C&^^>:Z);\#=;5=+'V=&F
M7FH643H <8&H@, <XAN2<P -MIE;;L?*5B4B'I(\K5-L5+W! @^ZJHD0 .K\
MZ:9_UI@$X>\":WGYR$-R4->O+YMS4=68',86 :7AH<",3 <[$S\C@'&1O:C:
M(-L3+PUI):061ID $P>DXY>2MAL64+6[JC%"*CU)!: .24CR*CPJ5PT(4Q"I
MC\Y0*IP 'ZB!O!1ZCK%LO@UX#FNP1D-'F/YHV&,=!S6N&UJ=X7A]/)!Q(^/A
MW&<3[\E8ROV[/,ELB5H3'6")2-MSYFBFE<Y!"/;0\4=R=(CA\555PFX%=)0_
MNI@"1?F#DI_< H&RU;BK#9U&]U4!A@!#69(>P\G3./,^A6:M+FG0C7WCO"?"
MT@M/E#GR1!Z1@+A\;;3:54X8*Y?+DS3G,EQ[J7M;1-4TDE(/Y!PL95BV"4+'
ML.#K*N%53JN"^PHX$J95BB)QN.&5F5 ,/G?V1,\Y,\\[$8W7L^I]X<74VZ ,
M>+PXYX;K,C'U@PBSELNK"4NZC]OUYE6K6,%0TT@WCC&C(<$Q$#))RZ;@L>^7
M)U%(A(I9[V'Y@ $^3!7?W5&CEU*J\#!:,S,]7?O/5;=P;10:PU)B&GP=.L$M
MS&[<0=]US&S3;]CRS7M:%ON2<C7*Y8TE&ED+1I./1CJZN @0S64:.$)R33ET
M@4:*HJ'>-62J8D%+I\HCKTL;BU>P5A1JM%3(9+?#$B?: ;/E.!M,)=U7TZU]
M5#M3*^GNP1#F ,#2'B2'0[((<8F(PKJ7A0?JOP S?X==-5 QP3]IN"9E  &Y
M4@ 3 '4/9-R4H"F)Q#D."C<.8*E=M4'2P:L$C6=4[;@3S,['R6L<!K.X7Q"M
M<70%6G4J.<UM++A))!.H,$B9P2)YD96<_2[N1\?Y=S'@YXLX5875M'9BK[=$
M/[(VG%1=U.V(#[QTA)Q$UFFJ(@@DJ!A5/[HI<$]SJ/8KBE/[Q]P(?J=1<]I\
M&CPEH,G7.HR,:>1D\EP[[=. 5Z]7_M=2?;BR+[:P-![G_?>\JON*C7:12-'N
MQ+I/?Z@?PYE7F>^4#"40-SR( /R\#P B(A\WT\#]?W?GKJ$XGWKYQ+2!..O/
MG[E])J%5 3% P !A+\P  \@ #]A'QY#5+'AXD2,QGW?NJ5J:J1-$31$T1-$3
M1$T1-$31$T1-$31$T1-$31$T1:"H<^/OUYX^_CG[:ISJGEI_7;]46S7*F9L;
MW1 I 51Y$1X#YE2% .?IY,(!P/UYXX'GC58)&RI<W6(F!O\ !0MW@.#2[;&>
M.')B)U^V7-!_=1,H9%->C5DS9:=8*J@<H)-W:$G[:J@CP $^H?36*OB V7.T
M@DR9C2&])'*?Q CR6Z]E;.I5=5K4*?>U:%(&C2AQ#ZCMVZ6$/)\+1X3M,+^>
MEN:S$?/FXC*6<<A2XM&-GO=A<LXTOM^\HP/,/#U>L015^XG<)1ZI&:#9(%%3
M@0  HB&N+<;?5O;TLI-[Q[B][BV-+&ZI>\D"&TV9<YYEK0"=@OI7@]9G!;)N
MMQITJ+64V:CXW%K=--C>\!+ZCH &Y<[DK8=BVP/,N5F;+)UT@FF+<;JM2QM4
MQI(,%SVZ?;N>CHMML,Q(&!S'O' +@C&L$VJ3<S5 IR)G'DQL;7M:9MRVD_O3
MLY[1+3 V9$R)U#43#A$!N9LW]I;A]T7//=-T^&GJIZV@EQU/EF#!'A@%N9.<
M6.SNT V+V;,[9RO(((%1;)+*%*=X_,DF'*K@$TR%*]533,NY3(0A2']P 3*4
MHE#1[JVJTW:(=I&T-(YQSF8'+XK,T^(??27ZI?L1X9 &QP!(Z0-LPL_X2K5#
MF#%C99BF5ZU6]@_N' @@X23146:J$-QRH9)9 XICP;JH0?H<-6]M:M?4 ?.\
M$F>>0?J/1475Q<4J3G4A)#>DGG$1'P\P,[KZMD8>PM).54*:#K3&:5@HF.KL
M>R16< T74+_:UW#9V0%!2;B)>R0]UNI2@4PE$-@=8MJ6CA #?",#:'-,"=]L
M>62O>W>6U:=(NU5'-+W!QR<02!B!JQB ,8.5 [<+MIG,Q1;5O6[B]9-X1PHY
M8OW3Y>/E&SE3@31QG$2K& 82]"*>U[8"4%>>/F#B[LK5E)NG$0.9!'Q)]<^>
MT+/V[@T@&/7$?"08QR/(^06"%ZAN\KF/HO$+*AP=ZAHU))I%35;EV\7* +-+
MH5!VX:LG#B<'VDQ _N*_BR@AW6?J']TRB^MN]8&Z9 'A$.)))& 09YR 9.,<
MEG;>XIT=560"8[QSJA #6MB0'>$8D'2!DZB9&?C:7BO)E+S+:LG9DK:F+(MI
M3&54CR6"5^ D)QXC(S,@L];INVS4'2!/Q$C85$TS<"ET.<R@&,:FWH"C0IL=
M#2QOLN,.RYPB'$N/F#USYWKWMKTM5,BIK.[/&UNQ .D^'!P<2.1A68K*?'I-
MWJ+ELNW.JF0",.OPZX&(8R"B2A!-[P'* ',<H^>?OSSJ'5"V8R#L>7GU$<Q_
M3.*J6Q8[41 W (,@S&9\CF.8Y+<X^N9<2;D<+WD0:((3MQ_J_DW0F*F1**N8
M0Q *Y4[ 4I&BT(X5 5!X(+HWCY@UL78^[=3XY2U8FF\;@ >*GC83B<SZ+GWV
MF6+N*=E*MHUKG.9=V]<!H<X_PV5P2 /^)LDX&9"]%B:Q0,14P>3 9-,OW,8Q
MN.2@(>>$P,<>/]T!'Z:^@V>-GA_E_3^T=5\;UW=UX"<DB<[XF,\P>07)(%ZD
M']YA'Z<<> _\-4TP "!MJ/OP,^7HO-:VO1$T1-$31$T1-$31$T1-$31$T1-$
M31$T1-$31%HCY5 /S3'_ #'1%L7ISHM@,B3W%NX"F7MTY./)2]E0#DB8"/*I
MB@8_M=P(0YQ*4:FMGZ^"\ZCM !YSM._6?S_)4%>K/O;A<&.9JC8_C;'DW-,?
M@F^.D*O0';=V- 0M@NF1[GDN96>L8FMUYBK#%4CT'[X+*Y12?+1T X1]M1;
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MISF(""AR@0!#D/'.4M9K-U3/B$]8.1OMT.2?FO&_HM:UQ($EA(\(\M\R#O\
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M3&,DF.AZQM^VZOPWH 3R/OQF(]/6)Q*ST& MS;9E_65M_N5/GXNR?])2]&L
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M;)%2.]K&%YUFW4;,+31ZQ;HUDJ/ZY&,L\0PG(\BBG4I3&29.R$,8$R@<P"(
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MBP<F)(-_TTARD%0Z<=-%<..E@61(H84'$8]D$R$,"1CIFX*&KAM1E0ZF:AJ
M#B0UP!.#B2[G@>?OT5O$ZEM4=0K<,H$ D.JU'A^K3C#=+M)ZG5D^F8IYFRM2
M/_2SV87=%Z[C&QU,G4.Q-IF#>1;IB,IC>Y3[1)PDJE_:0"3AF:8"GW+[G53G
M@O8-A:XW/#[FD[_+ITV/J9F *U)K?#'BEY;N1&8G 6NTK>RJ]I^%5Q<B@^K6
MN:;:3*9T_P"BN*CI= _#3($-R8G3DJ=!\I4$J1"#8&"JJ F57X8.!-T.')?
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M12EVA-0.Q#PD@4P?F MS@(:M[IQ9;5WMC4VFYPG:0)$K(<) /$[$'8W5*?\
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M;<I2N*&$X"5!U 4>2@': *<=$S$<#P)1\EZ^V(=A 2\:JXO73C13<TSB((9
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M4%!,)1  3$!\<FI4G\0KN?3+6ZVC_,)!U&HUT^ .W@YZYV)7U,RV_P +XO\
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MA3KBG7K=W4J,G34=$.#W@D3+3S5MIBE[E^4OV^P?GK>7$ZAGI^:Y; Z!?28
M!> #@.?H'C\M>BAOLCW_ )K4T52:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)
MHB:(FB)HB:(FB)HB:(FB)HB^!^H_W!_SU0?;'I^Z+9J&$J'8 Y'NF7C\P.IT
M'\_L8>-5G8^A^@J';M]?V5%GJBPX1\%>9 P@);#<, MW*8CR(1Z<[?T3CP(?
M*4#=Q#C]D1,/U$>.>=J3%CQ*-Q2$;0</&8WCU/DNT?9\/][X9 D1=2=X(%$X
MWR3O\"L_[4'2P[Y]S\:8Y?AF^*\/.6H#^V8J\:P%(W?GDY" )0'QQY+YY$-7
M78W%(Q$=PR"/Y8;&WI_3 C"]NW:F4C #A=5&OB/; >'G_P!0*M?'GL7GZ_+S
M_'G6ZN]MON_-<T7Z3Z?S_P! UZ*EGLCW_F5]Z*I-$31$T1-$31$T1-$31$T1
M-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1:9AX$?[@_ZC_IJG\8\F_N/U1:
M >4C<<?*(#Y^GCD0_P!-5'.%2X9:?/Z_)5">JA4SOL.Y)L":8A^"U_'T\=3@
M1(0M>F;Z\76$0XZ>T1TF)CB/4@<"/UUI/:JTU<,XC5#HTVKGD$9.GO)'UYCF
M5U_[-JY?Q+A] G!N:S),:6APMHG/++B)S*XK:W/M4=\))4RY ;9?V>U:P,U1
M. %=R=/F<=1+A$H_1PLDE)N#&,0>4RE.!B^>0L>QETWNJ+"-[:BS5."\-:"
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MB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB+26'A,1_[R?\
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M7'#*)V89MF<OY<F[N:P04ID:0L0UA:9DJZUKM9LB+N;75@SMBEG7<2B+)".
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M2I6>ZI5J/JU'&7/J.<][B=RYSB7$GJ2NGLILI,;3IL;38P!K6,:&M:!L&M:
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MQ7X>A>XAY&W"O-(R*C8I5O ,)IHT0,Y%R+<17((%!)!QC$#S'7W^2Z-E_(^
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MI^Y^IYK\S)[P$[@8S^6.?SW6[('!0X_?_GJI2OK1$T1-$31$T15:^LAF/'&
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MJ;R2YK'B'.;L"!@Z29$Q&".2["02F*4Q! 2F #%$!Y 0'R @/W =2I$QG?\
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MSAWV2"5VP/)4F-?%48E+^L.!YUC("5=$"I\@"? F(.N76- 6U_<6$?ZAYXD
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M< 4P@//D .( </J'R"8>?''.LRPASFP1DC',;'(W&ZUE[P&ND$$ ^%PAQC.
M8G]]U'/=.=,FW3,JQP _LX^GG")%! .#H( NT/\ K."@9%RFW. ]@$AB@(#R
M :U[C^H<%XP",A](M($ $7-/2 ?3H#G'FML[' U>TW FL=H#S7U:C'_P5>28
MVYR3_54U0 '>^H-3(Y0I7#:\[#:&UL3?P87IE)V^M@%R4>$U#@D $$QC'Y2!
M+@>/!=%JT'N[7<.IM<T-J=F:;JF3EQK5P3@$3 #2#M&3S7;V4Z=OV)XB^J*;
MS;]IWNHZ/$&Q1H.:2($0XO>2!&3B5;IL%;O6>S?;FR?E<$78XDH;, <B K"B
MVK$4DD8P@8_[1"@(<F$?/G@==%X,VHRPI-JD.<'/R"2-.KPQ(!V7#.UCJ#N-
MW+K=I93<VF[2X-!#RV7SI)$ZIG,RI?ZRJUM-$31$T1-$31$T1-$31$T1-$31
M$T1-$31$T14BQSC!F&DR53&5.8JK-$2&,A7F!WZ8+(('(DL+MTI(2:*@MOB#
M+&4?'0]H%>J)!X.3D=8-IWC@P"=9U$M!$Y +207!W_-!'X=H^F.%W'$*MG3;
M4J5N[8-#0TEA+702'Z &/;(:6DMUC2 7P3/0+UG&V,(P\JFK#59L4AE$19H*
M34L*).W)U(]1UP7@2F#P@ =BB'GR&JKRF'L#C!,-_FCX P!\.>ZV"RX/<<0=
MEM1P&9=3<2>8RV).3G)/N43LV;EZ'B27AX#).292.GY]/XDL38G\6S!!L  =
M1>31CFT*XCBE P !2G2()_U?' @&L;D_#8QRZ  <Q'PD1A9]EBT 0!G($',<
MYF3T!Z^2A'F+U%<=PPOH3##!+(UB4;_$NIIZ^>MZ,P230*11(J[)X23>D*)#
M'542G41 PJ%#J(!UI.3C'D8P8SCW;PKVG9 @8GELZ!B,Y D'EA1]E_4+1D,6
M)#C_ !Z\;7RQ*JM9J2GIB2D::S:+Q#]L^3J4051M("5;X@S@JTI-3*J)4$Q2
M4* '[W%%S6L<,SB<B#N!&.GF=NA5I?V+NZ>[P:"&]V&L>'>R=6IQ>0X$1I@-
MP#.=ND;<M[5IKN)L&5&)I$(2$BW5SKT^9,\\,Q/N'&1K1.O'D=)DF 3CU6I)
MWVT6YVSI$3=3*I*\]=>MR2RHYCC)ALX G4QKACD0"!ZYP2L/V:M&52*C6P'5
M:@ .IQ&BL]A(,Y$M)/0F.0"D7)[]@@[2DK&49T&.X]T*$M^)2L[(WUHDN"A5
MI!N[0?M(=5-NB"CHJ/X *BP)@4BI!-V#'O>TN@8U&,GD2,$XV$[#\EMG$+#-
M'4!)<T$AKN8Y ND#H"9C,E3 @]^.($H"'F(C*K K1\8H(QTF91>00)WZ<S2)
MY0IF("8! PB5+@H&^Y1U7W(D?U]>OZCXJQK<*!\0;T_ ^/+\6"?0;<U,F*SP
MS7=1L99(\O\ ;6:4O"RL<H9*/=LEDBJMU61FPIK+-%43E.@*[IVH9,2B=94W
MSC4*(Q,;8)D? APY8GW2K9EJ;<G&-G @D3&<&0-CUVV"YVR4_$>=8=S'6NMU
MB[LC <B[&7;&&0;"8G!TVLK&N64ZW$"CV(@A))D34.=7H)U3&&WJTAW@=@@-
MVSG/D08,#!GU!7B^E>_?:5[1N'T;:G1;1J-;1:X:Q4J/DO+2UDAX'L_HJI<D
M^FQ<,76\,I;*,M6_&MN;.%'K.K.YIJ@50W8ZR<;#OS,DX^0 5O9($19HRR.'
M"!#J L#A'WRY*WN^X(-!SZ6D D%S Z 1J(.D#)P!!,#<K<7=J^R]]PT<+XM8
M65S</EG?4[PM:'?@UT'NJ0Z&EKWDB2=+0TN"F)M(];RYXRM;?;]ZC5.2HUSA
MGT?$QN46[-S!,W;1P8$$Y.Z-Y%4S!FB"A%%7$VQ+%18( !@9$,F<YMDX=VE)
MN*%&K4TA[VM<XEDD&!#O#@9W$9.2N$=JOL<=>LON.\&TT[6A3?7^[4Z%>K38
MP OEE85-^NK4)R(&%=]O)MT.^V@92G8:09RL=9:Q6HN$?,WI%4I)M>+76H2-
M58N4# 5P1\672^$%+D' JI]!-W !S_&G,J\*O:0>UQKBD]F?:BM3<(B)Q)!;
MCJ"-N/<'I5^'<<LJQI.I/M7W#'B"W0>XK47@]X'003!#@>@@E5E5AFBV]0M@
M(E43/3=G5$@%50Y$&CMDO97:C9R)@'VERB\ YB&ZG IBB(?-KG7WLOX_1NFF
M6V_#FV1<"(:YKWO() @1KV(GGMMUCAUT^MV<JV=7)O.*ON@'0"6N#*<@ !SL
MTR 9T[@#!5RVTYBM&[:L&LG *%6;XNI":A%2]%"&+7(THD,7@.#%$! 0$.>0
M'G75>&-+;*WG=U-KLXC4 8]VRXSVC<UW&;_2  RO49CF6N<"=SN5(75^L(FB
M)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O"I>O5QPY6):PU2MU.YS-5C#N&C
M1VP2AXN*GGT0O\-$E=IFFB.54%>3/@Z,UQ[HD$Q"@43$XK=W!^_$@?C=L9$2
M<[1OX?*>?/[ X!1M:G#V5-+(TC=@,F  !,$DY(@'$YZU16/>AN7MV3WEQK&1
MKE2%IUX!D(R,GCIQ5?@"G C?X@J<HW3)\GN*'*4G7CG@=>MU<N-,$&(@#)WS
MRB/3&.BS%OQ>A852R& 'PZ=)AHVDEH.X_EG&^ 2L76F[6W*<V^L$Y+R,HI,.
MO@9NW2AUE)%Z<R@JBFR15.=P!55"=O)REZ\\\CJV/3IR/F.7/!_N95VVKJF,
M#^8R"<F0!G?K/YK*:5 DE*NP:()F9L7?OD0(H44Y"0(4I$3..@!S[1CD,4W<
MX\"4WCGG3)]\XY;3,#U$;^:R5-P+8  @#UV'[YD_HI(5O&:"<]7X@J93DAZ)
M,SK_ -A,!05,VKSADW$G   F*Y>I ;DH#V,' CJK5I;N';=>1SY;'?G).<!>
M%_4'<[=3',XCIC>?7GNL?[<*B]D\>,Y'VC@E3W]D?@F<@E+\0YM]@46-]P ?
M80;@(_EP'Y<+JJ'U7$$Y#-B<138,;3,1OLL'V:_AZ6N: >\K3&/:KU' ;03G
M]MBI4.L?18V@YW*29(RP-"*)"8A>@#*.$"LS"''  5LNJ(\ (\<^=8[6=0,G
M!G?:-^<YY9CD,E;;Q"H-5*8]MI&#,9B1!^4]/)1ZF\-R-.GI44&97<<E(GCG
M[$H<G79.N%T7+8HE H\IK' .1+YU[_>1@R8.(D[\HQR]F-MU>4&LJR(&1TP8
M'F1CI.1^60&-OR=6ZM^C4!>;0MC:4.#&5AF+Y5E(UY\[_5M =BX?-4OAFR_5
M(X)&4\< 0I@'0W(YF >I,SO)F)VVZ^\KPN[$%I<&M!( 'A$SY'5CX?L9!86W
M'6G&#)>GVQ"?L$[5Q,K%V:-= VESU]<B;QBV%P[<-Q<II.COC@N1R9(555"%
M !(.JVOU"=X/4[8)S'4],[[RM;K\.OZO@M^\^ZN]O0]C6&J1SIEX!(9$N@\L
M[*R3 6\>#S!$+'L;=^DU0.5NZ4D12?R[<IS W*L\2;KNS+-#*'(BJ"*BPI*+
M$<F)[*)U"SHU'. ,8@]8C;X9\I5B>SEI0 KO<P500XA]%NXR<M<XSN9'NW*R
M!N-VYXQW$TAI"7B.2G&B+9P-0N<8@W4L%(4=%$R9FD@IT,XC$U!!TNS0=I+I
M'$Y!;=N!'SK%U"BZN9_@-+FND@M#?%$B3&28Y&<9*NK+BMVRX'"J#GFWXB\4
M+FFVHX4Z@>.[)?2]ESBP!AG=K6@F  JYMO&3[MLHRI3-F6Z6VJK[9"VA;(U!
MG&)I)] K.*I"3%DK]<8D721!"K3<ZQAC1\0=L@X822<.W7C4/:46;9>UXK5N
M;W@EL]Q?2KT*E9_C+@8MGO'A<&DM>_3)(P8<X2(&M\2[%4JW#./\2M[;N[FE
M4M[1E-].DPTQ6O*+7R6/<UM2A3#N[<QSFQ--ATOD6C[66D]D]SN$W'RZ:K.>
MW VK^JG&#)01(O'1I(UJ@@J >?91*A(,ES%2-\ON_L@8-8WL_JNK/BEV07/'
M'+JR82)AC:=NXM#B00&Z\- CQ#J0M>[9\)I\ O."V3'-ITZ7!K'BM4@-9XC7
MO&M<]K2Z>]=2>"\YEN9PO1+78EE PL=#1Q"IL(MJBQ9$*4"E(U;)E10*!0
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MS&V((!\\>9B=X WE;-2ICO3(,B8W&WG$?O\ !36K;49=6%N12"R3G2)Q[L1
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MG< >^?B3@>41[QU5#A$[B<#5MM[@1N<_GA<E7(!TM2(^8>%*E)Y9LR:*?NE
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?J:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(FB)HB:(O_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g142578g30w28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g30w28.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MPKN#PM_>X5=[_FHB;>=S)DEF4CZ@
M
M
M
M                                           !;#,V4&[#.,Y5DET;
M%KV1'4Z"U*RMQA!"QY>7MV;X]'V@E2JNM2H]J/SLVH3%RBM2$)2B]6;;>63=
M9=*4W(-R4RB,;9@F3UDB08ARI 6*!SIMA;-D9EK$IPKR!&)#$75W7L"NXIW<
M89!'%"^1UZ1%(GEM/8KTMY3BVKFUR6$J#;$QI2FFVIRRJ7ZOB(GEEQY_?WL,
MAA!(
M
M   !;G+L?995C68QZ10)?E!D=6<U*Y0)J5-2%UDB>II5]4;4N>GV,-R)T)NL
MM6MRPZ1,IB5:E(/2.2186G.ME9\\M(,8].^&7AJS%+LS.44R7!6@S'+-C"(,
M68<IN65<CN9%LA52:1R!Y7*I[D=OC#/4XF/M,;CC;)E!QGR%Y>G=*A6.=A1D
MMY)9\L\BDM4EYM!BL\\J[[F_^N]/+Y#.(8F1\"YN3N-I=BB]=90JZMUM4+FY
M-EU:W4I2OC+VU6DO-MWJ?-:;=?;;7Y[:4K6M0]\T_.)3_P M>8\WBPV>D/\
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MM5T)K7A5X=2:%U,_IX?"X%G!B<_\)>8F4O\ +?G/1
M              8AXUU]:+LQ99.P7BW4QB.=Y8+.D"9-#8W+$+BN>543*/42
ME'&%A5=E2Q9&DZ18I?T<97NREG2HEJEP*3D(U)A0ET6LZ:]_?W:,O (
M       MA",SXOR/,<JP"$3%LD4QPC(F:)95845BRU7"Y%((VWRYF:W.Y2E(
M3FG+XZZ(',J] <L(M+/J2::6J)/(*"6;3F\Q<\
M
M                        >/(65+)6!\CJXY8G1/[.YLJL]O47)%Y"5U1'
MH5!R%792ZY*L+*/OO3*+:5N).ML,I2M;:4 &C;30^YSW,R0:0M"&IK'V,\J:
M=9!,E& ]'6KO%Y=C'*F&74BDP>8=!\\XB=TQQK#-Y3#VV6--V3,:OSJS.OBC
MZ25&4>]/3D6,W*ENJ2R/.UY5-I]]YGF1B1AO5ON@VH/&<*U>XE:=<$KR1-LX
M;29<)(<:Z<4FAD[ 2'.:F$2#&9CLXK",PV2%EQ<W.[FNRLK?"9+9E!N/1VMY
M$7I:@L$[FBFTY2EQM[J<K,V?BEFX^,R*RYK/U*8=8=T.TGW9 4O.K4W4WB7'
MVAJ5.C4Q%K+L=:_%J))AE>WH2VM.W/9>G)S;\U%NKHZ-RPBC9BI+M^Y;96\]
M8]_?.1N5\5R<I3?DS_IEM90N2-0.KS+.>M9F-\<3+7DWVZ1G6'81PB?IAQEI
MND44D.4D6%X?/WC)>I13E=/5VF1TPE<K;R"X/'$T:B"&"([U"&M\@>SU[:)D
MI+Y.7*YMYIM27>EW\MA>&1S?7+J%U,:'M/#]FR;:,5^5]SJE6?-5$7QC'\>.
M<X9,IQ::X297ICQ^_3-@GS1$'=%+)B>T&N:M#*4Q4*XPLY*.U]<4,A:A&1;I
MK*E22HSL>ZRO-8K/T,>YCJ0UNYJF>N!1AV1:[;)9I=S'-M.VFMCP'BW35(,$
M/TUPW"(JI/?M2*O(A:>731URQ.':]5)FABLC#%#L>N;*?#2['I4I76/>PF2R
M?)RY7-N:3XEWK<K>PW/9VR?EB.[GIF3,ZQ ;BO.3%HRR'D]4UI*HG ['&6&O
M"#Q*ST":JBKJW+38A+R+DY-3[G)$IO;K?&U6$7W5,&-%)TDLZ=)+OJ9K CN0
M-7N"VW<M-2TYU@3[.EVMK*^#<,YRP?(X9BJ/8B1->H'#4HFT>?\ #S7%X8@G
M,6><6NL>0J'1Q>9U+%$W;[GAP>[T)%;6XL3)/=R2^*IIY>*DO(\CLLS(MOF?
M6#D.*Y0QYFO &IK6EFB(.NOO&6 9@K?\+XF8M!JZ!3?4$DPU.L4PEZNQO&9T
M[.^/:N*B-,66H])Y?>\3F,+[ELB<TZL]*B$R65-)/<SXW2R49VRRRRIYK$5M
MJEU>ZFH#CG=I7S'^4#&*2Z<=1VC>(8&7*F!@7H8&T9&ANE-3*VPQ)1N(.?&U
M]6S>37N5KJJ4N-J=W5$-;BVU+17I1"2G0R9TV].6DO,D90XM6ZC-.>Z*XNT[
M9"U3Y(U-X^U&:5LQY9>R,I1C%[&=!<P8;GN*&I4ZXSMQQ"H?Q<QY)V+)*U%9
MC]W.E!C.<V-ZNV2KCZ*35 AR=&:4FJ27'E3F\N7BE8;?0,0
M
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M6P)Y)<3:>J=[+T 0
M                                  &/FJPQRLTZY;+:H,1DA2LB:AL-
MAZEJ='TAQ;794E;'E88QL9Z5\>:,#.K72&C2QJT;TY7-5$;2L2.)R907*SK+
M+2'F9C%I'0E,V:9DCBDVG.>84X8BA]7+-V36:0E2R/22-NMS4UXI121W;F=
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MIP*<'>W[M^/)+7^K9/EGJ_1(]$
M
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M(<9*N4.JB2O#RVJ$Z^U^6*BRR4Q;86835/2R^Z\R^E]:VTMI2FXXXI0F+=1
MUL-%1$0XJMKJNDJ^C5I455T*%).C\'1HY7NFG.9Z>#<(UD=2K:-.KH4/@Z-%
MK<MN>Z;66?>.@H4(]8
M                                                        *=ED
MLC<%CKI+)>\H8]&V4BQ2[/+F;XA"@(,/*36&J#=ZO MN//**MKO5W[S+:?\
MV +=X[U#X0RT^*XUC;)T2F;^@:C'Q8T,;E8J7IV<E6D0&N1B?@VWT2%K5Z-+
M>=2E;;3E)-E:[]]!,FLZ9$T\SF7F$$@         $;IX2Q]:ED7\*L,_D\D=
M#=CKN8A_I49ZTIN&NWJ?BZOT304+T>2     =>?@D7TRZS/PRQ3^:I6-4=E7
MM/!'TF*]55%AQ?\ G(GP*OTJ1W&C2Q9P
M
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M5))J=044H3J"C"3R#B[#23B3;*V&E&E7TNL,*,LNNL,+OMNLOLNK;=2M*UH
M/D:6EJ86QO9&-L;V5F:4:=N:FAI1)FYL;&]&5:0D0MZ!&62D1(TI%EA*=*F*
M+((*LM+*LMLMI2@'H           "-T\)8^M2R+^%6&?R>2.ANQUW,0_TJ,]
M:4W#7;U/Q=7Z)H*%Z/)     .O/P2+Z9=9GX98I_-4K&J.RKVG@CZ3%>JJBP
MXO\ SD3X%7Z5([C1I8LX
M
M             1NGA+'UJ61?PJPS^3R1T-V.NYB'^E1GK2FX:[>I^+J_1-!0
MO1Y(    !UY^"1?3+K,_#+%/YJE8U1V5>T\$?28KU546'%_YR)\"K]*D=QHT
ML6<
M                                           _FE]MU;J6W6W5LKP;
MZ4K2M;+MZEW!NI2N_;7@UI=O5WJ[U:5_XK0 ?T           (W3PECZU+(O
MX589_)Y(Z&['7<Q#_2HSUI3<-=O4_%U?HF@H7H\D     Z\_!(OIEUF?AEBG
M\U2L:H[*O:>"/I,5ZJJ+#B_\Y$^!5^E2.XT:6+.
M
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M\;9<^23_ ,ZBW>0)*U;;A-V/9>-LN?))_P"=1;O($E:MMPF['LO&V7/DD_\
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M8;98:5?88699:8687=2^PRR^E+K+[+[:UMNLNMK2ZVZVM:74K2M*UI4 ?V
M
M                                          "-T\)8^M2R+^%6&?R>
M2.ANQUW,0_TJ,]:4W#7;U/Q=7Z)H*%Z/)     .O/P2+Z9=9GX98I_-4K&J.
MRKVG@CZ3%>JJBPXO_.1/@5?I4CN-&EBSG,-N%V>,N1!>U8TU Y:GF1XOK"Q1
MDC5+@J593F;W*3H_,<)9QG&%M0^+6E]E;@O66(4T:1XCRH@9$RHIN:D[S+EY
M)%MIBNXL?2FN-2R.32R9TFOUU'H:,=0&3\G;J*Y:I)[E:?)-/6I#1]JTS!B/
M&+K*I#9C2(:=\'9UP)BS$,_)@5ZLQC0R*>QUCF>8EKZ0B-<3F[*%J0L^A-IE
MAP-?%:EE5*BIRRS:I36:>1J7D,NT.Z@Y_0XAQ?K5G6DR(130-EJ7XZ:FJ:%9
MT<'34A"<:Y@FC1!\7YUGV'OX4(X(5#Y&XR2+.;I%8SF"02V-Q^1I7(PMT.0K
MD%HAT4IJ;W2GDEDR<2<YV\6@_?4YK4U#Y&;]>N/]-6F**95PSI:BDPQ)F_(D
MFS9=CZ=2+(3QAPF93*/X-@M<>2&/R=3BB,2]@7R*Z>3['A,D=%1\?CA_C2"7
M%6(27Q9N4\V3,IM3;FI95Q3R%I<!:[5V#-).Y::8\7L^%7/,N0MSGP-F%T?=
M1F<2\!8<Q]C*+8OQG%2')XE*>'3V1265S"5.E62)0Z,Q@\\PAID3^\.;6ULM
MWRP3*;I-SS\2G-MO2BZ+ENN[XHTYXBRGC[3>GR;F">:YG+<_Y+AV)9E8%L:;
M,T(([D=S3O4-S%;&JQ^88X>%<2BSFAERIDCUJ>#R]1(UB"Q>P&,3A$\VERR$
M.C)M3R2G/1DXN)Z+<FDR&RAJ*UW8W@<-=G+3_HWCDKNBSL]9"69*UJ/<%QV=
M*D<CD:-HQMB=Z.T^N+[*7UZBC8Q216_S-D@$?8EDC*8R[WZYN<G!+(2HOCI:
M/BIZ_C9-I@U/-T)U>YJR/N0F2=(^-\?$XJUD0_+<R=,;Y0S6[0<Z7R]GP'D&
M5O..9XZ,6!\CFL,7QCL9!+HA.XS<Y.$\E2:L>=X=%&6VU]/&6YHK=JDW.BY9
M%ISYUGRY'WY\1?C-^ZC32(Y2S_CO$>/M-<@_TEM,=_C7_&S5FCPG()U/W6!-
M^27C%NG=BOQA+3)@XQV,NK2E/F,Y.@<=62QU3Q@E-9>C=W%O&.YR)Y9/-DGD
MG*;D[S8'&M2\6G^D1IU>P%M6.L/E&GLK4'%6-W,L:7-6S+\>\?VQB=S2+'(M
MK<JD7%M;G>38X6(5E%%2[5=I5M#!#4FT\Z<M1KLQING>H1VCNBW.F8=(47Q;
MI9UMRO#6,X/+&W/-9KF&%37/# 4MQ7)IQCE-C1IB:?&<^D1R5B8EK5DEPEC6
MV/#$_P MCS Y+%<2;Q+HI.DIY:.B4Y9^-Y5^CRVU_J8W0'.NE><)WO)>$M/J
M3 5<SX_Q7>G2ZJJJM5"^*9*R6Q8NCV:&?!UF)+(NJC5'B2M3LIAI.4E4I)CE
MRAQ<#FI2D7MZ %15+(FYR;S9,BGGG/1FSRM+>Y0UEQ/2Q-]V.S6R8>?)!*=+
M\>THRR:4<LSR]6R97XP8>2*F--'HD[MKQ&,-<6VA9>W.7$UM5%SA>78^R"RQ
MRK0PM;H_R2DWN5;-+)IMX_*7XQ9K3U!UU2XKT[ZG-,48P>DU)XPR=D_3^]17
M--,IR)-=B$V'*)GCK-+&7 HJRQ.>)8[.&9_N.A$HR!#RU%%;"@DCY>F-=J")
M*4TYR:6:6>>G1QR\\MF0&(
M                              8MY-U01+$$\R Q3]:QQ^-P7";%E5*I
M7NA:>23=S>Y)-V.^,PUI/O*L>%;9Q/0IU"9)50O/=YE'$=A!-I]ERF4IYK9=
M[2_?B(;\TUISY%[\93N(,L:@#<B0N%9ZCF-F<W+&,I7DZ*M,"LDQ3]CRZ'NL
M%1NT)G][^X+TK^NL29#9[*29D3L*&U[:GANJSW$'MZNLN4IJ>=+++C3N&7CE
MY)_]_P#6;+,S&&)(              !&Z>$L?6I9%_"K#/Y/)'0W8Z[F(?Z5
M&>M*;AKMZGXNK]$T%"]'D@    '7GX)%],NLS\,L4_FJ5C5'95[3P1])BO55
M18<7_G(GP*OTJ1W&C2Q9S0+.=QQR1*MSTTRZ6(WGIHQOJ TZ3O*B]JSS$VUU
MH5_#;/[WEF/YMA326I(HZ)>->(\L+&VTRXDK>EL=8U5BM$G*M7DC/=?&;E-.
M61Z)2MXUY5-<9G.LT%L=FI[%&2&,^/L^!,:Z",F:(2<6IBW EYL8)E+L6+V2
M]K6%EU0D,;1$("L8CK3#K5]JE2A-(+,+H=>6,9Y&K6G/O3O,16'<XM8;O@+$
M6@3+6=,#2'1'B"18I3&RN.P>=(-2F5,.X(FL?FV,,22A&L>KL;1 VIT0B4>E
MTYCRAV5NS S&V((\VK716H RW2FZ4OC.?>3<YM?HN*UEQIMH8U>1N>ZSF/33
MFW!L-P)KJD2W(>0;LDP&7RC*N',B2C&3!BS)3GB].TOB"%RQ-.F2*,KDWWS:
MJ4B%OMYJJK++4"6YK<A$U)3659)9DU-O+Q\>K3E**4;E_DZ$LVAV<8V7::<D
M9DTP:*X3HJR;#-1L">Y3A?*4-BS7#%B2411T;TBZ3X^ED;FL8=5S&ZW1I^L=
MXY*7-F<T3=?9:>8$TYIK(W/(\JOV?H7_ )/HORQD6$:.44F.TWXZE&GG6Y$-
M5$O8,$0"1PK&CA&(K$,H10J)QEO7K7)Q<9@H)FS0<X2MU)8D#K>WJ[K65I+M
M2)KEFBYK]2)Y]-Z?Z%)ZHM!V8,I:O?\ 4OC\[2S/FY]T_LV".+&K/&,AR@GP
M8M:9C)9.KRAA=E;%A+.YN4K3R-,CF,3=%$..?38G'ZF3LIOX3>E$IJ4FN.>1
MR;T/(\V66EEM(_N;>H7#^ MS,8\*9-PVX9WW.P^;HTQV3V::W8FR2PY+QA-<
M5RLI3?%C")>S.2%IE*9W8SBDYQ!CBA,3+;;$QM# )=)-TFYRI62SS7_944MW
M/_-T0U"YWS5AA@T0Y1:=3SG"YWD.+:IL5RAX7XURQ'((Q0"0R#&,ECI3XXO<
M(F;?'&AY70.1U9U#8_)U:EME99#HH(+$3323XIR:EFG.3VY=.8SUS$PN4>T9
MY5C+B3&*/+-IEG3*XD0*.'12&U=D&+75$NLAL2-<GM3'(U>M*-V!'C7AW4-+
M95(W&N;@:1<K.&)IVT2Z1M7FH#2=N5+1G/+>%#=+&"(;I#U21ELB$!F#%GJ9
M/6.L71Z487Q1/;G%[60!JC.-) XME7N5L:8]^R$EAK):N9(TN<7M6>/I2:5*
MG)99TEE>F3=LWEUG[3_<@,\2LO-L)22C2,LCF4=7R353_J%EV*I6]:N7AL(S
MK%<RM^(7R9W*;FYB;XD1'R84RR]G<G9.O@[2BB)4#C*9W7.C<(5-)IR>1-23
MDLTIYN-Y7I,G=26YMY!S<R;JVULV1(:RF[H+#L QN"&.:)[-+@2G$&.4<*=%
M$M^2I[[E9#NL2W+&^C/1084FOI:HMM-I6T+=-R7Z!4I.BY3W,_+,R\RQIID.
M0]8>C74F@D;,WQ[3-#]3\;D,=5D+KWF2*,\1S&+(R*&8\DNY"G)8S8*N/=:+
MC"[S2UJ2U)0RZT[@C'B:[VR=YF.!
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M0KUV> '&EF\XOZ%>NSP XTLWG%_0KUV> '&EF\XOZ%>NSP XTLWG%_0KUV>
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ML1%"R/EKR[*W-X<7-P=G!<?8C**.2(T9242WQ)25A$M=LB_(@D
MC=/"6/K4LB_A5AG\GDCH;L==S$/]*C/6E-PUV]3\75^B:"A>CR0    #KS\$
MB^F769^&6*?S5*QJCLJ]IX(^DQ7JJHL.+_SD3X%7Z5([C1I8LX
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M?S5*QJCLJ]IX(^DQ7JJHL.+_ ,Y$^!5^E2.XT:6+.
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MYJE8U1V5>T\$?28KU546'%_YR)\"K]*D=QHTL6<
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M/)3R7[Y6/J:O[?#]W*SE5#[*EUQPG0W](K^E5?\ 9-RNX[)O)=3;-TMD=_\
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M]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T.
M>-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5
MT^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=
MT. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N
M;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\
M-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCA
MN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QD
MAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^
MUCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I
M]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW
M=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'E
MB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQ
MPOW=6^UCAN@N;\5T^J]G'EB8I]QDAZ\-O=T. >-YQPOW=6^UCAN@N;\5T^J]
MG,/M?6NIEUG:0<VZ8FG'3I G'+3 S,R67.,A2/R)EO:Y;'I-<>>TIFMM/6VG
M%LEZ2TLM<GK9>HM-K==:76R[UL!=AF+P/A:"PE2P]#5]&%ITZ;JJ,#6U;I[N
MJK*J2IN)I)2W>Z^2YREDG,_/%]F>#B8>MJ%@&)HNLHI;IQU4TI4D\RA\N8Y0
M_)3R7[Y6/J:O[?&T?W<K.54/LJ77/ X3H;^D5_2JO^R/)3R7[Y6/J:O[?#]W
M*SE5#[*EUQPG0W](K^E5?]D>2GDOWRL?4U?V^'[N5G*J'V5+KCA.AOZ17]*J
M_P"R/)3R7[Y6/J:O[?#]W*SE5#[*EUQPG0W](K^E5?\ 9'DIY+]\K'U-7]OA
M^[E9RJA]E2ZXX3H;^D5_2JO^R=L<:W72+,,=8&._"3^IO9F5J:;U%DU;B[3[
MFY"0CN.M+K'[ZEVFU)K?2RMUU;:74MK=6M-^NFZWL$QM965E/]XX5;NG3IR_
M9U;DW5)N7;7%,LU'LVP2HI?L"*R)+M^JXE]&/:\L3%/N,D/7AM[NC#@'C><<
M+]W5OM9/#=!<WXKI]5[./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<WXKI]5[
M./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<WXKI]5[./+$Q3[C)#UX;>[H< \
M;SCA?NZM]K'#=!<WXKI]5[./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<WXKI
M]5[./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<WXKI]5[./+$Q3[C)#UX;>[H
M< \;SCA?NZM]K'#=!<WXKI]5[./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<W
MXKI]5[./+$Q3[C)#UX;>[H< \;SCA?NZM]K'#=!<WXKI]5[./+$Q3[C)#UX;
M>[H< \;SCA?NZM]K'#=!<WXKI]5[.:5]V.E96ZDL6 F>-HS,/7X8=LBN2L][
M-ME]K];.4<-2DE)[$%C%5!<W5BQEYMQMRFBBBRREM"O$W5,N.*/8OB<6:R.I
MUF%ZB+WY0AZ*5"$K*KX/X%UK;>ZKZ>ZW7PNB4N.>3S<(]E^$CE5*C@2(J_@W
M3;G&U5*>Z5&RH6;<FBKR4\E^^5CZFK^WQ=OW<K.54/LJ77/*X3H;^D5_2JO^
MR/)3R7[Y6/J:O[?#]W*SE5#[*EUQPG0W](K^E5?]D>2GDOWRL?4U?V^'[N5G
M*J'V5+KCA.AOZ17]*J_[(\E/)?OE8^IJ_M\/W<K.54/LJ77'"=#?TBOZ55_V
M3,[<]=*+EHDUBX6U1O$S0Y!;<4.,K7*8>VLRA@6O5)) )7"RRR'=4X.9".J4
MZ2%K[[C$*BAI:2\BVEEQMIMGCX?Q(KL-8(C,&4,(54/2BJ-4E74H>G64:'P4
M155V6@JVBW-5>Y^4I-SXI'Z8/LJPL+$U5>\#1%-5;I3HJ,JZ+>ZH4J&?X!YM
MU/-EE+)G.J_RQ,4^XR0]>&WNZ-8< \;SCA?NZM]K/>X;H+F_%=/JO9QY8F*?
M<9(>O#;W=#@'C><<+]W5OM8X;H+F_%=/JO9QY8F*?<9(>O#;W=#@'C><<+]W
M5OM8X;H+F_%=/JO9QY8F*?<9(>O#;W=#@'C><<+]W5OM8X;H+F_%=/JO9QY8
MF*?<9(>O#;W=#@'C><<+]W5OM8X;H+F_%=/JO9RJX)NL$8G,XAL*)PP_-QTP
ME<>BQ3@;,F]06A,D#NC:;%AB>Q@*N/L37*Z'7DVFEW&VV5LH996ZEU/Q82["
M<9@[!T?A"EC!#5M& @HJ,I52@*VBZQ0M165[JU2<525%TU0W*I--)N<GF/V8
M/[,<''Q\# T<!Q-72C8R&A*-8XVJI*K<374*E4W14.G25!T]TTFFTI31MP&C
MC<P    !;W*F,HYF"#NV/I::\DL#T>SJ%E[ [*65S\8Q/;<_H:%+TO\ N6DU
M<&M+\J3WVWD+$WC4J@LPDZ^VLIR<QG+(X6TV+\2YFS#DD_(,TE;5D!MA#:R(
M)/,WR1K[*1]I^2.:R36N)!:9<X$JBRR(TL+/4F-S.H<$?^S13=;672FDI2]^
M+]2$I-^^M\?ES<1E@,23SG)G:7DFU.\-;<ZI[+_&6$.2),N)L,I3>I?:4J*-
MLMOWOFX5+:7;W_V/I5UM;4TMW55E954Y-;NKITJ%*3SK=46G)\:F85E55UM'
M<5M70K*,T]S64*-.C-9G*DFIKB<CP^(,$Y%1+JXS_!C[[_CN6Q?2:[KGPWC!
M<CA>CU74'$&"<BHEU<9_@PW_ !W+8OI-=UQO&"Y'"]'JNH.(,$Y%1+JXS_!A
MO^.Y;%])KNN-XP7(X7H]5U!Q!@G(J)=7&?X,-_QW+8OI-=UQO&"Y'"]'JNH.
M(,$Y%1+JXS_!AO\ CN6Q?2:[KC>,%R.%Z/5=0CJ/"/52J-;J'D)JCBE1'VLO
M%V'C2VUD.,:D!9IT1)O.,L1H+B$]AAM]>&;?:72XR[^JZM:_..@>QY$1%9BS
M44J=?74Z6^HM;JG6TZ3R5N3*Z393\,PD*HZDE#0Z7P=7D535I?)T431#QJD_
M*-^Z8</B!>/AJW^;6?7I7GE;UAN3U'V57U1QJD_*-^Z8</B ^&K?YM9]>E>-
MZPW)ZC[*KZHXU2?E&_=,.'Q ?#5O\VL^O2O&]8;D]1]E5]4<:I/RC?NF'#X@
M/AJW^;6?7I7C>L-R>H^RJ^J=:/@H9)4NS!K#)E91<G)18UQ::C*D-EKT4D--
ME$IL-,3%N5%-I!AMMEMIEY5++K[;;:75K2E*4U7V48J)JX3!#JXBOJVXF*3=
M"NK*,_\ Q56?<TE,L& 8.$I5D3NH6'I2H5>>HJG_ .U*VB=LG$&"<BHEU<9_
M@QIK?\=RV+Z37=<LN\8+D<+T>JZ@X@P3D5$NKC/\&&_X[EL7TFNZXWC!<CA>
MCU74'$&"<BHEU<9_@PW_ !W+8OI-=UQO&"Y'"]'JNH.(,$Y%1+JXS_!AO^.Y
M;%])KNN-XP7(X7H]5U!Q!@G(J)=7&?X,-_QW+8OI-=UQO&"Y'"]'JNH.(,$Y
M%1+JXS_!AO\ CN6Q?2:[KC>,%R.%Z/5=0<08)R*B75QG^##?\=RV+Z37=<;Q
M@N1PO1ZKJ#B#!.142ZN,_P &&_X[EL7TFNZXWC!<CA>CU74'$&"<BHEU<9_@
MPW_'<MB^DUW7&\8+D<+T>JZ@X@P3D5$NKC/\&&_X[EL7TFNZXWC!<CA>CU74
M'$&"<BHEU<9_@PW_ !W+8OI-=UQO&"Y'"]'JNH.(,$Y%1+JXS_!AO^.Y;%])
MKNN-XP7(X7H]5U!Q!@G(J)=7&?X,-_QW+8OI-=UQO&"Y'"]'JNH.(,$Y%1+J
MXS_!AO\ CN6Q?2:[KC>,%R.%Z/5=0<08)R*B75QG^##?\=RV+Z37=<;Q@N1P
MO1ZKJ#B#!.142ZN,_P &&_X[EL7TFNZXWC!<CA>CU74'$&"<BHEU<9_@PW_'
M<MB^DUW7&\8+D<+T>JZ@X@P3D5$NKC/\&&_X[EL7TFNZXWC!<CA>CU74'$&"
M<BHEU<9_@PW_ !W+8OI-=UQO&"Y'"]'JNH.(,$Y%1+JXS_!AO^.Y;%])KNN-
MXP7(X7H]5U!Q!@G(J)=7&?X,-_QW+8OI-=UQO&"Y'"]'JNH.(,$Y%1+JXS_!
MAO\ CN6Q?2:[KC>,%R.%Z/5=0<08)R*B75QG^##?\=RV+Z37=<;Q@N1PO1ZK
MJ#B#!.142ZN,_P &&_X[EL7TFNZXWC!<CA>CU74'$&"<BHEU<9_@PW_'<MB^
MDUW7&\8+D<+T>JZ@X@P3D5$NKC/\&&_X[EL7TFNZXWC!<CA>CU74'$&"<BHE
MU<9_@PW_ !W+8OI-=UQO&"Y'"]'JNH:J-V]B\98MRMUA.S''6)F=44)B=Z-S
M:FAO;G!)??E&"E7WIEJ1.2I(NO*,,*NN*,LK<7??96M;;KJ5M&)<;&4\:,$T
M:<7$TJ+KJZ=&E7UM*B_]+7O*G3:>7+WS\.$X*#4#$M0D,FJ"RJHJD_ET?_@C
M(>-4GY1OW3#A\0.D?AJW^;6?7I7E(WK#<GJ/LJOJCC5)^4;]TPX?$!\-6_S:
MSZ]*\;UAN3U'V57U1QJD_*-^Z8</B ^&K?YM9]>E>-ZPW)ZC[*KZHXU2?E&_
M=,.'Q ?#5O\ -K/KTKQO6&Y/4?95?5'&J3\HW[IAP^(#X:M_FUGUZ5XWK#<G
MJ/LJOJDP-CZ"0<R!0@PR&Q0PPR(1J^^^^.M%U]]]S,BNNOONN1UNNNNNK6MU
MU:UK6M:UK7?')D1'QV^*_P#UL7\]6_\ ]%=_OI?_ &;#H0,%N:/^CA?DK_\
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M@CZ3%>JJBPXO_.1/@5?I4CN-&EBS@
M           !J8W=+ZI[67[#1']58$+5B3W4X(\=7?E(@_!A3M")\!>G1(N8
M=+%&       F3\=_1_!?8Z,_X1".18CMBO\ '5OITC8U#Y%'P:/F16(^)D
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M.80]M\W?JO*1SKV0NZF-\3!?E*HNF!OX?5>%6^LI&]<4D]0
M  U,;NE]4]K+]AHC^JL"%JQ)[J<$>.KORD0?@PIVA$^ O3HD7,.EBC
M 3)^._H_@OL=&?\ "(1R+$=L5_CJWTZ1L:A\BCX-'S(K$?$R
M   ..CPN?_I.A;VIU _XG$0VWV*?G\-^*@/3BBNXP?(A?"K?-5G$L-RE9
M  -P&X(?6WZ._:#*/Z%91%2QZ[E,+>!"_GH4]'!/\0A^_6>IK"4 '-A=P
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M2:65O_II?6ZEMN]MOL5.=?AKQ4#Q)?\ O%6%>Q@4J$+X5;QM\57:<4XW(5D
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M1%2QZ[E,+>!"_GH4]'!/\0A^_6>IK"4 '-A=P
M      "-T\)8^M2R+^%6&?R>2.ANQUW,0_TJ,]:4W#7;U/Q=7Z)H*%Z/)
M  .O/P2+Z9=9GX98I_-4K&J.RKVG@CZ3%>JJBPXO_.1/@5?I4CN-&EBS@
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MNWJ?BZOT304+T>2     =>?@D7TRZS/PRQ3^:I6-4=E7M/!'TF*]55%AQ?\
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M!E']"LHBI8]=RF%O A?ST*>C@G^(0_?K/4UA* #FPNX
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MA4U@\97;C+337=IKXG_)$>P]AW90MRAQE^7?_O\ :U%]NR_DF]\C^1U\=_\
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M?AEBG\U2L:H[*O:>"/I,5ZJJ+#B_\Y$^!5^E2.XT:6+.
M!#AY>^EG*'XB37\RN8ZYA>UH?Q%5ZNB:ZK/G*SPZ7I,MV/N8     $E3X-_]
M4YA#VWS=^J\I'.O9"[J8WQ,%^4JBZ8&_A]5X5;ZRD;UQ23U
M  #4QNZ7U3VLOV&B/ZJP(6K$GNIP1XZN_*1!^#"G:$3X"].B1<PZ6*,
M !,GX[^C^"^QT9_PB$<BQ';%?XZM].D;&H?(H^#1\R*Q'Q,@
M  #CH\+G_P"DZ%O:G4#_ (G$0VWV*?G\-^*@/3BBNXP?(A?"K?-5G$L-RE9
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M>%QD<M_@UK2E:TW_ /C?I2N]_P T'7,+VM#^(J?5T3759\Y6>'2])EO!]S
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MI8]=RF%O A?ST*>C@G^(0_?K/4UA* #FPNX
M    !&Z>$L?6I9%_"K#/Y/)'0W8Z[F(?Z5&>M*;AKMZGXNK]$T%"]'D@
M'7GX)%],NLS\,L4_FJ5C5'95[3P1])BO5518<7_G(GP*OTJ1W&C2Q9P
M           (</+WTLY0_$2:_F5S'7,+VM#^(JO5T3759\Y6>'2])ENQ]S
M    DJ?!O_JG,(>V^;OU7E(YU[(7=3&^)@ORE473 W\/JO"K?64C>N*2>H
M             :F-W2^J>UE^PT1_56!"U8D]U."/'5WY2(/P84[0B? 7IT2+
MF'2Q1@      )D_'?T?P7V.C/^$0CD6([8K_ !U;Z=(V-0^11\&CYD5B/B9
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M1W[091_0K*(J6/7<IA;P(7\]"GHX)_B$/WZSU-82@ YL+N
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MS@56G-1M#N%PN%0O9KDOK;4O@TX7CJ%4KP[>!6_>NX,>6>O]4B?)+5^C9Z(
M     I6<0F,9(B$B@<T:B7N*RMJ5,SXUG&'D6JD*NS@7T+4I32%:-25=P#T:
MY&>0L0JRB5:0\E224;8S94,^1E!XUP;$<9/+Q*$;K-9A+WQI:XZKF&19:Z3*
M1DQAE/5JFN--ZURO\6W,R9:O6KSB$:<D]T<%%R]X4.*RPDXJ6YV)6+(0E+S3
M><O,()
M
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MDQ2-U1J4AIC(XK;3*%T5IZG(#2E1AIK/[W$^_O[[)%SA
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M)'#'L@]-?P#*'LDI;&ETL*NW[;TZNB6Y&K*NM.2*#BZ\(8F14X
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M2FJ!1>6M852\JB:Y$NOK:@=6I2M-2_R@FGF][RYP@D
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M)
M
M
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M*;;P3R+*UIOQFR,9RL@
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M1IRDT]S+BHI/OS?Z2)2E/OS]_+,R#&)(
M
M
0                  '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g142578g54a00.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g54a00.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1344&AO=&]S:&]P(#,N,  X0DE-! 0
M     !<< 5H  QLE1QP!6@ #&R5'' (   (    X0DE-!"4      !#'71?E
M=+5N]=N^.93 Z7E<.$))300Z      #E    $     $       MP<FEN=$]U
M='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4
M0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%
M6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F
M "  4P!E '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T
M   ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0
M     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP
M     $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N
M=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP      $5M;$1B;V]L
M      !);G1R8F]O;       0F-K9T]B:F,    !        4D="0P    ,
M    4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX            $)L
M("!D;W5B0&_@            0G)D5%5N=$8C4FQT                0FQD
M(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&%8*0         *
M=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',     4&=00P
M  !,969T56YT1B-2;'0               !4;W @56YT1B-2;'0
M      !38VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG
M8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE
M9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E
M8W14;W!L;VYG       X0DE- ^T      ! #P     $  0/      0 !.$))
M300F       .             #^    X0DE- _(       H  /_______P
M.$))300-       $    >#A"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          3A"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #-0    8              *T   -I
M          $                          0             #:0   *T
M                     0                         0     0
M &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T,0    0
M5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P   *T
M    4F=H=&QO;F<   -I    !G-L:6-E<U9L3',    !3V)J8P    $
M  5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG
M          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N
M97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B
M;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
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M=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<      #A"24T$*
M    #     (_\        #A"24T$$0       0$ .$))3004       $
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MA289<US0-#*3_@0_[U__V0 X0DE-!"$      %4    ! 0    \ 00!D &\
M8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O
M '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !+DU- "H    (
M  <!$@ #     0 !   !&@ %     0   &(!&P %     0   &H!*  #
M 0 "   !,0 "    '@   '(!,@ "    %    )"':0 $     0   *0   #0
M !4L'@  )Q  %2P>   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,38Z,#,Z,#,@,30Z-# Z,#(   .@ 0 #     ?__  "@ @ $     0
M VF@ P $     0   *T         !@$#  ,    !  8   $:  4    !   !
M'@$;  4    !   !)@$H  ,    !  (   (!  0    !   !+@("  0    !
M              !(     0   $@    !.$))30/]       (          #_
MX0$P34T *@    @ !P$2  ,    !      $:  4    !    8@$;  4    !
M    :@$H  ,    !  (   $Q  (    >    <@$R  (    4    D(=I  0
M   !    I    -    /      0   \     !061O8F4@4&AO=&]S:&]P($-3
M-B H5VEN9&]W<RD ,C Q-CHP,SHP,R Q-#HT,#HP,@   Z !  ,    !__\
M * "  0    !   #:: #  0    !    K0         & 0,  P    $ !@
M 1H !0    $   $> 1L !0    $   $F 2@  P    $  @   @$ !     $
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M 0$!_\  $0@ > )< P$1  (1 0,1 ?_$ !\   $$ @,! 0            8
M!0<("0H" P0+ ?_$ &40  $$ 0($ P4#! D." D, P$" P0%!@<1  @2(1,Q
M00D4%2)1,F%Q%B.!D1<D0E*AL='3\ H8&24S.5=8E9:7M<'4-4-R=G>2L_%3
M56)U@Y.4HK8F.$5E9G."A(6DTN&RM,3_Q  = 0  !P$! 0
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MD%/OLA,:*ASK5NQIV9PBY>6E)LZMYVW47('7H--+7M?!@7-ON\?G?&C'K/S
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MBU]1N>H]GFO-#LM^"H2U%:0OB25WX@;G:YYBVVMP 3SQ"E%:.1YB%-?,MUM
M= !^5 2"@>>P&W<* "B=P?+<Z1]M"T '>PY>T>',_8<<]@OJCNW;V!Z<K\SX
M^6GPPZ768SD)3'2L]G"M7BDJW!2L$!(/VB3Y]AMN-_(\,M16V_6 U(&HTTT(
M^P<CYXFRZO(<2&^,FRKGI>Q%]2>NUA; :J_>?2YXSCR7%[[%)04;;[]P4]0^
MG;<??Q("0-/9R^ZWZN6*I3G>?7\^OLTU\OD'[.'(&KJY$>2E7[[E)Y<%?KT=
MPT\*.FF&<4U]H1JUANA%GFNKNH%B*K$,)PBIMK9Y'SRI;H+\6LKX492NF58V
M=K(KZ>M:" 7)MDPDJ4  +V &T1%/+^LA:@/*P/WX,>_KY>?+STQHL\WOM5>9
MCF;O[:!09==Z2:3^,XQ2X'A=H]627ZXA;07E.00? L[V9(;5U.LKDIJF5+4B
M)!;W4XY4RI+C[@('YL'J-!MRMX=?C@]-=>5AN=?#PW OJ-]]L=5+F678[;-W
M]#E.1TE\T\F0B[J+J=7VR'TJ\0/IL(SK<E+WB?,74+0X23NL[\,8+Y^?G\,;
M#/LR?;EZIZ79QB^D?-UDLS472*]G0:"'J9<*:=S33E4Z6TQ'L+RV<09.2XI'
MDO@S39F1<5T9MZ1$L'8J40.)[,GU4MWV  ]FA]]K==-=!J=AXWT\MA\\M_8=
MW2%)9EQ8D^%(;D193+,B/(96AUF1'?89?8D,N-GH<9>0\GPEI44K4A825!.Y
MF( UN/C[#I\VTPI//4<MM/'^_P!N"B$5N.-_.0$[%7S; C?T !]!W_5N.&E
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M4S6G[_3RV?7.P;)XGBH7*B3Z-?YB'+D)3LU>5@BV\1W9UJ0K=:%J0K@6E?\
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M0ZH[J6G[7D/0=SL#Z=^_UWX,6V/OUO\ /LP[M\_/X8'YC2U[I6M(<2>L]OM
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M@:<*4./%*5\0:2A5@^>GVGVL_/= J,(SVLP_3G07$KF%;85H_B=57O)KIE3
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MA)4A(*E )!/%[#JL512VA2BL6'U%FW2Y TO<6N;$Z W.,%4Z+W7&I;["D$W
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M.^MK#^_G@U?6-KCGIY?-_;B3Z9@(1U>O@!ORWW V4$[[;;).Q [=QQ6.@ 7
MM?733737SPD_/AX8)X*0MT G8#=6X[*';8E*O,;CL=CW'F-N&$DV<UZ6UVTW
MPZC:_.^]AX8+H:0I381W;3X8 /ITGZ'U ]?QXA.7*[7-_P "?L^&%$>',';Q
MU^S!NP E.VVWKMMZ$#;[AOWV'X\->>#MB!=1;)QW(3$FJ4FKALQ@AOI"F@XZ
ME:EONA(*@H]D-]0[D[ @<.)N+;Z\N5OD@W\+>&&%;GS.(X?M(L7K53S9#<CY
M2T8SKK!;<)ZFW-RO9(21OL6U(5]E6V_#C=R3Q:GV7OOY>_0^W4L2@[K7-I,
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M:$^._/38],%PIY@;]![,1S<W+3[JE!T=@2!V"/4;=0^7;OZG;\#MPZV!Q:6
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M  YVVUOA:"2=22+::DC6V)/L=4H+&,/2$*9K<C3,@TTF ^H/.0YLT[&8@?\
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MOPVI0X3<VN= ; \KZ?/XJ .NG(?$@_9AVAI<]$K*>HG8 D>?8_\ =Q -^($
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MZ<&$*5L%';:_]WAU.(_>GQ]_3V>&M\0=F6,]$5;0CJ=44J4IMMITK[@E/6E
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M[BUU;ZB^NE^NUSKCEM!FS*CQ%\'C#SB-B-$D6&MSU%^>'%\%Q)'3U;)*U=*
MK?I'4/)(/W>?Z_(T"[^CKY:C;??;W[:?''0*=WK<MEI0.J5[^""1\=O;;GA^
MTEOGXF:TT<("0J3,2C\UTJ4I5?*\B-B%;)'5M]H'UXS$WZQ/+G?<[CR'0;[;
M:XZ52_X /B-+['3[-?/PQ<QW()KI(+:FTE7S*W<*0GJ[[ D #;?SW_V<1
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M]2^GJVJJ_P O^2[Z^GK]>+NG_P"*GQ<(]UL*'*^EKF^^X'+GB-&MW'0D)VV
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M_O\ C:_V7+HEV,@#]L1ATC;?Q6_0;?7;OPP83MB>!_\ U$W^R_P]F%)J],)
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M^-]-_P!>'PT&.1UI$EIZ*\-RIM[Q@//<%;A6$I^797;8;>8X+T^GIV?F#_\
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M!>DP=N]F7_\ #.>PG]S^_KA=C_U#_P#K,_VL#\/$+2 77XT&1,D/)*>A*%]
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M2P1\B-OWHGS@ /H/0 >G;;[N :+2=0(43VT^#MY=W]^%C-.8-+OO \[5FI_
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M&U-J0M25"V+"-G'M6EN2VF*I6R[!I:JW+;6ON5LTI*&7#.*7BVI3);D,.(*
MI3B'4+;2I)OB-F_:#<ZC(V;YC]2$>O:QA@_K]PXLSV59!4;KRY#6>JRZM7O4
MX3\<5J.UGM$:3PMYKJJ$@DV2^0+FU]/9CN_LAW.U_C)ZE=MO*QA ]OO$#?\
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MP/R59 _1JG_S>#_*MVA#;-=6%M@)*P!Y &P\NNN^.*>>WF_2=T:_Y\@_5,N
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M]URD!3;FI.22&5(V5X]HLK*B=_6*[]2 2H_\GZ&.S?(BCQ+R[30O_P $RZ+
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MZ&WL>_[VKRG_ /,6[_\ CS+>/FWVG_\ I_FK_2CG^S:Q](.RO_)YE3_1:?\
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M"1S=:&2(R'$9*Z&W*\6C#;5?<.&=&0L-OKA(15*7+]SW4F:621%4A:7BA25
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M7?I1KBWD.(:JYYG33%%CN'9=E<6/*<B2JERNQJD2)(^*Q'I#KK5I$:+R94=
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MF7F9$Q58JSD/,].R]3:5&I]/2^N=4(@>8A4U;<AM4Q+@2MQ3T];+B%!21^;
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M_A"]B03,>8>7076H57C$?')N-XWIGAV=X];V<RP7"G');YF"VZI4)B:M$3P
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M>>X>[#G=I""D<"02"HE1JQQJ\9#"X&!A<# PN!@87 P,+@8&%P,#"X&!A<#
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?^X\#]N62_P"7J#_6<3\<#\G?:;_(&8?Z@J/^ZQ__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g142578g58g66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g58g66.jpg
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M=9&3M-(7(R4R<X&2H;&RL[75,T)RI<'64I;P)':"H[;A)C=#8H/C\43"_]H
M# ,!  (1 Q$ /P#?XPB81,(F$3")A$PB81,(F$3"+%+TO'-R3\+.-R1QK<PE
M-:UI/I\/ASLH(*4@C*-*AVLD4H(3* &)E3BW$GMR%L)4EC(*6.Q;B:6H"W[2
M*=@^AQLI!M3G3%=U./H1"S:8TEIF)=NPP$CB&/<'.>1Q+6;@TW]YOQ'4M97)
M8S!TYS5ER<LQGN-:U[Z>.J1&:[8A:\.8ZRX&*K6WVNCCGM1S2,>R)S':*TVM
MVT+(?ULHGL_ETND+B>:I6O$@?W-U<5!IP]C&(U6M4G*#.O>_2[9@M]75KK]+
M.MZF*QM"%L%.C5KPL :V.*"-K0!P&@#=%M>#T.]B88VLDV<QE]X W[.6KLRM
MR5W9?+:R L3.<X\3UX:"=&M:W1HB'AY[]=W+\M4>4RZZ'K^P0_1,^RJW4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6
MJ/*8Z'K^P0_1,^RG4!L-[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-
M[C]F? F-\W3P\]^N[E^6J/*8Z'K^P0_1,^RG4!L-[C]F? F-\W52ZLO^YZ4E
M+?,JNLJ80N0MJDI22N9'Q>CV=W,01;3K22SNX+D1^@]S5H%A9Z-81L:=40<0
M,98H_(X/$96N^M?Q]6Q"]I:6OA82W7^\P[NK'CG:]NCFGB""%:W/0YV/L0N9
M4PU3"V-T\C>P<4>*MP/_ +LC75&QQS 'B8;44]>0=;+$]I(6_KT;G+99S0XJ
M0VWGU*E1S=$O<H/81* H)#>9+XZ4A.4."(D/4!.4\M#HSO1J0L("$*MQ4H4V
MA)DQ)@^.MM]G&[+[0VL9$YSZI:RU3<\ZOZ&F+@UKSV3'(R2,.))<UC7.ZYQ
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MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*!Q+U26C[]&O]G$#R2O>E,/\
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M(LJ@YFZNW=.8:GKN).OO<1IK[W;5>>,<(I&X.;' ^GS94T<J^/''/H8898]
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M#MB[HRLVN3TKP@Y,-N5;>^!T_.\2:H9IPX/+M>MT-O-M?DYI*DAQM%IJ6'6
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M^WY%.6B]EC_3;XT[8/P@_"U_CCI%F^XV5\'V_(IRT7LL?Z;?&G;!^$'X6O\
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MXP<?>/ 7#Z2U20VOE+L4%.Z.C*V]M]<4H!A-+1K9 O,6/:I"6< )Q:$YP&D
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MEI]O8WOQGV4Z8M]IY'O.1/'P'L0GGR94>6QTM/M[&]^,^RG3%OM/(]YR)X^
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M:>1[SD7>1Z2(9(4X&)$[BC-:G';4XHG5":WK4JWO! YA+,(-Z^L)B!S0J2S
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M-]S@QIY&/K2=>NTW>.FFGO$@]A0VS%&?.9BM1DM6&Q.WI)B)GZ\G&TO>!UW
MD @>_H.RM>EXN.TGM<>X*Y[*2#3S!#[@V/*]I0D]H6]]A.@;3TJ0D >OLZT
MK0MAUKM"%OT\PLRR$Z[[OS$@?,- NA(,'B*\;8V8ZHX  ;TL$<TCM.RZ25KW
MN/PGX %U?TS+(]L&;_*M^_C\\Y23V1_Z3O&JW2K%]S:'>=?R:?3,LCVP9O\
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MZO(3[[HW^F46?<?]I'_C;^\%99+U.O\ Q*U_ D7HL]/?_8^OW^^H?S$6:#V
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M+PQ\I(^5^Y',UK=Z21SI'NT'%SW%SCJ2225]Y ESZSCIJZG7<= &C5S23H
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M^#BL@V@!&(Q((T+<AB@?>.A''\_#X5YN6;Z4:F$3")A$PB815]XP &.[H=H
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M^A;ZB9#Y5=]4K+!\SZOGY'J_7;RU&LV6K=,(IO6?VR*^]^\4_3R#/IGX[?\
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M7@\I&U\LLS6B1NK'$,WPUQW'-=HX>D@44626624 )910 %%%@UH("RRPZ"
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FI-A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g142578g58m29.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g58m29.jpg
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M 0$! 0$! 0$! ?_  !$( 0X"70,!$0 "$0$#$0'_Q  ?  $  00# 0$!
M        !P8("0L$!0H# @'_Q !C$  ! P0  @8%!P0,!PH,!P % P0&  $"
M!Q95"!$2%!65$Y26TM0)(5:CT]76"A<Y=QHB,3<X05=XE[2VMQ@9,UAVM=<C
M)"4R-')S='6S)S514U19<9.8L;+80D1286)DA/_$ !P! 0$  04!
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M")(NZ-T.%[C">'I6,BO5)ML.+3<99LY)#8\0Z0>P1!6$P^(@0<EF+(M/H:,
MR?!=SK4Z-E040/7..)TIB<ATI<1Q\\E]I@]= VB5I*?&2A?!2GQQNSD'>IR[
M;Z=-S@HQO*14V_T@,0I<D#.3@W,. MGDMFPYWK0;D/TF?$2Z.L([>%)MH4P(
MR(D/ O9,XCX$V6G.>PQX1O(F2#AIBKD0L%E"*@XN:G?A-7PD51QZ97='XQ.A
M;2[9D<=[%)0>92PI$ICTC!J!K<,M#,H>27C##HSP5(4Z\10T;+(\R!NI@&2C
MB,P2U7F))9CFHO$J@0.)&5T%&#A&%RG/G//"^9)J>+CAP63>4(1]LJB=T;!@
MDE$%-L2YU*0#/32,HDS2!@[CP80C'=>.Y5(I+)ADDU@%D2HF5N&N"48-!Y<'
MQ1E) =!W6OV*Z3YVO()W8P4>GA.LGC&XMT(]?4N]V4CK9QH$#*=5ZIUW.]91
M.4;8V[)'*T_F!2(")"1@#27$B>TMX/!,H?#7+V/)(HJ%8#!7K1XT7'&3$058
MIVQ'=E$G!MIN"NFYPDN/7U#A!\;X9WXE8"$]9F.EJBM%XVQA1Z",I,(D4C2B
M1 .?VS)3D?'Y>!9&L!2.!B"P@$P[[F\+D%&+N3I!F$73Q2C;[-R_NWQCPPAZ
M&_0.,>GK_"7'+KZL0CLR*[DF\@#')2G&Y;TJ58Z8A>4;!K1A]&''1@CC[BZQ
M)6.J2I-XWED?#LVY-K)4(]CDR5#JBUG3MTJHE#J__P!74)QE_B@Z7]7LZ3IH
M1-=U!F?1?)S;8DXF+W9<7@)F>Q!O%8?'Y*RDL[2C";W/$:TU)F/=:]A>2A16
M6"DY+%)I$!>920O3,A[8<<*2G!77.<(3SO?"]/ *,HN]72C'\*F0FL3(4 H!
M0"@% 6L=)/PCQ;3'YPD+N=)<:'OSG).VKEY%<G'!1W@?\X+9NFLV5A'$/_*<
M3B6<;M)>%LBUK7Q:WMDN,+X2QSAU$>+NXX3E,M,+B#,XC4DTIKJ,3U_J"?[>
MFTM@Z$1=-(PX":;A.N->(6=0Y]+CD38!@"O2=.9'X6/;DFS0K%!);.,,G,;N
MBJA8\7"*4)QOB[X9$644HOLPOA/@X<9<"@MHRN33DH+GI@,)';-8='_4SA&+
MO0)Q38SS;, V_M)MLF#Z//!LU;1V8DSD?4CN!:PHT+=LG\<>%VMP%\\\ZNN$
M7T0:4':7XKB.,<EG.<4LY0?X&4HW(-D,(GLLLE"PUS4?#21[KP:,D3V1KR]T
M/&DG(1$HQO'H_D&=DG: ]#,6S?&;6S=JHID\KHX++82EV]XZ&7?OW9 G1HVB
M>F\XGL<>;1?;4!!-4Z*E[8L2B8*+NA<LG93<C.:"$_ 8['$'C)GG# C9)LLV
M=NX^Z;O8^3?.3P\TJI;2AP2FU?A#'IRB1=].HA8-K.&3O670WD<I@,<E$F/[
M*[&Q2!6-L"[U9P;C.ZY=.@QMRY9KK9",-H/R)!TP>Y]R3/7P7S2L][&5(O\
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M>TNDF(FL=$R=(3I;4BD;$G!;4NU08J+;I?H%V#-ZBNFF_<R=N10S=H8674S
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M<&LIJCLHK-E!]X=%"<FQ;6CV<.BF+JQ"XZS*ZMS;?NMEN\63<>C]#G\/PB\
MK'(/)6VY27*EK>GLMIL;'O+W-;'G>_;6SLX^^?E.UAS>=&',<80E>;K<^5WO
M>\6-A[PMGSE:?.]\=N'-LNU\'F68QA"^1Z8.ZRKG8+V:??BFNN98.JT/M3Q5
M'J.ZRKG8+V:??BFDL'5:">*H]1W65<[!>S3[\4TE@ZK03Q5'J.ZRKG8+V:??
MBFDL'5:">*H]1W65<[!>S3[\4TE@ZK03Q5'J.ZRKG8+V:??BFDL'5:">*H]1
MW65<[!>S3[\4TE@ZK03Q5'J.ZRKG8+V:??BFDL'5:">*H]3&=E\H',<<LL>
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M@\06=HHHM)(T%N\V.4A W3<KJ.XV1<HN/!"BZ;7$RR2P+CDG 5\,(OL2E8T
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MOW:X1[H?S6WSS^Y?>=F?4Y'\?V7T=K]G:P-D=X!GSZ0^O(?"5YV.9P6=7J/
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M;0"0EP9J.!3DUGVS7J Q1H2G$TELT?;$6C[%JO9[89KEU-I"6.F1BQ5R[*M
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M_NLDU<(]T/YK;YY_<OO.S/J<C?*&R^CM?L[1LIJ\['-!0"@% * 4 H!0"@%
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MO)M4'C]^1R#R_#XB@YWDVJ#Q^_(Y!Y?A\10<[R;5!X_?D<@\OP^(H.=Y-JA
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MXX1'#+6$Y=\[";EDUQ:9.TW:.-_2H*VL=]\<TXA770R:@2=4** 4 H!0"@%
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M@HX(%&T0F%D6RSAF[?O34(<)36'>\+OW@BYZH44 H!0"@% * 4 H!0"@% *
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M#^+L_P#N,/>]I_R[?_3:T'YIMJ?R:; ]C9']VT_*MV_:-A_%V?\ W#WO:?\
M+M_]-K0R(?)*ZUV*+^4LZ%!$G 9J.'L^D!!EW;Y_%3K1FU0P?7OFLY<N&":"
M"6-O^,HKGCAC_'>U? \*=XW>UX.\LV;.WV-JT]PVZ26UL-MNS))*U%M\$C><
MGV+:WW=F[%I);6S-V6EQR-IA7F4YR* 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% 6M=*"3Y0-GK'8",O@0%W#IR\?-(]LR2&XE$9LH3ADG J"U9  !RA
MX+,#&Y58T'=KQB0,<5&:Z"P]%9=L4'5<5.:X3XID<NJ[AE?UGXZ*TEXZ#;-V
M!E,8!)%IGLQ8FY":PD9F6PV".1T+AL=6CC20G0L:>DRKNX6TD/N$HV 97*G'
M&*(R[C%V1('PDU+C)O,+IC$NHJ%+9-J='0;*0[^\'R&B31>>1V<RP7+7$DD,
M*V*B$)$";F(2X/F9RP0CI1V24?*(#6UV.#]D-[Z'*C&Z@M;).%^$)036?22&
M&,9S7'A',C*,]&+8D%( IW#))KL9,PLUV<<90;$">;:D 0[:P*$CC\'BJ#0C
M8R&21D< "S[Q!NU28OI&3DZ.$?&-2Z2K%%33C<IRC%<?9?&'$D')RBN'"&'9
M7A="0X[T=W8V(ZWUZ<D \Y%@!Z7;!V0JF,S8/-@SZ33)YL+N.#+-5ZD*@-YR
M>+R<@$4(OG3^X6*Q\@N0"9'TB2-[N=RR5WHU+#5PZ8PGPOB<WHV:**Z/$&F!
M4P#)+$V,-&J\.CG0UJ8?1$!8(0V%($W:ZRCJ?["7ZBTR?=I:ZSAJQ35(%%D%
M'ZT;C#\*2X+ND%WO]O?,N8J%.A4BL854S55CH-157/)11102PSS44SROEGGG
MGDA?++//*]\LLLKWOE>][WO>]ZL7BZD@L%0_'",5^C0#R<?\/2+Q=6(+!40X
M1BOT: >3C_AZ1>+JQ!8*B'",5^C0#R<?\/2+Q=6(+!40X1BOT: >3C_AZ1>+
MJQ!8*B'",5^C0#R<?\/2+Q=6(+!40X1BOT: >3C_ (>D7BZL06"HAPC%?HT
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M%1#A&*_1H!Y./^'I%XNK$%@J(<(Q7Z- /)Q_P](O%U8@L%1#A&*_1H!Y./\
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M34NN$;E>(X]X-QQNEU])>!I2>+[$B+@^0D,1+&539+Q,#$#08^EKZRV>#@9
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M0* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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..% * 4 H!0"@% * __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g142578g66e76.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g66e76.jpg
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M>+?2(2,U57%T=92TM20Q,C,T<W:RN"<V1E)E_\0 '0$!  $$ P$
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M_BIZ"-B_YH;+_ &)^B)]<SLD?T@[;_I7GOIZ>N//TMS]>K_%3T$;%_S0V7^
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MD\ZBKLT7@+>./U\R[F''0UBB+-F_'XQL:0R<"KNW)_ \S(,7;=#"%^I<T \
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M]0?+QXZ3C)I-'UETW6\X>>#DQB_GI8V]89J^9?-/S<\GU_NQ_P#A<O\ !O\
M_NGV*_96'_X<!\,?[57W^(5RY[$I3]8*\1I]?WL?_A<O\'#Z0GV+'96_ X#X
M7_VJ?B%<N>Q*4_6"O$:?7]['_P"%R_P</I"?8L=E;\#@/A?_ &J?B%<N>Q*4
M_6"O$:?7]['_ .%R_P '#Z0GV+'96_ X#X7_ -JI'^&6J]T:,@<HCLZTMLC
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MZS:#>>QS1J=W@-3Q4!7Q>_,'L3DGUPS[]6V?V0_8Z_"YGX,'TA>?OV(79@_
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MZZZ]'L%7,:0>([RF=J!2)1$HB41*(E$2B)1$HB41*(E$2B)1$HB^+C_PZ_\
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MA&$-B30Y)VP14GZ"Y9\Q;$W:[=(L9NT:7-&;IY%C%VC6Y-Z[NV1O@0-:W70
M:]2Q8M/YPX@8[5J\MD*VMQ$M,3T7!5"SS.*CYM( X2/G)6S!Y*W'MY 6!QL
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01*(E$2B)1$HB41*(E$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g142578g76r88.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g76r88.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[27 4&AO=&]S:&]P(#,N,  X0DE-! 0
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M<')I;G1E<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,
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M      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0
M     %)'0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6)
M;^            !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M             $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X
M;$!8@           "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !0
M9U!S     %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N
M=$8C4FQT                4V-L(%5N=$8C4')C0%D            08W)O
M<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P
M   ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M        "V-R;W!296-T5&]P;&]N9P      .$))30/M       0 \     !
M  $#P     $  3A"24T$)@      #@             _@   .$))30/R
M   *  #_______\  #A"24T$#0      !    '@X0DE-!!D       0    >
M.$))30/S       )           ! #A"24TG$       "@ !          $X
M0DE- _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8
M  $ ,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M     '   /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H
M /____________________________\#Z   .$))300(       0     0
M D    )      #A"24T$'@      !      X0DE-!!H      S4    &
M          &(   !<0         !                          $
M         7$   &(                      $
M    $     $       !N=6QL     @    9B;W5N9'-/8FIC     0
M %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M0G1O;6QO;F<   &(     %)G:'1L;VYG   !<0    9S;&EC97-6;$QS
M 4]B:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG
M  =G<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG
M:6X    -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M     $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4
M;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !B
M  !29VAT;&]N9P   7$    #=7)L5$585     $       !N=6QL5$585
M  $       !-<V=E5$585     $       9A;'1486=415A4     0
M#F-E;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0
M"6AO<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0
M   )=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L
M=     MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4
M3F]N90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
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M$Q@D "2I65;AM+9'@=0C-:UKH.@,D2C;01\-4&4@&PX]_3&N!=3[7?NGZ/\
MY@LU['-<6N!:YI@@\@KJS2!)6=U+!%K2ZL?I6#3^4/W/_2:DC+NT\_+BC* H
MC<=W M'Z)_\ 5/Y%[7];?_R;9/\ X2J_]%+Q:[^9?_5/Y%[3];?_ ,FV3_X2
MJ_\ 12>T2^*]_%*)/B3H G DP 228 [DKH^E]"V-#K-<APDGLS^0W_O[DDQB
M3LX]/3;GZV'TQ^[R[_S%6Z^FXS3+VN>!SN)_[[M6X,!K3#AMCQ1OL30.)!5@
M88D:&_%;9B=1]KCCI.#8 6U ? D?Q0;N@U$338ZL^#O<W_R:V&.;274N;N_=
M=W'DIAH.O<]BH9"B1V;481D+H:O(96'D8KMM[(!^B\:M/P<JY"[.[&;966V-
M#F.T<TZA<SU' .';[9=2_P"@X\@_Z-R:Q9,7#J-0TDD\)),3_]'BL"GU+2X\
M5-W?/\U:-=)<6EWT3J0.857I@BFWP<X GY+0K>PP.X4<MV_RT1PB^NK8II-<
M[8@&8(YA.T;G%SF[0[P!CY;D>EP9670"1P3V0LBPD%_,?E3:;8T/;HCLV=]>
MP1<>'"#R-)^*IEY<[>[[E:PVNU>/HS'S1$25LIQ!!O?1M[((@:<*M>-I'Y5>
M'@>R!<S3QC\I2I1+R?6*!1=< (:]AL;_ &@=P_SUZ_\ 6W_\FV3_ .$JO_12
M\M^LU8:&.'^C>T_( KU+ZV__ )-\G_PE5_Z*4HV<O**G(>+Y7]7\,79+\AXE
MM'T?ZY_\@U;_ -I]"73'@J7U?KV]-#N]CWNGY[1_U*EF20WPY2Z6R8Q0_%-;
MU5UC"VP2)T,*G^U,BDD5.AO[KM0@O)B#\D!Z,9D'0TJ0L:AM6]2WD.<T,>.X
MU2;U-]GM $CNJ#E/%;-A^",I$ZE$"8D ;.[CFQ]3MVLB57R\09.*ZHC5_#O!
MP^B[_.5W'K<QC21.[VSX+0HP X^,"83+;/"*UV+YUL>7^F!^DG;M_E3MV_YR
M2V<O%;3];10![79-+H_KEA23FCP^KA\>%__2Y+I1!;:P^(/\%=J;LMEWT3I*
MR,&_T<AKC]%WM=\UO%H.K>3V\5'+=T.6(E =XE*XAA+6'<WF?X(3R[8?,\*9
M;<T3 </Q3>][NS9[\H#1G()&B)C-SB )CGXK8Z3CE[;&G77\H52NFMK=7:G5
M;/U>K#LI]?[S01]ZFP'UCZM;F(&.,GJ*:5K378YCN1^(\4/GG4\A;OUAZ6YE
M/VJL&:_IQW;_ .8KF_6 !DQ U/9+)"I:;'9.'+QX[ZC23A_6=\N#.[:GN/ST
M_P"^KU+ZV_\ Y-LG_P )5?\ HI>/]3R/M-E]WYI:0S^J![5[!];?_P FV3_X
M2J_]%(-/)+BD2^?_ %>(LZ:UHY8Y[3]\JQF4.:W^2>/BL;ZN9AJR'XQ,-M]S
M/ZP^E_T5U7IML:18)D)>#-C^4'Z/.OKUENH/*"1V*U;\![)+ 2U5ACZ^YOS3
M=5\H@N?Z))T5O%QB'M$>YQ$!6JL8.(%;9>5N]-Z*UH#W>ZP]QJ C1*!$ K8]
M7IU[G-[1KW6KA,8YE9K_ #D'+#:Z"P]OO*&>HT].P/MMHVMQV%Q9XN_,']MR
M-,AGWV>0Z@YMGU[:UID-R\>HGS:ZMKDEA?;,C[9]NF<@V^O/\O=ZG_5)(M/B
M]?%X\3__T^ 'FMKH^>QVW'O/O'T''N/W?ZRQ)4@4"+9<>0PE8^KV98'-(!.N
M@"@S'?)DZ=BL+"ZWD4 ,M_2L'?\ ._\ ,EJU=:P[1J\-/@[3_JDPQ;T.9@1O
M7FW#6&P!PM3ZOO#.JU>#@6_/E8S>H8H$^HWXR%&OZPXF)DUWM=ZA8Z8;KHI,
M6D@Q\QD$H2%C4/JF1C5WX[FN$C:9':(7C?7\JJO)OPL5X?4QQ:ZQID$#\QI_
MZM:'6_K[U?J=+L6AWV+$<"U[:S^D>#^;9;^:S^16N5<>PT X4DB*K=S\9E$$
M UQ;H[S^B?\ U7?D7L_UM_\ R;9/_A*K_P!%+Q:X_HG_ -4_D7M/UM__ ";9
M/_A*K_T4HRE\68]S'AS#M<TRUP[$+K^C]9;EUAKH%S?YQG?^NW^2N.[J==CZ
MWBRMQ8]OT7-T(27PR&)[CJ'TFI]3AX^2L-PV:D-$%<7T_P"M#ZH;EL+O^$K_
M ._5_P#D5OX_UEZ6]@#;V@^#O:?^DD/%L>Y$[%VZ,:AAG8#YJTZ^NIFCH!Y(
M T'DN?LZ[A%A R:ZQXEP5;)^N/2J*XI+LJX")8/;/]=WM1U\E&40+)=Z][0#
M?;#:JQNAQC^T\K@?K#UUW4[?1J/ZK6[=/&]W[_\ 4;^8@=5Z]G]4]ESO3H[4
MLX/_ !COSUFI$]F"<[T4DF)208W_U+?_ (S-?_ES9_[#L_\ 2B?_ ,9FO_RY
ML_\ 8=G_ *47E>T>)_SG?WJ5=-EMC*:FOLML.VNMA<YSC^ZQC3N<DI]2'^)I
M@_[V;/\ V'9_Z43_ /C-L_\ +FS_ -AV?^E%RV+_ (OLJI^*>M7NP_M+X&-6
M2^T-&W<;;?=12[W_ ,W^E71#ZF?5K&L+1B?:-N@??8]Y/G >RO\ \#23:?\
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MC   ESW']S:@9'N?M0(0'Z,?\4.)]9LL-ZAT' GWWYPOV]]M375M_P ZR_\
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M222__]DX0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\
M= !O ', : !O '     3 $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P
M "  0P!3 #8    ! #A"24T$(@     !1DU- "H    (  @!$@ #     0 !
M   !&@ %     0   &X!&P %     0   '8!*  #     0 "   !,0 "
M'@   'X!,@ "    %    )P!.P "    "@   +"':0 $     0   +P   #H
M  [T(   )Q  #O0@   G$$%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I
M #(P,38Z,#,Z,#0@,#8Z-38Z-#( 1VEL($AA:VEM      .@ 0 #     ?__
M  "@ @ $     0   7&@ P $     0   8@         !@$#  ,    !  8
M  $:  4    !   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !
M   !1@("  0    !              !(     0   $@    !.$))30/]
M   (          #_X0%(34T *@    @ " $2  ,    !      $:  4    !
M    ;@$;  4    !    =@$H  ,    !  (   $Q  (    >    ?@$R  (
M   4    G $[  (    *    L(=I  0    !    O    .@   /      0
M \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q-CHP,SHP
M-" P-CHU-CHT,@!':6P@2&%K:6T      Z !  ,    !__\  * "  0    !
M   !<: #  0    !   !B          & 0,  P    $ !@   1H !0    $
M  $V 1L !0    $   $^ 2@  P    $  @   @$ !     $   %& @( !
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M 0$              0(#! 4&!PC_Q !,$0 ! @0#!@0% P0! @,%!0D! A$
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M=HT;57A9N!Q6#3B9.'F39*T)+RV0I09)*5,GQA%KQFKD[XH>RMROR*YZYQ>
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M(W7&+Q +79_F<!6\ P>$35.&D \)2!]HK]I9RA0!^UIX(1N1_P VN5>_7_\
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MCU!BD@XO$$$$,009C$$4J+4B?R) M)E#DA(;.C"D.1&E"0  E*0$@)$!(&P
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M6S@0M]HN-V>336VBJJIUPP/DS3CJ@3$G4E*D)(_ZT =_7%J)2YI"$(6LJ.Z
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M,?I#8GP]AMCX5")0"  #2ZF%!?.C$_:%"I,O$MMKT!2E(\35)WCNKWC?>#W
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M8[2-M@3Z>NT8KU[O9XU'#RV)?_6_, #U:K:P(4N8K7J\5U*14'<(4H$?$J@
M2/H^&+9'[C3_ %^XIU\FC)BY:94M!!!=:@PY$Y$,'H?N:0<*>Y4=THW"TE&Z
M%:DI(]^XWZSVB0().^-+-8=!WP&D<+$/^X.+>N;VY4IDT)#>W&4/5+.@I&_;
MW]1Z'N?=MC+.OG<]^WC%:99?BJHOGE1^<(SF"T4UY9J[=5TZ*JCJVULOM."4
M.(4#,SW W&_NV[Y"/\A&H/IQYTJU(MFX']3)F2E!]Y!-0^7+PUB'SCYPHJ^&
MF;ZFG9:<58[A-9;7]"DH0E9)4P21L4>\[B.^-$NI/!O(:]2.EX^%;=V1,V?C
M5G=(EJ42"U+NV8\['A"#ZP 2H[G<[>L1\?UG%T<)9*U.U_/[=ZQKNSH5IZ[1
M]8_1A*+ F(@L7C4A[W?6?Z\5[YX>?O$M\\//W@TH;EI;BC(2>@_*(( W]Y[]
M?JQ2P4VC ME4GVJS1M2 4;UG_P!>OEJT+EP9R@K,^8/%6T5LT38J'@$2D1)3
M)V'5..5M&8I21*!8U)4,\K4_-H]U\&[,&*Q2L0L_XY020E0<.[T+YF@:N=<W
M;K\.@=#>DJ2@!M*)@C3VGI[O3[ ?)K>2LDG?KRJ[\=;E[<H^_J4C]$B4A&Z1
M+2'!<ZVRX5,:+RW:A02&UI4I7D4$G2D'H20 # ZC;WSB"U_[:U L0]6]"^=>
M,68;#;^Z*N0&^E^&O*@XOI"RY&R+2U-K=J:UI*JMU)\!:=U),SK ]9^W$4+<
M,4WK?0L,H]/A]D2U2T$JW5;P.]N5+.PKD<M;T@[466GK;5TRJ9S4LJ*7 X@2
M%"=QOU"1$_3N)Q3,*6(">;ECS%/)K6O'8_2'Y7RY4HJ8@;]CD] #=[.&=N2I
MT%\NMNJZ1M^@4_1-Q+Z?,'!L-Y[J$B3WC88FA+H27 H*-ZL6IIS$5?HU2RDJ
M40JY!!H<ZNY/1AJ8$<R9^LUR"[?06:K#M.RI+ZU(A =_R#L?=YHQ5B4E,DJ#
M*8I&[:Y&=6UZ$".YL[![JA/^;8EDE(JX8UWC8.U"*\X ,O4K<-5"04J6=144
M]-?5, QY.A/<[P-QC,A"I@ *B-:.'!MD3?G3H/9R,6I$L2A*WFSWR.I^FMGS
MZW@YO6EAQ2:Y7AE:OG#YLZ1'0;?5[O3%GR-T_O)9J,SYZGLQ<<8=W<5*8YC?
M:]@Q3ZT,%ZH#:GTZT?BTJ3+:=DD2 9]=M]^_UXN% WIY\NG)F,<R?+_4(6@$
M(WG#_N%"#9QKK -<Z1 K*M#:&0THAUI("1"5(">G>/=U].YUX=;%BG>ZWX/>
MEO<&/G^T\.9,XLO>J!5+4\3X#\QCRW<PFI^15IT(!+;2^@62J&TD&(W@:M1W
M[;&=$Q!F_7^U@$@,]G)ZY ,+15A)RJ;]&4UV<!FM8%CR#7I"T4##2&D++:2X
M' D@[@$$#21W$>7W[F#,8S$,6\#W^8]-(Q(2AMT'Z:5_%:^F5P;J"VM(J6ZP
MMZ7 "0 2$"1_DQO[C[NVV)_+H:\Z0ES JE .!S+]Z?:ZZLI7^, DZ]1CNJ?*
M0=X$#WDGIB20W+EPYCIIQBIF!8N]*>#9O>T95MJK+:"4>9 ()GYW4#ML8'T^
MHPV#C++I3VCGS" MK,6=K9]>'."%<Z1*O(J$^$(.W4R(/NQ<D;M7?.U_-^5?
M>)*1O4=J?8PG%U#:'@ E,%Q())F/J$>;O/VXU)_R)7_KN@%[DY7HU(Y6.DJ2
MCY@7_P!,%2DM^X%LWHS:$5H'K#2N:O)*;]DP7^CI0;AEETU&M'SUT3I!?:5
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MXJDIUB)!W;\P@="._?;O$X\ZN9N%94;N*U-SK>A.EW!=H_2.R4"1LK#)LZ
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M[8M)8.:M#D#=6D&OI4$#P9^$(/Q"IW_&E*DE&E1(@S 3':>WYO6<8<5.!D3
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M2%:U'2GE6'5\NV<&+/>W;/6E?@7$-FG)5Y6EH24J5'2%I@]@%2.D#'-VA)=
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M)LHIQYT!*@8TP1^5(]-QJ_/AS<0=ZJC3-R2X-6ZZ'I2/ETZ8A-@$@V   #Z
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MZN07[KGD,"B2J-"?#"2=) (*1OMJV[R29^.'\DL?I+%-V-V=WN.@9XJ^EB0
M.5:,S6+Z]B!ZF*FV@VE <*01J*/$))]^\F?2=SZ[XA*2I1 ^HZ.:=<ZWX'.,
M]@PK:O3OGIE"C9$X67'.%<EQYE5/2*A2JA8*4D$S&J!"MO*G4/ACH(EI!8!S
MQ\+>-<ZQ!82DA2LZL.&9[\XDPX5<&;#9:*E;I"RZ^L-I<=<!+BEF-6HI!, R
M!TZ;#&Z3)24_4A+YDI!TI41 SG8.6-@"1P8G[#6IM#M+!E%]+S-/X0<:#:DZ
MDH,3L(2H C5'3H?=C6$C0>'\Q8M4MJ)E@M4@5XDEG&9\M84*JL3EFH9:9([^
M8:ID= #W!^!W)Q3.9(20&).5'H2W;GG"E*5O$;Z@DI 8'CSHWWL83:\OLL4Z
MG:YTH!"UEK6$Q(D>21IVZ"!ZXH<ZGQ[_ #'1EI2&+ YDLYZ&_,ZO6\,KXD55
M1>+JBEMVI30<!202H?.$21(U'N9!_/C#,D3E3"4$IJ5*8D4!H^>O6U(ZGS92
M9#3%)4Z0P40H <B:4(84;2'$<,;Q44E@3:[BYX90T$)+DR-( \H5*HVZB?KQ
MU%?5@_ED;R]X5(.]Q=[@MFQCRZ)8./$U*FE@+H% )WB*%B6LU^$-BYV.9JAX
M#<'LQ5K-S;:NU=2U5!:6@Z$N.5%0T4A009"D)G8'\O?KTT83=D)WB$@L#0 '
MAH;\_..;\2[61AL*9:5,H"C*8[PL?N!KI0QQA9HOM;F*^7:^7%]3U;=:YZLJ
M75JU+4X^HK5)]TZ8CIUD[XS3YBILU:U$DJ+U+Y4\H^,S9JITQ<XN5S5;Q>I?
MB:6IY905Y/J<9U_M/3U$5K_:>GJ(\Q3%,"B5@ #<'\TGXXJ2DW!&;9ZB-X4#
M8^1@39UHTF4NZBE6YZ)!.J>O0&!W/U8;,[D5H"U?!N)>Y/")I85.5OSY=TAS
M' +B(K+=V3:;B\DVZM4/#5K)2PYJD!([!9B?SG'+Q>&*U;Z&O5Z5R-.KW/5H
M^I?T\^(EX#&(E39A3+*G!-@:T8AJO1[<V,2H99-)>*-IY* M#B4*\5*PK2"!
MN!U,3T^/QQYV9AY:5*WG*@HB@)K>AT]X_3F!VEA\8$JEJ620[E(H6K7/6VD*
MI9\O@MJ+*M!3 )"2N4G?4!_E3'0=/IB"):%G=E [P%=X !J=CLQUU3$!('U7
MS# TOUR.5>$&E-504;7R=;1\4?BE.:/,J.\=!U]?KPE(*;^KY=^$+<6LND@4
MLX#/D_,?C. >]-T[='XC85*1*3IZCJ 2#N2)VGIBI<P)2;ENK5R'\U$=?!2]
M[< ;?:O//3+S=H3BIJ*)#C3KB4^,X#)GP]HG= '3<GZI VQ@,\)4YWMW@">6
MFOE'J48-:9)F)"3J KBS"]A7B(%*5NC 0^&D"?FJG43\/3W]NFPQ8F<A=GX.
M#>OFW+.IC%-FJE'ZDZVJ=/:OE ]2T=6_4(2P\4)5&DI/V>@Z[_K&A"266& .
M='IJ![ZBF=7ZL%&\S7R% +ZOK76D&QJV> GQWE+*SLJ5$S&V^V^_8^OU[$*2
M!NYEM6R/=>0K'.G8AR0"02[7%7&==>ZQ:U2G4EQLZ4J<@D#>)VD;=)V_1OC3
M)-1U]#X>CVTCF39RFO6XR[[?*#Q2,J::5H)4A*=1"I@F#,=1T'3;[,=&2A4X
MB6C=W_W$*9(W<J]'CS^*GRI<[YT_>*%2TH 2-XTWMU__ %$=.<2.\@=Y6N]U
M]O* ELJ;64GJ%:U21Z]8'0=/0G'W?X+G)7LC$2B^]) !#4!K8^+D^P'Y _K?
M)/\ <9.(DT0M1O10%'IS>_.C5Z(<@65NMH:?6D:5LI(G;?3M_N/?WG%6/Q'R
M5*))_<QW0';E<<A]S'Y[GK4I8E@L3K04I4M>GC KFO)[;E.ZRAI&I22E4[H(
M4G_*CWQ$XC@=H)F3  I6Z7NX+T-;W&>9YQS9ZCASO+WBH$5 WO1FSO;*MX-_
M:!<OKMYL9S%;J3PZVT_*'RXTC=YO;4E1$="#'H1((QU=J[-&VL&9*=Q4Z4"H
M;R@D,E)5?@U*N7UK'V?^FWQ0,"M/S9DX(.Z"P)>H +%ZZ@\M(Y_;U1)MY<14
MA84WK*TJ4KQ 6U>81O&\F#CXV<.$XDX4I(F@D,[))>CEKY@\M3'ZTPFUTS]G
MG&(4?DA#G?&ZNF>[;/B#ZM)X]<6J;*]A>MMO?)N=R;=9I6D+EQ(4D)4XN"-)
M2%D[$'TG%R<.94R8@@;R0AV+BKL >Z\X^6_%WQ))^4A(5,*YAG)0R;* 2"55
M(2*C,O6SQ%W6O.N/K<>4I;RG'5O+6=2E.N**EDJ,GS$DGKZ=,:4@)%A;S\OQ
M'QB;\V;-4M1!"B]39R]N='ZY0#.2%+[ $>8=3[O> -IG%1!<O74Z/FW#33H8
MJYQ.W]S4P?:U\%M"B0C(O%C6#ZJR=7C:=^LSO^<XI7^T<_M$9G[?_F^Q[O'T
M]L513'#7]V0.I;5R6!4^=7$9(@3!*;>!/N_-@@CAY8,.I/2 J#,;D?$3]<1B
M26!K#3NO]8<,>-<J<[<8/&6,Q5V6;U;+[;7ELU=MJ&WP6U%.L)ZMJ /S5@:5
M$]ML5J2%!C&K 8J;@L5+GH60$K22QJW1KVZW!CH:Y8^.]!G_ "I;:ANJ0*EI
MEABJ:#@\9JI0W#FI),Z5$'2HP2" !!VR&8F6HRU.Z<P*5J#EE_+Q]WV-M*7M
MG#23)40M26/S1N52=PU:[@ .&(#C*'XV.YFH0VI;J=+D%)*NHVG5^L;])C$Y
M4U*IB4I=R:.DM;V[H8VS<+-DSTRU@?78I+I%"U:,+%B]WU,&XLIJ%)$I)VDS
MM'IOU)[?'OC:64Y#!@*4'?'IK&F7)*?W!)N]AY>%M(W::ULH*7"E E6E2E)G
M;I ,ST^KMBF81O;KU(!T'.KZWS:]XMF2IBY?^/< K=02QN>[:Y0+UF0Z"Z,)
M4L(TJ@04QL1N1\[R]OAN,+Y9((+5# CITM?/6,\LKPX49BDTK]"@:6(YO;/E
M>$WOO!BA\9#K#:2D@$G1(U;P1]!)]0/2,4_(6?\ CU5W?\VC1+Q<M=@30U4E
MG:K%LK @'J8RV?@U9ENZ*F@9J%/-F=;<!)(@08$^HGW>_%\F4I*5;P3^ZA=\
MG<-X/4OD(SXQ1$R7NW*"*6(WFU/ TTSM&*MY=["IQ8%*M$JB6P"),'8>@GI[
M\7&632G\T?/+7C?/(5G--!77D+]10?:!3+O+;;G7R$TTE!\@<:$&1W! G;#1
MABFE*FI?B+&N7**_U*!8*8Y[K5>K5/3(<;0Z?)O )BE8IV74,T[" @IT)2V1
M,3J"1O Z3UZ^N-24!+#1ZW-;Z=^>><I4W=*'8.[ANHN[UT;2'!Y?R!EK+[K+
M:ZI;CI4E0ZZ3Z@)GUZ#UQJ0N6FX(Y!SQ\><4[B@S/2P!H_2U6-7A?J=FTVFE
M:<+24MJCYX2E8@;J@^[?W3\<5*G2T?N>M PU[X5:\5X5$^:HLS!1<JI;/QN^
M4$3,5Z%QUM4;6IE"MEC:")!Z_P#5GK[OABE,Y.+*I<MP98WSO_2&HFAS4^5V
MKG'2(^0'60Y+,FI!8G*S4ZEB8;'Q)0E>D)J%)<*U:@D@E0((T'^KW_'%:Q\O
M]Q%; 5YOU?KXQ<C&2$L#O@L'9);A6]Z\!:H@H94R-2J:?O=R8_%H!TA737!(
M,'W@$GM'7&Z7)^1+$Z=NJ3,2%H"64H V=(_:UV//./-8S:<[$3YLK#E0")BD
MM,=(IF,CS#O"79TSU:\J-W6XU=4U3T%O:><6XIT(2A+8)V43'80.A/UXC)DK
MG3M]( E%"FWB1DP^FH-<O6,TS:,W!R2J:KZWW04%[TO]J]&CEHY\^9^X\=>(
MU50T%:M65["^JGI&$+46*A]A2TE< Q">FH=53V Q5B%;BBD']MVJ'MUTYQX'
M;&T%8N:745)!SN2YXL6H/X!B/I:RHR8,[[1$^OT?;Z'IC+O@GGF6TYQP7 %'
M>SG3AH_D]\XHK!$=]OAB*E @@/V8C&/%<$"">L'>9C[!N?I[8B*4&7WK&Q%R
M>Z_Q&^TI* 0)E20!N0 ?]WOZ^N @%GU\>_QG%SENW_BEA3/2-^DJW&'&RA:D
MJ0 4+3Y84%:@=NZ3W[]<5E)9B'XBN=FY\'>)29TV0L+0HI(((:A%B"_.MCET
MD.Y;N.3)%-EJ_5<5@6E-$Z\K2W4MI  0%';Q($$&,<:?A "JCA1)!T<^5];5
M,?=?@KXU"C)P^)7_ )$A*"3_ +,P<<?72)2,GU]-6,(=0OSNI"UMI ("=,B%
M3&_I[L8/D"4=XY_3WR:Y<Q]RE;01BI:5((- 736AYZN#!K^26ZXOPE@!Q,DR
M(U03N2/6#N-Y]PQDGWSU>^5_/C'0D3U!DN2[MY<F8>]XNN5I9<I5-(9;((5Y
M?0A)Z>X>OPQ4J5O(!N5)<-3/71KCSCO82;N!"A6@TS&=G]*0E=XR:BH:2J$)
M=;3!(!E.J)C:-^L>_:-\<^;)(<TRY%Z$=.5J1Z/#[32&0HL&/*@HX<9G(_:-
MO+N7WV0VR\T7&D;!13)!5T.\B/ZYC#E2JU]'\LK^-[1BQNT9 >H+/Y/;GG"G
M6K+JZ=]-0X$E(W"4@1';5WVCH!U^)QM W::??NAY1PIN-'U%)+5:V=[=DQN7
M2B+@1I24PHE:1Z0?U@XDD%Z%N/JVL<V9C6+Y5XYT/M 124A<<#4!*4K!U0 H
M>@ZQZGIV]!C;)8&WK7*_EG4\8PSL8X)WCHSFSTI[?=X-SBZ9BD#*5:UA145
M#I A/V;CX'':P  FK+"B%,'>P.OEZ1R,7,^9+35_KX<,_P"8>-R.7=JW<2@R
MXH-IK6DI2DDP"%&([&?*3/<;'OCZQ\ 3OFR\?*K]0<#5JN>;-2V<?F[^M6&_
MQR%_\ H\^OXX:QT\<+U^-9J0E9)T-%*AW &^_7_AC3M@,5C_ +C3-OJ:W=X_
M+\T SD-1P"^=<S[0M9HV*AI25H2M1C=74@IC]'3Z\>;3.7)6%H)9)+M>@XW]
MHT+D2YB2E0!4;$\LO+KX0RWF.R31W#+]R:?;;-.]35*5H6@%,*$*.XZ]?=V'
M7'N]AXKYY017>^EG.C-U=L\M86SL5,P,PA+@(6D\@% Z4!N+M^W0#BCYX[Q;
M^#.<LS4"W4Z7ENO4+#6GQ5%YY>A*425!((23L-I]#CS?Q+L=&!VLB8$D)FA*
MV89U##O*/T;LWXS$WX>5+EKKN;I8N7I6^@\ZEG:#/..:+CF>[/WBX/J67B4M
M-N$_B$ G2&^NG8B3 GZ ,>:Q$O<G+54%395^GV!(OY/'@\1CYV,4%3"2$J44
M@DD!V/"M Y:K"$]?5YCY]9^<50!/??WCIOU^&,Y[[[XUC.%*KW7O^(!WUF9!
M,0H$]MQUCIL.@^K;%)-2PM?G9^F1-:\@(]^L3Q_<TK@3[6O@TVG<*R+Q7))B
M?^AM=^L?FQ7- W4W_<_"GAU\;-%:[#GK'T]\4Q7'#']V3?PG)3_I.(G]&@P0
M\CS'H8X>B"8@P09G!"@3I7E*VZ$0)]1MU_7M@AIN.8]8<%P,XQ7?A/F>FJV:
MET6E^I:3<*=*E06M6[B$B1K3.X@R(^C-.D[_ -0%;T&5+\X]-L#;DS9N*2-Y
M7RPH.'-'-2/N'KID)[.%G&>ES=8J*ZVNY)J:=Y.R6UI4MN3NEQ)A0$[$0<4[
MGR_K9MVKZ7]NZQ]\V?M+";4D)4G=,U20S9FYKZAQ4YVAW66<T)K&&O$<!4L(
M'F@1O!C^H_\ $_4&SF]#DVC7^[>6SY)>HI9ON?P(6ZVUUMJ66:=2FUJ.DJ5(
MB8&T]_3J?IQ6J<Z[Y#.M>[7RM6*)N&FUW/VC35[OJV9OU:#TRY3)8"0I$)(Z
M$=!'0=^_6<:T3OIK85Z&S>GA'-F86;O?4[?[>)?.#?36M5;1!U+04G1I1Y00
MHP(,CN-^Q&YGKBV4KYMKFW9[K%:DB2Q8M8-32E;TRI;)HOIK!4M%-0IB D%*
M@E'J=MX](CW$_3L,LRV!_P!@[\J-Z]VI5,"RXN 4\JAVK3.W"\&"BLFM7C.)
M$.20%"#Z#:('U?21OB/O^.^ '.($D\A;TSY"#=;Z(4RTK#2"$R5#1$_9L?T_
M9IB D%[4Z.![=YT4ZT/-N-MJUI;0?*H*D*.V\3O[NOU8JFK*-ULW?AIW_(9D
MF@9J=+COTM!ZHJ2U, 52@T\^C="W "$SW WV$=OT8I,]=6 ;+7N_E:$)-'?A
MI73@>L F8KJU6/M,IJ $ [!*H$09WVCI/N[#%/S/F.7)(>^O*@^T:T2Y:4'Y
M8 +"U@UQY=:UA-\QYOH+>R[0VI&IT(.MQ!U:G"(($ R1,]C^;%J):T_4FA4R
M2U*7J,@='CS,V;-&)F;Y)0WTDG4Y#D[U\(1EJS7&[U1N-S4XIA"RXA!5'0DQ
MI)Z;[?\ &-"<)/F%V<G_ )9C^,O<0OG@/4^]<_M?.]()_$_B$G+=FJ&"\*&A
MIF%K=45AM&D()U$F!,">NT?5NDRILP_+F6ELBKLR3S;RY"\9MZ3),R8:DE1+
MO=J\SQ^Y$<UO._SGO7]RY</LEW5P,*+M-=:BE4I(4G6=20L1*E#RCT'7?I/$
M8I$B7\E%%NQ.8:]M:??CXS;.UTS"J3++?4DDC)JV:E],GH8B%J'G'E%:I).I
M2E$[J49E1]5$[J5U)QR%*WG-W!)/C2M1Y_>/+S%E0<]#EQL?=ZQI#Z_U]V*C
M2C5%^,4Q1,;G" >@@BW6GU^P_P!6);BM/,>\$"H '3:4R3[YZ_7C.%&[Z>7C
MS[:-P8.VH&M&%KOF?6/>LPHSMUVV'IZ;G]'OP$DAC6H^X;3OP8)--*MHYSZ
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M<(F<9,9TS%"HJ"*CJ*/P/"-M+-"R$AI"% C8$$:2-B1W/7OZ#IB0E*2:"NO
M\[6]LXI7B3,HI:E:6\V[TM&JFJ\!X DE)4>_8_KMOTP_EKJ3]_;Q\8SF> =T
M&@RI3Q.L>.U2'%%"0)6"/6-MNL_FZ=/3#$M="+.WGPRSRK?6*E34L2;L<]=/
M'+ATU_O6XHMJ02C6B3 ,E1^KKWW'2?<-DM)H :\GXUJU#[Y/'/FSD:BI>G8?
M\TC(FWI8;6M]R8,Z"1\3&\R8.WK]$]:2%B6Z/I65%)4+[K  4\S=M<N5B\3N
M!!"BE((H"UR!;EP9ND+MRXWEFT<2[$[NAIVJ8:*AM"%%&J"3$;D_';W8^G_!
M"_TRT-]*ITU"%/\ [;Y9B#J"S^3Q\=_JS+1B]EE83O*3AYA!T4!0T\>EM.J3
M@I?F*JP4*4+3I%.RH*5Z:02>QWZ@G;X=^_MK#J,R8&JZN&K>#\O./R3B1\HI
M400:!R-/QEQARU%=[0P0JMK*9EL0I3C[B&D(;Z%16I20 /7IZ$X\9.PN,F+"
MI07NI&ZJ6D/O$UT]*4X1KPD_#D@+.\5&AK](;.O&Q\#$)?M9O:%<)N6&P/6>
MVYEMV9,W5U"\+=ENTUU-5U9J' F'*E#2EEE")DE42D>\8]I\,JDX)!F8]$R6
MH)64) 8[X2K=_<^>[[/&J?@3-(,B6%;Q&\JM4N'M?.OG6.!GF XW9KX[9ZO&
M=,U5A=>KJM;M+1ME08H&%K4MIA))A:FT'3L(B=\<7;&TYNT)@FSYIFK0-V6I
M3 I2#0.*?2-78M>\>HP4M.$E?)E#<E%R4"N\2*FNIRM5Z/5M-8]),J/51B 1
MT,].FP_WX\S-F+476HG(.QT.>KY9ZYZTL&:@\ ]->MO-H!E+U2I73YA!&D[_
M #5'X ]_C[L4.+Z_>M/Q$X"W5;+&H=QN9&QZ8I)J2#F:P91/!]S1$_NMW!D%
M23&1>*_3_P SJ_Z@,5KL*YV^\5KL.?7^/Q'U <517'#%]V3_ #^2K_/XB_T:
M#!#R/,>ACAS:6I2X))$'!"@1IU:7 -4 S,F-P-L$(N!2^7C J'1 F2>NH'OJ
M)V/T_K&"&'"M]RY(/A3O2T. X*<><P<*KO3Z*ARKL:GD)K:):RL(;4H:EM))
MC4 9(Z&=P,14@*"DFRKCP]NZ-ZC8WQ!B=G3I.Y/6F6E0) :C\[WMTO$Y7!OC
MEE//EHI:ZS7-HOJ2A*Z4/)+C3I3Y@MO5J$*D=,89DK=LECD?MX9YQ]HV'\1X
M?:$H"9,2J:0*E0<L,R&(J;'@(=KE_,BD^%K?UJ6!I*5; R(B#/?8]X/K.,2D
M*WB1PYCC7B8];*Q$E,EE$%142*AV+\Z6[:%OLEV=J&D!Q\*E20)5VVZ^I._N
MZ8L05E@31PX(JU!>];?S&.=.0K>8#.H'7IWS+BLK9HIF6D4E21H0$E"MMB!T
M&W0R3UC:-]L='#NDDI+>>?%_;[<J<99%0"'%*.]@+GGD7A1::]TCC"5F$G6=
MB!YDQ\X@@0!T&-X6N9^]1)% 6%M/>.>9B$4 W02Y UME_'5XT:^ZM!X&G\X)
M!,?-]Y'I'U=IPR^5#VQB!6C>IS+T8B_/SJ\&:EN5+\E;6X$C;4I4P9Z[]QOM
MOZ'MOBKYBQ=1'.-8*5#Z3>C"O,TO3\WBVJSC045.' IO65%*94")!VC<?#Z=
M^V,&,Q2D_* 7_P K7-,Z'MLHTX;!JGB:H$LC=I0?NS]=>4>'/#YI"M+B 5"0
M!'0].GZ!VB.N*Y<R=,J%$@Z-3-[$</2L->&3*(WO_P S^1@H72]5]P9**#7\
MJ6"'%$GR@GJ#T'QV!!Q=*E3035@=*TY7Y9B.5,G)2#NL@?50/6K<335JGQC5
MM=#2VI JKM5I<JW%3H4N=)W4.I(.VQ$=QU@X[F#E3IBU)=3)0#;,$"MJ\N-X
MX^*2,1_TU!*D$J4H9I9@G1JN/&D$[B-QFROD*S5MPNU=16ZC9:6I3C[[:#Y6
MU*(TJ4))"1MUV@#'=D2BFZNI8!JYG3AD^<>5QN+F851!F%TU+-3WI5KMUCFM
MYW?:!5_$"KK\H\/:Y;=L#CK%9<F5D)*!* W3E)(*CU5$I ^B,.+Q:994B064
M2=]2:N>_"W >>Q>U)ZDD)G*+WM5\CJU/M:(=*NMJ*UYZHJ7W'GGG%.NN.JUN
M.*)DJ6HRHR=\<)7UK*EDO4N;FM>;WCS:R5+*B747<O6^?KU>-$J)G<Q\?U_7
M;$'NS@&(QCU)]?L.+0 SD![DEN[0WX#S]XL<4-"X.^DD=MP)'7WX2@-TD <P
MVL(FE ,M=>< 7RA[_P HK%4$'+%1!^JC!@/!K>#O&W>32K<&[]8R@RHD"1M\
M?C\)Z_1@<!-P_  F[WM#20U- _A_,7 1/O,X@>^>L28^,"#+J4ZD.$I3(()3
M(,C?TCWF1MBXJ26W7>CAN3^7XI:26KO4%:@.;TSTC=8J@@@(5(2DQI44F0H%
M.Z05(@[ZD[@@=L5K0&<BCVRS\CI$D3/DK*T*(HP-N-=/P(<GPNYA<TY'=9I:
MNH<NEL2E"/"<=47F6TP):<6"I26TC8+\Q@QL<8)V%WJH\]6MIQ%K5I'M_A_X
MQQ>S9J?F3%% ;4L+<:#QH_")*N&',KEK-+#*$7-'BH*2:5]X-U"5Z1(*7="U
M:52) ((QD7*_U4FHIYL.&F;9AH^Q;-^,L#C0B8K%.J8 5CY:@7?-Q0.SN&AS
M]JXAVNK9EYQ"5&-.IT:3.P*%;ZMR>AVCKC*J4H'>W:<]:_84\.'NL)CY&)2G
MY4Y*B7-2 3_ZC0 5S@=8S#1U#DI=U@?-TK&E/K)^KXQB(0?^)(X%^>0Y6]XW
M#?:BDG_YDY]6K]J:1G?N"7BDM.-@#LIU&KM/<?5&(*2 6:M*&K'LMK2,\Q1"
MR"0#0:@V]=17A&>EN"O$W4V-.ZB!O [@[].X[_6,-*1R&C&K^]O+2,\Z8!+4
M0HL XK4\^OMP@=^_-."F7>O8 ^G2>W8^G3&V3+26Y??EX^4<:9B*/I2KL7]8
M [E<T*2H^(W 5J(*P(2.A@D=?2.\]S'5PR$[X06:AMF7'+4UKX/',QOSI^&>
M4$DB8074$G)V<N*:#VC8RGGVWY=S%:*A=>VV*=Y#SJE/ !/XU*HU=)ZDP9'U
M@>]V$F8G&8 2P-PXO#N2H)#?-14A1#!GZ5=P\?/OC!L9LN=)24JF_IYHW7#!
MD6WC<.#SN(FPRK[03AIPMR)17;,6:;3;FV+8R5_**UO6H(0F V@[J4HC: 3/
M0&,?8L;L7#S5S9J\3)1+"BZBI)%=6)]*Q^4=IX6>)R4&3I0*27X7RX=!$1G.
M5[=S-&:T77)_ 5AVD96'*4YQJ7E!+;104J<M]*&T>(L$DI+JBCO,X\_BL9L3
M9*0G"3$8_$J0KYBOEJ2B2MP$@%2662/]LJ7B^1LC$%<M2Y8DR_I5^Y*E*M1@
M:#)JYVCG'XD\2,W<1<P5N9\ZYBN>9;]<G'':NYW.I>?>!=65%%.E3A#2.T)V
M'0=)QX3&[8Q$Z:I7R4@*WP"Z?I=[,,M/LS^IEI3)EA %0-*GB]N=32$9K:LN
M)*0M*9,2#OL=P?B.L[R>N//[RB2[ASJ"]]#[B+4 !M[B]^GV@N5(6H$H4$D]
M/<9DD;]^A_1C/.-F-WS#9>K]T:\$&U?(<+_;P: QUXP1!4H#T)!VZ^_X?1C.
M\,N6\_8<]8#G7$]"=_$<41Z!:8'_ -:1MZ;@2,$.)Z/N9X?_ (6W@R?_ -Q>
M*X_^QU=BM=A$%VZ^\?4$Q7%4<,7W91\[DJ_S^(O]&@P0\CS'H8X<&U!*I)@0
M?UVP0HVDJ2KYIF/<1^?!!&TR\6]E'R] -Y$^A^D]>N" OEY]]Z1OI4% *2=N
MQW'Y\,<V'CY0J$\17Q?U@]Y)XA9FR#=&;IERY/4;R% J:2I7@N^YQ$@&=]XG
M?MUQ!20JA\?Y\HZ&!VAB,%-2N6L@ @FI8MRK;K5WB4;@CSUVRN-#9\\$VNH0
ME#7R]3FFG=6-@LJ*8;)W^>0.P)QC7)(4^ZXI6_E;\5RCZ5LSXPP\Q"48B<J7
M,%#]*R&X*R!XVTB4_AMQGRO?V*55MO-"^A>DI=35)=2K6!&Z9 (]_OWQ$)<L
M!4VXYW/ETCVV$Q<O$RM^7-2I(2Y!4E)(9_VN":V:[Z"'1Y?S8S4+:*'VUH2M
M!*DG4G>-@>_NC8[XU2D%/[J4R.?'MJ:Q7.6#^U0=OVOG5Z@^&ALT*^WF9AMA
M14XT9(()7V@2-AVC8==YQI"T)!"B02S  VL2_P"<J",1F*4:5(I8WT9JOYOS
MC)39NHQL'F1!.Y5.\_#IT](^S#^;+MO<*)-+#095Z1,(G*_TKDY9^3^_XOJ<
M[,)"@'6],$'S;S'8=?K]_P!&.<:$2RM?_F213PSH.(TSU2$+E$?,20+,%!7D
MY8@GCY0B^;LVW:KK&J>@4HL!:2"C41,C5)@@$#;<[[1VCDS<-CIZD?+D [A(
M400**.?5].9CU>S,3A9<O$CYGU$(<%)%@69PWJU'A<\BW"GJ*- NCX4M+(.Z
M@)@"=E0=OM]^.S@Y"Y8:=+*2[D;KY5%!3EZQY';.-F;Z_DD,2:[P#.3=V//3
M@\;6:\^Y8RM1/U3EQIJ5OPUE;CCR$)3H$SO VZ?KOZ&7LV:EE&6FP+[Z+&M:
MTIK09QYB?CD .N9]P/#C4/36L1:<>O:0Y"X?)KJ>W7!B\W9M"TM4U+4(=EY&
MJ!"4D-P1\Y2D_.&_K<5)P8=QO$,R2*V)M6X9^D<#'[;1)0DR)N],4HI6 DI9
M(2;6)^IA;(Q!1S \Y?$_CG7UK5?7U%ML#M0M2+<P^K4ZR2=*7EIT@2#$($1L
M2<8)V-G+<(+ O:E.]+BYCR.+Q\[$J).9=W(.5W-?5J'@SUQTE2E*6HZB3N5*
M)).\GJ9VZXP%:B39R_W>K^<<XJ+GPSRTMXQKJ5ZG;H#&_?W8"-X4+G*PH^?C
MPRB$6@@],1*2*D>D#V&MH\"TJ)2#)3UV/??K$'Z"<1@C1>J"?Q:$ H,2N8(@
M@](WW'KO."$ 1<O&M ]!]0P0X,^K<B.D?:1_7A7\QYM&B+@2#(,']>W3"*7;
M)N$2"MU^+1>E8!A4[DDD">ON_23B.Y2]>^O=HL"G#FC=T]HV2M4A4G;:1^L3
M'4>N()HH<_Q$HV&G1*B5.I2$[J2$$I$C> F2/7]'7%B[=>^Z0'OOGRC>IGDR
M5(=+@G2"ZC2K<#I!!TR9Z&29ZG%;9^0_EXG+O5K=]O U1W"JI'?$IZIRF=0L
MJ2\RI;2P 0=EH((@@2"3/0[8K5*2JI3?A?RC5)Q>(PZA\M2DA)^DAZ#SX<O*
M%NRGS <0,N^&C[Y*NM(B(9N"5*4 D=$."%)[=9WZR,4G" T#UU%#0T[R>/28
M/XPVEA6"9I( 9RX-12HH^3D5Y0XS+G."TAM#=WH7F'5)APTY<=;&V\* !._N
MZ1WPOTA!#BF5>%M!KIQ:D>NV?_4/$ @3YJ@PJ^\H9/W:N;-"L6GFRR4X4)>N
MRJ8P"H/-/H()]2H*&\F(,P.V*%X4[UBU.WN[<QI'?_\ M DK+F<D*8$@4\7%
M[99P=F^:+(90VX,Q4B%CKJ<<)5V (CN-XV[3@&$+BAO0%Z];,_IU@7\<R"A0
M^8FH8U%0[Z-X,+QJUW-ED>GE(OE,ZZD%80T'5KTQL=MH)G8R?KQLE84!G#G_
M (Y5&M;,.#Z1S)WQI)9A,%69B/MYCK>$NOG.'9 A_P"]PJ*EXB$'Y(ZE*B-O
MGJ'0;"-NL@;XVRY.Z0P:HS=^&1N<W'E'"QOQG,4"),P[N[D]W))#Z'/P,()F
M/F3S3>7%?(FTT"-EETNK<6"L^72D*1H4-SI.J#^21CNR,5,E@)EEEA@@O4*N
MD@T8A39TI'C<9M^?B2H.?J!2Q.2ANV##F#QX0EE\XAYES.0;]?[C<PC9IFIJ
M'Q3- ';2SK\/R_D I@#L=HV':6TB/ES<8LBQ>8:UR._7F>+UCR&(PR)DSYFX
M"1F6!IT?^8+;MQ*B(,3  ! W ZP  )/72!OU.()WI2253/F*F'>=R?N=;OK1
MXD6^FI=(;I7/ER@!J[A\XDD_2-B-HZ"?LC[<9)LZIS=]6-.WOK:(;I5^ZFGY
M#TZ-!=>?2HF2$ZE2"!'4])]W4CZMSC*5O2EVIK]K1=]-#GI1BP!\[<S:C0&/
M+"9\VD@D0I43Z0>P^OK]=*R#T^[6RB:2Y+4X-1J^!Y-U@+J%DJ*0I250#Y5Z
MDPH;1$=AOU&^(1(<^]#V#K <LJW,[C8]YWCO^IP0^7O$^7W,[M[7#@R#N3D/
MBP9Z?^TZM VQ!=NOV,5KL";T^[TCZ@^*HKCAB^[*/G<E7^?Q%_HT&"'D>8]#
M'#9@A1LL=%?$?FP01GP01ML/1I;T]3&J?T1^G!"LYX>C^\;HV(/I@@"@;&-A
M)U).X&^PW^F2(/U8&AA2DD,#0NX(%?%_2%!REQ.SSDA]%3EW,=?1EN"FG%0Z
M:8E)!'XE2XVC;;I[IQ'=3H.^_(:".CA]L[0PQ ES5I33Z744FW%@[96/D\G(
M/M!N)>7$-,7YENYMHT_CV'GFWR$E(!*2HI42 9Z$'MAURKSIXL*]&COX7XGG
MI*1.+BEB6R%B];T)%*-H[7+WM-[#4(9;O/WPH7/*%(72ONH(TC4I2TE0(F08
M4"(G<;X1<FH< 7(<L'H^5J W'&/0X?XKPH!WRQWJ$I8@->@+95T=X4^E]HKP
MTK E)S$EC:=+J*EH)/\ DSI),#O[^L8 U/I:NG?2G-HZ\KXLP&ZQ67:YH'ZA
MN=7^PJCV@?"9LI<?S+3+=$D)0[6*F!V$;^HF8W[XV_+PY_V47XG6[VR:O%KQ
M1-^*L*0?K'MX)H:TZ:F NX^TWX26Y"S2N/U[X!"$-4E<\%* ,=$B-74:OCTQ
MKPV)P^"W_P#&9OS-UMXONM>X+'P]^7/^+DHI)6H%3[S$EB 2 /I&77UAOV>?
M:MYG?0[39*LKU$5)T(J*AM=."#N%'4M3G?T3M[ML:?[M)_\ X9#\0GBW^AMX
M\08\[BOB2?./[B>FK&ZGZ?F&+<3.;WC=Q.4ZB]YNKJ:F=!'R2WU=2PG0=BE2
M_$DC3L=(1)VD=,8IN.GK'[B'L$TII:E!ZQQYVT\1-!&\4OD";=7R'=8;/5W"
MLJW%/U;ZWG75:EN/*+RU*ZZE+<*U*F=S.^,8F*63O%\[F_4QAWUK-:FBJYY4
M<Z9\8#U+4HD@3/< _K^O3$H&!JJAS#B+=<B(_P"/KTQ0JYYQ4;EK91B6/*3Z
M$?;.&C]W/^?M!%J?*%'K!CZO^.+%5.[KG^.D1ONGRYB-5QXIU-I$$&-<]8/I
M'T=<5*_<>?\ /G *LKGWV(TUJTI*HF(VZ=2!A1*,/C_]3_ZW^[!! Z;G;_\
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M<(,B#_U'A;B=/,^\2^;,_P"7D/:/?VAW)1_%,Y=_YH,B?V)AL./B?>#YJ_\
MEY#VBOVA_)1_%-Y=_P":#(O]B86Z.R?>#YLS_EY#VCS]H=R4$0>4WEW_ )H,
MB_V)B5H1F+/^QKT](K]H=R4?Q3>7C^:'(W]B8(BYU/B8K]H=R4?Q3>7C^:+(
MW]B8('.I\3%?M#>2?^*;R\?S0Y&_L3!!O'4^,>?M#>2?^*;R[_S0Y&_L3#WC
MJ?$P.=3XF*_:&\DY_P#%,Y=_YH<B_P!B8'.I\3 YU/C%?M#>2?\ BF<N_P#-
M#D7^Q,&\=3!O'4^,6GD+Y)3UY3.7?^:'(W]BX4(DF\>?M".2/^*3RZ_3P@R*
M?SV3!!%?M".2/^*3RZ?S/9$_L/!!%O[0;DA_BD<NG\S^1?[$P00<\@<IG*_P
MJS+2YSX9\O?!O(&;:%FIIZ+,N4.'65<O7RE8K&BQ5LT]SM=KIJQINI94II]"
M'0EQLE*P08P0?>'"8((K!!%8((K!!%8((K!!%8((K!!%8((K!!%8((K!!%8(
M(K!!%8((K!!%8((K!!%8((K!!%8((K!!%8((K!!'SZ5?=E_'TP4<F&0DA/S@
MKB'6DJGII_N#MWP0Z<?$>P[\[OWYCQZ_B79%_G$K/[/P04T/B/:*_?F/'K^)
M=D7^<2L_L_!!30^(]HK]^8\>OXEV1?YQ*S^S\$%-#XCVBOWYCQZ_B79%_G$K
M/[/P04T/B/:*_?F/'K^)=D7^<2L_L_!!30^(]HO_ 'Y=Q[(!')?D11(F!Q%K
M92(!E7][X$S'7K]&""FA\1[1ZG[LLX^N.)::Y+,C.N+$H;:XAUKCBO<$(MRE
ME6T:0"J=@"<$-JLRO%OMPA1\K_=9'.YG8L_@?[-IW,B*A00P_:KYF%]AU9,0
MEU5H0G8]3T'J<$*G:AETAQ]E^Z%_:G7YI#U#[+&G0A:=0^69^=HU 1.Z7Z5!
M!CL=\$%-#XCV@27]T">U3;5H5[+JT!6_E_9+1)@$[?B/=@[[[\H*:'Q'M"=Y
MI^Z4_:59/9=?O/LN5!MG=PT&;ZZXJ2GNK324+ATCN1T^.""FA\1[0W:\?=@O
M-)ERI71YBY![-E^J22/!O.;+W;U'3.HZG[2EL 09)6-P<'6&P9V/"HKKEE )
M^_+>/)!(Y,L@G2D*.GB-6*D*$B--O((/29CZ,$*FA\?_ -,8_P!^8\>OXEV1
M?YQ*S^S\$%-#XCVBOWYCQZ_B79%_G$K/[/P04T/B/:*_?F/'K^)=D7^<2L_L
M_!!30^(]HK]^8\>OXEV1?YQ*S^S\$%-#XCVBOWYCQZ_B79%_G$K/[/P04T/B
M/:*_?F/'K^)=D7^<2L_L_!!30^(]HM5]V9<>DI4H\EV182DD_P#.)6=A/_N?
M@@IH?$>T=GWLZ>:F\<[7)AP(YH[]E:CR5=N+N5ZG,%9EBWUKEPH[2MB]W2UI
M88K'6VUOI4W0(>*E(!"G"GH,$*'L8((Y]/;E>V:SY[)@<!OP*X+6+BV>+R\S
MIKOOUF)^P_>?[PBF+7@>#3O^/\H\=6K5&C2/7!#&IX>;\](Y]OWYCQZ_B79%
M_G$K/[/P04T/B/:/3]V7\>Q$\EN1A(D3Q$K1(DB?^]_J#@@IH?$>T>?OS'CU
M_$NR+_.)6?V?@@IH?$>T5^_,>/7\2[(O\XE9_9^""FA\1[17[\QX]?Q+LB_S
MB5G]GX(*:'Q'M%?OS'CU_$NR+_.)6?V?@@IH?$>T7G[LNX]RD#DOR(HJZ:>(
MM:8/H3][H!]TX(*:'Q__ $Q[^_+./OBH9');D93KD:&F^(5>ZXN>FAMJVN.+
M'KI2?3K@@IH?'\:5A3LI?=8'/#GU;*<F>S8=S(BH6EMFHMM]S NE6M2M( ?<
MM#2  ?G$P!OZ8(=*7K_W :YMP^T.(M_W0Q[4RY(;6Q[+2E;2\%*1\JS\[2J(
M3UE+U*DI/N.^"%30^(]HVW/N@SVIK6L.^R\M*"@%2PKB4D%( DR/D\_1$X.[
M=]UM!30^(]H2C-7W3K[1')C2WK[[,AMEIM2DK72YPN%: 4]?_P 6H%[#UP04
MT/\ Z@/40@]U^[$N9FPNK8OO(CEVROHV6S=,Y7>B<2?0AZU)$^Z<$-@SM3_S
M#1](#/WY=Q[TE?[2[(A0 3K'$6L4DQVE-O(U>XP<'6%30^(]HL_?F/'K^)=D
M7^<2L_L_!!30^(]HK]^8\>OXEV1?YQ*S^S\$%-#XCVBOWYCQZ_B79%_G$K/[
M/P04T/B/:*_?F/'K^)=D7^<2L_L_!!30^(]HK]^8\>OXEV1?YQ*S^S\$%-#X
MCVBOWYCQZ_B79%_G$K/[/P04T/B/:/#]V8\>@"?VEV1=@3_^42L[?^C\$%-#
MXCVB=;@][<7B!Q,X2<+>(]7P*R];:KB!PYR1G:IMS69JEUJ@J,UY9ME]>HFW
M32@NMTKE>IA#A *TMA1 G!$MP\?+_P"J/EW8(A&5USQ2E7AMMPD(_%ITI5IZ
M$CIK(^<>^"",6""*P01D92A:R%ZM/E!4D@:"HP%'5L0>A!V'7!!"_<O_ "L<
M?>:G.5!D/E_X9YGXA7^OJ P7Z"A<;L%M3U757._NH1;6&FVTN.P'UJ4E)3"5
M%))#;,T'KW=[>D2Y<#O8IWE>;J>V\PF;W:-5LO=-;+YE;)JTJ:2L5#3;[-3>
MB?%7H/C,J#"2@ZM23Y0<'???C!O"A'U<\Z:.PZYB^4=,&4_97\EG+BA*\B\%
M\OU)IK+2.??S-+*\PW)VJ#*'%/*J+BIY#;VIPZ2VD [;DX(B22.5F]"]3Y<L
MH/5CL=HL;"DVFTVVT4J5J^3LT%OI*-*4 D I\%I!$CI!Z#!$35F%P37*W?9<
MX4-<'W(?(++#:R@!/SG"F.T)5MN9WGZ<$/=L7LW\:U?6"X59?^45%3<JIY4J
MTH9:0OL9@D)V].HP0![,1Q<>/W\>N&LS'DYJCJVF2VD.(*(=:*I)&DA2E@D1
ML=CVW[8(?/\ COL0V?,/#+A%GIBOM6:<JY5S+25+JTK%PM5*^ZGQME@NJ;\4
M !1W![G!WWWYP#F^?C#&N+WL;>5KBY6-C)E,]PWN]=++MRR_5.MTE.G07/-1
M*=4P-*B2GR"4C3TP1+?4 UW!^S^M*Q$=S)^P\YG^#=)79AX7O4G&[*],EVH%
M/9%LLYI;I4.=K<@E-4ZVS*B@#4YI)!P0.DWH>7T]Y,(AWO\ EB_94O57EW-5
MDO&6;[0K4BJLM\HG;==&%-QXGBT=2E*Y @_B2M,;ZC@A0!* "B!N!T(,@CX]
M?C[\$$6X((K!!%8((QO?P3O^C7_1.""/KF^P'_Q0_)/_ ":5W^MV8L$,W/,^
ML3#X(4<*?W9OTY)O]-Q%_HV_!#R/,>ACA;P0H]))B3T$#W#K'UDX((\P016"
M",K38<)!5IZ0J0()F 9V (ZDP -\$$+QP)Y7N//,SFBERIP2X:9DSM65"TI?
MN5#2.-Y>MB"H!;UQO;K8HV6VTRHA"U'8B08P0^>N5_#TZWI'1?RV_<Z%,BDM
MV9^:GBM4(+J4.N\.N'HA*("5J8K[ZY+SZW02TH4WD;4D*"@23A.-81+.PIE1
M^#-GY],Y=N&7LZ>3S@:VQ3\-^ V7%5%M0@"^YEI',Q7IUY,0Z7KHJH#9*DA2
MO"2$SL!&'")+&K=#2]6IEPX5A3,C4#%NSAF&T6JT4%HHV$,J::I+=34C#2=9
M!\-#3*$H.H1L.D>F#\]^%X1K2UNO? O]W V3+U-5!RNN#R5LL.N:/%)4V0HG
M5Z293MZ$#!ZU/AW72$!>PY4X"A=GJU:@VA(>)C-MHG'KG1DA""I"D-DE3J4C
M<@;B" 0-OIP=_:)#P%M,R.CT^S0UK-%3455*IZVLJ6V^VI90\PEW0>P*5@C5
MZ[&-L&?'O+O.$XIG4#J^O6KFO4PVBJX*9%XAU]8UGO*-BN@>;6'&:JS4ZR02
M2'->@+2LCH4D;]NN"#ZA_-^5*%^0TX-GXC^R'Y>>(1?K<L)K<AW5W\:EZR/N
M"D5Y5:4NTBUJ84WJ5YT)0-72<$2!.=7Z@CFPUIFUC$4_'_V0G,5PG:K+SD L
M\6<NL(<J?DUI2BES(&D:UJ+5 H>'4^$V-.A'XQPP!N<$/Z>7GG;TZQ%M><NW
MC+MTK+)F"UW2P7NWEU-?9;U1NVVYT:FB-:'J.J0A[RR HIUIZJ22-@0H SL2
M)Z?F@'Z?C@@BL$$5@@BL$$6K^8K_ #5?F."".T3E0_P6N6O^0'@Y_L[RY@C1
M'%[@C/%Y6HH2@_-22H #\I0 )/J8 &_3>.IP019'?L<$$9Z6FJ*VNHK;24U3
M5U]PJ6:.AH:2G=J:VLJGU!#-/24K25.U#SBB A" 3O)( )P0"ITCI3]FE[ '
M/?, U9^)_-C\MR+PX?73UULX>4@4UF#,% "7T&]U0\/Y"EQ&DFB\Q4"#XA*(
M40%FI>M[=]2W.W89DKEPX/\ +1PJ_!?@QD^U9#M&6[&^:!VR4-/35;S]!1K"
M'JRJ2A%4Z\Z0/%+KA*UE2AUC ._XA&QSI;/OI6(&,GY[OC&=+G5W*[(5\LS@
M:DEY6I:BJYK*TA9/SE)$1,ZB8ZG!"=FNWBP;.O>0SB:GB#G9N]T+5.B%4K]!
M;O#:0K05@4=,I1*I&K200H=-O4X&SZ>GXA\N=&X_SI"/_>9-0VA06M#26]6@
M3 /5(D;$?#;!$0!D6?4N0!D'\#I&UEUFD2X6Z\!!0I7A  !!@[$@[&>_]>"'
M0VXN[@],\X,K]JHUZPW3TX*YW2VV9GN#IWVZ]<2H:T!TL,K6]XBY:Q9Z$W_D
M&UJM404:[)5'6,N,&E:*G5*4%I;0#J.XD@08Z_HQ'O2  BA+AZ._$$<\FKRS
M@@_L*.-OKJ$NMTX<5.H $&)B0(F ?S?27(\N_3G$[5UOWP@WV/ANW;E^(\^:
MDKC4H2VD"(]=X3MMVCUW&UY6[[O"Y<#>IY^6M*-"N6?*%N<J$M*U^$0E)2VX
MH*Z1WV@ ^:=M/OPG[:GMYP 4KY4T/!JU[:&@<W_LRN7+FPL-919VRTS:LR_)
MW%6G/%EIV*7,-LJDMGY.]\L:2A=0TA83J:=*@I((Z;A]C\]?*':U>!MZ9YO<
M\XXV>>OV8?'+DHN]1>JZG5Q"X0U+B_O5GVQT3RG+<A"CII\SVUA#QI%A)!76
MA8:)22L 205SZ<HD^\2,_O\ EWTJ';*,X;I"DB4$2E0'E(/2#TC?;??!"BL$
M$5@@C&]_!._Z-?\ 1.""/KF^P'_Q0_)/_)I7?ZW9BP0S<\SZQ,/@A1PI_=F_
M3DF_TW$7^C;\$/(\QZ&.%O!"BL$$5@@C;H**MN5QH;7;J2IK[G<:ANEH+=1T
MSE76UU2\=#5-24K25.OO/*(0A*$G<R2D J! (Z*>0WV&.:^(=#9N*G-DBLRI
ME-XM7*S\,*)18O%SI%:7659BK42JE"P4A5"A*XU%*U[3@@=K YN=.0]&?6E(
MZW>7K@APMX0Y?MF4^'^3K1DZRVVB8I*>CLU&Q2!QE#80A52\V@./ON $K6ZM
M:E*))W,8.7*HS[\8.)[>GG#M7,G43=*FJ8I0M 3*@4@P )/43TZ_J<$)N\O;
MO1X3+,:+90/AE3"4>.D%;B DF H3NGH(D2=O>.F$]?O]N[PX9^%4-9Q7S3;+
M4H$&G:4J (D=0B-H \Q@P"?K8]/QXWB!<D:@TT&?%[$9<H6RX4+-ORY64U&U
MXM4:-12"04@D3J '18DQM/?ONG>K-X?;[4/.TA0>9KGURA#JBP??*A+CT/.!
MO2$K(*02-^IB4]2#O[O1PG)<Y99NW=(0F\6<T+KS!9:"$+65>8!(CL-,@>^2
M!Z8*N>SQ>)7J(0*KN%4B\UYMM&I:E*#86 LH&D= J-N_?WC!$2 0-.GK6_GS
M@Q66KS*XTXDTSK2="TMD@) ($D(GYW28&_IZX*=^7G_!A5=@:YYYCI2MKW@'
MS+=<PM4K%/;Z]^EN=0\VTIUWSMLL%1+BDB>OEC;T@D"<$%Q46>PI2P\+/0OG
M#0>-?)SPSYIZ1VP<2+'2IS*V5KL^?K72MV_,E'4K#B6:CY4WX8K&@LP^S4>(
M?#&VF1@B041:Q9Q8#E3[Z,6K'/=S@^S^XS\H=:Y=;Y;QG'AG7.K%JS_9:5U3
M%&KHEK,=,VAY5MJH(2E]1^1N'J&R-1(E0VH=.EW.1Z\X8$.@]-((/8@@$$'H
M01$$$CWX(4>X((K!!%J_F*_S5?F."".T3E0_P6N6O^0'@Y_L[RY@C1'%[@C/
M%8((',N99S#G"^V;*^5;35W[,68:]JU6.S6]"GZZXW!\PW3L,I$P!+CSI(:9
M92IQQ0B"01W#^QF]B=D_A/1Y>XV\R]DH<R\6ZMA-TLUIN=,BKM&3F'(<9IJ&
MG<#K;MU1"0_6+1&QB"(!K[]_B N:9<KG\9&KCSZD49=MEGHT4E#3(IJ9A.EF
MFI$I"$H@ :P4I68 "4P$H0DP ) Q%R]TWKET'=W&4++.GC^81CC+7-6+ACGN
M\.)2AFDRW=25KDN(<^3N!HIGR[*5!D?9TEWWTA/G<&S=^9M6.1*S7:KO/$2U
MV>G><4;CFRD>*@OJA^XPA((D;N$A24@0)5TVP0[-WKW^8G5N]JJZ-JF76)54
M6]-*VR2TXI#S+K=,TB40?FA:#N#N/C@A<F?B2>6;YEJ%Z<((%XSS<;&QHM:%
M5:&6XT/KTJ@] 2J?F]C\?7!#8<GK1^_*IU@I9/XG7"[7BH1<T&G ,I1'E2!L
M>A]>W4@]#@@ %QGG=^_+)H</29A+ZF$-+4I4)5/AN)2 1_E%&D2.H)!.#[0F
M&C/1C2S/G6G[6H(/-'>J :*9Y;25:"XM;GE*-*=2E#4$C>( [G[#OOL09?4P
M/IXO;6-9>9+0Z%2LN)*BE!0#J4D&-TC5&_K]D[@<,Q\0]L[BO>;0B0=#U8U'
M+H ]<WRW*6^V912TIU* E(\JT*&P!$:HC4  #/<]1O@:]?'V?N@YMQ2SGQR;
M+C!DIKW;6-+K3C1@;#QQJCO(!.Y'7T],!&5FTX?;E#<=@^T;E3F>G<9*EA12
M H@I4I1"-)G8 =)]=XP,?RW$6-:/]JP/I?3NT-WSQ6Y.SC:KMEO,]NHK]8[D
MV_25EJNE$U7T%33/ I=0[3U#;B"J"0%) 6)V/?!W:%4"U],O$^E(Y&/:9>R]
M=X+F_P#'7EUM]1=.$9JWZW-^1:6:FX9">J'?'>N5L;4Y\IJ\NI\0RVAMS[WM
M2VR A"DX.WB3O?\ =E71A7L7KP@TTDMMO)*%LO!);=;6E:%ZD!P *!W(0I)5
M$I&H#5JD @BW!!&-[^"=_P!&O^B<$$?7-]@/_BA^2?\ DTKO];LQ8(9N>9]8
MF'P0HX4_NS?IR3?Z;B+_ $;?@AY'F/0QPMX(45@@@Q94RCFG/N9LOY*R58KA
MF?-V:[@W:LN9?M+)J+A=;@ZH)2PRV("$I)"GGW%(8800IUQ 4F2& ^; 7O'<
M#[*3V*N4^7?+%LXW<Q5DMV8^.-8PQ6L4592LU5OR.A:E%FVVNBJB\55R$Z35
M7<I\=;@*VPE 0A)FP^WX/E"*@:"W.A-C5F)X>0O$W5XM#2"W1V] :IF#H2G<
M!+:H\I*O.=(B( 2!MM@[?/G7OG":C4\*>$;MJ4Q0$V];J4'RJ;>!E6KJE,C>
M4_$_1V1MR^Q[:O/2#U[]A"J4>:UUUK<M32B:]F$+#<DEJ("RN=]0$J].^#MN
M]#!SY^V7YH.,(EFZGK*IUO2EY2SJ;TB0O65@=!N$Q(_R?LP?[5M1N'DSD\7M
M 7RKPUIY:O[PV3+%L%KXW5M.XE2:FJ8<2^A9UG=@JA)WG8"8B#L=\/OOND/C
MW^?2'4FT(=;>2ZVJ5MA"-I3(3$'T$1VZCMO* (OT;O+*L$-HXH5*,MT-6Q0L
M._*PA:T>$HI3X@!*!$@'4>W7IA^O??VA9_;OVAB=;GC-U8Y4M5U&:9'F_ADP
MX9)G<_.G8B-CU'N(*Z_CUX@UZ1@L;KC(6[4I"E.NA6H#S&3M(C:)]Y]<$1!
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M,1 %PQ=Z];0SZT_/W@W*;;<1X384E(C3!V]1 '3W^Z.D#$H(O32/:%*7!0
MGI^3M!VWZ=]]L$'VCCP^Z:^ :['FG@?S)VZA0NFS/17+AKFJX:$I<:K*=LW&
MQ+>,ZGBL-+M[:BGRITSY4;$ SL,^?EXCUCLJ]@/_ (H?DG_DTKO];LQ8(9N>
M9]8F'P0HX3_NSU;C;7)0IIOQ7O&XAH9;W_&/NFW-,-DCIXCRT(GMJP1(6+<"
M>0?\1.9[%KEU_:H^S7Y=>'=:TW3YES!E]?$C-[K;:14/7O.0:N,5:T'SO-T9
MI4EPRO9:"!@>C5I5J9YY::ZQ!JD]!2T245UP9=6$)2#I!UA203)(TJ^( (PG
M'37*'!5N+R$I)0 D(&F8WW\PV]W;KL=\1(=ZN'?/(-D,SY"G A)\S-.+.E]:
MMPHJ 40"(D=]N@Q,1$TK?2W$M;AQAN'$$H^0NH40DK06T;=2J1U_3[L$2AGP
MNM98+O;:I@J6S3/N,/!!$J*UD1]7OP1 %V+-=\M>.O.KZ0I@OEQKWV"PH-TK
MJR5J"@"%&/(0!OL1,'K&&UR*\Z:\<JP]Y^!+->MFR=LK5@R/6Y533GQWM8*)
M")/F4"/H&TGT'3;"[[[\3#(=C9G:&V<><C_A1DJ]4% S3KJJ%H50?4 %5 24
MZT4\[MJ1I/F3)V)]V"[$<+\LNGJT*QOQ8:7\<LGYPG7 6^45RR0WEMQ2$WBR
MON-OL*("RRI9\-[5MJ5*0"G;IUWV(+-9R1QRJV?4\7A6G,N,OH<=U$EL$ _-
MV/<J!W(P0$D9!J9_COT3V_4%PIJ=Y5-3AYILP5R! )C4 0>GKUP=G\0P7S?O
M37ITI":U5(EUD#Q-2R23,J@GJD=9T]/AUP0>>OO>GJ>D!+MK?2 ML@3\Z3N.
MT;Q[A/OP0C:E&+=,V8'TRK:!*DH":56LI#JO+K<\Y"28(!/Q]T?1@[[[]8!0
M?DL]!0FK:7=XR92L+S^8S00A25-K<:3.D:DC4H_]:0>GKL?>._@(+9EFS.;]
MN?S"NW>DKK0VTIAY I$J@ITC4VO;5N=X!]>G8>A#!R-[M1\QH._$@UNNBOEK
M:72VIEQP:U C?X[?;$GZ,$'?=0_C"QVE=C8=;KEEM+K<)1I;&KZY$[_G& =]
M;Q YW&9IH7!^GUX6T5^TYEK:ME--1TKC^R0'71I0O>4E)W/2!)&T1TP4K< O
MW?LQ)RPS+'R9Z\^G&.13[HWX+5ECXO\ "'F"8H&*>W\0<M560\POM2JH<OV7
M2JHMCU9 T)2N@%52^(5%3BV& 4RH$'???I$QF,Z9<>]<N$/_ .5#_!:Y:_Y
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MFU:WG$*EU"R@ :A$P =.K3 [**8[Q@AW[](2._9+0R^5:I^4.I!24DB%$'H
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M=M1IY00&UE2PHK#[SB$[>9H^<R =X'?T]([C!5W Y4HS4 +WM9JOE!"19GN
M5#B5N%" J5*( [A,I,$R"!TGW"(Q9"K6WB;6Z6R]8;9G6N-6UH<^>B1&\1![
M["=_CZX(#8FP.9'VY-[0UR\T25(JM?E_NI+B%'OY@>H_3'N[8(3 4-7L.5>_
M-ZF#!EYZH9!86X%%E\.-QV0ZA._?TC;?W8/2!PU,N=QKG]N4+G::4/T[:G5*
M674E&A"AJ2"/G*!Z@$01UD](!PB'[MH>_&)""1F"R>$T^5^$6VTNZVE#27&7
M"9;,A(VG7$C;;<^4-^&@\._&W&)#9FOW.5#R]JF(MLX6R[\*>);5YI7ZAFU7
M&M+Y0TXMI#S"W-1809T>23U@&=I.^"#BU] ^=V8%ZFOK#\[34IS%EJUW:W%*
M:>KI@Z%IW<+@V6AU9@ I[ Q.Y$QL0,'9^CL_@Q)MTO=XHVTOTQ8<4"3J!202
M7"?\F/M_JPZ-F_*GK$6)8@)&=W]!P\>,)?=LI%BI*FT:)/E1I,@G<DC8[_#"
MO$^G3\V@)?LKJDK"$-E?S%@0=!ZS/0R!UZ^IW&"'&)BTU4I;'A[;CI!.XB>Q
M[[]P(ZQA<_X[Y"$""*%VX5\(T6':RTYFMZJEM+3:6G5(<;3^.)<5H(2L2 (&
MQ41!W._5P5LU-?.V;VIQM#A18:.]T325K42X$Z-8*E:E#JI23I*NQ,P>DX.^
M^S$79V#DU.5N#<C76CP3\R\+*FVMT[MO>!<>5K+;@6$@*,R"D'>.@$_$#J#A
M:W?A$B]*5O3L4Y\*&##8K$Y24C2:AI)J&@"Z%E2DN$;@I*MAZ$2._P!!WWWI
M"K6I<NSY6HWW;K5RIV7+F_K\GX@H.DMI'\'[AV/KM/QP&@).3>=>O\0"][]1
M2EV'M>D0U?= F1_PTY"KGF=-.V*OAKQ(RCFE+A2E3Z:*H?K*.Y(2YL0A2&UO
M>69UJ 2I4 @'%R_KY:1)-%#C]B&]?*T$SE2:6GE<Y;$D %/ +@Z"-2#N.'>7
M0=PJ#OZ;8(OWAJ/&)M*G,=._0@.N*6I39T.KZS$F"=@2)2/CWZ8+>ULJ=^<9
MGH3H^K\ATXTTI")9YSI16NQ53:$.NK>6XSI<U)TJ6D@%"Q&K62 (B#OZ8(=G
ML^=?4U-N<+?RP\1'L[Y3<R17&:NF"D4M.M8*Q3HF"DF%RF>T@SM@A O9GYEG
M9Z#3MH=9PUN-19[H[9'_ !*>B;J'&_"\-2&O%0HZ2L*&K4X9.H*B3/0X7K7O
MBU+O#IP;V]K\(7>_UB$-,5](CPJBFTK#K0)*0 9*@F)3L!OW]3@ UY!M/?ET
MA.^HUMYO]NL:%1FQRLH"I;A*W0EMM&D2Z[TGH"/4[[3V&V!JO7F_VMY0^!K"
M-\:^'U+>>"/$=VXMLU%UJ,MU]6VITAQ5,BE2E]"6T3Y-*"4DP"/>(3@>O>K=
MZO >PU?9CY5AJGLN+2JQM\0JE&INFJJRTL$@^53J#4F4S[SMU.W88#:[6]80
MH=>+>3BF7#K$W%0BC7:7U.!MY3K:FPEPI(A:0"0#]$G[<.)0W"\61B@?6TPV
MM*'&W%GSI*1J))")!($GMTPM1Y]_8WTA, 7UX%_'[?F$[N=C34N()I=*$%*O
M%5I(400=OT^L]\. ,12W4>$67.R*+=K80VE:6WOE'E1!2#'629[B>@.%D_YY
M:]&]8!HWAZ9'R@[V2T,)K*+6UJ#=)5(6 DC=4+0=0,@C< '?N)Z8<*K]2]<A
MT&?VRL5KVQ\JKD%:'80K1LGH$J@S ,Q\.@P4U[9X=GS<]]^ RC8 4AT,MMJ#
M;3?SE(V.VV_;?KUF8,=SMX.^/+[<HI^GJ'V5*;0V5&$J*H 2"""!L9V[CI]>
M"#UYY ^&GI&>DRLW56YU3SY&G_P:4H E1)V4>H]Y@CM@@<-HWE1^VA*\V6NN
MMNH4P;JJ<?PGAG2L =MYGKN-MNN"#CE]H)^6[\'@\RA<J:<6DI60-*>R=)$B
M(.X'K!WPG9_M#A5**XMN,MI/AZTMIF0DD[#W3T]WIT&'!$;'M<;&WF7V?7-3
M0%E3@/"^OK]"BE+171UE/6:D%0A2VDI*=(W)4%#802%GQ'I]OQT$C_L!0![(
M3DD@R#PQK"-Y(G-N8MC[QWZ;]L$.)B,$$<G7W0#:6+Y[0+V.5MJUMII#QDS5
M5U*75!*'&J.G9=T**B!IUZ%J)V 3O[C\:?>'DK5J7JSZ/3AG2),+U<FN%_$B
MF:+Z6<I9M=912ZG$^#;[_ U--*,I":I&DA0(2H" #&"C<\FIWP:(9WTS/(4#
M"I\;-#AWK@A=)I1U<4H*\P*DE,2($Q.J0J=P01WQ$ YU;SN:YZ4?*&X8/G?3
MEQ[I!5KZWP4*B"(ZZITQZS,^[IM[A!E"9[NSV+?;[Z5A)LS5B5LN0J4[A2$G
M=0 GUC;OUWV]^")0@M^6JH6A"84@ZB(,J28@@F8,QZ#"!K0G(BE.A;[_ (#7
M\UA(K[1MK;>:6TH)TK)6#$F-B8';XX>GOVW*($LYOPLV5SERN33."?;KDFGJ
M:%(5(*0A4JDE3?E ([]/CM'7J[_89>K_ ,PP&<O0\!GF2VIY=++-E:^MT5T\
M&MJ%.%24FF<""&RM120C22?,!JDDD2".APCJW@(8I[.^?'NO*#OF2A%V96E(
MU+=5J6!Y"82"#Z$ ;;=Q$]L1H#9GSYY=6KYWAFH;PS;I:&E\:^&]#F.P.O%"
M7ZVPDUH8ZE"3N8*=PC:8,R3(Q/B*5-'R]FXUB#>EP!D"!<WT9FUS@!Y?*Y%7
M:+IEEM[_ +W/"H:941"4F0XVE*O/ 5OZ".F#T\>^;:\H-31V< %KW-.F9X&%
M_39%NN*<0D HD;;%'^:?FDGK$>GI@I70_M;[]UA@DT\2>6E#=Z^<:*\LJ<4Y
M4/>,\Z=@HR0 -D@'W #H1V^."AS\J4Y>U_& CAGPZT/.FE3STZ?*%."X4-RA
MU<K!201L>JC(ZQ,;;1.^S^D-5S0D=^';1$N22U0"!7[7?2V4 +^2DMN& 2KQ
M2M!:D*2-X!$]!\?G1[HC]^^\HE6K99$<#5ZD]*VXN1LRY3=*T+6M84A)"%E*
MORCL 9W@@R?2"!WP=]]+P9&YIE>EVY78\;UA9>$]O75T26'P7%LNZ I8(4$H
MV@$_T@.L8"^D2YT.G9X0X@Y3;KEMA3:G"TV$H 25[GH( [>\GO@[YP=Z04;_
M ,/KL@AVFHG%-P22$><09,)@$Q^?MUP ZU!=FHVF9O>OL(1M3SL>'A!"IZ-=
M+5^%X*VW"2%-N)\%PD=?*L"?4P=QB5-VU=7XZ/2(5WGR=JOGQ9FT#\N+&/:W
M983>_9U<S[50PV[\FR"[4(:<4!Y[;64U:T^A4D(+84ZDJZ^8F=]X#(]1W_'K
M%@H0?'B'\LNV9CO*@2OE:Y:ER#KX \'%3J!G5P[RX9F=YGKAQ,H/'P'_ -42
M8W/-ZKE;J532J=" TRH^$""2XGS$0-]XV[#:<$5@=O3U\\[F\(=F*IK+I6"D
M-4I\!PJ;_P @& #Y>A4 ?H,F#!P1$@/31B*<<O"K@Y:0KW N]C)6?,OO^(&D
M./,T]4I2_-H<6 9.WSI))CIL(P1-GB4J^7>G9S4NHI$MFGN-/2UC("4QK"4A
MQ6K: ?2!O)DX7?'S>#OOOA"NT:W+C;DK06TH-.2XJ-<[=/1(DSO/88#:MJ\/
M;3L0O70<2SG.D%.V 4M4'W"EQM#KA;"TRE"I(@#MI [&),X=N^D!'$Y6X>O\
M0A'-/QJMF3LAW'*5&169HS91.VQNB:6%+IZ>M 07G0G4H*>0-"&U)!!ZDX(1
M<"FINY=]&L2<AKE&#E5R6[PVX9TBZCQ&;M>:A%XJV]);?:"TJ-.RI$R2VAQ0
M6-M4S VP=]_QXP^>>?$>.0\H=E3<0'W EDK>=,@*F4I3.P '2"1]GOPFRJ.1
M^_CXP5:ONU>EM?5JLKY[.:?B%RY9.MV?,LY$K<WY<M]KKJ_-E10W3+=%5V^F
M:?8IV?!I+[<:%VK6XM]&U+X@3)U =<>K^'-GX+$X;:6*QVSYV.DX)*)BE2<8
MC"KDI+ EE?\ 5*B0&2Y CY9_4/;VV]F[0^'MF;#V_@]B8K;$R?)EC&[*G[1E
MXJ:@*4E._)IA@A*5.I;!5@79VS4GM +I:;#<*WBI<;5PSNMFR6UQ'NV7[D;1
M>ZJW9%J:SY#19AJ:RQU591!FIJ9:\!+IJ&E@I<0#./<I^&OA)$I:\?A,1@9D
MO#_K)DI6.,\HPI4$IG%<E!20I2@-T.H$U CXC-_J-_5?$8F5*V'M?9^V<//V
M@=E2<5+V&<(%[20A4R;A4R\5-1,_QH2H_,4-Q0JE5(*MT]JMPJM]]N&7:CBS
M:'KS:*^KLCU%0Y4KZY;M[M]O9O%98J/Y,PZFLO-/:7V[H[;J<KJ4T 74EL--
MK4*IFQ_Z?RUKE+7B?F2U*0M*5XI?^1 2I<M)3)._,2E25%"74$_40P>-F'^+
M/Z]XG"R,7*.ROT^(ERITN9,PN!E-(G*4B5B)H5BTF7(6M"I:9JP$&8 ERI0<
MSW/VFN0\M#)%35\8,MMTV?[!9<T6&NI[.NJH&LLYEN#=GL-_O553I6Q8K3=[
MHX;=0UUU72L5%6T^RA14P[ILF;!^ I0D;ZYH3BI<N?)4G$3EH^5-7\N7-G*3
M+(PZ%K^A*IVZZG&1C+AOCC^NV)_N7RDX(JV7B,1@\5+7LS#HFKQ>%E&?/P^$
ME+Q._C)TJ2TU:,.)A"%RU ,H.Z3E4YG\L<R6>.+V3+%FUG--^X35K%IS,W;K
M14TM#:;RS=*VV7BVKNA:^05-;1U++2*BD8?6ZPE:7(T*G'C_ (MP/P_@?T\O
M8GS3-1B,5A\<%F:M*9DD("9:)DQ"4*4A6_OA!+#=)8$&/KO]*-M_'VVT8_$_
M&9PGZ:?L[9F/V()$J1(FKD8Q4]2ITV5+FS)B4398DF49J$ONK <I4SV*BU5;
M05*%. D)B)*1TF8Z#;KN1[]\>,<>3](^Q,UAW=O.-)7@TR0VH0ZJ003/;T^J
M>\_:6U[[[ HG>VN;C^7%6\8U*:O\*C?UF$J<4D(G^$Z].P^CK.#I7OPMXPRY
M9BW!OX/3LD>NU/OK,"%$?BE]#O/4G<#N/RNF'#A-;[8#:ZI=\MR)6LD7!A"0
M4):,0ZVD0E!3*BJ)D1T/4X?QW2L)OMPL3QXQEMU<I"M:E'2M(4.^I!'E(^(W
M'KTZ8(<,A]J+=VZ;V?W-4_4.PQ^Q;>E(02-6NH%-3M);5$I2=9D1YC!)D 8(
MCG3ER([IG=J$Q(M[ ./W(/DCC_\ 5C63\?PMS%@B43%8((Y//N@*XT-IY^/9
M"UUR2HT?[)V>J1:DZ1X:JNA9;0K4HC3$$R).W;K@B0?=4UP/&A'W[N)&\\VE
MCBAP\O66AJ9S!:0:FU5VQ>;JJ9OQ[=4)4"#*DI#8CJ%;D;809SS]:U]_-X@;
M:=!3+RS:+> G$PYYR514]U*&,S61:[/F"E=5H?%7;I8==<!)4A3X0E8F1!/7
MLXC>[DBM.'D];![7A0[U==JIIG2G6@E ^=!$1!]X [=9';"8.^<2%!K7[U\(
M1>INGRERJIC^+6TI04%>I2>A/KV';MAP^4$WY.EQ>A*5$Z5*U$ZM14>@Z^O^
M[KB()HXNVO6X[]2"+F6UNI9=(2J5)6=DSMWW'N[">V)#C_)X<*^41(>V8()]
M*=Y]&W4X=1=U6^H7X+Z'BY0.#YIUJ42ER3N3VGYOT8(#:HHUM. ;@X?+E"GY
M6JU+K7+?5!1JF9<IWG24_C4Q"4@CSH\QWF.P/H0$9W2:M][]6S\X4]S,KE+3
MMBM414)):,*_A5J,)2GKI(208!WW.!N;9996!'%V@WO$/05-^#Y<JZ12;53U
MS#[+B5.+K&5-OD@J+B7-4#41/DU  GN!@[$-K:WZLW*&D</[)<,L\7:NPT-.
MZI=8_4,+"B4I;86I3@=6=@24?-F"??@A.'I<AWX.U+^SQ(98,KVY"&VZHN//
M@;N%1;2HG;2$ $0.DSOU/;"N^GB.7?CI*&=\X/-1DCE2SGP(RKF:DN%/;.-M
M^O&6VLPTU$S56?*];0HHOD=9F)Q3S;U);JZJKF*!%6TTXTU4OM!\MH4%8]7\
M-X?8,_Z-MR<0LXC%IP\B?*G?*E8=I:%$S@RB4+4M*=X?M=U!H^6_U%Q_QU@@
M)OP9C<!)_1;*FX_&X/%X3]3/QW^>;+2C!J*TI3,E2I4R8I"OW@ (^HL42//5
MPTM;6=7\V7!S*Z,H\4LR\*Z=A^VKN==F>[96H$76[7*QVZT.5E746FFMZS6U
M+ZVD?):=/BU ;2I,^T.P?@I'ZHXJ3C) PV.GX #]0N?,GS,.A,R8N5+DRU+,
ML)5O%1#) =5X^.I^./ZS8E6S4;/QFQ\8=H[#P>WEK_M\K#2L'(QTY<F1(Q,[
M$3Y<I.(7-04(0"?F*HARDL><_P#,75Y<X1_LV9 R_3\5LGIR]69OJJO+MUL5
MO3^!]!:*N\5%ZH'[S<:2GN,M4OA-4=*XJI6ZL>0!"R+\7\*_#4G ?W'"X'%8
M[#"5,Q"E2MHHE@89$M4U4U)F( F421\M/UO1KQS-D_U4_J/B]NGX>VKMW9FP
M]H*Q4K9\I.)^'YT\JQ\[$(PZ,-,3AUJ,@;RPHS9@" ,X)N4^:&QYOM.5*[B+
M9VN&MPSSD2X<4LFV.Z72U7:X7C(%GLUIOMVS"X;!6UE/0IME%>[>:NCJG$5*
M%O$)0H).(8;X9^%IDN2K%X'%8)>*PBMH8:4K'IGJF8)$A.(FSR9*"$;DI:2I
M"_JJ0'(+;-I?U'_JAAL1C96RML;+VU+V9M.5L7:,^3L1>$1AMJS\5-P<C"@8
MF8E4X3I\F8E$V6\NSLX@&I?:"\M.5:JC9I.*5H;776[+-WIW&K3=*RG<I\Z6
M]=TRFA3S;*VDU>8J1M:[31J4*BM6E33*%+\N*5;(_I\@@*G8D*(0H$3,0H?Y
M4[TL%29) 5,3^U!^HLS/&N5\6?U[G)6N7)V8R9F(DJ2O"X(+WL+,,K$$(5B0
MI4J2O_J3&*$#ZE$"ZL/>T6X799L65LUN<4+ U;<Y)K'+2H66IJ:I%/;*KY!=
M:NYT+:55%II+35GY/<ZFO:8:H7I34*09Q8O87P%+E29RYF($O$;WRB)TY:C\
MLA$PS):917)3+)99F!(3G&.5\<?UVQ&*QV"DR]G?/V=\O]0%;.PJ92C.29DE
M&'FG$IEXE<] WI*))6J8'*086/A%SI9.XH\2LS<,K/G*BS5F+*U&Q67>DM=J
MJ4T-O55L,5K*7+RA*[>7*BBJJ>I9IDO%UQAU+B$J23CS/Q7L[X;P&&2G8YFJ
MQ<O$!&(>9,FRTRS+"T@+,M,HJ((4&4200U*Q])_I7\1?U&V]CILWXO\ T:=E
M3MGKGX!,K#R<+B%3I<XRIBER4SUS@A*DJ1]4L)"DD.\.-KZFUYA"F[G0^"XE
M:BP^A.A2 =I2M(E6^\3O&/!N-0'HX;G?\9Y1]SB+OVJKM79N0+FC;KW4O('#
M:O896E0#;XK'VV*<P3I"R- 6V3TDS!Q+OP[,(7;37,$TSX:CC##.4];37*SR
MU-KA*V^ '!M"@%* "D<.LN)4  2  00 "0.Q."+G3J?%7VIX0^3*]WMUQR';
M+FTO6*BV4[A4Y"2E"T!27!/76E0()F009WP12^0ITZ-T)&=Z03LHOM7C.KEK
M8TO.,47C!.H&!4$A*R.T@'08[2-^A"%R:9DZTIE>U:T?Q<@UDD4JV;DTREQZ
MF4R_ $J*VE)40#U]2-^DX&]^_"!W<6UZ\>^4/)?KJJMLF5+JA#[:5T26GE%6
MD(+1"='6?R9TSO\ F(8#9D\^^^;PM>7<S52K.VPRI24J 0ITF&PD?.+JE1I1
M&Q,B?3!#AL_&+F/I\O:\N\/]%^S4X\:=Q5,DJIZ1]*BTH,1*'WB9U""(^O!!
MR[[_ (@F<)>!.9LRWVEXD<8:M536.O&MH;75.>,XZZ@A;*GFR5:6P8T-J&@:
M=DC!"XYZME3NM;P_.WT0?JFTA.EA*  E,)Z" D ;;;;#M[NI!2WVU@ROL427
M$4[#;27QWTIVTQLN!O(Z3Z3@A5 <D>'+5KV]H97SS<&LU<=^$E]X<97!9K<R
M62IM0N:J=RJI+:XJKHZ@.U#+/XU2%"G4D);$RH=L>Y^$\3@AL_;N#Q>.P^!5
MC),N5*7B%$))"@2H  D@,U-7UCXA_5; ;:F;=^"=K[)V)M#;<K9&*Q.)Q4G
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MI?ZY"$)Q>)V4O:1Q4S#;BE 27Q*5(EG=*$J#AR8D?N=O33K62D:5 F$F8),
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M.KN->\HM( 5.M0H4A4"2%[[*DOOOO6 $N.AS9\_MQ/2&U\JBD#E>Y;@"E0'
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MR>G9K*Q=4X-3@2(+JB D*6YY9@(!4I4)"2HP6 I1"4AU*(2D$@ J40 ZE$
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MJ2C\13"=FMR J 03.H]?>?AUPZN*T\R:^ \Z0B QH[#R^T))F&XT#R7Z93I
M#:@4) /8SN.OI^?#@;MS[PCKSU(^'&*=E383U4=B?-![;=S.^_NPK>@]O*'&
ME;+3455R6_2$J:92=2G#TT[PD&1N9W^G!H?+O3K!!@>>7;77#4SY5 I(Z$0"
M/TB1\1APJ\_+O\<:'S)V9J2V5E/6.(.AQDMDZ9TZEE95,$[3NG;UD3LCR[T/
M9ZV)QRJ-.OB//Q<A09H8JD:Z=UI:76DE*1I*Y@$2GJ(C<_1@);^"W%ND."7G
M3,%0$KTMEYH-R0@1Y@.BHF"!,;GW[8!X],\_SX:PGRSAMM;6%YUU3A6D+6H@
M$DE,GI$=N_\ OPX<6,526UM^&N%Z@-2W-*23M*E'RIV/4[3UZX((A^]LW[5"
MW<DO!:JX2<,[O15O,YQ>L-70Y<;0_K_8_P N5H50U><K@PR2NGK$,O.-VL5!
M84'4K4@A:VE @%3FPTSX5[\#'SY;A45577U5;75#]775KSM=75=4XIZJJ:^L
M>=J:ZIJG% *755-8Z_4U"E2HNO*)4H0<$,FK]\NEH#WOX)W_ $:_Z)P0H^N;
M[ ?_ !0_)/\ R:5W^MV8L$,W/,^L3#X(4<*?W9OTY)O]-Q%_HV_!#R/,>ACA
M>;66UA:8U)!TR 1)$2H$$*$$C2>LS.V"%#GN4#FHX@<G7'7*7'#A\5U*[(^S
M:<TY;\13;&;\FUK[:KQ8JCPTE+M8&$KJ;.\^TXFEJD*2E,U!4DX0Z-7A]^^;
M5I'T;^6_F/X9<S'!C)O&[AE>Z6ZY7S7:J&IT-N(^5VFY_)$.7.R7-D;TMPMK
MRBT67 DOI0MQ [%=6\/"V7+[PN[,^;PJ5TS,V6UEY;:O(0D@ ;]!\3WZ?;A]
MCC!"15]VIGBXE*7%$J5K<$B)&W4;B3]'NPPSU]_;U\H@:%\\\@QU.1#7Y-I"
M79@"4,E:4*6"I;@T[D]3':"?ICXQ*ABY8\\V.7%KT/A!7RZE-4Y<Z4M-A%0E
M%2WKV6@D%M20>I@B>HZ1@@+BM]<A?2O*'8<NW$15GN;V1+V^/#JG)LSCCF@+
M)*?Q8*@1.ZAI"A@@/*]GR57GXV:KZO+>IZ2\6^YV]UL)344]32O-+.HI<<;*
M$J/8[ $#H<#P6.KZ4MG<N;6TANW"Y35L;S;DRH9**ZAJWGZ>G^:MQ.L!"T ^
M82DA7ED 'O@ABE.O'G^85%IRM:I$45:Z\6UZB$J<60G;IU.J" !MOB 0@%PA
M((S"0&\J1+>4UU'J:^+#5_S!-N5:BW(<6V9)/<Q'7W'Z@.N)PH#*6[)JF7#4
M .$#RR?F]]C._NZ'WG"Y7S&=LX(%*6_L!M::A25I90HMLSX:2H#\KK.Q/:9
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M$IV4)2D^L*4"3O\ 9@AD#MJMX=\*0=KLBL;:I*RD=<8N%J>164=2RK0Z2"%
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M!(Y< ]0+MX<!>MX@ZSCG"_YZO=PS-FN]5M_S!=:ERKK;G6NJ=>>=>65K4%F
MRTDJT,TS82VT@#2-L$!]*!K=(*>""*P01:OYBO\ -5^8X(([1.5#_!:Y:_Y
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M=_MRX>GWA_'L_N$_'+EPLU1;LUY%N%+EQNI>9KZNI0ME09,)-3I='\&D*D+
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M9N^0.'SCG /@K5^)3MY=RW<W'LX7FWK3X2VLR9D8\-R'T:_$HZ=2DM:@&WH
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@01:OYBO\U7YC@@CM$Y4/\%KEK_D!X.?[.\N8(T1__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g142578g87e13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g87e13.jpg
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M 0$! 0$! 0'_P  1" $G 6X# 1$  A$! Q$!_\0 '@ !  $% 0$! 0
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M_P"'DE&..SNCKRA?:&TDSVDULG&CGU-H>YK,M4$F$S,,(^X-XB/@IV%@)A"
M9UZSP1JJ\E&!Y*6JR\++23^2D'KI^XAJ#[>;_P!DIQ,M.5\-D%%\I++83+TO
M5-D\K+G^G&.9-(OTG-]//S8_TQG/^@@DHG:$G<UAX2OXA,'E-:D16<GH.T).
MYK#PE?Q!!Y36HBLY/0=H2=S6'A*_B"#RFM1%9R>@[0D[FL/"5_$$'E-:B*SD
M]!VA)W-8>$K^((/*:U$5G)Z#M"3N:P\)7\00>4UJ(K.3T':$G<UAX2OX@@\I
MK416<GH.T).YK#PE?Q!!Y36HBLY/0=H2=S6'A*_B"#RFM1%9R>@[0D[FL/"5
M_$$'E-:B*SD]!VA)W-8>$K^((/*:U$5G)Z#M"3N:P\)7\00>4UJ(K.3T':$G
M<UAX2OX@@\IK416<GH.T).YK#PE?Q!!Y36HBLY/0=H2=S6'A*_B"#RFM1%9R
M>@[0D[FL/"5_$$'E-:B*SD]!VA)W-8>$K^((/*:U$5G)Z#M"3N:P\)7\00>4
MUJ(K.3T':$G<UAX2OX@@\IK416<GH.T).YK#PE?Q!!Y36HBLY/0=H2=S6'A*
M_B"#RFM1%9R>@[0D[FL/"5_$$'E-:B*SD]!VA)W-8>$K^((/*:U$5G)Z#M"3
MN:P\)7\00>4UJ(K.3T':$G<UAX2OX@@\IK416<GH.T).YK#PE?Q!!Y36HBLY
M/0=H2=S6'A*_B"#RFM1%9R>@[0D[FL/"5_$$'E-:B*SD]!VA)W-8>$K^((/*
M:U$5G)Z#M"3N:P\)7\00>4UJ(K.3T':$G<UAX2OX@@\IK416<GH.T).YK#PE
M?Q!!Y36HBLY/0=H2=S6'A*_B"#RFM1%9R>@[0D[FL/"5_$$'E-:B*SD]!VA)
MW-8>$K^((/*:U$5G)Z#M"3N:P\)7\00>4UJ(K.3T':$G<UAX2OX@@\IK416<
MGH.T).YK#PE?Q!!Y36HBLY/0=H2=S6'A*_B"#RFM1%9R>A<(@D #^&*4Q<E-
MC!BFQG!BFQC)38S]&<9QGZ,XSCZ,XS]&0!C65U%0Y;-E4,PFHAU;YZ+LUADJ
MG<KI29E_-0U>8U6/=DFZ=88*68D2K\:RC%6<<]:,7:*.5'C9PNJLJI,>T$Q#
MM%GUB]2Z[A6E5CXZL-$8^DM+"TK;!5S(.V+$UL*<EDDEVCQVX0E)^937D4WU
MEEDWUA53G+(3,G@MFG\241B"I4;7U2UO$+0=.C%HV/<.DGKG#J6F9QZZ<MXJ
M,@FBCJ5GY"4E76&,'"P\)'I+O5$H^'BHV+9$08LFR"4MM[QV^1>@@
M
M
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M/FK9%ZXY)+N770;)'7<K)-T$\=)19=0B229>?&.<ZBF2D+CGSC'.;.,<^<8
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MS?[%/P@!U1K[LW^Q3\( =4:^[-_L4_" '5&ONS?[%/P@#T
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M3TW0ZA72X^9;QAM3H:GUZIG0J,N&E0
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MZZ=^:;/YP,NQ>4EH:4@LYO4=F(SZZ=^:;/YP$7E):""SF]1V8C/KIWYIL_G
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MNEQ\RWC#:G0U/KU3.A49<-*@
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MLGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
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MZJXZ&$S+(X+GI9*;I]+/_CT>;Z>?%)<^GBY9/3=#J%=+CYEO&&U.AJ?7JF=
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M3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_'@!U"Q?$+;@:?X\ .H6+XA;<#3_ !X
MU=Y4BIUYW5L)"JQM:NDHC>UX#8TQMN:TZQ@8V.1JZE@JJ<U!P-D6LDC;RN(R
M1;5%]&&C5FE.D;.=PD_JL>57I8\,(1]ET\\R'P[3<'ON,@<F*R5"P:C@4ZFE
M',<1;VT,YJ,8W9381\SB=SLK:;LQ[>\PC+6AE>YYI+W*(M<NR8/K3'S*4XLS
M;*NU6Z44M\N$."N]2NUWA;KM38,02                !!IZ8[\Z<G[]0V;
M_$40:,YA?!<J/26/\-IF?^>_PO)OT=K?%9Q"D-"%#@      2Q^B%_3IL?\
M9,Z_G"J"DN?3Q<LGINAU"NEQ\RWC#:G0U/KU3.A49<-*@
M                          :C<J4Z^%M>,#N=0-&5L=3%!8O]I9IBCR!N
M%MDZ>A VFHQEPB)9.SR4%"L[<9.HQY"YG9YY6"RR*L&UD5V<KUXW1W878X\"
M'ZO7VPCP<HF2M!5-E5Z-T,-*D>8//6Z)D;#5XBDQB]CC*U=K1#55S934"*AZ
MTK:&U>19I69M%Q[)A&6<\ZS:Q\=@JC-(WY_7'BLPMT]WGAP,WB"0
M        (-/3'?G3D_?J&S?XBB#1G,+X+E1Z2Q_AM,S_ ,]_A>3?H[6^*SB%
M(:$*'       EC]$+^G38_[)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9
MT*C+AI4                                         "/GE06EK8K<R
MB(2'VVQF:),Q^O\ %[I=5H5TK[NWWDM#V=':P<U>PVR$L*C^7[*Z^E<6ULE#
MUFOJ.V;&<M+6,?SI6O2NP<>%Z<$FH^_%Y<3E[UZ\//"2CP-KM(5Z8K&LX*-L
M4?+QEB=/K58K$VGI&ORDP>P6^WSULG'L@XJ9"UA%Q)RLV[DC1D 9Q$0N'98=
M@]?-F*;U>'I[% Z[3,B3AX].%EU):0]D12<7('DY;$B:']F1Y6BIGLA[7(LW
M/%=2;84<^T2.$#,?5=9*LEE+!RP".J&A'-^HMTD-:;/=1&O+#MC74WKV$O>]
M=C1DG-5&NQR:EF,O=2S4_L>H,=LKQLK)0T!EP9PK"Q>+,YCV3N>EF37KBHJ]
M)Q@EQW7;KO><PNNXOBW??PW[[]QYE+7=Y6 U+M2@/7,80QYJDUN@.]F; N[<
M\YK:R[9AKI9D'RI2DVOK6UQJ,;9GEQMAXZ69TNGU]Q4V+NV6>%B$YNO3\]R2
MWPRNAN@KHO?"\7W0XN$'?CA-N/ VQY-=UC[EKDN&9;&=Y7W[1G.2-HDHV7DY
MV7M56K.SS3QG\.\>Q6<2T??X]TXC8PZ,779 [ZM1#=**AF72Y:@^W"[Y>O>[
MR5[OG?\ /0STY.NF@H=LB1PN4O.F@=;JY%#<^/\ "9;U:OJ\<W/GG]6?\G-S
M?3SX@DHO7K'\/LN/8\K$W8N2U(OP4WH.O6/X?9<>QY6%V+DM1?@IO0=>L?P^
MRX]CRL+L7):B_!3>@Z]8_A]EQ['E878N2U%^"F]!UZQ_#[+CV/*PNQ<EJ+\%
M-Z#KUC^'V7'L>5A=BY+47X*;T(1?2_KR*TGH+V@P18Y*QV5ZK"+[KOK<9<4;
MIY-GJK;U?0YB\V/\?3Z6?_'H_P"+1G,+#Z+E1!__ )+'X0_9M/-E <]\?I>3
M<?\ ;M;C']JSLD0Q#090X      $JWHDUGR.\-BF8,DGRN=4NL'36>=2*0G:
MZJYZ>%.KN>EGI8*7H= OT9R;I?1S9I+GS\7+)CY;H=0KN:+CYEO&&U(>1J?7
M:GDSH!Z]8_A]EQ['E8R[=BY+4TI?@IO0=>L?P^RX]CRL+L7):B_!3>@Z]8_A
M]EQ['E878N2U%^"F]!UZQ_#[+CV/*PNQ<EJ+\%-Z#KUC^'V7'L>5A=BY+47X
M*;T'7K'\/LN/8\K"[%R6HOP4WH.O6/X?9<>QY6%V+DM1?@IO0=>L?P^RX]CR
ML+L7):B_!3>@Z]8_A]EQ['E878N2U%^"F]!UZQ_#[+CV/*PNQ<EJ+\%-Z#KU
MC^'V7'L>5A=BY+47X*;T'7K'\/LN/8\K"[%R6HOP4WH.O6/X?9<>QY6%V+DM
M1?@IO0=>L?P^RX]CRL+L7):B_!3>@Z]8_A]EQ['E878N2U%^"F]!UZQ_#[+C
MV/*PNQ<EJ+\%-Z#KUC^'V7'L>5A=BY+47X*;T'7K'\/LN/8\K"[%R6HOP4WH
M.O6/X?9<>QY6%V+DM1?@IO0=>L?P^RX]CRL+L7):B_!3>@Z]8_A]EQ['E878
MN2U%^"F]!UZQ_#[+CV/*PNQ<EJ+\%-Z#KUC^'V7'L>5A=BY+47X*;T'7K'\/
MLN/8\K"[%R6HOP4WH.O6/X?9<>QY6%V+DM1?@IO0=>L?P^RX]CRL+L7):B_!
M3>AK3O"D<EUI:X6;VKKEG8KC?I:.0;N6-=GYN17-&KUJI)V.:/#<[:)B($\U
M5(5W8I0[5!IF1AH\CA1PY:-SRG2A=N7FS?'UAI1C?%X1^1GO6J5(:5!G&ZZ:
M),*G!REHKC1@@@];)L).MVJ:@;*QPE(8PZZ3.SQTPW.H;)DECIF6;**ME$5#
M<N/$DO9RV;O&Z[1V@BZ:.D56SIJY2(NW<MUR&260715*9-9%9,QDU4E"F(H0
MQB'+DN<X %G%UGK<D>^B":^I!(J34:JR486J0)8^058Y5,R4?,L,,-G:C,RZ
MQFIUTU#-\K*Y2R3*A^>8O%S$$MR@7.C$13=5@NA&1Z"\6P7BHQ9%DV35CHMR
M9B=S&L%")E.T8.#QD:9=FWRFW5-'L3*)FRT0RG /S%0T1 LRQT'%1L-'D577
M*QBF+6.9E7=+'<.5BMF:2*&%7"ZBBZZF"8.LL<ZBF3'-DV0*D
M(-/3'?G3D_?J&S?XBB#1G,+X+E1Z2Q_AM,S_ ,]_A>3?H[6^*SB%(:$*'
M    EC]$+^G38_[)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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MEO&&U.AJ?7JF="HRX:5
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M>)D-+5+$1!8AU$TR$1;I>R6?66:;=]T5.M>O5Y?:%^I)?@
M   "#3TQWYTY/WZALW^(H@T9S"^"Y4>DL?X;3,_\]_A>3?H[6^*SB%(:$*'
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MB%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,-J=#4^O5,Z%1EPTJ
M          %NV_\ RG:/]NS?_&N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2/T
M&,(@       !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[(R
M"/EGT@           /BX<-VC==V[71:M6J*KARY<*D1;MVZ)#*++KK*&*FDB
MDF4RBJJABD3(4QC&P7&<@##[7E ZG?TQ2_1UD>2=;Q;%Z,T4C*O;9"8F+:@_
MS&^PZ_66D$K9;"Z6<%.JT4A(E^V=QR:LPV75B45GQ)@XP(BMY_(3E!ZEL3^L
MQD19G+E]:S'1CD#UBV-,L'I)6S0/LJTJ/(-NE29M2?I=M@$(2XG@Y5Q.UR8A
MD6:DDR5;80?;Y8^H17;M=ZS(U6M$+=(-G9:XZ._@Y$[SV;(9;.&R$DV:/G+$
MLE']922,\B) S8SN'E4"G83,6LSEHQPZC7K5RM!.\N$           0:>F._
M.G)^_4-F_P 11!HSF%\%RH])8_PVF9_Y[_"\F_1VM\5G$*0T(4.      !+'
MZ(7].FQ_V3.OYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
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MOYPJ@I+GT\7+)Z;H=0KI<?,MXPVIT-3Z]4SH5&7#2H
M6[;_ /*=H_V[-_\ &N1ZJC]MJ?XJK_FT#RU[[%7/PM8_*IG%2/T&,(@
M  !V;ZE_15K/]GU,_ER-& [<^^K8Z4M#K>V-S6-]SV5T;4>J[(R"/EGT@
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MI?T5:S_9]3/Y<C1@.W/OJV.E+0ZWMC<UC?<]E=&U'JNR,@CY9](
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MOEV2_J@+L'-:"_%2>HZO:^]Z]\NR7]4!=@YK07XJ3U+A$$@
M      $&GICOSIR?OU#9O\11!HSF%\%RH])8_P -IF?^>_PO)OT=K?%9Q"D-
M"%#@      2Q^B%_3IL?]DSK^<*H*2Y]/%RR>FZ'4*Z7'S+>,-J=#4^O5,Z%
M1EPTJ                  %NV__ "G:/]NS?_&N1ZJC]MJ?XJK_ )M \M>^
MQ5S\+6/RJ9Q4C]!C"(        =F^I?T5:S_ &?4S^7(T8#MS[ZMCI2T.M[8
MW-8WW/971M1ZKLC((^6?2                              (-/3'?G3D
M_?J&S?XBB#1G,+X+E1Z2Q_AM,S_SW^%Y-^CM;XK.(4AH0H<      "6/T0OZ
M=-C_ +)G7\X504ESZ>+ED]-T.H5TN/F6\8;4Z&I]>J9T*C+AI4
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M2Y_5I)E*C'>"X@
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M/7N54U'*QN+"4% RJ()
M
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MA6B_PW*&6CU)TMRVO*PY=962U1&I[=$/))C3PA'&_AO?%1]4,.,"8P#D
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M_IR /[@I2YSDI2XR;/2-G&,8R8V<8QG.>;\N>;&,<^?IYL8Q_I@ ?H
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7G+"NZ;FE\1[,0S.X           __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g142578g89m59.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g142578g89m59.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[14F4&AO=&]S:&]P(#,N,  X0DE-! 0
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M4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M"G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@
M  EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN=$]U
M='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O
M;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M        1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
M     %)S;'15;G1&(U!X;$!BP           "G9E8W1O<D1A=&%B;V]L 0
M  !09U!S96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M            5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C
M0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T
M0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O
M<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))
M30/M       0 \     !  $#P     $  3A"24T$)@      #@
M   _@   .$))300-       $    >#A"24T$&0      !    !XX0DE- _,
M      D           $ .$))300*       !   X0DE-)Q        H  0
M       ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9
MF@ &       ! #(    ! %H    &       ! #4    ! "T    &       !
M.$))30/X      !P  #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z     #_____________________________ ^@  #A"24T$"
M$     $   )    "0      X0DE-!!X       0     .$))300:      ,U
M    !@              :@   (D          0
M   !              ")    :@                     !
M             !     !        ;G5L;     (    &8F]U;F1S3V)J8P
M  $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M         $)T;VUL;VYG    :@    !29VAT;&]N9P   (D    &<VQI8V5S
M5FQ,<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N
M9P         '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L
M:6-E3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L
M:6-E5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0
M  0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N
M9P   &H     4F=H=&QO;F<   ")     W5R;%1%6%0    !        ;G5L
M;%1%6%0    !        37-G951%6%0    !       &86QT5&%G5$585
M  $       YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585
M  $       EH;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D
M969A=6QT    "79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N
M!V1E9F%U;'0    +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4
M>7!E     $YO;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E
M=&QO;F<         #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T
M<V5T;&]N9P      .$))300H       ,     C_P        .$))3001
M   ! 0 X0DE-!!0       0    ".$))300,      I<     0   (D   !J
M   !G   JI@   I  !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(
M   !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,
M# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.
M#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,
M# S_P  1" !J (D# 2(  A$! Q$!_]T !  )_\0!/P   04! 0$! 0$
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ME<34Y/2EM<75Y?569G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$
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M,K)]V)4_\QI^C=K^ZW^90/\ '#TJZW$P^J5@N9C%U5Y'+0X[F._SEZ.U@#0
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MA)2224LF*DDDIBG3I)*4DDDDI22222E))))*?__9.$))300A      !5
M 0$    / $$ 9 !O &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <  @ $, 4P V     0 X0DE-!"(
M     49-30 J    "  ( 1(  P    $  0   1H !0    $   !N 1L !0
M  $   !V 2@  P    $  @   3$  @   !X   !^ 3(  @   !0   "< 3L
M @    D   "PAVD !     $   "\    Z  6XV   "<0 !;C8   )Q!!9&]B
M92!0:&]T;W-H;W @0U,V("A7:6YD;W=S*0 R,#$V.C S.C T(#$Q.C(V.C(V
M ')R-3 V,C,X       #H $  P    '__P  H ( !     $   ")H , !
M  $   !J          8! P #     0 &   !&@ %     0   38!&P %
M 0   3X!*  #     0 "   " 0 $     0   48" @ $     0
M    2     $   !(     3A"24T#_0      "           _^$!2$U- "H
M   (  @!$@ #     0     !&@ %     0   &X!&P %     0   '8!*  #
M     0 "   !,0 "    '@   'X!,@ "    %    )P!.P "    "0   +"'
M:0 $     0   +P   #H   #P     $   /      4%D;V)E(%!H;W1O<VAO
M<"!#4S8@*%=I;F1O=W,I #(P,38Z,#,Z,#0@,3$Z,C8Z,C8 <G(U,#8R,S@
M      .@ 0 #     ?__  "@ @ $     0   (F@ P $     0   &H
M    !@$#  ,    !  8   $:  4    !   !-@$;  4    !   !/@$H  ,
M   !  (   (!  0    !   !1@("  0    !              /      0
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M 0$! 0$! 0$!_\  $0@ 1 !8 P$1  (1 0,1 ?_$ !\   $"!P$!
M       ("@$" P0&!PD%"__$ #<0   & 0,# @,&!00#      $" P0%!@<
M"!$)$B$3,0H5(A8705%AD10C,G&A)#-"@5*BL?_$ !T! 0 !! ,!
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M[BP=NWL?"I.W3Y-@W.W>-BE3([>.%RG,4RH&4$ 4 OTZ(K7;KTV=C.TBWO\
M(NV[;9CK$%UDH9Y6GUAJ#%VS?N8)\X:OGD:H=5XN3T7#IBS45,! 5-_#)E%3
ML[BF(EQ)% QA ?;CG_(:(J_HD_7]]$4PID'\ #^W ?\ S1%'M#M[?PX$/^AT
:12>B3]?WT15 #@  /8 X_;1%'1$:(C1%_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
